# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

A-1 APPENDIX A

STUDY PROTOCOL AND AMENDMENTS

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

B-1 APPENDIX B

ANALYSES OF BULK TEST SUBSTANCE

B-1 Interim Sponsor Gasoline MTBE Vapor Condensate Characterization

(Gas Chromatographic Profile)

B-2 Gasoline MTBE Vapor Condensate Anal ysis at LRRI (Gas Chromatographic

Profile) of Individual 420-P ound Tanks Used During Study

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

B-1 Interim Sponsor Gasoline MT BE Vapor Condensate Characterization

(Gas Chromatographic Profile)

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

B-2 Gasoline MTBE Vapor Condensate Analysis at LRRI

(Gas Chromatographic Profile) of Indi vidual 420-Pound Tanks Used During Study

# Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A16**

Measured Measured EMBSI

Component A re a A rea % A rea %

Isobutane 2.2

n-Butane 11.1

Isopentane 31.0

n-Pentane 9.1

trans-2-pentene 2.0

2-methyl-2-butene 2.9

MTBE/2,3-dimethylbutane

MTBE 21.3

2,3-dimethylbutane 0.9

2-methylpentane 4.5

3-methylpentane 2.6

n-Hexane 2.1

Methylcyclopentane 1.1

2,4-dimethylpentane 0.9

Benzene 1.5

2-methylhexane 1.0

2,3-dimethylpentane 1.0

3-methylhexane 1.1

Isooctane 1.2

Toluene 2.5

0 0.0 100.00 Date Used: 5-17-01 thru 6-28-01

** Note: This tank was inadvertently not analyzed prior to use.

However, hydrocarbon profiles were obtained during use. These

results are included on the following pages. Animal exposures

began on May 23, 2001, so chamber hydrocarbon

characterization began on that date.

A16_051701Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting5-23-01WeekStarting5-28-01WeekStarting5-23-01WeekStarting5-28-01WeekStarting5-23-01WeekStarting5-28-01Isobutane2.2 2.5 2.2 2.2 2.2 2.1 2.3n-butane11.1 10.2 9.3 10.2 10.5 10.5 10.9Isopentane31.0 26.9 26.6 30.1 30.2 30.7 31.5n-pentane9.1 8.7 8.7 8.9 9.0 8.9 9.1trans-2-pentene2.0 2.9 2.7 2.1 2.2 2.1 2.12-methyl-2-butene 2.9 3.9 3.7 2.9 2.9 2.9 3.1MTBE/2,3-dimethylbutaneMTBE21.3 20.9 20.7 23.0 22.7 22.8 22.92,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 1.0 1.02-methylpentane4.5 4.6 5.2 4.6 4.4 4.4 4.53-methylpentane2.6 2.7 3.1 2.4 2.6 2.6 2.6n-hexane2.1 2.2 2.5 2.1 2.2 2.2 2.0Methylcyclopentane 1.1 2.1 1.5 1.2 1.0 1.2 1.12,4-dimethylpentane 0.9 2.3 0.9 1.1 1.0 0.9 0.9Benzene1.5 1.7 2.5 1.6 1.5 1.5 1.22-methylhexane1.0 1.1 1.2 1.0 1.0 1.1 0.92,3-dimethylpentane 1.0 2.4 1.7 1.2 1.2 1.2 1.13-methylhexane1.1 1.3 2.1 1.3 1.2 1.2 0.9Isooctane1.2 0.7 1.9 1.3 1.4 1.5 1.2Toluene2.5 2.0 2.5 1.8 1.7 1.3 0.8Low (2.0g/m3) Mid (10g/m3) Mid (10g/m3)May 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting6-4-01WeekStarting6-11-01WeekStarting6-18-01WeekStarting6-25-01WeekStarting6-4-01WeekStarting6-11-01WeekStarting6-18-01WeekStarting6-25-01WeekStarting6-4-01WeekStarting6-11-01WeekStarting6-18-01WeekStarting6-25-01Isobutane 2.2 2.6 2.2 2.3 2.2 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1n-butane 11.1 8.8 9.1 9.6 9.8 10.2 10.4 10.5 10.3 10.9 10.7 10.5 10.5Isopentane 31.0 24.9 26.0 26.8 26.2 29.9 30.0 30.2 29.8 31.9 31.1 30.7 30.6n-pentane 9.1 7.7 8.5 7.8 8.6 8.8 8.8 8.9 8.9 9.1 9.1 8.9 8.9trans-2-pentene 2.0 3.8 3.0 3.0 3.0 2.2 2.2 2.1 2.2 2.1 2.2 2.0 2.12-methyl-2-butene 2.9 4.0 4.3 3.7 3.6 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 20.9 21.8 21.0 19.0 22.6 23.4 21.9 22.4 23.0 22.5 22.3 22.32,3-dimethylbutane 0.9 0.9 0.9 0.9 0.8 1.0 1.0 0.9 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.3 4.9 4.3 4.9 4.5 4.4 4.6 4.5 4.4 4.5 4.5 4.43-methylpentane 2.6 2.9 2.9 2.7 2.7 2.5 2.5 2.6 2.7 2.5 2.5 2.6 2.6n-hexane 2.1 2.6 2.3 2.5 3.2 2.1 2.1 2.2 2.1 1.9 2.1 2.2 2.3Methylcyclopentane 1.1 1.8 1.4 1.7 1.7 1.2 1.1 1.2 1.2 1.0 1.1 1.2 1.22,4-dimethylpentane 0.9 2.0 1.5 1.0 0.9 1.0 1.1 1.0 1.0 1.1 1.0 0.9 1.0Benzene 1.5 2.0 2.2 1.8 2.4 2.0 1.8 1.7 2.0 1.1 1.5 1.6 1.72-methylhexane 1.0 2.0 1.0 1.4 1.9 1.0 1.0 1.0 1.1 0.9 1.0 1.0 1.02,3-dimethylpentane 1.0 2.7 2.2 2.2 2.3 1.3 1.2 1.3 1.3 1.0 1.1 1.1 1.13-methylhexane 1.1 1.5 1.8 1.6 1.0 1.1 1.2 1.2 1.1 1.0 1.1 1.2 1.2Isooctane 1.2 1.8 1.9 2.2 1.8 1.4 1.2 1.3 1.4 1.2 1.2 1.3 1.4Toluene 2.5 2.9 2.3 3.6 3.9 2.0 1.6 2.2 2.0 0.6 1.4 2.0 2.0Low (2.0g/m3)Mid (10g/m3)High (20g/m3)June 2001

# Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A20

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 12081 1.8 2.2

n-Butane 62083 9.3 11.1

Isopentane 200525 29.9 31.0

n-Pentane 59754 8.9 9.1

trans-2-pentene 13883 2.1 2.0

2-methyl-2-butene 19538 2.9 2.9

MTBE/2,3-dimethylbutane 163911

MTBE 157273 23.4 21.3

2,3-dimethylbutane 6638 1.0 0.9

2-methylpentane 31116 4.6 4.5

3-methylpentane 17790 2.7 2.6

n-Hexane 15557 2.3 2.1

Methylcyclopentane 7639 1.1 1.1

2,4-dimethylpentane 6766 1.0 0.9

Benzene 11990 1.8 1.5

2-methylhexane 7347 1.1 1.0

2,3-dimethylpentane 8189 1.2 1.0

3-methylhexane 8232 1.2 1.1

Isooctane 9140 1.4 1.2

Toluene 15135 2.3 2.5

670676 100.0 100.00 Date: 6-28-01

A20_062801.xls 

# Study Nu m b er FY0 1

- 013

B- 8

# Study Nu m b er FY0 1 -01 3

B

- 9

# Study Nu m b er FY0 1 -01 3

B

- 1 0

# Study Nu m b er FY0 1 -01 3

B

- 1 1

# Study Nu m b er FY0 1 -01 3

B

- 1 2

# Study Nu m b er FY0 1 -01 3

B

- 1 3

# Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A23

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 24066 1.9 2.2

n-Butane 124208 9.6 11.1

Isopentane 390755 30.3 31.0

n-Pentane 114755 8.9 9.1

trans-2-pentene 26072 2.0 2.0

2-methyl-2-butene 37329 2.9 2.9

MTBE/2,3-dimethylbutane 316483

MTBE 303665 23.6 21.3

2,3-dimethylbutane 12818 1.0 0.9

2-methylpentane 58671 4.6 4.5

3-methylpentane 33731 2.6 2.6

n-Hexane 27840 2.2 2.1

Methylcyclopentane 14535 1.1 1.1

2,4-dimethylpentane 11639 0.9 0.9

Benzene 21799 1.7 1.5

2-methylhexane 13446 1.0 1.0

2,3-dimethylpentane 14314 1.1 1.0

3-methylhexane 15329 1.2 1.1

Isooctane 16033 1.2 1.2

Toluene 27858 2.2 2.5

1288863 100.0 100.00 Date: 7-9-02

A23_02190.xls 

# Study Nu m b er FY0 1 -01 3

B

- 1 4

# Protocol Number FY01-013

Chronic Inhalation of Gasoline MTBE Vapor Condensate

Test Article Characterization

Tank: A12

Measured Measured EMBSI

Component Area Area % Area %

Isobutane 45580 1.8 2.2

n-Butane 239088 9.5 11.1

Isopentane 767122 30.6 31.0

n-Pentane 223541 8.9 9.1

trans-2-pentene 50305 2.0 2.0

2-methyl-2-butene 71894 2.9 2.9

MTBE/2,3-dimethylbutane 606223 24.2

MTBE 581671 23.2 21.3

2,3-dimethylbutane 24552 1.0 0.9

2-methylpentane 115101 4.6 4.5

3-methylpentane 65991 2.6 2.6

n-Hexane 53855 2.1 2.1

Methylcyclopentane 29026 1.2 1.1

2,4-dimethylpentane 24922 1.0 0.9

Benzene 42066 1.7 1.5

2-methylhexane 25308 1.0 1.0

2,3-dimethylpentane 27214 1.1 1.0

3-methylhexane 29182 1.2 1.1

Isooctane 31795 1.3 1.2

Toluene 56890 2.3 2.5

2505103 100.0 100.00 Date: 9/12/02

A12_022253.xls 

# Study Nu m b er FY0 1 -01 3

B

- 1 5

# Study Nu m b er FY0 1 -01 3

B

- 1 6

# Study Nu m b er FY0 1 -01 3

B

- 1 7

# Study Nu m b er FY0 1 -01 3

B

- 1 8

# Study Nu m b er FY0 1 -01 3

B

- 19

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

C-1 APPENDIX C

RESULTS OF PERIODIC SEROLOGICAL EVALUATIONS

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

D-1 APPENDIX D

RESULTS OF FEED AND WATER ANALYSES

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

E-1 APPENDIX E

SUMMARIES OF GMVC ANALYSES IN EXPOSURE CHAMBERS AND

EXPOSURE ROOM AND AEROSOL SCIENTIST’S REPORT

E-1 Three Day Stability Assessment and Nominal GMVC Usage

E-2 Pre-Study Homogeneity Study

E-3 T90 Determination

E-4 Absence of Aerosol Confirmation

E-5 GMVC Daily Exposure Concentrations and Nominal Usage

E-6 Summary of GMVC Room Air Sampling Results

E-7 Aerosol Scientist’s Report

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-1 Three Day Stability Assessment and Nominal GMVC Usage

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-2 Pre-Study Homogeneity Study

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-3 T90 Determination

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-4 Absence of Aerosol Confirmation

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-5 GMVC Daily Exposure Concentrations and Nominal Usage

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated)

5/23/2001 1 2.08 0.08 9.73 0.53 19.17 0.57 4909 4700 96

5/24/2001 2 1.93 0.16 9.14 0.49 17.76 1.50 4534 4390 97

5/25/2001 3 2.02 0.07 9.92 0.53 19.50 0.46 5195 4955 95

5/28/2001 4 1.96 0.03 9.80 0.17 18.73 0.11 5086 4985 98

5/29/2001 5 1.98 0.05 10.19 0.62 19.18 0.60 5246 5045 96

5/30/2001 6 2.03 0.11 9.57 0.19 18.84 0.12 5096 4660 91

5/31/2001 7 1.98 0.15 8.74 0.75 18.28 1.73 4860 4505 93

6/1/2001 8 1.97 0.04 9.56 0.27 18.89 0.38 5171 4780 92

6/4/2001 9 2.05 0.08 9.27 0.45 19.12 0.48 5155 4720 92

6/5/2001 10 1.94 0.04 9.34 0.39 19.48 0.21 5171 4865 94

6/6/2001 11 1.93 0.10 9.62 0.11 21.02 0.33 5564 5355 96

6/7/2001 12 1.88 0.06 9.93 0.39 20.65 0.63 5427 5220 96

6/8/2001 13 1.92 0.04 9.76 0.39 20.14 1.25 5310 5055 95

6/11/2001 14 2.00 0.08 9.73 0.24 20.35 0.53 5581 5360 96

6/12/2001 15 1.94 0.03 9.52 0.08 20.16 0.55 5450 5265 97

6/13/2001 16 1.98 0.04 9.46 0.07 19.47 0.85 5330 5110 96

6/14/2001 17 2.01 0.06 10.13 0.52 19.87 0.82 5529 5280 95

6/15/2001 18 1.98 0.06 9.66 0.16 20.29 0.47 5499 5225 95

6/18/2001 19 2.01 0.08 9.60 0.33 19.96 0.93 5450 5145 94

6/19/2001 20 2.00 0.07 9.62 0.11 20.51 0.48 5409 5085 94

6/20/2001 21 2.05 0.05 10.15 0.49 20.48 1.27 5506 5170 94

6/21/2001 22 2.02 0.02 9.70 0.31 21.02 0.62 5484 5105 93

6/22/2001 23 2.08 0.06 10.00 0.19 21.31 0.42 5579 4970 89

6/25/2001 24 2.04 0.06 9.99 0.11 20.44 0.42 5411 5195 96

6/26/2001 25 2.06 0.10 10.27 0.07 20.41 0.36 5498 5280 96

6/27/2001 26 2.08 0.09 10.09 0.20 20.67 0.25 5456 5135 94

6/28/2001 27 2.11 0.06 10.33 0.09 20.67 0.42 5521 5160 93

6/29/2001 28 2.12 0.06 10.21 0.04 20.61 0.15 5511 5120 93

7/2/2001 29 2.10 0.11 10.21 0.58 19.27 0.62 5270 4885 93

7/3/2001 30 1.98 0.09 10.10 0.16 20.60 0.34 5460 5040 92

7/4/2001 ** Holiday Holiday Holiday Holiday

7/5/2001 31 2.04 0.08 9.66 0.48 20.27 0.33 5600 5170 92

7/6/2001 32 2.08 0.06 10.37 0.13 20.53 0.33 6027 5610 93

7/9/2001 33 2.26 0.08 10.09 0.06 21.84 0.17 5778 5395 93

7/10/2001 34 1.94 0.12 10.17 0.10 20.85 0.27 5556 5185 93

7/11/2001 35 2.03 0.08 10.02 0.54 19.67 0.27 5449 5160 95

7/12/2001 36 2.07 0.07 10.11 0.40 20.66 0.95 5438 5165 95

7/13/2001 37 1.99 0.11 10.60 0.14 20.45 0.39 5519 5200 94

7/16/2001 38 1.99 0.09 10.10 0.47 20.25 0.64 5438 5135 94

7/17/2001 39 1.99 0.02 9.56 0.13 19.85 0.19 5268 5040 96

7/18/2001 40 1.96 0.08 10.21 0.22 20.62 0.42 5498 5190 94

7/19/2001 41 1.86 0.13 10.00 0.42 19.75 0.98 5332 5160 97

7/20/2001 42 2.11 0.06 10.14 0.22 20.77 0.51 5614 5390 96

7/23/2001 43 1.98 0.09 10.16 0.27 19.56 0.50 5247 5035 96

7/24/2001 44 1.97 0.03 10.70 0.04 21.49 0.39 5756 5450 95

7/25/2001 45 2.01 0.08 10.39 0.31 20.08 0.45 5406 5350 99

7/26/2001 46 2.01 0.14 10.14 0.16 19.43 0.87 5254 4945 94

7/27/2001 47 2.11 0.08 10.58 0.07 20.32 0.10 5481 5385 98

7/30/2001 48 1.86 0.03 10.43 0.15 20.70 0.30 5662 5675 100

7/31/2001 49 1.98 0.14 9.93 0.09 19.71 0.57 5225 5180 99

8/1/2001 50 1.99 0.07 10.25 0.35 19.67 0.80 5250 5100 97

8/2/2001 51 1.97 0.07 10.00 0.22 19.28 0.40 5416 5235 97

8/3/2001 52 2.01 0.04 9.83 0.25 20.73 0.35 5422 5280 97

8/6/2001 53 2.03 0.03 10.68 0.13 20.36 0.72 5521 5365 97

8/7/2001 54 2.04 0.07 9.67 0.38 20.92 0.27 5226 5095 97

8/8/2001 55 1.96 0.04 9.73 0.41 19.70 0.63 5046 4840 96

8/9/2001 56 1.99 0.10 10.40 0.45 21.03 0.36 5371 5175 96

8/10/2001 57 2.05 0.07 10.47 0.06 20.32 0.32 5473 5275 96

8/13/2001 58 2.01 0.02 10.18 0.15 20.76 0.15 5491 5185 94

8/14/2001 59 2.00 0.09 9.99 0.46 18.71 0.30 5083 4805 95

8/15/2001 60 1.99 0.04 9.56 0.27 20.33 0.23 5291 5075 96

8/16/2001 61 1.96 0.10 10.04 0.44 20.19 0.38 5392 5130 95

8/17/2001 62 1.96 0.03 9.85 0.38 19.37 0.72 5197 4990 96

8/20/2001 63 2.05 0.03 10.02 0.56 19.61 0.46 5184 5085 98

8/21/2001 64 1.94 0.03 9.66 0.13 20.34 0.25 5314 5175 97

8/22/2001 65 1.94 0.06 9.86 0.33 20.01 0.38 5548 5375 97

8/23/2001 66 2.13 0.03 10.45 0.12 19.17 0.12 5513 5285 96

Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

8/24/2001 67 2.09 0.06 10.18 0.03 19.03 0.31 5728 5480 96

8/27/2001 68 2.00 0.02 9.97 0.08 20.26 0.35 5345 5195 97

8/28/2001 69 1.99 0.06 9.54 0.06 19.92 0.31 5159 5020 97

8/29/2001 70 2.11 0.03 9.87 0.15 20.97 0.08 5437 5235 96

8/30/2001 71 1.96 0.03 9.93 0.29 20.26 0.40 5346 5130 96

8/31/2001 72 2.04 0.03 9.73 0.17 19.21 0.34 5118 5005 98

9/3/2001 73 2.08 0.10 9.35 0.16 20.87 0.03 5702 5550 97

9/4/2001 74 2.14 0.05 9.80 0.25 19.45 0.33 5322 5140 97

9/5/2001 75 1.92 0.05 9.47 0.40 19.84 0.40 5381 5210 97

9/6/2001 76 1.99 0.05 9.73 0.21 20.09 0.62 5350 5180 97

9/7/2001 77 1.96 0.04 9.27 0.08 18.98 0.60 5618 5255 94

9/10/2001 78 1.97 0.03 9.64 0.11 19.58 0.20 5452 5195 95

9/11/2001 79 1.99 0.11 9.75 0.14 19.33 0.37 5440 5160 95

9/12/2001 80 1.95 0.06 9.79 0.77 19.29 0.34 5472 5290 97

9/13/2001 81 1.89 0.05 9.98 0.62 19.65 0.27 5563 5375 97

9/14/2001 82 1.88 0.02 9.63 0.26 19.03 0.37 5306 5150 97

9/17/2001 83 2.18 0.03 9.98 0.04 19.81 0.11 5809 5625 97

9/18/2001 84 2.04 0.11 9.25 0.04 18.71 0.30 5444 5330 98

9/19/2001 85 1.94 0.03 10.36 0.27 20.90 0.09 6045 5860 97

9/20/2001 86 2.04 0.05 10.11 0.22 20.03 0.20 5830 5625 96

9/21/2001 87 2.00 0.11 10.03 0.33 20.11 0.25 5927 5700 96

9/24/2001 88 1.91 0.03 9.45 0.16 20.35 0.08 5332 5475 103

9/25/2001 89 2.04 0.13 10.02 0.16 20.44 0.14 5700 5505 97

9/26/2001 90 2.04 0.07 10.04 0.17 20.76 0.35 5775 5610 97

9/27/2001 91 2.03 0.08 10.49 0.50 20.49 0.57 5776 5670 98

9/28/2001 92 2.12 0.06 10.67 0.41 20.76 0.71 6074 5920 97

10/1/2001 93 2.12 0.06 10.69 0.22 21.45 0.05 6015 5945 99

10/2/2001 94 2.16 0.06 10.74 0.04 21.61 0.04 6055 6025 100

10/3/2001 95 2.04 0.02 10.82 0.30 21.09 0.09 5969 5825 98

10/4/2001 96 1.99 0.01 10.56 0.10 21.65 0.19 6114 6025 99

10/5/2001 97 1.99 0.10 10.02 0.22 18.99 0.24 5584 5595 100

10/8/2001 98 2.18 0.03 10.82 0.03 21.36 0.10 6218 5850 94

10/9/2001 99 2.00 0.02 10.68 0.11 20.58 0.60 6015 5700 95

10/10/2001 100 2.06 0.02 9.95 0.18 21.06 0.12 6029 5655 94

10/11/2001 101 1.97 0.06 10.13 0.23 20.08 0.23 5909 5555 94

10/12/2001 102 1.94 0.08 9.58 0.31 19.31 0.47 5595 5315 95

10/15/2001 103 1.99 0.07 10.16 0.17 19.91 0.12 5545 5520 100

10/16/2001 104 2.05 0.01 9.84 0.21 20.12 0.30 5423 5435 100

10/17/2001 105 2.00 0.08 9.95 0.67 20.03 0.80 5402 5130 95

10/18/2001 106 1.96 0.10 10.14 0.53 19.77 0.71 5366 5055 94

10/19/2001 107 1.95 0.07 10.40 0.40 19.98 0.42 5553 5220 94

10/22/2001 108 2.01 0.04 10.35 0.13 19.82 0.32 5500 5220 95

10/23/2001 109 2.05 0.15 9.70 0.64 19.93 0.71 5404 5270 98

10/24/2001 110 2.03 0.09 10.32 0.14 20.94 0.03 5754 5510 96

10/25/2001 111 2.03 0.04 10.63 0.08 21.31 0.22 5805 5520 95

10/26/2001 112 2.08 0.01 10.72 0.01 20.31 0.05 5732 5330 93

10/29/2001 113 1.95 0.02 10.80 0.18 20.71 0.03 5880 5375 91

10/30/2001 114 1.92 0.02 9.99 0.42 20.19 0.41 5610 5155 92

10/31/2001 115 1.99 0.07 9.88 0.51 18.75 0.43 5333 4900 92

11/1/2001 116 1.91 0.12 9.98 0.26 20.51 0.43 5708 5250 92

11/2/2001 117 1.91 0.02 10.44 0.37 20.67 0.02 5731 5400 94

11/5/2001 118 2.01 0.07 10.01 0.60 21.48 0.26 5953 5340 90

11/6/2001 119 2.02 0.06 9.96 0.69 19.38 0.83 5545 4940 89

11/7/2001 120 2.10 0.09 10.39 0.06 20.87 0.11 5908 5290 90

11/8/2001 121 2.05 0.06 10.72 0.22 21.30 0.37 5973 5365 90

11/9/2001 122 2.04 0.09 10.17 0.06 21.25 0.34 6046 5495 91

11/12/2001 123 2.04 0.11 9.89 0.08 20.44 0.20 5642 5595 99

11/13/2001 124 2.12 0.11 9.65 0.38 20.76 0.25 5639 5665 100

11/14/2001 125 1.96 0.09 9.43 0.08 19.34 0.03 5325 5330 100

11/15/2001 126 2.14 0.03 10.05 0.65 21.20 0.34 5813 5725 98

11/16/2001 127 2.13 0.02 10.60 0.33 20.29 0.17 5599 5410 97

11/19/2001 128 1.96 0.13 9.86 0.23 19.44 0.35 5482 5410 99

11/20/2001 129 1.88 0.04 10.86 0.27 18.73 0.78 5397 5595 104

11/21/2001 130 2.05 0.03 10.25 0.37 18.28 0.25 5257 5470 104

11/22/2001 ** Holiday Holiday Holiday Holiday

11/23/2001 131 2.03 0.04 10.54 0.13 20.18 0.60 5766 5875 102

11/26/2001 132 2.13 0.09 10.54 0.62 19.38 0.11 5479 5210 95

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

11/27/2001 133 2.11 0.04 10.16 0.39 20.13 0.48 5561 5240 94

11/28/2001 134* N/A* N/A* N/A* N/A* N/A* N/A* N/A* N/A* N/A*

11/29/2001 135 1.89 0.09 10.94 0.10 19.23 0.12 5453 5165 95

11/30/2001 136 2.00 0.08 10.02 0.23 19.55 0.69 5348 5275 99

12/3/2001 137 1.96 0.04 10.65 0.22 21.67 0.36 5849 5310 91

12/4/2001 138 1.95 0.06 10.08 0.36 20.63 0.55 5589 5080 91

12/5/2001 139 1.92 0.06 10.77 0.29 19.95 0.01 5635 5080 90

12/6/2001 140 2.00 0.04 9.73 0.32 21.27 0.10 5711 5215 91

12/7/2001 141 1.98 0.03 10.26 0.07 21.90 0.02 5926 5575 94

12/10/2001 142 2.07 0.05 10.02 0.42 20.42 0.75 5478 5760 105

12/11/2001 143 2.11 0.04 9.82 0.38 19.70 0.28 5353 5505 103

12/12/2001 144 1.97 0.10 10.34 0.47 20.80 0.11 5614 5610 100

12/13/2001 145 2.00 0.09 10.41 0.15 21.36 0.19 5818 5890 101

12/14/2001 146 2.02 0.02 10.75 0.05 21.47 0.08 5769 5650 98

12/17/2001 147 2.08 0.02 10.72 0.06 21.24 0.20 5817 5830 100

12/18/2001 148 2.05 0.13 9.79 0.05 21.59 0.22 5714 5760 101

12/19/2001 149 2.00 0.12 9.99 0.39 20.07 0.99 5500 5640 103

12/20/2001 150 1.94 0.06 9.86 0.16 19.82 0.32 5391 5850 109

12/21/2001 151 1.99 0.10 10.13 0.34 19.68 0.49 5373 5540 103

12/24/2001 152 1.90 0.07 9.92 0.01 20.67 0.46 5452 5390 99

12/25/2001 ** Holiday Holiday Holiday Holiday

12/26/2001 153 1.98 0.04 10.02 0.24 20.78 0.25 5507 5365 97

12/27/2001 154 1.96 0.06 10.69 0.14 21.66 0.27 5727 5560 97

12/28/2001 155 2.05 0.05 10.35 0.36 21.17 0.12 5625 5500 98

12/31/2001 156 2.03 0.12 10.48 0.16 21.74 0.07 5735 5710 100

1/1/2002 ** Holiday Holiday Holiday Holiday

1/2/2002 157 2.01 0.02 9.92 0.05 21.45 0.25 5635 5520 98

1/3/2002 158 1.95 0.04 10.44 0.11 21.34 0.25 5662 5475 97

1/4/2002 159 2.11 0.06 10.47 0.11 21.63 0.11 5664 5630 99

1/7/2002 160 2.04 0.03 10.78 0.03 21.43 0.05 5761 5650 98

1/8/2002 161 2.01 0.03 10.67 0.04 21.76 0.15 5754 5505 96

1/9/2002 162 2.02 0.08 10.75 0.13 21.48 0.28 5639 5425 96

1/10/2002 163 2.04 0.05 10.40 0.51 20.55 0.33 5393 5375 100

1/11/2002 164 1.93 0.01 10.84 0.06 21.04 0.03 5538 5250 95

1/14/2002 165 1.99 0.02 10.85 0.18 21.77 0.16 5692 5275 93

1/15/2002 166 1.90 0.07 10.12 0.68 21.35 0.58 5434 5240 96

1/16/2002 167 2.15 0.06 10.64 0.12 21.05 0.54 5526 5320 96

1/17/2002 168 1.99 0.07 10.93 0.19 19.55 0.24 5599 4970 89

1/18/2002 169 1.99 0.06 10.46 0.01 21.18 0.23 5785 5720 99

1/21/2002 170 2.10 0.07 10.11 0.02 20.96 0.07 5721 5825 102

1/22/2002 171 2.14 0.01 10.38 0.19 21.68 0.17 5875 5975 102

1/23/2002 172 1.99 0.01 9.37 0.04 20.55 0.05 5471 5600 102

1/24/2002 173 2.01 0.01 10.05 0.13 20.55 0.20 5320 5390 101

1/25/2002 174 2.06 0.03 10.43 0.03 21.43 0.12 5606 5690 101

1/28/2002 175 1.93 0.05 9.77 0.18 21.50 0.23 5460 5585 102

1/29/2002 176 2.07 0.01 10.38 0.05 20.10 0.08 5356 5385 101

1/30/2002 177 2.09 0.01 10.30 0.01 21.25 0.03 5540 5635 102

1/31/2002 178 2.00 0.01 10.35 0.06 21.50 0.35 5749 5815 101

2/1/2002 179 2.12 0.06 10.21 0.05 21.04 0.13 5340 5390 101

2/4/2002 180 2.07 0.03 10.07 0.07 21.01 0.09 5493 5645 103

2/5/2002 181 2.13 0.08 10.03 0.24 21.59 0.41 5496 5595 102

2/6/2002 182 1.86 0.03 9.27 0.20 19.92 1.47 5160 5335 103

2/7/2002 183 2.03 0.06 9.81 0.09 19.12 0.11 5533 5665 102

2/8/2002 184 2.09 0.06 9.39 0.10 19.00 0.09 5369 5585 104

2/11/2002 185 2.01 0.01 9.96 0.08 21.73 0.01 5672 5750 101

2/12/2002 186 2.05 0.09 9.91 0.39 20.63 0.23 5666 5775 102

2/13/2002 187 2.12 0.04 9.31 0.09 20.45 0.49 5571 5930 106

2/14/2002 188 1.94 0.06 9.27 0.07 19.85 0.19 5424 5640 104

2/15/2002 189 1.94 0.03 9.36 0.02 20.97 0.03 5667 5770 102

2/18/2002 190 2.07 0.07 9.76 0.17 20.64 0.33 5667 5750 101

2/19/2002 191 2.07 0.08 9.94 0.23 20.55 0.32 5650 5650 100

2/20/2002 192 2.00 0.01 10.65 0.11 21.26 0.33 5875 5910 101

2/21/2002 193 2.05 0.08 10.51 0.11 20.96 0.16 5857 5855 100

2/22/2002 194 2.05 0.04 9.93 0.04 21.05 0.20 5763 5660 98

2/25/2002 195 2.12 0.06 10.12 0.27 21.70 0.05 5747 5610 98

2/26/2002 196 2.00 0.13 10.35 0.41 20.98 0.47 5673 5540 98

2/27/2002 197 1.95 0.02 10.00 0.08 20.93 0.17 5720 5685 99

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

2/28/2002 198 2.16 0.01 10.48 0.04 19.34 0.03 5484 5495 100

3/1/2002 199 2.03 0.11 10.42 0.07 20.51 0.22 5173 5255 102

3/4/2002 200 2.06 0.03 9.74 0.18 21.02 0.03 5244 5275 101

3/5/2002 201 2.12 0.06 10.13 0.07 21.12 0.02 5312 5330 100

3/6/2002 202 2.08 0.07 9.54 0.05 20.44 0.47 5079 5165 102

3/7/2002 203 2.07 0.02 9.99 0.05 20.82 0.41 5177 5195 100

3/8/2002 204 2.06 0.06 10.38 0.03 21.22 0.30 5237 5280 101

3/11/2002 205 1.95 0.02 10.24 0.31 19.46 0.09 5169 5505 107

3/12/2002 206 1.97 0.03 10.35 0.04 19.60 0.27 5215 5505 106

3/13/2002 207 2.07 0.06 10.24 0.08 19.47 0.18 5170 5610 109

3/14/2002 208 1.92 0.06 10.67 0.08 19.85 0.34 5299 5655 107

3/15/2002 209 2.10 0.05 10.88 0.12 18.78 0.16 5230 5775 110

3/18/2002 210 1.91 0.02 10.06 0.29 20.79 0.08 5152 5235 102

3/19/2002 211 2.12 0.08 10.40 0.24 20.97 0.28 5267 5345 101

3/20/2002 212 2.14 0.01 10.30 0.03 21.36 0.23 5308 5360 101

3/21/2002 213 1.86 0.02 10.05 0.18 20.58 0.36 5122 5130 100

3/22/2002 214 2.10 0.06 10.27 0.05 21.52 0.09 5313 5365 101

3/25/2002 215 1.98 0.04 10.37 0.08 21.35 0.03 5281 5450 103

3/26/2002 216 2.04 0.02 9.43 0.12 20.04 0.22 5092 5310 104

3/27/2002 217 2.08 0.08 9.87 0.11 20.84 0.06 5316 5540 104

3/28/2002 218 2.04 0.10 9.61 0.11 20.16 0.04 5193 5410 104

3/29/2002 219 2.03 0.05 10.11 0.03 18.86 0.10 5110 5345 105

4/1/2002 220 1.88 0.01 10.18 0.07 19.55 0.11 5265 5320 101

4/2/2002 221 1.96 0.10 10.76 0.04 20.72 0.12 5555 5750 104

4/3/2002 222 1.96 0.03 10.36 0.05 20.30 0.07 5454 5570 102

4/4/2002 223 1.94 0.02 9.84 0.20 19.47 0.13 5214 5360 103

4/5/2002 224 2.06 0.04 9.84 0.06 20.07 0.14 5354 5485 102

4/8/2002 225 2.07 0.01 10.28 0.03 20.51 0.03 5490 5575 102

4/9/2002 226 1.90 0.03 9.39 0.02 20.40 0.15 5283 5390 102

4/10/2002 227 2.06 0.03 9.65 0.11 21.51 0.03 5542 5680 102

4/11/2002 228 1.99 0.04 9.34 0.08 20.77 0.06 5440 5460 100

4/12/2002 229 2.09 0.02 10.07 0.03 20.19 0.05 5437 5440 100

4/15/2002 230 2.08 0.01 9.94 0.23 20.96 0.16 5516 5580 101

4/16/2002 231 2.10 0.02 10.02 0.04 21.67 0.08 5331 5370 101

4/17/2002 232 1.98 0.05 9.82 0.02 20.84 0.13 5145 5220 101

4/18/2002 233 2.00 0.03 10.01 0.07 21.00 0.08 5192 5275 102

4/19/2002 234 2.08 0.08 10.52 0.38 20.78 0.14 5251 5325 101

4/22/2002 235 1.96 0.02 9.70 0.10 20.85 0.10 5402 5525 102

4/23/2002 236 1.97 0.02 9.89 0.05 20.02 0.02 5292 5330 101

4/24/2002 237 2.10 0.08 10.42 0.28 20.62 0.05 5484 5540 101

4/25/2002 238 2.11 0.02 10.17 0.09 20.35 0.21 5401 5495 102

4/26/2002 239 2.08 0.06 9.88 0.07 20.67 0.15 5446 5470 100

4/29/2002 240 2.14 0.10 9.58 0.14 20.53 0.03 5483 5475 100

4/30/2002 241 2.08 0.03 9.85 0.11 21.07 0.12 5641 5640 100

5/1/2002 242 2.03 0.08 10.41 0.13 21.07 0.06 5672 5535 98

5/2/2002 243 1.91 0.04 9.98 0.03 20.18 0.08 5440 5335 98

5/3/2002 244 1.95 0.05 9.89 0.16 19.97 0.34 5197 5300 102

5/6/2002 245 1.99 0.04 9.74 0.01 21.15 0.03 5488 5630 103

5/7/2002 246 1.99 0.03 10.15 0.10 20.41 0.01 5473 5510 101

5/8/2002 247 1.90 0.01 9.79 0.02 21.20 0.19 5493 5600 102

5/9/2002 248 2.10 0.04 10.00 0.04 20.66 0.03 5477 5545 101

5/10/2002 249 1.95 0.07 9.41 0.33 20.22 0.37 5255 5360 102

5/13/2002 250 2.04 0.06 9.26 0.07 21.04 0.11 5409 5440 101

5/14/2002 251 2.09 0.04 9.87 0.01 20.89 0.02 5486 5525 101

5/15/2002 252 1.97 0.06 9.44 0.07 20.08 0.44 5241 5130 98

5/16/2002 253 2.13 0.04 9.92 0.03 20.82 0.04 5559 5415 97

5/17/2002 254 2.04 0.05 9.69 0.10 20.95 0.35 5478 5295 97

5/20/2002 255 2.03 0.02 9.74 0.03 21.05 0.10 5513 5330 97

5/21/2002 256 1.98 0.03 10.06 0.12 20.73 0.64 5477 5455 100

5/22/2002 257 2.17 0.00 9.78 0.13 20.77 0.08 5513 5270 96

5/23/2002 258 2.09 0.03 10.32 0.09 21.39 0.07 5680 5495 97

5/24/2002 259 1.94 0.05 9.58 0.21 20.89 0.25 5467 5345 98

5/27/2002 260 2.08 0.02 10.32 0.03 21.25 0.10 5707 5495 96

5/28/2002 261 1.91 0.05 10.29 0.03 21.84 0.08 5782 5615 97

5/29/2002 262 1.99 0.14 9.65 0.26 19.87 0.15 5381 5132 95

5/30/2002 263 2.02 0.10 9.42 0.46 20.13 0.35 5394 5250 97

5/31/2002 264 2.02 0.03 10.12 0.14 21.63 0.04 5679 5415 95

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

6/3/2002 265 1.97 0.03 9.90 0.07 20.86 0.19 5575 5335 96

6/4/2002 266 1.90 0.08 9.34 0.07 20.71 0.03 5502 5280 96

6/5/2002 267 1.91 0.03 10.11 0.06 21.45 0.09 5640 5320 94

6/6/2002 268 1.92 0.02 10.08 0.09 20.57 0.34 5380 5130 95

6/7/2002 269 2.02 0.05 9.55 0.01 21.06 0.11 5310 5050 95

6/10/2002 270 2.03 0.05 10.14 0.05 21.42 0.01 5454 5285 97

6/11/2002 271 2.06 0.05 10.10 0.06 20.82 0.03 5372 5370 100

6/12/2002 272 1.92 0.03 9.83 0.11 20.77 0.29 5274 5205 99

6/13/2002 273 2.01 0.09 9.47 0.05 20.47 0.11 5276 5205 99

6/14/2002 274 2.04 0.01 9.55 0.06 20.39 0.08 5316 5245 99

6/17/2002 275 2.01 0.03 10.26 0.09 20.85 0.05 5504 5460 99

6/18/2002 276 2.10 0.01 9.81 0.24 20.15 0.04 5357 5390 101

6/19/2002 277 2.08 0.03 9.85 0.04 19.92 0.05 5361 5250 98

6/20/2002 278 2.16 0.01 9.61 0.03 20.17 0.09 5302 5160 97

6/21/2002 279 2.11 0.01 9.91 0.05 21.23 0.10 5404 5310 98

6/24/2002 280 1.94 0.05 10.04 0.08 20.68 0.18 5472 5385 98

6/25/2002 281 2.03 0.02 10.55 0.04 20.76 0.09 5533 5480 99

6/26/2002 282 1.98 0.06 9.84 0.07 19.73 0.18 5322 5335 100

6/27/2002 283 2.17 0.01 9.45 0.06 20.08 0.19 5332 5305 99

6/28/2002 284 2.14 0.03 9.92 0.17 20.35 0.24 5413 5450 101

7/1/2002 285 1.99 0.04 9.80 0.12 21.20 0.23 5409 5405 100

7/2/2002 286 2.12 0.05 10.02 0.09 21.43 0.17 5489 5415 99

7/3/2002 287 1.90 0.01 9.99 0.04 20.61 0.05 5368 5290 99

7/4/2002 ** Holiday Holiday Holiday Holiday

7/5/2002 288 2.05 0.02 9.84 0.14 20.69 0.18 5443 5360 98

7/8/2002 289 2.06 0.02 9.47 0.07 21.01 0.15 5375 5280 98

7/9/2002 290 2.09 0.08 9.89 0.18 20.54 0.27 5425 5295 98

7/10/2002 291 2.01 0.05 9.98 0.15 21.40 0.21 5496 5420 99

7/11/2002 292 2.06 0.03 10.51 0.05 21.19 0.24 5545 5470 99

7/12/2002 293 2.09 0.02 10.01 0.07 21.08 0.04 5403 5380 100

7/15/2002 294 2.11 0.03 10.16 0.08 20.52 0.34 5425 5315 98

7/16/2002 295 2.04 0.13 9.81 0.03 20.77 0.09 5385 5275 98

7/17/2002 296 1.86 0.04 9.74 0.02 20.62 0.11 5287 5230 99

7/18/2002 297 2.03 0.15 9.54 0.26 19.88 0.92 5188 5025 97

7/19/2002 298 2.00 0.09 9.74 0.04 20.32 0.41 5312 5125 96

7/22/2002 299 1.96 0.13 10.23 0.11 19.82 0.08 5259 5005 95

7/23/2002 300 2.10 0.06 10.48 0.25 20.95 0.35 5496 5225 95

7/24/2002 301 2.01 0.05 10.78 0.15 21.71 0.15 5655 5355 95

7/25/2002 302 1.94 0.02 10.79 0.03 21.03 0.23 5496 5230 95

7/26/2002 303 1.86 0.06 10.52 0.13 20.09 0.52 5220 5035 96

7/29/2002 304 2.02 0.05 10.57 0.07 19.64 0.31 5343 5285 99

7/30/2002 305 2.10 0.04 10.55 0.06 18.83 0.08 5241 5210 99

7/31/2002 306 1.98 0.01 9.69 0.28 19.90 0.06 5233 5160 99

8/1/2002 307 1.99 0.04 9.96 0.14 20.59 0.25 5339 5235 98

8/2/2002 308 2.01 0.02 9.46 0.42 20.07 0.10 5332 5235 98

8/5/2002 309 1.94 0.04 9.50 0.08 20.50 0.09 5108 4890 96

8/6/2002 310 2.00 0.09 10.08 0.09 21.09 0.13 5346 5165 97

8/7/2002 311 1.94 0.05 9.91 0.31 19.81 0.54 5070 4895 97

8/8/2002 312 1.94 0.03 9.56 0.07 21.65 0.07 5309 5100 96

8/9/2002 313 2.15 0.02 10.23 0.08 21.24 0.08 5317 5090 96

8/12/2002 314 2.07 0.03 9.69 0.02 18.53 0.25 5236 5620 107

8/13/2002 315 1.96 0.07 10.12 0.21 20.87 0.23 5484 5315 97

8/14/2002 316 2.11 0.09 9.78 0.10 19.28 0.72 5143 5620 109

8/15/2002 317 2.09 0.05 10.43 0.36 21.10 0.55 5609 5525 99

8/16/2002 318 2.04 0.04 9.51 0.45 20.70 0.41 5285 5095 96

8/19/2002 319 1.95 0.04 10.44 0.10 21.05 0.05 5281 4930 93

8/20/2002 320 2.02 0.06 9.88 0.04 21.55 0.06 5254 4960 94

8/21/2002 321 1.99 0.06 10.51 0.13 20.57 0.16 5218 4940 95

8/22/2002 322 2.10 0.04 10.50 0.05 21.17 0.35 5357 5040 94

8/23/2002 323 2.01 0.05 10.32 0.04 21.02 0.04 5280 5020 95

8/26/2002 324 1.92 0.01 10.26 0.04 21.14 0.08 5377 5020 93

8/27/2002 325 2.09 0.04 9.92 0.15 21.05 0.27 5339 5140 96

8/28/2002 326 2.07 0.04 10.56 0.06 21.20 0.04 5464 5110 94

8/29/2002 327 2.13 0.03 10.10 0.08 20.49 0.07 5290 4990 94

8/30/2002 328 2.01 0.01 10.62 0.03 21.18 0.09 5524 5170 94

9/2/2002 329 1.95 0.07 10.03 0.37 20.49 0.64 5037 4850 96

9/3/2002 330 2.07 0.03 10.21 0.14 19.20 0.12 5018 4915 98

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

9/4/2002 331 2.00 0.01 9.44 0.09 20.54 0.03 5065 5215 103

9/5/2002 332 1.98 0.02 9.69 0.05 19.41 0.08 5007 5080 101

9/6/2002 333 2.03 0.03 10.24 0.04 21.28 0.38 5388 5135 95

9/9/2002 334 1.94 0.02 10.56 0.02 20.72 0.11 5377 5245 98

9/10/2002 335 1.99 0.01 9.96 0.08 21.38 0.17 5397 4990 92

9/11/2002 336 1.87 0.08 10.40 0.01 21.27 0.26 5438 5145 95

9/12/2002 337 2.00 0.03 10.08 0.04 19.89 0.20 5176 4835 93

9/13/2002 338 2.12 0.05 10.00 0.06 21.53 0.12 5462 5115 94

9/16/2002 339 1.96 0.02 10.15 0.03 21.28 0.03 5428 5160 95

9/17/2002 340 2.07 0.12 9.34 0.07 20.08 1.01 5242 4985 95

9/18/2002 341 2.07 0.02 9.83 0.13 19.26 0.12 5491 5290 96

9/19/2002 342 1.93 0.02 9.43 0.03 19.32 0.12 5328 5285 99

9/20/2002 343 1.96 0.07 9.78 0.02 19.44 0.06 5310 5260 99

9/23/2002 344 1.91 0.01 9.33 0.02 20.15 0.21 5466 5280 97

9/24/2002 345 1.90 0.02 9.70 0.16 19.63 0.05 5426 5230 96

9/25/2002 346 2.03 0.09 9.61 0.14 19.92 0.08 5505 5250 95

9/26/2002 347 2.01 0.05 9.92 0.04 19.43 0.18 5472 5305 97

9/27/2002 348 2.09 0.07 9.72 0.06 19.56 0.55 5516 5375 97

9/30/2002 349 2.02 0.01 9.43 0.03 20.09 0.05 5398 5330 99

10/1/2002 350 1.89 0.03 10.09 0.05 19.61 0.24 5410 5410 100

10/2/2002 351 1.94 0.03 9.98 0.02 20.09 0.02 5487 5420 99

10/3/2002 352 1.94 0.02 9.96 0.03 20.16 0.03 5505 5445 99

10/4/2002 353 2.03 0.01 9.87 0.12 19.72 0.22 5394 5280 98

10/7/2002 354 2.11 0.03 9.74 0.07 19.68 0.06 5405 5285 98

10/8/2002 355 2.10 0.05 10.27 0.10 19.53 0.11 5450 5400 99

10/9/2002 356 2.16 0.02 10.02 0.01 19.86 0.16 5463 5375 98

10/10/2002 357 2.10 0.02 9.73 0.07 18.65 0.19 5146 5140 100

10/11/2002 358 1.90 0.01 9.31 0.05 18.44 0.12 5015 5075 101

10/14/2002 359 2.12 0.04 10.15 0.05 19.58 0.14 5430 5370 99

10/15/2002 360 1.98 0.02 10.18 0.07 19.45 0.04 5429 5415 100

10/16/2002 361 2.03 0.04 9.54 0.31 19.15 0.05 5285 5220 99

10/17/2002 362 2.02 0.02 9.81 0.06 19.96 0.16 5513 5605 102

10/18/2002 363 2.05 0.02 9.53 0.17 20.09 0.09 5419 5455 101

10/21/2002 364 1.99 0.03 9.56 0.04 20.06 0.08 5430 5480 101

10/22/2002 365 1.99 0.09 9.99 0.15 19.69 0.48 5432 5505 101

10/23/2002 366 1.96 0.03 10.13 0.04 20.07 0.16 5487 5550 101

10/24/2002 367 2.16 0.02 10.47 0.04 18.95 0.08 5391 5420 101

10/25/2002 368 2.06 0.03 9.45 0.02 19.62 0.08 5317 5465 103

10/28/2002 369 1.93 0.01 9.93 0.04 19.98 0.03 5449 5670 104

10/29/2002 370 2.07 0.02 9.99 0.06 19.87 0.03 5464 5665 104

10/30/2002 371 2.06 0.07 10.29 0.12 19.77 0.08 5492 5320 97

10/31/2002 372 2.07 0.01 9.88 0.10 20.29 0.05 5503 5670 103

11/1/2002 373 1.99 0.01 9.83 0.14 19.53 0.06 5312 5330 100

11/4/2002 374 2.05 0.01 10.33 0.08 19.74 0.13 5469 5580 102

11/5/2002 375 2.02 0.01 9.78 0.08 19.74 0.07 5355 5480 102

11/6/2002 376 1.98 0.02 9.84 0.03 20.04 0.10 5415 5550 102

11/7/2002 377 1.97 0.03 10.09 0.04 20.11 0.05 5456 5595 103

11/8/2002 378 1.90 0.02 10.23 0.03 19.89 0.05 5429 5725 105

11/11/2002 379 1.95 0.01 9.58 0.02 21.03 0.06 5365 5595 104

11/12/2002 380 2.16 0.01 10.30 0.11 20.23 0.10 5443 5600 103

11/13/2002 381 2.08 0.01 9.45 0.04 21.16 0.04 5364 5565 104

11/14/2002 382 1.96 0.02 10.43 0.02 20.66 0.08 5448 5535 102

11/15/2002 383 2.05 0.02 10.19 0.04 20.46 0.02 5392 5515 102

11/18/2002 384 2.05 0.02 10.49 0.01 20.48 0.06 5528 5565 101

11/19/2002 385 2.06 0.06 10.02 0.03 19.82 0.02 5339 5345 100

11/20/2002 386 1.88 0.02 10.49 0.01 19.99 0.02 5405 5370 99

11/21/2002 387 1.94 0.11 10.22 0.07 20.08 0.09 5385 5365 100

11/22/2002 388 1.88 0.01 9.70 0.08 20.39 0.05 5422 5445 100

11/25/2002 389 2.05 0.03 10.31 0.06 21.10 0.09 5567 5650 101

11/26/2002 390 1.92 0.06 9.91 0.06 20.51 0.10 5389 5370 100

11/27/2002 391 2.00 0.01 10.15 0.09 20.50 0.06 5443 5330 98

11/28/2002 ** Holiday Holiday Holiday Holiday

11/29/2002 392 2.09 0.01 10.14 0.04 19.44 0.03 5342 5475 102

12/2/2002 393 1.99 0.03 10.04 0.05 20.51 0.03 5487 5510 100

12/3/2002 394 1.92 0.06 10.53 0.17 19.68 0.09 5393 5415 100

12/4/2002 395 1.86 0.02 10.22 0.07 19.56 0.11 5286 5290 100

12/5/2002 396 1.98 0.02 9.44 0.21 19.65 0.06 5182 5170 100

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

12/6/2002 397 1.87 0.02 9.68 0.02 20.52 0.08 5377 5310 99

12/9/2002 398 2.10 0.01 9.56 0.35 20.32 0.37 5318 5330 100

12/10/2002 399 1.97 0.07 9.88 0.05 19.44 0.02 5210 5245 101

12/11/2002 400 1.96 0.10 9.65 0.13 20.72 0.14 5388 5460 101

12/12/2002 401 2.04 0.04 9.72 0.20 20.41 0.09 5323 5405 102

12/13/2002 402 1.99 0.07 9.87 0.18 19.76 0.26 5252 5325 101

12/16/2002 403 1.97 0.02 10.03 0.04 19.69 0.36 5323 5390 101

12/17/2002 404 2.14 0.04 9.62 0.12 19.81 0.53 5297 5380 102

12/18/2002 405 2.08 0.03 9.82 0.19 20.13 0.14 5366 5400 101

12/19/2002 406 2.06 0.03 9.69 0.12 19.60 0.13 5280 5195 98

12/20/2002 407 2.12 0.00 10.00 0.07 19.85 0.05 5403 5370 99

12/23/2002 408 1.96 0.09 9.81 0.10 19.54 0.40 5178 5355 103

12/24/2002 409 1.96 0.02 9.76 0.17 19.37 0.16 5171 5265 102

12/25/2002 ** Holiday Holiday Holiday Holiday

12/26/2002 410 2.01 0.03 9.75 0.06 20.02 0.48 5269 5360 102

12/27/2002 411 1.99 0.07 9.86 0.20 19.68 0.31 5248 5235 100

12/30/2002 412 2.00 0.04 9.57 0.31 19.71 0.48 5266 5120 97

12/31/2002 413 1.99 0.03 9.35 0.16 20.34 0.48 5335 5230 98

1/1/2003 ** Holiday Holiday Holiday Holiday

1/2/2003 414 2.07 0.04 10.17 0.23 21.00 0.37 5597 5490 98

1/3/2003 415 2.11 0.03 10.22 0.06 19.61 0.21 5335 5335 100

1/6/2003 416 2.04 0.01 9.74 0.14 20.11 0.20 5254 5165 98

1/7/2003 417 2.04 0.08 9.63 0.24 19.97 0.37 5247 5115 97

1/8/2003 418 2.11 0.01 10.40 0.09 20.44 0.05 5464 5325 97

1/9/2003 419 2.14 0.01 10.56 0.03 20.22 0.13 5472 5410 99

1/10/2003 420 2.09 0.03 10.18 0.02 20.46 0.02 5414 5355 99

1/13/2003 421 2.01 0.04 10.46 0.07 19.81 0.50 5318 5140 97

1/14/2003 422 1.96 0.05 10.16 0.33 19.82 0.19 5243 5155 98

1/15/2003 423 2.01 0.06 9.93 0.41 20.14 0.19 5375 5525 103

1/16/2003 424 1.98 0.02 9.97 0.22 19.49 0.42 5223 5415 104

1/17/2003 425 2.03 0.04 9.60 0.25 19.69 0.20 5196 5560 107

1/20/2003 426 2.10 0.04 9.61 0.08 20.23 0.10 5282 5750 109

1/21/2003 427 2.00 0.01 9.82 0.09 19.80 0.06 5231 5590 107

1/22/2003 428 2.02 0.06 9.70 0.17 19.23 0.58 5126 5405 105

1/23/2003 429 1.98 0.06 9.59 0.29 19.82 0.47 5195 5665 109

1/24/2003 430 1.99 0.04 10.36 0.13 19.20 0.08 5175 5535 107

1/27/2003 431 2.07 0.06 10.31 0.45 20.07 0.32 5345 5420 101

1/28/2003 432 1.91 0.03 9.70 0.05 20.51 0.06 5287 5430 103

1/29/2003 433 2.11 0.04 10.23 0.01 20.05 0.06 5330 5460 102

1/30/2003 434 1.89 0.03 10.47 0.04 20.58 0.07 5418 5550 102

1/31/2003 435 2.04 0.08 9.76 0.05 19.34 0.55 5152 5250 102

2/3/2003 436 2.05 0.05 9.95 0.19 19.99 0.14 5260 5470 104

2/4/2003 437 2.09 0.10 9.91 0.18 19.23 0.49 5128 5395 105

2/5/2003 438 2.06 0.04 9.90 0.47 19.33 0.37 5139 5430 106

2/6/2003 439 1.97 0.07 9.52 0.25 19.88 0.13 5137 5415 105

2/7/2003 440 2.10 0.07 9.58 0.14 20.39 0.07 5277 5530 105

2/10/2003 441 2.00 0.02 9.90 0.07 21.20 0.01 5425 5620 104

2/11/2003 442 1.90 0.05 10.30 0.07 20.68 0.08 5478 5650 103

2/12/2003 443 1.97 0.06 9.71 0.17 19.79 0.36 5231 5400 103

2/13/2003 444 1.99 0.01 10.12 0.02 19.34 0.22 5217 5360 103

2/14/2003 445 2.01 0.02 9.80 0.06 20.36 0.02 5423 5655 104

2/17/2003 446 2.05 0.02 9.62 0.08 18.88 0.04 5173 5450 105

2/18/2003 447 1.90 0.08 9.91 0.10 19.23 0.11 5269 5515 105

2/19/2003 448 2.05 0.14 9.79 0.17 18.94 0.39 5253 5450 104

2/20/2003 449 1.88 0.03 10.28 0.14 19.36 0.08 5376 5605 104

2/21/2003 450 2.05 0.05 9.68 0.22 20.54 0.20 5274 5420 103

2/24/2003 451 2.08 0.02 10.26 0.03 19.70 0.11 5159 5475 106

2/25/2003 452 1.99 0.07 9.61 0.24 19.48 0.35 5121 5395 105

2/26/2003 453 1.94 0.06 9.77 0.29 19.69 0.28 5179 5390 104

2/27/2003 454 1.94 0.03 9.90 0.29 19.91 0.21 5242 5435 104

2/28/2003 455 2.00 0.03 9.49 0.06 20.42 0.04 5294 5585 105

3/3/2002 456 1.96 0.02 9.56 0.26 20.10 0.18 5190 5440 105

3/4/2002 457 2.04 0.01 10.02 0.16 20.59 0.14 5352 5520 103

3/5/2002 458 1.99 0.04 9.80 0.20 19.94 0.27 5205 5405 104

3/6/2002 459 2.00 0.04 9.79 0.02 20.80 0.02 5317 5525 104

3/7/2002 460 1.94 0.04 10.66 0.29 21.64 0.25 5598 5730 102

3/10/2003 461 2.09 0.03 9.62 0.16 19.53 0.06 5205 5335 102

# GMVC Daily Exposure Concentrations and Nominal Usage

Conc. Stdev Conc. Stdev Conc. Stdev Anticipated

Usage (g) Actual

Usage (g) % U sage

(Actual /

Anticipated) Date Exposure

Da y Nominal Usage (Mass Balance) Chamber 6 (2g/m 3 

# ) Chamber 7 (10 g/m 3 

# ) Chamber 8 (20g/m 3 

# )

3/11/2003 462 1.99 0.08 9.48 0.16 20.22 0.15 5280 5380 102

3/12/2003 463 1.93 0.08 9.63 0.23 19.63 0.43 5208 5320 102

3/13/2003 464 2.06 0.01 9.60 0.15 19.60 0.40 5210 5310 102

3/14/2003 465 1.99 0.04 9.56 0.10 19.62 0.39 5168 5285 102

3/17/2003 466 1.96 0.02 9.60 0.12 19.93 0.07 5315 5610 106

3/18/2003 467 2.07 0.03 9.98 0.13 20.37 0.19 5339 5600 105

3/19/2003 468 1.97 0.03 9.56 0.20 20.15 0.15 5232 5420 104

3/20/2003 469 1.97 0.06 9.38 0.08 20.99 0.08 5340 5490 103

3/21/2003 470 2.05 0.03 9.76 0.18 20.04 0.15 5229 5525 106

3/24/2003 471 1.97 0.03 10.31 0.41 20.26 0.17 5276 5395 102

3/25/2003 472 2.02 0.04 9.91 0.18 20.48 0.13 5267 5320 101

3/26/2003 473 2.00 0.06 10.27 0.22 20.13 0.27 5242 5160 98

3/27/2003 474 1.95 0.03 10.01 0.13 19.74 0.58 5278 5210 99

3/28/2003 475 1.98 0.01 9.78 0.29 20.05 0.10 5308 5190 98

3/31/2003 476 2.03 0.06 9.82 0.24 19.20 0.27 5138 5250 102

4/1/2003 477 1.97 0.07 9.67 0.30 19.97 0.40 5236 5420 104

4/2/2003 478 2.05 0.08 9.76 0.29 19.62 0.15 5165 5230 101

4/3/2003 479 2.00 0.15 9.69 0.23 19.78 0.19 5221 5420 104

4/4/2003 480 1.97 0.02 9.72 0.10 19.50 0.06 5137 5310 103

4/7/2003 481 1.97 0.05 9.71 0.20 21.04 0.06 5391 5510 102

4/8/2003 482 1.97 0.09 10.09 0.09 19.69 0.34 5230 5330 102

4/9/2003 483 2.01 0.02 10.42 0.06 20.19 0.06 5491 5555 101

4/10/2003 484 1.97 0.07 9.81 0.19 19.90 0.28 5218 5370 103

4/11/2003 485 2.06 0.04 9.90 0.06 20.57 0.06 5393 5515 102

4/14/2003 486 2.13 0.03 10.29 0.02 20.29 0.22 5454 5755 106

4/15/2003 487 2.12 0.01 9.95 0.24 19.43 0.34 5263 5474 104

4/16/2003 488 2.02 0.03 10.05 0.09 20.60 0.05 5452 5465 100

4/17/2003 489 1.95 0.01 10.07 0.26 20.68 0.21 5455 5530 101

4/18/2003 490 2.08 0.01 10.13 0.17 19.87 0.36 5326 5325 100

4/21/2003 491 2.06 0.04 10.10 0.13 19.85 0.45 5285 5325 101

4/22/2003 492 1.97 0.02 10.06 0.04 19.98 0.38 5283 5345 101

4/23/2003 493 1.99 0.03 9.80 0.04 20.16 0.30 5287 5410 102

4/24/2003 494 1.96 0.07 9.87 0.23 19.73 0.28 5216 5090 98

4/25/2003 495 2.05 0.06 9.73 0.14 19.94 0.27 5249 5085 97

4/28/2003 496 2.02 0.02 9.56 0.66 19.53 1.05 5107 4930 97

4/29/2003 497 2.03 0.02 9.97 0.13 20.10 0.06 5271 5370 102

4/30/2003 498 2.01 0.10 10.27 0.30 19.87 0.33 5277 5175 98

5/1/2003 499 2.01 0.03 9.81 0.12 19.93 0.17 5213 5090 98

5/2/2003 500 2.03 0.01 9.69 0.12 20.36 0.11 5293 5135 97

5/5/2003 501 2.13 0.04 10.16 0.05 20.55 0.34 5408 5230 97

5/6/2003 502 1.99 0.03 10.38 0.27 19.53 0.19 5230 5270 101

5/7/2003 503 2.00 0.06 9.88 0.16 19.72 0.34 5188 5125 99

5/8/2003 504 2.03 0.04 9.97 0.04 20.16 0.07 5288 5140 97

5/9/2003 505 2.06 0.02 9.91 0.10 19.97 0.06 5254 5105 97

5/12/2003 506 1.99 0.11 9.77 0.11 19.59 0.11 5154 4965 96

5/13/2003 507 2.08 0.03 9.84 0.05 20.01 0.04 5246 5030 96

5/14/2003 508 2.02 0.07 9.74 0.04 19.77 0.06 5185 5325 103

5/15/2003 509 2.01 0.02 9.52 0.50 19.30 0.48 5075 5280 104

5/16/2003 510 2.09 0.03 10.04 0.15 19.94 0.52 5271 5465 104

5/19/2003 511 2.08 0.03 10.11 0.08 20.48 0.21 5251 5500 105

5/20/2003 512 2.13 0.01 9.80 0.30 20.74 0.17 5248 5365 102

5/21/2003 513 2.09 0.01 9.75 0.28 20.02 0.17 5203 5365 103

5/22/2003 514 2.05 0.01 10.09 0.59 20.56 0.78 5331 5525 104

5/23/2003 515 2.04 0.03 10.07 0.52 20.81 0.24 5380 5605 104

5/26/2003 516 2.01 0.05 10.07 0.09 19.84 0.13 5155 5295 103

5/27/2003 517 1.99 0.03 10.08 0.12 20.54 0.40 5265 5465 104

5/28/2003 518 2.06 0.04 9.89 0.23 20.35 0.13 5241 5445 104

5/29/2003 519 2.02 0.01 9.91 0.15 19.93 0.34 5312 5555 105

5/30/2003 520 1.94 0.03 9.85 0.42 19.90 0.15 5286 5515 104

Average 2.02 10.00 20.29 5413 5359 99

STDEV 0.07 0.37 0.74 211 234 4

% Target 100.82 99.98 101.45

*11/28/01 (Exposure Day 134). Did not expose for a full day because of fluctuations in the chamber supply air. We exposed for approximately 40 minutes

at average concentrations of 1.53 g/m 3 

# , 7.88 g/m 3 

# , and 13.62 g/m 3 

# . The supply air system was repaired and normal exposures were conducted the

following day.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-6 Summary of GMVC Room Air Sampling Results

# Summary of GMVC Room Air Sampling Results

Date Exposure

Day Measured

Room Air

Conc. (g/m 3 

# ) Stdev. Sample

Time

(min)

9/13/2001 81 0.02 0.01 20

11/13/2001 124 0.5 0.02 13

11/14/2001 125 0.31 0.01 21

2/5/2002 181 -0.2 0.04 18

4/29/2002 240 0.14 0.02 30

7/22/2002 299 0.06 0.01 30

10/14/2002 359 0.11 0.06 20

1/2/2003 414 -0.06 0.02 20

5/28/2003 518 0.07 0.01 20

* Samples taken using the Low Miran during last part of exposure day

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-7 Aerosol Scientist’s Report

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-45 METHOD

Test Substance Identifica tion, Source, and Storage

Gasoline MTBE Vapor Condensate (GMVC; Lo t Number API 00-02) was prepared and

supplied in 420-pound and 20-pound gas cylinders by Chevron Research and Technology Center

(CRTC; Richmond, CA). Original characterization of the test substance was performed by

CRTC. The reference gas chromatographic prof ile of the 19 key components was provided by

ExxonMobil Biomedical Sciences, Inc. (EMBSI), Annandale, NJ. Twenty-pound cylinders and

some 420-pound cylinders were stored at ambient temperature in a storage building dedicated for

that purpose at the Lovelace Respiratory Research Institute (LRRI). The remaining 420-pound

cylinders were stored in an outsi de, controlled area at ambient te mperature. The test substance

was transferred, as needed, from the 420-pound to the 20-pound cylinders. Only authorized

personnel were allowed access to the test substance. Receipt, use, and inventory of this test

substance were documented.

Analysis . Before dispensing GMVC from each 420 pound tank, a liquid sample was transferred

from the 420-pound tank to a small glass vial with a crimp top. A 50 μL sample of liquid was

injected into a Tedlar bag for gas chromatographi c analysis at LRRI. The analytical method is

described under Section “Qualitative Analysis of the Hydrocarbon Composition of the Test

Substance and Exposure Atmosphere by Gas Chromatography.”

Reserve Sample . The Sponsor-contracted archives have re tained samples of th e test substance.

Exposure System

The exposure system consisted of four leve l [low, mid, and high target concentration

levels and control (air only)] H-2000 whole-bod y chambers [Lab Products, Inc., Seaford, DE],

the vapor generation system, and the on-line gas anal ysis system [Miran infr ared spectrometers].

Figure E-1 is a schematic representation of a typical H-2000 chamber in the exposure system.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-46 MAIN EXHAUST DUCT MAIN SUPPLY AIR

DUCT

H-2000

EXPOSURE

CHAMBER CHAMBER

DILUTION

Vapor

Generation

System

CHAMBER

EXHAUST 2" Delivery Line

MIRAN

Infrared

Spectrometer



# Figure E-1. Gasoline MTBE Vapor Exposure System

Figure E-2 shows the layout of the four ch amber system in room 408 and the adjacent

room housing the Miran 1A infrared spectrometers and other equipment. The chamber system

was housed in a separate room for safety re quirements. Room 408 was modified to meet

National Fire Protection Associ ation (NFPA) requirements for cl ass I liquids. Electrical

equipment was excluded from use in room 408, so the Miran 1A infrared spectrometers used for

analyzing the chamber atmospheres and other elec trical equipment were operated in a separate

room.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-47 Gasoline MTBE Vapor Condensate

Room 408MiranMIR6TableMiranMIR7TableMiranMIR8TableN2N2N2N2



# Control

Cabinet Computer Change

Chamber

Change

Chamber

Control

CBR5 High Level

CBR8

Mid Level

CBR7

Low Level

CBR6

SS

Flex Freezer

FR409



# Monitoring & Controls

Room 409 MobileTedlar

Bag Setup

Ar He H

2



# GC1 GC2

Ar He H

2



# Computer Miran

MIR1 LN

2 

# LNT1 LN

2 

# LNT2

Generator

Cabinet 20# Gas Tank

Work Table



# Figure E-2. Gasoline Vapor Condensate Exposure System Room Layout

H-2000 Whole-Body Chambers . The rats were housed 24 hour s per day during quarantine and

exposure in the H-2000 whole-body i nhalation chambers (Figure E-1). Rats were exposed 6

hours/day (plus 14 minutes, the time for the vapor concentration to reach T90), 5 days/week for

104 weeks (520 exposure days). In itially, all rats were housed se parately in 3.8-inch wide by

11-inch long by 8-inch high compartments within stainless steel baskets. When male rats

reached 400 g they were transferre d to baskets with 5.7-inch by 11-inch by 8-inch compartments.

Each chamber contained six baskets.

The chambers and cage racks were washed weekly. The cage racks were rotated

clockwise weekly when the rats were transf erred from the dirty to the clean chamber.

The chambers were held at a pproximately 1 inch of water ne gative pressure with respect

to the exposure room, and the chamber flow rate s were maintained at 12 to 15 air changes per

hour (400–500 liters per minute [LPM]). Chambe r temperatures were maintained at 20 ° to 24 ° C.

Temperature, relative humidity, and chamber ai r flow rates were continuously monitored 24

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-48 hours per day. Values for the three parameters were recorded at 30-minute intervals by a

computer-based monitoring system. Oxygen concen tration in the chambers was maintained at

19%. This parameter was checked daily but not recorded.

A 12-hour light cycle was maintained with light s on at 0600. Light leve ls in the exposure

room and noise levels in the cham bers were determined periodically.

Vapor Generation System . A schematic of the vapor generation system is shown in Figure E-3.

The daily supply of GMVC for each exposure chamber was contained in 20-pound gas storage

cylinders. Exposure atmospheres were generate d by controlling the flow of pressurized GMVC

through a rotameter, into a heated stainless stee l transfer line where the GMVC was completely

vaporized. Chamber concentrations were contro lled by adjusting the flow rates of the GMVC

and dilution air rate. Chamber exhaust was carri ed to a thermal oxidizer on the roof of the

exposure facility where it was burned.

On-line Gas Analysis System . Chamber atmospheres were monitored continuously by Miran 1A

infrared spectrometers (Foxboro Wilks, Foxboro, CT). The high-, mid-, and low-level exposure

chambers were each monitored with their own an alyzer. The analyzers for the high-, mid-, and

low-level chambers underwent weekly five-point calibrations and daily one-point calibration

checks using test substance. A fourth analyzer was devoted to monitoring the control chamber,

the room air, and the hood enclosing the 20-pound tank of test substance. This Miran underwent

a three-point calibration periodically. The Miran 1A analy zers dedicated to the mid- and highlevel chambers were calibrate d over a range of 6–35 g/m 3 

# . The Miran 1A analyzers for the

control chamber and the low-level chamber were calibrated over a concentration range of

1–7 g/m 3



# .

The absorbance signals, recorded continuously from the first 2 hours, second 2 hours, and

third 2 hours, were averaged to provide three concentration values for each chamber each

exposure day. The mean of the three values from each exposure chamber was reported as the

day’s exposure concentration for that chamber.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-49 Gasoline MTBE Vapor Condensate Vapor Generator

Sight

Bowl Bypass

To Main

Exhaust

Duct GMVC

Vapor and

Air Mixture

To CBR6



# Bench Scale

Gasoline

MTBE

Vapor

Condensat

e P



# Liquid Pressurizing

N

2 

# (60-80 psig) Nitrogen

Carrier Gas

Pneumatic

Shutoff

Valve Pressure

Gauge

GMVC

Rotameter Nitrogen

Rotameter

Heat Exchanger

(Vaporizer) Orifice

Meter Low Level

Chamber

Supply Air

Mid Level

Chamber

Supply Air

High Level

Chamber

Supply Air GMVC

Vapor and

Air Mixture

To CBR7

GMVC

Vapor and

Air Mixture

To CBR8 

# Dilution

Tee Liquid GMVC Line

Nitrogen Line

GMVC Vapor Line

Chamber

Bypass

(3-way Valve) 

# Hot

Water

Retur

n Hot

Water

In

Heat Exchanger

(Vaporizer) Heat Exchanger

(Vaporizer)

Dilution

Tee Dilution

Tee

Nitrogen

Rotameter Nitrogen

Rotameter

Hot

Water

Return

Hot Water

Return Hot Water

In

Hot Water

In Sight

Bowl Sight

Bowl

Orifice

Meter Orifice

Meter

Chamber

Bypass

(3-way Valve) Chamber

Bypass

(3-way Valve)



# GMVC

Rotameter GMVC

Rotameter



# Figure E-3. Vapor Generator for GMVC

Qualitative Assessment of Exposure Atmospheres . The qualitative composition of the exposure

atmosphere in each chamber was determined w eekly by gas chromatography using a Shimadzu

Model GC-17A/FID (Columbia, MD). Exposure atmosphere samples were collected from the

chambers into Tedlar sampling bags each week. The atmosphere samples were transferred from

the sampling bags directly to the sampling loop of the GC. The percent peak area of each of 19

components was compared to the EMBSI hydrocarbon profile.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-50 Qualitative Analysis of the Hydrocarbon Compos ition of the Test Substance and Exposure

Atmosphere by Gas Chromatography

The hydrocarbon profile of the test subs tance and the exposure atmosphere was

determined using a Shimadzu Model GC-17A/FID (Columbia, MD) equipped with a Petrocol

DH150 capillary column (Supelco, 150 m × 0.25 mm ID, 1.0 μm film thickness). The

chromatographic method was adapted from that used by EMBSI and is summarized in Table

E-1. To validate the system before the exposur es began, the retention times and relative peak

intensities of 19 standards of the 19 major compone nts in the test substance were determined.

Each standard vapor was prepared in the con centration expected in the test substance as

determined by EMBSI (see Appendix B) and inj ected on the GC. These standards and their

relative peak intensities as expected in GMVC are listed in Table E-2. The gas chromatographic

profile of the 19 major peaks (r etention time and relative peak area) was compared with that

originally determined for the GMVC by EMBSI and subsequently used as the benchmark for

comparison of the profiles obtained on test substance and exposure atmosphere samples.

Two types of performance checks on the gas chromatograph were conducted during the

study. Each week during the study, the retention times of eight re presentative components were

determined using a certified mixture contai ning 760 ppm butane, 2270 pp m isopentane, 160 ppm

trans-2-pentene, 430 ppm 2-methylpentane, 220 ppm hexane, 90 ppm 2,4-dimethylpentane,

100 ppm 2-methylhexane, and 220 ppm isooctane in nitrogen (Matheson Tri-Gas, Irving TX). In

addition, one-point performance qualifications were performed on each day in which chamber

profiles were analyzed. The one-point check wa s performed using a cer tified standard of 840

ppm butane in N 2 

# (Matheson Tri-Gas, Irving, TX).

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-51 Table E-1. Gas Chromatogra ph Operating Conditions for Vapor Condensate Analysis

Analytical Column: Supelco PetrocolTM DH150

(150 m × 0.25mm) 1.0 μm film thickness

Oven Temperature Program:

Initial Temp 35 ° C

Initial Time 96 minutes

Rate 1 5 ° C/min to 130 ° C

Rate 2 20 ° C/min to 200 ° C

Final Time 15 minutes

Injector:

Temperature 225 ° C

Mode Split

Ratio 111:1

Injection Volume 500 μL (vapor)

Detector:

Type Flame Ionizing Detector (FID)

Temperature 225 ° C

Fuel Hydrogen @ 30–60 mL/min

Oxidizer Air @ 300–600 mL/min

Make-up Gas Helium @ 30 mL/min

Table E-2. The Hydrocarbon Components of GMVC

and Their Relative Amounts in BGVC as

Determined by Gas Chromatography

Component Area Percent

Isobutane 2.2

n-Butane 11.1

Isopentane 31.0

n-Pentane 9.1

Trans-2-pentene 2.0

2-Methyl-2-butene 2.9

MtBE 21.3

2,3-Dimethylbutane 0.9

2-Methylpentane 4.5

3-Methylpentane 2.6

n-Hexane 2.1

Methylcyclopentane 1.1

2,4-Dimethylpentane 0.9

Benzene 1.5

2-Methylhexane 1.0

2,3-Dimethylpentane 1.0

3-Methylhexane 1.1

Isooctane 1.2

Toluene 2.5

Totals 100

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-52 Computer Environmental Monitoring System

A general layout of the Comput er Environmental Monitoring System (CEMS) is shown

in Figure E-4. The system is comprised of a computer, LabVIEW data acquisition software,

input/output (I/O) hardware, transducers, and in struments. LabVIEW serves as the interface

between the operator and the monitoring syst em. The computer executes the LabVIEW

monitoring program and performs data acquisition, data storage, and directs communications via

data acquisition, serial interface, and signal conditioning hardware. LabVIEW (version 6.0,

National Instruments Corporation, Austin, TX) is a software program that was used to develop

the automation, control, and monitoring applica tion for this study. The LabVIEW application

(“Gas Condensate CEMS”) acquires the signals fr om the exposure system transducers via I/O

hardware that converts the tr ansducer signals to voltage measurements. The LabVIEW

application then converts the voltage measuremen ts to physical parameters (i.e., temperature,

pressure, flow, RH).



# Computer and

Data Acquisiton

software

[LabVIEW] I/O Hardare Transducers/

Instruments

Figure E-4. Computer Envir onmental Monitoring System

Chamber and room temperatures were measur ed using calibrated series 400 thermistor

probes (Omega Engineering, Stamford, CN), chamber humidities were measured by model

5103VHH calibrated RH sensors (Thermalogic, Hudson, MA), and pressures measured by series

PX41 and PX163 calibrated pressure transducers (Omega Engineering, Stamford, CN). Flows

were calculated from pressure differential meas urements across 2-inch orifice meters. The

acquired parameters were summarized by the LabV IEW application in a summary data file each

day, and the mean, minimum, maximum, and standard deviation of each environmental

parameter is written to the file every 30 minutes. The LabVIEW application also is used to start

and stop the exposures and to reco rd average vapor concentrations every 2 hours to a data file.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-53 RESULTS

Pre-exposure Characterization

The exposure system was tested prior to animal exposures. Characterization included the

following: 1) within-day and be tween-day consistency of the hydr ocarbon profile as determined

by gas chromatography; 2) uniformity of the dist ribution of total vapor within each chamber;

3) determination of the time for vapor concentrat ion to achieve 90% of the equilibrium target

value (T90); and 4) the exposure atmosphere in the animals’ breathing zone was also examined

for the presence of aerosol partic les using a TSI Scanning Mobility Particle Sizer (TSI Industries,

Shoreview, MN). One time, prio r to the initiation of animal exposures, the concentration of the

test substance in the generator containment hood and in the exposure room were measured to

ensure that the generator containm ent hood was operating satisfactorily.

Three-Day Stability Evaluati on and Nominal GMVC Usage . Before exposures were initiated the

system was operated for 6 hours/day for 3 consecu tive days to determine system stability. The

concentration of vapor in each chamber was close to target and constant w ithin each day, and the

concentrations were reproducible from day to day (Table E-3). Gas chromatographic analysis of

the chamber atmospheres indicated that the rela tive percentages of the major components were

constant over the 3-day period. The percenta ges of actual GMVC usage/anticipated usage

(nominal usage) on the 3 days of stability testing were 95, 97, and 90 for Days 1, 2, and 3,

respectively.

Table E-3. Results of 3- Day Stability Evaluations

Target Exposure

Concentration (g/m 3 

# )/

Chamber number Achieved Concentration ± SD (n = 3)

Day

(5/17/01) Day 2

(5/18/01) Day 3

(5/19/01)

2 (Chamber 6) 2.06 ± 0.04 1.97 ± 0.10 1.93 ± 0.05

10 (Chamber 7) 9.45 ± 0.23 9.37 ± 0.15 9.37 ± 0.28

20 (Chamber 8) 18.8 ± 0.28 18.9 ± 1.14 19.5 ± 0.37

Homogeneity of Vapor Concentration . The homogeneity of vapor concentration throughout the

exposure chambers was determined by c onducting a chamber distribution study. The

concentrations of GMVC were measured from four sampling ports located in front and four

sampling ports located in the back of the chambe rs during an exposure day and compared to the

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-54 concentration obtained in a refe rence location within the chamber. The spatial variations

measured in Chambers 6 (2 g/m 3 

# ), 7 (10 g/m 3 

# ), and 8 (20 g/m 3 

# ) were 3.0%, 1.3%, and 0.8%,

respectively. These results indicate the vapor was distributed evenly within each of the

chambers.

T90 Determination . The amounts of time required to reach T90 were 13, 14.1, and 14.2 minutes

for Chambers 6, 7, and 8, respectively. A T90 of 14 minutes was chosen fo r use with this study.

Daily exposures periods to GMVC were then 6 hours and 14 minutes.

Confirmation of the Absence of Aerosols . The particle concentrati ons of air inside Chamber 8,

operated at a target concentration 20 g GMVC/m 3 

# , and the control chamber (Chamber 5) were

determined using a TSI Aerodynamic Particle Sizer (model 3321, TSI, Inc., St. Paul, MN).

There was less than 1 particle per cubic centimeter air in the control and high-level chambers,

indicating that there were no GMVC aerosols at the highest target vapor concentration used in

this study.

In-Study Data

Test Substance . The composition of the test substan ce remained acceptably constant throughout

the study. Results of gas chromatography analys es of the test substance are provided in

Appendix B.

Chamber Distribution Evaluation During Exposures . During the second week of exposures, the

uniformity of vapor distribution wa s re-evaluated to determine the distribution in the presence of

the test animals. The spatial variations meas ured in Chambers 6 (low-level chamber, 2 g/m 3 

# ), 7

(mid-level chamber, 10 g/m 3 

# ), and 8 (high-level chamber, 20 g/m 3 

# ) were 2.8%, 0.86%, and 1.8%,

respectively. These results indicated the vapor was distributed evenly within each of the

chambers.

Determination of Nominal Concentration . Daily nominal or “anticip ated” usage was calculated

by multiplying the average GMVC concentra tion in each chamber (low, mid, high; g/m 3 

# ) by the

total flow through each respective chamber ([L/min * min]/[1000 L/m 3 

# ]) and then summing the

values for all three chambers. This value was compared to the actual GMVC usage determined

by taking the difference between the weight of the 20-pound cylinder before and after each

exposure.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-55 Concentration of Test Substance in the Exposure Room . Concentration of the test substance in

the exposure room was determined periodical ly during the study (at approximately 60-day

intervals) using a Miran 1A In frared Spectrometer (Foxboro Wilk s, Foxboro, CT) operated using

the same settings as used to monitor the low-level exposure chamber.

Chamber Concentrations and Nominal Usage . The overall study means of the daily vapor

concentrations achieved for the 2, 10, and 20 g GMVC/m 3 

# vapors are provided in Table E-4.

The overall achieved means were within 2% of ta rget for each exposure co ncentration. Thus, all

future references to exposure c oncentration are in terms of target concentration. For the control

chambers, concentrations of “zero” were obtained on all but 15 of the 520 exposure days. On

these 15 days, the readings were below the lowest concentration on the standard curve used to

calibrate the control cham ber Miran 1A (1 g GMVC/m 3 

# ). Daily results are provided in Appendix

E-5. Concentrations of GMVC in room air were below the concentration of the lowest standard

used to calibrate the Miran 1A (1 g/m 3 

# ; Appendix E-6).

Table E-4. Summary of GM VC Vapor Concentrations a



# Target

g GMVC/m 3 

# Achieved Concentrations,

g GMVC/m 3 

# Percent of Target

0 < 1 b 

# NA

2 2.02 ± 0.07 101

10 10.0 ± 0.37 100

20 20.3 ± 0.74 101

a 

# Results are the mean ± SD of vapor concentrations obtained in 520

exposure days.

b 

# Concentrations of “zero” were obtained on all but 15 of the 520

exposure days. On these 15 days, th e readings were below the lowest

concentration on the standard curve used to calibrate the control

chamber Miran 1A (1 g GMVC/m 3 

# ).

The overall average of the daily percen t nominal usage was 99% ± 4%, indicating

excellent agreement between anticipated and actual GMVC usage.

Gas Chromatographic Profiles of GMVC Exposure Atmospheres

Gas chromatographic profiles were obtained from each exposure chamber weekly to

assess whether the animals were exposed to the relative amounts of the same 19 major

components throughout the study. The peak areas of the 19 major components were summed to

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

E-56 provide a “total peak area” for those components. The peak area of each of the components was

divided by the total peak area for the components to obtain a relati ve peak area (in percent) for

each of the components. These were compared to the reference values provided by EMBSI.

Profiles remained acceptably constant throughout the study. Results are pr ovided in Appendix F.

Environmental Data

Results of analyses of the chamber e nvironment are provided in Appendix G.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

F-1 APPENDIX F

WEEKLY GAS CHROMATOGRAPHIC PROFILES OF CHAMBER ATMOSPHERESProtocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting5-23-01WeekStarting5-28-01WeekStarting5-23-01WeekStarting5-28-01WeekStarting5-23-01WeekStarting5-28-01Isobutane2.2 2.5 2.2 2.2 2.2 2.1 2.3n-butane11.1 10.2 9.3 10.2 10.5 10.5 10.9Isopentane31.0 26.9 26.6 30.1 30.2 30.7 31.5n-pentane9.1 8.7 8.7 8.9 9.0 8.9 9.1trans-2-pentene2.0 2.9 2.7 2.1 2.2 2.1 2.12-methyl-2-butene 2.9 3.9 3.7 2.9 2.9 2.9 3.1MTBE/2,3-dimethylbutaneMTBE21.3 20.9 20.7 23.0 22.7 22.8 22.92,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 1.0 1.02-methylpentane4.5 4.6 5.2 4.6 4.4 4.4 4.53-methylpentane2.6 2.7 3.1 2.4 2.6 2.6 2.6n-hexane2.1 2.2 2.5 2.1 2.2 2.2 2.0Methylcyclopentane 1.1 2.1 1.5 1.2 1.0 1.2 1.12,4-dimethylpentane 0.9 2.3 0.9 1.1 1.0 0.9 0.9Benzene1.5 1.7 2.5 1.6 1.5 1.5 1.22-methylhexane1.0 1.1 1.2 1.0 1.0 1.1 0.92,3-dimethylpentane 1.0 2.4 1.7 1.2 1.2 1.2 1.13-methylhexane1.1 1.3 2.1 1.3 1.2 1.2 0.9Isooctane1.2 0.7 1.9 1.3 1.4 1.5 1.2Toluene2.5 2.0 2.5 1.8 1.7 1.3 0.8Low (2.0g/m3) Mid (10g/m3) Mid (10g/m3)May 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting6-4-01WeekStarting6-11-01WeekStarting6-18-01WeekStarting6-25-01WeekStarting6-4-01WeekStarting6-11-01WeekStarting6-18-01WeekStarting6-25-01WeekStarting6-4-01WeekStarting6-11-01WeekStarting6-18-01WeekStarting6-25-01Isobutane 2.2 2.6 2.2 2.3 2.2 2.1 2.1 2.2 2.2 2.2 2.2 2.1 2.1n-butane 11.1 8.8 9.1 9.6 9.8 10.2 10.4 10.5 10.3 10.9 10.7 10.5 10.5Isopentane 31.0 24.9 26.0 26.8 26.2 29.9 30.0 30.2 29.8 31.9 31.1 30.7 30.6n-pentane 9.1 7.7 8.5 7.8 8.6 8.8 8.8 8.9 8.9 9.1 9.1 8.9 8.9trans-2-pentene 2.0 3.8 3.0 3.0 3.0 2.2 2.2 2.1 2.2 2.1 2.2 2.0 2.12-methyl-2-butene 2.9 4.0 4.3 3.7 3.6 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 20.9 21.8 21.0 19.0 22.6 23.4 21.9 22.4 23.0 22.5 22.3 22.32,3-dimethylbutane 0.9 0.9 0.9 0.9 0.8 1.0 1.0 0.9 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.3 4.9 4.3 4.9 4.5 4.4 4.6 4.5 4.4 4.5 4.5 4.43-methylpentane 2.6 2.9 2.9 2.7 2.7 2.5 2.5 2.6 2.7 2.5 2.5 2.6 2.6n-hexane 2.1 2.6 2.3 2.5 3.2 2.1 2.1 2.2 2.1 1.9 2.1 2.2 2.3Methylcyclopentane 1.1 1.8 1.4 1.7 1.7 1.2 1.1 1.2 1.2 1.0 1.1 1.2 1.22,4-dimethylpentane 0.9 2.0 1.5 1.0 0.9 1.0 1.1 1.0 1.0 1.1 1.0 0.9 1.0Benzene 1.5 2.0 2.2 1.8 2.4 2.0 1.8 1.7 2.0 1.1 1.5 1.6 1.72-methylhexane 1.0 2.0 1.0 1.4 1.9 1.0 1.0 1.0 1.1 0.9 1.0 1.0 1.02,3-dimethylpentane 1.0 2.7 2.2 2.2 2.3 1.3 1.2 1.3 1.3 1.0 1.1 1.1 1.13-methylhexane 1.1 1.5 1.8 1.6 1.0 1.1 1.2 1.2 1.1 1.0 1.1 1.2 1.2Isooctane 1.2 1.8 1.9 2.2 1.8 1.4 1.2 1.3 1.4 1.2 1.2 1.3 1.4Toluene 2.5 2.9 2.3 3.6 3.9 2.0 1.6 2.2 2.0 0.6 1.4 2.0 2.0Low (2.0g/m3)Mid (10g/m3)High (20g/m3)June 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting7-2-01WeekStarting7-9-01WeekStarting7-16-01WeekStarting7-23-01WeekStarting7-30-01WeekStarting7-2-01WeekStarting7-9-01WeekStarting7-16-01WeekStarting7-23-01WeekStarting7-30-01WeekStarting7-2-01WeekStarting7-9-01WeekStarting7-16-01WeekStarting7-23-01WeekStarting7-30-01Isobutane2.2 2.7 2.0 2.82.4 2.1 2.2 2.22.1 2.1 2.1 2.21.8n-butane11.1 8.8 8.1 10.010.1 10.0 10.4 10.410.2 10.3 10.3 10.68.8Isopentane31.0 25.1 22.8 27.927.8 30.1 30.5 30.230.6 30.5 30.5 30.729.6n-pentane9.1 8.6 7.1 8.88.3 8.8 9.0 8.98.8 8.9 8.9 8.98.6trans-2-pentene2.0 3.7 2.8 2.72.2 2.1 2.1 2.22.0 2.1 2.1 2.12.02-methyl-2-butene 2.9 5.7 2.6 4.02.9 2.9 2.9 2.82.8 3.0 2.9 2.92.7MTBE/2,3-dimethylbutaneMTBE21.3 19.9 19.7 20.422.5 22.7 22.6 22.323.9 22.6 22.5 22.425.32,3-dimethylbutane 0.9 0.8 0.8 0.90.9 1.0 1.0 0.91.0 1.0 0.9 0.91.12-methylpentane4.5 4.8 5.4 4.24.6 4.5 4.5 4.54.5 4.5 4.5 4.54.93-methylpentane2.6 3.1 2.6 2.22.6 2.6 2.6 2.72.6 2.6 2.4 2.62.7n-hexane2.1 2.0 2.8 2.32.0 2.2 2.1 2.22.0 2.3 2.5 2.22.2Methylcyclopentane 1.1 1.9 2.1 1.91.3 1.2 1.2 1.21.1 1.1 1.0 1.11.12,4-dimethylpentane 0.9 1.2 4.7 1.31.4 1.0 0.9 1.11.0 1.0 0.9 1.01.1Benzene1.5 2.1 1.9 1.81.6 1.6 1.9 1.81.4 1.6 1.6 1.61.32-methylhexane1.0 1.3 1.2 1.41.0 1.1 1.1 1.01.0 1.0 1.2 1.01.22,3-dimethylpentane 1.0 2.0 1.3 2.71.4 1.3 1.2 1.11.1 1.2 1.4 1.11.33-methylhexane1.1 1.2 4.6 1.01.9 1.2 1.2 1.11.1 1.2 1.2 1.11.3Isooctane1.2 1.9 5.2 2.01.6 1.2 1.3 1.21.3 1.2 1.2 1.31.6Toluene2.5 3.2 2.4 1.83.4 2.1 1.4 2.01.4 2.0 2.0 1.91.5Low (2.0g/m3)Mid (10g/m3)High (20g/m3)July 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting8-6-01WeekStarting8-13-01WeekStarting8-20-01WeekStarting8-27-01WeekStarting8-6-01WeekStarting8-13-01WeekStarting8-20-01WeekStarting8-27-01WeekStarting8-6-01WeekStarting8-13-01WeekStarting8-20-01WeekStarting8-27-01Isobutane2.2 2.2 2.2 2.7 2.2 2.2 2.2 2.2 2.2 2.1 2.2 2.2 2.1n-butane11.1 9.8 9.0 10.4 10.1 10.3 10.5 10.5 10.5 10.4 10.6 10.6 10.5Isopentane31.0 27.4 26.4 28.6 28.5 30.0 30.1 30.1 30.3 30.4 30.5 30.5 30.5n-pentane9.1 8.3 8.4 8.6 8.4 8.8 8.8 8.8 8.8 8.8 8.8 8.8 8.8trans-2-pentene2.0 2.3 2.5 2.2 2.4 2.1 2.1 2.0 2.0 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 2.7 3.4 2.7 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE21.3 22.2 22.3 22.3 22.2 23.3 23.1 23.1 23.2 23.0 22.9 22.8 22.92,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.5 5.1 4.4 4.5 4.5 4.5 4.4 4.4 4.4 4.4 4.4 4.43-methylpentane2.6 2.9 2.8 2.6 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 3.0n-hexane2.1 2.6 2.2 2.1 2.2 2.1 2.1 2.1 2.1 2.3 2.1 2.2 2.2Methylcyclopentane 1.1 1.6 1.4 1.2 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.1 1.1 1.3 1.0 1.0 1.1 1.1 1.0 0.9 0.9 1.0Benzene1.5 1.7 2.0 1.6 1.6 1.6 1.6 1.8 1.5 1.5 1.6 1.6 1.52-methylhexane1.0 1.4 1.5 1.3 1.3 1.0 1.1 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.7 1.7 1.6 1.7 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane1.1 1.5 1.7 1.4 1.3 1.2 1.2 1.1 1.1 1.1 1.1 1.1 1.1Isooctane1.2 1.6 1.9 1.3 1.7 1.3 1.3 1.3 1.2 1.3 1.2 1.2 1.2Toluene2.5 3.5 3.5 3.1 3.1 2.0 2.0 2.0 1.9 1.9 2.1 2.0 1.8Low (2.0g/m3)Mid (10g/m3)High (20g/m3)August 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting9-3-01WeekStarting9-10-01WeekStarting9-17-01WeekStarting9-24-01WeekStarting9-3-01WeekStarting9-10-01WeekStarting9-17-01WeekStarting9-24-01WeekStarting9-3-01WeekStarting9-10-01WeekStarting9-17-01WeekStarting9-24-01Isobutane2.2 2.22.4 2.1 2.12.1 2.0 2.01.6 2.0n-butane11.1 9.910.3 10.1 10.210.4 10.2 9.77.3 9.9Isopentane31.0 28.429.3 28.7 30.431.2 30.1 30.428.8 30.3n-pentane9.1 8.78.6 8.8 8.79.0 8.8 8.88.6 8.9trans-2-pentene2.0 2.42.9 2.6 2.02.0 2.1 2.02.1 2.02-methyl-2-butene 2.9 2.93.2 3.1 2.82.9 2.9 2.72.5 2.9MTBE/2,3-dimethylbutaneMTBE21.3 22.820.6 22.3 23.323.4 23.4 23.925.5 23.52,3-dimethylbutane 0.9 1.00.9 0.9 1.01.0 1.0 1.01.1 1.02-methylpentane4.5 4.94.5 4.4 4.54.6 4.5 4.65.4 4.63-methylpentane2.6 3.02.6 2.7 2.62.6 2.6 2.73.2 2.6n-hexane2.1 2.12.0 2.7 2.12.1 2.1 2.22.6 2.1Methylcyclopentane 1.1 1.41.2 1.2 1.21.0 1.1 1.11.3 1.12,4-dimethylpentane 0.9 1.12.2 1.6 1.00.9 1.0 1.21.1 1.1Benzene1.5 1.71.2 2.4 1.81.2 1.5 1.41.2 1.52-methylhexane1.0 1.21.0 1.1 1.00.9 1.0 1.11.0 1.02,3-dimethylpentane 1.0 1.41.8 1.3 1.11.1 1.2 1.21.8 1.13-methylhexane1.1 1.21.2 1.1 1.11.0 1.2 1.21.3 1.1Isooctane1.2 1.42.1 1.3 1.31.3 1.3 1.41.9 1.4Toluene2.5 2.32.1 1.6 1.81.3 1.8 1.61.9 1.8Low (2.0g/m3)Mid (10g/m3)High (20g/m3)September 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting10-01-01WeekStarting10-08-01WeekStarting10-15-01WeekStarting10-22-01WeekStarting10-29-01WeekStarting10-01-01WeekStarting10-08-01WeekStarting10-15-01WeekStarting10-22-01WeekStarting10-29-01WeekStarting10-01-01WeekStarting10-08-01WeekStarting10-15-01WeekStarting10-22-01WeekStarting10-29-01Isobutane2.2 2.3 2.6 2.0 2.1 1.9 2.0 2.1 2.1 2.1 2.0 2.0 2.1 2.1 2.2 1.9n-butane11.1 9.0 9.7 9.8 10.3 9.7 10.0 10.5 10.2 10.3 10.0 10.2 10.4 10.4 10.4 9.1Isopentane31.0 26.2 25.9 28.0 28.6 28.5 29.5 30.3 30.1 30.2 30.3 30.2 30.5 30.5 30.4 30.0n-pentane9.1 8.5 8.2 8.4 8.5 8.8 8.8 8.9 8.8 8.9 8.9 9.0 8.9 8.9 8.9 8.8trans-2-pentene2.0 3.3 2.6 3.0 1.9 2.5 2.1 2.0 2.0 1.9 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 3.0 3.7 3.5 2.9 3.0 2.8 3.0 2.8 2.9 2.8 2.9 2.9 3.0 2.9 2.8MTBE/2,3-dimethylbutaneMTBE21.3 21.0 21.5 22.8 22.8 22.0 22.8 22.9 23.8 23.2 23.8 22.8 22.9 23.1 22.9 24.32,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.6 5.3 4.3 4.9 4.7 4.6 4.5 4.5 4.5 4.6 4.5 4.5 4.5 4.5 4.73-methylpentane2.6 2.7 2.6 3.2 2.7 2.7 2.7 2.6 2.5 2.6 2.6 2.7 2.6 2.5 2.6 2.7n-hexane2.1 2.6 2.2 2.1 2.2 2.2 2.2 2.1 2.1 2.1 2.1 2.2 2.1 2.1 2.1 2.2Methylcyclopentane 1.1 1.4 2.0 1.4 1.3 1.3 1.3 1.1 1.1 1.2 1.2 1.2 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.7 1.6 1.1 1.6 1.5 1.5 0.9 0.9 1.0 1.0 1.0 0.9 0.9 1.0 1.0Benzene1.5 2.0 1.8 2.1 1.6 1.8 1.7 1.8 1.8 1.6 1.5 1.6 1.6 1.6 1.6 1.62-methylhexane1.0 1.6 1.8 1.0 1.3 1.3 1.1 0.9 1.0 0.9 0.9 1.1 1.0 1.0 1.0 1.12,3-dimethylpentane 1.0 2.1 2.1 1.4 1.4 1.3 1.3 1.1 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.23-methylhexane1.1 2.3 1.5 1.2 1.2 1.3 1.2 1.1 1.1 1.2 1.1 1.2 1.1 1.1 1.1 1.2Isooctane1.2 2.1 1.9 1.4 1.3 1.7 1.3 1.2 1.2 1.2 1.3 1.3 1.2 1.2 1.2 1.4Toluene2.5 2.8 2.1 2.4 2.3 2.8 2.0 2.0 2.1 2.1 1.9 2.0 2.1 2.0 2.1 1.8Low (2.0g/m3)Mid (10g/m3)High (20g/m3)October 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting11-5-01WeekStarting11-12-01WeekStarting11-19-01WeekStarting11-26-01WeekStarting11-5-01WeekStarting11-12-01WeekStarting11-19-01WeekStarting11-26-01WeekStarting11-5-01WeekStarting11-12-01WeekStarting11-19-01WeekStarting11-26-01Isobutane2.2 2.1 2.3 2.2 2.1 2.0 2.1 1.8 2.0 2.0 2.1 2.0 2.0n-butane11.1 10.1 9.4 9.7 10.1 10.1 10.3 9.2 10.0 10.2 10.4 10.3 10.1Isopentane31.0 29.6 25.6 28.0 29.1 30.4 30.3 36.1 30.2 30.4 30.6 30.5 30.3n-pentane9.1 8.7 8.0 8.5 8.7 8.9 8.9 9.6 8.9 8.9 8.9 9.0 8.9trans-2-pentene2.0 2.0 3.0 2.3 2.0 2.0 2.0 2.4 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.1 2.9 2.8 2.9 2.9 2.5 2.9 2.9 2.9 2.9 3.0MTBE/2,3-dimethylbutaneMTBE21.3 23.0 21.2 22.4 23.4 23.5 23.1 19.8 23.9 22.9 22.8 22.9 23.02,3-dimethylbutane 0.9 1.0 0.9 0.9 1.0 1.0 1.0 0.8 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.6 4.3 4.7 4.5 4.6 4.5 4.1 4.6 4.5 4.5 4.5 4.53-methylpentane2.6 2.6 2.6 2.8 2.6 2.6 2.6 2.3 2.6 2.6 2.6 2.6 2.6n-hexane2.1 2.4 2.2 2.3 2.2 2.1 2.1 1.9 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.5 1.3 1.2 1.1 1.1 1.0 1.1 1.2 1.1 1.1 1.12,4-dimethylpentane 0.9 1.0 1.6 1.2 1.1 1.0 0.9 0.9 1.0 1.0 0.9 0.9 0.9Benzene1.5 1.7 2.6 2.1 1.7 1.5 1.5 1.9 1.5 1.6 1.6 1.6 1.62-methylhexane1.0 1.1 1.9 1.4 1.0 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.3 2.0 1.8 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane1.1 1.2 2.7 1.4 1.5 1.1 1.1 1.1 1.1 1.2 1.2 1.1 1.2Isooctane1.2 1.5 2.0 1.8 1.5 1.3 1.2 1.2 1.2 1.3 1.3 1.3 1.3Toluene2.5 2.0 3.2 2.3 2.2 1.8 2.1 1.8 1.9 2.1 2.0 2.0 2.1Low (2.0g/m3)Mid (10g/m3)High (20g/m3)November 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting12-03-01WeekStarting12-10-01WeekStarting12-17-01WeekStarting12-24-01WeekStarting12-31-01WeekStarting12-03-01WeekStarting12-10-01WeekStarting12-17-01WeekStarting12-24-01WeekStarting12-31-01WeekStarting12-03-01WeekStarting12-10-01WeekStarting12-17-01WeekStarting12-24-01WeekStarting12-31-01Isobutane 2.2 2.2 1.8 1.9 2.0 2.1 2.1 1.9 2.1 2.1 2.1 2.1 1.8 2.1 2.1 2.1n-butane 11.1 9.8 9.1 9.1 9.9 10.3 10.2 9.8 10.2 10.2 10.2 10.3 9.2 10.3 10.4 10.3Isopentane 31.0 28.6 28.7 26.1 29.0 28.9 30.3 30.3 29.6 30.3 30.5 30.4 29.4 30.2 30.7 30.2n-pentane 9.1 8.5 8.8 8.2 8.7 8.6 8.9 8.9 8.9 8.9 8.9 8.9 8.9 8.9 9.0 8.9trans-2-pentene 2.0 2.2 2.2 3.0 2.1 2.3 2.0 2.0 2.4 2.0 2.0 2.0 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 3.1 2.8 3.3 2.9 3.0 2.8 2.9 3.1 2.9 2.9 3.0 3.0 3.0 2.9 3.0MTBE/2,3-dimethylbutaneMTBE 21.3 23.0 22.8 21.9 23.7 22.3 23.6 23.7 22.8 23.2 23.2 22.9 23.4 22.7 22.6 22.82,3-dimethylbutane 0.9 1.0 1.0 0.9 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.5 4.7 4.5 4.5 4.5 4.6 4.5 4.5 4.6 4.5 4.7 4.5 4.5 4.53-methylpentane 2.6 2.5 2.6 3.0 2.7 3.0 2.6 2.6 2.5 2.6 2.6 2.6 2.8 2.6 2.6 2.6n-hexane 2.1 2.2 2.5 2.8 2.1 2.0 2.1 2.2 2.2 2.1 2.1 2.1 2.3 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.3 1.7 1.2 1.3 1.1 1.1 1.2 1.1 1.1 1.1 1.2 1.2 1.1 1.22,4-dimethylpentane 0.9 2.0 1.2 1.1 1.4 1.2 1.0 1.0 1.1 0.9 1.0 1.0 1.1 1.0 0.9 1.0Benzene 1.5 1.9 1.8 2.0 1.6 1.7 1.5 1.8 1.9 1.8 1.5 1.6 1.7 1.7 1.6 1.62-methylhexane 1.0 1.1 1.4 1.6 1.1 1.2 1.0 1.0 0.9 1.0 0.9 1.0 1.1 1.1 1.0 1.12,3-dimethylpentane 1.0 1.5 1.4 2.3 1.2 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.1 1.1 1.23-methylhexane 1.1 1.4 1.5 2.0 1.2 1.3 1.1 1.1 1.3 1.1 1.2 1.1 1.2 1.2 1.1 1.2Isooctane 1.2 1.3 1.6 2.0 1.3 1.6 1.2 1.2 1.2 1.2 1.3 1.3 1.4 1.3 1.3 1.3Toluene 2.5 2.0 2.9 2.4 2.3 2.4 1.9 1.9 1.9 2.1 1.8 2.1 2.3 2.0 2.1 1.9Low (2.0g/m3)Mid (10g/m3)High (20g/m3)December 2001Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting1-7-02WeekStarting1-14-02WeekStarting1-21-02WeekStarting1-28-02WeekStarting1-7-02WeekStarting1-14-02WeekStarting1-21-02WeekStarting1-28-02WeekStarting1-7-02WeekStarting1-14-02WeekStarting1-21-02WeekStarting1-28-02Isobutane 2.2 2.3 2.1 2.1 2.2 2.1 2.1 2.2 2.1 2.1 2.2 2.1 2.1n-butane 11.1 10.1 9.9 10.1 10.4 10.3 10.3 10.3 10.1 10.4 10.4 10.3 10.3Isopentane 31.0 29.0 28.6 29.1 28.7 30.4 30.3 29.9 30.3 30.6 30.6 30.5 30.4n-pentane 9.1 8.5 8.8 8.6 8.8 8.9 8.9 8.9 8.9 9.0 8.9 8.9 8.9trans-2-pentene 2.0 2.1 2.3 1.9 2.5 2.0 2.0 2.2 2.0 2.0 2.0 2.0 2.12-methyl-2-butene 2.9 2.8 3.1 2.9 3.1 2.9 2.9 2.9 2.9 2.9 2.9 3.0 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.0 22.5 23.2 22.6 22.9 23.1 22.9 23.5 22.7 22.6 22.8 22.72,3-dimethylbutane 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.5 4.7 4.6 4.5 4.5 4.6 4.5 4.5 4.5 4.5 4.63-methylpentane 2.6 2.7 2.7 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.2 2.2 2.3 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.3 1.2 1.2 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.22,4-dimethylpentane 0.9 1.3 1.4 1.1 1.5 0.9 0.9 1.0 1.0 1.0 0.9 1.0 1.0Benzene 1.5 2.0 1.7 1.5 1.6 1.8 1.8 1.9 1.5 1.6 1.6 1.6 1.62-methylhexane 1.0 1.1 1.2 1.2 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 2.1 1.3 1.3 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.3 1.4 1.3 1.4 1.1 1.1 1.1 1.1 1.2 1.1 1.2 1.2Isooctane 1.2 1.3 1.5 1.5 1.4 1.2 1.2 1.2 1.2 1.3 1.3 1.2 1.3Toluene 2.5 2.4 2.4 2.4 1.8 2.1 2.0 2.0 1.9 2.0 2.0 1.9 2.0Low (2.0g/m3)Mid (10g/m3)High (20g/m3)January 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting2-4-02WeekStarting2-11-02WeekStarting2-18-02WeekStarting2-25-02WeekStarting2-4-02WeekStarting2-11-02WeekStarting2-18-02WeekStarting2-25-02WeekStarting2-4-02WeekStarting2-11-02WeekStarting2-18-02WeekStarting2-25-02Isobutane2.2 2.2 2.1 2.7 2.1 2.1 2.1 2.1 1.8 2.1 2.1 2.0 2.1n-butane11.1 10.6 10.0 10.0 9.9 10.3 10.2 10.2 9.3 10.2 10.2 9.9 10.5Isopentane31.0 29.8 29.5 27.4 29.2 30.4 30.3 30.3 29.4 30.5 30.5 30.7 32.5n-pentane9.1 8.9 8.9 8.5 8.6 8.9 8.9 8.9 8.8 8.9 8.9 8.9 9.3trans-2-pentene2.0 2.2 2.2 3.2 2.1 2.0 2.0 2.1 2.0 2.0 2.0 2.0 2.12-methyl-2-butene 2.9 3.2 3.3 3.5 3.0 2.9 2.9 3.0 2.9 3.0 3.0 3.0 3.0MTBE/2,3-dimethylbutaneMTBE21.3 21.9 21.2 19.8 21.7 23.0 22.7 22.7 23.3 22.8 22.8 23.2 22.82,3-dimethylbutane 0.9 0.9 0.9 0.8 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.6 4.7 5.2 4.7 4.5 4.5 4.6 4.7 4.5 4.5 4.6 4.43-methylpentane2.6 2.6 2.8 2.8 2.9 2.6 2.6 2.6 2.7 2.6 2.6 2.7 2.5n-hexane2.1 2.2 2.1 2.7 2.2 2.1 2.2 2.1 2.3 2.1 2.1 2.2 1.9Methylcyclopentane 1.1 1.2 1.4 1.4 1.3 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.02,4-dimethylpentane 0.9 0.9 1.2 1.4 1.3 0.9 1.0 1.1 1.0 0.9 0.9 1.0 0.8Benzene1.5 1.7 1.6 1.9 1.8 1.6 1.9 1.6 1.8 1.9 1.6 1.5 1.52-methylhexane1.0 1.1 1.3 2.5 1.2 1.0 1.0 1.0 1.1 1.0 1.0 1.0 0.72,3-dimethylpentane 1.0 1.3 1.3 1.7 1.3 1.1 1.1 1.1 1.3 1.1 1.1 1.1 0.83-methylhexane1.1 1.2 1.4 1.0 1.4 1.1 1.1 1.1 1.3 1.1 1.1 1.2 0.8Isooctane1.2 1.4 1.6 1.3 1.7 1.2 1.2 1.2 1.5 1.3 1.3 1.3 0.9Toluene2.5 2.2 2.5 2.2 2.9 2.1 2.3 2.2 2.6 2.0 2.1 1.7 1.2Low (2.0g/m3)Mid (10g/m3)High (20g/m3)February 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting3-4-02WeekStarting3-11-02WeekStarting3-18-02WeekStarting3-25-02WeekStarting3-4-02WeekStarting3-11-02WeekStarting3-18-02WeekStarting3-25-02WeekStarting3-4-02WeekStarting3-11-02WeekStarting3-18-02WeekStarting3-25-02Isobutane 2.2 2.1 2.1 2.2 2.2 2.1 2.1 2.2 2.2 2.0 2.1 2.2 2.2n-butane 11.1 9.9 10.0 10.8 10.1 10.2 10.3 10.5 10.6 9.7 10.3 10.5 10.7Isopentane 31.0 28.3 29.1 29.4 30.4 30.3 30.4 30.6 30.6 30.4 30.4 30.6 30.8n-pentane 9.1 8.7 8.7 8.7 9.4 8.9 8.9 8.9 9.0 8.9 9.1 8.9 9.0trans-2-pentene 2.0 2.3 2.0 2.3 3.1 2.0 2.0 1.9 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 3.0 2.9 3.0 3.0 2.9 3.0 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 21.2 21.8 20.7 20.7 22.8 22.8 22.7 22.4 23.3 22.4 22.4 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.4 4.6 4.5 4.4 4.5 4.5 4.5 4.5 4.7 4.5 4.5 4.53-methylpentane 2.6 2.5 2.7 2.6 2.5 2.6 2.6 2.6 2.6 2.7 2.6 2.6 2.6n-hexane 2.1 2.1 2.3 2.2 2.1 2.1 2.1 2.1 2.1 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.6 1.3 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.3 1.7 1.1 1.1 1.0 1.0 1.0 1.0 0.9 0.9 0.9Benzene 1.5 1.8 1.9 1.7 1.6 1.6 1.6 1.5 1.5 1.5 2.0 1.6 1.62-methylhexane 1.0 1.2 1.1 1.3 1.2 1.0 1.0 1.0 1.0 1.1 1.0 1.0 1.02,3-dimethylpentane 1.0 1.2 1.3 1.3 1.2 1.1 1.1 1.1 1.1 1.2 1.1 1.1 1.13-methylhexane 1.1 4.6 1.3 1.2 1.2 1.1 1.1 1.1 1.1 1.2 1.1 1.2 1.1Isooctane 1.2 1.4 1.5 1.8 1.4 1.2 1.2 1.2 1.2 1.3 1.2 1.3 1.2Toluene 2.5 2.2 2.6 2.5 2.1 2.2 2.2 2.0 2.0 1.9 2.3 2.0 2.0Low (2.0g/m3)Mid (10g/m3)High (20g/m3)March 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting4-1-02WeekStarting4-8-02WeekStarting4-15-02WeekStarting4-22-02WeekStarting4-29-02WeekStarting4-1-02WeekStarting4-8-02WeekStarting4-15-02WeekStarting4-22-02WeekStarting4-29-02WeekStarting4-1-02WeekStarting4-8-02WeekStarting4-15-02WeekStarting4-22-02WeekStarting4-29-02Isobutane2.2 2.3 2.6 2.2 2.3 2.3 2.1 2.2 2.1 2.2 2.2 2.0 2.1 2.2 2.2 2.2n-butane11.1 10.4 10.7 10.6 10.5 10.6 10.4 10.7 10.3 10.4 10.6 9.8 10.1 10.6 10.6 10.7Isopentane31.0 29.7 30.0 30.2 29.8 29.8 30.6 30.5 30.6 30.4 30.3 30.3 30.6 30.6 30.5 30.6n-pentane9.1 8.8 8.9 9.0 8.7 8.9 8.9 8.9 8.9 8.9 9.0 8.9 8.9 8.9 8.9 8.9trans-2-pentene2.0 2.0 2.2 2.2 2.6 2.2 1.9 2.0 2.1 2.1 2.1 2.0 1.9 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.1 3.0 2.9 3.0 2.9 2.9 2.9 2.8 2.9 2.8 2.9 3.0 3.0 3.0MTBE/2,3-dimethylbutaneMTBE21.3 22.3 21.0 21.5 21.1 21.1 22.7 22.4 22.8 22.7 22.3 23.1 22.9 22.4 22.4 22.32,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 1.0 0.9 1.0 1.0 0.9 1.0 1.0 0.9 0.9 0.92-methylpentane4.5 4.5 4.4 4.5 4.5 4.6 4.6 4.5 4.6 4.6 4.5 4.7 4.6 4.5 4.5 4.53-methylpentane2.6 2.6 2.7 2.6 2.9 2.7 2.6 2.6 2.6 2.6 2.6 2.7 2.7 2.6 2.6 2.6n-hexane2.1 2.2 2.1 2.3 2.2 2.1 2.1 2.1 2.1 2.2 2.1 2.2 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.2 1.2 1.2 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.2 1.2 1.1 1.1 1.1 1.0 1.0 0.9 0.8 0.9 1.0 1.1 0.9 0.9 1.0Benzene1.5 1.7 1.7 1.6 1.8 1.8 1.5 1.6 1.5 1.5 1.8 1.7 1.5 1.6 1.6 1.62-methylhexane1.0 1.2 1.0 1.1 1.1 1.1 1.0 0.9 1.0 1.0 0.9 1.1 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.1 1.1 1.1 1.4 1.4 1.1 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.1 1.13-methylhexane1.1 1.3 1.4 1.2 1.2 1.2 1.1 1.1 1.1 1.2 1.1 1.2 1.2 1.1 1.1 1.1Isooctane1.2 1.4 1.5 1.3 1.4 1.5 1.2 1.2 1.2 1.2 1.2 1.3 1.3 1.3 1.3 1.3Toluene2.5 2.2 2.3 2.4 2.3 2.5 2.0 2.1 2.0 2.0 2.1 1.9 1.9 2.1 2.1 2.1Low (2.0g/m3)Mid (10g/m3)High (20g/m3)April 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting5-6-02WeekStarting5-13-02WeekStarting5-20-02WeekStarting5-27-02WeekStarting5-6-02WeekStarting5-13-02WeekStarting5-20-02WeekStarting5-27-02WeekStarting5-6-02WeekStarting5-13-02WeekStarting5-20-02WeekStarting5-27-02Isobutane 2.2 2.3 2.4 2.3 2.4 2.2 2.2 2.3 2.3 2.2 2.3 2.2 2.2n-butane 11.1 10.6 10.5 10.6 11.3 10.6 10.8 10.7 10.6 10.6 11.0 10.8 10.7Isopentane 31.0 29.9 29.6 29.0 30.1 30.4 30.6 30.4 29.9 30.5 30.9 30.5 30.9n-pentane 9.1 9.0 9.3 8.9 8.8 8.9 8.9 9.0 8.9 8.9 9.0 8.9 9.0trans-2-pentene 2.0 2.8 2.6 2.9 2.7 2.1 2.0 2.1 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 3.0 3.1 3.2 2.9 2.9 3.0 3.1 3.0 3.0 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 20.8 20.8 21.0 20.4 22.2 22.2 22.1 21.8 22.2 22.1 22.1 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.92-methylpentane 4.5 4.4 4.6 4.5 4.5 4.5 4.5 4.4 4.5 4.5 4.5 4.5 4.53-methylpentane 2.6 2.6 2.6 2.5 2.6 2.6 2.6 2.5 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.1 2.2 2.2 2.2 2.1 2.1 2.1 2.2 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.3 1.3 1.1 1.2 1.1 1.1 1.2 1.1 1.1 1.2 1.12,4-dimethylpentane 0.9 1.2 1.2 1.0 1.2 0.9 0.9 0.9 1.0 0.9 0.9 1.0 0.9Benzene 1.5 2.2 1.6 2.2 2.1 1.8 1.8 1.8 1.9 1.6 1.6 1.6 1.62-methylhexane 1.0 0.9 1.2 1.1 1.1 1.0 1.0 1.0 1.1 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.1 1.3 1.4 1.4 1.1 1.1 1.1 1.3 1.1 1.0 1.1 1.13-methylhexane 1.1 1.2 1.1 1.3 1.3 1.1 1.1 1.1 1.2 1.1 1.1 1.2 1.1Isooctane 1.2 1.4 1.4 1.5 1.3 1.2 1.2 1.2 1.3 1.3 1.2 1.2 1.3Toluene 2.5 2.4 2.1 2.2 1.8 2.1 2.0 2.1 2.1 2.1 1.9 2.1 2.0Low (2.0g/m3)Mid (10g/m3)High (20g/m3)May2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting6-03-02WeekStarting6-10-02WeekStarting6-17-02WeekStarting6-24-02WeekStarting6-03-02WeekStarting6-10-02WeekStarting6-17-02WeekStarting6-24-02WeekStarting6-03-02WeekStarting6-10-02WeekStarting6-17-02WeekStarting6-24-02Isobutane 2.2 2.4 2.1 2.4 2.3 2.3 2.2 2.3 2.1 2.3 2.1 2.3 2.1n-butane 11.1 9.9 10.3 10.6 10.1 11.0 10.4 10.9 10.4 11.4 10.1 11.0 10.0Isopentane 31.0 27.3 28.7 29.1 28.6 30.9 30.3 30.6 30.6 31.8 30.7 31.4 30.4n-pentane 9.1 8.5 8.5 8.9 8.6 8.9 8.8 8.9 8.8 9.0 8.8 8.9 8.8trans-2-pentene 2.0 2.2 2.1 2.2 2.3 2.0 2.0 2.1 2.0 2.0 1.9 2.0 1.92-methyl-2-butene 2.9 2.9 2.8 2.8 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 22.6 22.5 22.6 22.2 23.3 23.7 23.1 23.4 22.8 23.9 22.8 23.62,3-dimethylbutane 0.9 1.0 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.6 4.6 4.4 4.5 4.5 4.5 4.4 4.6 4.3 4.5 4.4 4.63-methylpentane 2.6 2.9 2.5 2.5 2.5 2.5 2.6 2.5 2.6 2.5 2.6 2.5 2.6n-hexane 2.1 2.2 2.3 2.1 2.2 2.0 2.1 2.1 2.1 2.0 2.1 2.0 2.1Methylcyclopentane 1.1 1.2 1.5 1.3 1.3 1.1 1.1 1.1 1.1 1.0 1.1 1.1 1.12,4-dimethylpentane 0.9 1.3 1.7 1.1 1.1 0.9 1.0 0.9 1.0 0.9 1.0 0.9 1.0Benzene 1.5 2.2 1.7 3.8 1.8 1.4 1.4 1.4 1.4 1.3 1.6 1.4 1.72-methylhexane 1.0 1.4 1.1 1.2 1.4 0.9 1.0 0.9 1.0 0.9 1.0 0.9 1.12,3-dimethylpentane 1.0 1.8 1.3 1.5 2.3 1.1 1.1 1.1 1.1 1.0 1.1 1.0 1.13-methylhexane 1.1 1.4 1.3 1.3 1.2 1.1 1.1 1.1 1.1 1.0 1.1 1.0 1.1Isooctane 1.2 1.7 1.5 1.6 1.6 1.1 1.2 1.2 1.2 1.1 1.2 1.2 1.3Toluene 2.5 2.5 2.4 1.9 2.0 1.3 1.8 1.7 1.8 0.9 1.4 1.4 1.7Low (2.0g/m3)Mid (10g/m3)High (20g/m3)June 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting7-01-02WeekStarting7-08-02WeekStarting7-15-02WeekStarting7-22-02WeekStarting7-29-02WeekStarting7-01-02WeekStarting7-08-02WeekStarting7-15-02WeekStarting7-22-02WeekStarting7-29-02WeekStarting7-01-02WeekStarting7-08-02WeekStarting7-15-02WeekStarting7-22-02WeekStarting7-29-02Isobutane2.2 2.3 2.4 2.4 2.4 2.3 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.1n-butane11.1 10.1 10.5 11.1 10.4 10.2 10.6 10.6 10.7 10.6 10.5 10.9 10.9 10.8 10.8 10.1Isopentane31.0 28.3 28.7 30.4 28.3 28.5 30.2 30.4 30.2 30.3 30.5 31.1 31.2 31.0 30.8 30.5n-pentane9.1 8.5 8.4 9.3 8.4 8.7 8.8 8.8 8.8 8.8 8.8 8.9 8.9 8.9 8.9 8.8trans-2-pentene2.0 2.1 2.5 3.0 2.2 2.4 2.0 2.1 2.2 2.1 2.0 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 2.9 2.8 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.9 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE21.3 22.3 22.6 19.8 22.2 21.6 22.7 22.7 22.9 22.9 23.6 22.5 22.5 22.7 22.6 23.62,3-dimethylbutane 0.9 0.9 1.0 0.8 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.4 4.5 4.3 4.5 4.5 4.4 4.5 4.4 4.5 4.5 4.4 4.4 4.4 4.4 4.63-methylpentane2.6 2.7 2.8 2.2 2.7 2.6 2.6 2.6 2.5 2.6 2.6 2.5 2.5 2.5 2.5 2.6n-hexane2.1 2.3 2.2 1.9 2.7 2.3 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.0 2.0 2.1Methylcyclopentane 1.1 1.4 1.3 1.4 1.1 1.3 1.1 1.1 1.1 1.1 1.0 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.1 2.1 1.3 1.3 1.0 0.9 1.1 1.0 1.1 1.0 0.9 1.0 0.9 1.0Benzene1.5 1.8 1.7 1.8 2.3 1.9 1.9 1.8 1.5 1.8 1.4 1.5 1.5 1.5 1.6 1.42-methylhexane1.0 1.2 1.4 1.1 1.3 1.4 1.1 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.0 1.02,3-dimethylpentane 1.0 1.6 1.4 1.4 1.6 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.0 1.0 1.1 1.13-methylhexane1.1 1.5 1.2 1.2 1.5 1.8 1.1 1.1 1.1 1.1 1.0 1.1 1.1 1.1 1.1 1.1Isooctane1.2 1.7 1.4 1.3 1.3 1.4 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.3Toluene2.5 3.0 2.2 2.0 2.2 2.9 2.1 2.0 2.0 2.0 1.6 1.7 1.7 1.7 2.0 1.8Low (2.0g/m3)Mid (10g/m3)High (20g/m3)July 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting8-05-02WeekStarting8-12-02WeekStarting8-19-02WeekStarting8-26-02WeekStarting8-05-02WeekStarting8-12-02WeekStarting8-19-02WeekStarting8-26-02WeekStarting8-05-02WeekStarting8-12-02WeekStarting8-19-02WeekStarting8-26-02Isobutane2.2 2.0 2.3 2.1 2.3 2.2 2.2 2.2 2.2 2.2 2.1 2.2 2.2n-butane11.1 10.0 10.7 10.0 10.0 10.5 10.6 10.5 10.5 10.8 10.2 10.8 10.7Isopentane31.0 28.3 28.3 27.1 27.5 30.8 30.6 30.3 30.5 31.0 30.5 31.0 30.9n-pentane9.1 8.5 8.3 8.1 8.3 8.8 8.9 8.8 8.9 8.9 8.8 8.9 8.9trans-2-pentene2.0 2.3 2.0 2.8 2.6 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.7 2.9 2.9 3.0 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE21.3 22.2 22.0 21.3 21.2 23.3 23.3 22.9 23.2 22.7 23.5 22.6 22.92,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.4 4.6 4.4 4.9 4.5 4.5 4.4 4.5 4.4 4.5 4.4 4.43-methylpentane2.6 2.6 2.5 2.8 2.6 2.6 2.7 2.6 2.6 2.5 2.6 2.5 2.5n-hexane2.1 2.4 2.2 2.2 2.3 2.1 2.1 2.1 2.1 2.0 2.1 2.0 2.0Methylcyclopentane 1.1 1.2 1.4 1.4 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.5 1.6 1.3 2.4 0.9 0.9 1.0 0.7 0.9 0.9 1.0 0.9Benzene1.5 2.1 1.4 1.9 1.7 1.4 1.4 1.8 1.4 1.5 1.6 1.5 1.52-methylhexane1.0 1.2 1.1 1.7 1.3 0.9 1.0 1.0 1.0 1.0 1.0 0.9 1.02,3-dimethylpentane 1.0 1.6 1.7 2.3 1.9 1.1 1.1 1.1 1.1 1.1 1.1 1.0 1.13-methylhexane1.1 1.4 1.7 1.9 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1Isooctane1.2 1.7 1.9 1.9 1.5 1.2 1.2 1.2 1.1 1.2 1.3 1.2 1.2Toluene2.5 2.9 2.3 3.0 2.6 1.7 1.7 2.2 1.9 1.8 1.7 1.8 1.8Low (2.0g/m3)Mid (10g/m3)High (20g/m3)August 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting9-2-02WeekStarting9-9-02WeekStarting9-16-02WeekStarting9-23-02WeekStarting9-30-02WeekStarting9-2-02WeekStarting9-9-02WeekStarting9-16-02WeekStarting9-23-02WeekStarting9-30-02WeekStarting9-2-02WeekStarting9-9-02WeekStarting9-16-02WeekStarting9-23-02WeekStarting9-30-02Isobutane2.2 2.5 2.1 2.3 2.2 2.5 2.2 2.2 2.0 2.1 2.1 2.3 2.1 2.0 2.1 2.2n-butane11.1 9.6 9.8 10.2 9.7 9.8 10.5 10.7 10.0 10.4 10.2 11.0 10.0 9.6 10.5 10.4Isopentane31.0 26.4 28.4 28.1 27.5 27.5 30.2 30.3 30.5 30.4 30.1 30.7 30.6 30.3 31.0 30.7n-pentane9.1 8.4 8.4 8.8 8.7 8.2 8.8 8.8 8.8 8.9 8.8 8.9 8.8 8.8 8.9 8.9trans-2-pentene2.0 2.9 2.1 2.9 2.8 2.5 2.0 1.9 2.0 2.0 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.7 2.6 2.9 2.8 2.7 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8MTBE/2,3-dimethylbutaneMTBE21.3 21.7 22.5 22.9 22.0 21.7 22.8 22.8 23.9 23.2 23.0 22.5 23.7 24.0 22.9 22.82,3-dimethylbutane 0.9 0.9 0.9 1.0 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.4 5.0 4.4 5.0 4.4 4.4 4.4 4.6 4.5 4.5 4.4 4.6 4.6 4.4 4.43-methylpentane2.6 2.8 3.0 2.5 2.5 2.7 2.6 2.5 2.6 2.6 2.6 2.5 2.6 2.7 2.6 2.6n-hexane2.1 2.1 2.2 2.3 2.1 2.3 2.1 2.1 2.1 2.1 2.1 2.0 2.1 2.2 2.1 2.1Methylcyclopentane 1.1 1.4 1.2 1.4 1.6 1.5 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.2 1.1 1.12,4-dimethylpentane 0.9 2.5 1.0 1.0 1.1 2.3 1.0 1.0 1.0 0.9 1.0 0.9 1.0 0.8 1.0 1.0Benzene1.5 2.0 1.7 2.0 2.0 1.8 1.8 1.8 1.3 1.9 1.8 1.8 1.4 1.4 1.5 1.62-methylhexane1.0 1.2 1.3 1.1 1.3 1.2 1.0 1.0 1.0 1.0 1.1 0.9 1.0 1.0 0.9 1.02,3-dimethylpentane 1.0 1.9 2.0 1.7 1.7 2.0 1.1 1.1 1.1 1.0 1.3 1.0 1.1 1.2 1.0 1.13-methylhexane1.1 1.6 1.3 1.2 1.6 1.5 1.0 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.1 1.1Isooctane1.2 1.6 1.9 1.3 1.7 2.1 1.2 1.2 1.3 1.2 1.2 1.2 1.3 1.4 1.2 1.3Toluene2.5 3.5 2.6 2.0 2.6 2.5 2.1 2.1 1.7 2.0 2.2 1.9 1.7 1.9 1.7 1.9Low (2.0g/m3)Mid (10g/m3)High (20g/m3)September 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting10-7-02WeekStarting10-14-02WeekStarting10-21-02WeekStarting10-28-02WeekStarting10-7-02WeekStarting10-14-02WeekStarting10-21-02WeekStarting10-28-02WeekStarting10-7-02WeekStarting10-14-02WeekStarting10-21-02WeekStarting10-28-02Isobutane 2.2 2.3 2.0 2.1 1.9 2.0 2.1 2.0 2.1 1.9 2.1 2.1 2.1n-butane 11.1 9.8 10.1 9.5 9.0 9.9 10.3 10.1 10.1 9.5 10.4 10.3 10.3Isopentane 31.0 28.1 28.3 27.6 25.7 30.2 30.1 30.2 30.1 30.2 30.7 30.9 31.0n-pentane 9.1 8.6 8.7 8.8 7.9 8.8 8.7 8.8 8.8 8.8 8.8 8.9 8.9trans-2-pentene 2.0 2.5 2.6 2.6 2.2 2.0 1.9 2.1 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 2.7 2.9 2.9 2.8 2.8 2.8 2.8 2.8 2.8 2.9 2.8MTBE/2,3-dimethylbutaneMTBE 21.3 23.2 22.1 21.7 24.9 23.5 23.0 23.1 22.7 24.0 23.1 23.0 23.12,3-dimethylbutane 0.9 1.0 0.9 0.9 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.7 4.6 5.4 4.5 4.5 4.5 4.5 4.7 4.5 4.5 4.53-methylpentane 2.6 2.6 2.7 2.7 2.8 2.6 2.6 2.6 2.6 2.6 2.5 2.6 2.6n-hexane 2.1 2.2 2.2 2.6 1.9 2.1 2.1 2.1 2.1 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.4 1.4 1.5 1.1 1.1 1.1 1.2 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.2 1.1 1.5 3.2 1.1 1.1 0.9 1.0 0.9 0.9 0.8 1.0Benzene 1.5 1.9 1.8 2.2 2.0 1.5 1.8 1.8 1.5 1.5 1.6 1.6 1.52-methylhexane 1.0 1.0 1.2 1.4 1.0 1.0 1.0 1.0 1.1 1.1 1.0 1.0 0.92,3-dimethylpentane 1.0 1.3 1.6 1.8 1.3 1.1 1.2 1.1 1.1 1.2 1.1 1.1 1.13-methylhexane 1.1 1.3 1.4 1.7 1.4 1.2 1.1 1.2 2.3 1.2 1.1 1.1 1.1Isooctane 1.2 1.6 1.5 1.4 1.4 1.3 1.3 1.3 1.1 1.4 1.3 1.2 1.2Toluene 2.5 2.8 2.8 2.8 2.4 2.1 2.1 2.2 2.0 1.9 1.9 1.8 1.6Low (2.0g/m3)Mid (10g/m3)High (20g/m3)October 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting11-4-02WeekStarting11-11-02WeekStarting11-18-02WeekStarting11-25-02WeekStarting11-4-02WeekStarting11-11-02WeekStarting11-18-02WeekStarting11-25-02WeekStarting11-4-02WeekStarting11-11-02WeekStarting11-18-02WeekStarting11-25-02Isobutane2.2 2.1 2.1 2.5 2.1 2.0 2.0 2.0 2.0 2.1 1.9 1.9 2.1n-butane11.1 9.5 9.8 9.6 9.5 9.8 9.9 9.8 9.9 10.3 9.4 9.2 10.3Isopentane31.0 27.5 27.7 27.1 26.6 30.0 30.3 30.3 30.1 30.7 30.1 30.0 30.7n-pentane9.1 8.4 8.5 8.5 8.7 9.0 8.8 8.9 9.0 9.0 8.8 8.8 8.9trans-2-pentene2.0 2.7 2.6 3.1 2.7 2.2 2.0 2.1 2.1 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 3.3 4.0 3.0 2.9 2.8 2.9 2.9 2.9 2.8 2.8 2.9MTBE/2,3-dimethylbutaneMTBE21.3 22.6 23.2 22.5 22.4 23.5 23.4 23.6 23.4 22.8 23.9 24.2 22.72,3-dimethylbutane 0.9 1.0 1.0 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane4.5 4.5 4.6 4.4 4.7 4.6 4.6 4.6 4.7 4.5 4.7 4.8 4.53-methylpentane2.6 2.6 2.4 2.4 2.7 2.7 2.6 2.7 2.7 2.6 2.7 2.7 2.6n-hexane2.1 2.1 2.0 2.0 2.1 2.1 2.2 2.1 2.2 2.1 2.1 2.2 2.1Methylcyclopentane 1.1 1.3 1.3 1.9 1.5 1.1 1.2 1.2 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.6 1.3 1.8 1.8 1.0 1.3 1.0 0.9 1.0 1.0 1.0 1.0Benzene1.5 2.1 2.0 1.7 2.6 1.4 1.4 1.5 1.5 1.6 1.6 1.4 1.62-methylhexane1.0 1.2 1.4 1.4 1.3 0.9 0.9 1.0 1.0 1.0 1.2 1.1 1.02,3-dimethylpentane 1.0 1.5 1.6 1.7 1.7 1.1 1.2 1.2 1.3 1.1 1.2 1.2 1.13-methylhexane1.1 1.7 1.6 1.2 1.4 1.2 1.2 1.1 1.2 1.2 1.2 1.2 1.2Isooctane1.2 1.7 1.5 1.4 1.9 1.3 1.3 1.3 1.2 1.3 1.4 1.4 1.2Toluene2.5 2.9 2.3 2.0 2.5 2.1 1.9 1.9 2.0 1.9 1.9 1.8 2.0Low (2.0g/m3)Mid (10g/m3)High (20g/m3)November 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting12-2-02WeekStarting12-9-02WeekStarting12-16-02WeekStarting12-23-02WeekStarting12-30-02WeekStarting12-2-02WeekStarting12-9-02WeekStarting12-16-02WeekStarting12-23-02WeekStarting12-30-02WeekStarting12-2-02WeekStarting12-9-02WeekStarting12-16-02WeekStarting12-23-02WeekStarting12-30-02Isobutane2.2 2.2 2.6 2.0 2.1 2.2 2.1 1.8 2.0 2.1 2.1 2.1 1.8 2.1 2.1 2.0n-butane 11.1 10.0 9.5 9.6 9.6 9.8 10.2 9.4 10.1 10.1 10.1 10.3 9.5 10.3 10.4 10.2Isopentane 31.0 27.9 28.2 27.7 27.5 28.7 30.4 30.0 30.2 30.4 30.3 30.8 30.6 31.0 30.9 30.7n-pentane 9.1 8.9 8.6 8.5 8.4 8.7 8.9 9.0 8.9 9.0 9.0 9.0 9.0 9.0 9.0 9.0trans-2-pentene 2.0 2.6 2.7 2.8 2.0 2.5 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.12-methyl-2-butene 2.9 2.8 2.9 2.8 2.8 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.9 21.9 22.8 22.8 21.8 23.1 23.4 22.9 22.9 23.0 22.7 23.3 22.8 22.6 22.62,3-dimethylbutane 0.9 1.0 0.9 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.5 4.4 4.4 4.6 4.4 4.6 4.6 4.6 4.6 4.6 4.6 4.7 4.5 4.5 4.53-methylpentane 2.6 2.7 2.5 2.5 2.6 2.8 2.6 2.7 2.6 2.7 2.6 2.6 2.7 2.6 2.6 2.6n-hexane 2.1 2.2 2.1 2.4 2.3 2.2 2.1 2.2 2.1 2.2 2.1 2.1 2.2 2.1 2.1 2.1Methylcyclopentane 1.1 1.1 1.3 1.2 1.5 1.3 1.1 1.2 1.2 1.2 1.1 1.1 1.2 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.3 1.0 1.2 1.2 0.9 1.0 1.0 0.9 1.0 0.9 1.0 1.0 0.9 0.9Benzene 1.5 1.9 1.7 2.1 1.9 2.1 1.5 1.6 1.5 1.5 1.6 1.6 1.6 1.5 1.6 1.62-methylhexane 1.0 1.3 1.4 1.4 1.3 1.5 1.0 1.0 1.0 0.9 1.0 1.0 1.1 1.0 1.0 1.02,3-dimethylpentane 1.0 1.7 1.6 2.0 1.5 1.3 1.1 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.13-methylhexane 1.1 1.3 1.5 1.6 1.3 1.4 1.1 1.3 1.2 1.1 1.1 1.1 1.2 1.1 1.1 1.2Isooctane 1.2 1.7 1.4 1.5 2.9 1.6 1.2 1.3 1.3 1.3 1.2 1.3 1.3 1.2 1.2 1.2Toluene 2.5 2.1 3.6 2.8 2.8 2.7 2.0 2.2 2.2 2.1 2.2 1.9 1.9 1.6 1.9 2.1Low (2.0g/m3)Mid (10g/m3)High (20g/m3)December 2002Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting1-6-03WeekStarting1-13-03WeekStarting1-20-03WeekStarting1-27-03WeekStarting1-6-03WeekStarting1-13-03WeekStarting1-20-03WeekStarting1-27-03WeekStarting1-6-03WeekStarting1-13-03WeekStarting1-20-03WeekStarting1-27-03Isobutane 2.2 2.1 2.2 2.1 2.2 2.0 2.0 2.1 2.2 2.0 2.0 2.1 2.1n-butane 11.1 9.4 9.1 10.0 10.0 10.1 9.9 10.2 10.5 10.2 10.2 10.0 10.6Isopentane 31.0 27.9 27.3 28.4 27.5 30.7 30.2 30.3 30.5 30.8 30.7 30.8 31.1n-pentane 9.1 8.5 8.7 8.8 8.8 8.9 8.9 8.8 8.9 9.0 8.9 8.9 9.0trans-2-pentene 2.0 2.4 2.3 2.4 2.5 2.2 2.2 1.9 2.1 2.1 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 2.9 3.3 3.3 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 23.3 22.7 22.3 22.6 23.6 23.3 23.3 23.0 22.9 22.8 22.8 22.62,3-dimethylbutane 0.9 1.0 1.0 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02-methylpentane 4.5 4.9 4.5 4.4 4.6 4.6 4.6 4.7 4.6 4.6 4.6 4.6 4.53-methylpentane 2.6 2.8 3.1 2.6 2.5 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.2 2.3 2.3 2.1 2.1 2.2 2.2 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.4 1.2 1.5 1.1 1.2 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.0 1.9 1.3 1.1 0.9 1.0 1.0 0.7 1.0 1.0 0.9 0.9Benzene 1.5 1.8 2.0 1.9 2.0 1.4 1.5 1.5 1.5 1.6 1.6 1.5 1.52-methylhexane 1.0 1.1 1.0 1.1 1.3 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.3 1.9 1.3 1.9 1.1 1.3 1.2 1.2 1.1 1.1 1.1 1.13-methylhexane 1.1 1.9 1.4 1.4 1.4 1.1 1.0 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.6 1.4 1.4 1.3 1.2 1.2 1.2 1.2 1.2 1.3 1.3 1.2Toluene 2.5 2.7 2.8 2.8 2.7 1.5 2.0 2.1 2.0 1.8 2.0 1.9 1.7Low (2.0g/m3)Mid (10g/m3)High (20g/m3)January 2003Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting2-3-03WeekStarting2-10-03WeekStarting2-17-03WeekStarting2-24-03WeekStarting2-3-03WeekStarting2-10-03WeekStarting2-17-03WeekStarting2-24-03WeekStarting2-3-03WeekStarting2-10-03WeekStarting2-17-03WeekStarting2-24-03Isobutane2.2 2.0 2.7 2.2 2.2 2.1 2.1 2.2 2.1 2.1 2.1 2.2 2.1n-butane11.1 9.5 9.9 9.8 10.1 10.2 10.2 10.6 10.3 10.4 10.0 10.8 10.0Isopentane31.0 27.1 27.4 27.1 28.5 30.3 30.3 30.5 30.3 30.7 30.7 30.9 30.7n-pentane9.1 8.9 8.6 8.6 8.5 8.9 8.8 8.9 8.9 8.9 8.9 9.0 8.9trans-2-pentene2.0 3.2 2.3 2.6 2.0 2.1 2.0 2.0 2.1 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.8 3.0 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.8 2.9 2.8MTBE/2,3-dimethylbutaneMTBE21.3 22.7 22.1 21.7 21.8 23.3 23.2 22.7 23.0 22.7 23.4 22.3 23.32,3-dimethylbutane 0.9 1.0 0.9 0.9 0.9 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.02-methylpentane4.5 4.7 4.7 4.3 4.5 4.6 4.6 4.5 4.6 4.5 4.7 4.4 4.63-methylpentane2.6 2.7 2.7 2.8 3.1 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.7n-hexane2.1 2.1 2.2 2.5 2.2 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.4 1.2 1.3 1.4 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.4 1.2 1.1 0.9 1.0 1.0 1.0 1.0 1.0 0.9 1.0Benzene1.5 1.8 1.7 1.8 2.1 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.62-methylhexane1.0 1.4 1.4 1.6 1.2 1.0 1.0 1.0 0.9 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.8 1.9 1.8 1.5 1.2 1.2 1.1 1.2 1.1 1.1 1.1 1.13-methylhexane1.1 1.7 1.5 1.7 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1Isooctane1.2 1.2 1.5 1.8 1.7 1.3 1.2 1.2 1.3 1.3 1.3 1.2 1.3Toluene2.5 3.1 2.9 3.3 2.9 2.0 2.1 2.1 2.0 2.0 1.5 1.9 1.5Low (2.0g/m3)Mid (10g/m3)High (20g/m3)February 2003Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)ComponentTargetWeekStarting3-3-03WeekStarting3-10-03WeekStarting3-17-03WeekStarting3-24-03WeekStarting3-31-03WeekStarting3-3-03WeekStarting3-10-03WeekStarting3-17-03WeekStarting3-24-03WeekStarting3-31-03WeekStarting3-3-03WeekStarting3-10-03WeekStarting3-17-03WeekStarting3-24-03WeekStarting3-31-03Isobutane2.2 2.1 2.3 2.2 2.4 2.1 2.2 2.1 2.2 2.2 2.2 2.2 2.1 2.3 2.2 2.2n-butane 11.1 9.8 10.1 10.5 9.9 10.4 10.5 10.2 10.7 10.6 10.6 10.7 10.1 10.9 10.8 10.7Isopentane 31.0 28.0 28.3 28.8 28.0 28.5 30.3 30.4 30.5 30.4 30.5 30.9 30.8 31.0 31.0 30.7n-pentane 9.1 8.9 8.4 8.9 8.4 8.7 8.8 8.9 8.8 8.9 8.9 8.9 8.9 8.9 8.9 8.9trans-2-pentene 2.0 2.7 2.3 2.3 2.4 2.6 2.1 2.0 2.0 2.1 2.1 2.0 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.4 2.9 3.3 3.5 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 22.4 22.3 22.1 21.5 21.9 22.7 23.2 22.5 22.4 22.7 22.4 23.3 22.3 22.3 22.42,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 1.0 1.0 0.9 0.9 1.0 0.9 1.0 0.9 0.9 0.92-methylpentane 4.5 4.4 4.6 4.4 4.5 4.6 4.5 4.6 4.5 4.5 4.5 4.5 4.6 4.5 4.5 4.53-methylpentane 2.6 2.7 2.5 2.7 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6n-hexane 2.1 2.2 2.3 2.1 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.3 1.2 1.6 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.2 1.1 1.0 1.4 1.2 1.0 1.0 1.0 1.0 0.8 1.0 0.9 0.8 0.9 0.9Benzene 1.5 2.1 1.8 1.9 1.8 2.3 1.5 1.4 1.6 1.5 1.6 1.6 1.4 1.5 1.5 1.62-methylhexane 1.0 1.4 1.1 1.1 1.1 1.2 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.4 1.4 1.3 1.6 1.3 1.1 1.2 1.1 1.2 1.1 1.0 1.1 1.1 1.1 1.13-methylhexane 1.1 1.4 1.4 1.3 1.7 1.2 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1Isooctane 1.2 1.5 1.7 1.4 1.9 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.3 1.2 1.2 1.2Toluene 2.5 2.8 2.7 2.9 2.8 2.5 2.1 2.0 2.2 2.2 2.1 1.9 1.6 1.9 1.8 2.1Low (2.0g/m3)Mid (10g/m3)High (20g/m3)March 2003Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting4-7-03WeekStarting4-14-03WeekStarting4-21-03WeekStarting4-28-03WeekStarting4-7-03WeekStarting4-14-03WeekStarting4-21-03WeekStarting4-28-03WeekStarting4-7-03WeekStarting4-14-03WeekStarting4-21-03WeekStarting4-28-03Isobutane 2.2 2.4 2.3 2.2 2.5 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.3n-butane 11.1 10.5 10.4 10.4 10.2 10.6 10.7 10.6 10.8 10.9 10.9 10.8 10.9Isopentane 31.0 28.6 29.1 28.6 28.3 30.5 30.6 30.7 30.7 30.8 31.0 30.8 31.0n-pentane 9.1 8.9 8.6 8.5 8.5 8.9 8.9 8.9 8.9 8.9 8.9 8.9 8.9trans-2-pentene 2.0 2.6 2.4 2.3 2.2 2.1 2.1 2.0 2.0 2.0 2.1 2.0 2.02-methyl-2-butene 2.9 3.8 3.4 3.5 3.3 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE 21.3 21.6 22.1 22.2 22.0 22.9 22.5 22.9 22.6 22.3 22.3 22.3 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 1.0 0.9 1.0 1.0 0.9 0.9 0.9 0.92-methylpentane 4.5 4.5 4.5 4.5 4.4 4.5 4.5 4.5 4.5 4.4 4.5 4.5 4.43-methylpentane 2.6 2.6 2.5 2.6 2.7 2.6 2.6 2.6 2.6 2.5 2.5 2.6 2.5n-hexane 2.1 2.1 2.2 2.3 2.3 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.2 1.2 1.5 1.3 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.4 1.2 1.3 1.0 0.9 0.9 0.9 0.9 0.9 0.9 0.9 1.0Benzene 1.5 1.6 1.9 1.8 2.0 1.5 1.5 1.4 1.5 1.6 1.6 1.6 1.62-methylhexane 1.0 1.3 1.2 1.2 1.4 0.9 0.9 0.9 0.9 1.0 1.0 1.0 1.02,3-dimethylpentane 1.0 1.5 1.3 1.3 1.5 1.2 1.1 1.1 1.1 1.0 1.0 1.1 1.13-methylhexane 1.1 1.2 1.1 1.5 1.3 1.1 1.1 1.0 1.0 1.1 1.1 1.1 1.1Isooctane 1.2 1.4 1.6 1.4 1.5 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2Toluene 2.5 2.3 2.2 2.1 2.6 1.9 2.1 1.8 2.0 2.0 1.9 2.0 1.9Low (2.0g/m3)Mid (10g/m3)High (20g/m3)April 2003Protocol Number FY01-013Chronic Inhalation of Gasoline MTBE Vapor CondensateWeekly Gas Chromatographic Profiles of Chamber Atmospheres (Area %)Component TargetWeekStarting5-5-03WeekStarting5-12-03WeekStarting5-19-03WeekStarting5-26-03WeekStarting5-5-03WeekStarting5-12-03WeekStarting5-19-03WeekStarting5-26-03WeekStarting5-5-03WeekStarting5-12-03WeekStarting5-19-03WeekStarting5-26-03Isobutane2.2 2.2 2.2 2.4 2.4 2.2 2.1 2.1 2.2 2.2 2.2 2.2 2.2n-butane11.1 10.2 10.2 10.6 10.2 10.6 10.1 10.5 10.3 10.9 10.7 10.8 10.7Isopentane31.0 28.9 28.3 29.1 28.5 30.5 30.4 30.2 30.2 31.1 31.0 31.0 30.8n-pentane9.1 8.6 8.7 8.6 8.7 8.9 8.8 8.8 8.9 9.0 9.0 9.0 8.9trans-2-pentene2.0 2.6 2.2 2.3 2.4 2.1 1.9 2.1 2.2 2.0 2.0 2.0 2.02-methyl-2-butene 2.9 2.9 3.5 3.2 3.0 2.9 3.3 2.9 2.9 2.9 2.9 2.9 2.9MTBE/2,3-dimethylbutaneMTBE21.3 21.7 21.5 21.2 21.8 22.4 23.0 22.1 22.7 22.3 22.4 22.3 22.22,3-dimethylbutane 0.9 0.9 0.9 0.9 0.9 0.9 1.0 0.9 1.0 0.9 0.9 0.9 0.92-methylpentane4.5 4.6 4.7 4.5 5.2 4.5 4.7 4.7 4.6 4.4 4.5 4.5 4.53-methylpentane2.6 2.5 2.5 2.8 2.7 2.6 2.7 2.7 2.7 2.5 2.6 2.6 2.6n-hexane2.1 2.2 2.2 2.2 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1Methylcyclopentane 1.1 1.3 1.4 1.4 1.1 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.12,4-dimethylpentane 0.9 1.1 1.0 1.2 1.0 0.9 1.0 1.1 1.0 0.9 0.9 0.9 0.9Benzene1.5 2.1 2.2 1.8 2.1 1.6 1.4 1.6 1.4 1.5 1.5 1.5 1.52-methylhexane1.0 1.2 1.3 1.1 1.1 1.0 1.0 1.0 1.0 0.9 1.0 1.0 1.02,3-dimethylpentane 1.0 1.3 1.6 1.6 1.6 1.1 1.3 1.2 1.3 1.0 1.1 1.1 1.13-methylhexane1.1 1.2 1.4 1.4 1.4 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.1Isooctane1.2 1.8 1.6 1.2 1.2 1.2 1.3 1.2 1.3 1.2 1.2 1.2 1.3Toluene2.5 2.4 2.7 2.7 2.5 2.2 1.9 2.3 2.0 1.8 1.8 1.8 1.9Low (2.0g/m3)Mid (10g/m3)High (20g/m3)May 2003

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

G-1 APPENDIX G

ENVIRONMENTAL DATA

G-1 Light and Sound Measurements

G-2 Monthly Summaries of Chambe r Flow, Relative Humidity, and

Temperature

G-3 Monthly Summaries of Percen t Time Environmental Conditions

were Out of Specified Ranges

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

G-1 Light and Sound MeasurementsLight and Sound Measurements FY01-013Date Chamber 5 (Control) Chamber 6 (2 g/m3) Chamber 7 (10 g/m3) Chamber 8 (20 g/m3)Decibels FootCandlesDecibels FootCandlesDecibels FootCandlesDecibels FootCandles3/15/01 81 40 77 30 74 45 73.5 445/16/01 ND 40 ND 20 ND 35 ND 515/18/01 84 31 80 13 80 28 80 2410/2/01 76 30.1 76 13.5 72 27.8 77 24.25/13/02 79 25 74 13 77 26.5 75 24.88/15/02 80 23.3 72 12.5 74 22 72.5 181/14/03 82 28.6 74 16.1 76 22.2 75 22.15/23/03 82 30 76 15 77 28 78 23aND. No value recorded. Measurements of both sound and light were recorded two days later.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

G-2 Monthly Summaries of Chamber Flow, Relative Humid ity, and Temperature

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 5 (Control)

Month Yea r Mean SD Max* Min*

May 2001 440 9 451 428

June 2001 462 23 499 430

July 2001 447 12 475 429

August 2001 447 12 476 423

September 2001 457 11 479 443

October 2001 454 13 476 431

November 2001 473 12 491 448

December 2001 455 10 468 427

January 2002 436 16 470 412

February 2002 479 22 522 443

March 2002 476 34 530 416

April 2002 430 6 443 416

May 2002 452 14 486 431

June 2002 449 9 469 433

July 2002 471 15 504 443

August 2002 443 16 500 419

September 2002 428 7 441 415

October 2002 432 7 445 416

November 2002 440 7 459 430

December 2002 437 7 454 423

January 2003 451 15 473 422

February 2003 446 4 456 438

March 2003 441 8 456 416

April 2003 449 9 463 436

May 2003 448 8 464 439

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:_____________

Summary of Relative Humidity Data (%RH)

Chamber 5 (Control)

Month Yea r Mean SD Max* Min*

May 2001 71 6 85 65

June 2001 73 8 84 51

July 2001 69 7 79 55

August 2001 68 6 78 58

September 2001 65 7 77 53

October 2001 55 12 74 30

November 2001 50 6 62 39

December 2001 48 8 72 38

January 2002 52 8 73 41

February 2002 39 6 49 24

March 2002 38 5 50 30

April 2002 42 6 61 30

May 2002 58 9 72 37

June 2002 67 4 75 56

July 2002 66 5 75 57

August 2002 67 5 84 59

September 2002 69 5 78 60

October 2002 63 11 84 45

November 2002 43 10 66 29

December 2002 40 4 50 34

January 2003 44 4 53 38

February 2003 41 8 60 28

March 2003 37 8 52 21

April 2003 32 9 50 17

May 2003 41 13 59 17

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data ( o 

# C)

Chamber 5 (Control)

Month Yea r Mean SD Max* Min*

May 2001 22 1 24 22

June 2001 23 1 24 21

July 2001 22 0 23 21

August 2001 22 1 23 21

September 2001 22 1 23 21

October 2001 22 1 23 21

November 2001 22 1 23 21

December 2001 22 1 23 21

January 2002 21 1 23 20

February 2002 22 1 23 20

March 2002 22 1 24 21

April 2002 22 0 23 21

May 2002 22 0 23 21

June 2002 22 0 22 21

July 2002 22 0 23 22

August 2002 22 0 23 21

September 2002 22 0 22 21

October 2002 22 0 23 21

November 2002 23 1 23 21

December 2002 23 0 23 22

January 2003 22 0 23 21

February 2003 21 0 22 21

March 2003 22 1 23 20

April 2003 21 0 22 21

May 2003 22 0 22 21

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 6 (2g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 451 23 467 411

June 2001 466 4 478 456

July 2001 465 12 484 443

August 2001 455 7 470 437

Septembe r 2001 459 6 467 446

October 2001 454 11 471 434

November 2001 450 22 484 419

December 2001 456 7 475 447

January 2002 451 19 494 423

February 2002 490 28 539 438

March 2002 439 15 452 368

April 2002 441 6 460 432

May 2002 444 18 474 395

June 2002 452 5 466 441

July 2002 473 16 501 450

August 2002 455 24 497 430

Septembe r 2002 453 24 485 413

October 2002 460 23 489 411

November 2002 462 7 479 453

December 2002 469 11 492 453

January 2003 460 6 468 451

February 2003 455 6 475 450

March 2003 441 13 477 420

April 2003 445 3 453 440

May 2003 443 3 447 438

*Min and Max of daily average

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Relative Humidity Data (%RH)

Chamber 6 (2g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 67 5 77 62

June 2001 78 4 85 71

July 2001 71 2 75 67

August 2001 69 3 74 64

Septembe r 2001 69 6 78 58

October 2001 59 9 72 47

November 2001 60 8 73 46

December 2001 57 6 72 47

January 2002 54 7 65 38

February 2002 45 9 59 25

March 2002 44 6 57 34

April 2002 46 10 71 29

May 2002 58 9 74 35

June 2002 57 1 57 51

July 2002 57 1 57 52

August 2002 57 1 58 55

Septembe r 2002 57 0 57 55

October 2002 57 2 57 47

November 2002 41 5 52 33

December 2002 41 4 48 34

January 2003 46 6 57 36

February 2003 45 5 54 36

March 2003 41 9 55 24

April 2003 43 6 55 34

May 2003 50 9 61 32

*Min and Max of daily average

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data ( o 

# C)

Chamber 6 (2g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 25 0 26 24

June 2001 24 1 25 22

July 2001 22 0 23 22

August 2001 23 0 23 22

Septembe r 2001 23 0 23 22

October 2001 23 0 23 22

November 2001 23 0 23 22

December 2001 22 1 23 21

January 2002 22 0 23 22

February 2002 22 1 23 19

March 2002 22 0 23 22

April 2002 22 0 23 22

May 2002 22 0 23 21

June 2002 22 0 23 21

July 2002 22 0 23 21

August 2002 22 1 23 21

Septembe r 2002 22 1 23 21

October 2002 22 1 23 21

November 2002 22 0 23 22

December 2002 22 0 22 21

January 2003 22 1 22 21

February 2003 22 0 23 21

March 2003 22 0 23 21

April 2003 22 1 22 21

May 2003 22 0 23 21

*Min and Max of daily average

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 7 (10g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 437 15 459 411

June 2001 452 9 470 437

July 2001 448 10 466 430

August 2001 446 9 472 428

Septembe r 2001 455 10 476 441

October 2001 444 11 461 421

November 2001 444 20 476 418

December 2001 438 5 447 431

January 2002 451 13 472 425

February 2002 481 33 546 429

March 2002 422 12 442 383

April 2002 440 17 497 410

May 2002 456 12 483 426

June 2002 470 9 491 457

July 2002 421 18 495 421

August 2002 448 10 465 429

Septembe r 2002 433 13 459 396

October 2002 440 6 452 430

November 2002 432 8 445 419

December 2002 444 6 458 436

January 2003 442 8 456 428

February 2003 434 4 439 424

March 2003 437 9 460 424

April 2003 430 5 438 422

May 2003 429 3 434 423

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Relative Humidity Data (%RH)

Chamber 7 (10g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 60 3 66 54

June 2001 71 9 83 52

July 2001 64 4 72 57

August 2001 67 4 75 59

Septembe r 2001 65 4 70 55

October 2001 54 11 73 38

November 2001 55 10 70 36

December 2001 52 6 69 43

January 2002 50 5 59 42

February 2002 40 9 56 25

March 2002 39 5 46 26

April 2002 44 12 75 27

May 2002 56 11 71 36

June 2002 65 7 77 50

July 2002 70 3 75 64

August 2002 70 7 82 58

Septembe r 2002 72 5 82 64

October 2002 59 7 72 48

November 2002 41 7 58 30

December 2002 40 5 48 33

January 2003 45 12 79 33

February 2003 41 6 57 29

March 2003 40 9 62 27

April 2003 36 5 52 27

May 2003 45 10 60 27

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data ( o 

# C)

Chamber 7 (10g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 24 0 25 24

June 2001 24 1 26 23

July 2001 23 0 23 22

August 2001 23 0 23 22

Septembe r 2001 23 0 23 22

October 2001 23 0 23 22

November 2001 23 0 24 23

December 2001 22 1 24 22

January 2002 22 0 23 22

February 2002 22 1 23 21

March 2002 22 0 23 22

April 2002 23 0 23 22

May 2002 22 0 23 22

June 2002 22 0 23 21

July 2002 22 1 23 21

August 2002 22 1 23 20

Septembe r 2002 22 1 23 21

October 2002 22 1 23 21

November 2002 23 0 23 22

December 2002 22 1 23 21

January 2003 22 1 23 21

February 2003 22 0 23 22

March 2003 22 0 23 21

April 2003 21 0 22 21

May 2003 22 0 23 21

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Exhaust Flow Data (Liters Per Minute)

Chamber 8 (20g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 444 9 452 429

June 2001 452 4 460 444

July 2001 452 7 462 440

August 2001 453 12 474 426

Septembe r 2001 480 19 516 447

October 2001 476 15 510 458

November 2001 470 19 491 409

December 2001 461 9 475 449

January 2002 448 7 456 430

February 2002 457 17 487 433

March 2002 437 22 471 368

April 2002 457 13 473 422

May 2002 458 6 476 449

June 2002 439 15 474 413

July 2002 439 15 476 420

August 2002 444 19 483 422

Septembe r 2002 444 23 486 414

October 2002 457 4 464 452

November 2002 443 10 456 429

December 2002 437 4 444 430

January 2003 430 4 440 424

February 2003 432 17 459 386

March 2003 437 17 458 390

April 2003 437 4 444 431

May 2003 431 6 434 422

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Relative Humidity Data (%RH)

Chamber 8 (20g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 62 5 73 58

June 2001 72 6 81 61

July 2001 64 2 68 57

August 2001 65 2 69 59

Septembe r 2001 60 4 68 48

October 2001 53 10 70 31

November 2001 52 6 63 37

December 2001 50 7 68 39

January 2002 49 6 58 38

February 2002 49 11 73 30

March 2002 45 5 56 38

April 2002 46 5 61 38

May 2002 56 7 68 36

June 2002 66 6 76 56

July 2002 71 3 77 65

August 2002 66 3 73 60

Septembe r 2002 68 5 82 64

October 2002 59 6 69 47

November 2002 48 7 65 38

December 2002 44 6 57 34

January 2003 47 4 54 39

February 2003 49 6 66 38

March 2003 43 9 60 28

April 2003 42 5 51 33

May 2003 49 10 59 31

*Min and Max of daily averages

# MTBE Protocol No. FY01-013 Reviewed By:______________

Summary of Temperature Data ( o 

# C)

Chamber 8 (20g/m 3 

# )

Month Yea r Mean SD Max* Min*

May 2001 23 1 24 22

June 2001 23 1 25 21

July 2001 22 0 23 21

August 2001 22 0 23 21

Septembe r 2001 22 0 22 21

October 2001 22 0 23 21

November 2001 22 0 23 22

December 2001 22 1 23 21

January 2002 22 1 23 21

February 2002 21 1 22 20

March 2002 21 1 23 20

April 2002 22 0 23 20

May 2002 23 0 23 21

June 2002 22 0 23 21

July 2002 22 1 23 21

August 2002 22 1 23 20

Septembe r 2002 22 1 23 21

October 2002 22 1 22 21

November 2002 22 1 22 20

December 2002 22 1 23 20

January 2003 21 0 22 21

February 2003 21 0 22 20

March 2003 21 1 23 20

April 2003 21 0 22 21

May 2003 21 0 22 21

*Min and Max of daily averages

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

G-3 Monthly Summaries of Pe rcent Time Environmental Conditions

were Out of Specified Ranges

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

H-1 APPENDIX H

INDIVIDUAL ANIMA L DISPOSITION

H-1 Males

H-2 Females

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

H-1 MalesLovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 1Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6831E401 1 M Dosing phase 25-Mar-03 12:45 128 21-Mar-03 668 u Sacrificed moribund 350.8 C C6831E402 1 M Dosing phase 12-Dec-02 13:56 128 12-Dec-02 569 u Sacrificed moribund 375.6 C C6831E403 1 M Dosing phase 28-Jan-03 09:10 8 21-Jan-03 609 u Sacrificed moribund 276.1 C C6831E404 1 M Dosing phase 03-Mar-03 16:53 128 27-Feb-03 646 u Sacrificed moribund 494.2 C C6831E405 1 M Dosing phase 18-Mar-03 10:28 8 14-Mar-03 661 u Sacrificed moribund 311.3 C C6831E406 1 M Dosing phase 03-Jun-03 15:54 128 13-May-03 721 u Sacrificed moribund 224.4 C C6831E407 1 M Dosing phase 04-Jun-03 13:52 128 28-May-03 736 s Final phase sacrifice 403.2 C C6831E408 1 M Dosing phase 20-Dec-01 14:18 128 17-Dec-01 209 u Sacrificed moribund 312.1 C -6831E409 1 M Dosing phase 13-Feb-03 16:55 128 12-Feb-03 631 u Sacrificed moribund 300.4 C C6831E410 1 M Dosing phase 25-Feb-03 13:18 8 25-Feb-03 644 u Sacrificed moribund 369.2 C C6831E411 1 M Dosing phase 01-Apr-03 11:25 8 28-Mar-03 675 u Sacrificed moribund 339.4 C C6831E412 1 M Dosing phase 12-Dec-02 13:38 128 01-Dec-02 558 u Sacrificed moribund 331.9 C C6831E413 1 M Dosing phase 09-Jun-03 08:20 -1 29-May-03 737 s Final phase sacrifice 379.5 C C6831E414 1 M Dosing phase 29-Jan-03 11:03 8 28-Jan-03 616 u Sacrificed moribund 255.3 C C6831E415 1 M Dosing phase 09-Jun-03 08:30 -1 27-May-03 735 s Final phase sacrifice 395.5 C C6831E416 1 M Dosing phase 25-Mar-03 13:06 128 19-Mar-03 666 u Sacrificed moribund 385.4 C C6831E417 1 M Dosing phase 28-May-03 16:51 128 26-May-03 734 u Sacrificed moribund 372.5 C C6831E418 1 M Dosing phase 09-Jun-03 16:41 128 29-May-03 737 s Final phase sacrifice 398.8 C C6831E419 1 M Dosing phase 21-Apr-03 17:09 128 17-Apr-03 695 u Sacrificed moribund 359.2 C C6831E420 1 M Dosing phase 24-Apr-03 17:19 128 24-Apr-03 702 u Sacrificed moribund 355.4 C C6831E421 1 M Dosing phase 20-Dec-02 11:37 -1 19-Dec-02 576 u Sacrificed moribund 385.2 C C6831E422 1 M Dosing phase 09-Jun-03 16:42 128 30-May-03 738 s Final phase sacrifice 384.3 C C6831E423 1 M Dosing phase 10-Jan-03 16:20 128 09-Jan-03 597 u Sacrificed moribund 381.1 C C6831E424 1 M Dosing phase 10-Feb-03 09:41 -1 07-Feb-03 626 u Sacrificed moribund 365.0 C C6831E425 1 M Dosing phase 11-Feb-03 11:03 8 10-Feb-03 629 u Found Dead 434.1 C C6831E426 1 M Dosing phase 08-May-03 16:30 128 02-May-03 710 u Sacrificed moribund 282.1 C C6831E427 1 M Dosing phase 21-May-03 16:27 128 21-May-03 729 u Sacrificed moribund 294.9 C C6831E428 1 M Dosing phase 10-Feb-03 09:56 -1 10-Feb-03 629 u Sacrificed moribund 355.2 C C6831E429 1 M Dosing phase 18-Mar-03 10:29 8 14-Mar-03 661 u Sacrificed moribund 352.3 C C6831E430 1 M Dosing phase 10-Mar-03 16:56 128 04-Mar-03 651 u Sacrificed moribund 327.7 C C6831E431 1 M Dosing phase 28-Aug-02 09:17 8 15-Jun-02 389 u Sacrificed moribund 346.8 C C6831E432 1 M Dosing phase 06-Mar-03 16:10 128 06-Mar-03 653 u Sacrificed moribund 379.0 C C6831E433 1 M Dosing phase 01-Apr-03 11:26 8 28-Mar-03 675 u Sacrificed moribund 311.2 C C6831E434 1 M Dosing phase 06-Mar-03 16:42 128 05-Mar-03 652 u Sacrificed moribund 317.5 C C6831E435 1 M Dosing phase 09-Jun-03 16:42 128 30-May-03 738 s Final phase sacrifice 355.1 C C6831E436 1 M Dosing phase 09-Jun-03 16:42 128 30-May-03 738 s Final phase sacrifice 393.1 C C6831E437 1 M Dosing phase 09-Jun-03 16:43 128 27-May-03 735 s Final phase sacrifice 398.3 C C6831E438 1 M Dosing phase 04-Apr-03 16:56 128 02-Apr-03 680 u Sacrificed moribund 331.8 C C6831E439 1 M Dosing phase 23-May-02 14:25 128 22-May-02 365 u Sacrificed moribund 417.3 C C6831E440 1 M Dosing phase 04-Jun-03 13:57 128 28-May-03 736 s Final phase sacrifice 396.8 C C6831E441 1 M Dosing phase 10-Feb-03 10:25 8 05-Feb-03 624 u Sacrificed moribund 366.9 C C6831E442 1 M Dosing phase 04-Jun-03 13:58 128 28-May-03 736 s Final phase sacrifice 383.6 C C6831E443 1 M Dosing phase 09-Jun-03 16:43 128 29-May-03 737 s Final phase sacrifice 404.7 C C6831E444 1 M Dosing phase 18-Mar-03 10:30 8 14-Mar-03 661 u Sacrificed moribund 331.1 C C6831E445 1 M Dosing phase 10-Feb-03 10:21 8 05-Feb-03 624 u Sacrificed moribund 369.9 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6831E446 1 M Dosing phase 09-Jun-03 16:43 128 27-May-03 735 s Final phase sacrifice 352.3 C C6831E447 1 M Dosing phase 21-Feb-03 16:35 128 21-Feb-03 640 u Sacrificed moribund 353.4 C C6831E448 1 M Dosing phase 09-Jun-03 16:44 128 27-May-03 735 s Final phase sacrifice 396.0 C C6831E449 1 M Dosing phase 09-Jun-03 16:44 128 29-May-03 737 s Final phase sacrifice 418.7 C C6831E450 1 M Dosing phase 06-Jan-03 15:17 -1 24-Dec-02 581 u Sacrificed moribund 440.7 C C6833F501 2 M Dosing phase 25-Feb-03 13:17 8 24-Feb-03 643 u Found Dead 357.8 C C6833F502 2 M Dosing phase 04-Jun-03 14:18 128 30-May-03 738 s Final phase sacrifice 384.3 C C6833F503 2 M Dosing phase 20-May-03 12:06 128 20-May-03 728 u Found Dead 328.8 C C6833F504 2 M Dosing phase 04-Apr-03 17:09 128 04-Apr-03 682 u Sacrificed moribund 344.8 C C6833F505 2 M Dosing phase 04-Jun-03 14:18 128 30-May-03 738 s Final phase sacrifice 400.1 C C6833F506 2 M Dosing phase 21-Feb-03 16:40 128 21-Feb-03 640 u Sacrificed moribund 299.2 C C6833F507 2 M Dosing phase 18-Mar-03 10:30 8 14-Mar-03 661 u Sacrificed moribund 367.4 C C6833F508 2 M Dosing phase 09-Jun-03 16:49 128 27-May-03 735 s Final phase sacrifice 387.3 C C6833F509 2 M Dosing phase 07-Jan-03 10:09 -1 31-Dec-02 588 u Sacrificed moribund 503.4 C C6833F510 2 M Dosing phase 03-Mar-03 16:28 128 26-Feb-03 645 u Sacrificed moribund 314.7 C C6833F511 2 M Dosing phase 09-Jun-03 16:49 128 27-May-03 735 s Final phase sacrifice 411.5 C C6833F512 2 M Dosing phase 19-Sep-02 14:24 128 17-Sep-02 483 u Sacrificed moribund 306.8 C C6833F513 2 M Dosing phase 09-Jun-03 16:50 128 29-May-03 737 s Final phase sacrifice 280.5 C C6833F514 2 M Dosing phase 06-Jan-03 14:29 8 20-Dec-02 577 u Sacrificed moribund 395.1 C C6833F515 2 M Dosing phase 22-Nov-02 15:32 8 20-Nov-02 547 u Sacrificed moribund 352.0 C C6833F516 2 M Dosing phase 04-Jun-03 14:21 128 30-May-03 738 s Final phase sacrifice 377.9 C C6833F517 2 M Dosing phase 18-Feb-03 13:24 8 14-Feb-03 633 u Sacrificed moribund 408.0 C C6833F518 2 M Dosing phase 03-Mar-03 17:03 128 28-Feb-03 647 u Sacrificed moribund 407.4 C C6833F519 2 M Dosing phase 04-Jun-03 14:22 128 30-May-03 738 s Final phase sacrifice 416.2 C C6833F520 2 M Dosing phase 29-May-03 17:19 128 21-May-03 729 u Sacrificed moribund 324.1 C C6833F521 2 M Dosing phase 09-Jun-03 16:50 128 28-May-03 736 s Final phase sacrifice 335.6 C C6833F522 2 M Dosing phase 16-Apr-03 17:29 128 11-Apr-03 689 u Sacrificed moribund 377.2 C C6833F523 2 M Dosing phase 09-Jun-03 16:50 128 28-May-03 736 s Final phase sacrifice 408.3 C C6833F524 2 M Dosing phase 25-Jun-02 14:28 128 21-Jun-02 395 u Found Dead 479.0 C C6833F525 2 M Dosing phase 09-Jun-03 16:51 128 29-May-03 737 s Final phase sacrifice 393.6 C C6833F526 2 M Dosing phase 09-Jun-03 16:51 128 28-May-03 736 s Final phase sacrifice 362.5 C C6833F527 2 M Dosing phase 20-Dec-02 11:37 -1 19-Dec-02 576 u Sacrificed moribund 357.5 C C6833F528 2 M Dosing phase 19-Sep-02 14:32 128 12-Sep-02 478 u Sacrificed moribund 309.8 C C6833F529 2 M Dosing phase 30-Sep-02 09:14 128 20-Sep-02 486 u Sacrificed moribund 444.5 C C6833F530 2 M Dosing phase 07-May-03 17:31 128 29-Apr-03 707 u Sacrificed moribund 329.6 C C6833F531 2 M Dosing phase 21-Apr-03 17:13 128 17-Apr-03 695 u Sacrificed moribund 355.2 C C6833F532 2 M Dosing phase 05-Sep-02 08:59 8 28-Aug-02 463 u Sacrificed moribund 314.7 C C6833F533 2 M Dosing phase 07-Jan-03 10:09 -1 31-Dec-02 588 u Sacrificed moribund 388.3 C C6833F534 2 M Dosing phase 25-Feb-03 13:18 8 25-Feb-03 644 u Sacrificed moribund 247.0 C C6833F535 2 M Dosing phase 11-Jun-03 08:03 8 28-May-03 736 s Final phase sacrifice 409.1 C C6833F536 2 M Dosing phase 09-Jun-03 16:51 128 29-May-03 737 s Final phase sacrifice 340.7 C C6833F537 2 M Dosing phase 18-Feb-03 13:24 8 14-Feb-03 633 u Sacrificed moribund 338.3 C C6833F538 2 M Dosing phase 21-Apr-03 16:45 128 18-Apr-03 696 u Sacrificed moribund 369.0 C C6833F539 2 M Dosing phase 26-Mar-03 18:25 128 26-Mar-03 673 u Sacrificed moribund 259.2 C C6833F540 2 M Dosing phase 09-Aug-02 13:29 128 07-Aug-02 442 u Sacrificed moribund 300.4 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 3Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6833F541 2 M Dosing phase 11-Mar-03 13:09 8 07-Mar-03 654 u Found Dead 379.4 C C6833F542 2 M Dosing phase 09-Jun-03 16:51 128 27-May-03 735 s Final phase sacrifice 365.4 C C6833F543 2 M Dosing phase 06-Mar-03 16:53 128 05-Mar-03 652 u Sacrificed moribund 325.3 C C6833F544 2 M Dosing phase 25-Mar-03 12:47 128 21-Mar-03 668 u Sacrificed moribund 352.7 C C6833F545 2 M Dosing phase 13-Dec-02 11:59 8 15-Nov-02 542 u Sacrificed moribund 367.1 C C6833F546 2 M Dosing phase 09-May-03 13:16 8 29-Apr-03 707 u Sacrificed moribund 350.7 C C6833F547 2 M Dosing phase 04-Jun-03 14:27 128 30-May-03 738 s Final phase sacrifice 366.3 C C6833F548 2 M Dosing phase 14-Apr-03 16:50 128 09-Apr-03 687 u Sacrificed moribund 472.7 C C6833F549 2 M Dosing phase 21-Feb-03 16:31 128 20-Feb-03 639 u Found Dead 288.9 C C6833F550 2 M Dosing phase 09-Jun-03 16:52 128 27-May-03 735 s Final phase sacrifice 368.4 C C6835G601 3 M Dosing phase 04-Jun-03 14:28 128 28-May-03 736 s Final phase sacrifice 382.8 C C6835G602 3 M Dosing phase 09-Jun-03 16:45 128 29-May-03 737 s Final phase sacrifice 368.3 C C6835G603 3 M Dosing phase 09-Jun-03 16:45 128 27-May-03 735 s Final phase sacrifice 375.0 C C6835G604 3 M Dosing phase 11-Mar-03 13:02 8 10-Mar-03 657 u Sacrificed moribund 334.8 C C6835G605 3 M Dosing phase 09-Jun-03 16:45 128 29-May-03 737 s Final phase sacrifice 354.7 C C6835G606 3 M Dosing phase 07-Jan-03 10:08 -1 31-Dec-02 588 u Sacrificed moribund 411.5 C C6835G607 3 M Dosing phase 04-Jun-03 14:31 128 28-May-03 736 s Final phase sacrifice 372.0 C C6835G608 3 M Dosing phase 21-Apr-03 17:45 128 16-Apr-03 694 u Sacrificed moribund 319.0 C C6835G609 3 M Dosing phase 09-Jun-03 16:45 128 30-May-03 738 s Final phase sacrifice 394.9 C C6835G610 3 M Dosing phase 09-Jun-03 16:46 128 29-May-03 737 s Final phase sacrifice 368.2 C C6835G611 3 M Dosing phase 09-Aug-02 13:24 128 02-Aug-02 437 u Sacrificed moribund 290.7 C C6835G612 3 M Dosing phase 18-Feb-03 13:22 8 14-Feb-03 633 u Sacrificed moribund 317.1 C C6835G613 3 M Dosing phase 09-Jun-03 16:46 128 27-May-03 735 s Final phase sacrifice 374.6 C C6835G614 3 M Dosing phase 09-Jun-03 16:47 128 27-May-03 735 s Final phase sacrifice 389.1 C C6835G615 3 M Dosing phase 09-Jun-03 16:47 128 29-May-03 737 s Final phase sacrifice 349.7 C C6835G616 3 M Dosing phase 21-Apr-03 17:42 128 21-Apr-03 699 u Sacrificed moribund 350.1 C C6835G617 3 M Dosing phase 09-Jun-03 16:47 128 27-May-03 735 s Final phase sacrifice 359.5 C C6835G618 3 M Dosing phase 18-Feb-03 13:17 8 07-Feb-03 626 u Sacrificed moribund 333.2 C C6835G619 3 M Dosing phase 18-Feb-03 13:22 8 14-Feb-03 633 u Sacrificed moribund 321.5 C C6835G620 3 M Dosing phase 18-Feb-03 13:17 8 07-Feb-03 626 u Sacrificed moribund 334.6 C C6835G621 3 M Dosing phase 09-Jun-03 16:47 128 30-May-03 738 s Final phase sacrifice 350.0 C C6835G622 3 M Dosing phase 23-May-03 17:23 128 22-May-03 730 u Sacrificed moribund 312.8 C C6835G623 3 M Dosing phase 07-Nov-02 14:45 -1 06-Nov-02 533 u Sacrificed moribund 381.3 C C6835G624 3 M Dosing phase 25-Mar-03 13:10 128 19-Mar-03 666 u Sacrificed moribund 310.6 C C6835G625 3 M Dosing phase 04-Mar-03 13:40 8 04-Mar-03 651 u Found Dead 323.9 C C6835G626 3 M Dosing phase 01-Apr-03 11:44 -1 28-Mar-03 675 u Sacrificed moribund 347.1 C C6835G627 3 M Dosing phase 12-May-03 11:30 -1 05-Apr-03 683 u Found Dead 372.8 C C6835G628 3 M Dosing phase 09-Jun-03 16:48 128 30-May-03 738 s Final phase sacrifice 378.2 C C6835G629 3 M Dosing phase 06-Mar-03 16:14 128 06-Mar-03 653 u Sacrificed moribund 316.6 C C6835G630 3 M Dosing phase 09-Jun-03 16:48 128 27-May-03 735 s Final phase sacrifice 366.6 C C6835G631 3 M Dosing phase 21-Apr-03 17:18 128 17-Apr-03 695 u Sacrificed moribund 362.6 C C6835G632 3 M Dosing phase 14-Apr-03 16:58 128 09-Apr-03 687 u Sacrificed moribund 323.8 C C6835G633 3 M Dosing phase 16-Apr-03 17:30 128 11-Apr-03 689 u Sacrificed moribund 420.2 C C6835G634 3 M Dosing phase 09-Jun-03 16:48 128 27-May-03 735 s Final phase sacrifice 396.2 C C6835G635 3 M Dosing phase 18-Feb-03 13:18 8 07-Feb-03 626 u Sacrificed moribund 307.0 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 4Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6835G636 3 M Dosing phase 03-Feb-03 09:11 8 02-Feb-03 621 u Found Dead 297.7 C C6835G637 3 M Dosing phase 03-Mar-03 16:31 128 26-Feb-03 645 u Sacrificed moribund 326.4 C C6835G638 3 M Dosing phase 04-Jun-03 14:37 128 28-May-03 736 s Final phase sacrifice 392.6 C C6835G639 3 M Dosing phase 04-Jun-03 14:37 128 28-May-03 736 s Final phase sacrifice 383.2 C C6835G640 3 M Dosing phase 20-Dec-02 11:38 -1 19-Dec-02 576 u Sacrificed moribund 291.4 C C6835G641 3 M Dosing phase 18-Mar-03 10:31 8 14-Mar-03 661 u Sacrificed moribund 349.9 C C6835G642 3 M Dosing phase 25-Mar-03 12:52 128 21-Mar-03 668 u Sacrificed moribund 334.1 C C6835G643 3 M Dosing phase 28-Jan-03 08:47 -1 15-Jan-03 603 u Sacrificed moribund 407.3 C C6835G644 3 M Dosing phase 07-Nov-02 13:43 -1 22-Oct-02 518 u Sacrificed moribund 353.4 C C6835G645 3 M Dosing phase 21-May-03 16:39 128 21-May-03 729 u Sacrificed moribund 323.0 C C6835G646 3 M Dosing phase 21-Feb-03 16:51 128 21-Feb-03 640 u Sacrificed moribund 356.0 C C6835G647 3 M Dosing phase 04-Jun-03 14:38 128 28-May-03 736 s Final phase sacrifice 401.1 C C6835G648 3 M Dosing phase 09-Jun-03 16:48 128 29-May-03 737 s Final phase sacrifice 268.6 C C6835G649 3 M Dosing phase 09-Jun-03 16:49 128 29-May-03 737 s Final phase sacrifice 349.5 C C6835G650 3 M Dosing phase 10-Feb-03 10:31 8 06-Feb-03 625 u Sacrificed moribund 341.9 C C6837H701 4 M Dosing phase 21-Apr-03 17:26 128 17-Apr-03 695 u Sacrificed moribund 253.6 C C6837H702 4 M Dosing phase 04-Jun-03 14:03 128 27-May-03 735 s Final phase sacrifice 382.2 C C6837H703 4 M Dosing phase 18-Mar-03 10:28 8 14-Mar-03 661 u Sacrificed moribund 435.2 C C6837H704 4 M Dosing phase 09-Jun-03 16:52 128 30-May-03 738 s Final phase sacrifice 397.1 C C6837H705 4 M Dosing phase 09-Jun-03 16:53 128 30-May-03 738 s Final phase sacrifice 399.2 C C6837H706 4 M Dosing phase 09-Jun-03 16:53 128 30-May-03 738 s Final phase sacrifice 356.7 C C6837H707 4 M Dosing phase 06-Mar-03 16:46 128 05-Mar-03 652 u Sacrificed moribund 353.8 C C6837H708 4 M Dosing phase 09-Jun-03 16:53 128 29-May-03 737 s Final phase sacrifice 346.6 C C6837H709 4 M Dosing phase 11-Mar-03 13:03 8 10-Mar-03 657 u Sacrificed moribund 362.3 C C6837H710 4 M Dosing phase 14-Apr-03 16:28 128 10-Apr-03 688 u Sacrificed moribund 305.8 C C6837H711 4 M Dosing phase 29-Apr-03 17:32 128 25-Apr-03 703 u Sacrificed moribund 358.8 C C6837H712 4 M Dosing phase 03-Feb-03 10:27 8 22-Jan-03 610 u Sacrificed moribund 348.6 C C6837H713 4 M Dosing phase 09-May-03 16:21 128 08-May-03 716 u Sacrificed moribund 301.4 C C6837H714 4 M Dosing phase 09-Jun-03 16:53 128 28-May-03 736 s Final phase sacrifice 335.0 C C6837H715 4 M Dosing phase 10-Feb-03 09:48 -1 07-Feb-03 626 u Sacrificed moribund 365.1 C C6837H716 4 M Dosing phase 08-May-03 10:26 -1 05-Sep-02 471 u Sacrificed moribund 411.5 C C6837H717 4 M Dosing phase 09-Jun-03 16:54 128 29-May-03 737 s Final phase sacrifice 371.8 C C6837H718 4 M Dosing phase 20-May-03 12:52 8 19-May-03 727 u Found Dead 349.8 C C6837H719 4 M Dosing phase 07-Nov-02 14:36 -1 22-Oct-02 518 u Sacrificed moribund 365.4 C C6837H720 4 M Dosing phase 18-Feb-03 13:23 8 14-Feb-03 633 u Sacrificed moribund 301.7 C C6837H721 4 M Dosing phase 09-May-03 16:40 128 14-Apr-03 692 u Sacrificed moribund 362.5 C C6837H722 4 M Dosing phase 04-Jun-03 14:08 128 27-May-03 735 s Final phase sacrifice 335.5 C C6837H723 4 M Dosing phase 06-Jan-03 10:30 8 24-Dec-02 581 u Sacrificed moribund 333.5 C C6837H724 4 M Dosing phase 09-Jun-03 16:54 128 28-May-03 736 s Final phase sacrifice 351.4 C C6837H725 4 M Dosing phase 09-Jun-03 16:54 128 28-May-03 736 s Final phase sacrifice 271.3 C C6837H726 4 M Dosing phase 04-Jun-03 14:11 128 27-May-03 735 s Final phase sacrifice 376.6 C C6837H727 4 M Dosing phase 11-Mar-03 13:04 8 10-Mar-03 657 u Sacrificed moribund 304.8 C C6837H728 4 M Dosing phase 04-Jun-03 14:11 128 27-May-03 735 s Final phase sacrifice 348.4 C C6837H729 4 M Dosing phase 04-Jun-03 14:12 128 27-May-03 735 s Final phase sacrifice 355.9 C C6837H730 4 M Dosing phase 24-Apr-03 17:28 128 24-Apr-03 702 u Sacrificed moribund 334.0 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 5Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6837H731 4 M Dosing phase 06-Mar-03 16:50 128 05-Mar-03 652 u Sacrificed moribund 304.6 C C6837H732 4 M Dosing phase 06-Jan-03 15:43 -1 30-Dec-02 587 u Found Dead 378.8 C C6837H733 4 M Dosing phase 10-Jan-03 16:33 128 09-Jan-03 597 u Sacrificed moribund 298.5 C C6837H734 4 M Dosing phase 24-Apr-03 17:29 128 24-Apr-03 702 u Sacrificed moribund 316.5 C C6837H735 4 M Dosing phase 09-Jun-03 16:54 128 28-May-03 736 s Final phase sacrifice 357.6 C C6837H736 4 M Dosing phase 09-Jun-03 16:55 128 29-May-03 737 s Final phase sacrifice 371.5 C C6837H737 4 M Dosing phase 06-Mar-03 16:52 128 05-Mar-03 652 u Sacrificed moribund 323.8 C C6837H738 4 M Dosing phase 24-Apr-03 17:31 128 24-Apr-03 702 u Sacrificed moribund 330.4 C C6837H739 4 M Dosing phase 09-Jun-03 16:55 128 28-May-03 736 s Final phase sacrifice 371.6 C C6837H740 4 M Dosing phase 21-Feb-03 16:55 128 21-Feb-03 640 u Sacrificed moribund 315.5 C C6837H741 4 M Dosing phase 09-Jun-03 16:55 128 29-May-03 737 s Final phase sacrifice 361.3 C C6837H742 4 M Dosing phase 10-Jan-03 16:24 128 09-Jan-03 597 u Sacrificed moribund 307.8 C C6837H743 4 M Dosing phase 09-May-03 16:33 128 08-May-03 716 u Sacrificed moribund 301.2 C C6837H744 4 M Dosing phase 04-Sep-02 13:41 128 03-Sep-02 469 u Sacrificed moribund 296.4 C C6837H745 4 M Dosing phase 25-Mar-03 12:28 128 24-Mar-03 671 u Sacrificed moribund 273.9 C C6837H746 4 M Dosing phase 03-Mar-03 16:40 128 26-Feb-03 645 u Sacrificed moribund 287.8 C C6837H747 4 M Dosing phase 09-Jun-03 16:55 128 30-May-03 738 s Final phase sacrifice 365.8 C C6837H748 4 M Dosing phase 06-Jan-03 15:36 -1 30-Dec-02 587 u Sacrificed moribund 364.1 C C6837H749 4 M Dosing phase 09-Jun-03 16:56 128 29-May-03 737 s Final phase sacrifice 328.0 C C6837H750 4 M Dosing phase 14-Apr-03 17:01 128 09-Apr-03 687 u Sacrificed moribund 305.6 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

H-2 FemalesLovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 1Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6832E451 1 F Dosing phase 13-Jun-03 12:31 128 03-Jun-03 735 s Final phase sacrifice 290.9 C C6832E452 1 F Dosing phase 13-Jun-03 12:31 128 03-Jun-03 735 s Final phase sacrifice 265.5 C C6832E453 1 F Dosing phase 08-May-03 17:11 128 06-May-03 707 u Sacrificed moribund 219.3 C C6832E454 1 F Dosing phase 03-Feb-03 10:42 8 31-Jan-03 612 u Found Dead 273.6 C C6832E455 1 F Dosing phase 14-Apr-03 16:32 128 09-Apr-03 680 u Sacrificed moribund 279.2 C C6832E456 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 272.8 C C6832E457 1 F Dosing phase 10-Jan-03 16:45 128 07-Jan-03 588 u Sacrificed moribund 201.2 C C6832E458 1 F Dosing phase 04-Jun-03 14:40 128 02-Jun-03 734 s Final phase sacrifice 257.4 C C6832E459 1 F Dosing phase 18-Feb-03 13:19 8 14-Feb-03 626 u Sacrificed moribund 223.0 C C6832E460 1 F Dosing phase 13-Jun-03 12:39 128 04-Jun-03 736 s Final phase sacrifice 277.6 C C6832E461 1 F Dosing phase 04-Jun-03 14:41 128 02-Jun-03 734 s Final phase sacrifice 300.6 C C6832E462 1 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 304.3 C C6832E463 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 277.1 C C6832E464 1 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 217.4 C C6832E465 1 F Dosing phase 10-Jan-03 16:49 128 07-Jan-03 588 u Sacrificed moribund 192.6 C -6832E466 1 F Dosing phase 16-Apr-03 17:25 128 11-Apr-03 682 u Sacrificed moribund 237.0 C C6832E467 1 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 301.9 C -6832E468 1 F Dosing phase 14-Apr-03 16:34 128 09-Apr-03 680 u Sacrificed moribund 260.6 C C6832E469 1 F Dosing phase 21-Feb-03 16:29 128 20-Feb-03 632 u Sacrificed moribund 201.9 C C6832E470 1 F Dosing phase 22-Nov-02 15:30 8 20-Nov-02 540 u Sacrificed moribund 239.4 C C6832E471 1 F Dosing phase 04-Apr-03 17:00 128 02-Apr-03 673 u Sacrificed moribund 236.9 C C6832E472 1 F Dosing phase 13-Jun-03 12:17 128 06-Jun-03 738 s Final phase sacrifice 165.8 C C6832E473 1 F Dosing phase 18-Mar-03 10:16 8 17-Mar-03 657 u Found Dead 227.3 C C6832E474 1 F Dosing phase 21-Feb-03 16:21 128 20-Feb-03 632 u Sacrificed moribund 189.3 C C6832E475 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 260.0 C C6832E476 1 F Dosing phase 23-May-03 17:29 128 22-May-03 723 u Sacrificed moribund 259.5 C C6832E477 1 F Dosing phase 10-Jan-03 16:53 128 07-Jan-03 588 u Found Dead 187.7 C C6832E478 1 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 263.4 C C6832E479 1 F Dosing phase 09-May-03 16:35 128 08-May-03 709 u Sacrificed moribund 263.3 C C6832E480 1 F Dosing phase 01-Apr-03 11:29 8 29-Mar-03 669 u Found Dead 225.3 C C6832E481 1 F Dosing phase 29-Apr-02 15:15 -1 10-Apr-02 316 u Sacrificed moribund 203.4 C C6832E482 1 F Dosing phase 11-Mar-03 13:09 8 07-Mar-03 647 u Sacrificed moribund 250.2 C C6832E483 1 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 271.8 C C6832E484 1 F Dosing phase 25-Mar-03 13:02 128 19-Mar-03 659 u Sacrificed moribund 212.8 C C6832E485 1 F Dosing phase 03-Oct-02 16:19 128 24-Sep-02 483 u Sacrificed moribund 211.2 C C6832E486 1 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 265.4 C -6832E487 1 F Dosing phase 10-Jan-03 17:01 128 08-Jan-03 589 u Sacrificed moribund 226.0 C C6832E488 1 F Dosing phase 14-Apr-03 16:26 128 10-Apr-03 681 u Sacrificed moribund 220.2 C C6832E489 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 263.9 C C6832E490 1 F Dosing phase 13-Jun-03 12:26 128 05-Jun-03 737 s Final phase sacrifice 223.6 C C6832E491 1 F Dosing phase 09-Apr-03 16:56 128 07-Apr-03 678 u Sacrificed moribund 217.6 C C6832E492 1 F Dosing phase 29-Oct-02 15:49 8 23-Oct-02 512 u Sacrificed moribund 186.5 C C6832E493 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 230.8 C C6832E494 1 F Dosing phase 25-Feb-03 13:20 8 25-Feb-03 637 u Sacrificed moribund 276.5 C C6832E495 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 301.6 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6832E496 1 F Dosing phase 25-Feb-03 13:21 8 25-Feb-03 637 u Sacrificed moribund 200.1 C C6832E497 1 F Dosing phase 13-Jun-03 12:18 128 06-Jun-03 738 s Final phase sacrifice 269.1 C C6832E498 1 F Dosing phase 04-Jun-03 14:42 128 02-Jun-03 734 s Final phase sacrifice 254.1 C -6832E499 1 F Dosing phase 12-Dec-02 13:52 128 12-Dec-02 562 u Sacrificed moribund 248.6 C C6832E500 1 F Dosing phase 04-Jun-03 14:42 128 02-Jun-03 734 s Final phase sacrifice 303.6 C C6834F551 2 F Dosing phase 04-Jun-03 14:43 128 02-Jun-03 734 s Final phase sacrifice 280.6 C C6834F552 2 F Dosing phase 06-Jan-03 14:54 -1 24-Dec-02 574 u Sacrificed moribund 229.7 C C6834F553 2 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 278.5 C C6834F554 2 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 281.2 C -6834F555 2 F Dosing phase 13-Jun-03 12:32 128 03-Jun-03 735 s Final phase sacrifice 297.4 C C6834F556 2 F Dosing phase 04-Apr-03 16:48 128 01-Apr-03 672 u Sacrificed moribund 225.7 C C6834F557 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 264.6 C C6834F558 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 263.2 C C6834F559 2 F Dosing phase 13-Jun-03 12:40 128 04-Jun-03 736 s Final phase sacrifice 245.3 C C6834F560 2 F Dosing phase 04-Jun-03 14:44 128 02-Jun-03 734 s Final phase sacrifice 283.1 C -6834F561 2 F Dosing phase 04-Jun-03 14:45 128 02-Jun-03 734 s Final phase sacrifice 277.0 C C6834F562 2 F Dosing phase 03-Oct-02 16:23 128 29-Sep-02 488 u Sacrificed moribund 238.4 C C6834F563 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 288.7 C C6834F564 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 221.5 C C6834F565 2 F Dosing phase 03-Mar-03 17:20 128 28-Feb-03 640 u Sacrificed moribund 268.4 C C6834F566 2 F Dosing phase 07-Nov-02 13:05 -1 19-Oct-02 508 u Sacrificed moribund 226.8 C C6834F567 2 F Dosing phase 12-May-03 10:54 8 09-May-03 710 u Sacrificed moribund 282.2 C C6834F568 2 F Dosing phase 10-Jan-03 17:06 128 08-Jan-03 589 u Sacrificed moribund 203.6 C C6834F569 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 312.4 C C6834F570 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 268.6 C C6834F571 2 F Dosing phase 23-May-03 17:27 128 22-May-03 723 u Sacrificed moribund 211.9 C C6834F572 2 F Dosing phase 21-Apr-03 17:32 128 17-Apr-03 688 u Sacrificed moribund 256.4 C C6834F573 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 258.5 C C6834F574 2 F Dosing phase 04-Jun-03 14:45 128 02-Jun-03 734 s Final phase sacrifice 265.2 C C6834F575 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 309.2 C C6834F576 2 F Dosing phase 16-Apr-03 17:32 128 14-Apr-03 685 u Found Dead 212.6 C C6834F577 2 F Dosing phase 08-May-03 16:53 128 07-May-03 708 u Sacrificed moribund 248.1 C C6834F578 2 F Dosing phase 25-Mar-03 12:36 128 24-Mar-03 664 u Sacrificed moribund 218.3 C C6834F579 2 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 299.6 C C6834F580 2 F Dosing phase 04-Jun-03 14:46 128 02-Jun-03 734 s Final phase sacrifice 296.3 C C6834F581 2 F Dosing phase 28-May-03 17:04 128 28-May-03 729 u Sacrificed moribund 207.5 C C6834F582 2 F Dosing phase 25-Feb-03 13:19 8 24-Feb-03 636 u Sacrificed moribund 248.6 C C6834F583 2 F Dosing phase 04-Jun-03 14:46 128 02-Jun-03 734 s Final phase sacrifice 276.2 C -6834F584 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 258.5 C C6834F585 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 234.6 C C6834F586 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 286.9 C C6834F587 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 282.6 C -6834F588 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 267.6 C -6834F589 2 F Dosing phase 14-Apr-03 16:36 128 09-Apr-03 680 u Sacrificed moribund 267.9 C C6834F590 2 F Dosing phase 21-May-02 11:05 8 14-May-02 350 u Sacrificed moribund 234.0 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 3Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6834F591 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 256.1 C C6834F592 2 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 274.7 C C6834F593 2 F Dosing phase 28-May-03 16:49 128 24-May-03 725 u Found Dead 257.4 C C6834F594 2 F Dosing phase 10-Jan-03 17:11 128 08-Jan-03 589 u Sacrificed moribund 299.0 C C6834F595 2 F Dosing phase 03-Oct-02 16:30 128 29-Sep-02 488 u Sacrificed moribund 214.2 C C6834F596 2 F Dosing phase 04-Jun-03 14:47 128 02-Jun-03 734 s Final phase sacrifice 262.2 C C6834F597 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 280.2 C -6834F598 2 F Dosing phase 13-Jun-03 12:19 128 06-Jun-03 738 s Final phase sacrifice 252.7 C -6834F599 2 F Dosing phase 12-Dec-02 13:17 128 11-Dec-02 561 u Sacrificed moribund 200.0 C C6834F600 2 F Dosing phase 13-Jun-03 12:27 128 05-Jun-03 737 s Final phase sacrifice 280.6 C C6836G651 3 F Dosing phase 04-Jun-03 14:47 128 02-Jun-03 734 s Final phase sacrifice 262.8 C C6836G652 3 F Dosing phase 04-Jun-03 14:48 128 02-Jun-03 734 s Final phase sacrifice 277.7 C C6836G653 3 F Dosing phase 03-Oct-02 16:36 128 30-Sep-02 489 u Sacrificed moribund 207.9 C C6836G654 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 238.3 C C6836G655 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 259.9 C C6836G656 3 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 277.7 C -6836G657 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 263.5 C C6836G658 3 F Dosing phase 13-Jun-03 12:41 128 04-Jun-03 736 s Final phase sacrifice 274.9 C -6836G659 3 F Dosing phase 29-May-03 16:58 128 29-May-03 730 u Sacrificed moribund 232.0 C C6836G660 3 F Dosing phase 04-Jun-03 14:48 128 02-Jun-03 734 s Final phase sacrifice 295.8 C C6836G661 3 F Dosing phase 13-Jun-03 12:33 128 03-Jun-03 735 s Final phase sacrifice 242.0 C C6836G662 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 234.8 C -6836G663 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 258.5 C C6836G664 3 F Dosing phase 16-Dec-02 14:23 8 12-Dec-02 562 u Sacrificed moribund 223.0 C C6836G665 3 F Dosing phase 07-Nov-02 13:57 -1 22-Oct-02 511 u Found Dead 191.0 C C6836G666 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 226.0 C C6836G667 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 271.4 C C6836G668 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 212.8 C C6836G669 3 F Dosing phase 13-Jun-03 12:22 128 06-Jun-03 738 s Final phase sacrifice 256.3 C C6836G670 3 F Dosing phase 04-Jun-03 14:49 128 02-Jun-03 734 s Final phase sacrifice 267.4 C C6836G671 3 F Dosing phase 12-Dec-02 13:42 128 28-Nov-02 548 u Found Dead 240.6 C C6836G672 3 F Dosing phase 04-Jun-03 14:49 128 02-Jun-03 734 s Final phase sacrifice 283.2 C C6836G673 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 242.1 C C6836G674 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 287.6 C C6836G675 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 257.6 C C6836G676 3 F Dosing phase 18-Mar-03 10:18 8 14-Mar-03 654 u Sacrificed moribund 232.8 C C6836G677 3 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 268.4 C C6836G678 3 F Dosing phase 29-Apr-03 17:36 128 25-Apr-03 696 u Sacrificed moribund 235.4 C C6836G679 3 F Dosing phase 18-Mar-03 10:20 8 14-Mar-03 654 u Sacrificed moribund 217.4 C C6836G680 3 F Dosing phase 06-Mar-03 17:17 128 05-Mar-03 645 u Sacrificed moribund 213.1 C C6836G681 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 272.3 C C6836G682 3 F Dosing phase 11-Mar-03 13:10 8 07-Mar-03 647 u Sacrificed moribund 223.1 C C6836G683 3 F Dosing phase 08-May-03 16:34 128 01-May-03 702 u Sacrificed moribund 240.7 C C6836G684 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 287.6 C C6836G685 3 F Dosing phase 22-Nov-02 15:31 8 20-Nov-02 540 u Sacrificed moribund 186.6 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 4Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6836G686 3 F Dosing phase 04-Jun-03 14:50 128 02-Jun-03 734 s Final phase sacrifice 231.0 C C6836G687 3 F Dosing phase 14-Apr-03 16:40 128 09-Apr-03 680 u Sacrificed moribund 223.0 C C6836G688 3 F Dosing phase 26-Mar-03 18:27 128 26-Mar-03 666 u Sacrificed moribund 246.4 C C6836G689 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 241.1 C C6836G690 3 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 236.8 C C6836G691 3 F Dosing phase 30-Aug-01 12:40 128 28-Aug-01 91 u Sacrificed moribund 156.8 C -6836G692 3 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 244.1 C C6836G693 3 F Dosing phase 25-Mar-03 13:12 128 18-Mar-03 658 u Found Dead 260.8 C C6836G694 3 F Dosing phase 13-Jun-03 12:28 128 05-Jun-03 737 s Final phase sacrifice 255.8 C C6836G695 3 F Dosing phase 25-Mar-03 12:38 128 21-Mar-03 661 u Sacrificed moribund 204.4 C C6836G696 3 F Dosing phase 30-Aug-01 12:39 128 28-Aug-01 91 u Sacrificed moribund 175.2 C -6836G697 3 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 252.0 C C6836G698 3 F Dosing phase 14-Feb-03 11:42 8 13-Feb-03 625 u Sacrificed moribund 226.0 C C6836G699 3 F Dosing phase 24-Sep-01 14:00 128 20-Sep-01 114 u Sacrificed moribund 153.9 C C6836G700 3 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 209.6 C C6838H751 4 F Dosing phase 25-Mar-03 13:04 128 19-Mar-03 659 u Sacrificed moribund 197.9 C C6838H752 4 F Dosing phase 21-Apr-03 16:58 128 16-Apr-03 687 u Sacrificed moribund 216.2 C C6838H753 4 F Dosing phase 03-Jun-03 15:49 128 14-May-03 715 u Sacrificed moribund 188.8 C C6838H754 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 267.9 C C6838H755 4 F Dosing phase 04-Jun-03 14:51 128 02-Jun-03 734 s Final phase sacrifice 229.6 C C6838H756 4 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 250.7 C C6838H757 4 F Dosing phase 09-May-03 13:10 8 30-Apr-03 701 u Sacrificed moribund 183.6 C C6838H758 4 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 247.8 C C6838H759 4 F Dosing phase 13-Jun-03 12:42 128 04-Jun-03 736 s Final phase sacrifice 230.5 C C6838H760 4 F Dosing phase 13-Jun-03 12:34 128 03-Jun-03 735 s Final phase sacrifice 245.1 C -6838H761 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 244.4 C C6838H762 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 237.7 C C6838H763 4 F Dosing phase 03-Oct-02 16:53 128 01-Oct-02 490 u Sacrificed moribund 229.8 C C6838H764 4 F Dosing phase 07-Nov-02 14:43 -1 06-Nov-02 526 u Sacrificed moribund 186.0 C C6838H765 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 259.5 C -6838H766 4 F Dosing phase 19-Sep-02 14:00 128 19-Sep-02 478 u Sacrificed moribund 198.3 C C6838H767 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 251.5 C C6838H768 4 F Dosing phase 13-Jun-03 12:44 128 04-Jun-03 736 s Final phase sacrifice 242.4 C C6838H769 4 F Dosing phase 13-Jun-03 12:43 128 04-Jun-03 736 s Final phase sacrifice 232.5 C C6838H770 4 F Dosing phase 25-Mar-03 12:41 128 21-Mar-03 661 u Sacrificed moribund 198.8 C C6838H771 4 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 217.7 C C6838H772 4 F Dosing phase 28-May-03 16:54 128 28-May-03 729 u Sacrificed moribund 185.1 C C6838H773 4 F Dosing phase 04-Jun-03 14:51 128 02-Jun-03 734 s Final phase sacrifice 256.8 C C6838H774 4 F Dosing phase 03-Oct-02 16:34 128 30-Sep-02 489 u Sacrificed moribund 190.1 C C6838H775 4 F Dosing phase 21-Apr-03 17:36 128 17-Apr-03 688 u Sacrificed moribund 191.6 C C6838H776 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 261.4 C C6838H777 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 242.5 C C6838H778 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 218.1 C C6838H779 4 F Dosing phase 04-Jun-03 14:52 128 02-Jun-03 734 s Final phase sacrifice 265.1 C C6838H780 4 F Dosing phase 04-Jun-03 14:52 128 02-Jun-03 734 s Final phase sacrifice 236.3 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.Lovelace Respiratory Dead Animal Status List for All Animals Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 5Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Date and Time Oper. Date of Phase Death Term. BodyNumber Grp Sex Study Phase Data was Entered No. Death Day Typ Status Wt. (g) Ow Grs6838H781 4 F Dosing phase 13-Jun-03 12:43 128 04-Jun-03 736 s Final phase sacrifice 244.3 C -6838H782 4 F Dosing phase 13-Jun-03 12:35 128 03-Jun-03 735 s Final phase sacrifice 240.3 C C6838H783 4 F Dosing phase 12-May-03 10:51 8 09-May-03 710 u Sacrificed moribund 196.1 C C6838H784 4 F Dosing phase 13-Jun-03 12:23 128 06-Jun-03 738 s Final phase sacrifice 202.7 C -6838H785 4 F Dosing phase 19-Sep-02 14:26 128 17-Sep-02 476 u Sacrificed moribund 230.0 C C6838H786 4 F Dosing phase 19-May-03 16:24 128 15-May-03 716 u Found Dead 240.4 C C6838H787 4 F Dosing phase 13-Jun-03 12:43 128 04-Jun-03 736 s Final phase sacrifice 266.0 C C6838H788 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 244.1 C C6838H789 4 F Dosing phase 13-Jun-03 12:29 128 05-Jun-03 737 s Final phase sacrifice 247.7 C -6838H790 4 F Dosing phase 04-Jun-03 14:53 128 02-Jun-03 734 s Final phase sacrifice 238.2 C C6838H791 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 265.6 C C6838H792 4 F Dosing phase 29-May-03 17:01 128 29-May-03 730 u Sacrificed moribund 199.7 C C6838H793 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 231.8 C C6838H794 4 F Dosing phase 13-Jun-03 12:24 128 06-Jun-03 738 s Final phase sacrifice 258.7 C -6838H795 4 F Dosing phase 19-May-03 16:22 128 15-May-03 716 u Found Dead 219.8 C C6838H796 4 F Dosing phase 13-Jun-03 12:44 128 04-Jun-03 736 s Final phase sacrifice 240.6 C -6838H797 4 F Dosing phase 28-Jan-03 09:17 8 24-Jan-03 605 u Sacrificed moribund 223.3 C C6838H798 4 F Dosing phase 13-Jun-03 12:30 128 05-Jun-03 737 s Final phase sacrifice 256.0 C C6838H799 4 F Dosing phase 13-Jun-03 12:30 128 05-Jun-03 737 s Final phase sacrifice 215.8 C C6838H800 4 F Dosing phase 04-Jun-03 14:54 128 02-Jun-03 734 s Final phase sacrifice 247.9 C CNote: * = pretest animal no. P = partial data. C = complete data. - = no data.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

I-1 APPENDIX I

INDIVIDUAL ANIMAL IN -LIFE BODY WEIGHTS

I-1 Males – Individual Animal Body Weight Data

I-2 Males – Summary St atistics - Body Weight Data

I-3 Females – Individu al Animal Body Weight Data

I-4 Females – Summary Statistics - Body Weight Data

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

I-1 Males

Individual Animal Body Weight DataLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 1Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84M a l e A n i m a l s6831E401 1 187.6 195.9 219.1 234.5 250.3 260.1 270.3 283.2 296.3 302.6 302.0 314.7 321.86831E402 195.5 206.4 220.7 239.1 249.7 263.4 269.2 282.0 291.8 297.5 299.7 311.5 313.86831E403 174.0 177.4 196.4 212.8 228.7 237.4 245.3 255.1 265.6 273.0 282.7 290.7 296.96831E404 190.4 194.3 212.4 229.3 245.6 258.6 264.9 280.2 289.1 299.1 309.7 325.8 326.96831E405 181.4 184.0 202.7 213.7 217.8 233.8 236.9 249.7 258.4 265.6 272.8 285.9 288.96831E406 184.7 191.2 200.0 208.1 215.0 219.8 223.8 243.2 248.4 253.5 261.2 272.9 280.56831E407 181.8 193.8 214.4 230.8 243.5 257.4 263.0 278.1 288.2 298.8 301.3 308.5 317.86831E408 189.7 194.7 222.9 237.2 257.5 267.9 280.2 293.8 300.0 306.7 319.6 334.2 340.86831E409 189.0 195.8 214.7 229.1 243.9 255.7 265.6 283.3 290.7 290.9 299.6 314.2 316.26831E410 185.7 204.1 226.2 241.8 258.1 273.2 282.6 292.6 302.8 312.3 317.7 331.0 340.76831E411 182.2 188.5 203.4 226.1 243.0 259.4 269.4 284.7 289.4 302.1 311.9 328.1 334.16831E412 185.4 193.0 211.1 225.1 236.2 253.5 262.2 273.1 285.0 286.4 294.8 306.5 313.46831E413 160.0 161.9 176.6 192.7 199.8 221.9 228.7 245.2 252.8 260.7 270.8 282.0 291.86831E414 189.3 201.9 222.0 242.8 255.8 267.4 274.2 283.5 296.7 308.6 314.1 314.5 321.36831E415 180.0 184.1 206.4 222.6 232.3 244.1 255.0 271.1 282.1 290.8 302.0 311.7 314.36831E416 191.9 197.0 220.4 239.1 248.8 264.4 271.3 288.3 290.8 298.7 306.5 319.1 323.56831E417 178.8 189.9 208.3 230.1 237.2 251.1 259.0 274.1 284.3 293.6 303.0 312.1 319.56831E418 177.1 182.4 201.5 230.1 246.6 255.3 266.7 280.5 292.0 299.0 305.9 317.9 323.36831E419 199.0 195.9 227.2 252.4 274.5 290.9 301.0 316.8 325.6 336.0 344.3 357.0 367.26831E420 180.1 183.8 199.5 219.8 232.2 245.6 256.7 268.1 275.9 277.0 285.9 299.5 304.56831E421 186.0 186.3 203.0 227.2 243.5 258.7 269.2 276.3 285.8 292.4 301.0 312.9 317.26831E422 185.3 182.8 199.8 221.4 228.4 243.6 250.2 262.9 274.2 279.8 287.6 301.7 301.26831E423 183.5 167.2 186.5 207.3 216.4 222.9 227.4 242.2 256.0 261.2 272.7 285.0 293.36831E424 186.6 171.1 198.4 229.2 239.8 249.5 257.9 269.4 279.9 287.1 294.2 304.9 309.76831E425 193.9 177.4 211.5 239.7 252.5 265.6 271.9 284.6 301.4 307.5 310.4 319.3 326.76831E426 186.7 171.5 194.9 214.7 221.4 225.8 228.6 241.4 255.3 260.0 266.1 278.2 282.66831E427 173.3 184.1 193.5 214.0 230.5 243.4 248.8 266.0 274.8 283.8 289.6 301.1 307.06831E428 179.7 177.7 191.2 214.2 222.9 235.4 244.5 259.4 272.2 277.0 282.8 291.8 300.06831E429 192.6 202.2 229.2 252.4 262.8 273.7 284.0 305.3 310.5 321.3 325.3 335.5 334.66831E430 188.5 187.0 227.7 244.9 257.8 272.0 283.3 295.0 309.3 310.5 321.2 328.0 333.16831E431 185.8 190.2 207.4 229.2 248.2 264.3 272.3 286.1 297.8 310.3 324.5 339.2 341.96831E432 182.0 166.0 196.1 221.0 234.2 242.5 255.1 265.6 280.2 282.6 288.1 301.5 305.56831E433 185.9 173.4 195.8 218.4 231.1 240.7 246.5 263.0 280.2 280.3 288.2 302.7 309.46831E434 193.2 180.8 214.2 243.1 250.5 260.6 272.6 283.5 279.6 301.8 305.3 328.5 328.36831E435 189.1 192.6 208.9 226.3 242.4 246.1 249.4 264.5 272.9 279.2 285.2 298.3 300.26831E436 182.3 192.1 209.3 229.6 242.6 250.9 254.8 265.7 278.1 288.1 288.6 292.3 306.66831E437 173.3 179.4 201.4 215.6 232.6 241.9 250.4 264.4 278.2 283.0 285.8 292.6 296.46831E438 193.9 200.1 218.8 239.4 253.7 266.7 272.8 281.8 293.7 302.1 314.4 320.9 324.06831E439 176.1 181.1 192.3 207.5 219.3 228.0 237.9 248.8 257.9 265.0 274.0 286.3 292.26831E440 185.0 197.4 209.0 219.1 235.5 241.5 250.1 268.9 284.5 292.9 300.8 316.5 326.46831E441 180.7 188.8 197.2 211.4 224.6 231.6 238.8 251.4 261.3 271.9 275.6 289.3 292.2Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84M a l e A n i m a l s6831E442 1 181.6 201.5 214.8 236.0 259.6 273.0 281.7 291.7 298.6 311.4 320.4 334.7 336.56831E443 183.5 193.4 209.5 229.2 238.9 249.6 255.1 264.8 275.0 284.8 288.1 295.8 301.86831E444 174.0 179.3 196.3 215.8 234.1 237.7 247.4 259.1 273.4 279.7 281.2 290.1 297.66831E445 203.3 216.3 239.3 259.1 270.6 282.0 286.3 299.0 310.8 314.9 319.3 330.9 335.36831E446 178.6 186.8 203.5 228.4 246.2 259.1 264.2 277.7 295.2 304.9 314.3 327.1 334.36831E447 186.3 194.2 212.4 221.3 234.5 243.3 257.6 274.2 283.1 290.6 296.5 308.4 312.06831E448 170.9 173.6 185.4 192.3 203.9 213.6 219.9 233.8 248.8 255.5 266.1 276.1 284.36831E449 196.8 210.3 224.2 245.0 265.7 279.7 288.1 299.3 312.4 315.9 322.7 335.7 346.36831E450 179.5 187.7 197.7 213.0 225.9 237.9 243.4 261.9 268.1 276.9 282.2 294.3 299.4(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 184.4 188.2 207.5 226.5 239.7 251.2 259.1 272.7 283.1 290.5 297.6 309.1 314.7Sdevs 7.8 11.5 12.9 14.3 16.1 17.3 18.2 17.8 17.5 18.3 18.4 19.0 18.86833F501 2 185.6 197.1 211.5 232.0 245.7 258.3 266.0 277.7 287.4 298.7 306.8 317.3 321.86833F502 177.0 196.2 212.2 232.3 245.7 258.3 266.8 279.2 283.2 285.2 293.9 300.6 307.86833F503 174.8 188.8 203.6 228.5 241.6 251.6 262.6 273.0 279.6 285.9 290.2 299.7 308.66833F504 190.4 204.5 222.4 241.0 254.8 265.0 275.5 286.5 299.3 303.6 316.4 323.9 327.06833F505 188.7 206.6 221.9 241.1 254.7 266.8 277.5 287.9 296.2 303.6 318.0 328.7 337.46833F506 191.3 200.2 221.2 238.9 251.5 258.4 271.3 279.0 287.1 290.5 302.7 306.3 311.96833F507 172.5 174.2 182.9 196.7 204.5 212.3 218.9 237.1 241.6 252.5 259.3 274.3 277.46833F508 188.3 194.1 203.0 222.0 234.7 249.5 260.3 272.6 282.4 289.8 302.0 309.6 314.76833F509 192.1 202.3 219.2 235.7 253.0 263.1 271.2 287.2 292.8 300.0 312.7 320.6 324.16833F510 181.7 196.5 213.1 230.5 241.5 253.7 264.9 275.7 280.9 287.2 291.7 300.6 305.56833F511 183.9 199.7 215.8 234.7 257.6 266.7 280.5 297.2 302.4 311.2 320.3 327.3 336.76833F512 184.6 188.1 200.6 215.3 227.8 239.4 244.2 261.4 265.1 269.4 277.6 290.8 293.96833F513 166.0 168.6 177.6 190.2 205.0 214.4 228.7 244.2 253.1 258.6 266.8 270.2 278.86833F514 164.5 174.7 189.9 209.1 223.6 226.0 239.8 253.4 265.8 273.4 280.8 293.2 299.56833F515 177.8 196.2 212.7 229.2 243.1 253.0 263.1 278.8 287.8 292.4 298.0 316.3 327.66833F516 192.6 202.1 215.5 232.0 248.8 260.8 270.5 288.0 291.5 298.1 303.1 315.5 324.06833F517 182.6 196.1 212.2 230.7 245.3 258.3 268.6 282.7 291.7 295.2 304.7 313.3 315.06833F518 171.9 183.2 196.8 214.5 234.1 247.0 260.1 273.1 284.9 293.0 300.4 312.8 318.26833F519 192.3 207.3 229.9 247.4 260.8 274.0 284.9 294.8 308.8 333.7 326.5 338.7 342.96833F520 187.2 203.9 223.8 243.1 254.0 267.8 276.7 287.4 300.0 323.7 313.2 323.3 327.06833F521 180.5 196.5 215.2 228.0 242.3 254.5 263.1 273.2 280.8 302.1 295.0 300.7 305.96833F522 176.6 186.6 201.4 210.9 225.4 237.9 250.0 257.5 266.7 294.3 288.7 291.5 304.26833F523 179.2 184.4 198.2 207.7 214.4 222.7 236.3 250.2 260.8 285.6 277.4 284.1 299.16833F524 197.2 217.8 236.2 255.2 265.7 283.1 290.1 303.5 308.0 332.3 326.9 336.5 342.86833F525 185.7 198.7 219.0 243.5 255.5 270.7 279.5 292.2 300.2 327.0 324.3 330.0 335.66833F526 182.1 190.7 213.4 232.0 245.5 255.0 267.0 276.2 286.9 306.8 297.6 303.6 311.96833F527 163.5 176.8 190.8 208.9 222.3 233.0 239.1 247.3 253.8 275.7 263.2 277.5 287.16833F528 171.2 178.2 186.7 208.5 223.6 234.4 243.2 253.7 263.8 290.5 278.9 286.7 297.1Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 3Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84M a l e A n i m a l s6833F529 2 181.3 202.0 210.7 225.9 242.2 251.8 261.9 277.0 285.5 295.2 305.0 312.7 315.76833F530 189.4 196.2 209.5 223.1 238.2 247.5 258.2 272.7 281.3 284.3 293.6 301.1 311.66833F531 157.2 179.8 204.5 220.9 237.4 248.2 261.6 274.3 285.8 292.1 306.8 315.2 322.26833F532 183.2 199.3 211.4 227.1 236.0 244.0 250.1 264.5 271.9 276.6 282.9 290.3 298.36833F533 189.6 211.2 228.5 242.9 255.6 269.6 273.3 278.0 288.1 293.6 299.3 308.1 310.46833F534 163.3 172.5 177.6 191.1 203.8 213.0 222.8 235.1 242.5 250.1 262.5 269.9 274.66833F535 190.0 199.6 150.3 208.5 231.6 255.8 267.8 278.0 292.0 302.8 311.4 320.6 325.46833F536 176.8 186.5 203.5 219.3 236.5 244.7 255.6 264.4 273.3 296.1 283.0 289.2 298.46833F537 179.1 188.2 198.5 213.4 227.6 241.3 251.5 268.0 280.7 308.6 300.1 309.8 322.16833F538 185.7 189.9 202.9 223.7 241.2 250.2 259.8 271.2 286.6 308.3 304.9 307.9 312.46833F539 205.3 219.1 236.3 259.9 271.0 278.0 285.3 298.8 305.2 328.3 319.9 328.6 336.16833F540 189.7 195.7 202.2 222.8 235.3 250.3 262.1 277.9 288.7 310.6 302.7 315.7 325.56833F541 191.0 206.5 220.4 241.3 251.6 264.6 273.2 284.0 288.8 308.7 304.0 315.6 316.16833F542 167.0 169.3 181.0 198.0 212.6 224.3 236.7 249.2 258.5 284.8 272.5 284.8 293.06833F543 174.8 189.2 206.8 226.5 237.5 249.6 236.5 272.7 281.8 304.3 289.2 294.3 301.36833F544 178.2 192.3 206.9 224.5 242.8 248.5 278.4 285.3 308.4 294.8 307.7 317.76833F545 191.1 205.4 220.8 240.3 253.8 262.6 278.2 292.1 296.9 325.6 318.4 329.1 336.46833F546 185.2 199.1 215.4 237.9 250.6 262.0 272.9 293.4 290.4 311.9 298.4 311.1 315.36833F547 182.0 184.4 201.2 209.6 221.3 230.1 243.1 251.8 263.4 286.2 282.1 285.2 291.16833F548 177.4 193.2 212.7 233.2 249.0 257.7 268.5 276.7 284.8 307.6 296.2 306.8 306.96833F549 189.2 199.4 218.4 237.1 252.0 256.3 269.6 280.5 293.4 299.3 303.3 310.7 312.36833F550 194.3 202.4 224.7 236.6 247.9 260.3 263.7 273.5 282.1 281.8 287.8 294.5 298.7(n) 50 50 50 50 50 50 49 50 50 50 50 50 50Means 182.1 193.8 207.8 226.1 240.0 250.9 260.7 273.7 282.2 296.5 297.1 306.1 312.5Sdevs 9.8 11.6 16.2 15.6 15.6 16.4 16.6 15.9 15.7 18.5 16.7 17.0 16.66835G601 3 184.0 190.3 202.4 220.9 233.8 245.2 253.6 265.8 275.9 287.2 292.7 305.7 312.46835G602 178.8 189.9 208.8 230.1 246.5 258.7 269.5 279.5 289.0 292.5 302.4 308.8 317.96835G603 190.9 193.0 201.1 220.7 233.3 247.5 257.3 266.9 275.9 284.0 291.7 299.7 303.56835G604 188.6 195.4 211.4 235.5 244.4 255.9 265.4 276.3 287.6 292.1 296.2 309.0 315.86835G605 172.8 180.7 200.2 217.2 230.3 245.4 253.7 265.3 274.0 282.2 290.8 299.6 304.06835G606 211.4 227.1 250.8 272.5 289.6 305.8 316.7 330.0 340.2 348.5 357.8 367.3 379.66835G607 179.5 185.0 198.0 213.6 218.8 225.2 235.2 238.6 250.6 256.1 259.8 273.8 282.46835G608 200.3 204.9 220.7 236.4 244.0 255.6 267.6 277.5 285.7 288.5 297.7 307.4 315.26835G609 187.4 191.2 208.2 227.7 237.8 255.5 267.4 283.0 288.0 297.6 306.5 315.1 327.86835G610 181.9 192.6 213.5 229.5 247.1 262.1 275.9 273.2 292.2 299.4 306.7 315.0 324.06835G611 176.7 182.3 195.2 216.7 232.8 246.4 260.8 257.7 280.2 286.9 296.2 303.4 313.16835G612 195.4 208.4 224.0 246.6 258.1 274.9 284.9 298.0 308.5 317.5 325.1 338.4 339.06835G613 170.1 174.7 185.8 210.7 221.9 240.5 249.9 264.2 274.0 284.4 294.8 302.5 305.56835G614 195.2 203.4 223.9 240.8 255.0 265.7 272.8 282.1 295.5 305.4 312.3 320.7 327.16835G615 180.2 187.3 196.2 210.3 223.3 235.9 248.0 257.6 273.6 278.0 285.0 293.1 298.1Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 4Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84M a l e A n i m a l s6835G616 3 186.1 197.7 216.9 231.5 237.9 253.8 265.4 274.7 284.3 288.3 295.9 306.5 312.06835G617 179.9 188.6 199.6 210.2 223.5 238.9 249.4 265.2 273.2 280.2 288.7 298.6 301.06835G618 178.0 184.3 196.8 213.1 224.9 233.2 243.1 259.0 272.9 276.3 280.4 286.6 298.26835G619 188.4 194.8 205.8 226.2 238.5 251.9 263.9 275.3 278.3 286.9 295.9 310.0 311.16835G620 188.5 196.2 211.6 226.6 234.5 255.0 263.2 276.9 282.3 290.0 298.7 310.5 317.26835G621 159.9 163.0 179.0 198.7 212.4 228.0 237.5 251.4 261.7 273.6 281.8 290.3 298.86835G622 178.3 182.9 195.1 209.8 223.4 233.1 240.9 253.0 260.7 271.5 277.4 282.9 289.06835G623 194.9 201.7 220.9 236.8 251.7 262.9 272.4 285.0 289.9 298.0 306.2 307.9 318.46835G624 175.6 180.3 192.1 205.7 215.5 225.4 232.1 243.9 249.0 255.1 266.1 270.6 279.26835G625 178.5 186.1 203.2 224.1 238.5 253.4 263.0 273.1 281.9 290.5 294.6 306.6 314.76835G626 176.9 181.9 193.1 206.7 217.0 229.5 239.1 251.4 257.4 265.5 272.1 280.4 287.56835G627 169.2 178.8 190.9 212.0 229.8 242.8 254.7 267.0 277.2 287.1 296.5 305.6 311.76835G628 184.8 195.6 209.7 227.7 243.2 257.3 266.1 276.8 286.5 290.7 301.2 309.7 310.66835G629 195.1 209.1 217.6 236.7 253.4 266.9 275.5 285.0 299.3 303.2 315.7 323.6 324.06835G630 193.3 209.8 228.1 242.8 270.6 264.7 270.5 281.5 290.9 294.0 296.2 305.8 310.66835G631 196.8 218.8 234.9 258.2 257.2 292.5 306.1 317.3 328.9 336.4 342.0 359.6 367.66835G632 205.0 212.7 224.5 238.8 252.7 254.6 265.3 279.6 289.8 298.8 304.8 309.7 319.36835G633 186.0 187.9 195.7 207.3 219.4 230.4 245.3 259.4 275.9 281.3 288.2 297.9 303.86835G634 196.2 209.6 217.6 239.9 252.1 265.8 275.4 285.3 299.6 302.5 311.0 323.9 330.16835G635 182.2 190.6 207.5 221.3 232.5 245.8 256.1 264.7 273.2 277.7 288.9 296.5 303.06835G636 191.2 197.8 224.4 245.6 263.6 276.0 286.3 296.6 312.3 317.8 334.4 344.7 352.46835G637 183.4 193.7 211.9 234.9 244.2 256.9 265.6 275.7 288.1 291.3 307.4 314.1 321.56835G638 174.1 188.3 201.2 218.9 232.1 242.8 260.5 273.0 282.1 285.9 294.1 309.2 318.96835G639 188.0 203.5 222.3 236.9 250.2 265.7 279.0 282.3 291.2 302.9 306.7 320.7 324.46835G640 177.0 185.9 202.2 211.6 222.7 239.9 240.8 249.5 262.7 265.4 275.9 283.5 291.16835G641 184.4 196.3 216.5 231.8 244.5 252.0 260.1 270.4 281.3 289.6 295.4 305.8 309.06835G642 196.0 211.0 226.6 244.9 257.7 274.3 278.7 290.2 303.3 308.9 315.7 324.3 331.36835G643 171.1 183.5 198.6 216.8 226.1 239.8 247.3 256.5 268.4 274.7 281.8 287.2 293.06835G644 197.7 211.6 217.7 238.3 249.8 259.6 264.9 276.6 280.2 290.1 298.5 305.0 309.26835G645 188.7 194.2 201.3 214.2 222.0 242.5 248.3 257.0 267.2 275.9 280.9 294.3 299.16835G646 195.3 208.7 221.1 228.4 247.4 259.6 268.2 281.2 293.5 301.4 310.4 321.1 332.16835G647 169.8 185.8 199.7 215.9 226.3 235.5 254.1 256.5 264.8 275.2 285.7 294.8 299.66835G648 171.5 188.1 202.7 217.6 230.4 237.9 245.5 262.1 278.1 287.9 292.0 296.8 301.86835G649 165.3 174.4 189.2 209.6 217.8 229.5 238.3 250.5 260.9 264.0 272.8 279.2 287.26835G650 166.1 171.7 184.1 197.8 206.6 215.5 221.8 233.1 241.3 250.1 259.6 270.4 271.5(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 184.1 193.4 208.0 225.3 237.7 250.7 260.5 271.0 281.6 288.6 296.6 305.9 312.3Sdevs 10.9 12.9 14.3 15.3 16.5 17.4 17.8 17.9 18.3 18.3 18.7 19.6 20.26837H701 4 169.9 185.0 200.8 224.5 238.0 253.1 267.2 279.2 295.3 306.7 319.7 327.7 334.3Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 5Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84M a l e A n i m a l s6837H702 4 184.9 189.1 205.3 225.7 241.8 254.2 266.3 275.8 290.4 298.6 312.0 315.5 329.46837H703 180.0 191.8 211.5 234.3 249.3 267.2 276.2 287.9 299.7 313.0 323.1 328.0 331.96837H704 134.2 177.8 201.8 215.7 230.0 242.2 255.6 267.9 278.7 287.7 293.6 301.2 307.46837H705 182.1 194.7 210.7 230.9 243.1 259.0 267.4 283.6 292.9 303.6 316.8 320.9 328.86837H706 190.4 195.6 205.9 225.5 239.4 256.0 267.6 277.6 286.6 297.0 308.6 320.5 326.56837H707 183.3 191.1 203.8 219.9 230.9 245.0 253.8 262.9 272.1 282.9 289.4 298.4 301.76837H708 174.9 181.3 197.2 212.5 224.6 235.9 248.0 255.4 269.9 279.6 281.7 289.2 294.06837H709 187.9 203.3 214.8 233.4 248.1 258.5 269.2 280.2 290.3 299.8 309.5 310.8 317.66837H710 180.2 180.2 188.5 208.8 224.6 231.8 250.0 262.6 277.1 280.8 294.8 307.2 311.36837H711 183.2 199.0 219.4 235.6 252.4 266.6 278.5 291.9 300.4 309.5 318.1 328.0 333.36837H712 173.5 182.1 191.3 212.1 222.2 240.7 250.3 262.3 273.7 281.2 288.5 296.2 298.16837H713 194.9 205.0 222.9 243.6 255.6 263.6 275.1 288.4 294.2 299.6 308.9 314.9 314.96837H714 168.8 172.4 185.5 205.7 218.1 229.3 238.2 251.1 262.6 268.1 277.4 287.2 291.16837H715 185.5 199.9 215.0 237.6 248.4 259.2 270.2 280.4 294.1 310.4 317.4 321.6 323.06837H716 174.9 187.6 202.8 216.4 226.9 239.3 246.7 259.1 266.7 274.8 277.6 288.9 292.56837H717 189.8 209.3 224.2 243.2 254.4 266.2 279.7 291.0 298.5 308.7 314.6 321.6 330.96837H718 168.7 166.5 183.5 199.4 211.2 221.2 234.0 246.5 262.2 264.8 272.4 284.0 287.66837H719 167.7 175.0 191.0 206.5 223.3 234.8 242.4 256.9 265.9 270.8 286.1 290.6 302.16837H720 172.7 174.1 183.9 198.2 203.2 215.4 222.5 233.5 243.4 249.7 255.7 261.2 267.36837H721 193.6 200.4 212.4 236.9 249.4 264.2 273.0 282.3 292.7 296.7 305.4 312.7 316.06837H722 173.8 180.8 195.7 211.7 222.1 238.2 247.3 256.1 269.1 276.5 286.8 295.8 303.66837H723 177.4 186.3 200.2 217.7 226.4 242.3 252.6 264.5 275.0 279.8 292.7 302.3 304.06837H724 198.2 212.0 227.1 244.7 253.5 270.3 280.4 294.8 310.2 317.8 326.0 339.0 345.06837H725 178.5 161.4 179.6 204.8 217.8 231.0 242.6 253.6 265.5 274.6 283.3 288.0 294.06837H726 182.0 190.9 201.5 217.3 226.8 239.5 248.7 258.2 266.6 272.8 278.8 288.0 293.06837H727 171.9 178.7 196.3 220.3 231.8 243.8 257.2 270.3 286.9 291.6 300.5 310.6 319.26837H728 166.0 168.6 179.6 202.0 213.5 221.1 228.8 239.8 249.9 259.1 266.3 273.1 279.96837H729 192.9 200.2 214.1 227.1 236.5 246.3 253.5 266.9 278.1 279.9 288.3 293.5 298.26837H730 179.4 190.5 201.0 213.2 224.0 234.0 243.3 260.5 271.2 275.6 284.3 291.8 295.36837H731 186.4 190.3 200.3 215.0 224.9 238.8 249.9 259.5 271.6 275.8 284.1 290.5 298.46837H732 195.7 205.1 217.8 234.7 243.9 257.9 266.8 278.0 293.7 299.7 306.6 316.8 321.56837H733 182.9 187.9 201.3 216.2 228.9 237.7 245.8 259.2 267.9 271.8 279.8 288.2 293.16837H734 176.8 182.6 196.5 210.1 219.3 226.5 234.3 244.6 259.6 261.2 271.8 281.2 282.66837H735 160.2 164.3 175.8 192.0 201.2 210.1 220.9 231.3 245.7 251.6 259.2 270.3 278.86837H736 166.7 106.6 165.5 198.0 224.6 241.7 252.3 262.5 275.7 280.6 294.9 304.3 311.96837H737 182.5 200.5 215.7 236.3 245.2 254.5 263.9 274.1 287.6 289.9 298.4 305.2 312.66837H738 162.0 104.1 161.0 193.5 219.5 234.2 245.7 257.8 268.5 275.3 287.0 293.7 312.96837H739 184.8 189.3 199.5 210.0 213.9 227.9 235.8 243.0 259.9 266.7 279.2 284.0 298.36837H740 180.2 191.0 209.5 229.9 242.3 261.7 270.5 285.5 290.8 296.7 309.9 322.5 332.56837H741 179.7 189.3 198.2 215.3 233.6 242.7 257.0 270.1 274.9 286.4 293.7 302.3 309.96837H742 191.1 199.3 211.3 224.4 235.4 244.6 254.2 260.6 275.5 279.4 287.7 296.4 296.4Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 6Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84M a l e A n i m a l s6837H743 4 170.3 172.3 188.2 206.4 219.0 226.4 237.1 251.5 263.8 271.6 278.6 291.5 300.36837H744 159.4 183.7 199.4 215.8 226.8 235.4 249.9 257.2 270.8 277.4 287.6 296.0 303.06837H745 170.1 183.7 197.8 213.4 224.9 235.9 247.4 258.2 267.3 278.5 284.6 295.7 299.16837H746 181.4 196.7 204.7 223.1 235.4 247.3 257.5 268.0 281.0 288.3 298.0 310.4 317.06837H747 187.7 193.9 200.9 213.0 221.7 232.4 245.7 255.3 264.5 269.5 283.9 298.1 302.36837H748 178.6 183.6 193.9 211.7 219.7 231.1 241.8 245.5 261.4 265.8 273.8 282.8 287.56837H749 159.1 164.6 172.3 181.3 193.3 202.6 212.0 221.6 232.7 239.1 248.2 257.4 263.96837H750 179.8 190.3 195.7 204.3 214.7 226.7 237.4 243.8 256.8 263.6 273.9 285.3 294.6(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 177.9 184.2 199.5 217.4 229.5 241.7 252.2 263.4 275.0 282.0 291.2 299.6 305.8Sdevs 11.6 20.2 14.5 14.3 14.3 15.5 15.8 16.6 16.2 17.3 17.8 17.6 17.8Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 7Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427M a l e A n i m a l s6831E401 1 325.0 346.7 358.5 373.8 379.4 395.3 399.1 399.4 407.8 421.1 422.9 426.8 430.16831E402 322.3 339.8 346.8 361.1 366.6 382.2 382.1 382.9 405.4 418.0 387.0 405.6 413.26831E403 300.9 316.7 331.3 347.2 353.7 366.5 367.0 373.0 386.5 390.8 359.4 385.9 377.86831E404 331.2 350.9 361.6 382.6 393.4 408.3 413.4 410.7 429.6 448.7 445.3 454.9 460.26831E405 294.5 315.1 323.6 346.3 353.1 371.6 370.6 375.8 393.0 399.0 404.6 415.1 409.46831E406 285.6 306.1 318.7 332.6 338.8 355.7 359.3 359.6 377.0 383.4 367.3 379.3 389.66831E407 322.1 342.1 352.9 360.1 378.4 390.0 389.0 397.3 420.9 416.1 411.9 420.1 423.06831E408 341.9 344.8 359.5 345.5 352.76831E409 323.6 340.7 356.1 370.6 376.4 382.9 388.4 401.7 410.1 419.6 419.0 431.6 435.06831E410 346.4 360.3 367.1 380.2 393.1 408.8 410.9 424.6 445.4 449.8 453.7 474.2 470.06831E411 341.8 361.0 374.3 384.1 393.2 401.8 403.8 404.2 418.5 431.0 431.5 446.0 450.76831E412 319.3 333.9 351.9 362.3 375.9 389.0 391.5 397.7 419.1 429.0 424.0 433.2 430.66831E413 300.2 330.9 353.1 367.3 386.2 410.9 399.4 406.4 420.2 429.9 419.7 435.2 428.36831E414 323.1 354.3 369.6 383.1 395.4 410.9 417.7 412.3 431.7 445.2 439.1 448.3 453.36831E415 329.6 339.9 351.1 371.6 379.4 383.2 395.0 401.8 403.6 419.4 417.2 426.0 430.56831E416 328.7 348.7 365.6 371.4 384.2 403.6 399.2 408.1 419.2 432.9 432.2 442.8 448.86831E417 328.4 344.2 357.7 376.5 374.8 388.6 394.0 401.3 414.1 428.8 429.0 442.4 448.06831E418 325.7 343.3 363.2 372.9 388.1 409.1 403.1 406.2 426.4 433.8 429.9 441.1 430.46831E419 372.2 390.6 399.4 416.1 437.6 457.5 431.9 458.3 474.1 454.3 481.7 490.5 482.56831E420 312.6 334.0 351.0 364.1 375.9 392.0 392.5 397.6 403.0 400.5 412.0 413.9 413.96831E421 312.9 349.6 367.4 377.6 393.9 413.5 418.0 427.6 436.3 441.1 444.8 452.6 457.66831E422 302.9 320.0 329.1 337.9 351.6 360.3 369.2 383.0 388.4 397.5 401.0 408.2 405.86831E423 296.6 315.0 335.9 354.5 369.8 383.7 390.6 398.5 400.9 415.4 425.0 428.2 427.66831E424 313.0 337.7 355.0 370.9 382.0 406.0 411.5 418.0 429.1 438.0 441.1 451.2 442.36831E425 332.6 362.4 376.8 394.9 408.8 430.9 434.8 444.1 451.0 462.9 469.0 477.5 472.66831E426 287.0 308.9 324.8 340.6 352.1 368.2 369.5 373.6 389.5 392.5 371.0 396.1 390.46831E427 316.2 338.3 349.8 366.5 378.7 400.5 393.5 404.2 395.0 413.5 410.5 424.0 421.06831E428 302.8 325.8 338.1 361.6 366.0 384.5 390.7 404.4 411.5 423.9 429.1 430.1 428.46831E429 340.3 359.1 377.6 390.3 405.9 427.8 427.2 442.4 452.3 461.3 466.7 475.7 472.76831E430 333.6 362.9 375.4 397.4 412.3 423.2 435.9 444.5 446.8 456.5 472.3 481.6 483.16831E431 352.4 372.3 385.7 394.5 402.7 426.2 407.9 431.6 424.6 439.8 410.86831E432 307.4 331.4 347.9 354.9 373.8 396.1 387.8 401.3 411.2 420.9 431.6 437.6 444.86831E433 312.5 335.2 355.9 372.7 382.8 398.7 401.6 411.2 420.3 429.8 432.9 436.1 429.06831E434 331.2 346.6 363.3 383.0 385.9 403.2 403.4 410.1 417.4 426.4 433.1 435.3 437.86831E435 301.0 327.5 341.6 355.2 363.7 375.0 376.9 387.4 398.8 409.7 411.0 414.6 416.96831E436 302.3 314.9 330.4 340.6 355.7 371.6 375.6 390.1 387.4 403.5 392.8 409.8 408.26831E437 299.5 331.7 336.2 349.8 357.0 374.3 376.8 382.5 389.1 401.0 407.2 421.3 416.26831E438 325.9 346.8 355.5 361.1 379.7 387.7 383.0 394.6 405.7 420.0 374.2 402.8 407.56831E439 295.0 320.6 336.9 355.3 361.8 373.0 384.0 383.8 391.1 404.76831E440 330.6 357.1 373.8 396.4 395.5 415.6 415.9 441.5 442.2 451.9 462.4 461.4 465.56831E441 301.0 328.9 336.1 349.7 354.5 375.5 384.8 391.5 410.9 419.8 423.8 435.8 446.1Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 8Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427M a l e A n i m a l s6831E442 1 341.6 362.1 374.1 381.9 386.3 410.2 415.0 430.0 437.9 447.9 454.0 466.5 470.96831E443 314.6 334.8 356.1 360.7 369.5 394.9 386.4 382.9 394.5 410.9 422.0 433.1 447.76831E444 306.5 323.7 337.0 347.8 357.9 378.7 373.5 370.4 377.3 397.1 399.4 405.2 412.26831E445 339.4 358.1 364.8 380.7 398.6 404.4 405.2 409.0 416.4 441.6 436.5 443.1 446.16831E446 339.2 363.5 381.6 391.3 399.3 416.4 414.0 426.8 444.3 458.5 452.9 466.9 468.36831E447 317.1 347.2 368.7 386.1 401.5 416.3 425.3 431.6 443.9 458.3 425.2 442.9 459.66831E448 288.4 317.1 336.0 353.3 360.0 370.4 373.8 377.4 386.7 392.9 398.0 408.5 405.56831E449 345.5 367.1 378.9 390.9 411.0 427.7 429.7 444.0 455.7 469.5 473.9 482.7 486.16831E450 302.8 330.9 344.5 363.1 375.8 394.0 384.3 404.5 413.3 421.0 429.1 433.9 442.7(n) 50 50 50 50 50 49 49 49 49 49 48 47 47Means 319.3 340.8 355.0 368.6 379.4 396.3 397.0 405.3 415.8 426.1 424.8 435.7 437.0Sdevs 18.9 18.1 17.9 18.3 19.9 21.0 19.4 22.5 22.5 21.9 27.9 25.8 26.26833F501 2 327.9 347.6 356.5 373.9 383.7 382.8 394.7 390.7 399.9 405.2 406.4 415.6 406.86833F502 311.2 330.5 341.2 356.1 369.2 376.4 380.4 391.4 403.7 421.4 412.3 427.1 421.06833F503 313.1 333.9 339.8 348.6 368.6 376.8 383.1 378.7 396.6 406.7 406.0 420.6 411.36833F504 332.7 350.9 359.6 371.8 393.3 402.7 413.0 413.6 423.5 434.4 439.7 452.2 441.86833F505 337.5 357.4 365.9 374.2 382.9 400.2 405.2 411.3 421.2 432.3 437.1 442.8 431.16833F506 320.8 337.7 354.0 365.9 377.5 392.0 400.9 392.3 404.9 408.3 407.2 418.1 406.36833F507 278.2 305.7 320.4 329.3 344.1 358.8 362.3 370.2 386.1 395.7 402.7 410.6 412.76833F508 324.9 343.3 361.5 373.2 385.1 397.1 402.1 412.6 406.8 423.5 424.5 437.0 429.86833F509 325.1 345.2 361.6 375.4 386.2 397.0 402.5 404.1 416.6 435.0 430.3 443.7 425.76833F510 305.4 323.3 337.3 351.6 355.8 367.8 377.8 378.0 389.9 396.5 413.1 411.9 399.16833F511 338.3 361.7 371.0 383.6 405.8 419.1 424.2 428.0 441.8 463.2 462.2 470.3 466.36833F512 296.3 325.5 355.1 364.1 378.0 395.1 407.4 401.7 413.5 428.7 438.2 434.3 431.56833F513 286.4 312.7 323.6 339.4 342.3 361.7 366.7 357.3 379.6 385.1 383.8 394.2 376.66833F514 302.9 324.1 342.0 345.5 353.8 370.2 380.4 381.0 385.2 389.5 393.2 394.9 398.16833F515 330.9 349.4 370.4 375.0 382.8 402.6 409.5 408.3 421.2 427.3 424.8 432.2 430.16833F516 331.6 350.3 363.3 375.4 384.9 404.3 405.7 420.9 438.8 437.6 438.2 439.8 436.36833F517 324.0 339.4 356.7 378.3 379.6 397.7 403.7 412.4 421.7 430.2 426.3 430.0 433.66833F518 320.8 347.4 360.1 378.5 393.3 407.0 410.0 411.0 417.3 438.1 445.7 459.5 456.46833F519 350.4 370.3 381.6 397.5 410.8 427.0 435.6 434.3 440.2 454.1 461.9 473.4 470.26833F520 334.1 353.3 358.8 372.3 383.0 395.0 405.0 396.2 398.8 413.3 412.5 420.6 417.36833F521 311.3 330.5 338.9 349.5 356.9 373.7 384.8 390.7 396.9 411.4 406.8 408.2 409.56833F522 309.2 334.5 349.9 351.5 368.6 386.7 392.7 407.7 404.5 417.9 424.4 426.6 431.06833F523 309.3 336.0 357.6 367.5 383.9 385.1 400.1 406.9 419.6 427.6 431.7 437.4 447.76833F524 345.7 368.3 379.8 391.2 400.9 412.3 422.3 436.9 446.4 455.9 460.56833F525 341.7 363.6 369.2 384.4 399.3 415.4 412.7 427.1 436.7 448.6 443.0 456.7 449.26833F526 317.5 339.3 359.4 364.2 375.8 388.8 399.1 402.2 412.4 421.2 424.0 424.8 428.56833F527 287.9 315.4 335.5 353.0 367.1 379.6 387.2 385.7 388.6 393.1 401.7 390.2 407.06833F528 301.8 320.7 335.5 346.6 359.4 370.8 380.2 389.0 392.6 391.3 393.6 389.7 394.9Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 9Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427M a l e A n i m a l s6833F529 2 322.9 347.2 361.2 368.8 381.2 392.7 402.8 403.5 410.8 418.8 410.4 418.1 430.66833F530 317.5 337.8 352.3 363.6 374.6 388.1 386.5 396.0 401.1 408.9 412.7 421.0 426.16833F531 331.4 354.4 377.8 383.5 392.6 413.1 411.9 418.3 428.2 434.3 424.8 406.7 451.46833F532 303.1 328.7 343.3 354.4 364.1 376.0 380.5 387.0 403.5 414.1 421.7 419.4 426.86833F533 317.7 338.3 352.7 361.2 376.4 391.3 392.0 399.4 400.2 413.4 412.5 406.7 414.66833F534 279.7 306.9 329.7 335.4 348.0 361.6 370.8 390.0 383.6 387.2 397.8 391.0 405.46833F535 331.9 364.8 381.4 387.8 402.6 415.5 416.2 435.9 440.4 454.5 459.3 460.0 472.16833F536 306.5 318.5 329.4 337.5 355.2 363.5 365.0 375.3 381.4 391.7 397.0 395.6 404.26833F537 322.4 344.9 360.7 370.3 381.1 394.9 402.9 405.2 416.1 423.9 428.5 437.2 447.86833F538 319.8 334.0 354.2 355.0 364.4 384.7 385.3 388.9 399.8 415.9 413.8 401.8 410.96833F539 337.5 349.8 369.1 375.8 383.3 400.2 406.2 418.2 425.5 435.8 429.0 435.1 441.26833F540 327.3 350.1 366.1 379.7 388.2 403.3 410.7 420.9 429.3 439.7 440.4 444.6 413.66833F541 318.6 336.4 349.1 355.6 375.7 385.5 382.4 394.3 395.6 403.7 402.6 409.7 411.96833F542 296.8 316.4 332.5 344.3 351.9 363.2 370.3 374.0 383.9 391.2 386.7 396.9 396.16833F543 305.0 322.4 345.6 344.2 351.4 367.3 370.7 370.4 368.4 383.7 386.4 402.7 398.86833F544 317.4 341.4 358.4 358.9 374.3 394.1 393.6 393.5 402.6 415.2 422.8 431.2 425.06833F545 340.4 355.3 371.9 377.1 389.6 403.8 390.4 406.2 414.3 428.4 422.3 432.9 430.06833F546 317.4 345.6 351.4 360.8 375.4 395.2 390.7 400.6 409.4 425.1 422.5 430.3 427.76833F547 297.7 318.0 338.9 346.2 363.2 375.2 380.4 390.3 400.5 411.3 417.5 415.8 413.76833F548 310.4 336.0 342.8 354.0 373.4 390.7 398.8 405.3 410.0 427.7 432.7 438.6 438.06833F549 310.6 335.2 345.0 347.9 364.0 383.8 380.2 397.0 405.8 411.8 409.4 414.9 414.86833F550 298.2 324.4 342.9 352.2 370.3 385.6 389.5 397.3 413.7 424.7 420.6 424.0 422.9(n) 50 50 50 50 50 50 50 50 50 50 50 49 49Means 316.9 338.5 353.3 363.0 375.5 389.5 394.5 400.2 408.6 419.1 420.5 424.4 424.4Sdevs 16.8 15.8 15.0 15.8 16.2 16.5 16.4 17.7 18.1 19.7 19.5 20.9 20.46835G601 3 310.4 337.6 339.6 354.1 357.8 379.2 382.2 374.6 387.4 401.0 401.6 405.5 398.16835G602 314.7 339.2 346.1 365.1 382.8 395.8 402.7 404.8 410.9 420.7 422.9 433.1 419.96835G603 309.2 334.5 344.1 354.7 370.5 388.4 391.1 398.1 405.7 417.9 417.5 430.5 426.06835G604 311.2 339.4 355.7 362.6 389.1 402.7 403.0 396.8 419.5 428.5 435.0 442.4 431.26835G605 303.6 335.9 348.5 361.3 374.8 385.6 382.8 394.9 404.1 413.5 415.1 423.6 416.56835G606 370.9 404.4 421.3 437.4 457.3 473.3 466.3 464.7 486.1 499.2 500.0 502.9 492.96835G607 280.5 311.0 322.6 339.8 356.4 369.5 376.2 375.7 388.7 395.1 399.3 404.5 403.36835G608 318.2 349.2 358.9 367.6 384.4 388.3 397.5 404.3 404.7 411.5 416.7 424.4 417.76835G609 326.1 351.6 372.4 383.9 399.9 412.6 411.1 429.9 444.5 452.8 452.1 457.3 454.26835G610 314.2 351.9 364.8 377.7 385.7 395.0 394.3 400.7 418.8 420.5 417.7 424.8 417.76835G611 303.7 327.8 341.4 353.7 366.6 380.1 382.4 381.8 394.6 410.7 407.1 423.6 381.56835G612 335.7 370.1 385.1 398.4 414.4 432.4 408.6 426.8 441.0 456.9 451.4 461.6 450.06835G613 309.8 335.9 349.3 354.8 376.8 385.3 384.0 388.3 396.4 413.4 410.9 414.9 415.16835G614 318.1 348.3 356.2 370.1 383.7 395.0 394.1 398.1 410.4 422.5 423.7 421.2 420.06835G615 299.3 325.1 345.5 354.8 369.1 388.7 395.8 408.5 410.5 413.1 418.0 425.5 430.1Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 10Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427M a l e A n i m a l s6835G616 3 307.9 336.9 352.1 365.0 379.3 394.0 390.2 400.8 411.5 416.7 416.5 421.6 417.26835G617 299.5 329.3 348.1 363.1 372.9 395.3 395.0 403.0 413.3 426.1 430.9 432.9 431.96835G618 300.0 329.3 351.2 355.0 369.7 383.2 383.6 398.7 401.0 418.9 422.1 424.9 428.76835G619 311.9 337.2 341.9 358.8 369.8 379.6 376.8 386.1 392.3 404.6 401.4 412.7 405.96835G620 318.2 341.8 355.0 364.7 383.8 390.4 392.9 402.8 405.9 414.3 422.2 424.4 422.96835G621 307.2 337.1 334.9 349.7 355.5 367.7 374.1 369.3 379.5 388.7 390.5 391.6 393.96835G622 295.1 315.6 329.8 334.8 343.8 349.2 349.6 358.5 368.5 374.9 377.8 388.5 378.36835G623 318.3 341.9 344.6 355.3 371.1 382.5 384.8 400.8 399.5 416.6 412.1 416.8 414.76835G624 278.9 302.4 315.3 326.4 343.2 353.3 352.4 372.2 366.7 378.9 383.8 390.5 387.56835G625 320.9 342.8 353.5 368.7 375.8 388.3 382.7 391.8 397.6 405.4 412.0 417.3 410.96835G626 296.7 318.8 330.4 347.4 359.4 372.5 363.5 381.9 389.1 390.1 391.5 390.6 393.76835G627 320.7 348.3 364.7 373.7 392.0 404.1 400.0 409.9 415.0 428.0 430.3 428.0 427.86835G628 320.0 339.0 348.0 360.2 381.1 383.2 387.2 385.1 399.2 408.5 416.4 415.1 415.76835G629 319.8 350.6 369.9 385.0 398.4 410.1 415.8 426.1 430.4 444.5 447.2 447.5 444.26835G630 310.0 329.8 338.3 345.4 357.7 377.1 373.2 383.8 389.4 394.0 405.6 409.0 400.16835G631 367.4 392.3 410.4 424.2 444.4 456.9 459.5 462.6 473.3 493.4 490.6 490.7 489.26835G632 318.7 344.5 359.4 371.2 386.0 390.9 397.2 406.5 416.3 434.3 436.9 439.2 434.26835G633 303.9 330.6 350.4 364.0 378.5 393.4 390.9 400.3 406.6 425.4 426.5 419.4 419.26835G634 334.1 349.5 368.8 379.1 394.9 410.4 410.7 416.8 419.3 419.4 429.1 434.6 437.36835G635 305.1 325.2 335.8 349.0 353.7 371.6 368.1 374.3 375.7 387.1 387.5 394.1 384.96835G636 353.9 383.0 397.2 417.7 422.0 442.9 439.6 450.9 458.2 463.4 467.7 459.5 461.16835G637 320.9 342.4 359.7 371.7 388.5 395.0 395.9 403.3 416.2 425.9 423.9 428.4 427.96835G638 311.3 335.0 345.2 358.4 374.0 386.8 381.7 381.0 393.2 406.0 411.2 405.1 402.96835G639 325.4 355.5 365.3 370.4 387.1 396.3 399.1 410.2 417.3 425.3 423.9 424.2 424.26835G640 297.4 313.3 331.0 338.2 356.5 357.1 361.8 377.3 376.6 387.4 387.4 385.9 387.26835G641 311.2 334.8 349.8 366.4 374.2 383.2 381.3 399.1 403.0 385.3 401.4 413.0 411.66835G642 332.5 353.3 365.0 377.2 392.7 398.8 403.4 416.0 424.8 438.3 436.8 438.8 435.56835G643 298.7 323.9 334.3 344.2 353.3 368.7 365.8 374.4 379.7 390.2 388.7 388.1 389.26835G644 314.6 330.7 338.1 346.9 364.3 380.3 384.8 389.0 402.7 426.6 413.9 423.2 419.36835G645 305.5 325.3 336.3 346.4 357.1 363.6 368.8 378.7 379.7 383.0 389.2 388.7 386.56835G646 336.2 363.6 366.9 386.6 404.7 420.6 419.3 427.0 436.3 451.7 460.5 458.5 452.86835G647 306.6 322.1 329.8 347.8 360.5 373.3 373.1 378.2 390.1 406.0 416.1 414.8 418.16835G648 309.7 330.9 344.0 355.2 375.3 384.8 383.3 400.8 411.9 427.4 433.0 437.9 440.76835G649 294.3 315.0 320.0 336.8 353.6 369.5 369.6 380.9 388.0 401.8 403.2 404.3 408.06835G650 277.1 306.4 319.8 335.1 350.7 363.7 366.2 371.1 374.2 384.8 386.8 388.8 402.4(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 313.5 338.8 351.1 363.5 377.9 390.2 390.3 398.3 406.5 417.0 419.3 422.9 419.6Sdevs 18.4 19.8 21.1 21.9 23.0 23.9 22.8 22.7 24.6 26.3 25.5 24.9 24.66837H701 4 334.7 361.2 369.2 385.8 398.6 401.4 402.7 399.5 409.1 424.2 411.6 415.7 411.2Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 11Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427M a l e A n i m a l s6837H702 4 326.1 355.8 365.4 387.3 401.4 410.5 413.6 414.7 425.7 440.0 427.5 437.3 436.56837H703 335.2 363.4 374.7 387.6 404.4 416.3 417.9 423.2 439.8 455.5 434.4 445.5 448.06837H704 320.2 344.2 354.7 372.8 384.9 400.8 404.4 410.3 414.1 430.5 427.3 419.8 421.46837H705 335.2 360.0 369.4 383.8 394.4 419.3 417.0 424.9 437.1 446.2 443.2 447.9 444.26837H706 329.8 355.8 369.0 375.9 393.1 405.6 406.9 408.9 420.6 435.8 424.8 435.2 440.26837H707 303.8 329.6 342.8 357.1 370.0 381.7 389.3 390.9 404.1 407.1 401.4 397.1 408.26837H708 299.6 321.8 339.5 343.4 353.7 343.5 363.7 363.4 367.0 365.9 378.0 378.1 367.76837H709 316.6 339.8 354.9 363.1 373.4 386.6 390.4 388.9 406.0 415.3 417.3 413.9 410.96837H710 314.8 333.4 348.3 369.3 379.1 386.7 392.7 395.9 414.7 421.8 423.4 424.5 421.56837H711 330.9 349.1 363.9 379.8 391.9 409.3 405.9 410.4 426.1 448.5 443.4 439.9 445.66837H712 300.9 325.8 342.4 359.6 383.2 392.4 387.0 392.3 410.0 425.5 418.1 422.4 417.56837H713 322.5 338.7 349.4 364.8 377.6 392.6 390.3 392.9 401.0 412.0 411.2 411.2 402.76837H714 296.2 321.4 339.0 353.9 358.9 379.1 376.1 375.5 384.9 389.4 393.4 390.0 384.26837H715 327.5 355.4 372.8 383.7 390.4 406.4 402.6 407.4 417.5 418.6 426.7 429.5 428.76837H716 298.3 321.3 334.7 355.5 362.9 376.4 382.7 393.8 402.4 413.2 409.9 415.8 417.16837H717 332.8 359.8 376.7 390.9 401.4 411.8 411.0 424.0 431.2 444.3 449.1 446.8 445.16837H718 290.1 305.0 325.6 340.7 350.2 352.9 361.5 371.4 376.0 383.7 377.6 378.2 375.26837H719 300.1 324.1 334.1 352.1 364.3 380.9 380.1 387.9 400.0 414.4 405.1 407.6 405.66837H720 273.2 297.3 306.0 319.7 325.7 340.0 340.1 335.5 342.6 363.1 362.1 364.5 368.96837H721 323.8 342.5 352.0 363.9 366.7 379.1 378.9 390.4 396.9 402.8 402.2 408.7 400.56837H722 305.4 319.7 336.4 352.2 365.8 372.2 375.3 371.1 397.9 403.4 376.8 405.3 393.46837H723 309.4 327.9 338.5 352.1 367.8 375.0 380.3 388.3 396.8 410.2 414.5 418.3 411.16837H724 350.4 364.5 374.2 393.2 405.4 415.0 419.4 425.5 432.5 446.7 446.8 447.4 441.96837H725 297.0 318.8 333.5 341.9 350.2 359.7 362.9 372.8 377.2 390.3 390.9 389.7 392.16837H726 297.9 307.1 319.5 333.8 353.5 357.6 364.7 366.8 376.5 385.3 389.2 395.8 398.66837H727 327.6 353.9 366.6 383.1 387.0 404.3 400.2 404.1 398.7 422.0 414.6 419.6 407.46837H728 283.7 308.3 316.1 336.7 335.2 344.8 349.8 354.5 361.6 378.5 377.6 377.6 375.46837H729 299.3 311.2 329.1 340.1 355.1 361.4 368.5 380.2 378.4 401.9 404.8 413.1 408.96837H730 301.6 324.2 344.8 361.0 382.6 386.5 383.1 387.5 388.9 406.7 412.9 412.2 401.26837H731 306.8 320.4 330.9 345.9 357.5 367.9 376.2 373.7 392.6 393.8 394.5 388.9 381.16837H732 320.8 332.3 340.6 362.6 375.4 395.8 393.9 396.3 403.5 416.8 418.6 421.1 421.06837H733 290.7 306.9 315.5 317.6 327.7 340.6 340.8 350.4 344.6 353.5 351.8 356.1 352.96837H734 289.1 307.8 320.2 339.0 348.4 360.8 363.8 373.5 366.4 388.7 390.1 382.9 385.36837H735 281.0 307.1 333.6 350.1 348.2 362.9 366.6 377.0 374.6 390.2 384.8 391.5 398.36837H736 314.4 338.9 355.0 372.6 379.0 395.6 396.9 397.8 387.1 413.2 413.2 421.3 419.66837H737 316.0 334.9 350.7 362.5 367.6 377.7 379.1 381.4 389.0 400.8 401.7 384.9 397.56837H738 304.3 315.2 327.7 346.4 365.5 377.8 379.9 386.0 390.0 404.9 400.5 410.0 410.16837H739 295.6 315.6 334.7 348.2 355.9 372.7 377.8 389.7 374.8 394.3 394.6 393.2 394.86837H740 333.7 346.9 364.6 377.0 391.6 409.6 406.1 420.5 418.9 441.8 440.8 436.1 440.06837H741 307.7 325.4 335.3 352.3 365.9 373.1 383.6 388.6 388.9 407.3 409.4 409.5 406.56837H742 303.4 318.3 326.7 337.1 350.8 368.5 368.6 375.2 384.3 393.0 399.4 402.2 394.3Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 12Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427M a l e A n i m a l s6837H743 4 304.6 331.1 347.7 368.0 372.1 383.5 388.1 394.1 396.5 415.6 418.2 425.2 411.36837H744 306.4 322.6 333.9 344.1 353.8 371.7 371.6 378.4 384.7 394.5 392.4 391.8 386.26837H745 309.4 329.3 346.7 360.2 367.6 381.9 383.4 394.7 400.7 398.0 412.0 380.2 391.16837H746 318.7 339.0 357.5 374.0 380.4 391.7 385.8 398.7 404.8 418.4 422.1 400.5 411.66837H747 308.0 328.4 348.2 365.5 372.2 382.3 379.8 394.5 400.3 409.6 413.7 417.0 411.36837H748 296.0 318.0 337.0 356.4 363.4 382.1 376.2 377.4 388.0 403.8 382.6 407.6 401.66837H749 270.7 288.6 297.4 319.0 333.5 343.3 350.2 359.9 358.2 362.7 362.6 360.8 357.16837H750 297.0 326.3 344.5 358.4 365.8 381.8 381.6 390.9 390.5 404.4 417.3 414.2 422.1(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 309.2 329.9 343.8 358.8 369.4 381.4 383.4 389.0 395.5 408.2 406.7 408.1 406.5Sdevs 17.2 18.5 18.5 18.8 19.7 21.1 19.2 19.6 22.1 23.2 22.2 22.8 23.0Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 13Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 455 487 515 539 567 595 623 651 679 707M a l e A n i m a l s6831E401 1 424.7 432.4 425.1 416.8 409.3 406.8 402.6 391.26831E402 419.5 423.8 428.2 410.9 375.96831E403 389.2 390.4 388.5 376.9 375.5 354.76831E404 461.9 471.1 474.2 459.6 470.8 472.2 484.96831E405 413.9 419.8 421.4 410.6 408.7 402.3 403.5 375.86831E406 394.6 398.2 407.2 400.5 403.5 395.1 404.9 398.3 386.5 334.36831E407 416.8 419.4 427.6 413.9 417.6 417.4 414.8 413.7 412.2 409.46831E409 439.0 449.3 456.7 435.6 439.1 404.7 337.46831E410 477.1 475.3 477.2 449.3 455.0 454.1 445.96831E411 447.0 453.6 457.3 459.6 450.0 443.9 435.7 426.46831E412 439.7 440.1 434.4 450.76831E413 431.1 431.6 430.6 417.9 416.8 406.1 397.5 396.2 392.0 377.46831E414 454.4 445.2 454.7 437.2 424.6 413.76831E415 432.5 437.9 440.1 425.9 422.0 413.1 417.0 409.9 403.0 403.56831E416 454.6 459.2 430.1 433.8 436.5 425.5 419.8 408.16831E417 461.4 471.6 469.8 471.0 466.1 463.2 473.8 476.0 460.3 447.86831E418 434.0 439.6 436.3 428.6 434.8 429.0 426.6 424.8 420.8 403.06831E419 463.9 484.1 479.4 463.4 459.2 455.3 460.4 438.6 415.86831E420 416.8 415.2 409.4 392.1 396.0 394.1 381.4 382.9 373.26831E421 463.9 466.4 466.4 452.6 439.56831E422 408.9 412.8 415.0 408.4 406.2 410.9 402.9 401.3 391.9 392.16831E423 433.9 445.3 449.6 435.3 432.0 396.76831E424 445.5 439.3 442.7 403.1 425.8 419.7 378.16831E425 490.4 499.6 493.0 481.0 468.8 457.8 448.06831E426 405.3 410.3 415.5 406.0 396.6 400.5 394.7 387.0 382.7 304.66831E427 427.4 426.3 412.4 432.3 426.9 405.8 387.2 367.1 351.7 341.26831E428 433.2 430.3 430.4 409.7 405.1 404.7 366.16831E429 481.6 481.5 481.0 466.2 468.2 465.0 462.1 424.36831E430 493.2 491.6 482.1 477.0 469.7 455.7 459.1 324.46831E432 444.8 454.2 444.2 436.0 438.5 444.2 411.5 377.26831E433 438.2 436.7 444.2 424.7 422.0 405.3 384.8 347.66831E434 439.8 438.5 444.0 432.6 430.3 421.1 413.9 322.36831E435 421.3 426.0 426.3 413.2 407.9 411.3 406.8 398.3 389.7 363.86831E436 417.4 420.4 426.7 417.5 414.5 409.3 405.6 400.5 400.2 400.16831E437 424.3 438.7 429.7 425.2 425.2 429.3 417.9 417.2 404.3 409.76831E438 424.8 421.8 414.6 405.2 406.0 405.2 393.1 377.2 343.66831E440 482.3 483.1 485.6 469.2 471.8 455.9 444.8 438.2 433.1 420.16831E441 461.2 458.2 455.5 442.8 448.7 446.5 375.46831E442 482.3 479.9 472.5 463.5 465.1 464.1 457.3 442.8 434.4 416.56831E443 422.6 459.2 454.1 442.6 436.5 440.1 433.3 428.6 415.0 406.96831E444 422.5 428.2 425.2 416.2 408.6 412.1 409.0 367.9Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 14Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 455 487 515 539 567 595 623 651 679 707M a l e A n i m a l s6831E445 1 443.3 446.7 443.0 431.7 435.4 424.6 372.56831E446 472.4 472.4 466.6 453.0 445.9 445.1 442.0 431.8 416.5 394.56831E447 464.3 468.6 463.1 450.4 455.5 449.0 429.26831E448 413.1 410.3 413.5 411.9 404.8 407.2 402.4 404.6 397.1 399.06831E449 489.7 498.3 484.5 472.5 474.4 466.1 460.5 449.4 433.6 428.96831E450 442.9 450.0 448.7 443.7 449.2(n) 47 47 47 47 46 43 40 31 21 18Means 441.8 445.8 444.2 433.6 431.3 425.7 416.6 401.6 402.7 391.8Sdevs 26.1 26.6 25.0 24.6 25.9 26.1 32.5 34.7 27.6 35.76833F501 2 420.1 418.8 422.5 415.5 405.2 392.8 398.76833F502 434.4 436.1 429.5 421.2 426.1 415.0 411.4 396.6 389.3 384.76833F503 418.8 422.2 429.9 421.5 410.9 409.1 399.5 394.3 392.4 387.46833F504 444.2 444.8 445.3 435.7 430.2 421.6 417.4 408.4 345.86833F505 436.1 447.7 449.5 438.8 440.5 424.9 419.6 412.2 415.6 397.66833F506 404.2 413.6 412.6 404.7 403.0 399.3 386.26833F507 415.3 431.1 439.8 436.2 432.6 417.5 418.4 401.36833F508 435.8 427.8 435.8 430.3 429.2 414.2 407.2 398.6 392.0 380.46833F509 434.0 432.7 442.4 405.3 453.06833F510 409.7 412.3 415.7 403.8 394.3 389.9 383.36833F511 469.1 467.6 473.6 456.1 453.0 443.6 441.5 433.4 431.2 416.46833F512 430.16833F513 388.7 382.6 388.6 380.6 379.6 378.3 369.4 353.9 354.8 342.36833F514 392.3 399.4 404.5 395.8 390.06833F515 423.0 430.3 435.9 396.26833F516 435.9 445.9 447.3 436.3 421.2 417.0 412.3 405.9 395.6 388.56833F517 438.1 445.1 443.1 433.2 431.9 424.6 408.36833F518 467.6 473.2 469.9 457.6 456.3 435.4 434.16833F519 472.4 480.9 482.2 476.6 467.6 465.3 452.9 447.3 439.0 427.46833F520 418.2 422.4 422.6 414.7 405.7 401.7 398.6 389.6 384.3 372.96833F521 410.9 417.7 419.4 414.2 402.5 390.2 389.7 381.0 365.8 355.06833F522 434.8 441.0 442.5 439.2 426.3 413.3 414.9 415.7 393.06833F523 445.4 455.9 447.8 440.3 432.3 429.8 424.0 422.6 425.3 417.76833F525 449.2 459.1 453.1 451.2 444.2 433.3 430.6 431.4 435.4 412.86833F526 431.4 437.7 434.7 418.4 416.3 410.5 397.5 390.0 381.1 380.56833F527 395.5 396.6 388.8 380.2 360.66833F528 381.26833F529 429.06833F530 428.3 431.8 428.8 426.6 422.7 426.3 425.9 423.5 413.8 329.16833F531 453.4 459.2 458.7 449.6 435.0 434.3 429.4 419.7 413.16833F532 353.4Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 15Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 455 487 515 539 567 595 623 651 679 707M a l e A n i m a l s6833F533 2 411.9 411.6 406.9 402.5 403.76833F534 404.0 414.1 415.5 408.4 401.1 395.3 377.36833F535 469.0 476.6 473.4 459.7 449.8 445.8 447.0 439.2 436.8 430.16833F536 408.0 413.1 409.4 405.2 399.0 398.3 395.4 390.3 393.0 367.96833F537 456.0 452.7 455.6 441.6 441.4 431.3 399.86833F538 416.7 421.7 416.0 402.6 395.8 393.9 396.8 386.0 391.46833F539 448.7 448.2 441.6 428.6 429.1 430.2 418.1 372.06833F541 412.3 414.7 407.4 396.9 391.7 386.9 382.6 370.76833F542 405.0 410.0 405.8 392.1 392.7 391.9 391.0 387.3 384.4 378.36833F543 401.8 408.7 407.4 399.2 393.8 395.0 401.5 325.86833F544 423.7 428.0 426.9 419.3 413.2 411.9 410.1 402.26833F545 424.2 426.8 423.9 374.16833F546 430.3 435.6 428.4 416.8 418.2 414.4 417.0 415.6 412.8 351.16833F547 420.1 419.5 419.4 414.3 405.3 398.9 396.3 391.7 388.6 374.26833F548 441.3 440.8 435.1 430.2 434.4 426.7 431.3 436.4 457.36833F549 409.6 418.6 410.3 406.0 406.5 397.5 385.56833F550 413.2 423.9 407.7 405.1 402.8 395.1 397.7 389.4 391.6 382.9(n) 48 44 44 44 42 38 38 30 25 20Means 424.9 431.8 430.8 420.1 417.8 413.2 408.4 401.1 400.9 383.9Sdevs 23.8 21.6 22.1 22.9 23.0 19.4 19.7 26.2 26.9 27.66835G601 3 400.2 401.1 405.6 397.3 399.6 399.0 400.3 392.7 391.5 383.06835G602 420.2 411.1 420.0 409.3 415.4 403.2 405.6 405.3 403.8 389.76835G603 431.7 435.4 436.6 422.1 417.6 407.4 391.5 393.0 376.9 371.76835G604 429.5 433.0 439.6 430.8 428.1 423.7 421.5 349.66835G605 418.3 423.8 420.5 406.7 401.9 400.9 393.5 388.7 380.5 372.06835G606 498.4 489.2 487.4 475.6 456.66835G607 407.0 408.0 412.8 401.8 393.7 385.4 379.1 377.4 374.4 374.76835G608 419.4 421.5 418.1 410.5 394.0 403.5 404.9 402.6 403.56835G609 457.3 431.8 435.1 424.1 421.4 419.5 420.4 417.3 408.9 400.86835G610 415.8 419.7 417.6 408.2 398.4 384.4 384.5 376.4 375.7 374.06835G612 459.8 459.2 461.8 437.6 438.1 424.1 374.06835G613 409.5 417.5 410.2 407.4 402.3 398.0 395.0 390.9 382.7 378.46835G614 422.0 424.4 421.1 434.7 409.9 404.9 402.2 396.9 389.2 389.46835G615 432.3 430.7 422.4 415.3 407.9 407.2 397.4 392.4 387.8 382.86835G616 419.5 423.3 416.1 410.7 413.8 406.4 397.5 391.4 375.56835G617 433.5 443.8 441.1 432.0 413.0 416.8 409.5 402.3 400.1 392.46835G618 436.2 429.0 420.2 415.1 413.9 414.1 342.86835G619 415.9 419.6 423.7 409.9 409.3 409.1 382.76835G620 423.3 422.6 391.6 410.7 413.7 406.5 334.36835G621 394.3 386.4 411.1 379.4 380.4 372.2 366.2 371.8 362.5 354.9Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 16Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 455 487 515 539 567 595 623 651 679 707M a l e A n i m a l s6835G622 3 385.7 386.7 400.0 388.3 382.6 381.0 374.7 377.5 372.5 372.56835G623 420.3 424.5 411.16835G624 394.1 399.7 400.0 397.0 393.6 392.1 386.0 380.36835G625 415.0 418.3 411.9 413.9 409.9 412.7 405.26835G626 398.6 396.8 398.2 391.4 389.7 380.8 378.0 374.06835G627 432.5 430.4 429.6 418.7 418.8 417.7 409.7 405.3 376.46835G628 415.6 423.7 421.1 413.0 406.0 406.0 405.5 401.9 394.2 388.86835G629 449.3 451.8 448.3 435.8 439.3 430.9 419.7 322.46835G630 407.6 412.3 412.3 402.6 398.5 395.1 389.3 384.5 381.1 374.66835G631 502.4 499.0 503.5 485.8 475.7 480.6 468.4 448.1 406.56835G632 444.3 453.8 450.0 441.0 431.8 425.1 403.9 393.3 370.76835G633 421.5 423.9 422.3 419.1 414.5 410.5 409.0 410.4 408.56835G634 439.4 443.3 439.8 427.1 423.0 410.3 420.1 413.6 407.1 395.56835G635 392.7 395.1 390.2 386.4 382.0 350.0 308.46835G636 463.1 464.6 456.9 452.6 430.2 392.76835G637 429.6 432.2 428.9 421.2 417.8 398.1 386.96835G638 408.5 418.5 415.4 403.2 402.1 403.5 396.5 394.5 399.1 391.36835G639 428.1 438.8 431.9 420.7 416.9 410.4 404.2 402.8 397.0 382.26835G640 386.4 385.1 382.8 380.6 349.86835G641 416.7 412.2 409.8 391.4 396.3 398.4 377.2 369.56835G642 435.0 429.0 431.2 413.6 410.7 408.0 387.5 376.36835G643 389.5 397.9 395.8 387.1 389.6 399.16835G644 428.0 422.5 378.66835G645 390.9 381.0 384.2 375.4 380.2 384.3 378.6 358.7 365.8 364.66835G646 455.1 444.6 457.8 434.7 435.2 429.8 423.86835G647 430.0 439.9 442.1 421.2 422.3 425.2 412.6 419.6 412.6 410.16835G648 446.5 449.2 449.3 435.1 431.9 425.2 418.1 418.0 412.2 385.06835G649 414.1 415.5 413.7 399.3 399.1 394.4 384.3 376.6 374.5 369.96835G650 409.9 415.1 419.7 410.5 401.2 395.3 344.7(n) 49 49 49 47 47 45 43 34 28 22Means 424.4 425.2 423.4 415.0 410.2 405.4 392.9 390.5 389.0 381.7Sdevs 25.0 24.0 24.8 22.3 21.2 19.7 27.0 22.8 15.4 12.66837H701 4 418.7 419.8 424.0 403.2 402.4 376.5 381.6 369.2 341.06837H702 436.6 433.8 425.9 407.7 404.5 392.3 399.3 397.7 388.0 383.56837H703 444.6 459.8 460.8 446.8 447.9 425.8 406.1 435.96837H704 426.1 428.0 426.1 413.9 411.9 389.9 385.4 393.1 385.3 385.86837H705 445.7 454.6 450.1 436.4 429.8 419.2 426.8 419.4 413.4 404.26837H706 435.5 442.5 439.9 422.7 418.7 401.6 408.6 392.1 369.2 356.56837H707 410.3 409.5 414.5 392.4 381.8 375.9 386.4 339.3Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 17Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 455 487 515 539 567 595 623 651 679 707M a l e A n i m a l s6837H708 4 378.3 374.4 385.3 371.4 366.8 357.6 360.6 360.0 353.0 353.66837H709 421.2 416.4 410.4 396.6 391.9 374.8 362.3 356.96837H710 416.9 423.8 418.2 393.5 383.5 348.2 344.3 336.4 309.76837H711 443.7 458.9 462.3 442.8 445.5 427.3 426.9 418.7 378.96837H712 418.6 421.3 422.5 407.6 402.5 368.96837H713 408.8 412.8 415.7 376.2 401.7 381.0 372.3 362.9 336.1 305.46837H714 388.3 388.9 390.7 376.5 370.3 361.1 362.7 357.3 346.9 339.16837H715 437.3 437.8 436.0 430.4 428.1 419.7 371.96837H716 419.56837H717 449.9 445.6 437.8 429.3 419.6 427.2 419.1 416.9 410.9 404.06837H718 379.4 381.5 377.7 366.5 363.7 360.9 357.5 351.3 355.2 349.46837H719 407.1 409.0 376.96837H720 372.1 374.0 370.0 349.5 361.8 358.2 335.06837H721 402.8 403.9 406.1 389.4 385.8 383.6 381.2 378.0 370.16837H722 404.3 398.5 404.1 386.5 386.9 371.2 378.6 377.8 370.5 353.46837H723 416.1 422.3 416.7 409.5 364.06837H724 446.8 445.3 443.7 433.1 425.0 424.9 420.4 408.1 397.6 377.06837H725 395.5 403.8 402.8 396.0 393.6 392.0 393.7 389.3 371.9 355.26837H726 403.6 402.6 402.7 387.6 385.7 385.9 384.7 392.6 384.7 375.96837H727 405.6 402.4 397.4 392.5 381.8 375.0 370.5 346.66837H728 376.9 378.8 372.2 366.9 358.2 361.1 353.7 339.0 335.5 333.76837H729 411.2 414.3 409.4 403.2 391.3 397.6 393.9 380.4 366.1 366.36837H730 412.4 417.0 409.1 401.6 386.1 399.6 392.8 389.7 380.66837H731 380.5 387.8 386.4 375.1 365.9 369.3 367.8 302.46837H732 432.4 420.6 419.3 401.8 389.76837H733 361.6 361.9 364.5 360.2 347.3 289.66837H734 390.2 388.8 382.3 376.2 372.0 373.9 364.1 365.9 344.86837H735 403.8 409.9 406.5 398.3 387.3 394.4 383.9 390.4 380.6 369.96837H736 419.3 421.8 419.1 409.6 397.6 406.8 392.6 394.3 387.3 385.56837H737 404.0 415.9 409.6 392.0 371.7 372.9 347.6 319.86837H738 407.7 417.6 408.1 398.2 392.5 396.5 395.1 387.1 381.76837H739 398.6 403.1 403.4 398.4 383.1 392.8 389.0 384.0 382.2 384.06837H740 438.9 440.9 439.4 430.7 419.2 418.7 381.96837H741 414.1 408.9 409.0 394.8 391.6 387.3 388.0 384.7 373.8 355.36837H742 374.7 390.6 390.3 392.7 321.3 301.36837H743 412.0 414.0 410.7 393.1 385.1 393.8 394.7 393.4 382.7 356.26837H744 342.16837H745 369.0 399.2 400.2 386.9 397.6 375.0 376.8 367.46837H746 416.1 418.7 421.5 407.0 397.4 395.6 371.96837H747 412.1 408.8 408.7 388.4 383.6 381.8 369.0 377.2 370.6 363.16837H748 406.9 408.6 392.2 379.7 369.8Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 18Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 455 487 515 539 567 595 623 651 679 707M a l e A n i m a l s6837H749 4 354.4 358.0 354.6 342.4 342.0 336.6 340.0 338.2 342.9 320.06837H750 417.1 433.0 430.4 418.2 409.4 410.0 406.4 399.9 383.0(n) 50 48 48 47 47 44 41 37 30 22Means 407.8 412.3 409.7 397.3 389.7 383.0 381.6 376.0 369.8 362.6Sdevs 24.9 23.6 23.9 23.1 25.5 29.3 22.6 29.1 23.2 24.7Note: Data for Dosing phase

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

I-2 Males

Summary Statistics - Body Weight DataLovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06Research Institute Study number: FY01013M Page: 1Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________D a y o f P h a s eGroup(s) 16! 7" 14 21 28 35 42 49 56 63 70 77 84-----------------------------------------------------------------------------------------------------------------------------------M a l e A n i m a l s1 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 184.4 188.2 207.5 226.5 239.7 251.2 259.1 272.7 283.1 290.5 297.6 309.1 314.7Sdevs 7.8 11.5 12.9 14.3 16.1 17.3 18.2 17.8 17.5 18.3 18.4 19.0 18.82 (N) 50 50 50 50 50 50 49 50 50 50 50 50 50Means 182.1 193.8% 207.8 226.1 240.0 250.9 260.7 273.7 282.2 296.5 297.1 306.1 312.5Sdevs 9.8 11.6 16.2 15.6 15.6 16.4 16.6 15.9 15.7 18.5 16.7 17.0 16.63 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 184.1 193.4% 208.0 225.3 237.7 250.7 260.5 271.0 281.6 288.6 296.6 305.9 312.3Sdevs 10.9 12.9 14.3 15.3 16.5 17.4 17.8 17.9 18.3 18.3 18.7 19.6 20.24 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 177.9$ 184.2 199.5* 217.4+ 229.5+ 241.7* 252.2 263.4* 275.0* 282.0 291.2 299.6* 305.8*Sdevs 11.6 20.2 14.5 14.3 14.3 15.5 15.8 16.6 16.2 17.3 17.8 17.6 17.8-----------------------------------------------------------------------------------------------------------------------------------Note: ! = Pretest phase; " = Dosing phase*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06Research Institute Study number: FY01013M Page: 2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________D a y o f P h a s eGroup(s) 91 119 147 175 203 231 259 287 315 343 371 399 427-----------------------------------------------------------------------------------------------------------------------------------M a l e A n i m a l s1 (N) 50 50 50 50 50 49 49 49 49 49 48 47 47Means 319.3 340.8 355.0 368.6 379.4 396.3 397.0 405.3 415.8 426.1 424.8 435.7 437.0Sdevs 18.9 18.1 17.9 18.3 19.9 21.0 19.4 22.5 22.5 21.9 27.9 25.8 26.22 (N) 50 50 50 50 50 50 50 50 50 50 50 49 49Means 316.9 338.5 353.3 363.0 375.5 389.5 394.5 400.2 408.6 419.1 420.5 424.4 424.4*Sdevs 16.8 15.8 15.0 15.8 16.2 16.5 16.4 17.7 18.1 19.7 19.5 20.9 20.43 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 313.5 338.8 351.1 363.5 377.9 390.2 390.3 398.3 406.5 417.0 419.3 422.9* 419.6+Sdevs 18.4 19.8 21.1 21.9 23.0 23.9 22.8 22.7 24.6 26.3 25.5 24.9 24.64 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 309.2* 329.9+ 343.8+ 358.8* 369.4* 381.4+ 383.4+ 389.0+ 395.5+ 408.2+ 406.7+ 408.1+ 406.5+Sdevs 17.2 18.5 18.5 18.8 19.7 21.1 19.2 19.6 22.1 23.2 22.2 22.8 23.0-----------------------------------------------------------------------------------------------------------------------------------Note: Data for Dosing phase*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06Research Institute Study number: FY01013M Page: 3Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________D a y o f P h a s eGroup(s) 455 487 515 539 567 595 623 651 679 707-----------------------------------------------------------------------------------------------------------------------------------M a l e A n i m a l s1 (N) 47 47 47 47 46 43 40 31 21 18Means 441.8 445.8 444.2 433.6 431.3 425.7 416.6 401.6 402.7 391.8Sdevs 26.1 26.6 25.0 24.6 25.9 26.1 32.5 34.7 27.6 35.72 (N) 48 44 44 44 42 38 38 30 25 20Means 424.9+ 431.8* 430.8* 420.1* 417.8* 413.2% 408.4 401.1 400.9 383.9Sdevs 23.8 21.6 22.1 22.9 23.0 19.4 19.7 26.2 26.9 27.63 (N) 49 49 49 47 47 45 43 34 28 22Means 424.4+ 425.2+ 423.4+ 415.0+ 410.2+ 405.4$ 392.9$ 390.5 389.0 381.7Sdevs 25.0 24.0 24.8 22.3 21.2 19.7 27.0 22.8 15.4 12.64 (N) 50 48 48 47 47 44 41 37 30 22Means 407.8+ 412.3+ 409.7+ 397.3+ 389.7+ 383.0$ 381.6$ 376.0+ 369.8$ 362.6$Sdevs 24.9 23.6 23.9 23.1 25.5 29.3 22.6 29.1 23.2 24.7-----------------------------------------------------------------------------------------------------------------------------------Note: Data for Dosing phase*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

I-3 Females

Individual Animal Body Weight DataLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 1Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84F e m a l e A n i m a l s6832E451 1 122.4 129.0 142.9 152.9 159.5 166.5 166.5 172.1 172.6 177.4 178.5 181.2 186.26832E452 121.3 130.7 142.9 146.8 151.3 153.9 156.2 163.1 163.2 164.6 171.4 172.1 175.76832E453 130.3 139.4 152.9 154.6 159.8 165.1 166.2 171.4 170.1 174.6 177.9 180.3 184.06832E454 122.0 130.9 136.2 139.7 139.8 146.5 149.4 155.4 155.5 158.8 167.5 166.4 168.36832E455 128.1 140.4 146.2 153.8 165.0 164.9 172.0 175.0 181.9 180.1 185.9 188.3 190.46832E456 126.8 140.7 148.7 153.1 158.0 162.5 164.5 166.2 170.5 174.5 179.7 184.6 183.86832E457 122.9 136.1 146.6 149.6 142.9 152.4 160.2 164.1 170.0 170.1 176.1 178.7 179.46832E458 125.2 135.9 144.7 151.3 155.7 161.3 165.1 167.0 167.2 173.3 176.7 180.3 194.66832E459 131.2 137.2 148.7 151.9 158.3 165.7 166.8 169.4 170.7 177.0 182.5 186.1 193.66832E460 134.7 142.8 154.5 160.2 167.6 169.3 171.9 180.4 185.0 187.3 192.2 191.7 193.56832E461 126.1 134.4 146.7 150.5 159.4 167.3 168.5 174.7 176.9 176.8 188.9 190.5 195.66832E462 131.4 143.5 154.5 162.7 168.8 170.4 176.4 182.8 183.0 186.7 190.6 191.4 194.26832E463 135.5 140.6 151.3 157.1 162.7 166.8 172.8 177.7 178.6 182.9 188.6 191.4 193.26832E464 118.0 128.0 134.7 139.6 140.9 147.4 149.0 154.2 157.2 159.9 161.5 163.8 167.26832E465 123.1 131.2 143.5 153.0 161.9 166.1 169.8 172.6 175.0 177.3 177.4 181.8 183.76832E466 122.6 134.8 144.2 153.5 158.6 169.9 168.2 171.8 176.3 181.0 184.1 184.2 185.36832E467 136.0 147.7 152.5 159.4 164.6 167.2 173.6 177.3 178.5 184.3 188.1 192.8 195.26832E468 122.4 135.1 148.1 156.1 162.6 169.1 170.3 175.5 178.7 182.5 185.7 189.8 193.86832E469 120.5 132.9 140.9 150.8 155.7 160.4 162.8 171.4 176.2 177.5 183.4 185.6 190.06832E470 128.2 138.5 146.5 156.7 161.2 170.1 168.3 176.0 178.0 180.1 185.0 187.1 189.96832E471 126.5 131.3 141.4 146.3 152.9 158.2 162.4 167.5 167.6 173.4 175.8 177.0 183.96832E472 117.5 125.2 133.1 139.5 142.5 126.5 150.8 155.1 157.5 161.2 164.5 164.9 165.86832E473 120.8 132.8 143.8 148.1 154.2 158.4 164.1 166.7 169.8 176.6 177.3 181.0 180.46832E474 122.8 131.5 141.4 146.1 151.2 154.2 161.5 161.6 161.0 167.6 167.9 172.3 170.56832E475 121.5 131.4 140.3 136.6 135.4 152.1 159.9 157.6 164.4 162.9 176.4 180.1 175.46832E476 125.7 137.2 149.1 147.2 149.6 160.2 171.3 171.1 172.8 166.2 193.9 190.2 184.36832E477 126.3 133.5 146.6 154.1 160.2 163.7 167.9 174.2 175.0 179.1 184.5 188.4 188.76832E478 128.6 138.0 150.7 160.1 165.2 169.7 173.7 178.1 178.7 183.3 191.2 189.8 192.86832E479 127.9 140.8 154.3 164.6 172.1 178.2 179.3 184.1 185.4 190.1 194.8 198.0 199.26832E480 116.3 119.8 128.0 133.6 135.9 140.8 144.7 147.6 150.9 156.3 163.4 164.2 162.96832E481 132.2 136.9 145.7 156.9 159.3 164.5 165.8 171.7 174.6 177.2 183.1 192.6 188.36832E482 129.9 140.0 152.0 159.8 164.1 170.0 172.0 178.0 181.9 192.0 194.3 199.5 200.06832E483 121.2 127.8 134.6 143.6 146.9 152.1 157.0 160.2 160.8 169.4 174.7 176.4 178.46832E484 134.0 148.6 162.1 162.2 173.0 174.5 174.4 179.3 182.4 186.7 192.6 194.9 197.46832E485 133.9 144.5 158.3 168.9 172.2 172.9 172.6 176.0 176.1 179.4 188.6 187.0 190.06832E486 122.9 132.1 143.0 147.5 155.8 160.4 166.8 170.9 173.9 176.9 182.1 186.3 183.76832E487 120.1 131.5 141.2 146.5 150.7 156.7 160.5 166.3 168.5 170.7 183.7 181.0 180.96832E488 125.6 137.6 148.0 157.6 157.5 160.4 165.7 171.7 174.5 177.6 183.0 184.1 184.56832E489 121.9 134.2 145.9 154.4 155.8 158.1 163.4 167.4 170.3 172.7 174.7 175.6 175.26832E490 120.1 133.1 141.7 155.1 154.4 157.5 159.2 166.1 167.2 163.1 171.4 172.2 173.06832E491 119.0 133.0 142.9 156.5 160.8 164.0 168.9 176.3 176.7 183.2 189.3 188.9 192.6Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84F e m a l e A n i m a l s6832E492 1 121.1 129.9 133.9 144.7 139.7 146.3 153.4 156.1 156.7 164.2 167.4 170.9 169.66832E493 130.2 139.1 152.0 164.5 165.5 170.3 174.2 178.9 178.7 187.8 188.4 187.6 190.06832E494 127.9 134.6 149.8 159.4 162.8 162.9 167.7 173.7 174.7 177.2 183.6 187.2 187.46832E495 123.4 139.0 148.5 165.6 166.7 174.1 179.5 185.9 187.5 195.2 198.4 203.8 200.56832E496 123.9 132.8 139.8 150.7 152.6 158.1 160.2 163.4 165.0 174.2 180.5 181.6 182.06832E497 127.8 134.1 145.4 155.9 154.9 158.7 161.5 169.6 172.0 178.2 183.9 187.9 186.96832E498 131.0 143.4 153.3 161.2 156.9 164.0 163.4 175.0 173.8 179.0 188.0 186.1 181.76832E499 112.9 124.2 130.8 143.2 140.0 142.2 145.4 152.2 154.8 162.2 166.6 167.4 169.36832E500 129.1 142.5 154.7 168.5 168.4 173.3 178.1 184.4 188.7 194.0 196.4 200.1 199.7(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 125.4 135.4 145.6 153.0 156.6 161.3 165.3 170.1 172.1 176.1 181.6 183.7 185.1Sdevs 5.3 5.9 7.1 8.1 9.6 9.9 8.3 8.8 8.9 9.3 9.2 9.5 9.86834F551 2 124.5 139.1 149.3 167.8 166.7 171.2 176.1 179.6 182.7 189.7 191.2 195.6 193.36834F552 121.0 134.0 144.8 153.8 157.9 160.0 165.0 170.1 175.3 179.9 183.9 185.8 186.06834F553 127.5 140.3 150.1 163.3 162.9 165.4 172.6 177.4 181.8 169.9 189.8 190.7 191.86834F554 126.7 131.8 143.0 146.5 149.1 152.0 157.5 163.4 165.8 170.1 172.6 174.8 176.66834F555 128.4 139.5 145.5 155.8 162.0 161.4 169.9 174.8 179.8 182.1 184.6 187.6 189.06834F556 122.4 130.9 139.3 142.2 152.4 156.7 159.4 166.1 168.6 175.6 177.8 182.5 186.16834F557 116.1 126.7 144.2 150.3 156.6 159.7 163.2 172.6 173.8 179.6 179.5 182.0 185.96834F558 122.6 132.9 139.0 142.9 145.9 150.1 154.3 163.1 163.4 168.7 168.6 173.4 173.46834F559 122.1 130.7 138.5 147.1 148.4 152.0 157.2 162.8 164.6 171.3 173.6 174.8 175.46834F560 124.3 138.4 147.1 162.7 161.1 165.0 168.1 173.6 178.1 180.7 186.6 186.6 186.96834F561 121.1 131.5 142.9 149.4 155.4 156.9 161.2 168.7 170.1 177.1 180.0 181.2 184.06834F562 127.5 134.6 142.0 149.4 155.8 156.9 159.4 165.3 167.6 173.1 176.4 178.0 183.36834F563 123.4 135.0 143.1 149.8 146.7 159.2 165.3 169.0 176.4 185.7 184.2 187.1 189.96834F564 118.0 128.7 136.3 144.7 146.4 153.7 155.6 161.8 163.4 167.9 171.3 171.5 174.86834F565 124.2 138.7 143.8 155.2 159.1 164.9 168.9 178.6 177.2 183.0 186.6 189.5 203.46834F566 120.3 134.5 141.8 150.2 154.9 158.2 166.4 173.8 178.8 184.4 186.5 190.0 193.96834F567 126.5 138.0 147.3 160.7 165.7 165.8 172.8 177.8 178.1 187.3 185.3 189.4 193.86834F568 120.2 126.9 137.0 146.6 150.1 151.4 156.5 166.3 170.6 171.8 180.7 178.2 177.86834F569 129.8 143.3 157.4 170.9 173.3 175.8 183.0 187.6 191.7 190.6 192.9 191.5 192.26834F570 118.0 131.0 143.9 151.4 155.6 161.8 166.0 170.8 173.4 180.7 180.3 183.0 182.76834F571 119.5 128.9 137.9 144.6 145.2 152.9 159.1 162.2 165.0 168.3 173.8 173.4 175.76834F572 119.2 130.9 142.2 151.9 156.3 161.3 166.7 174.3 177.4 187.7 187.4 187.1 192.86834F573 123.2 132.7 140.9 151.0 152.4 158.8 163.3 164.6 166.0 169.5 168.0 174.8 175.36834F574 127.0 135.2 139.5 145.3 151.2 153.6 158.8 162.9 163.7 171.7 170.3 175.2 175.56834F575 126.7 140.2 150.3 157.8 164.6 173.5 173.2 179.4 182.0 186.7 191.3 195.5 193.06834F576 123.5 132.8 140.6 147.1 147.2 153.5 156.4 161.2 165.7 171.7 174.1 175.9 175.66834F577 118.7 134.4 149.5 161.6 169.3 170.6 176.0 178.7 183.0 186.5 190.7 195.8 191.96834F578 121.4 130.4 139.1 148.1 149.9 157.9 160.8 166.7 171.6 168.6 172.6 175.2 171.1Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 3Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84F e m a l e A n i m a l s6834F579 2 125.8 135.5 145.9 155.7 159.3 164.2 166.0 173.5 175.9 182.3 186.5 190.2 190.26834F580 119.7 132.2 144.5 154.2 158.8 164.7 173.8 177.4 180.3 188.9 190.5 196.6 195.76834F581 121.4 135.2 145.0 155.4 160.4 163.9 172.1 173.9 175.7 183.9 183.5 187.8 192.66834F582 124.5 136.0 140.4 148.0 154.0 157.0 163.0 164.6 163.7 172.2 171.3 174.1 177.76834F583 115.0 128.0 146.4 153.0 156.9 161.2 165.6 168.4 172.6 176.2 179.5 184.0 182.36834F584 128.9 136.0 147.4 150.0 152.3 154.7 157.7 164.2 164.7 171.3 172.7 174.3 176.86834F585 120.0 131.9 141.9 148.5 150.0 157.4 161.0 166.9 171.2 174.9 180.7 182.1 184.06834F586 122.0 136.9 145.8 152.0 160.9 158.7 162.4 171.2 174.1 179.1 178.2 178.2 183.76834F587 126.1 140.3 148.8 155.4 168.8 166.8 169.1 174.8 178.1 184.9 184.3 184.1 186.66834F588 126.1 137.7 146.4 150.8 162.7 159.8 164.8 171.9 175.9 184.0 184.6 188.7 194.66834F589 131.9 145.2 156.9 159.8 147.8 171.6 172.9 179.3 184.1 189.4 193.7 195.2 199.46834F590 126.8 138.5 143.9 154.8 154.7 161.3 167.6 172.7 176.5 183.7 193.8 186.7 188.86834F591 121.0 136.2 144.8 155.3 138.7 154.8 160.3 163.8 173.6 175.9 176.7 183.6 183.66834F592 123.1 138.5 145.1 150.5 170.2 159.2 161.6 163.0 165.6 171.6 173.0 176.9 179.26834F593 124.8 141.9 146.5 150.6 149.4 157.8 159.4 171.2 173.2 174.2 179.6 179.1 184.16834F594 128.8 141.5 151.1 161.2 148.7 173.1 173.8 175.4 180.2 186.1 186.5 190.6 190.36834F595 129.1 141.1 148.5 157.0 153.6 162.4 165.8 170.6 174.6 177.9 179.6 180.9 178.76834F596 127.5 138.0 149.3 157.6 155.3 165.6 169.4 175.8 175.5 180.0 179.6 182.3 182.96834F597 116.3 129.6 141.7 151.1 145.7 154.4 161.6 165.7 171.3 177.8 177.1 183.9 181.56834F598 121.5 128.6 138.0 142.7 160.6 150.5 154.2 159.8 162.9 168.4 172.4 172.5 169.66834F599 127.1 137.6 149.8 157.5 148.8 166.1 171.5 178.4 179.9 186.2 187.8 187.3 189.36834F600 130.0 142.4 155.2 166.6 172.1 175.7 177.1 186.2 186.1 194.1 192.8 197.4 198.5(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 123.6 135.2 144.8 153.1 155.8 160.8 165.3 170.8 173.8 178.9 181.3 183.7 185.2Sdevs 4.0 4.6 4.9 6.6 7.9 6.7 6.7 6.7 6.9 7.2 7.3 7.3 8.06836G651 3 128.2 141.0 150.2 155.0 162.0 167.7 171.4 172.8 177.6 183.1 186.4 183.4 186.76836G652 126.3 137.1 147.7 152.8 156.7 160.2 165.4 170.5 175.9 181.8 186.5 185.7 189.66836G653 113.9 126.3 131.8 138.4 142.9 147.6 155.4 158.5 164.2 169.3 172.1 171.6 170.66836G654 116.2 123.6 131.5 138.9 142.9 148.3 154.2 160.1 169.0 176.3 176.8 177.5 182.96836G655 133.2 137.6 144.5 149.7 156.3 161.7 165.2 173.1 175.4 177.2 181.8 188.6 190.56836G656 130.1 137.7 150.7 154.5 156.0 159.1 165.7 169.5 174.1 176.9 181.7 183.3 186.06836G657 127.5 138.6 146.0 149.4 158.6 158.3 164.3 168.2 168.1 178.7 178.9 179.6 181.86836G658 117.8 129.1 140.8 147.7 152.7 156.7 162.3 163.2 170.4 174.1 176.4 177.3 189.26836G659 124.9 139.2 147.5 147.6 158.1 161.9 170.6 171.9 175.9 184.0 183.5 187.2 189.26836G660 121.7 130.3 141.1 146.5 152.9 154.3 157.0 165.0 165.8 171.9 171.8 177.6 177.86836G661 126.8 134.6 140.5 145.0 147.4 151.8 156.0 159.6 161.3 166.8 168.8 174.2 176.06836G662 127.0 133.8 137.2 143.2 148.5 149.7 157.0 160.9 161.9 164.6 166.3 169.3 169.06836G663 126.3 142.5 148.5 154.9 159.6 160.0 165.8 169.2 172.4 176.6 178.0 182.3 186.76836G664 128.4 144.8 148.3 150.6 156.5 157.6 158.8 161.4 164.3 170.2 176.8 176.1 176.16836G665 115.9 120.8 125.3 132.2 134.6 135.3 140.1 144.5 145.4 153.8 153.5 154.4 153.5Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 4Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84F e m a l e A n i m a l s6836G666 3 117.2 122.7 131.5 141.8 150.7 150.8 153.0 155.0 158.0 164.2 166.4 168.1 169.26836G667 116.2 124.2 130.6 138.9 140.2 142.9 144.9 153.5 156.4 163.1 165.8 164.5 165.36836G668 109.4 120.2 122.8 127.9 131.5 134.1 139.6 145.0 149.2 154.7 156.0 159.3 158.86836G669 123.6 130.1 138.6 143.3 149.1 150.2 160.2 158.3 163.7 167.5 171.3 171.8 174.76836G670 129.4 136.9 144.5 150.1 155.3 160.2 163.4 168.4 172.1 178.0 179.4 178.2 179.96836G671 113.5 127.8 132.9 134.6 143.0 145.6 150.7 155.2 154.3 159.6 162.3 166.1 166.86836G672 121.2 134.0 138.3 139.8 149.2 154.0 159.2 166.6 166.9 178.3 176.3 177.1 184.96836G673 117.8 124.5 130.1 136.1 140.7 139.6 144.7 148.2 151.8 157.4 157.8 160.0 164.76836G674 129.8 144.0 155.8 161.8 166.4 169.5 175.5 179.5 182.6 189.1 187.4 188.6 190.26836G675 119.3 132.4 139.6 143.2 147.9 150.1 156.4 159.1 165.2 166.9 172.1 171.4 172.56836G676 120.1 136.8 145.4 152.8 155.1 160.6 166.3 168.4 175.4 177.7 184.4 185.5 187.06836G677 123.8 136.7 144.2 155.2 161.3 161.6 170.5 169.6 174.1 183.3 186.3 187.4 189.06836G678 120.3 131.8 142.4 148.6 154.8 159.7 166.8 166.7 169.7 173.2 177.2 176.9 178.86836G679 126.2 136.7 145.9 158.9 164.6 164.7 167.1 171.4 171.3 179.1 178.4 179.4 181.16836G680 130.1 140.5 149.0 157.7 164.9 166.9 172.6 179.6 184.5 190.3 188.3 191.1 193.26836G681 131.2 144.2 155.3 159.2 164.6 169.1 176.3 177.9 182.5 188.1 194.2 195.5 198.06836G682 116.7 131.0 136.9 141.7 144.0 147.1 151.7 155.0 158.6 162.1 169.5 168.1 169.26836G683 126.2 140.0 146.7 146.1 156.6 162.5 165.2 166.7 173.9 180.4 178.8 179.5 179.16836G684 117.4 130.9 141.6 150.0 154.8 158.2 164.0 169.1 173.8 179.5 181.1 179.7 182.66836G685 121.5 131.6 139.1 144.7 150.3 153.4 155.4 161.5 162.8 165.4 169.7 171.1 175.76836G686 124.7 137.9 148.2 153.2 161.5 166.7 172.5 179.6 181.6 184.8 186.4 189.7 192.06836G687 129.1 142.9 152.7 164.3 168.2 170.4 177.2 183.6 184.9 187.0 189.7 190.0 192.56836G688 127.4 140.5 149.7 154.5 162.6 167.3 171.9 178.5 181.5 186.0 189.2 190.8 195.56836G689 115.7 125.2 136.2 140.7 148.0 151.4 154.0 159.4 159.1 167.5 169.3 170.9 171.36836G690 124.6 135.8 147.8 153.8 157.6 159.9 164.4 166.0 169.5 173.9 176.8 178.8 179.36836G691 121.1 135.3 144.5 149.1 155.6 161.2 163.7 169.8 177.8 182.8 181.9 184.2 188.76836G692 108.5 122.1 132.9 135.4 139.4 141.3 144.8 151.1 154.4 159.2 160.9 162.4 167.16836G693 138.9 151.3 161.3 169.0 170.6 174.6 178.8 181.5 184.6 187.8 192.1 193.1 193.26836G694 117.3 131.9 139.0 147.8 148.0 158.0 160.8 167.7 170.2 169.9 172.9 173.2 171.36836G695 124.9 135.8 144.5 149.6 153.2 156.4 158.3 162.6 166.5 172.2 172.8 172.6 174.06836G696 122.3 136.7 146.3 152.2 155.5 165.0 166.2 168.4 172.6 175.3 177.1 175.1 183.86836G697 122.1 133.7 138.6 142.2 145.5 151.7 154.3 159.6 163.2 164.6 167.6 171.1 171.16836G698 132.8 139.9 145.7 154.5 160.1 165.8 173.1 173.6 181.7 189.2 188.1 190.3 192.36836G699 126.7 134.1 141.7 145.2 148.2 150.9 158.7 141.5 166.5 178.7 181.3 184.6 185.16836G700 109.3 114.3 121.5 126.3 129.8 132.1 135.5 138.2 140.3 144.8 148.2 147.0 149.5(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 122.8 133.8 141.9 147.5 152.7 156.1 160.9 164.5 168.5 173.7 175.9 177.2 179.5Sdevs 6.6 7.4 8.4 8.9 9.2 9.7 10.1 10.5 10.4 10.5 10.3 10.4 11.06838H751 4 125.4 129.4 139.4 140.5 144.2 148.1 151.1 157.4 161.7 162.9 165.8 166.3 170.8Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 5Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84F e m a l e A n i m a l s6838H752 4 127.6 135.0 139.7 149.2 156.8 161.0 165.8 171.1 176.2 178.4 181.0 182.7 181.86838H753 124.0 129.6 142.7 142.3 149.3 151.2 152.2 157.7 160.8 165.6 167.5 170.4 170.76838H754 124.7 133.7 138.2 147.1 154.7 157.2 158.7 163.2 165.8 170.0 171.1 174.4 176.36838H755 116.4 119.0 126.1 130.3 132.3 136.5 138.5 140.2 141.3 147.5 151.4 152.2 155.66838H756 123.3 129.7 133.8 137.0 140.1 147.7 149.0 153.7 157.1 161.4 164.7 164.0 165.36838H757 120.6 130.2 139.4 145.7 152.0 154.6 156.0 161.1 162.4 168.0 170.2 171.1 173.06838H758 131.0 139.4 149.4 159.3 167.0 168.6 172.4 177.8 180.4 185.2 184.5 181.9 187.46838H759 120.1 126.1 130.9 136.0 145.2 148.7 149.9 154.9 158.2 164.1 165.3 164.1 168.26838H760 117.1 128.2 135.4 141.3 147.2 152.3 154.1 157.8 158.4 163.3 169.3 168.3 174.56838H761 121.8 128.0 134.7 142.1 147.4 153.3 147.8 160.0 160.8 166.8 170.1 170.8 173.26838H762 117.2 124.7 131.1 135.7 142.4 143.2 158.3 149.9 150.0 151.1 157.1 157.7 162.46838H763 119.5 129.4 136.1 141.6 145.1 154.9 160.3 161.7 165.2 170.4 172.6 178.2 177.86838H764 119.9 136.5 137.4 141.0 148.0 151.8 153.1 159.7 164.1 167.3 168.7 172.1 173.36838H765 127.9 136.4 145.3 153.5 161.5 164.2 171.9 176.4 177.1 184.7 182.3 186.4 193.46838H766 123.4 129.5 134.9 140.4 143.7 145.1 146.8 150.7 156.3 160.0 158.9 161.6 166.76838H767 122.9 131.8 134.9 143.3 147.2 149.0 150.2 157.0 160.5 163.4 164.8 165.2 168.36838H768 122.8 130.0 137.0 142.9 147.2 149.1 149.4 155.6 158.2 164.0 164.3 164.6 168.96838H769 114.7 121.8 126.0 131.9 140.1 143.4 145.8 150.6 154.7 160.6 161.0 164.9 165.76838H770 130.4 137.2 142.6 148.7 154.0 153.9 160.8 163.4 168.6 174.1 175.6 178.0 181.86838H771 110.5 118.6 123.7 128.6 138.0 140.9 144.0 151.6 153.0 158.1 159.1 162.3 165.76838H772 118.0 129.2 136.3 142.3 149.9 154.2 155.8 163.2 165.6 173.7 173.0 175.7 182.76838H773 122.1 131.5 135.1 141.2 148.7 150.6 151.7 157.9 160.8 167.5 168.3 169.6 171.16838H774 112.1 118.9 120.7 130.5 136.0 137.1 141.8 147.8 152.4 161.8 161.3 161.2 165.26838H775 115.0 125.5 130.6 138.1 146.9 146.8 150.3 153.7 155.6 162.5 163.1 166.4 165.76838H776 120.4 128.2 124.3 139.3 145.2 146.7 150.2 157.6 159.5 163.6 165.1 168.8 168.76838H777 112.2 117.2 124.0 129.5 139.2 144.1 143.3 150.0 153.7 158.7 158.9 159.8 160.46838H778 127.2 134.3 141.1 142.0 145.8 148.7 148.2 157.0 156.9 159.8 164.2 165.7 165.56838H779 129.4 132.5 135.5 145.5 152.1 157.5 158.0 160.1 165.5 168.6 176.2 172.0 176.06838H780 125.1 137.0 143.4 146.0 154.0 152.5 155.7 161.1 164.3 170.7 172.8 174.4 175.96838H781 125.3 131.9 140.4 142.8 151.2 154.6 159.3 164.1 169.8 173.6 179.2 178.9 176.76838H782 119.6 128.7 134.3 140.2 144.6 149.8 151.3 159.3 161.9 169.4 172.1 170.7 180.56838H783 125.5 135.3 138.6 150.3 155.4 158.4 161.5 167.1 169.8 176.9 179.3 178.4 179.96838H784 120.1 132.6 137.7 140.6 145.8 148.6 149.6 157.1 160.7 167.8 170.3 171.4 172.46838H785 128.8 134.5 142.9 149.1 154.3 158.6 164.6 169.1 175.4 180.4 182.7 184.6 185.46838H786 120.4 130.6 139.5 145.5 149.8 153.3 160.4 162.6 166.1 172.5 175.2 177.3 173.86838H787 128.0 138.2 141.0 151.2 154.1 159.2 162.9 165.3 170.6 177.9 181.2 182.6 180.96838H788 114.3 122.8 127.6 135.3 139.8 142.9 148.2 152.6 155.7 165.7 161.9 162.4 164.56838H789 124.3 134.2 142.7 149.9 158.2 159.5 164.9 170.7 175.7 181.4 187.4 188.1 183.66838H790 120.6 127.5 134.5 142.7 151.4 158.3 156.5 160.8 164.1 169.6 170.4 175.3 171.26838H791 118.8 127.1 132.7 141.3 149.2 150.6 153.9 157.6 163.5 167.7 167.0 171.7 177.06838H792 124.2 136.8 142.1 147.8 152.1 153.0 157.7 160.9 162.2 170.5 168.7 170.4 170.5Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 6Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 16! 7" 14 21 28 35 42 49 56 63 70 77 84F e m a l e A n i m a l s6838H793 4 125.4 131.2 138.4 142.9 148.5 151.6 153.8 161.2 164.8 172.5 170.8 169.4 173.56838H794 122.8 133.3 138.9 142.3 150.6 154.0 153.9 160.3 160.3 165.2 167.2 167.0 167.46838H795 119.6 129.7 137.8 141.2 151.1 151.9 159.6 164.0 166.3 175.0 175.6 173.9 176.86838H796 121.0 128.8 136.1 140.2 147.3 150.6 156.9 158.7 163.7 171.8 172.0 172.7 172.56838H797 120.1 127.5 136.1 142.3 152.4 152.2 152.4 157.6 161.8 170.6 171.2 167.5 176.06838H798 125.6 133.5 141.1 150.8 155.8 156.4 157.0 161.4 162.8 162.8 167.3 167.2 164.56838H799 116.2 125.2 129.1 131.8 136.6 139.2 142.5 148.7 153.1 159.5 161.9 163.5 165.96838H800 126.9 138.2 146.7 155.9 167.9 168.2 169.0 176.8 176.2 179.1 181.0 182.5 181.4(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 121.8 130.1 136.2 142.3 148.7 151.7 154.5 159.5 162.6 168.1 169.8 170.9 172.9Sdevs 4.9 5.4 6.3 6.7 7.2 6.9 7.5 7.4 7.6 7.8 7.8 7.8 7.5Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 7Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427F e m a l e A n i m a l s6832E451 1 189.5 195.5 200.9 210.0 211.9 215.4 219.2 222.1 228.3 236.0 250.8 249.8 263.26832E452 176.6 186.5 188.4 200.9 196.3 204.5 205.3 209.3 210.0 214.8 219.8 220.9 225.56832E453 181.9 190.5 194.6 204.7 207.6 209.7 209.6 214.4 223.5 226.7 233.7 231.1 232.96832E454 172.4 182.6 191.5 203.5 200.5 206.1 204.9 217.9 219.7 228.1 232.9 240.5 249.56832E455 193.0 195.7 204.2 216.8 209.8 218.0 218.9 224.3 229.3 234.8 236.3 239.7 254.36832E456 183.5 190.8 192.1 201.6 207.5 211.5 215.3 224.2 231.2 234.4 241.5 249.3 251.66832E457 179.9 187.8 189.7 198.1 201.6 202.0 202.4 208.5 212.0 213.3 217.1 223.1 230.86832E458 183.0 193.5 194.8 200.1 203.3 207.8 206.4 213.2 213.5 210.6 213.9 225.9 227.06832E459 193.6 202.3 212.5 220.4 221.1 221.4 222.3 226.7 227.6 235.0 239.0 246.3 240.96832E460 194.5 200.1 204.1 215.3 213.6 220.5 223.2 226.8 227.5 233.2 227.9 234.0 234.16832E461 198.8 203.6 206.4 216.5 211.7 222.6 221.5 226.1 226.6 235.2 241.2 241.1 251.66832E462 196.6 208.3 214.0 222.4 221.5 228.2 230.5 235.4 238.6 245.8 251.4 265.2 265.96832E463 199.9 210.1 207.9 217.4 220.9 226.7 224.8 229.2 233.0 232.5 239.0 242.2 247.16832E464 166.6 176.6 182.5 190.5 196.5 194.8 194.5 204.3 205.6 209.0 216.1 220.0 229.06832E465 182.8 192.7 194.9 197.2 205.1 201.0 202.3 209.3 208.9 213.9 214.7 215.7 215.56832E466 187.0 201.0 200.5 206.8 209.9 212.6 201.8 212.1 217.7 222.4 229.1 232.2 239.56832E467 196.0 206.9 212.3 215.8 219.9 219.3 223.5 232.3 232.8 240.3 251.9 261.3 276.96832E468 192.0 198.1 203.2 210.6 216.6 214.7 218.8 228.6 228.6 234.5 236.2 232.0 238.76832E469 187.1 194.4 202.8 210.4 207.3 210.1 209.5 214.5 213.9 221.1 226.1 223.3 223.86832E470 191.7 204.3 209.3 214.6 220.9 221.8 217.5 231.4 240.0 240.1 249.1 255.4 272.96832E471 183.5 198.1 198.0 207.9 209.8 212.0 211.7 213.8 215.1 220.3 225.2 229.4 235.26832E472 162.3 173.3 173.7 179.4 182.0 181.6 185.0 181.9 186.6 187.0 176.9 182.0 179.36832E473 182.2 194.4 199.2 210.1 211.3 214.4 220.2 223.6 231.4 228.3 240.4 241.9 252.16832E474 172.5 180.6 177.1 183.8 190.5 193.1 198.0 210.7 204.5 208.2 221.1 220.1 231.86832E475 175.0 191.8 193.0 199.0 201.6 205.6 208.9 213.5 214.3 213.7 218.2 223.9 228.06832E476 183.7 201.6 210.3 209.9 214.3 218.9 219.6 226.2 227.2 229.2 237.9 241.7 251.06832E477 189.6 198.5 202.9 213.5 214.9 216.2 215.9 214.6 219.6 225.2 228.8 232.0 244.96832E478 192.2 200.9 208.3 212.3 212.5 212.2 216.2 214.8 219.4 220.4 224.9 228.4 231.16832E479 201.4 208.6 210.5 218.8 221.4 222.4 222.0 225.8 229.1 233.0 240.0 245.4 254.76832E480 169.3 174.3 181.4 187.9 194.3 197.2 201.4 204.4 207.9 209.0 221.1 218.2 220.16832E481 196.5 196.8 198.6 207.7 212.9 212.7 215.7 212.0 207.76832E482 203.2 212.4 218.0 227.8 231.7 227.9 223.7 230.0 234.5 239.7 251.6 256.7 267.26832E483 177.6 188.7 194.2 200.5 201.2 200.4 205.2 211.7 212.7 223.1 231.7 241.0 247.06832E484 200.4 209.4 208.9 216.9 214.5 217.0 221.7 222.9 236.0 236.9 249.5 259.6 265.06832E485 190.2 201.6 206.4 216.4 217.8 221.8 220.6 221.5 222.6 235.3 240.8 254.3 252.16832E486 189.1 198.6 207.7 213.8 215.7 218.5 220.9 225.3 229.7 231.0 247.7 259.3 255.16832E487 186.0 198.6 201.3 205.9 211.4 215.2 215.9 224.3 220.0 224.3 226.4 233.3 240.06832E488 188.5 191.7 200.4 208.5 210.1 217.7 218.3 216.8 217.5 227.4 233.9 248.9 252.86832E489 181.3 195.5 199.3 205.0 202.2 205.0 212.3 216.9 217.7 226.6 227.1 222.8 223.56832E490 176.6 186.3 188.6 195.7 196.5 200.0 203.8 202.9 202.2 206.6 211.2 212.2 216.16832E491 194.3 200.5 203.1 212.9 217.2 218.9 221.3 226.9 223.6 232.8 239.2 242.6 247.3Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 8Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427F e m a l e A n i m a l s6832E492 1 168.9 180.3 183.8 191.7 190.3 189.9 201.3 202.9 206.1 205.1 210.7 211.3 217.06832E493 192.4 200.9 201.6 209.1 225.4 215.5 218.6 223.2 224.2 227.7 245.1 253.2 256.16832E494 187.1 195.6 198.7 207.5 211.7 212.7 218.5 224.4 226.7 223.8 240.0 251.7 265.16832E495 202.5 215.5 219.7 218.9 228.4 229.8 234.8 236.7 247.8 243.0 252.0 260.9 269.26832E496 185.7 193.9 197.6 196.4 211.3 210.7 210.5 214.4 214.5 219.1 223.5 229.3 239.16832E497 190.5 203.7 208.0 212.6 215.4 215.6 221.6 229.8 230.8 237.1 245.8 253.8 261.56832E498 182.6 200.2 199.9 201.4 214.6 212.4 214.7 222.2 219.4 220.7 228.5 227.4 229.56832E499 171.0 183.3 183.5 189.2 200.8 196.8 203.6 204.9 207.6 209.8 218.1 221.5 224.96832E500 200.7 214.4 216.9 222.0 237.4 227.5 236.4 240.7 250.1 259.8 272.2 280.0 287.3(n) 50 50 50 50 50 50 50 50 50 49 49 49 49Means 186.5 196.2 199.9 207.1 210.5 212.2 214.2 219.0 221.5 225.8 232.6 237.4 243.2Sdevs 10.1 9.9 10.5 10.6 10.8 10.5 10.2 10.7 12.2 12.9 15.5 17.6 19.66834F551 2 195.3 202.1 210.4 209.0 213.8 216.7 215.2 218.8 220.1 226.9 231.9 229.8 236.96834F552 192.5 200.2 208.2 213.8 215.7 218.2 216.9 228.7 225.8 234.7 244.7 248.2 252.86834F553 197.3 199.4 206.0 208.3 211.0 215.4 215.7 216.8 220.7 226.6 231.9 230.4 238.16834F554 181.2 186.2 193.2 200.6 196.9 204.6 206.5 210.8 217.8 225.4 236.8 235.9 242.66834F555 194.4 194.8 200.5 201.0 214.3 211.2 225.2 226.1 221.7 231.6 239.0 243.5 245.96834F556 187.7 196.7 203.8 205.3 207.0 206.8 216.6 220.8 219.1 222.3 223.3 229.8 227.86834F557 191.0 194.0 202.7 207.5 208.0 203.4 213.8 220.7 220.1 223.8 224.8 231.9 233.76834F558 174.2 186.1 195.6 201.1 201.0 206.0 213.3 215.7 214.2 221.7 230.0 233.1 236.06834F559 178.5 185.7 188.9 197.0 197.5 203.1 203.7 206.7 198.9 206.7 209.6 214.1 216.56834F560 189.3 197.9 205.2 209.8 209.2 214.9 213.4 219.6 223.4 231.2 235.9 246.1 243.36834F561 188.6 200.3 203.3 209.1 209.1 210.5 215.0 220.4 221.5 220.7 230.1 230.3 239.36834F562 184.1 192.3 191.3 199.5 206.8 208.4 208.5 217.1 214.1 217.7 222.6 223.2 227.06834F563 195.1 209.2 206.7 212.2 216.4 215.7 216.9 223.5 231.2 223.0 229.5 236.2 237.46834F564 178.6 187.2 195.0 201.2 203.4 208.6 207.5 215.9 217.1 218.4 225.0 238.4 247.86834F565 201.1 215.0 217.0 227.3 237.0 232.9 242.9 244.7 247.3 249.3 259.1 279.5 299.06834F566 192.9 204.5 208.5 220.0 216.3 218.1 223.4 230.9 225.3 229.5 238.1 237.6 245.16834F567 194.5 203.4 207.0 212.6 218.4 220.3 224.8 229.2 227.0 235.5 243.9 247.1 251.96834F568 180.4 192.6 195.5 192.6 196.3 202.0 198.5 198.8 193.6 203.0 202.3 204.2 205.16834F569 194.5 204.9 211.2 220.3 218.3 227.7 224.7 232.1 236.0 242.0 244.2 247.6 251.66834F570 182.6 192.3 194.0 201.6 200.7 202.8 206.7 206.1 212.0 212.5 216.6 227.1 232.26834F571 181.7 188.7 198.0 201.2 200.0 206.1 205.7 212.1 220.4 229.4 234.1 238.2 241.26834F572 195.5 203.0 208.8 213.6 213.3 219.9 218.9 228.6 231.4 229.5 234.4 238.9 246.56834F573 181.1 190.4 191.2 197.7 200.3 201.8 205.3 212.1 210.1 213.3 221.3 219.7 223.76834F574 174.7 188.1 195.9 200.0 207.4 207.2 209.8 218.0 218.0 221.0 232.8 224.7 228.16834F575 201.3 203.8 214.4 215.9 216.1 221.1 228.2 238.9 240.5 243.8 256.8 263.5 268.46834F576 183.4 190.8 200.0 206.0 203.8 209.8 214.6 221.3 220.4 225.9 235.9 235.9 247.76834F577 193.4 204.2 213.8 213.2 216.8 222.1 220.5 232.5 227.9 233.9 239.8 247.7 251.56834F578 174.5 184.3 189.9 193.6 190.6 196.7 197.2 202.0 203.4 203.8 211.5 218.0 215.5Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 9Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427F e m a l e A n i m a l s6834F579 2 194.3 203.6 210.0 212.5 209.9 220.8 220.4 223.5 225.0 230.6 238.4 243.0 244.06834F580 196.3 207.6 213.8 219.3 221.0 216.8 221.2 224.8 228.0 227.8 235.3 242.9 254.26834F581 195.1 204.6 206.2 211.4 219.4 218.0 221.3 222.6 225.6 232.5 234.7 236.1 242.36834F582 177.2 187.0 190.9 197.8 199.3 197.7 203.4 212.4 218.8 212.9 216.4 214.3 220.16834F583 188.0 194.9 204.3 203.5 204.3 206.7 213.5 220.4 215.3 216.8 224.3 224.8 229.96834F584 179.5 192.4 196.4 201.6 203.7 207.6 208.1 224.9 222.2 221.1 230.7 233.8 247.96834F585 183.9 197.2 198.2 203.7 207.8 202.5 202.5 210.2 212.9 215.2 222.5 223.1 225.86834F586 186.2 193.8 199.8 204.4 212.4 210.8 209.3 219.4 221.5 221.6 232.5 237.1 246.96834F587 189.3 199.2 203.6 211.5 215.1 218.1 216.9 219.2 225.6 225.2 231.1 235.8 235.46834F588 198.5 208.1 209.8 219.0 217.4 222.4 221.6 226.6 228.5 235.6 251.7 252.2 251.46834F589 203.0 212.8 211.2 221.9 227.0 233.7 232.6 240.2 247.4 250.1 258.5 258.5 264.46834F590 192.0 201.6 213.0 212.3 217.1 225.3 222.8 233.3 227.3 234.06834F591 183.8 191.5 197.9 204.6 204.8 210.7 209.2 215.9 212.4 214.8 223.2 220.2 234.46834F592 187.8 194.9 199.4 207.4 212.6 213.0 219.9 225.2 230.7 223.4 235.8 243.4 260.46834F593 183.8 194.1 200.1 203.5 206.9 213.2 209.5 216.4 221.6 224.6 234.8 245.9 250.06834F594 189.3 200.7 208.1 211.2 216.2 218.7 213.5 226.4 228.6 226.1 242.9 256.9 263.06834F595 182.8 192.0 198.7 202.0 206.0 210.3 208.5 210.0 208.6 211.6 217.8 215.0 219.86834F596 187.1 191.3 201.7 204.6 208.3 210.1 214.8 218.6 219.8 222.5 230.9 236.1 241.76834F597 182.4 192.5 197.1 199.8 206.5 211.1 213.6 218.9 221.4 220.9 234.8 235.3 249.16834F598 175.3 183.9 188.5 197.2 195.7 202.1 203.8 206.5 207.4 207.9 216.2 217.6 219.86834F599 191.5 200.0 204.0 208.0 214.4 216.5 219.8 227.5 227.0 225.1 236.6 244.4 246.56834F600 195.0 209.3 211.0 216.9 221.8 222.3 229.7 230.5 247.4 258.7 267.0 270.7 268.5(n) 50 50 50 50 50 50 50 50 50 50 49 49 49Means 188.0 197.0 202.4 207.3 209.9 212.8 214.9 220.8 222.0 225.2 232.7 236.5 241.8Sdevs 7.6 7.8 7.5 7.8 8.8 8.5 9.0 9.5 10.9 11.4 12.8 14.8 16.36836G651 3 188.6 197.7 198.1 208.5 207.7 214.7 214.4 225.7 221.5 224.5 229.3 232.6 229.66836G652 189.8 198.1 206.4 212.0 216.6 217.0 216.5 229.0 226.8 231.7 235.6 240.2 246.56836G653 174.1 181.4 185.9 196.7 199.8 198.8 199.9 207.3 209.0 211.3 219.6 218.2 221.06836G654 181.9 190.4 194.2 197.2 204.8 205.8 203.3 210.2 213.3 212.0 217.1 222.3 230.46836G655 191.9 200.5 203.2 210.2 211.0 214.8 213.7 219.1 221.0 224.7 231.5 236.9 246.86836G656 189.1 196.4 198.0 206.4 207.6 209.6 211.5 216.1 222.7 221.6 229.3 234.3 237.86836G657 182.5 189.7 191.8 198.7 208.0 207.8 210.0 219.9 218.0 223.8 223.6 233.6 238.86836G658 183.3 193.3 191.7 202.0 208.5 208.1 213.3 219.6 222.0 243.1 246.5 259.0 258.06836G659 192.0 196.6 202.2 206.3 212.9 217.0 213.2 222.3 218.3 220.4 225.6 234.7 242.06836G660 181.9 189.3 196.9 205.8 207.4 209.0 213.2 221.7 222.1 220.6 229.3 235.3 240.86836G661 177.3 188.4 192.4 207.9 202.2 204.2 203.9 211.4 209.9 209.2 204.7 215.4 214.06836G662 170.6 181.4 186.7 191.9 194.9 196.9 197.4 203.7 202.3 201.4 205.6 205.8 210.46836G663 186.7 202.7 206.7 208.3 217.9 219.0 216.6 221.9 219.3 223.8 229.5 230.4 233.16836G664 177.6 185.5 191.2 195.2 199.7 206.5 198.4 207.4 203.7 210.2 210.6 211.1 214.06836G665 156.1 161.8 169.0 170.6 174.9 180.6 179.4 187.4 186.6 182.0 189.8 207.2 211.5Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 10Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427F e m a l e A n i m a l s6836G666 3 168.8 174.8 180.9 185.5 194.5 194.9 197.3 199.6 203.6 204.8 213.5 224.4 225.66836G667 169.9 175.5 181.0 181.1 190.2 191.6 195.3 202.8 205.3 202.7 207.8 234.2 227.16836G668 160.0 171.5 172.7 179.5 187.9 182.5 187.8 190.6 191.7 193.4 196.5 204.2 204.76836G669 178.4 189.4 190.2 195.8 197.3 204.6 200.9 198.4 206.1 209.9 212.3 215.0 231.36836G670 186.1 193.9 197.5 201.6 205.6 213.3 208.2 215.5 220.2 217.2 218.9 226.1 234.96836G671 171.6 180.1 186.2 193.5 193.2 199.8 200.7 202.5 211.4 208.6 212.0 211.8 219.56836G672 184.2 194.1 200.1 211.3 213.8 218.1 215.5 223.4 226.0 225.6 234.4 240.3 246.76836G673 165.8 179.8 176.3 186.2 186.5 189.5 190.2 190.7 193.7 196.3 198.6 203.4 206.16836G674 197.2 199.5 207.2 217.1 215.4 220.5 218.5 224.0 228.2 228.8 232.9 234.2 241.86836G675 179.2 182.3 191.2 194.4 194.6 203.1 198.1 198.1 210.3 210.3 222.4 221.1 230.76836G676 194.1 197.1 207.0 211.8 216.5 218.4 217.7 219.7 227.5 227.1 240.9 245.7 259.26836G677 189.6 198.0 197.0 205.0 213.4 217.7 218.0 218.7 222.5 222.2 223.8 233.0 235.66836G678 182.6 189.0 191.9 194.0 205.7 205.9 200.1 199.3 203.0 205.8 204.8 211.1 209.56836G679 181.0 188.7 191.9 195.5 201.2 205.2 210.3 220.1 235.7 237.0 237.0 239.7 243.16836G680 193.1 205.9 206.8 209.9 215.8 217.3 218.2 220.4 222.4 223.6 224.0 232.6 228.96836G681 195.2 207.5 209.4 214.4 222.3 224.4 224.1 230.0 235.6 231.3 238.5 237.5 240.96836G682 170.5 182.1 187.7 198.0 199.4 204.1 203.8 212.7 217.2 213.1 217.0 219.5 219.66836G683 183.5 192.9 196.9 203.8 214.9 211.1 215.1 218.7 214.4 216.7 220.8 224.7 221.46836G684 186.6 191.6 196.1 198.0 209.1 221.4 219.7 225.4 224.0 230.3 232.5 238.2 246.76836G685 176.8 182.8 182.6 191.7 193.5 195.0 195.2 198.8 205.2 204.6 208.8 214.8 214.46836G686 193.2 199.9 205.1 209.1 213.0 216.4 215.3 222.0 226.0 226.4 229.4 232.2 235.36836G687 198.0 202.2 210.7 213.9 221.3 220.6 225.7 225.3 229.4 227.9 243.6 257.8 259.36836G688 197.6 202.6 198.9 206.7 213.8 216.8 215.6 221.4 222.5 219.1 229.6 235.5 236.06836G689 173.2 181.2 183.3 187.5 191.0 193.2 194.4 199.4 198.5 200.3 200.6 202.1 201.66836G690 180.7 186.3 189.3 196.9 195.3 201.0 199.9 204.5 207.4 210.1 210.4 213.1 212.16836G691 154.56836G692 166.5 178.9 179.4 186.8 191.8 195.8 198.9 203.8 211.3 208.5 218.4 228.2 232.06836G693 195.4 198.6 209.9 215.3 220.7 222.2 220.3 219.7 231.7 226.6 233.2 240.3 237.66836G694 173.7 184.6 179.9 188.0 194.0 197.0 195.6 202.9 204.9 203.6 206.8 216.8 216.46836G695 177.8 188.6 189.2 200.4 205.6 206.1 205.0 208.2 213.8 227.9 229.5 230.3 233.96836G696 173.76836G697 176.8 181.1 184.0 190.1 194.7 199.1 195.9 203.8 202.3 204.6 209.5 214.5 215.06836G698 196.7 204.6 208.0 210.5 223.9 217.4 223.8 227.4 230.0 228.1 235.3 237.7 233.96836G699 182.96836G700 154.8 163.3 171.2 180.0 186.5 190.9 188.4 196.5 193.7 188.1 196.7 202.2 201.5(n) 50 47 47 47 47 47 47 47 47 47 47 47 47Means 180.7 189.4 193.1 199.4 204.2 206.9 206.8 212.1 214.7 215.8 220.6 226.4 229.3Sdevs 11.4 10.6 10.9 10.9 11.3 11.0 11.0 11.5 12.0 13.0 13.8 14.0 15.16838H751 4 171.5 181.9 186.4 199.2 196.2 198.4 199.6 203.0 205.5 212.3 209.9 214.7 216.3Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 11Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427F e m a l e A n i m a l s6838H752 4 183.1 190.8 193.4 210.0 202.3 204.5 203.8 207.6 209.3 215.2 217.2 222.9 228.06838H753 171.7 182.1 186.5 201.4 197.9 199.4 202.0 203.2 205.8 214.8 212.8 220.6 226.46838H754 177.6 184.7 184.5 196.1 190.6 193.8 200.1 201.5 207.0 209.6 210.7 210.9 212.56838H755 156.8 165.8 167.8 182.6 180.6 180.4 186.2 184.9 193.9 198.4 197.0 205.9 212.26838H756 167.1 173.7 178.0 189.4 191.2 191.1 191.6 194.4 199.5 203.5 206.2 215.1 217.16838H757 177.4 179.4 181.0 199.3 194.0 197.1 202.6 201.9 202.4 204.9 205.7 223.9 226.96838H758 191.2 197.3 199.4 219.4 211.0 209.3 211.0 214.6 216.7 221.6 223.1 229.8 222.36838H759 169.8 177.2 176.7 193.4 189.5 190.0 197.2 196.4 196.8 199.5 199.2 203.8 205.36838H760 173.6 182.0 181.9 193.0 198.3 198.6 201.0 202.1 206.0 211.2 210.3 215.1 214.46838H761 177.5 187.6 190.2 199.3 201.9 197.6 202.3 207.5 209.7 209.9 206.0 218.5 217.06838H762 161.9 168.9 172.0 179.9 184.4 185.1 187.7 189.4 194.8 200.4 200.3 204.7 205.16838H763 177.8 185.6 186.6 192.4 196.9 198.8 202.1 206.2 205.9 212.1 211.1 220.6 220.26838H764 174.0 180.3 185.0 186.7 194.5 194.1 196.3 197.0 199.8 202.8 202.3 206.5 208.36838H765 192.3 196.6 201.1 207.7 211.1 210.7 212.7 212.5 220.0 212.2 223.2 224.4 229.36838H766 163.4 172.0 178.3 184.7 188.0 189.6 192.6 193.4 195.7 199.4 199.4 207.3 216.86838H767 169.5 176.4 181.4 189.2 196.8 195.5 205.9 202.3 206.0 211.4 211.0 217.8 218.46838H768 169.9 172.8 176.3 181.3 190.1 189.4 191.2 192.4 188.1 194.3 193.6 199.0 196.86838H769 167.2 175.5 178.6 186.2 192.4 190.8 190.6 195.8 195.4 198.3 197.2 200.8 200.16838H770 181.9 193.3 194.8 198.4 208.7 207.9 207.8 211.1 211.1 213.5 218.4 222.9 225.46838H771 166.8 177.1 178.7 178.2 183.2 183.5 183.8 184.7 188.7 188.5 191.9 192.8 189.86838H772 182.9 188.8 192.1 197.5 206.4 208.6 206.9 208.7 209.9 217.3 218.8 221.2 218.06838H773 174.1 177.8 181.9 190.8 190.3 199.0 198.6 203.7 208.4 205.0 207.0 210.0 211.66838H774 167.3 168.5 174.3 182.4 180.7 184.5 185.0 185.4 193.7 187.9 188.9 198.4 197.56838H775 169.6 177.0 180.9 189.4 194.9 194.7 196.0 197.6 198.1 203.3 206.1 207.5 206.26838H776 172.6 183.9 188.2 195.1 198.2 193.4 199.2 202.3 209.5 209.3 209.2 220.3 219.26838H777 164.6 164.8 168.6 176.3 177.2 182.6 181.8 184.4 190.7 191.0 192.9 201.1 198.96838H778 168.3 174.2 178.6 184.5 188.1 192.7 192.8 187.8 191.6 196.7 197.0 204.6 203.36838H779 178.0 184.6 192.9 198.0 202.0 203.8 204.6 204.3 209.7 211.6 214.4 227.1 229.76838H780 176.8 181.8 189.6 193.9 198.4 199.3 196.8 200.8 201.0 200.2 207.6 205.9 208.06838H781 181.1 184.7 189.2 196.6 202.5 205.1 203.8 208.1 209.5 211.4 208.8 219.8 220.06838H782 175.3 181.7 185.1 193.4 193.5 193.7 193.9 193.7 198.4 198.7 195.7 205.8 208.66838H783 183.0 188.0 192.0 203.6 202.3 202.9 202.2 212.0 210.5 214.5 212.9 220.3 220.76838H784 176.0 178.6 186.6 191.1 193.8 197.1 199.4 199.7 203.5 205.0 206.4 209.1 208.06838H785 188.2 199.1 197.9 208.6 210.9 216.1 213.6 218.9 227.5 220.5 224.8 234.9 236.96838H786 179.3 186.2 190.4 193.7 200.2 203.9 199.3 202.5 201.7 208.8 210.8 213.0 212.06838H787 184.5 192.4 197.9 203.9 207.1 208.8 210.7 210.5 216.2 217.7 221.1 228.1 231.86838H788 165.0 175.0 182.9 189.0 190.3 194.5 192.3 195.0 196.5 199.5 200.3 212.9 218.26838H789 189.3 195.1 204.4 206.9 209.2 214.0 212.8 209.5 214.6 217.3 219.5 222.4 227.56838H790 173.3 184.6 188.9 193.2 198.1 200.8 196.9 198.9 201.1 201.2 202.3 205.0 209.46838H791 176.5 191.7 199.7 206.2 207.5 213.0 205.5 219.7 221.9 225.5 237.5 245.8 246.06838H792 174.6 185.8 190.5 198.2 200.3 202.9 202.5 208.1 207.3 212.5 212.7 217.4 217.3Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 12Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 91 119 147 175 203 231 259 287 315 343 371 399 427F e m a l e A n i m a l s6838H793 4 175.6 187.2 188.7 196.8 201.0 205.3 208.2 210.2 213.7 215.5 216.2 222.6 224.66838H794 170.5 176.2 177.9 189.8 192.8 196.3 201.9 201.5 203.8 211.3 216.6 221.0 221.96838H795 181.6 184.4 187.9 192.0 195.7 196.9 198.9 206.0 206.7 208.3 211.1 210.4 210.46838H796 175.0 182.1 188.2 191.0 196.0 198.9 199.2 205.1 204.1 208.3 205.5 211.4 214.66838H797 174.1 182.1 185.4 198.4 199.1 200.3 196.5 207.9 207.2 212.7 209.6 221.0 228.86838H798 169.9 172.9 176.6 183.0 185.9 190.9 189.0 195.2 198.2 201.5 201.8 205.2 207.76838H799 168.7 178.1 182.0 184.3 188.7 187.2 186.6 192.1 201.7 202.9 209.4 222.0 219.26838H800 185.8 195.1 201.1 206.0 210.0 212.6 213.6 223.2 219.0 218.2 222.8 227.2 227.5(n) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 174.9 182.1 186.0 194.0 196.4 198.1 199.1 201.9 204.7 207.3 208.7 215.0 216.2Sdevs 7.7 8.2 8.5 9.1 8.4 8.6 8.1 9.2 8.7 8.6 9.8 10.4 11.0Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 13Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 459 487 512 539 567 595 623 651 679 707F e m a l e A n i m a l s6832E451 1 271.9 282.5 279.5 272.4 278.9 278.0 284.0 285.7 285.1 282.86832E452 243.5 260.9 244.0 247.5 246.6 254.7 259.5 263.5 270.3 268.46832E453 242.1 250.6 239.8 245.2 243.6 251.2 248.0 249.7 246.3 217.86832E454 262.4 265.1 262.9 276.2 266.3 271.96832E455 279.5 288.2 286.7 287.6 289.3 290.1 294.8 298.5 281.46832E456 273.8 270.3 269.9 269.7 270.9 271.0 277.1 281.5 277.2 275.76832E457 246.7 249.7 246.2 252.2 264.06832E458 236.9 257.9 243.7 248.9 254.7 252.9 251.1 254.2 259.1 256.76832E459 252.1 263.1 257.9 254.4 273.6 263.8 229.56832E460 248.4 255.0 258.0 255.4 271.0 266.8 271.7 270.3 277.5 274.86832E461 260.1 281.0 279.4 284.6 286.5 290.3 293.5 301.1 299.7 297.66832E462 288.8 290.1 288.4 283.8 291.8 288.3 293.5 304.5 307.0 306.16832E463 244.9 255.2 256.8 255.5 271.8 270.6 271.6 279.6 283.4 280.06832E464 244.7 249.8 246.0 250.9 252.4 247.7 252.0 254.5 256.2 261.16832E465 221.7 225.7 225.5 221.3 225.86832E466 247.0 257.5 257.3 252.5 252.4 265.4 266.6 265.2 232.86832E467 288.8 288.4 294.5 290.8 286.7 295.0 300.5 305.1 308.3 304.26832E468 251.9 254.1 253.8 259.5 262.0 276.5 274.5 275.9 253.16832E469 236.9 232.4 232.7 240.2 242.0 243.2 236.76832E470 273.6 279.9 279.3 235.66832E471 252.6 253.4 255.9 254.5 256.3 260.2 266.1 268.06832E472 184.2 187.0 187.2 189.3 192.7 193.6 187.7 186.7 183.8 159.46832E473 276.8 280.0 274.9 277.5 283.3 294.0 289.6 266.46832E474 248.9 250.5 243.3 251.2 262.0 258.4 216.86832E475 244.5 249.5 245.5 251.7 253.1 257.3 260.3 262.3 260.2 260.16832E476 268.7 271.5 269.9 267.0 280.0 287.3 285.1 288.6 285.8 272.26832E477 250.8 265.9 259.0 255.4 259.86832E478 238.1 241.7 239.6 242.6 251.6 251.3 256.3 265.7 262.5 267.16832E479 276.7 276.4 282.0 276.2 286.6 279.0 285.0 286.9 284.2 262.46832E480 229.9 234.6 231.6 231.1 234.4 230.0 233.3 239.96832E482 289.8 294.5 289.8 294.3 291.7 291.3 297.26832E483 262.3 264.8 256.7 259.1 263.9 267.8 264.2 273.4 274.4 276.76832E484 272.7 278.0 276.8 273.0 273.9 267.9 255.7 213.16832E485 268.56832E486 258.5 257.8 258.6 260.5 258.2 259.2 256.5 265.6 265.3 262.56832E487 263.2 262.6 274.6 264.8 271.06832E488 269.8 271.6 276.9 273.7 271.8 269.6 260.5 266.3 223.76832E489 229.8 232.2 235.2 231.7 245.2 251.1 253.2 263.0 264.0 268.86832E490 223.9 223.7 233.3 221.7 233.0 237.5 241.3 252.6 232.7 239.56832E491 253.3 256.7 253.4 257.1 242.0 246.1 240.3 228.46832E492 226.6 226.9 185.9Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 14Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 459 487 512 539 567 595 623 651 679 707F e m a l e A n i m a l s6832E493 1 281.9 284.9 282.4 282.2 289.5 289.1 284.6 290.1 287.7 286.66832E494 270.6 277.9 274.2 271.9 265.0 269.0 267.26832E495 282.3 288.6 288.5 296.2 292.2 293.6 296.5 296.9 298.4 299.26832E496 246.4 248.3 251.9 251.3 250.9 245.0 229.76832E497 279.2 278.4 274.9 277.1 269.9 276.4 271.5 271.7 272.0 266.56832E498 238.9 236.2 242.3 242.9 245.6 248.5 252.8 253.5 261.0 261.06832E499 235.5 246.1 240.1 243.16832E500 301.0 305.9 304.3 314.0 310.5 307.7 308.5 311.5 310.6 302.9(n) 49 48 48 47 45 41 40 34 29 25Means 255.9 260.5 258.1 259.5 263.7 266.1 264.1 268.8 269.1 268.4Sdevs 22.0 22.4 24.4 22.5 21.5 21.6 25.4 26.2 27.6 30.46834F551 2 248.6 245.4 245.5 250.9 258.5 260.4 262.2 265.7 271.6 274.56834F552 262.6 271.2 269.3 269.8 258.66834F553 248.9 258.8 255.9 258.7 260.4 259.4 266.5 275.1 275.9 279.86834F554 263.8 265.1 258.2 268.4 271.4 277.3 279.7 284.0 281.1 285.46834F555 263.1 271.0 268.8 267.2 270.4 275.7 276.3 285.0 288.5 288.56834F556 238.4 244.7 238.1 249.7 249.6 259.2 264.9 261.16834F557 245.5 250.6 252.1 259.8 255.9 259.4 260.9 263.2 258.3 264.36834F558 255.8 263.4 251.0 251.3 253.7 258.0 265.2 269.3 268.3 266.16834F559 228.5 226.4 230.4 233.8 232.9 237.1 241.3 239.4 238.2 240.06834F560 259.7 266.5 263.9 272.7 268.1 275.2 272.6 282.4 283.1 277.86834F561 253.0 262.0 254.8 258.7 256.2 266.7 270.6 275.5 270.8 279.86834F562 240.3 235.06834F563 247.4 252.0 251.5 260.3 262.6 268.6 277.3 279.1 283.7 283.36834F564 247.9 259.0 257.3 263.9 252.2 257.1 266.4 271.2 260.6 261.46834F565 315.3 323.3 310.7 321.8 296.0 301.4 294.96834F566 252.1 248.5 267.16834F567 265.6 269.1 267.4 266.2 270.1 274.5 274.3 286.7 291.0 288.46834F568 213.5 217.1 211.9 216.4 218.06834F569 275.7 282.5 276.1 289.9 284.9 292.2 296.5 306.5 309.8 308.86834F570 255.2 266.3 256.3 256.5 253.1 255.5 256.5 259.1 258.1 260.56834F571 258.6 252.8 252.9 249.6 246.9 254.4 248.2 252.9 254.7 251.36834F572 267.6 273.6 271.0 270.6 279.7 277.9 278.0 281.1 282.26834F573 239.0 235.7 247.6 248.2 249.4 251.7 256.2 263.6 267.2 264.26834F574 244.3 239.9 239.9 237.6 247.7 251.9 259.7 265.2 269.4 263.66834F575 289.1 291.9 283.7 289.2 281.7 286.3 294.6 298.9 302.0 307.06834F576 261.9 270.0 262.6 263.0 272.0 272.4 274.4 279.7 250.96834F577 274.1 272.8 281.1 282.0 281.5 286.3 287.1 295.1 301.2 248.86834F578 227.8 222.6 224.3 239.4 236.0 242.6 247.6 244.06834F579 262.1 267.1 267.9 273.9 275.5 278.2 285.5 292.4 300.2 300.4Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 15Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 459 487 512 539 567 595 623 651 679 707F e m a l e A n i m a l s6834F580 2 255.3 270.1 259.9 269.2 265.3 270.8 281.3 287.4 289.7 296.46834F581 269.4 266.8 261.8 274.3 278.4 276.3 280.0 280.2 282.1 278.56834F582 238.4 230.2 230.3 229.2 232.0 241.4 248.26834F583 248.7 246.1 251.6 251.5 253.2 263.0 267.0 269.0 277.2 276.36834F584 263.3 265.0 263.7 266.3 275.2 276.3 277.1 267.3 271.0 270.96834F585 245.5 237.3 243.5 236.9 232.2 236.3 237.2 243.2 246.5 247.56834F586 258.8 266.7 270.2 268.7 272.5 278.6 281.5 281.1 287.0 286.96834F587 250.7 255.6 257.8 256.4 265.9 264.3 272.3 270.6 276.6 280.16834F588 261.8 258.6 256.8 252.8 262.5 258.4 257.8 262.3 266.1 258.96834F589 279.8 285.3 292.3 285.8 290.4 291.0 291.5 292.9 274.16834F591 237.6 252.2 244.3 252.2 249.1 252.3 255.1 258.5 258.7 252.86834F592 262.9 275.3 268.3 276.1 268.4 273.1 280.0 284.7 283.6 282.06834F593 260.2 267.8 254.9 266.5 257.1 265.4 276.6 275.9 275.9 271.16834F594 282.2 279.4 277.6 287.3 280.76834F595 221.56834F596 248.1 257.4 255.7 261.6 259.5 265.5 266.2 264.7 264.2 255.26834F597 264.8 269.9 266.7 275.0 271.9 274.4 271.3 280.2 279.6 280.86834F598 229.7 230.3 231.0 235.4 236.9 241.1 244.4 255.5 258.8 262.16834F599 266.6 264.3 263.7 256.56834F600 281.5 283.9 274.1 277.5 271.1 277.3 280.6 283.8 282.2 283.4(n) 49 48 47 46 45 42 42 40 38 35Means 255.8 259.7 258.3 261.9 261.5 266.3 269.7 273.3 274.7 273.6Sdevs 18.1 19.6 17.7 18.6 16.8 15.2 14.8 15.2 15.9 16.76836G651 3 252.1 247.3 250.7 249.2 252.4 266.1 258.0 259.1 262.9 261.76836G652 265.2 263.0 260.3 260.4 266.7 267.4 274.0 276.9 277.7 274.96836G653 229.8 205.26836G654 249.8 250.1 253.0 256.1 261.4 264.0 262.8 261.8 256.3 259.86836G655 252.4 253.7 257.2 250.2 252.9 255.9 262.0 257.1 265.5 262.36836G656 246.1 251.7 245.6 249.7 247.7 260.1 258.0 273.6 273.7 276.36836G657 248.2 250.4 246.4 254.4 253.3 258.5 252.9 263.9 262.8 263.56836G658 272.1 272.4 269.9 272.6 264.3 262.7 267.1 271.3 273.3 274.86836G659 256.8 260.3 252.3 262.1 259.4 263.8 260.4 265.4 261.5 265.76836G660 257.7 261.5 263.3 273.4 282.9 290.6 301.3 315.3 323.7 331.06836G661 216.5 214.9 217.6 219.3 217.4 227.4 228.4 236.4 238.3 244.86836G662 212.7 215.8 213.1 214.5 213.8 219.5 217.7 225.2 227.5 224.36836G663 240.0 239.4 233.6 238.9 238.4 255.1 252.4 252.4 261.4 257.56836G664 218.0 221.1 222.5 220.96836G665 219.9 211.0 226.66836G666 227.5 233.4 244.2 231.0 226.3 233.6 231.4 233.4 232.4 225.26836G667 236.0 247.2 244.3 256.5 252.5 257.2 259.8 262.6 273.1 266.7Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 16Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 459 487 512 539 567 595 623 651 679 707F e m a l e A n i m a l s6836G668 3 206.2 213.2 205.8 207.9 212.1 208.0 213.0 218.9 218.4 210.36836G669 245.7 250.1 243.2 243.7 241.7 252.0 255.1 258.2 254.6 249.96836G670 249.3 251.1 244.0 250.7 253.6 259.0 263.1 264.4 264.2 264.66836G671 233.0 234.2 228.6 227.46836G672 267.4 273.8 268.4 274.1 270.4 276.7 278.3 281.6 285.3 279.16836G673 211.3 212.9 211.3 215.0 219.4 229.2 221.5 234.5 237.1 237.66836G674 259.6 262.4 256.8 264.5 270.3 271.8 273.8 278.0 277.6 273.66836G675 240.5 245.2 238.0 243.2 241.8 254.0 257.3 264.7 263.1 259.76836G676 263.3 268.9 269.4 273.9 270.0 272.6 273.8 239.66836G677 244.2 259.9 247.6 257.6 254.3 255.6 256.1 257.9 262.2 257.96836G678 215.8 216.0 217.0 218.2 219.2 228.6 223.8 229.5 230.16836G679 255.1 258.0 251.0 257.9 252.9 246.7 253.7 228.36836G680 239.0 239.0 240.7 243.0 243.9 253.6 266.06836G681 254.7 261.2 253.6 251.7 255.9 256.2 257.6 265.2 268.5 273.26836G682 230.0 233.3 235.8 237.3 238.9 257.1 248.06836G683 230.1 234.3 231.4 234.8 230.2 232.1 232.8 238.7 243.16836G684 269.0 262.4 265.9 271.3 274.9 274.4 275.2 284.9 292.3 293.96836G685 225.2 228.5 226.7 188.26836G686 246.8 246.6 247.7 247.8 250.2 253.3 257.1 252.6 271.2 242.96836G687 268.8 268.7 265.2 269.3 266.4 267.9 263.6 268.1 222.76836G688 245.0 253.2 251.7 252.4 259.4 255.5 253.2 252.66836G689 213.8 209.8 211.0 210.3 213.0 225.7 225.9 232.1 236.1 232.36836G690 219.1 219.2 219.5 217.2 217.6 220.6 219.2 222.2 225.4 221.26836G692 240.6 243.5 243.7 246.7 236.8 247.7 248.9 249.8 248.9 250.16836G693 249.2 252.7 251.9 254.2 250.0 261.4 261.2 261.46836G694 223.2 226.7 226.4 234.3 242.3 247.9 247.3 248.9 254.1 252.26836G695 240.9 251.9 248.4 252.0 244.2 248.1 216.5 218.36836G697 220.5 227.5 226.5 230.3 227.0 230.1 231.9 236.2 243.9 248.46836G698 245.9 252.8 249.9 255.1 255.2 260.0 222.66836G700 205.2 210.7 206.9 207.8 208.0 211.7 205.5 205.9 201.5 204.4(n) 47 47 46 45 42 42 42 39 34 31Means 239.6 241.8 241.0 243.3 245.5 250.9 249.7 252.5 255.6 256.1Sdevs 18.3 19.4 17.8 20.9 19.3 18.6 21.2 22.1 24.2 25.26838H751 4 224.4 235.3 238.3 231.7 232.4 235.6 233.1 216.26838H752 235.9 243.7 241.2 241.0 238.0 240.2 246.6 246.5 240.16838H753 241.2 243.5 242.9 241.0 239.9 243.6 235.1 242.7 238.1 207.96838H754 221.2 219.9 224.9 226.7 234.1 243.1 242.4 251.4 257.4 263.26838H755 217.9 219.5 227.9 224.0 226.5 232.1 230.0 232.9 231.3 227.56838H756 226.5 238.5 236.4 231.6 240.8 240.0 238.6 249.8 250.8 251.3Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 17Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 459 487 512 539 567 595 623 651 679 707F e m a l e A n i m a l s6838H757 4 230.2 233.9 233.0 232.0 233.7 226.2 224.0 227.8 217.56838H758 236.8 235.2 233.9 237.1 235.5 241.7 243.9 261.1 257.8 259.36838H759 209.0 208.2 210.9 209.7 212.1 211.3 211.8 216.3 221.9 232.56838H760 223.8 225.9 225.0 222.5 222.6 224.7 226.4 232.6 239.1 233.96838H761 224.0 222.3 223.9 236.7 226.6 231.1 231.9 234.5 238.7 242.66838H762 219.2 221.9 221.2 226.8 225.6 234.2 227.5 234.5 238.7 236.66838H763 235.6 245.26838H764 216.9 223.1 214.26838H765 234.4 241.4 235.6 236.5 236.7 242.7 240.1 257.7 255.5 260.96838H766 225.66838H767 234.0 248.6 238.1 241.9 252.3 246.2 241.2 254.8 253.9 247.16838H768 205.1 198.2 202.1 202.7 204.1 212.5 214.0 225.4 229.3 234.66838H769 203.1 209.5 208.4 207.3 209.5 216.6 221.1 221.7 225.6 229.46838H770 237.0 242.4 245.6 240.9 243.8 240.8 241.4 210.76838H771 198.9 198.6 199.9 199.6 198.5 201.6 208.7 210.7 208.4 208.76838H772 225.0 233.1 237.2 240.6 241.1 252.6 246.9 251.3 239.2 226.06838H773 225.2 221.7 226.3 233.6 224.7 241.0 236.0 242.9 247.6 255.06838H774 207.5 190.26838H775 211.4 212.3 214.6 213.2 209.7 216.7 228.3 221.0 211.96838H776 235.5 240.1 238.3 248.8 236.4 249.1 246.8 255.2 258.3 251.86838H777 225.5 221.7 219.6 213.0 223.8 224.9 227.8 228.5 236.8 236.06838H778 213.7 213.2 218.2 218.3 219.2 227.6 228.0 229.5 236.4 238.16838H779 242.2 245.6 243.8 238.7 246.6 251.3 248.3 250.1 256.8 263.36838H780 218.3 227.5 215.8 217.0 219.4 219.1 222.4 226.0 228.2 230.76838H781 233.8 246.1 233.4 238.9 238.8 244.4 241.5 245.0 250.1 252.06838H782 215.3 216.6 219.6 224.2 221.1 226.7 227.2 237.6 240.6 244.66838H783 231.5 240.9 239.2 242.3 236.8 243.0 243.9 244.3 237.8 196.26838H784 213.2 219.2 215.8 219.8 219.3 226.1 223.8 227.0 228.5 232.36838H785 256.36838H786 217.6 222.3 223.9 223.1 223.1 227.0 220.9 230.9 238.8 241.96838H787 217.7 257.2 253.3 247.0 247.5 256.0 255.2 254.6 257.0 257.56838H788 231.0 229.1 229.1 226.6 222.8 228.4 233.3 240.7 242.5 243.46838H789 242.7 250.6 243.2 240.2 240.5 241.4 247.6 251.9 248.6 248.66838H790 216.1 220.3 217.7 217.8 218.6 222.5 225.1 235.3 233.7 232.76838H791 261.8 266.3 259.0 265.7 259.5 268.8 266.6 263.2 258.0 272.76838H792 229.7 231.5 222.8 223.6 229.0 232.7 232.6 231.4 235.2 232.16838H793 229.8 229.5 234.8 231.7 227.6 235.9 232.5 234.9 230.7 233.76838H794 234.7 240.4 235.0 233.8 230.4 241.8 241.0 252.7 245.5 253.26838H795 219.9 225.7 225.6 231.8 230.3 230.1 233.3 234.9 229.1 224.56838H796 237.4 229.4 226.4 226.9 228.5 228.1 229.2 234.9 231.8 234.66838H797 245.9 246.0 242.0 245.6 243.0 241.8Note: Data for Dosing phaseLovelace Respiratory Animal body weights in (g) Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 18Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicD a y o f P h a s eAnimal Group 459 487 512 539 567 595 623 651 679 707F e m a l e A n i m a l s6838H798 4 210.3 218.6 215.5 213.7 211.5 223.2 218.4 230.8 234.3 238.06838H799 228.2 233.9 225.8 229.8 224.1 230.4 224.7 220.4 215.0 218.36838H800 235.0 236.9 235.5 235.6 236.2 239.2 238.8 240.2 238.0 241.3(n) 50 48 46 45 45 45 44 44 42 39Means 226.3 229.6 228.6 229.6 229.4 234.1 233.6 237.3 238.4 239.3Sdevs 13.0 15.5 12.7 13.2 12.7 12.8 11.7 13.6 13.0 16.1Note: Data for Dosing phase

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

I-4 Females

Summary Statistics - Body Weight DataLovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06Research Institute Study number: FY01013F Page: 1Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________D a y o f P h a s eGroup(s) 16! 7" 14 21 28 35 42 49 56 63 70 77 84-----------------------------------------------------------------------------------------------------------------------------------F e m a l e A n i m a l s1 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 125.4 135.4 145.6 153.0 156.6 161.3 165.3 170.1 172.1 176.1 181.6 183.7 185.1Sdevs 5.3 5.9 7.1 8.1 9.6 9.9 8.3 8.8 8.9 9.3 9.2 9.5 9.82 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 123.6 135.2 144.8 153.1 155.8 160.8 165.3 170.8 173.8 178.9 181.3 183.7 185.2Sdevs 4.0 4.6 4.9 6.6 7.9 6.7 6.7 6.7 6.9 7.2 7.3 7.3 8.03 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 122.8% 133.8 141.9% 147.5+ 152.7 156.1% 160.9% 164.5$ 168.5 173.7 175.9+ 177.2$ 179.5%Sdevs 6.6 7.4 8.4 8.9 9.2 9.7 10.1 10.5 10.4 10.5 10.3 10.4 11.04 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 121.8$ 130.1$ 136.2$ 142.3+ 148.7+ 151.7$ 154.5$ 159.5$ 162.6$ 168.1$ 169.8+ 170.9$ 172.9$Sdevs 4.9 5.4 6.3 6.7 7.2 6.9 7.5 7.4 7.6 7.8 7.8 7.8 7.5-----------------------------------------------------------------------------------------------------------------------------------Note: ! = Pretest phase; " = Dosing phase*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06Research Institute Study number: FY01013F Page: 2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________D a y o f P h a s eGroup(s) 91 119 147 175 203 231 259 287 315 343 371 399 427-----------------------------------------------------------------------------------------------------------------------------------F e m a l e A n i m a l s1 (N) 50 50 50 50 50 50 50 50 50 49 49 49 49Means 186.5 196.2 199.9 207.1 210.5 212.2 214.2 219.0 221.5 225.8 232.6 237.4 243.2Sdevs 10.1 9.9 10.5 10.6 10.8 10.5 10.2 10.7 12.2 12.9 15.5 17.6 19.62 (N) 50 50 50 50 50 50 50 50 50 50 49 49 49Means 188.0 197.0 202.4 207.3 209.9 212.8 214.9 220.8 222.0 225.2 232.7 236.5 241.8Sdevs 7.6 7.8 7.5 7.8 8.8 8.5 9.0 9.5 10.9 11.4 12.8 14.8 16.33 (N) 50 47 47 47 47 47 47 47 47 47 47 47 47Means 180.7$ 189.4+ 193.1$ 199.4+ 204.2+ 206.9* 206.8+ 212.1+ 214.7+ 215.8$ 220.6$ 226.4$ 229.3$Sdevs 11.4 10.6 10.9 10.9 11.3 11.0 11.0 11.5 12.0 13.0 13.8 14.0 15.14 (N) 50 50 50 50 50 50 50 50 50 50 50 50 50Means 174.9$ 182.1+ 186.0$ 194.0+ 196.4+ 198.1+ 199.1+ 201.9+ 204.7+ 207.3$ 208.7$ 215.0$ 216.2$Sdevs 7.7 8.2 8.5 9.1 8.4 8.6 8.1 9.2 8.7 8.6 9.8 10.4 11.0-----------------------------------------------------------------------------------------------------------------------------------Note: Data for Dosing phase*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Mean Animal Body Weights in (g) Printed: 10-Jul-06Research Institute Study number: FY01013F Page: 3Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________D a y o f P h a s eGroup(s) 459 487 512 539 567 595 623 651 679 707-----------------------------------------------------------------------------------------------------------------------------------F e m a l e A n i m a l s1 (N) 49 48 48 47 45 41 40 34 29 25Means 255.9 260.5 258.1 259.5 263.7 266.1 264.1 268.8 269.1 268.4Sdevs 22.0 22.4 24.4 22.5 21.5 21.6 25.4 26.2 27.6 30.42 (N) 49 48 47 46 45 42 42 40 38 35Means 255.8 259.7 258.3 261.9 261.5 266.3 269.7 273.3 274.7 273.6Sdevs 18.1 19.6 17.7 18.6 16.8 15.2 14.8 15.2 15.9 16.73 (N) 47 47 46 45 42 42 42 39 34 31Means 239.6$ 241.8+ 241.0$ 243.3$ 245.5$ 250.9$ 249.7$ 252.5$ 255.6% 256.1Sdevs 18.3 19.4 17.8 20.9 19.3 18.6 21.2 22.1 24.2 25.24 (N) 50 48 46 45 45 45 44 44 42 39Means 226.3$ 229.6+ 228.6$ 229.6$ 229.4$ 234.1$ 233.6$ 237.3$ 238.4$ 239.3$Sdevs 13.0 15.5 12.7 13.2 12.7 12.8 11.7 13.6 13.0 16.1-----------------------------------------------------------------------------------------------------------------------------------Note: Data for Dosing phase*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett's test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

J-1 APPENDIX J

INDIVIDUAL ANIMAL SUMMARIES OF CLINICAL OBSERVATIONS

J-1 Males

J-2 Females

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

J-1 MalesLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 1Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6831E401 1 Hair/skin/Jaundiced (yellow tinge to skin) 665"Hair/skin/Skin growth (small) 609"-6656831E402 1 Hair/skin/Jaundiced (yellow tinge to skin) 567"Hair/skin/Sore (superficial wound/lesion) 546"-5676831E403 1 Hair/skin/Jaundiced (yellow tinge to skin) 602"-609Hair/skin/Pallor (pale/grey tinge to skin) 539", 5956831E404 1 Hair/skin/Sore (superficial wound/lesion) 519"-644Tissue mass/Body dorsal 455"-467, 560-630Tissue mass/Body ventral 637"-6446831E405 1 Appendages/injured/Left-rear-foot-injured 567"-602Hair/skin/Jaundiced (yellow tinge to skin) 658"Hair/skin/Skin growth (small) 602"-630Toes/Injured toes 112"-1196831E406 1 Eyes/Left eye red discharge 406", 700-721Hair/skin/Jaundiced (yellow tinge to skin) 721"Hair/skin/Pallor (pale/grey tinge to skin) 707"-714Hair/skin/Skin growth (small) 630", 679Toes/Injured toes 112", 154, 189-203None/Dead 728"6831E407 1 Appendages/injured/Right-front-foot-injured 259"-294Eyes/Left eye red discharge 294", 343-385, 413-480, 495-509, 519-539550, 580, 609, 651-658, 679-728Hair/skin/Skin growth (small) 616"-714Tissue mass/Body dorsal 474"-480Toes/Injured toes 112"-119, 147-175, 189-196, 2316831E408 1 Toes/Injured toes 112"-119, 154-161, 189-203None/Dead 210"6831E409 1 Hair/skin/Skin growth (small) 546"-630Hair/skin/Sore (superficial wound/lesion) 495"-519Movements/activity/Hypoactivity 616"-630Tissue mass/Body dorsal 392"-420, 441, 474-480Tissue mass/Body ventral 455"-467Toes/Injured toes 112"-119, 189-196Total body/Emaciated 616"-6306831E410 1 Appendages/injured/Tail injured 474"-480Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 2Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6831E410 1 Eyes/Right eye red discharge 474"-480, 495-580, 602-637Hair/skin/Jaundiced (yellow tinge to skin) 637"Hair/skin/Skin growth (small) 546"-637Toes/Injured toes 455"-4676831E411 1 Eyes/Right eye red discharge 539"Hair/skin/Jaundiced (yellow tinge to skin) 672"Hair/skin/Skin growth (small) 602"-672Hair/skin/Sore (superficial wound/lesion) 502"-539Tissue mass/Body dorsal 420"-4676831E412 1 Tissue mass/Body ventral 546"-550Toes/Injured toes 287"-301Toes/Missing toes 406"None/Dead 560"-5676831E413 1 Feces/urine/Urine stain 448", 509-515Hair/skin/Pallor (pale/grey tinge to skin) 707"-714Hair/skin/Skin growth (small) 546"-616, 630-700Tissue mass/Genital area 525"-5396831E414 1 Eyes/Left eye red discharge 36"-63, 84-91, 140, 182, 203-210, 238-245406-434, 448-455, 474-480, 515-539, 580-609Hair/skin/Pallor (pale/grey tinge to skin) 609"Hair/skin/Skin growth (small) 546"-609None/Dead 616"6831E415 1 Hair/skin/Skin growth (small) 546"-728Tissue mass/Body ventral 595"-6096831E416 1 Eyes/Right eye red discharge 315"-322Hair/skin/Jaundiced (yellow tinge to skin) 665"Hair/skin/Pallor (pale/grey tinge to skin) 658"Hair/skin/Skin growth (small) 546"-567, 609-616, 630-665Tissue mass/Body ventral 502"-5396831E417 1 Appendages/injured/Left-front-foot-injured 259"Appendages/injured/Right-front-foot-injured 259"Appendages/injured/Left-rear-foot-injured 133"-140, 364Appendages/injured/Tail injured 210"-218Eyes/Right eye red discharge 336", 357Hair/skin/Pallor (pale/grey tinge to skin) 728"Hair/skin/Skin growth (small) 560"-728Toes/Injured toes 189"-218, 301-322Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 3Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6831E418 1 Hair/skin/Skin growth (small) 546"-728Toes/Injured toes 189"-1966831E419 1 Appendages/injured/Right-rear-foot-injured 546"-560Eyes/Left eye red discharge 98"-480, 515-693Hair/skin/Jaundiced (yellow tinge to skin) 679"-693Hair/skin/Skin growth (small) 546"-693Toes/Injured toes 308"-3226831E420 1 Appendages/injured/Left-front-foot-injured 455"Appendages/injured/Right-front-foot-injured 455"Appendages/injured/Left-rear-foot-injured 525"-567Feces/urine/Urine stain 112", 509Eyes/Left eye red discharge 495"Hair/skin/Jaundiced (yellow tinge to skin) 686"-700Hair/skin/Skin growth (small) 546"-595, 644-700Tissue mass/Body ventral 602"-609Toes/Injured toes 343"Toes/Missing toes 336"Total body/Emaciated 700"6831E421 1 Hair/skin/Jaundiced (yellow tinge to skin) 574"6831E422 1 Eyes/Right eye red discharge 259"-364, 413-467, 488-495Hair/skin/Skin growth (small) 546"-728Hair/skin/Sore (superficial wound/lesion) 502"-5156831E423 1 Eyes/Left eye red discharge 406"Hair/skin/Jaundiced (yellow tinge to skin) 595"Hair/skin/Skin growth (small) 580"-595Tissue mass/Body dorsal 455"-4676831E424 1 Feces/urine/Urine stain 273"-357, 385-623Eyes/Left eye red discharge 57"-78, 140-147, 218, 238-245, 301-371385-467, 488-515, 525-616Hair/skin/Pallor (pale/grey tinge to skin) 623"6831E425 1 Appendages/injured/Right-rear-foot-injured 441"-467Hair/skin/Skin growth (small) 580"-6166831E426 1 Hair/skin/Jaundiced (yellow tinge to skin) 707"Hair/skin/Pallor (pale/grey tinge to skin) 700"Hair/skin/Skin growth (small) 574"-707Tissue mass/Body dorsal 488"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 4Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6831E426 1 Tissue mass/Body ventral 546"-567None/Dead 714"6831E427 1 Appendages/injured/Left-rear-foot-injured 686"-707Ears/nose/Red nasal discharge 154"Eyes/Right eye red discharge 495"Hair/skin/Pallor (pale/grey tinge to skin) 721"-728Hair/skin/Skin growth (small) 574"-623, 644-6586831E428 1 Hair/skin/Pallor (pale/grey tinge to skin) 623"Hair/skin/Skin growth (small) 574"Hair/skin/Sore (superficial wound/lesion) 525"-567Tissue mass/Body dorsal 515"6831E429 1 Hair/skin/Pallor (pale/grey tinge to skin) 658"Hair/skin/Skin growth (small) 550"-616, 644-658Toes/Injured toes 189"-2036831E430 1 Eyes/Corneal opacity left eye 189"-480, 495-651Eyes/Micro-ophthalmia left eye 161"-182Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Skin growth (small) 580"-616Hair/skin/Sore (superficial wound/lesion) 546"-5746831E431 1 Total body/Emaciated 385"None/Dead 392"-3996831E432 1 Eyes/Left eye red discharge 57"-78, 140-147, 182, 210-218, 315-329427-480, 495Eyes/Right eye red discharge 98"Hair/skin/Jaundiced (yellow tinge to skin) 630", 651Hair/skin/Pallor (pale/grey tinge to skin) 616"-623, 637-644Hair/skin/Skin growth (small) 587"-651Toes/Injured toes 112"6831E433 1 Feces/urine/Urine stain 350"-357Eyes/Right eye red discharge 84", 105, 119-140, 218-231, 259-294, 308-329378-413, 448-480, 546-567, 602-672Hair/skin/Jaundiced (yellow tinge to skin) 658"-672Hair/skin/Pallor (pale/grey tinge to skin) 644"-651Hair/skin/Skin growth (small) 580"-672Toes/Injured toes 182"6831E434 1 Appendages/injured/Tail injured 378"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 5Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6831E434 1 Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Skin growth (small) 580"-616Toes/Injured toes 182", 210-218Total body/Emaciated 651"6831E435 1 Eyes/Left eye red discharge 119", 413, 546Eyes/Right eye red discharge 78", 140, 161-175, 218, 231, 259-301, 315-329385, 434, 448, 467-474, 488-495, 509, 532550-587, 616-721Hair/skin/Pallor (pale/grey tinge to skin) 728"Hair/skin/Skin growth (small) 546"-728Tissue mass/Body ventral 679"-714Toes/Injured toes 154"-1756831E436 1 Appendages/missing/Tail missing (tip/portion) 371"-480, 495-728Feces/urine/Urine stain 329"-357, 434-480, 495, 532-587Hair/skin/Skin growth (small) 602"-616, 665-7286831E437 1 Hair/skin/Skin growth (small) 546"-728Tissue mass/Body ventral 672"-6936831E438 1 Hair/skin/Jaundiced (yellow tinge to skin) 651"-679Hair/skin/Skin growth (small) 602"-616Tissue mass/Body dorsal 560"-6796831E439 1 Tissue mass/Body dorsal 315"-3646831E440 1 Eyes/Left eye red discharge 154"-175, 502-519Eyes/Right eye red discharge 98"-105, 182-189, 308-336, 378-385, 399-420441-480, 525-539, 609-728Hair/skin/Skin growth (small) 550"-728Tissue mass/Body dorsal 665"-7286831E441 1 Eyes/Left eye red discharge 595"-623Eyes/Right eye red discharge 495", 515-623Hair/skin/Jaundiced (yellow tinge to skin) 623"Hair/skin/Skin growth (small) 574"-623Hair/skin/Sore (superficial wound/lesion) 515"6831E442 1 Hair/skin/Skin growth (small) 602"-679, 721-728Toes/Injured toes 287"-3366831E443 1 Eyes/Left eye red discharge 495"Eyes/Right eye red discharge 189"-196, 329-336, 385, 434-448, 515-519Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 6Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6831E443 1 Eyes/Right eye red discharge 539, 616-637, 672-693, 707Hair/skin/Skin growth (small) 580"-728Hair/skin/Sore (superficial wound/lesion) 532"-5746831E444 1 Eyes/Right eye red discharge 126"-133, 218-231, 399-658Hair/skin/Pallor (pale/grey tinge to skin) 651"-658Hair/skin/Sore (superficial wound/lesion) 532"-539, 580-658Tissue mass/Body ventral 301"Toes/Injured toes 287"-329Total body/Emaciated 651"-6586831E445 1 Eyes/Left eye red discharge 495"-502Eyes/Corneal opacity left eye 609"-623Hair/skin/Jaundiced (yellow tinge to skin) 623"Hair/skin/Skin growth (small) 587"-623Tissue mass/Right-front-leg/foot 98"-1336831E446 1 Hair/skin/Skin growth (small) 602"-728Hair/skin/Sore (superficial wound/lesion) 679"-728Tissue mass/Body ventral 495"-5096831E447 1 Hair/skin/Jaundiced (yellow tinge to skin) 637"6831E448 1 Appendages/injured/Left-rear-foot-injured 161"Eyes/Corneal opacity right eye 686"-707Hair/skin/Skin growth (small) 602"-7286831E449 1 Eyes/Right eye red discharge 189", 399-448, 467-679, 693-728Hair/skin/Skin growth (small) 602"-7286831E450 1 Appendages/injured/Left-rear-foot-injured 406"Feces/urine/Urine stain 252"-364, 385-413Eyes/Left eye red discharge 78", 98-105Hair/skin/Jaundiced (yellow tinge to skin) 580"Toes/Injured toes 154"-189None/Dead 587"6833F501 2 Hair/skin/Skin growth (small) 623"-6376833F502 2 Appendages/injured/Tail injured 140"Eyes/Left eye red discharge 364"-686, 700-714Hair/skin/Skin growth (small) 574"-623Hair/skin/Sore (superficial wound/lesion) 665"-686, 721-728Tissue mass/Body ventral 630"-658Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 7Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6833F502 2 Tissue mass/Tail 700"-7146833F503 2 Feces/urine/Urine stain 133"-196, 301-364Hair/skin/Jaundiced (yellow tinge to skin) 721"Hair/skin/Skin growth (small) 546"-7216833F504 2 Appendages/injured/Left-front-foot-injured 550"-587Eyes/Left eye red discharge 98"-126, 140-182, 245-252, 266-273, 301343-364, 378-385, 399-406, 434-474, 488-509525-539, 560-679Eyes/Right eye red discharge 546"Hair/skin/Jaundiced (yellow tinge to skin) 679"Hair/skin/Pallor (pale/grey tinge to skin) 665"-672Hair/skin/Skin growth (small) 580"-6796833F505 2 Appendages/injured/Tail injured 343"-350Eyes/Left eye red discharge 91", 140-161, 182, 210-218, 308-728Hair/skin/Skin growth (small) 595"-630Tissue mass/Tail 371"-6166833F506 2 Feces/urine/Urine stain 630"-637Hair/skin/Jaundiced (yellow tinge to skin) 637"Hair/skin/Skin growth (small) 574"-616Toes/Injured toes 455"-4676833F507 2 Hair/skin/Jaundiced (yellow tinge to skin) 651"-658Hair/skin/Skin growth (small) 574"-6586833F508 2 Appendages/injured/Right-rear-foot-injured 480"-488Appendages/injured/Tail injured 495"-509, 574-686Hair/skin/Pallor (pale/grey tinge to skin) 721"Hair/skin/Skin growth (small) 602"-700Hair/skin/Sore (superficial wound/lesion) 495"-502Tissue mass/Right-rear-leg/foot 509"Toes/Injured toes 467"6833F509 2 Swelling/Swollen abdomen 574"-5876833F510 2 Eyes/Left eye red discharge 637"-644Eyes/Right eye red discharge 126", 154-161, 364-609, 623-644Hair/skin/Skin growth (small) 595"-644Tissue mass/Face 644"6833F511 2 Ears/nose/Injured nose 63"-70Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 8Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6833F511 2 Eyes/Right eye red discharge 36"-70Hair/skin/Skin growth (small) 595"-7286833F512 2 Hair/skin/Jaundiced (yellow tinge to skin) 480"Tissue mass/Body ventral 392"-3996833F513 2 Feces/urine/Urine stain 329"-343, 515-519Hair/skin/Pallor (pale/grey tinge to skin) 728"Hair/skin/Skin growth (small) 546"-595Tissue mass/Body ventral 602"-728Tissue mass/Genital area 539"6833F514 2 Eyes/Left eye red discharge 364", 399-406, 427-467, 495, 509Hair/skin/Sore (superficial wound/lesion) 539"-574None/Dead 580"-5876833F515 2 Appendages/injured/Tail injured 308"-488Feces/urine/Urine stain 112", 133-225, 238-546Hair/skin/Jaundiced (yellow tinge to skin) 546"6833F516 2 Feces/urine/Urine stain 112", 133-161, 182-287, 301-364, 385, 399-467488-539, 550Hair/skin/Skin growth (small) 623"-728Hair/skin/Sore (superficial wound/lesion) 546"-5676833F517 2 Feces/urine/Urine stain 112", 133-161, 182-287, 336-364, 448-467495Hair/skin/Pallor (pale/grey tinge to skin) 623"-630Toes/Missing toes 406"6833F518 2 Discolor/Body-dorsal 509"-602Hair/skin/Dermatitis 609"-644Hair/skin/Ulcer (open sore,skin broken) 560"-644Tissue mass/Body ventral 644"6833F519 2 Appendages/injured/Left-rear-foot-injured 580"-587, 714-728Feces/urine/Urine stain 378", 495-5196833F520 2 Hair/skin/Pallor (pale/grey tinge to skin) 721"-728Hair/skin/Skin growth (small) 693"6833F521 2 Eyes/Left eye red discharge 210"-225, 308-322, 343-413, 427-441, 455-495515-532, 574-580, 609-623, 693-700, 714-728Hair/skin/Skin growth (small) 644"-651Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 9Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6833F521 2 Toes/Injured toes 413"6833F522 2 Eyes/Right eye red discharge 231"Hair/skin/Jaundiced (yellow tinge to skin) 679"-686Hair/skin/Skin growth (small) 595"-616, 637-651, 665-686Tissue mass/Body dorsal 686"None/Dead 693"6833F523 2 Appendages/injured/Tail injured 218"-238Appendages/missing/Tail missing (tip/portion) 245"-728Feces/urine/Urine stain 112", 154-182Hair/skin/Sore (superficial wound/lesion) 728"6833F524 2 None/Dead 399"6833F525 2 Appendages/injured/Tail injured 378"-385Hair/skin/Skin growth (small) 580"-595Hair/skin/Sore (superficial wound/lesion) 502"-574Tissue mass/Tail 392"-4746833F526 2 Feces/urine/Urine stain 133"-147, 182, 238-574, 587-595, 651-658672-6866833F527 2 Eyes/Left eye red discharge 364", 378, 495, 550Hair/skin/Pallor (pale/grey tinge to skin) 574"Hair/skin/Skin growth (small) 550"-5746833F528 2 Appendages/injured/Right-rear-leg-injured 154"-161Hair/skin/Jaundiced (yellow tinge to skin) 474"None/Dead 480"6833F529 2 Feces/urine/Urine stain 189"-203, 231-480Tissue mass/Body dorsal 474"-480None/Dead 488"-4956833F530 2 Appendages/injured/Tail injured 455"-474Hair/skin/Jaundiced (yellow tinge to skin) 707"Hair/skin/Skin growth (small) 580"-700Hair/skin/Sore (superficial wound/lesion) 519"-700None/Dead 714"6833F531 2 Ears/nose/Injured nose 98"Feces/urine/Urine stain 140"-147, 364Eyes/Left eye red discharge 57"-84, 105-119, 133-140, 218, 231-245Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 10Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6833F531 2 Eyes/Left eye red discharge 350-495, 539-546, 560-595Eyes/Right eye red discharge 42"-98, 112-161, 189-693Hair/skin/Pallor (pale/grey tinge to skin) 686"-693Hair/skin/Skin growth (small) 602"-651Hair/skin/Sore (superficial wound/lesion) 532"-6236833F532 2 Total body/Emaciated 455"None/Dead 467"6833F533 2 Hair/skin/Jaundiced (yellow tinge to skin) 587"6833F534 2 Eyes/Left eye red discharge 57"-78, 225Eyes/Right eye red discharge 105"-112, 609Hair/skin/Jaundiced (yellow tinge to skin) 637"Hair/skin/Skin growth (small) 602"-6376833F535 2 Hair/skin/Skin growth (small) 602"-728Hair/skin/Sore (superficial wound/lesion) 532"Tissue mass/Genital area 539"Total body/Dehydrated 14"6833F536 2 Hair/skin/Skin growth (small) 623"6833F537 2 Hair/skin/Jaundiced (yellow tinge to skin) 630"Hair/skin/Pallor (pale/grey tinge to skin) 623"6833F538 2 Hair/skin/Jaundiced (yellow tinge to skin) 693"Hair/skin/Pallor (pale/grey tinge to skin) 679"-686Hair/skin/Skin growth (small) 574"-693Hair/skin/Sore (superficial wound/lesion) 539"-6936833F539 2 Eyes/Left eye red discharge 665"-672Hair/skin/Skin growth (small) 550"-672Hair/skin/Sore (superficial wound/lesion) 644"-672Tissue mass/Body ventral 539"-546Total body/Emaciated 672"6833F540 2 Feces/urine/Urine stain 364", 434-441Eyes/Left eye red discharge 126"-196, 218Eyes/Right eye red discharge 119"-147, 231-273, 308-315, 329Hair/skin/Jaundiced (yellow tinge to skin) 441"6833F541 2 Normal throughout intervalNote: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 11Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6833F542 2 Eyes/Right eye red discharge 658"-728Hair/skin/Skin growth (small) 550"-602, 616-728Toes/Injured toes 112"6833F543 2 Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Skin growth (small) 550"-651Tissue mass/Body dorsal 616"-651Tissue mass/Body ventral 644"-6516833F544 2 Hair/skin/Jaundiced (yellow tinge to skin) 665"Hair/skin/Skin growth (small) 609"-6656833F545 2 Feces/urine/Urine stain 189"-203, 231-322Hair/skin/Jaundiced (yellow tinge to skin) 539"None/Dead 546"-5676833F546 2 Hair/skin/Alopecia 630"-707Hair/skin/Pallor (pale/grey tinge to skin) 707"Hair/skin/Skin growth (small) 616"-707Total body/Emaciated 707"None/Dead 714"6833F547 2 Feces/urine/Urine stain 721"-728Eyes/Right eye red discharge 218", 231-238, 308-329, 364, 378-385, 434-637658-7286833F548 2 Feces/urine/Urine stain 238"-322, 343-357, 413Eyes/Left eye red discharge 168"-175Hair/skin/Skin growth (small) 574"-609, 623-630Tissue mass/Body ventral 644"-6866833F549 2 Eyes/Left eye red discharge 84"-91, 105-112, 126-133, 154-175, 189-218273, 308-378, 413-467, 509-519, 532-539567-637Eyes/Right eye red discharge 392"-399Hair/skin/Jaundiced (yellow tinge to skin) 637"Hair/skin/Skin growth (small) 602"-6376833F550 2 Feces/urine/Urine stain 231"-357, 441-467, 502-525, 539Eyes/Left eye red discharge 98", 196-203Hair/skin/Skin growth (small) 623"-7286835G601 3 Feces/urine/Urine stain 231"-357, 434-467Eyes/Corneal opacity left eye 665"-728Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 12Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6835G601 3 Hair/skin/Skin growth (small) 644"-6586835G602 3 Appendages/injured/Right-rear-foot-injured 480"Feces/urine/Constipation 434"-448Eyes/Right eye red discharge 357", 413-420, 441-448, 480-488, 509-546567-574, 595, 658-665Hair/skin/Skin growth (small) 644"-672, 700-721Tissue mass/Body ventral 616"6835G603 3 Hair/skin/Skin growth (small) 616", 637-7216835G604 3 Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Skin growth (small) 574"-595, 623-6516835G605 3 Eyes/Left eye red discharge 728"Hair/skin/Skin growth (small) 580"-7286835G606 3 Appendages/injured/Right-rear-foot-injured 385"-427Feces/urine/Diarrhea 488"Hair/skin/Pallor (pale/grey tinge to skin) 580"-587Hair/skin/Skin growth (small) 574"-587Hair/skin/Sore (superficial wound/lesion) 574"-5876835G607 3 Appendages/injured/Right-rear-foot-injured 427"Eyes/Right eye red discharge 140", 252Hair/skin/Skin growth (small) 574"-728Hair/skin/Sore (superficial wound/lesion) 700"-728Toes/Injured toes 210"-218, 329-3436835G608 3 Hair/skin/Jaundiced (yellow tinge to skin) 686"-693Hair/skin/Pallor (pale/grey tinge to skin) 679"Hair/skin/Skin growth (small) 580"-693Tissue mass/Body ventral 539"-574Toes/Injured toes 210"6835G609 3 Eyes/Right eye red discharge 495"-714, 728Hair/skin/Skin growth (small) 602"-728Tissue mass/Tail 455"-4806835G610 3 Eyes/Left eye red discharge 336", 357-519, 532-714Eyes/Right eye red discharge 651"-700Hair/skin/Skin growth (small) 602"-616, 644-714Tissue mass/Body ventral 406"-434, 474-488Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 13Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6835G611 3 None/Dead 441"6835G612 3 Eyes/Right eye red discharge 495"-630Hair/skin/Jaundiced (yellow tinge to skin) 623"-630Hair/skin/Sore (superficial wound/lesion) 546"-6096835G613 3 Eyes/Right eye red discharge 532"Hair/skin/Skin growth (small) 546"-700, 721-728Toes/Injured toes 218"-2386835G614 3 Hair/skin/Skin growth (small) 546"-651, 665-7286835G615 3 Eyes/Left eye red discharge 480", 519, 546-644, 665-693, 728Hair/skin/Skin growth (small) 602"-728Hair/skin/Sore (superficial wound/lesion) 532"-728Tissue mass/Body dorsal 488"-7286835G616 3 Appendages/injured/Right-rear-foot-injured 98"-105Appendages/injured/Tail injured 474"-480Hair/skin/Pallor (pale/grey tinge to skin) 679"-693Hair/skin/Sore (superficial wound/lesion) 519"-6656835G617 3 Appendages/injured/Tail injured 36"-161, 225-480, 550-637Hair/skin/Skin growth (small) 580"-728Hair/skin/Sore (superficial wound/lesion) 519"-595Tissue mass/Body ventral 546"-574Tissue mass/Tail 441"-4676835G618 3 Hair/skin/Jaundiced (yellow tinge to skin) 623"Hair/skin/Skin growth (small) 560"-623None/Dead 630"6835G619 3 Feces/urine/Urine stain 133", 154-161, 182-210, 231-467, 480-488532-630Hair/skin/Jaundiced (yellow tinge to skin) 630"6835G620 3 Hair/skin/Jaundiced (yellow tinge to skin) 616"-623Hair/skin/Skin growth (small) 546"-623None/Dead 630"6835G621 3 Hair/skin/Skin growth (small) 602"-7286835G622 3 Eyes/Left eye red discharge 112"-126, 140, 154-161, 218, 231-259, 294-301350-364, 378-385, 420, 441-448, 474-480Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 14Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6835G622 3 Eyes/Left eye red discharge 539-630, 644-728Hair/skin/Jaundiced (yellow tinge to skin) 728"Hair/skin/Skin growth (small) 574"-7286835G623 3 Eyes/Right eye red discharge 49"-78, 112Tissue mass/Body dorsal 502"-5326835G624 3 Appendages/injured/Right-front-foot-injured 119"Eyes/Left eye red discharge 364", 539Hair/skin/Jaundiced (yellow tinge to skin) 665"Hair/skin/Skin growth (small) 602"-6306835G625 3 Feces/urine/Urine stain 329"-350, 385, 434Eyes/Left eye red discharge 231", 259, 273, 308-315, 595-609, 637-644Hair/skin/Pallor (pale/grey tinge to skin) 644"6835G626 3 Hair/skin/Pallor (pale/grey tinge to skin) 672"Hair/skin/Skin growth (small) 574"-672Tissue mass/Body ventral 539"-5676835G627 3 Feces/urine/Urine stain 350"-364Hair/skin/Jaundiced (yellow tinge to skin) 672"-679Hair/skin/Skin growth (small) 644"-679None/Dead 686"-7146835G628 3 Feces/urine/Urine stain 560"Hair/skin/Skin growth (small) 574"-580, 700-7286835G629 3 Hair/skin/Jaundiced (yellow tinge to skin) 637", 651Hair/skin/Pallor (pale/grey tinge to skin) 644"Hair/skin/Abscess(puss filled mass/wound) 420"Hair/skin/Skin growth (small) 567"-6516835G630 3 Eyes/Left eye red discharge 98"-119, 140-147, 385, 399, 420, 480Hair/skin/Skin growth (small) 644"-651Toes/Injured toes 336"-3436835G631 3 Appendages/injured/Right-front-foot-injured 672"-693Feces/urine/Urine stain 133"-161, 266-287, 308-364, 392-474, 488-623Eyes/Right eye red discharge 210", 455-474, 488-502, 519-546, 651-658Hair/skin/Jaundiced (yellow tinge to skin) 686"-693Tissue mass/Body ventral 587"-693Tissue mass/Right-front-leg/foot 392"Toes/Injured toes 385"-406Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 15Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6835G632 3 Hair/skin/Jaundiced (yellow tinge to skin) 686"Hair/skin/Pallor (pale/grey tinge to skin) 679"Hair/skin/Skin growth (small) 644"-686Hair/skin/Sore (superficial wound/lesion) 539"-5876835G633 3 Hair/skin/Skin growth (small) 546"-623, 637-693Tissue mass/Body ventral 658"-6936835G634 3 Appendages/injured/Left-rear-foot-injured 550"-580Hair/skin/Skin growth (small) 609"-728Hair/skin/Sore (superficial wound/lesion) 539"-595Tissue mass/Body ventral 672"-6936835G635 3 Eyes/Bulging left eye 609"-616Eyes/Corneal opacity left eye 609"-616Eyes/Missing left eye 623"Hair/skin/Skin growth (small) 616"Tissue mass/Face 623"None/Dead 630"6835G636 3 Appendages/injured/Left-rear-foot-injured 580"-616Feces/urine/Urine stain 133", 154-210, 231-364, 385-595Hair/skin/Jaundiced (yellow tinge to skin) 616"Hair/skin/Sore (superficial wound/lesion) 595"-6166835G637 3 Eyes/Right eye red discharge 225", 280-287, 308-644Hair/skin/Pallor (pale/grey tinge to skin) 644"Hair/skin/Skin growth (small) 574"-644Respiration/Wheezing 623"-644Total body/Emaciated 644"6835G638 3 Hair/skin/Skin growth (small) 539"-7286835G639 3 Hair/skin/Skin growth (small) 550"-658, 686-728Tissue mass/Body ventral 539"-5466835G640 3 Hair/skin/Jaundiced (yellow tinge to skin) 574"Hair/skin/Pallor (pale/grey tinge to skin) 567"Tissue mass/Body ventral 392", 539-574Tissue mass/Right-front-leg/foot 392"6835G641 3 Appendages/injured/Tail injured 225"-280, 294-480Eyes/Right eye red discharge 658"Hair/skin/Pallor (pale/grey tinge to skin) 658"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 16Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6835G641 3 Hair/skin/Skin growth (small) 644"-658Hair/skin/Sore (superficial wound/lesion) 519"-6166835G642 3 Appendages/injured/Left-rear-foot-injured 140"-161Hair/skin/Jaundiced (yellow tinge to skin) 665"Hair/skin/Pallor (pale/grey tinge to skin) 658"Hair/skin/Skin growth (small) 595"-6656835G643 3 Eyes/Right eye red discharge 161"-175, 329-336, 371, 413, 441-448, 474-495525-574, 602Tissue mass/Body dorsal 519"-602None/Dead 609"6835G644 3 Eyes/Left eye red discharge 189"-196, 385, 399, 420-434Hair/skin/Jaundiced (yellow tinge to skin) 515"None/Dead 519"-5326835G645 3 Appendages/injured/Tail injured 343"-392Appendages/missing/Tail missing (tip/portion) 399"-728Eyes/Left eye red discharge 273"-280, 308-336Eyes/Right eye red discharge 371"Eyes/Corneal opacity right eye 378"-728Hair/skin/Skin growth (small) 574"-728Movements/activity/Limb paralysis 728"6835G646 3 Appendages/injured/Right-rear-foot-injured 602"-616Hair/skin/Jaundiced (yellow tinge to skin) 637"Hair/skin/Skin growth (small) 574"-6376835G647 3 Hair/skin/Skin growth (small) 560"-616, 644-7286835G648 3 Eyes/Corneal opacity left eye 595"-728Hair/skin/Skin growth (small) 686"-7286835G649 3 Hair/skin/Skin growth (small) 574"-616, 665-728Hair/skin/Sore (superficial wound/lesion) 539"Tissue mass/Body ventral 707"-7286835G650 3 Appendages/injured/Right-front-foot-injured 609"-623Hair/skin/Skin growth (small) 602"-623Hair/skin/Sore (superficial wound/lesion) 525"-567Movements/activity/Hypoactivity 616"-623Total body/Emaciated 616"-623Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 17Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H701 4 Appendages/injured/Tail ring lesions 406"-467Feces/urine/Urine stain 308"-371, 385-574, 587-623Eyes/Right eye red discharge 378", 623Eyes/Micro-ophthalmia right eye 371"Hair/skin/Jaundiced (yellow tinge to skin) 686"-693Hair/skin/Pallor (pale/grey tinge to skin) 672"-679Hair/skin/Skin growth (small) 623"-6936837H702 4 Appendages/injured/Tail injured 392"-448, 707-728Hair/skin/Skin growth (small) 595"-728Hair/skin/Sore (superficial wound/lesion) 532"-616Tissue mass/Body dorsal 467"Tissue mass/Body ventral 474"6837H703 4 Appendages/injured/Left-front-foot-injured 651"-658Feces/urine/Urine stain 480"Swelling/Swollen abdomen 560"-595, 6586837H704 4 Appendages/injured/Tail ring lesions 406"-467Feces/urine/Urine stain 329"-350, 385, 406-480, 495-567Hair/skin/Skin growth (small) 574"-602, 623-728Hair/skin/Sore (superficial wound/lesion) 560"-567Tissue mass/Body ventral 686"-7286837H705 4 Hair/skin/Skin growth (small) 550"-7286837H706 4 Appendages/injured/Right-rear-foot-injured 161"Feces/urine/Urine stain 112", 133, 231-287, 308-480, 495-602Eyes/Right eye red discharge 49"-78Hair/skin/Pallor (pale/grey tinge to skin) 714"-728Hair/skin/Skin growth (small) 595"-602, 616, 630-7286837H707 4 Appendages/injured/Left-front-foot-injured 161"Appendages/injured/Left-rear-foot-injured 616"Appendages/injured/Tail injured 364"-474Eyes/Left eye red discharge 133"-161Eyes/Right eye red discharge 119", 140, 406-420, 495Hair/skin/Jaundiced (yellow tinge to skin) 644"-651Hair/skin/Skin growth (small) 550"-587Tissue mass/Body ventral 595"-651Toes/Injured toes 336"-3436837H708 4 Appendages/injured/Left-rear-foot-injured 161", 539-567Appendages/injured/Tail ring lesions 406"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 18Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H708 4 Hair/skin/Jaundiced (yellow tinge to skin) 721"Hair/skin/Pallor (pale/grey tinge to skin) 728"Hair/skin/Skin growth (small) 602"-6166837H709 4 Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Sore (superficial wound/lesion) 644"-6516837H710 4 Hair/skin/Jaundiced (yellow tinge to skin) 672"Hair/skin/Pallor (pale/grey tinge to skin) 679"Hair/skin/Sore (superficial wound/lesion) 602"-686Respiration/Wheezing 623"-686Toes/Injured toes 420"Total body/Emaciated 686"6837H711 4 Appendages/injured/Left-rear-foot-injured 392"-399Appendages/injured/Tail ring lesions 406"-474Feces/urine/Urine stain 665"-700Hair/skin/Jaundiced (yellow tinge to skin) 672"-700Hair/skin/Skin growth (small) 560"-700Toes/Injured toes 420"Total body/Emaciated 700"None/Dead 707"6837H712 4 Appendages/injured/Left-front-foot-injured 364"Hair/skin/Jaundiced (yellow tinge to skin) 609"Hair/skin/Skin growth (small) 546"-609None/Dead 616"6837H713 4 Hair/skin/Jaundiced (yellow tinge to skin) 707"-714Hair/skin/Pallor (pale/grey tinge to skin) 686"-700Hair/skin/Skin growth (small) 546"-550, 587-714Hair/skin/Sore (superficial wound/lesion) 519"Tissue mass/Body ventral 474"-5156837H714 4 Tissue mass/Genital area 519"-7286837H715 4 Appendages/injured/Tail injured 392"-467Feces/urine/Urine stain 231"Eyes/Left eye red discharge 154"-161, 182-218Hair/skin/Skin growth (small) 595"Total body/Emaciated 623"6837H716 4 Appendages/injured/Tail injured 273"-413, 427-467Eyes/Left eye red discharge 168"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 19Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H716 4 Tissue mass/Face 441"-467Tissue mass/Tail 420"None/Dead 474"6837H717 4 Hair/skin/Skin growth (small) 595", 609-7216837H718 4 Eyes/Left eye red discharge 49"-78, 218, 259-315, 371, 420-434, 480495-707Eyes/Right eye red discharge 448", 488Hair/skin/Skin growth (small) 546"-574, 595-721Hair/skin/Sore (superficial wound/lesion) 595"-616Tissue mass/Body ventral 651"-721Tissue mass/Genital area 519"-5396837H719 4 Hair/skin/Jaundiced (yellow tinge to skin) 515"None/Dead 519"-5326837H720 4 Hair/skin/Jaundiced (yellow tinge to skin) 630"Hair/skin/Skin growth (small) 546"-630Tissue mass/Genital area 539"6837H721 4 Appendages/injured/Tail ring lesions 406"-467Feces/urine/Urine stain 133", 182-210, 231-580Eyes/Left eye red discharge 182"-196, 308-315, 580-595, 623-686Eyes/Right eye red discharge 245", 336-350, 378, 488, 665-686Hair/skin/Skin growth (small) 616", 644-686None/Dead 693"-7146837H722 4 Hair/skin/Jaundiced (yellow tinge to skin) 728"Hair/skin/Pallor (pale/grey tinge to skin) 721"Hair/skin/Skin growth (small) 546"-7286837H723 4 Eyes/Left eye red discharge 49"-91, 140-161, 182-580Hair/skin/Jaundiced (yellow tinge to skin) 580"Hair/skin/Pallor (pale/grey tinge to skin) 567"-574None/Dead 587"6837H724 4 Hair/skin/Skin growth (small) 587"-7286837H725 4 Eyes/Corneal opacity right eye 550"-728Hair/skin/Jaundiced (yellow tinge to skin) 721"-728Hair/skin/Pallor (pale/grey tinge to skin) 707"-714Hair/skin/Skin growth (small) 546"-728Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 20Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H726 4 Hair/skin/Skin growth (small) 609"-616, 665-686, 721-728Toes/Injured toes 112"-119, 2106837H727 4 Appendages/injured/Left-rear-foot-injured 587"Appendages/injured/Tail ring lesions 406"-480Feces/urine/Urine stain 231"-371, 392-480Eyes/Right eye red discharge 210", 225-651Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Sore (superficial wound/lesion) 539"-616Tissue mass/Genital area 580"-5876837H728 4 Appendages/injured/Tail ring lesions 406"-441Eyes/Left eye red discharge 84"-98, 112, 245-280, 308-441, 455-480509-728Eyes/Right eye red discharge 57"-78Hair/skin/Pallor (pale/grey tinge to skin) 693"Hair/skin/Skin growth (small) 550"-7216837H729 4 Eyes/Right eye red discharge 509"-728Hair/skin/Skin growth (small) 560"-7286837H730 4 Hair/skin/Jaundiced (yellow tinge to skin) 700"Hair/skin/Skin growth (small) 560"-7006837H731 4 Appendages/injured/Tail injured 140"-147Feces/urine/Urine stain 336"-371, 385-420, 441-467Eyes/Left eye red discharge 474"-651Eyes/Right eye red discharge 539"-567, 580-651Hair/skin/Jaundiced (yellow tinge to skin) 651"Hair/skin/Pallor (pale/grey tinge to skin) 644"Total body/Emaciated 651"6837H732 4 Hair/skin/Skin growth (small) 546"-580Hair/skin/Sore (superficial wound/lesion) 495"-580Tissue mass/Genital area 539"Tissue mass/Tail 455"-474None/Dead 587"6837H733 4 Appendages/injured/Left-front-foot-injured 480"Appendages/injured/Right-front-foot-injured 480"Appendages/injured/Left-rear-foot-injured 480"Appendages/injured/Right-rear-foot-injured 480"Hair/skin/Jaundiced (yellow tinge to skin) 595"Hair/skin/Pallor (pale/grey tinge to skin) 580"-587Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 21Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H733 4 Toes/Injured toes 112"-1196837H734 4 Eyes/Right eye red discharge 49"-63Hair/skin/Jaundiced (yellow tinge to skin) 700"Hair/skin/Pallor (pale/grey tinge to skin) 679"Hair/skin/Skin growth (small) 546"-700Hair/skin/Sore (superficial wound/lesion) 616"Tissue mass/Genital area 406"-4486837H735 4 Hair/skin/Skin growth (small) 550"-728Tissue mass/Body dorsal 420"6837H736 4 Hair/skin/Skin growth (small) 546"-728Tissue mass/Genital area 539"Total body/Dehydrated 7"6837H737 4 Appendages/injured/Right-rear-foot-injured 616"Eyes/Right eye red discharge 105"-112, 140-147Hair/skin/Jaundiced (yellow tinge to skin) 630"-651Hair/skin/Pallor (pale/grey tinge to skin) 616"Hair/skin/Skin growth (small) 574"-651Hair/skin/Sore (superficial wound/lesion) 525"-6166837H738 4 Appendages/injured/Tail ring lesions 406"-467Hair/skin/Jaundiced (yellow tinge to skin) 700"Hair/skin/Pallor (pale/grey tinge to skin) 665"-672, 693Total body/Dehydrated 7"6837H739 4 Hair/skin/Skin growth (small) 550"-616, 644-7286837H740 4 Appendages/injured/Left-rear-foot-injured 392"-427Feces/urine/Urine stain 231"-609Eyes/Right eye red discharge 161", 357-364, 488-637Hair/skin/Jaundiced (yellow tinge to skin) 637"Tissue mass/Body dorsal 532"-637Tissue mass/Body ventral 515"-5196837H741 4 Eyes/Right eye red discharge 448"-455, 539-567, 623-651, 686-728Hair/skin/Skin growth (small) 721"6837H742 4 Eyes/Right eye red discharge 49"-57Hair/skin/Jaundiced (yellow tinge to skin) 595"Hair/skin/Pallor (pale/grey tinge to skin) 580"-587Hair/skin/Skin growth (small) 546"-595Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 22Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H743 4 Appendages/injured/Tail injured 488"-502Appendages/missing/Tail missing (tip/portion) 532"-714Hair/skin/Jaundiced (yellow tinge to skin) 707"-714Hair/skin/Skin growth (small) 560"-7146837H744 4 Eyes/Left eye red discharge 133", 308-315, 357, 385-392, 406-467Eyes/Right eye red discharge 49"-78, 189-210, 225-245, 259-467Hair/skin/Jaundiced (yellow tinge to skin) 467"6837H745 4 Appendages/injured/Tail ring lesions 406"-474Feces/urine/Bloody feces 539"Eyes/Left eye red discharge 602"Eyes/Right eye red discharge 119"-133, 154-595, 609-665Hair/skin/Pallor (pale/grey tinge to skin) 630", 658-665Hair/skin/Skin growth (small) 550"-665Hair/skin/Sore (superficial wound/lesion) 519"-616Total body/Emaciated 665"6837H746 4 Eyes/Left eye red discharge 364"-371, 385-420, 448, 474, 488-525, 550567, 595-609Hair/skin/Jaundiced (yellow tinge to skin) 637"-644Hair/skin/Skin growth (small) 602"-6096837H747 4 Hair/skin/Jaundiced (yellow tinge to skin) 658"Hair/skin/Pallor (pale/grey tinge to skin) 665"Hair/skin/Skin growth (small) 560"-728Toes/Injured toes 112"6837H748 4 Eyes/Left eye red discharge 308"-315, 371, 392-399, 434, 502-515Eyes/Right eye red discharge 218", 392-399Hair/skin/Pallor (pale/grey tinge to skin) 580"Hair/skin/Skin growth (small) 560"-580Tissue mass/Body dorsal 420"-434Tissue mass/Genital area 539"None/Dead 587"6837H749 4 Appendages/injured/Tail injured 455"-467Eyes/Left eye red discharge 273"-728Eyes/Right eye red discharge 42"-63, 78-728Hair/skin/Pallor (pale/grey tinge to skin) 672"-728Hair/skin/Skin growth (small) 602"-7286837H750 4 Appendages/injured/Tail ring lesions 406"-467Hair/skin/Jaundiced (yellow tinge to skin) 679"-686Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013M Page: 23Dates 22-May-01 to 20-May-03Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6837H750 4 Hair/skin/Skin growth (small) 546"-686Movements/activity/Hypoactivity 686"Toes/Injured toes 105"-112, 308-322Total body/Emaciated 686"Note: ! = Pretest phase; " = Dosing phase

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

J-2 FemalesLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 1Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6832E451 1 Feces/urine/Urine stain 218"-364, 442-448, 502, 518-525, 573Eyes/Left eye red discharge 63"-448, 467-7286832E452 1 Eyes/Left eye red discharge 700"-707Eyes/Micro-ophthalmia left eye 182"-211Tissue mass/Body ventral 532"-5436832E453 1 Appendages/missing/Tail missing (tip/portion) 322"-420Feces/urine/Urine stain 105"-329, 616Feces/urine/Red Vaginal Discharge 707"Eyes/Left eye red discharge 378", 434-448, 473, 518, 532-539Eyes/Corneal opacity left eye 539"-707Hair/skin/Pallor (pale/grey tinge to skin) 686", 7076832E454 1 Appendages/injured/Tail injured 119"-154, 252-427, 467-6096832E455 1 Feces/urine/Red Vaginal Discharge 679"6832E456 1 Feces/urine/Urine stain 266"-315Eyes/Left eye red discharge 35"-56, 84-112, 133-154, 336, 364, 378400-420, 442, 502-512Eyes/Right eye red discharge 175"-182, 218-280, 294, 392-413, 427-448467-488, 525-532, 543, 560-567, 580-616644-672, 693-7006832E457 1 Eyes/Left eye red discharge 29"-42, 218-224, 238-343, 357-364, 378-420473-532, 560, 580-588Eyes/Right eye red discharge 42"Hair/skin/Jaundiced (yellow tinge to skin) 588"6832E458 1 Eyes/Left eye red discharge 378"-400, 413-448, 488-512, 693Eyes/Right eye red discharge 400", 679-686Toes/Injured toes 147"-1546832E459 1 Appendages/missing/Tail missing (tip/portion) 595"-623Eyes/Right eye red discharge 336", 378-392, 467, 488, 508-518, 560-567Tissue mass/Body ventral 609"-6236832E460 1 Tissue mass/Genital area 679"-6936832E461 1 Feces/urine/Urine stain 147"-154, 182-448, 467-543Eyes/Left eye red discharge 42"-56, 77-98, 133-140, 161-203, 218-357371-448, 467-573, 595-707, 721-728Eyes/Corneal opacity left eye 364", 413-420Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 2Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6832E461 1 Tissue mass/Body ventral 707"6832E462 1 Feces/urine/Urine stain 133"-1616832E463 1 Eyes/Left eye red discharge 42", 133-154, 218-266, 294, 364-448, 5436832E464 1 Feces/urine/Urine stain 126"-133, 147-357, 406-434Feces/urine/Red Vaginal Discharge 392"6832E465 1 Appendages/injured/Left-rear-foot-injured 231"-245Appendages/injured/Right-rear-foot-injured 231"-245Appendages/injured/Right-front-leg-injured 588"Ears/nose/Red nasal discharge 231"Feces/urine/Urine stain 133", 147-245, 336-357, 588Eyes/Left eye red discharge 364"-420, 434Hair/skin/Sore (superficial wound/lesion) 580"-588Total body/Dehydrated 588"6832E466 1 Appendages/injured/Left-front-foot-injured 406"-420Hair/skin/Jaundiced (yellow tinge to skin) 679"None/Dead 686"6832E467 1 Eyes/Left eye red discharge 196"-2116832E468 1 Appendages/injured/Tail injured 371"-385Feces/urine/Urine stain 364"Movements/activity/Limb paralysis 679"6832E469 1 Feces/urine/Urine stain 133"-161, 322-364, 392-400Hair/skin/Jaundiced (yellow tinge to skin) 630"Total body/Emaciated 630"6832E470 1 Feces/urine/Urine stain 91", 119, 147-154Eyes/Right eye red discharge 350"-357Hair/skin/Jaundiced (yellow tinge to skin) 539"6832E471 1 Eyes/Right eye red discharge 84"-294, 308-448, 467-672Hair/skin/Jaundiced (yellow tinge to skin) 672"Hair/skin/Pallor (pale/grey tinge to skin) 665"6832E472 1 Appendages/injured/Right-rear-foot-injured 91"Appendages/injured/Tail injured 371"-385Feces/urine/Urine stain 364", 413-420, 448Eyes/Left eye red discharge 105", 287-357, 378-448, 467-588, 616-623Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 3Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6832E472 1 Eyes/Left eye red discharge 658Eyes/Right eye red discharge 266"-357, 378-448, 467-481, 532-543, 573-623658Hair/skin/Pallor (pale/grey tinge to skin) 686"-707Toes/Injured toes 182"Total body/Emaciated 686"-7286832E473 1 Hair/skin/Pallor (pale/grey tinge to skin) 651"6832E474 1 Appendages/injured/Left-rear-foot-injured 91"Eyes/Left eye red discharge 488"-630Hair/skin/Jaundiced (yellow tinge to skin) 630"Hair/skin/Pallor (pale/grey tinge to skin) 623"Toes/Injured toes 105"-1126832E475 1 Appendages/injured/Right-front-foot-injured 91"Eyes/Left eye red discharge 211"-364, 385-448, 473-7146832E476 1 Appendages/injured/Left-rear-foot-injured 91"Appendages/injured/Right-rear-foot-injured 91"Feces/urine/Urine stain 147"-154, 189-203, 252-301, 350-364, 406-473532-543, 609, 714-721Eyes/Right eye red discharge 364"Eyes/Corneal opacity right eye 460"-721Hair/skin/Jaundiced (yellow tinge to skin) 721"6832E477 1 Appendages/injured/Tail injured 467"-518Eyes/Left eye red discharge 42"Toes/Injured toes 329"None/Dead 588"6832E478 1 Feces/urine/Urine stain 91"-112, 126-448, 473-616Eyes/Left eye red discharge 266"-448, 467-665, 728Eyes/Corneal opacity left eye 672"-7006832E479 1 Feces/urine/Urine stain 133", 231-245, 357-364, 442-448Eyes(continued)/Corneal defect right eye 182"-2116832E480 1 Eyes/Left eye red discharge 287"-294, 322-448, 467-508, 539-543, 602-630Eyes/Right eye red discharge 161", 211-294, 322-448, 467-6656832E481 1 Feces/urine/Urine stain 126"-133, 231-308Feces/urine/Red Vaginal Discharge 315"Eyes/Left eye red discharge 42"-71, 98-112, 133, 161, 211-231, 252-315Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 4Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6832E481 1 None/Dead 322"-3296832E482 1 Feces/urine/Urine stain 231"-350, 371-378, 406-448, 488Eyes/Right eye red discharge 392"-400, 413-434, 488-502Hair/skin/Jaundiced (yellow tinge to skin) 644"Hair/skin/Pallor (pale/grey tinge to skin) 637"6832E483 1 Appendages/injured/Right-rear-foot-injured 231"-245Eyes/Left eye red discharge 112"-126, 182-203, 218, 231, 609Eyes/Right eye red discharge 112"-161, 182-203, 218-224, 336-413, 434-448518-595, 616-6236832E484 1 Hair/skin/Jaundiced (yellow tinge to skin) 658"Hair/skin/Pallor (pale/grey tinge to skin) 644"-6516832E485 1 Appendages/injured/Right-rear-foot-injured 91"Eyes/Left eye red discharge 218"-273, 287-294, 308-448, 467-481Hair/skin/Jaundiced (yellow tinge to skin) 481"Toes/Injured toes 473"-481None/Dead 488"6832E486 1 Appendages/injured/Left-rear-foot-injured 460"-481Appendages/injured/Right-rear-foot-injured 560"Feces/urine/Urine stain 133"-203, 218-364, 392-481Eyes/Right eye red discharge 343"-364, 378-488, 512-602, 630, 658-6657146832E487 1 Appendages/injured/Left-rear-foot-injured 460"Feces/urine/Urine stain 133"-154, 182-203, 252-357, 448-467Hair/skin/Pallor (pale/grey tinge to skin) 580"-5886832E488 1 Feces/urine/Urine stain 336"-357, 467Eyes/Right eye red discharge 672"-679Hair/skin/Pallor (pale/grey tinge to skin) 679"6832E489 1 Appendages/injured/Right-rear-foot-injured 460"-481Eyes/Right eye red discharge 336"-658, 672-7286832E490 1 Feces/urine/Urine stain 98"-203, 218-294, 336-392, 420-448Eyes/Right eye red discharge 693", 728Hair/skin/Pallor (pale/grey tinge to skin) 728"6832E491 1 Appendages/injured/Tail injured 371"-378None/Dead 679"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 5Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6832E492 1 Feces/urine/Urine stain 119"-133, 168-175Eyes/Right eye red discharge 495"-512None/Dead 518"6832E493 1 Hair/skin/Pallor (pale/grey tinge to skin) 728"Swelling/Swollen abdomen 543"-5886832E494 1 Feces/urine/Urine stain 231"-245Eyes/Left eye red discharge 616"-630Eyes/Right eye red discharge 71", 84, 105-119, 133-154, 218-224, 252-357371-488, 512-567, 588-595, 609-630Eyes/Micro-ophthalmia right eye 224"Hair/skin/Ulcer (open sore,skin broken) 539"-560Tissue mass/Body ventral 567"-6306832E495 1 Appendages/injured/Tail injured 147"-154Feces/urine/Urine stain 329"-357, 442-467, 539-553Eyes/Right eye red discharge 525"-609, 630-7286832E496 1 Eyes/Right eye red discharge 539"Hair/skin/Pallor (pale/grey tinge to skin) 630"Total body/Emaciated 630"6832E497 1 Appendages/injured/Left-front-foot-injured 543"-560Appendages/injured/Tail injured 371"-385Eyes/Left eye red discharge 448", 679-686, 700-707, 728Eyes/Right eye red discharge 147"-154, 343-448, 4816832E498 1 Appendages/injured/Tail injured 29"-71Toes/Injured toes 29"-716832E499 1 Hair/skin/Pallor (pale/grey tinge to skin) 560"Tissue mass/Body ventral 553"-5606832E500 1 Appendages/injured/Right-rear-foot-injured 91"Feces/urine/Urine stain 105"-154, 168-203, 218-392, 442-448Swelling/Swollen abdomen 560"-5886834F551 2 Appendages/injured/Right-rear-foot-injured 580"-609Ears/nose/Injured nose 385"Feces/urine/Urine stain 119"-203, 224-357, 406-420, 442-448, 525-532543-630, 644-714Eyes/Left eye red discharge 71", 91-119, 336-357, 427-448, 473-630Tissue mass/Body dorsal 728"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 6Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6834F551 2 Tissue mass/Body ventral 693"-7146834F552 2 Eyes/Left eye red discharge 573"Eyes/Right eye red discharge 406"-448, 467-532, 573Hair/skin/Pallor (pale/grey tinge to skin) 573"None/Dead 580"6834F553 2 Appendages/injured/Right-front-foot-injured 567"-602Feces/urine/Urine stain 133"-140, 245-357, 442-448Eyes/Left eye red discharge 560"-595Toes/Injured toes 182"6834F554 2 Ears/nose/Red nasal discharge 182"Feces/urine/Urine stain 105"-161, 224-357, 385, 406-427, 442-448Eyes/Left eye red discharge 442"-448Eyes/Right eye red discharge 400"Toes/Injured toes 182"6834F555 2 Feces/urine/Urine stain 119", 133-161, 308, 413-427, 448Eyes/Left eye red discharge 35"-56Eyes/Right eye red discharge 42"-98, 147-161, 231-245, 336-343, 385-420Eyes/Corneal opacity right eye 658"-728Swelling/Swollen abdomen 567"-5886834F556 2 Appendages/injured/Right-rear-foot-injured 406"-420Feces/urine/Red Vaginal Discharge 651"-672Eyes/Left eye red discharge 434"-448, 467-495, 588-616, 630, 672Eyes/Right eye red discharge 350"-357, 392-420, 442-448, 532-539, 672Hair/skin/Pallor (pale/grey tinge to skin) 658"-672Toes/Injured toes 182"-2036834F557 2 Feces/urine/Urine stain 91", 126, 322-357Eyes/Left eye red discharge 371"-413, 473-481, 679-707Swelling/Swollen abdomen 567"-580Toes/Injured toes 105"-1126834F558 2 Appendages/injured/Left-front-foot-injured 406"Appendages/injured/Right-front-foot-injured 406"-427Feces/urine/Urine stain 126"-400, 413-448, 473-532Eyes/Left eye red discharge 385"6834F559 2 Appendages/injured/Right-rear-foot-injured 406"-448Appendages/missing/Tail missing (most/entire) 315"-448, 467-728Feces/urine/Urine stain 91", 119-357, 406-420, 442-448, 658-665Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 7Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6834F559 2 Eyes/Left eye red discharge 350"-357, 378-448, 532-543, 616, 637-6516834F560 2 Appendages/missing/Tail missing (tip/portion) 336"-442Feces/urine/Urine stain 119"-154, 168-364, 378-448, 467-543, 567-623637-651, 700Eyes/Right eye red discharge 161", 336-350, 364-400, 413-442, 467-488512-5606834F561 2 Eyes/Left eye red discharge 126"-203, 218-400, 460-473, 518-543, 588-595616, 644-651Eyes/Right eye red discharge 42"-50, 84-105, 218-315, 392-400, 413-467707-7286834F562 2 Feces/urine/Diarrhea 488"Feces/urine/Excessive urination 488"Feces/urine/Red urine 473"Feces/urine/Urine stain 105"-154, 182-329, 420Eyes/Right eye red discharge 105"-154, 175-238, 329, 371, 385-400, 413-448473-488Hair/skin/Pallor (pale/grey tinge to skin) 488"6834F563 2 Eyes/Left eye red discharge 460", 512, 532-543Eyes/Right eye red discharge 322"-539, 553-728Swelling/Swollen abdomen 573"-588Tissue mass/Body dorsal 644"-7286834F564 2 Feces/urine/Urine stain 322"-357, 413-420, 488-512Eyes/Left eye red discharge 385"-448, 481, 518-616Eyes/Right eye red discharge 460"-473, 488-512Swelling/Swollen abdomen 567"-5886834F565 2 Swelling/Swollen abdomen 539"-560Tissue mass/Neck 623"-637Tissue mass/Body ventral 567"-6376834F566 2 Feces/urine/Red Vaginal Discharge 508"None/Dead 518"-5256834F567 2 Feces/urine/Urine stain 161"-357, 420-427, 442-448, 616-637Tissue mass/Body ventral 580"-707Toes/Injured toes 105"-1196834F568 2 Feces/urine/Urine stain 182"-203, 273-588Eyes/Left eye red discharge 154", 231, 245-406, 427-488, 502-508, 518-543Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 8Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6834F568 2 Eyes/Right eye red discharge 196"-203, 218-231, 364-371, 400-420, 434-448488, 502-512Hair/skin/Jaundiced (yellow tinge to skin) 588"6834F569 2 Eyes/Left eye red discharge 460"-473, 539-543, 721-728Swelling/Swollen abdomen 560"-588, 686-7286834F570 2 Feces/urine/Urine stain 294"-357, 406-448, 481-525, 560-623Toes/Injured toes 301"6834F571 2 Feces/urine/Urine stain 147"-154, 168-203, 231-287, 301-357, 371-448473-567, 644-651, 665-686, 707-721Feces/urine/Red Vaginal Discharge 294"Eyes/Left eye red discharge 196"-203, 231, 245, 273-448, 473-637, 651-672686Eyes/Right eye red discharge 196"-203, 322-400, 420-448, 467-637, 651-672686-693, 707-721Hair/skin/Jaundiced (yellow tinge to skin) 721"6834F572 2 Eyes/Corneal opacity right eye 119"-448, 467-686Eyes/Micro-ophthalmia right eye 371"-448Hair/skin/Jaundiced (yellow tinge to skin) 686"Hair/skin/Pallor (pale/grey tinge to skin) 679"Swelling/Swollen abdomen 567"-588, 665-6726834F573 2 Feces/urine/Urine stain 273"-301Eyes/Right eye red discharge 77"-154, 196-315, 329-357, 371-448, 473-481495-602, 623, 658-6866834F574 2 Feces/urine/Urine stain 161"-357, 406-448, 502-512, 539-580, 7216834F575 2 Swelling/Swollen abdomen 539"-5886834F576 2 Appendages/injured/Tail injured 336"-448Feces/urine/Urine stain 133", 161-357Hair/skin/Pallor (pale/grey tinge to skin) 679"Hair/skin/Sore (superficial wound/lesion) 658"-679Swelling/Swollen abdomen 567"-588Tissue mass/Body dorsal 539"-651, 672-679Toes/Injured toes 105"-112None/Dead 686"6834F577 2 Appendages/injured/Tail injured 371"-385Appendages/missing/Tail missing (tip/portion) 392"-448, 467-707Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 9Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6834F577 2 Feces/urine/Diarrhea 707"Feces/urine/Urine stain 105"-112, 126-203, 294-315, 336-357Hair/skin/Skin growth (small) 686"-707Hair/skin/Sore (superficial wound/lesion) 495"-609, 623-6516834F578 2 Feces/urine/Urine stain 294"-357, 400-448, 467-532, 560-588Eyes/Left eye red discharge 406", 448, 481-495, 518, 532, 580-588Eyes/Right eye red discharge 91"-119, 133, 147-154, 238-266, 406, 420-427488-495, 616-623, 637-6586834F579 2 Eyes/Left eye red discharge 182"-203, 231, 378, 420-427, 467-473, 488-5326306834F580 2 Hair/skin/Sore (superficial wound/lesion) 679"Swelling/Swollen abdomen 539"-543, 714-7286834F581 2 Feces/urine/Urine stain 224"-245, 420, 442-448, 721-728Eyes/Left eye red discharge 105"-112, 161, 182-273, 294, 357, 378-392Hair/skin/Jaundiced (yellow tinge to skin) 728"Hair/skin/Pallor (pale/grey tinge to skin) 721"6834F582 2 Feces/urine/Urine stain 442"-448Eyes/Left eye red discharge 182", 442-448Eyes/Right eye red discharge 273", 294-301, 336-357, 371-427, 467-495525, 539, 580-602, 6166834F583 2 Eyes/Left eye red discharge 161"6834F584 2 Eyes/Left eye red discharge 686", 700-707Eyes/Right eye red discharge 385", 602-637, 658-7216834F585 2 Eyes/Left eye red discharge 84"-98, 119-133, 154-273, 378-448, 467-488512-543Eyes/Right eye red discharge 442"Eyes/Corneal opacity left eye 218"-448, 467-7286834F586 2 Normal throughout interval6834F587 2 Feces/urine/Urine stain 91"-112, 133, 168-182, 336-357, 400-448488-580Swelling/Swollen abdomen 560"6834F588 2 Eyes/Left eye red discharge 84", 133, 218-245, 343-385, 400Eyes/Right eye red discharge 442"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 10Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6834F588 2 Hair/skin/Sore (superficial wound/lesion) 721"-7286834F589 2 Feces/urine/Red Vaginal Discharge 658", 679Hair/skin/Pallor (pale/grey tinge to skin) 679"Swelling/Swollen abdomen 588"6834F590 2 Feces/urine/Urine stain 119"-182, 224-315Feces/urine/Prolapsed uterus 350"6834F591 2 Appendages/injured/Left-front-foot-injured 91"Appendages/injured/Right-front-foot-injured 91"Feces/urine/Urine stain 119", 133-357, 442-448Eyes/Right eye red discharge 364", 392-448, 467-488, 502-543, 602, 630679Toes/Injured toes 112"6834F592 2 Feces/urine/Urine stain 133"-420, 434-448, 495-5536834F593 2 Feces/urine/Urine stain 126", 161-308Eyes/Left eye red discharge 126"-140, 218, 231-400, 413-448, 467-488512, 539-553, 609-637, 658, 714None/Dead 728"6834F594 2 Eyes/Left eye red discharge 231", 343, 364, 385-448, 467-588Eyes/Right eye red discharge 231"-448, 467-495, 512-580Swelling/Swollen abdomen 539"-588Tissue mass/Genital area 567"-5886834F595 2 Appendages/missing/Tail missing (tip/portion) 322"-448Feces/urine/Urine stain 301"-357, 427-448Feces/urine/Red Vaginal Discharge 294", 392None/Dead 488"6834F596 2 Eyes/Left eye red discharge 105"-119, 245-448, 473-488, 543-553Eyes/Right eye red discharge 218"-364, 400-448, 467-7286834F597 2 Eyes/Left eye red discharge 161"Eyes/Right eye red discharge 400", 658-665, 679-693, 728Swelling/Swollen abdomen 543"6834F598 2 Appendages/injured/Right-rear-foot-injured 91"Feces/urine/Urine stain 420"Eyes/Left eye red discharge 512"-525, 553-560Eyes/Right eye red discharge 336"-378, 420-448, 488-495, 525, 553, 595Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 11Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6834F598 2 Eyes/Right eye red discharge 630-637, 658-686, 707-7286834F599 2 Feces/urine/Urine stain 126"-133, 147-154, 168-175, 224-329Eyes/Left eye red discharge 133", 161, 364-378, 406-427, 532-560Hair/skin/Jaundiced (yellow tinge to skin) 560"Hair/skin/Pallor (pale/grey tinge to skin) 553"-560Swelling/Swollen abdomen 543"-5606834F600 2 Normal throughout interval6836G651 3 Feces/urine/Urine stain 442"Eyes/Left eye red discharge 434"-442, 502-508, 525Eyes/Right eye red discharge 616"6836G652 3 Appendages/injured/Tail injured 413"Feces/urine/Urine stain 105"-119, 133, 147-203, 224-357Eyes/Left eye red discharge 532"6836G653 3 Appendages/injured/Tail injured 413"-448Eyes/Left eye red discharge 63", 84-448, 467-488Eyes/Right eye red discharge 350"-448, 467-488Respiration/Dyspnea (labored breathing) 488"6836G654 3 Eyes/Left eye red discharge 329"Eyes/Right eye red discharge 218"-448, 467-7286836G655 3 Feces/urine/Urine stain 140", 161-203, 350-357, 406-448, 512Eyes/Left eye red discharge 119"-154, 182-203, 218-406, 420-448, 467-707728Eyes/Micro-ophthalmia left eye 105"6836G656 3 Eyes/Right eye red discharge 196"-218, 385-392, 413, 427-448, 467, 532-560616-6236836G657 3 Appendages/injured/Right-front-foot-injured 467"Eyes/Left eye red discharge 133"-140, 385, 488-512, 532-560, 658, 693-700714-728Eyes/Right eye red discharge 371"-448, 473-7286836G658 3 Feces/urine/Urine stain 105", 147-154, 168-175, 189-357, 4426836G659 3 Appendages/injured/Tail injured 175"-231Feces/urine/Urine stain 182"-245, 329-357, 442-448Eyes/Left eye red discharge 672"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 12Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6836G659 3 Hair/skin/Jaundiced (yellow tinge to skin) 728"Hair/skin/Pallor (pale/grey tinge to skin) 721"6836G660 3 Eyes/Left eye red discharge 532"-573, 609Eyes/Right eye red discharge 133"-140, 196-203, 413-420, 467, 539-543616-637Swelling/Swollen abdomen 567"-588, 665-7286836G661 3 Appendages/injured/Right-rear-foot-injured 364"-371Eyes/Right eye red discharge 460"Eyes/Micro-ophthalmia right eye 231"6836G662 3 Feces/urine/Urine stain 147"-161, 182-357, 413-420, 460, 543-560Eyes/Right eye red discharge 460", 473-553, 595, 609-672, 7006836G663 3 Eyes/Left eye red discharge 273"-413, 442-448, 488-623, 644-658, 672-679728Eyes/Right eye red discharge 473"-481Hair/skin/Sore (superficial wound/lesion) 525"-6236836G664 3 Feces/urine/Urine stain 133", 147-357, 427-448, 473-560Feces/urine/Red Vaginal Discharge 385"-406Eyes/Left eye red discharge 133", 413-420, 434-442Eyes/Right eye red discharge 322"-336, 413-448, 473-5436836G665 3 Appendages/injured/Right-front-foot-injured 91"Eyes/Left eye red discharge 502"-512Eyes/Right eye red discharge 413"-420Hair/skin/Sore (superficial wound/lesion) 512"Toes/Injured toes 98"None/Dead 518"-5256836G666 3 Eyes/Left eye red discharge 329"-357, 481-525, 573-728Eyes/Right eye red discharge 609"Hair/skin/Skin growth (small) 467"-508, 532-609Tissue mass/Face 343"-4486836G667 3 Feces/urine/Urine stain 161"Eyes/Left eye red discharge 488"-512, 543, 567-5806836G668 3 Normal throughout interval6836G669 3 Appendages/injured/Left-rear-foot-injured 406"-442Feces/urine/Cloudy urine 105"-112Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 13Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6836G669 3 Feces/urine/Urine stain 133", 147-154, 609Eyes/Left eye red discharge 35"-71, 133, 385-481, 525-532, 658-665Eyes/Right eye red discharge 686"6836G670 3 Eyes/Left eye red discharge 406"-420Eyes/Right eye red discharge 42"-71, 294-392, 427-467, 488, 525-588644-665, 714-7216836G671 3 Eyes/Left eye red discharge 406"Eyes/Right eye red discharge 280"-287, 301-315, 385-420, 442-488, 512-518539None/Dead 553"-5606836G672 3 Eyes/Right eye red discharge 224"-245, 273-442, 473-560, 595-602, 616-728Tissue mass/Body ventral 721"-7286836G673 3 Feces/urine/Urine stain 280"Eyes/Left eye red discharge 280"Eyes/Right eye red discharge 280"Total body/Dehydrated 280"6836G674 3 Appendages/injured/Left-front-foot-injured 91"Eyes/Left eye red discharge 105", 400-481, 525-543, 616-623Eyes/Right eye red discharge 280"-357, 371-488, 512-553, 567-595, 616-623651, 672-686, 707-7146836G675 3 Feces/urine/Urine stain 413"-420, 442-460Eyes/Left eye red discharge 84"-105, 119-364, 385-518, 532-602, 616-630658Eyes/Right eye red discharge 133"-140, 218-287, 308-400, 442-460, 567-580Eyes/Corneal opacity left eye 721"-7286836G676 3 Appendages/injured/Left-rear-foot-injured 448"-460Appendages/injured/Right-rear-foot-injured 595"-609Feces/urine/Urine stain 91"-98, 161-273, 287-357, 371-460, 488-495512-580Feces/urine/Red Vaginal Discharge 448"-460Eyes/Left eye red discharge 400"Eyes/Right eye red discharge 231"-245, 413-427, 616-623Hair/skin/Pallor (pale/grey tinge to skin) 651"Hair/skin/Sore (superficial wound/lesion) 525"-623Oral cavity/dental/tissue mass 133"-140Oral cavity/dental/Sore 147"-1546836G677 3 Normal throughout intervalNote: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 14Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6836G678 3 Eyes/Left eye red discharge 105"-112, 413-420, 434, 448-481, 518-532553-580, 616-637Eyes/Right eye red discharge 105"-112, 343-532, 553-623Tissue mass/Genital area 532"-693None/Dead 700"6836G679 3 Eyes/Right eye red discharge 273"-357, 406-420, 488, 539-560, 573-580630-644Hair/skin/Pallor (pale/grey tinge to skin) 651"Hair/skin/Skin growth (small) 637"-6516836G680 3 Eyes/Left eye red discharge 413"-442, 580-588Eyes/Right eye red discharge 442"Hair/skin/Jaundiced (yellow tinge to skin) 644"Hair/skin/Pallor (pale/grey tinge to skin) 637"6836G681 3 Normal throughout interval6836G682 3 Eyes/Left eye red discharge 385"-392Hair/skin/Jaundiced (yellow tinge to skin) 644"6836G683 3 Feces/urine/Urine stain 560"Eyes/Right eye red discharge 442"6836G684 3 Feces/urine/Urine stain 518"Eyes/Right eye red discharge 322"-357, 385-4736836G685 3 Hair/skin/Jaundiced (yellow tinge to skin) 539"6836G686 3 Eyes/Right eye red discharge 133", 196-203, 231-728Hair/skin/Pallor (pale/grey tinge to skin) 728"6836G687 3 Feces/urine/Urine stain 91"-98, 119, 133-203, 224-357, 400-448488-495, 539-560Hair/skin/Jaundiced (yellow tinge to skin) 679"Tissue mass/Body ventral 672"-6796836G688 3 Appendages/injured/Right-front-foot-injured 665"Ears/nose/Red nasal discharge 658"Hair/skin/Pallor (pale/grey tinge to skin) 658"6836G689 3 Feces/urine/Urine stain 133", 336-357, 413-460, 525-560, 573-580665Eyes/Right eye red discharge 336"-343, 357, 371-728Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 15Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6836G689 3 Hair/skin/Skin growth (small) 539"-580Hair/skin/Sore (superficial wound/lesion) 512"-532, 595-7286836G690 3 Eyes/Left eye red discharge 133", 154, 273-280, 413-442, 467-481, 495-512539-693, 707-728Hair/skin/Sore (superficial wound/lesion) 512"Toes/Injured toes 147"-1546836G691 3 Ears/nose/Injured nose 91"Eyes/Left eye red discharge 91"Respiration/Dyspnea (labored breathing) 91"6836G692 3 Normal throughout interval6836G693 3 Eyes/Left eye red discharge 308"-473, 488, 512-525, 539-580, 595-637Eyes/Right eye red discharge 196"-218, 616-623None/Dead 658"6836G694 3 Feces/urine/Urine stain 350"-357, 488, 560Eyes/Left eye red discharge 161", 287-315, 371-609Eyes/Right eye red discharge 357", 385-460, 488-5326836G695 3 Eyes/Left eye red discharge 630"-658Eyes/Right eye red discharge 616"-658Hair/skin/Pallor (pale/grey tinge to skin) 630"-6586836G696 3 Ears/nose/Injured nose 91"Eyes/Left eye red discharge 91"Respiration/Dyspnea (labored breathing) 91"6836G697 3 Eyes/Left eye red discharge 161", 189-728Eyes/Right eye red discharge 287", 385-420, 434-442, 467-488, 512-595Hair/skin/Skin growth (small) 665"-728Tissue mass/Body dorsal 700"-7286836G698 3 Feces/urine/Urine stain 105"-112, 126-154, 168-357, 413-460, 488-623Eyes/Left eye red discharge 392"-420, 442, 467-508, 525-560, 573-580602-623Eyes/Right eye red discharge 385"-488, 518-588, 602-623Hair/skin/Jaundiced (yellow tinge to skin) 623"Hair/skin/Alopecia 119"6836G699 3 Eyes/Left eye red discharge 50"-56Eyes/Corneal opacity left eye 91"-112Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 16Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6836G699 3 Oral cavity/dental/Malocclusion/overgrown teeth 112"Oral cavity/dental/Broken teeth 56"Total body/Skinny 50"-566836G700 3 Feces/urine/Urine stain 400"Eyes/Left eye red discharge 602"Hair/skin/Pallor (pale/grey tinge to skin) 119"6838H751 4 Appendages/injured/Tail injured 448"-658Eyes/Left eye red discharge 71", 105, 119, 231-238, 336-658Eyes/Right eye red discharge 71", 231-539, 560-567, 588-602, 616-623637-658Hair/skin/Pallor (pale/grey tinge to skin) 651"-658Total body/Emaciated 651"-6586838H752 4 Eyes/Left eye red discharge 273", 287-329, 364, 400, 442-448Eyes/Right eye red discharge 364", 385-392, 413-448, 495-508Hair/skin/Jaundiced (yellow tinge to skin) 679"-686Hair/skin/Skin growth (small) 508"-5126838H753 4 Appendages/injured/Right-rear-foot-injured 448"-460Feces/urine/Urine stain 714"-721Feces/urine/Red Vaginal Discharge 707"Eyes/Left eye red discharge 252"-266, 371-495Eyes/Right eye red discharge 119", 133-154, 252-266, 392-427, 460None/Dead 728"6838H754 4 Appendages/injured/Left-rear-foot-injured 448"-460Appendages/injured/Tail injured 400"-442Appendages/injured/Tail ring lesions 442"-467Appendages/missing/Tail missing (tip/portion) 502"-728Feces/urine/Urine stain 133", 168-203, 218-364, 413-721Eyes/Left eye red discharge 133", 322-357, 378-392, 406-420, 442-467630-6446838H755 4 Eyes/Left eye red discharge 378"-400, 442, 539-686, 700-728Eyes/Right eye red discharge 357", 371, 406-434, 448-518, 539-580, 616-630651-6656838H756 4 Appendages/missing/Tail missing (tip/portion) 378"-728Eyes/Left eye red discharge 231"-273, 308-357, 385-400, 420-481, 588-6026838H757 4 Eyes/Left eye red discharge 196"-211, 252-273, 350-400, 427, 460-467539, 560-567, 616, 644-658Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 17Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6838H757 4 Eyes/Right eye red discharge 392", 406, 434-442, 467, 512-573, 616644-658, 672-700Hair/skin/Jaundiced (yellow tinge to skin) 693"-700Hair/skin/Pallor (pale/grey tinge to skin) 679"-686Toes/Injured toes 329"Toes/Missing toes 336"-427None/Dead 707"6838H758 4 Eyes/Left eye red discharge 427", 637-693Hair/skin/Sore (superficial wound/lesion) 707"6838H759 4 Appendages/injured/Left-rear-foot-injured 91"Eyes/Left eye red discharge 707"-728Eyes/Right eye red discharge 133", 252-273, 400, 442-460, 543-553, 630-665686-693Toes/Injured toes 329"-3506838H760 4 Eyes/Left eye red discharge 161", 273, 467-693, 714-728Eyes/Right eye red discharge 273"6838H761 4 Appendages/injured/Tail injured 658"-707Eyes/Left eye red discharge 442"Eyes/Right eye red discharge 161", 4426838H762 4 Feces/urine/Urine stain 287"-364, 420-460, 473-508, 518-532, 580Eyes/Left eye red discharge 385"-543, 580, 630-637, 665-7286838H763 4 Feces/urine/Urine stain 126"-133, 336-357Feces/urine/Red Vaginal Discharge 473"Eyes/Right eye red discharge 287"-2946838H764 4 Feces/urine/Urine stain 322"-357, 525Eyes/Left eye red discharge 442"-525Hair/skin/Jaundiced (yellow tinge to skin) 525"6838H765 4 Eyes/Right eye red discharge 543"-553, 602-693, 707-7216838H766 4 Hair/skin/Jaundiced (yellow tinge to skin) 473"6838H767 4 Feces/urine/Urine stain 672"Eyes/Left eye red discharge 385"Eyes/Right eye red discharge 543"-700Eyes/Corneal opacity right eye 63"-728Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 18Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6838H768 4 Eyes/Right eye red discharge 442"6838H769 4 Feces/urine/Urine stain 147"-588, 609, 6516838H770 4 Appendages/injured/Left-rear-foot-injured 460"Appendages/injured/Right-rear-foot-injured 460"Eyes/Right eye red discharge 71", 133-154, 385-460Hair/skin/Jaundiced (yellow tinge to skin) 658"Hair/skin/Pallor (pale/grey tinge to skin) 651"6838H771 4 Eyes/Left eye red discharge 434"6838H772 4 Appendages/injured/Left-rear-foot-injured 91"Feces/urine/Urine stain 126"-154, 168-175, 189-203, 224-364, 392-488567, 707-728Eyes/Right eye red discharge 512"-672Hair/skin/Jaundiced (yellow tinge to skin) 700"-728Tissue mass/Body ventral 679"-7146838H773 4 Appendages/injured/Tail injured 218"-224Eyes/Left eye red discharge 385"-400Tissue mass/Body ventral 658"-686Tissue mass/Genital area 693"-7286838H774 4 Eyes/Left eye red discharge 273", 481-488Hair/skin/Alopecia 467"-4886838H775 4 Eyes/Left eye red discharge 133", 224, 336-357, 385-413, 442-467, 488-644Eyes/Right eye red discharge 686"Hair/skin/Jaundiced (yellow tinge to skin) 686"6838H776 4 Appendages/injured/Right-front-foot-injured 231"-245Appendages/injured/Left-rear-foot-injured 161"Eyes/Left eye red discharge 413"Eyes/Right eye red discharge 406"-460, 473-637, 658-728Toes/Injured toes 168"-1756838H777 4 Appendages/injured/Left-front-foot-injured 140"-154Eyes/Left eye red discharge 161", 378-473Eyes/Right eye red discharge 406", 518Eyes/Corneal opacity left eye 211"-728Toes/Injured toes 112"-1196838H778 4 Eyes/Left eye red discharge 488"-495Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 19Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6838H778 4 Eyes/Right eye red discharge 420"-442Hair/skin/Pallor (pale/grey tinge to skin) 728"Hair/skin/Sore (superficial wound/lesion) 525"6838H779 4 Feces/urine/Urine stain 133", 147-154, 168-560, 580-588Eyes/Left eye red discharge 364"-5256838H780 4 Feces/urine/Urine stain 658"-665Eyes/Left eye red discharge 385"-488, 588-630, 665, 686Eyes/Right eye red discharge 488", 553-5606838H781 4 Eyes/Left eye red discharge 567"-5806838H782 4 Feces/urine/Urine stain 168"-203, 252-364, 392-473, 488, 502-560588, 609-630Eyes/Left eye red discharge 161", 543-553, 728Tissue mass/Body ventral 714"-7286838H783 4 Feces/urine/Urine stain 273"-473, 488-623, 637-686Eyes/Left eye red discharge 336"-343, 400, 420-427, 488, 518-573, 630651-672, 686-707Eyes/Right eye red discharge 336"-343, 406, 467-473, 488, 567, 637Hair/skin/Jaundiced (yellow tinge to skin) 700"Hair/skin/Pallor (pale/grey tinge to skin) 707"6838H784 4 Feces/urine/Urine stain 322"-336Eyes/Left eye red discharge 442", 481Eyes/Right eye red discharge 161"Toes/Injured toes 105"-1126838H785 4 Eyes/Left eye red discharge 218"-473Eyes/Right eye red discharge 231", 252-336, 350-357, 371-392, 413-473Hair/skin/Jaundiced (yellow tinge to skin) 473"6838H786 4 Feces/urine/Red urine 488"-495, 588Feces/urine/Urine stain 119", 133, 147-364, 400-481, 502-609Feces/urine/Red Vaginal Discharge 602"Eyes/Left eye red discharge 413", 473-543, 5606838H787 4 Feces/urine/Urine stain 273"-350, 442, 532Eyes/Left eye red discharge 442"-460Eyes/Right eye red discharge 442"6838H788 4 Feces/urine/Urine stain 357"Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 20Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6838H788 4 Eyes/Left eye red discharge 196"-211, 252-273, 350, 467-495, 518-658672-728Eyes/Right eye red discharge 539"-6096838H789 4 Appendages/injured/Tail injured 467"-488Feces/urine/Urine stain 231"-266Eyes/Left eye red discharge 133", 350-357, 371-488, 532, 560, 580-609644-679Eyes/Right eye red discharge 350"-357, 413-420, 658-7286838H790 4 Appendages/injured/Left-rear-foot-injured 238"-266Feces/urine/Urine stain 147"-357, 371-560, 623Eyes/Right eye red discharge 413"-420, 467-560, 580-602, 630-637, 6586838H791 4 Appendages/injured/Tail injured 29"-119, 147-154, 218-224, 336-481Appendages/injured/Tail ring lesions 442"-460Eyes/Right eye red discharge 400"Toes/Injured toes 413"-4276838H792 4 Eyes/Right eye red discharge 385"-392Hair/skin/Jaundiced (yellow tinge to skin) 714"-728Toes/Injured toes 98"6838H793 4 Appendages/injured/Tail injured 371"-442Feces/urine/Urine stain 442", 567Eyes/Left eye red discharge 161", 385-442, 4676838H794 4 Feces/urine/Urine stain 679"-686Eyes/Left eye red discharge 392", 406, 420-442Eyes/Right eye red discharge 84", 518, 573-616Eyes/Left eye closed 385"Hair/skin/Alopecia 105"-1126838H795 4 Appendages/injured/Left-rear-foot-injured 400"Feces/urine/Urine stain 126", 147-154, 224-329, 350-357, 442-460693-700Eyes/Left eye red discharge 161", 442Eyes/Right eye red discharge 616"6838H796 4 Appendages/injured/Tail injured 481"-495Feces/urine/Urine stain 119"-126, 147-161, 224-357, 427-495, 518-637658, 679-714Feces/urine/Red Vaginal Discharge 448"Eyes/Right eye red discharge 140", 329, 364, 392-481, 495, 518-637Note: ! = Pretest phase; " = Dosing phaseLovelace Respiratory Individual Clinical Observations Table Printed: 14-Jun-04Research Institute Study number: FY01013F Page: 21Dates 29-May-01 to 27-May-03Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group Observation Days observed6838H796 4 Eyes/Right eye red discharge 658-7286838H797 4 Eyes/Left eye red discharge 273", 336-350, 406, 567-573Eyes/Right eye red discharge 42"-112, 140, 273-280, 385-560, 573-6026838H798 4 Appendages/injured/Tail injured 413"-460Feces/urine/Urine stain 91"-728Eyes/Right eye red discharge 385"-392, 413-434, 573-630Eyes/Corneal opacity left eye 413"-728Hair/skin/Skin growth (small) 686"-728Tissue mass/Genital area 721"-7286838H799 4 Ears/nose/Injured nose 147"-154, 385-3926838H800 4 Eyes/Left eye red discharge 686"Note: ! = Pretest phase; " = Dosing phase

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

K-1 APPENDIX K

BODY AND ORGAN WEIGHTS AT NECROPSY

K-1 Absolute Organ Weights, Male and Female, Final Sacrifice

K-2 Percent Organ to Body Wei ght, Male and Female, Final Sacrifice

K-3 Percent Organ to Brain Wei ght, Male and Female, Final Sacrifice

K-4 Absolute Organ Weights, Male and Female, Euthanized Rats

K-5 Percent Organ to Body Weight , Male and Female, Euthanized Rats

K-6 Percent Organ to Brain Wei ght, Male and Female, Euthanized Rats

K-7 Organ Weights for Animals that Died

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-1 Absolute Organ Weights, Male and Female, Final SacrificeLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys LungsM a l e A n i m a l s6831E407/M 1/1 403.2 0.077 2.185 0.765 1.389 3.157 15.081 1.8636831E413/M 1/1 379.5 0.078 2.123 0.284 1.165 2.588 14.429 1.8276831E415/M 1/1 395.5 0.064 2.085 0.518 1.102 2.941 22.487 2.2206831E418/M 1/1 398.8 0.075 2.168 0.628 1.268 3.057 14.154 1.8636831E422/M 1/1 384.3 0.054 2.075 0.731 1.122 2.873 13.236 1.7226831E435/M 1/1 355.1 0.077 2.039 0.777 1.291 3.273 16.985 1.7356831E436/M 1/1 393.1 0.069 2.054 0.342 1.153 2.916 15.136 1.6396831E437/M 1/1 398.3 0.075 2.130 0.978 1.223 2.718 12.255 1.7356831E440/M 1/1 396.8 0.440 2.107 0.376 1.231 2.870 14.131 1.8096831E442/M 1/1 383.6 0.096 2.089 0.494 1.082 3.339 30.447 2.5056831E443/M 1/1 404.7 0.069 2.080 0.457 1.162 2.796 13.070 1.6686831E446/M 1/1 352.3 0.059 2.038 0.472 1.234 2.681 15.988 2.4466831E448/M 1/1 396.0 0.060 2.042 0.495 1.020 2.638 12.794 1.7716831E449/M 1/1 418.7 0.080 2.180 0.370 1.321 2.836 14.940 2.040M e a n: 390.0 0.098 2.100 0.549 1.197 2.906 16.081 1.917Standard deviation: 18.2 0.099 0.051 0.200 0.101 0.230 4.838 0.281Number of observ. : (14) (14) (14) (14) (14) (14) (14) (14)6833F502/M 2/1 384.3 0.084 2.125 0.359 1.345 2.804 13.466 1.8086833F505/M 2/1 400.1 0.060 1.999 0.391 1.227 2.953 15.398 1.9226833F508/M 2/1 387.3 0.071 2.070 0.620 1.257 2.929 13.579 2.1626833F511/M 2/1 411.5 0.068 2.142 0.396 1.324 2.909 14.293 2.0056833F513/M 2/1 280.5 0.072 2.021 0.350 1.034 2.558 11.897 2.9926833F516/M 2/1 377.9 0.073 2.049 0.425 1.083 2.595 17.607 2.5536833F519/M 2/1 416.2 0.066 2.094 0.435 1.362 3.182 13.189 1.9696833F521/M 2/1 335.6 0.082 2.052 0.385 1.254 2.633 19.093 3.8706833F523/M 2/1 408.3 0.052 2.069 0.477 1.087 2.757 12.645 2.1826833F525/M 2/1 393.6 1.742 2.097 0.369 1.199 3.369 17.624 2.4956833F526/M 2/1 362.5 0.086 2.041 0.519 1.141 3.960 17.942 2.5036833F535/M 2/1 409.1 0.071 2.069 0.383 1.197 3.133 13.062 2.2706833F536/M 2/1 340.7 0.071 2.090 0.561 1.141 2.635 11.522 1.6506833F542/M 2/1 365.4 0.067 2.028 0.478 1.151 2.682 12.958 1.8136833F547/M 2/1 366.3 0.069 1.993 0.483 1.242 2.892 13.078 1.7416833F550/M 2/1 368.4 0.066 2.059 0.337 1.084 4.855 18.891 1.853M e a n: 375.5 0.175 2.062 0.436 1.196 3.053 14.765 2.237Standard deviation: 35.2 0.418 0.042 0.081 0.099 0.598 2.589 0.566Number of observ. : (16) (16) (16) (16) (16) (16) (16) (16)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6835G601/M 3/1 382.8 0.050 2.077 0.397 0.992 2.717 12.481 1.8596835G602/M 3/1 368.3 0.112 2.100 0.353 1.200 3.096 14.508 2.1006835G603/M 3/1 375.0 0.062 2.028 0.331 1.051 2.857 13.108 1.8786835G605/M 3/1 354.7 0.096 2.026 0.362 1.225 3.018 14.370 2.8586835G607/M 3/1 372.0 0.068 2.059 0.377 1.136 3.061 14.932 1.6896835G609/M 3/1 394.9 0.071 2.173 0.399 1.253 3.072 14.141 1.9596835G610/M 3/1 368.2 0.064 2.137 0.325 1.123 2.714 12.084 2.0106835G613/M 3/1 374.6 0.063 2.070 0.365 1.187 2.648 12.740 1.9096835G614/M 3/1 389.1 0.072 2.090 0.591 1.456 3.088 14.386 1.9746835G615/M 3/1 349.7 0.073 2.090 0.392 1.116 3.219 16.784 3.2136835G617/M 3/1 359.5 0.088 1.989 0.407 1.148 3.122 13.169 1.7056835G621/M 3/1 350.0 0.094 2.053 0.389 1.053 2.609 13.974 1.7396835G628/M 3/1 378.2 0.067 2.043 0.412 1.302 2.799 13.500 1.9656835G630/M 3/1 366.6 0.077 2.074 0.301 1.095 2.824 13.706 2.0136835G634/M 3/1 396.2 0.069 2.124 0.543 1.323 3.401 16.109 2.0226835G638/M 3/1 392.6 0.068 2.135 0.498 1.535 3.154 16.469 2.4956835G639/M 3/1 383.2 0.080 2.015 0.404 1.290 2.880 14.085 2.6296835G647/M 3/1 401.1 0.070 2.099 0.474 1.209 2.818 15.258 1.8476835G648/M 3/1 268.6 0.076 2.001 0.574 1.006 3.395 13.383 2.4276835G649/M 3/1 349.5 0.072 2.066 0.421 1.132 2.707 14.052 1.773M e a n: 368.7 0.075 2.072 0.416% 1.192 2.960 14.162 2.103Standard deviation: 28.5 0.014 0.048 0.081 0.140 0.236 1.268 0.411Number of observ. : (20) (20) (20) (20) (20) (20) (20) (20)6837H702/M 4/1 382.2 0.073 2.102 0.428 1.160 3.075 14.279 1.9766837H704/M 4/1 397.1 0.073 2.076 0.541 1.206 2.818 14.026 1.7046837H705/M 4/1 399.2 0.067 2.167 0.453 1.223 3.699 18.642 3.6696837H706/M 4/1 356.7 0.070 2.117 0.571 1.217 3.199 14.762 1.9366837H708/M 4/1 346.6 0.064 1.966 0.312 1.054 3.024 22.278 2.3646837H714/M 4/1 335.0 0.067 2.032 0.452 0.974 2.967 14.172 1.6676837H717/M 4/1 371.8 0.076 1.974 0.398 1.177 3.435 12.522 1.9056837H722/M 4/1 335.5 0.070 2.074 0.392 1.006 2.950 21.799 3.2916837H724/M 4/1 351.4 0.070 2.132 0.383 1.271 3.993 16.022 2.7106837H725/M 4/1 271.3 0.091 1.988 0.443 1.040 3.077 17.512 2.7256837H726/M 4/1 376.6 0.081 2.055 0.351 1.129 2.942 15.164 1.8596837H728/M 4/1 348.4 0.060 1.978 0.301 1.068 2.578 14.001 1.6646837H729/M 4/1 355.9 0.071 2.078 0.342 1.151 2.620 13.647 1.9226837H735/M 4/1 357.6 0.076 2.061 0.527 1.103 2.833 13.693 1.7746837H736/M 4/1 371.5 0.076 2.024 0.605 1.244 3.245 15.902 1.946*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6837H739/M 4/1 371.6 0.056 2.041 0.535 1.164 2.937 13.007 1.7886837H741/M 4/1 361.3 0.079 2.000 0.380 1.113 2.744 14.641 1.9086837H747/M 4/1 365.8 0.096 2.119 0.433 1.155 3.273 16.088 1.7266837H749/M 4/1 328.0 0.055 2.050 0.305 1.092 2.622 11.872 1.889M e a n: 357.0+ 0.072 2.054* 0.429 1.134 3.054 15.475 2.128Standard deviation: 28.4 0.010 0.058 0.092 0.082 0.365 2.832 0.570Number of observ. : (19) (19) (19) (19) (19) (19) (19) (19)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 4Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) SpleenM a l e A n i m a l s6831E407/M 1/1 403.2 1.198 3.9056831E413/M 1/1 379.5 1.802 5.7076831E415/M 1/1 395.5 4.540 14.3076831E418/M 1/1 398.8 2.320 4.8686831E422/M 1/1 384.3 2.251 4.1346831E435/M 1/1 355.1 1.624 2.7606831E436/M 1/1 393.1 1.667 4.8186831E437/M 1/1 398.3 1.309 2.9236831E440/M 1/1 396.8 1.076 2.0716831E442/M 1/1 383.6 7.643 5.2916831E443/M 1/1 404.7 1.661 4.8816831E446/M 1/1 352.3 4.662 2.6416831E448/M 1/1 396.0 2.389 5.3456831E449/M 1/1 418.7 1.810 8.908M e a n: 390.0 2.568 5.183Standard deviation: 18.2 1.831 3.133Number of observ. : (14) (14) (14)6833F502/M 2/1 384.3 1.854 6.8286833F505/M 2/1 400.1 1.839 8.8866833F508/M 2/1 387.3 1.783 5.9706833F511/M 2/1 411.5 1.719 7.0546833F513/M 2/1 280.5 5.401 1.5756833F516/M 2/1 377.9 6.050 6.5916833F519/M 2/1 416.2 1.982 5.1736833F521/M 2/1 335.6 20.968 3.2126833F523/M 2/1 408.3 3.037 5.2496833F525/M 2/1 393.6 3.886 4.3716833F526/M 2/1 362.5 4.917 4.2006833F535/M 2/1 409.1 4.343 5.3186833F536/M 2/1 340.7 0.956 4.3026833F542/M 2/1 365.4 1.865 4.6456833F547/M 2/1 366.3 1.208 3.8216833F550/M 2/1 368.4 2.079 8.859M e a n: 375.5 3.993 5.378Standard deviation: 35.2 4.794 1.948Number of observ. : (16) (16) (16)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 5Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6835G601/M 3/1 382.8 1.599 10.1876835G602/M 3/1 368.3 2.412 9.1806835G603/M 3/1 375.0 1.846 2.8166835G605/M 3/1 354.7 9.039 3.0636835G607/M 3/1 372.0 1.270 5.6166835G609/M 3/1 394.9 2.114 9.0096835G610/M 3/1 368.2 2.150 9.4056835G613/M 3/1 374.6 1.613 7.6766835G614/M 3/1 389.1 1.543 7.2716835G615/M 3/1 349.7 10.668 3.6316835G617/M 3/1 359.5 2.434 2.1836835G621/M 3/1 350.0 1.832 7.6216835G628/M 3/1 378.2 1.297 6.5596835G630/M 3/1 366.6 2.737 4.1226835G634/M 3/1 396.2 2.057 4.4176835G638/M 3/1 392.6 4.180 6.3986835G639/M 3/1 383.2 2.829 5.8726835G647/M 3/1 401.1 1.397 7.1266835G648/M 3/1 268.6 3.024 3.7716835G649/M 3/1 349.5 3.861 3.995M e a n: 368.7 2.995 5.996Standard deviation: 28.5 2.489 2.419Number of observ. : (20) (20) (20)6837H702/M 4/1 382.2 2.074 9.0606837H704/M 4/1 397.1 2.239 4.0116837H705/M 4/1 399.2 8.413 4.4976837H706/M 4/1 356.7 1.411 2.6806837H708/M 4/1 346.6 13.658 8.0156837H714/M 4/1 335.0 0.914 8.2646837H717/M 4/1 371.8 1.868 6.3656837H722/M 4/1 335.5 19.599 1.9476837H724/M 4/1 351.4 2.348 4.7616837H725/M 4/1 271.3 20.175 2.0316837H726/M 4/1 376.6 1.523 10.8306837H728/M 4/1 348.4 1.366 9.1146837H729/M 4/1 355.9 3.987 6.6456837H735/M 4/1 357.6 1.689 7.0526837H736/M 4/1 371.5 0.756 7.363*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 6Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6837H739/M 4/1 371.6 1.405 6.7496837H741/M 4/1 361.3 3.900 7.6236837H747/M 4/1 365.8 1.788 6.6096837H749/M 4/1 328.0 1.634 6.537M e a n: 357.0+ 4.776 6.324Standard deviation: 28.4 6.159 2.448Number of observ. : (19) (19) (19)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver OvariesF e m a l e A n i m a l s6832E451/F 1/1 290.9 0.069 1.874 1.031 1.932 10.320 1.452 0.0926832E452/F 1/1 265.5 0.076 1.896 0.910 1.915 8.751 1.276 0.1306832E456/F 1/1 272.8 0.069 1.821 0.929 1.821 9.353 1.367 0.0876832E458/F 1/1 257.4 0.054 1.858 0.873 1.732 8.619 1.206 0.1106832E460/F 1/1 277.6 0.066 1.883 0.933 1.840 9.696 1.354 0.0946832E461/F 1/1 300.6 0.076 1.955 1.135 2.027 10.562 1.328 0.0976832E462/F 1/1 304.3 0.070 1.915 0.853 2.087 12.338 1.907 0.1046832E463/F 1/1 277.1 0.072 1.952 0.933 1.901 10.556 1.873 0.0936832E464/F 1/1 217.4 0.061 1.833 0.938 1.809 6.630 2.025 0.0706832E467/F 1/1 301.9 0.068 1.894 0.903 1.898 9.325 1.428 0.1156832E472/F 1/1 165.8 0.075 1.746 0.881 3.437 6.561 1.250 0.0876832E475/F 1/1 260.0 0.059 1.948 0.813 1.794 7.974 1.322 0.1136832E478/F 1/1 263.4 0.056 1.915 0.807 1.885 8.604 1.292 0.1016832E483/F 1/1 271.8 0.063 1.849 0.820 1.725 8.851 1.251 0.1216832E486/F 1/1 265.4 0.058 1.858 0.852 1.865 8.641 1.325 0.0986832E489/F 1/1 263.9 0.068 1.944 0.858 1.850 8.490 1.214 0.0946832E490/F 1/1 223.6 0.052 1.898 0.925 1.811 11.856 2.951 0.0716832E493/F 1/1 230.8 0.064 1.946 0.991 2.005 10.077 2.948 0.0356832E495/F 1/1 301.6 0.083 1.980 1.061 2.082 9.832 1.501 0.5496832E497/F 1/1 269.1 0.063 1.811 0.909 1.740 9.759 1.458 0.0936832E498/F 1/1 254.1 0.063 1.988 0.874 1.782 7.261 1.227 0.1066832E500/F 1/1 303.6 0.063 1.900 1.044 1.993 9.295 1.413 0.105M e a n: 265.4 0.066 1.894 0.922 1.951 9.243 1.562 0.117Standard deviation: 33.3 0.008 0.060 0.085 0.348 1.452 0.503 0.099Number of observ. : (22) (22) (22) (22) (22) (22) (22) (22)6834F551/F 2/1 280.6 0.049 1.874 0.810 1.973 10.661 1.421 0.0996834F553/F 2/1 278.5 0.069 1.940 0.890 1.982 8.888 1.346 0.1046834F554/F 2/1 281.2 0.060 1.853 0.880 1.918 9.170 1.439 0.1066834F555/F 2/1 297.4 0.071 1.894 0.914 1.943 9.952 1.431 0.1486834F557/F 2/1 264.6 0.056 1.905 0.966 1.940 8.148 1.307 0.1366834F558/F 2/1 263.2 0.066 1.833 0.923 1.944 10.176 1.225 0.1076834F559/F 2/1 245.3 0.069 1.865 0.911 1.805 7.877 1.243 0.1076834F560/F 2/1 283.1 0.060 1.937 0.894 2.025 8.558 1.336 0.0966834F561/F 2/1 277.0 0.066 1.814 0.913 2.000 9.070 1.342 0.1156834F563/F 2/1 288.7 0.074 1.864 1.043 2.109 10.619 1.259 0.1336834F564/F 2/1 221.5 0.059 1.783 0.781 1.945 7.715 1.193 0.1176834F569/F 2/1 312.4 0.081 1.912 0.974 2.028 11.000 1.315 0.116*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6834F570/F 2/1 268.6 0.060 1.924 0.783 1.834 9.343 1.281 0.1226834F573/F 2/1 258.5 0.060 1.819 0.850 1.795 8.141 1.244 0.0696834F574/F 2/1 265.2 0.062 1.817 0.847 1.869 8.390 1.299 0.1116834F575/F 2/1 309.2 0.067 1.913 0.878 2.059 9.295 1.350 0.1076834F579/F 2/1 299.6 0.071 1.912 1.013 2.202 12.317 1.680 0.1126834F580/F 2/1 296.3 0.064 1.893 0.899 1.964 8.956 1.214 0.1126834F583/F 2/1 276.2 0.056 1.917 1.003 1.878 8.571 1.453 0.1426834F584/F 2/1 258.5 0.049 1.885 0.841 1.159 23.096 1.549 0.1846834F585/F 2/1 234.6 0.057 1.891 0.964 1.788 8.638 1.851 0.0976834F586/F 2/1 286.9 0.073 1.858 0.821 1.849 8.973 1.326 0.1036834F587/F 2/1 282.6 0.062 1.921 0.966 1.951 8.796 1.319 0.1186834F588/F 2/1 267.6 0.048 1.701 0.980 1.767 8.660 1.360 0.1266834F591/F 2/1 256.1 0.062 1.907 0.897 1.922 8.576 1.357 0.1096834F592/F 2/1 274.7 0.057 1.869 0.900 1.867 8.069 1.367 0.1086834F596/F 2/1 262.2 0.065 1.862 0.830 1.889 11.183 1.271 0.4346834F597/F 2/1 280.2 0.066 1.886 0.843 1.842 8.743 1.359 0.1336834F598/F 2/1 252.7 0.057 1.856 0.809 1.908 8.509 1.233 0.0886834F600/F 2/1 280.6 0.063 1.946 0.788 1.854 9.964 1.603 0.132M e a n: 273.5 0.063 1.875 0.894 1.900 9.668 1.366 0.126Standard deviation: 20.4 0.008 0.052 0.072 0.171 2.759 0.145 0.062Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30)6836G651/F 3/1 262.8 0.065 1.900 0.892 2.080 9.121 1.315 0.0806836G652/F 3/1 277.7 0.067 1.919 0.827 1.936 9.920 1.391 0.1256836G654/F 3/1 238.3 0.065 1.831 0.855 2.056 9.973 1.192 0.0616836G655/F 3/1 259.9 0.074 1.883 0.847 2.097 10.385 1.398 0.0766836G656/F 3/1 277.7 0.063 1.858 0.849 1.952 8.622 1.255 0.0836836G657/F 3/1 263.5 0.059 1.839 0.911 1.931 8.523 1.247 0.1126836G658/F 3/1 274.9 0.061 1.888 0.919 1.977 9.044 1.216 0.0886836G660/F 3/1 295.8 0.086 1.878 0.965 2.105 20.228 1.736 0.0946836G661/F 3/1 242.0 0.044 1.872 1.025 1.846 8.977 1.432 0.4216836G662/F 3/1 234.8 0.066 1.923 0.838 1.753 7.870 1.206 0.0946836G663/F 3/1 258.5 0.051 1.855 0.849 1.899 9.525 1.310 0.0986836G666/F 3/1 226.0 0.054 1.914 0.813 1.694 7.733 1.165 0.0836836G667/F 3/1 271.4 0.066 1.811 0.806 1.744 8.448 1.278 0.1106836G668/F 3/1 212.8 0.172 1.852 0.831 1.615 6.904 1.090 0.1276836G669/F 3/1 256.3 0.057 1.805 1.022 1.998 10.512 1.439 0.1036836G670/F 3/1 267.4 0.058 1.849 0.856 2.104 9.011 1.235 0.0916836G672/F 3/1 283.2 0.066 1.850 0.944 1.788 8.869 1.186 0.106*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6836G673/F 3/1 242.1 0.051 1.848 0.895 1.664 7.308 1.321 0.1136836G674/F 3/1 287.6 0.064 1.903 0.880 2.030 9.768 1.300 0.0926836G675/F 3/1 257.6 0.052 1.890 0.993 1.987 11.252 1.996 0.1226836G677/F 3/1 268.4 0.062 1.938 0.794 1.950 8.928 1.268 0.1036836G681/F 3/1 272.3 0.063 1.927 1.099 1.960 8.460 1.261 0.1176836G684/F 3/1 287.6 0.065 1.978 0.872 1.919 9.125 1.270 0.1286836G686/F 3/1 231.0 0.075 1.925 0.986 2.364 10.609 2.675 0.1026836G689/F 3/1 241.1 0.060 1.857 0.847 1.849 8.139 1.230 0.0976836G690/F 3/1 236.8 0.056 1.823 0.836 1.849 8.875 1.192 0.1106836G692/F 3/1 244.1 0.055 1.813 0.820 1.706 8.416 1.266 0.0756836G694/F 3/1 255.8 0.057 1.842 0.838 1.806 9.304 1.460 0.0706836G697/F 3/1 252.0 0.068 1.841 0.842 2.010 8.485 1.339 0.1356836G700/F 3/1 209.6 0.065 1.828 0.730 1.580 6.587 1.126 1.002M e a n: 256.3 0.066 1.871 0.883 1.908 9.297 1.360 0.141Standard deviation: 21.9 0.022 0.043 0.081 0.171 2.322 0.305 0.174Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30)6838H754/F 4/1 267.9 0.055 1.865 1.086 1.945 9.362 1.316 0.1246838H755/F 4/1 229.6 0.049 1.786 0.775 2.366 7.711 1.108 0.0966838H756/F 4/1 250.7 0.057 1.803 0.905 1.809 8.085 1.136 0.0896838H758/F 4/1 247.8 0.062 1.861 0.904 2.164 8.813 1.297 0.1246838H759/F 4/1 230.5 0.074 1.869 0.832 1.954 8.936 1.413 0.1746838H760/F 4/1 245.1 0.060 1.885 0.909 1.892 8.921 1.333 0.1046838H761/F 4/1 244.4 0.070 1.888 0.881 1.920 9.530 1.360 0.1186838H762/F 4/1 237.7 0.057 1.829 0.894 1.920 8.646 1.304 0.0786838H765/F 4/1 259.5 0.050 1.894 1.019 2.000 9.208 1.526 0.0866838H767/F 4/1 251.5 0.059 1.893 0.794 1.895 8.634 1.403 0.0906838H768/F 4/1 242.4 0.062 1.865 0.930 1.901 10.119 1.316 0.0916838H769/F 4/1 232.5 0.050 1.885 0.795 1.745 7.909 1.191 0.0986838H771/F 4/1 217.7 0.052 1.891 0.772 1.671 7.602 1.178 0.1116838H773/F 4/1 256.8 0.060 1.835 0.782 1.892 9.364 1.235 0.1026838H776/F 4/1 261.4 0.076 1.921 0.975 2.090 9.261 1.277 0.0886838H777/F 4/1 242.5 0.058 1.704 0.890 1.853 8.051 1.159 0.1076838H778/F 4/1 218.1 0.054 1.811 1.009 1.836 8.259 2.364 0.1086838H779/F 4/1 265.1 0.060 1.836 0.896 2.017 8.468 1.281 0.1036838H780/F 4/1 236.3 0.060 1.880 0.897 1.899 12.439 1.536 0.1566838H781/F 4/1 244.3 0.050 1.878 0.934 1.891 8.720 1.280 0.1106838H782/F 4/1 240.3 0.069 1.810 0.933 1.842 8.641 1.146 0.1156838H784/F 4/1 202.7 0.061 1.935 0.834 1.689 5.137 1.264 0.090*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 4Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6838H787/F 4/1 266.0 0.072 1.867 0.802 2.198 11.416 1.727 0.1166838H788/F 4/1 244.1 0.053 1.782 0.766 1.859 9.184 1.169 0.1076838H789/F 4/1 247.7 0.056 1.928 0.957 1.997 8.518 1.366 0.1486838H790/F 4/1 238.2 0.026 1.861 1.049 1.867 8.661 1.321 0.1066838H791/F 4/1 265.6 0.057 1.893 0.987 2.142 11.866 2.178 0.0756838H793/F 4/1 231.8 0.051 1.837 0.853 1.956 11.979 1.673 0.0906838H794/F 4/1 258.7 0.066 1.846 0.843 1.965 8.605 1.213 0.1116838H796/F 4/1 240.6 0.055 1.856 0.848 1.958 8.097 1.253 0.0996838H798/F 4/1 256.0 0.057 1.878 0.808 1.920 9.152 1.196 0.0986838H799/F 4/1 215.8 0.059 1.862 0.767 1.604 7.680 1.193 0.0756838H800/F 4/1 247.9 0.062 1.832 0.837 2.140 11.218 1.616 0.094M e a n: 243.6$ 0.058$ 1.857* 0.884 1.933 9.036 1.374 0.105Standard deviation: 15.7 0.009 0.046 0.086 0.155 1.452 0.278 0.022Number of observ. : (33) (33) (33) (33) (33) (33) (33) (33)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 5Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) SpleenF e m a l e A n i m a l s6832E451/F 1/1 290.9 0.896 0.5926832E452/F 1/1 265.5 0.986 0.6236832E456/F 1/1 272.8 2.478 0.9836832E458/F 1/1 257.4 0.592 0.6466832E460/F 1/1 277.6 1.318 3.9976832E461/F 1/1 300.6 0.764 0.7286832E462/F 1/1 304.3 1.789 0.7546832E463/F 1/1 277.1 4.344 0.7326832E464/F 1/1 217.4 4.264 0.6096832E467/F 1/1 301.9 0.744 0.5736832E472/F 1/1 165.8 0.552 0.7366832E475/F 1/1 260.0 0.600 0.5096832E478/F 1/1 263.4 0.670 0.8096832E483/F 1/1 271.8 0.601 0.6076832E486/F 1/1 265.4 0.721 0.5546832E489/F 1/1 263.9 0.536 0.8116832E490/F 1/1 223.6 4.246 0.5956832E493/F 1/1 230.8 15.518 0.5176832E495/F 1/1 301.6 0.665 0.9756832E497/F 1/1 269.1 1.997 0.8426832E498/F 1/1 254.1 0.500 0.8236832E500/F 1/1 303.6 1.635 0.527M e a n: 265.4 2.110 0.843Standard deviation: 33.3 3.251 0.718Number of observ. : (22) (22) (22)6834F551/F 2/1 280.6 1.344 0.6786834F553/F 2/1 278.5 0.899 0.5766834F554/F 2/1 281.2 0.517 0.5366834F555/F 2/1 297.4 0.861 0.6806834F557/F 2/1 264.6 0.592 1.3066834F558/F 2/1 263.2 0.795 0.7266834F559/F 2/1 245.3 0.807 0.5916834F560/F 2/1 283.1 0.634 0.6176834F561/F 2/1 277.0 0.815 0.9246834F563/F 2/1 288.7 0.649 1.3106834F564/F 2/1 221.5 0.572 0.4876834F569/F 2/1 312.4 0.771 0.801*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 6Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6834F570/F 2/1 268.6 2.156 0.7096834F573/F 2/1 258.5 0.626 0.7746834F574/F 2/1 265.2 0.617 0.9856834F575/F 2/1 309.2 1.030 1.4606834F579/F 2/1 299.6 4.593 0.6356834F580/F 2/1 296.3 1.260 0.7336834F583/F 2/1 276.2 0.609 0.8806834F584/F 2/1 258.5 2.657 0.8856834F585/F 2/1 234.6 1.469 0.7706834F586/F 2/1 286.9 0.783 0.5956834F587/F 2/1 282.6 0.854 0.6236834F588/F 2/1 267.6 0.697 0.7456834F591/F 2/1 256.1 1.207 0.6676834F592/F 2/1 274.7 0.721 0.5736834F596/F 2/1 262.2 0.729 0.7466834F597/F 2/1 280.2 0.631 0.6676834F598/F 2/1 252.7 0.522 0.8396834F600/F 2/1 280.6 2.074 0.620M e a n: 273.5 1.083 0.771Standard deviation: 20.4 0.842 0.232Number of observ. : (30) (30) (30)6836G651/F 3/1 262.8 0.645 1.1396836G652/F 3/1 277.7 1.535 0.6156836G654/F 3/1 238.3 0.848 0.5836836G655/F 3/1 259.9 1.405 0.5856836G656/F 3/1 277.7 0.718 0.8586836G657/F 3/1 263.5 0.615 0.6206836G658/F 3/1 274.9 0.963 0.5346836G660/F 3/1 295.8 2.544 0.7346836G661/F 3/1 242.0 0.955 3.0956836G662/F 3/1 234.8 0.615 0.7316836G663/F 3/1 258.5 0.702 0.6996836G666/F 3/1 226.0 0.393 0.6776836G667/F 3/1 271.4 0.638 1.2996836G668/F 3/1 212.8 0.338 1.0956836G669/F 3/1 256.3 0.670 1.3726836G670/F 3/1 267.4 0.689 0.8296836G672/F 3/1 283.2 1.147 0.569*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 7Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6836G673/F 3/1 242.1 0.530 1.1486836G674/F 3/1 287.6 0.697 0.8816836G675/F 3/1 257.6 3.393 0.7076836G677/F 3/1 268.4 0.758 0.6756836G681/F 3/1 272.3 0.589 0.9116836G684/F 3/1 287.6 0.830 0.6216836G686/F 3/1 231.0 2.587 0.7656836G689/F 3/1 241.1 0.828 0.9136836G690/F 3/1 236.8 0.635 1.0786836G692/F 3/1 244.1 0.508 0.5436836G694/F 3/1 255.8 1.738 0.7306836G697/F 3/1 252.0 0.641 0.9496836G700/F 3/1 209.6 0.463 3.191M e a n: 256.3 0.987 0.972Standard deviation: 21.9 0.714 0.632Number of observ. : (30) (30) (30)6838H754/F 4/1 267.9 0.578 0.6746838H755/F 4/1 229.6 0.727 0.6596838H756/F 4/1 250.7 0.686 0.5856838H758/F 4/1 247.8 0.760 0.8556838H759/F 4/1 230.5 1.062 0.9606838H760/F 4/1 245.1 0.667 0.7286838H761/F 4/1 244.4 2.194 0.7856838H762/F 4/1 237.7 1.199 0.6946838H765/F 4/1 259.5 0.564 0.9706838H767/F 4/1 251.5 4.216 1.2206838H768/F 4/1 242.4 1.189 0.6486838H769/F 4/1 232.5 0.564 2.0096838H771/F 4/1 217.7 0.483 0.6636838H773/F 4/1 256.8 0.658 0.8526838H776/F 4/1 261.4 0.841 0.6936838H777/F 4/1 242.5 0.800 0.5566838H778/F 4/1 218.1 8.518 0.7066838H779/F 4/1 265.1 0.865 0.5636838H780/F 4/1 236.3 2.942 2.1216838H781/F 4/1 244.3 0.576 0.6796838H782/F 4/1 240.3 0.515 0.5946838H784/F 4/1 202.7 0.445 0.598*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 8Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6838H787/F 4/1 266.0 1.822 0.9066838H788/F 4/1 244.1 0.638 0.5996838H789/F 4/1 247.7 0.698 0.7066838H790/F 4/1 238.2 0.605 0.7386838H791/F 4/1 265.6 12.388 0.7166838H793/F 4/1 231.8 2.487 0.8516838H794/F 4/1 258.7 0.652 0.9466838H796/F 4/1 240.6 0.696 0.7006838H798/F 4/1 256.0 0.630 0.7186838H799/F 4/1 215.8 0.505 0.5226838H800/F 4/1 247.9 3.306 1.049M e a n: 243.6$ 1.681 0.826Standard deviation: 15.7 2.486 0.356Number of observ. : (33) (33) (33)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-2 Percent Organ to Body Wei ght, Male and Female, Final SacrificeLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys LungsM a l e A n i m a l s6831E407/M 1/1 403.2 0.019 0.542 0.190 0.344 0.783 3.740 0.4626831E413/M 1/1 379.5 0.021 0.559 0.075 0.307 0.682 3.802 0.4816831E415/M 1/1 395.5 0.016 0.527 0.131 0.279 0.744 5.685 0.5616831E418/M 1/1 398.8 0.019 0.544 0.157 0.318 0.767 3.549 0.4676831E422/M 1/1 384.3 0.014 0.540 0.190 0.292 0.748 3.444 0.4486831E435/M 1/1 355.1 0.022 0.574 0.219 0.364 0.922 4.784 0.4896831E436/M 1/1 393.1 0.018 0.522 0.087 0.293 0.742 3.850 0.4176831E437/M 1/1 398.3 0.019 0.535 0.246 0.307 0.682 3.077 0.4366831E440/M 1/1 396.8 0.111 0.531 0.095 0.310 0.723 3.561 0.4566831E442/M 1/1 383.6 0.025 0.545 0.129 0.282 0.871 7.938 0.6536831E443/M 1/1 404.7 0.017 0.514 0.113 0.287 0.691 3.229 0.4126831E446/M 1/1 352.3 0.017 0.578 0.134 0.350 0.761 4.538 0.6946831E448/M 1/1 396.0 0.015 0.516 0.125 0.258 0.666 3.231 0.4476831E449/M 1/1 418.7 0.019 0.521 0.088 0.316 0.677 3.568 0.487M e a n: 390.0 0.025 0.539 0.141 0.308 0.747 4.143 0.494Standard deviation: 18.2 0.025 0.020 0.052 0.030 0.074 1.302 0.085Number of observ. : (14) (14) (14) (14) (14) (14) (14) (14)6833F502/M 2/1 384.3 0.022 0.553 0.093 0.350 0.730 3.504 0.4706833F505/M 2/1 400.1 0.015 0.500 0.098 0.307 0.738 3.849 0.4806833F508/M 2/1 387.3 0.018 0.535 0.160 0.325 0.756 3.506 0.5586833F511/M 2/1 411.5 0.017 0.521 0.096 0.322 0.707 3.474 0.4876833F513/M 2/1 280.5 0.026 0.720 0.125 0.369 0.912 4.241 1.0676833F516/M 2/1 377.9 0.019 0.542 0.112 0.287 0.687 4.659 0.6766833F519/M 2/1 416.2 0.016 0.503 0.105 0.327 0.764 3.169 0.4736833F521/M 2/1 335.6 0.024 0.611 0.115 0.374 0.784 5.688 1.1536833F523/M 2/1 408.3 0.013 0.507 0.117 0.266 0.675 3.097 0.5346833F525/M 2/1 393.6 0.443 0.533 0.094 0.305 0.856 4.477 0.6346833F526/M 2/1 362.5 0.024 0.563 0.143 0.315 1.092 4.949 0.6906833F535/M 2/1 409.1 0.017 0.506 0.094 0.293 0.766 3.193 0.5556833F536/M 2/1 340.7 0.021 0.613 0.165 0.335 0.773 3.382 0.4846833F542/M 2/1 365.4 0.018 0.555 0.131 0.315 0.734 3.547 0.4966833F547/M 2/1 366.3 0.019 0.544 0.132 0.339 0.790 3.570 0.4756833F550/M 2/1 368.4 0.018 0.559 0.091 0.294 1.318 5.128 0.503M e a n: 375.5 0.046 0.554 0.117 0.320 0.818 3.965 0.609Standard deviation: 35.2 0.106 0.056 0.024 0.029 0.167 0.793 0.209Number of observ. : (16) (16) (16) (16) (16) (16) (16) (16)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6835G601/M 3/1 382.8 0.013 0.543 0.104 0.259 0.710 3.260 0.4866835G602/M 3/1 368.3 0.030 0.570 0.096 0.326 0.841 3.939 0.5706835G603/M 3/1 375.0 0.017 0.541 0.088 0.280 0.762 3.495 0.5016835G605/M 3/1 354.7 0.027 0.571 0.102 0.345 0.851 4.052 0.8066835G607/M 3/1 372.0 0.018 0.553 0.101 0.305 0.823 4.014 0.4546835G609/M 3/1 394.9 0.018 0.550 0.101 0.317 0.778 3.581 0.4966835G610/M 3/1 368.2 0.017 0.580 0.088 0.305 0.737 3.282 0.5466835G613/M 3/1 374.6 0.017 0.553 0.097 0.317 0.707 3.401 0.5106835G614/M 3/1 389.1 0.019 0.537 0.152 0.374 0.794 3.697 0.5076835G615/M 3/1 349.7 0.021 0.598 0.112 0.319 0.920 4.799 0.9196835G617/M 3/1 359.5 0.024 0.553 0.113 0.319 0.869 3.663 0.4746835G621/M 3/1 350.0 0.027 0.587 0.111 0.301 0.745 3.992 0.4976835G628/M 3/1 378.2 0.018 0.540 0.109 0.344 0.740 3.569 0.5206835G630/M 3/1 366.6 0.021 0.566 0.082 0.299 0.770 3.738 0.5496835G634/M 3/1 396.2 0.017 0.536 0.137 0.334 0.858 4.065 0.5106835G638/M 3/1 392.6 0.017 0.544 0.127 0.391 0.803 4.195 0.6366835G639/M 3/1 383.2 0.021 0.526 0.105 0.337 0.752 3.675 0.6866835G647/M 3/1 401.1 0.017 0.523 0.118 0.301 0.703 3.804 0.4616835G648/M 3/1 268.6 0.028 0.745 0.214 0.375 1.264 4.983 0.9046835G649/M 3/1 349.5 0.021 0.591 0.120 0.324 0.775 4.021 0.507M e a n: 368.7 0.020 0.565% 0.114 0.324 0.810 3.861 0.577%Standard deviation: 28.5 0.005 0.047 0.029 0.032 0.122 0.443 0.142Number of observ. : (20) (20) (20) (20) (20) (20) (20) (20)6837H702/M 4/1 382.2 0.019 0.550 0.112 0.304 0.805 3.736 0.5176837H704/M 4/1 397.1 0.018 0.523 0.136 0.304 0.710 3.532 0.4296837H705/M 4/1 399.2 0.017 0.543 0.113 0.306 0.927 4.670 0.9196837H706/M 4/1 356.7 0.020 0.594 0.160 0.341 0.897 4.139 0.5436837H708/M 4/1 346.6 0.018 0.567 0.090 0.304 0.873 6.428 0.6826837H714/M 4/1 335.0 0.020 0.606 0.135 0.291 0.886 4.230 0.4986837H717/M 4/1 371.8 0.020 0.531 0.107 0.317 0.924 3.368 0.5126837H722/M 4/1 335.5 0.021 0.618 0.117 0.300 0.879 6.497 0.9816837H724/M 4/1 351.4 0.020 0.607 0.109 0.362 1.136 4.559 0.7716837H725/M 4/1 271.3 0.034 0.733 0.163 0.383 1.134 6.456 1.0056837H726/M 4/1 376.6 0.022 0.546 0.093 0.300 0.781 4.027 0.4946837H728/M 4/1 348.4 0.017 0.568 0.086 0.307 0.740 4.019 0.4786837H729/M 4/1 355.9 0.020 0.584 0.096 0.323 0.736 3.835 0.5406837H735/M 4/1 357.6 0.021 0.576 0.147 0.308 0.792 3.829 0.4966837H736/M 4/1 371.5 0.020 0.545 0.163 0.335 0.874 4.281 0.524*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6837H739/M 4/1 371.6 0.015 0.549 0.144 0.313 0.790 3.500 0.4816837H741/M 4/1 361.3 0.022 0.554 0.105 0.308 0.760 4.053 0.5286837H747/M 4/1 365.8 0.026 0.579 0.118 0.316 0.895 4.398 0.4726837H749/M 4/1 328.0 0.017 0.625 0.093 0.333 0.799 3.620 0.576M e a n: 357.0+ 0.020 0.579$ 0.120 0.319 0.860$ 4.378 0.602%Standard deviation: 28.4 0.004 0.048 0.026 0.023 0.118 0.991 0.181Number of observ. : (19) (19) (19) (19) (19) (19) (19) (19)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 4Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) SpleenM a l e A n i m a l s6831E407/M 1/1 403.2 0.297 0.9686831E413/M 1/1 379.5 0.475 1.5046831E415/M 1/1 395.5 1.148 3.6176831E418/M 1/1 398.8 0.582 1.2216831E422/M 1/1 384.3 0.586 1.0766831E435/M 1/1 355.1 0.457 0.7776831E436/M 1/1 393.1 0.424 1.2266831E437/M 1/1 398.3 0.329 0.7346831E440/M 1/1 396.8 0.271 0.5226831E442/M 1/1 383.6 1.993 1.3796831E443/M 1/1 404.7 0.410 1.2066831E446/M 1/1 352.3 1.323 0.7506831E448/M 1/1 396.0 0.603 1.3506831E449/M 1/1 418.7 0.432 2.128M e a n: 390.0 0.666 1.318Standard deviation: 18.2 0.489 0.774Number of observ. : (14) (14) (14)6833F502/M 2/1 384.3 0.482 1.7776833F505/M 2/1 400.1 0.460 2.2216833F508/M 2/1 387.3 0.460 1.5426833F511/M 2/1 411.5 0.418 1.7146833F513/M 2/1 280.5 1.925 0.5616833F516/M 2/1 377.9 1.601 1.7446833F519/M 2/1 416.2 0.476 1.2436833F521/M 2/1 335.6 6.247 0.9576833F523/M 2/1 408.3 0.744 1.2866833F525/M 2/1 393.6 0.987 1.1106833F526/M 2/1 362.5 1.356 1.1596833F535/M 2/1 409.1 1.062 1.3006833F536/M 2/1 340.7 0.281 1.2636833F542/M 2/1 365.4 0.510 1.2716833F547/M 2/1 366.3 0.330 1.0436833F550/M 2/1 368.4 0.564 2.405M e a n: 375.5 1.119 1.412Standard deviation: 35.2 1.451 0.470Number of observ. : (16) (16) (16)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 5Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6835G601/M 3/1 382.8 0.418 2.6616835G602/M 3/1 368.3 0.655 2.4936835G603/M 3/1 375.0 0.492 0.7516835G605/M 3/1 354.7 2.549 0.8646835G607/M 3/1 372.0 0.341 1.5106835G609/M 3/1 394.9 0.535 2.2816835G610/M 3/1 368.2 0.584 2.5546835G613/M 3/1 374.6 0.431 2.0496835G614/M 3/1 389.1 0.397 1.8696835G615/M 3/1 349.7 3.050 1.0386835G617/M 3/1 359.5 0.677 0.6076835G621/M 3/1 350.0 0.523 2.1776835G628/M 3/1 378.2 0.343 1.7346835G630/M 3/1 366.6 0.746 1.1246835G634/M 3/1 396.2 0.519 1.1156835G638/M 3/1 392.6 1.065 1.6306835G639/M 3/1 383.2 0.738 1.5326835G647/M 3/1 401.1 0.348 1.7776835G648/M 3/1 268.6 1.126 1.4046835G649/M 3/1 349.5 1.105 1.143M e a n: 368.7 0.832 1.616Standard deviation: 28.5 0.720 0.617Number of observ. : (20) (20) (20)6837H702/M 4/1 382.2 0.543 2.3716837H704/M 4/1 397.1 0.564 1.0106837H705/M 4/1 399.2 2.107 1.1276837H706/M 4/1 356.7 0.396 0.7516837H708/M 4/1 346.6 3.941 2.3136837H714/M 4/1 335.0 0.273 2.4676837H717/M 4/1 371.8 0.502 1.7126837H722/M 4/1 335.5 5.841 0.5806837H724/M 4/1 351.4 0.668 1.3556837H725/M 4/1 271.3 7.438 0.7496837H726/M 4/1 376.6 0.404 2.8766837H728/M 4/1 348.4 0.392 2.6166837H729/M 4/1 355.9 1.120 1.8676837H735/M 4/1 357.6 0.472 1.9726837H736/M 4/1 371.5 0.204 1.982*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 6Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6837H739/M 4/1 371.6 0.378 1.8166837H741/M 4/1 361.3 1.080 2.1106837H747/M 4/1 365.8 0.489 1.8076837H749/M 4/1 328.0 0.498 1.993M e a n: 357.0+ 1.437 1.762Standard deviation: 28.4 2.046 0.667Number of observ. : (19) (19) (19)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver OvariesF e m a l e A n i m a l s6832E451/F 1/1 290.9 0.024 0.644 0.354 0.664 3.548 0.499 0.0326832E452/F 1/1 265.5 0.029 0.714 0.343 0.721 3.296 0.481 0.0496832E456/F 1/1 272.8 0.025 0.667 0.341 0.667 3.428 0.501 0.0326832E458/F 1/1 257.4 0.021 0.722 0.339 0.673 3.348 0.469 0.0436832E460/F 1/1 277.6 0.024 0.678 0.336 0.663 3.492 0.488 0.0346832E461/F 1/1 300.6 0.025 0.650 0.378 0.674 3.513 0.442 0.0326832E462/F 1/1 304.3 0.023 0.629 0.280 0.686 4.054 0.627 0.0346832E463/F 1/1 277.1 0.026 0.704 0.337 0.686 3.810 0.676 0.0346832E464/F 1/1 217.4 0.028 0.843 0.431 0.832 3.050 0.931 0.0326832E467/F 1/1 301.9 0.023 0.627 0.299 0.629 3.089 0.473 0.0386832E472/F 1/1 165.8 0.045 1.053 0.531 2.073 3.957 0.754 0.0526832E475/F 1/1 260.0 0.023 0.749 0.313 0.690 3.066 0.508 0.0436832E478/F 1/1 263.4 0.021 0.727 0.306 0.716 3.266 0.490 0.0386832E483/F 1/1 271.8 0.023 0.680 0.302 0.635 3.257 0.460 0.0456832E486/F 1/1 265.4 0.022 0.700 0.321 0.703 3.255 0.499 0.0376832E489/F 1/1 263.9 0.026 0.737 0.325 0.701 3.218 0.460 0.0366832E490/F 1/1 223.6 0.023 0.849 0.414 0.810 5.302 1.320 0.0326832E493/F 1/1 230.8 0.028 0.843 0.429 0.869 4.366 1.277 0.0156832E495/F 1/1 301.6 0.028 0.657 0.352 0.690 3.260 0.498 0.1826832E497/F 1/1 269.1 0.023 0.673 0.338 0.647 3.627 0.542 0.0356832E498/F 1/1 254.1 0.025 0.782 0.344 0.701 2.858 0.483 0.0426832E500/F 1/1 303.6 0.021 0.626 0.344 0.656 3.061 0.465 0.035M e a n: 265.4 0.025 0.725 0.353 0.763 3.506 0.606 0.043Standard deviation: 33.3 0.005 0.100 0.056 0.299 0.542 0.252 0.032Number of observ. : (22) (22) (22) (22) (22) (22) (22) (22)6834F551/F 2/1 280.6 0.017 0.668 0.289 0.703 3.799 0.506 0.0356834F553/F 2/1 278.5 0.025 0.697 0.320 0.712 3.192 0.483 0.0376834F554/F 2/1 281.2 0.021 0.659 0.313 0.682 3.261 0.512 0.0386834F555/F 2/1 297.4 0.024 0.637 0.307 0.653 3.347 0.481 0.0506834F557/F 2/1 264.6 0.021 0.720 0.365 0.733 3.079 0.494 0.0516834F558/F 2/1 263.2 0.025 0.696 0.351 0.739 3.866 0.465 0.0416834F559/F 2/1 245.3 0.028 0.760 0.371 0.736 3.211 0.507 0.0446834F560/F 2/1 283.1 0.021 0.684 0.316 0.715 3.023 0.472 0.0346834F561/F 2/1 277.0 0.024 0.655 0.330 0.722 3.274 0.484 0.0426834F563/F 2/1 288.7 0.026 0.646 0.361 0.731 3.679 0.436 0.0466834F564/F 2/1 221.5 0.027 0.805 0.353 0.878 3.483 0.539 0.0536834F569/F 2/1 312.4 0.026 0.612 0.312 0.649 3.521 0.421 0.037*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6834F570/F 2/1 268.6 0.022 0.716 0.292 0.683 3.479 0.477 0.0456834F573/F 2/1 258.5 0.023 0.704 0.329 0.694 3.149 0.481 0.0276834F574/F 2/1 265.2 0.023 0.685 0.319 0.705 3.164 0.490 0.0426834F575/F 2/1 309.2 0.022 0.619 0.284 0.666 3.006 0.437 0.0356834F579/F 2/1 299.6 0.024 0.638 0.338 0.735 4.111 0.561 0.0376834F580/F 2/1 296.3 0.022 0.639 0.303 0.663 3.022 0.410 0.0386834F583/F 2/1 276.2 0.020 0.694 0.363 0.680 3.103 0.526 0.0516834F584/F 2/1 258.5 0.019 0.729 0.325 0.448 8.934 0.599 0.0716834F585/F 2/1 234.6 0.024 0.806 0.411 0.762 3.682 0.789 0.0416834F586/F 2/1 286.9 0.025 0.648 0.286 0.644 3.127 0.462 0.0366834F587/F 2/1 282.6 0.022 0.680 0.342 0.690 3.113 0.467 0.0426834F588/F 2/1 267.6 0.018 0.636 0.366 0.660 3.236 0.508 0.0476834F591/F 2/1 256.1 0.024 0.745 0.350 0.750 3.349 0.530 0.0436834F592/F 2/1 274.7 0.021 0.680 0.328 0.680 2.938 0.498 0.0396834F596/F 2/1 262.2 0.025 0.710 0.317 0.720 4.265 0.485 0.1666834F597/F 2/1 280.2 0.024 0.673 0.301 0.657 3.120 0.485 0.0476834F598/F 2/1 252.7 0.023 0.734 0.320 0.755 3.367 0.488 0.0356834F600/F 2/1 280.6 0.022 0.694 0.281 0.661 3.552 0.571 0.047M e a n: 273.5 0.023 0.689 0.328 0.697 3.548 0.502 0.047Standard deviation: 20.4 0.002 0.049 0.031 0.067 1.069 0.068 0.024Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30)6836G651/F 3/1 262.8 0.025 0.723 0.339 0.792 3.471 0.500 0.0306836G652/F 3/1 277.7 0.024 0.691 0.298 0.697 3.572 0.501 0.0456836G654/F 3/1 238.3 0.027 0.768 0.359 0.863 4.185 0.500 0.0266836G655/F 3/1 259.9 0.028 0.724 0.326 0.807 3.996 0.538 0.0296836G656/F 3/1 277.7 0.023 0.669 0.306 0.703 3.105 0.452 0.0306836G657/F 3/1 263.5 0.022 0.698 0.346 0.733 3.234 0.473 0.0436836G658/F 3/1 274.9 0.022 0.687 0.334 0.719 3.290 0.442 0.0326836G660/F 3/1 295.8 0.029 0.635 0.326 0.712 6.839 0.587 0.0326836G661/F 3/1 242.0 0.018 0.774 0.424 0.763 3.710 0.592 0.1746836G662/F 3/1 234.8 0.028 0.819 0.357 0.746 3.351 0.514 0.0406836G663/F 3/1 258.5 0.020 0.718 0.328 0.735 3.684 0.507 0.0386836G666/F 3/1 226.0 0.024 0.847 0.360 0.750 3.422 0.516 0.0376836G667/F 3/1 271.4 0.024 0.667 0.297 0.643 3.113 0.471 0.0416836G668/F 3/1 212.8 0.081 0.870 0.390 0.759 3.244 0.512 0.0606836G669/F 3/1 256.3 0.022 0.704 0.399 0.780 4.102 0.562 0.0406836G670/F 3/1 267.4 0.022 0.691 0.320 0.787 3.369 0.462 0.0346836G672/F 3/1 283.2 0.023 0.653 0.333 0.631 3.132 0.419 0.037*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6836G673/F 3/1 242.1 0.021 0.763 0.370 0.687 3.019 0.546 0.0476836G674/F 3/1 287.6 0.022 0.662 0.306 0.706 3.397 0.452 0.0326836G675/F 3/1 257.6 0.020 0.734 0.385 0.771 4.368 0.775 0.0476836G677/F 3/1 268.4 0.023 0.722 0.296 0.727 3.326 0.472 0.0386836G681/F 3/1 272.3 0.023 0.708 0.404 0.720 3.106 0.463 0.0436836G684/F 3/1 287.6 0.023 0.688 0.303 0.667 3.173 0.442 0.0456836G686/F 3/1 231.0 0.032 0.833 0.427 1.023 4.592 1.158 0.0446836G689/F 3/1 241.1 0.025 0.770 0.351 0.767 3.376 0.510 0.0406836G690/F 3/1 236.8 0.024 0.770 0.353 0.781 3.748 0.503 0.0466836G692/F 3/1 244.1 0.023 0.743 0.336 0.699 3.447 0.519 0.0316836G694/F 3/1 255.8 0.022 0.720 0.328 0.706 3.637 0.571 0.0276836G697/F 3/1 252.0 0.027 0.731 0.334 0.798 3.368 0.531 0.0546836G700/F 3/1 209.6 0.031 0.872 0.348 0.754 3.143 0.537 0.478M e a n: 256.3 0.026 0.735 0.346 0.747 3.617 0.534 0.058Standard deviation: 21.9 0.011 0.063 0.036 0.072 0.726 0.135 0.083Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30)6838H754/F 4/1 267.9 0.021 0.696 0.405 0.726 3.494 0.491 0.0466838H755/F 4/1 229.6 0.021 0.778 0.338 1.030 3.358 0.483 0.0426838H756/F 4/1 250.7 0.023 0.719 0.361 0.722 3.225 0.453 0.0366838H758/F 4/1 247.8 0.025 0.751 0.365 0.873 3.557 0.523 0.0506838H759/F 4/1 230.5 0.032 0.811 0.361 0.848 3.876 0.613 0.0756838H760/F 4/1 245.1 0.024 0.769 0.371 0.772 3.640 0.544 0.0426838H761/F 4/1 244.4 0.029 0.772 0.360 0.786 3.899 0.556 0.0486838H762/F 4/1 237.7 0.024 0.770 0.376 0.808 3.638 0.549 0.0336838H765/F 4/1 259.5 0.019 0.730 0.393 0.771 3.549 0.588 0.0336838H767/F 4/1 251.5 0.023 0.753 0.316 0.754 3.433 0.558 0.0366838H768/F 4/1 242.4 0.026 0.769 0.384 0.784 4.174 0.543 0.0386838H769/F 4/1 232.5 0.022 0.811 0.342 0.751 3.402 0.512 0.0426838H771/F 4/1 217.7 0.024 0.869 0.355 0.768 3.492 0.541 0.0516838H773/F 4/1 256.8 0.023 0.715 0.305 0.737 3.646 0.481 0.0406838H776/F 4/1 261.4 0.029 0.735 0.373 0.800 3.543 0.489 0.0346838H777/F 4/1 242.5 0.024 0.703 0.367 0.764 3.319 0.478 0.0446838H778/F 4/1 218.1 0.025 0.830 0.463 0.842 3.786 1.084 0.0506838H779/F 4/1 265.1 0.023 0.693 0.338 0.761 3.194 0.483 0.0396838H780/F 4/1 236.3 0.025 0.796 0.380 0.804 5.264 0.650 0.0666838H781/F 4/1 244.3 0.020 0.769 0.382 0.774 3.569 0.524 0.0456838H782/F 4/1 240.3 0.029 0.753 0.388 0.766 3.595 0.477 0.0486838H784/F 4/1 202.7 0.030 0.955 0.412 0.833 2.535 0.624 0.044*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 4Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6838H787/F 4/1 266.0 0.027 0.702 0.302 0.826 4.293 0.649 0.0446838H788/F 4/1 244.1 0.022 0.730 0.314 0.761 3.762 0.479 0.0446838H789/F 4/1 247.7 0.023 0.778 0.386 0.806 3.439 0.551 0.0606838H790/F 4/1 238.2 0.011 0.781 0.440 0.784 3.636 0.555 0.0446838H791/F 4/1 265.6 0.021 0.713 0.372 0.807 4.468 0.820 0.0286838H793/F 4/1 231.8 0.022 0.792 0.368 0.844 5.168 0.722 0.0396838H794/F 4/1 258.7 0.026 0.714 0.326 0.760 3.326 0.469 0.0436838H796/F 4/1 240.6 0.023 0.771 0.352 0.814 3.365 0.521 0.0416838H798/F 4/1 256.0 0.022 0.734 0.316 0.750 3.575 0.467 0.0386838H799/F 4/1 215.8 0.027 0.863 0.355 0.743 3.559 0.553 0.0356838H800/F 4/1 247.9 0.025 0.739 0.338 0.863 4.525 0.652 0.038M e a n: 243.6$ 0.024 0.766 0.364 0.795 3.706 0.566 0.043Standard deviation: 15.7 0.004 0.056 0.036 0.058 0.540 0.123 0.010Number of observ. : (33) (33) (33) (33) (33) (33) (33) (33)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 5Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) SpleenF e m a l e A n i m a l s6832E451/F 1/1 290.9 0.308 0.2046832E452/F 1/1 265.5 0.371 0.2356832E456/F 1/1 272.8 0.908 0.3606832E458/F 1/1 257.4 0.230 0.2516832E460/F 1/1 277.6 0.475 1.4406832E461/F 1/1 300.6 0.254 0.2426832E462/F 1/1 304.3 0.588 0.2486832E463/F 1/1 277.1 1.568 0.2646832E464/F 1/1 217.4 1.961 0.2806832E467/F 1/1 301.9 0.246 0.1906832E472/F 1/1 165.8 0.333 0.4446832E475/F 1/1 260.0 0.231 0.1966832E478/F 1/1 263.4 0.254 0.3076832E483/F 1/1 271.8 0.221 0.2236832E486/F 1/1 265.4 0.272 0.2096832E489/F 1/1 263.9 0.203 0.3076832E490/F 1/1 223.6 1.899 0.2666832E493/F 1/1 230.8 6.723 0.2246832E495/F 1/1 301.6 0.220 0.3236832E497/F 1/1 269.1 0.742 0.3136832E498/F 1/1 254.1 0.197 0.3246832E500/F 1/1 303.6 0.538 0.174M e a n: 265.4 0.852 0.319Standard deviation: 33.3 1.419 0.258Number of observ. : (22) (22) (22)6834F551/F 2/1 280.6 0.479 0.2426834F553/F 2/1 278.5 0.323 0.2076834F554/F 2/1 281.2 0.184 0.1916834F555/F 2/1 297.4 0.290 0.2296834F557/F 2/1 264.6 0.224 0.4946834F558/F 2/1 263.2 0.302 0.2766834F559/F 2/1 245.3 0.329 0.2416834F560/F 2/1 283.1 0.224 0.2186834F561/F 2/1 277.0 0.294 0.3346834F563/F 2/1 288.7 0.225 0.4546834F564/F 2/1 221.5 0.258 0.2206834F569/F 2/1 312.4 0.247 0.256*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 6Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6834F570/F 2/1 268.6 0.803 0.2646834F573/F 2/1 258.5 0.242 0.2996834F574/F 2/1 265.2 0.233 0.3716834F575/F 2/1 309.2 0.333 0.4726834F579/F 2/1 299.6 1.533 0.2126834F580/F 2/1 296.3 0.425 0.2476834F583/F 2/1 276.2 0.220 0.3196834F584/F 2/1 258.5 1.028 0.3426834F585/F 2/1 234.6 0.626 0.3286834F586/F 2/1 286.9 0.273 0.2076834F587/F 2/1 282.6 0.302 0.2206834F588/F 2/1 267.6 0.260 0.2786834F591/F 2/1 256.1 0.471 0.2606834F592/F 2/1 274.7 0.262 0.2096834F596/F 2/1 262.2 0.278 0.2856834F597/F 2/1 280.2 0.225 0.2386834F598/F 2/1 252.7 0.207 0.3326834F600/F 2/1 280.6 0.739 0.221M e a n: 273.5 0.395 0.282Standard deviation: 20.4 0.293 0.080Number of observ. : (30) (30) (30)6836G651/F 3/1 262.8 0.245 0.4336836G652/F 3/1 277.7 0.553 0.2216836G654/F 3/1 238.3 0.356 0.2456836G655/F 3/1 259.9 0.541 0.2256836G656/F 3/1 277.7 0.259 0.3096836G657/F 3/1 263.5 0.233 0.2356836G658/F 3/1 274.9 0.350 0.1946836G660/F 3/1 295.8 0.860 0.2486836G661/F 3/1 242.0 0.395 1.2796836G662/F 3/1 234.8 0.262 0.3116836G663/F 3/1 258.5 0.272 0.2706836G666/F 3/1 226.0 0.174 0.3006836G667/F 3/1 271.4 0.235 0.4796836G668/F 3/1 212.8 0.159 0.5156836G669/F 3/1 256.3 0.261 0.5356836G670/F 3/1 267.4 0.258 0.3106836G672/F 3/1 283.2 0.405 0.201*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 7Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6836G673/F 3/1 242.1 0.219 0.4746836G674/F 3/1 287.6 0.242 0.3066836G675/F 3/1 257.6 1.317 0.2746836G677/F 3/1 268.4 0.282 0.2516836G681/F 3/1 272.3 0.216 0.3356836G684/F 3/1 287.6 0.289 0.2166836G686/F 3/1 231.0 1.120 0.3316836G689/F 3/1 241.1 0.343 0.3796836G690/F 3/1 236.8 0.268 0.4556836G692/F 3/1 244.1 0.208 0.2226836G694/F 3/1 255.8 0.679 0.2856836G697/F 3/1 252.0 0.254 0.3776836G700/F 3/1 209.6 0.221 1.522M e a n: 256.3 0.383 0.391Standard deviation: 21.9 0.275 0.293Number of observ. : (30) (30) (30)6838H754/F 4/1 267.9 0.216 0.2526838H755/F 4/1 229.6 0.317 0.2876838H756/F 4/1 250.7 0.274 0.2336838H758/F 4/1 247.8 0.307 0.3456838H759/F 4/1 230.5 0.461 0.4166838H760/F 4/1 245.1 0.272 0.2976838H761/F 4/1 244.4 0.898 0.3216838H762/F 4/1 237.7 0.504 0.2926838H765/F 4/1 259.5 0.217 0.3746838H767/F 4/1 251.5 1.676 0.4856838H768/F 4/1 242.4 0.490 0.2676838H769/F 4/1 232.5 0.243 0.8646838H771/F 4/1 217.7 0.222 0.3056838H773/F 4/1 256.8 0.256 0.3326838H776/F 4/1 261.4 0.322 0.2656838H777/F 4/1 242.5 0.330 0.2296838H778/F 4/1 218.1 3.905 0.3246838H779/F 4/1 265.1 0.326 0.2126838H780/F 4/1 236.3 1.245 0.8976838H781/F 4/1 244.3 0.236 0.2786838H782/F 4/1 240.3 0.214 0.2476838H784/F 4/1 202.7 0.220 0.295*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 8Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6838H787/F 4/1 266.0 0.685 0.3416838H788/F 4/1 244.1 0.261 0.2456838H789/F 4/1 247.7 0.282 0.2856838H790/F 4/1 238.2 0.254 0.3106838H791/F 4/1 265.6 4.664 0.2706838H793/F 4/1 231.8 1.073 0.3676838H794/F 4/1 258.7 0.252 0.3666838H796/F 4/1 240.6 0.289 0.2916838H798/F 4/1 256.0 0.246 0.2806838H799/F 4/1 215.8 0.234 0.2426838H800/F 4/1 247.9 1.334 0.423M e a n: 243.6$ 0.689 0.341Standard deviation: 15.7 1.003 0.152Number of observ. : (33) (33) (33)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-3 Percent Organ to Brain Wei ght, Male and Female, Final SacrificeLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys LungsM a l e A n i m a l s6831E407/M 1/1 403.2 3.524 100.000 35.011 63.570 144.485 690.206 85.2636831E413/M 1/1 379.5 3.674 100.000 13.377 54.875 121.903 679.651 86.0576831E415/M 1/1 395.5 3.070 100.000 24.844 52.854 141.055 1078.513 106.4756831E418/M 1/1 398.8 3.459 100.000 28.967 58.487 141.006 652.860 85.9326831E422/M 1/1 384.3 2.602 100.000 35.229 54.072 138.458 637.880 82.9886831E435/M 1/1 355.1 3.776 100.000 38.107 63.315 160.520 833.006 85.0916831E436/M 1/1 393.1 3.359 100.000 16.650 56.134 141.967 736.904 79.7966831E437/M 1/1 398.3 3.521 100.000 45.915 57.418 127.606 575.352 81.4556831E440/M 1/1 396.8 20.883 100.000 17.845 58.424 136.213 670.669 85.8576831E442/M 1/1 383.6 4.596 100.000 23.648 51.795 159.837 1457.492 119.9146831E443/M 1/1 404.7 3.317 100.000 21.971 55.865 134.423 628.365 80.1926831E446/M 1/1 352.3 2.895 100.000 23.160 60.550 131.551 784.495 120.0206831E448/M 1/1 396.0 2.938 100.000 24.241 49.951 129.187 626.543 86.7296831E449/M 1/1 418.7 3.670 100.000 16.972 60.596 130.092 685.321 93.578M e a n: 390.0 4.663 100.000 26.138 56.993 138.450 766.947 91.382Standard deviation: 18.2 4.693 0.000 9.394 4.133 11.172 234.397 13.819Number of observ. : (14) (14) (14) (14) (14) (14) (14) (14)6833F502/M 2/1 384.3 3.953 100.000 16.894 63.294 131.953 633.694 85.0826833F505/M 2/1 400.1 3.002 100.000 19.560 61.381 147.724 770.285 96.1486833F508/M 2/1 387.3 3.430 100.000 29.952 60.725 141.498 655.990 104.4446833F511/M 2/1 411.5 3.175 100.000 18.487 61.811 135.808 667.274 93.6046833F513/M 2/1 280.5 3.563 100.000 17.318 51.163 126.571 588.669 148.0466833F516/M 2/1 377.9 3.563 100.000 20.742 52.855 126.647 859.297 124.5976833F519/M 2/1 416.2 3.152 100.000 20.774 65.043 151.958 629.847 94.0316833F521/M 2/1 335.6 3.996 100.000 18.762 61.111 128.314 930.458 188.5966833F523/M 2/1 408.3 2.513 100.000 23.055 52.537 133.253 611.165 105.4626833F525/M 2/1 393.6 83.071 100.000 17.597 57.177 160.658 840.439 118.9796833F526/M 2/1 362.5 4.214 100.000 25.429 55.904 194.023 879.079 122.6366833F535/M 2/1 409.1 3.432 100.000 18.511 57.854 151.426 631.320 109.7156833F536/M 2/1 340.7 3.397 100.000 26.842 54.593 126.077 551.292 78.9476833F542/M 2/1 365.4 3.304 100.000 23.570 56.755 132.249 638.955 89.3986833F547/M 2/1 366.3 3.462 100.000 24.235 62.318 145.108 656.197 87.3566833F550/M 2/1 368.4 3.205 100.000 16.367 52.647 235.794 917.484 89.995M e a n: 375.5 8.402 100.000 21.131 57.948 148.066 716.340 108.565Standard deviation: 35.2 19.916 0.000 3.984 4.391 29.120 127.367 27.970Number of observ. : (16) (16) (16) (16) (16) (16) (16) (16)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6835G601/M 3/1 382.8 2.407 100.000 19.114 47.761 130.814 600.915 89.5046835G602/M 3/1 368.3 5.333 100.000 16.810 57.143 147.429 690.857 100.0006835G603/M 3/1 375.0 3.057 100.000 16.321 51.824 140.878 646.351 92.6046835G605/M 3/1 354.7 4.738 100.000 17.868 60.464 148.963 709.279 141.0666835G607/M 3/1 372.0 3.303 100.000 18.310 55.172 148.664 725.206 82.0306835G609/M 3/1 394.9 3.267 100.000 18.362 57.662 141.371 650.759 90.1526835G610/M 3/1 368.2 2.995 100.000 15.208 52.550 127.000 565.466 94.0576835G613/M 3/1 374.6 3.043 100.000 17.633 57.343 127.923 615.459 92.2226835G614/M 3/1 389.1 3.445 100.000 28.278 69.665 147.751 688.325 94.4506835G615/M 3/1 349.7 3.493 100.000 18.756 53.397 154.019 803.062 153.7326835G617/M 3/1 359.5 4.424 100.000 20.463 57.717 156.963 662.092 85.7216835G621/M 3/1 350.0 4.579 100.000 18.948 51.291 127.082 680.662 84.7056835G628/M 3/1 378.2 3.279 100.000 20.166 63.730 137.004 660.793 96.1826835G630/M 3/1 366.6 3.713 100.000 14.513 52.797 136.162 660.849 97.0596835G634/M 3/1 396.2 3.249 100.000 25.565 62.288 160.122 758.427 95.1986835G638/M 3/1 392.6 3.185 100.000 23.326 71.897 147.728 771.382 116.8626835G639/M 3/1 383.2 3.970 100.000 20.050 64.020 142.928 699.007 130.4716835G647/M 3/1 401.1 3.335 100.000 22.582 57.599 134.254 726.918 87.9946835G648/M 3/1 268.6 3.798 100.000 28.686 50.275 169.665 668.816 121.2896835G649/M 3/1 349.5 3.485 100.000 20.378 54.792 131.026 680.155 85.818M e a n: 368.7 3.605 100.000 20.067% 57.469 142.887 683.239 101.556Standard deviation: 28.5 0.697 0.000 3.899 6.335 11.804 57.029 20.173Number of observ. : (20) (20) (20) (20) (20) (20) (20) (20)6837H702/M 4/1 382.2 3.473 100.000 20.362 55.186 146.289 679.305 94.0066837H704/M 4/1 397.1 3.516 100.000 26.060 58.092 135.742 675.626 82.0816837H705/M 4/1 399.2 3.092 100.000 20.904 56.437 170.697 860.268 169.3126837H706/M 4/1 356.7 3.307 100.000 26.972 57.487 151.110 697.307 91.4506837H708/M 4/1 346.6 3.255 100.000 15.870 53.611 153.815 1133.164 120.2446837H714/M 4/1 335.0 3.297 100.000 22.244 47.933 146.014 697.441 82.0376837H717/M 4/1 371.8 3.850 100.000 20.162 59.625 174.012 634.347 96.5056837H722/M 4/1 335.5 3.375 100.000 18.901 48.505 142.237 1051.061 158.6796837H724/M 4/1 351.4 3.283 100.000 17.964 59.615 187.289 751.501 127.1116837H725/M 4/1 271.3 4.577 100.000 22.284 52.314 154.779 880.885 137.0726837H726/M 4/1 376.6 3.942 100.000 17.080 54.939 143.163 737.908 90.4626837H728/M 4/1 348.4 3.033 100.000 15.217 53.994 130.334 707.836 84.1256837H729/M 4/1 355.9 3.417 100.000 16.458 55.390 126.083 656.737 92.4936837H735/M 4/1 357.6 3.688 100.000 25.570 53.518 137.458 664.386 86.0756837H736/M 4/1 371.5 3.755 100.000 29.891 61.462 160.326 785.672 96.146*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6837H739/M 4/1 371.6 2.744 100.000 26.213 57.031 143.900 637.286 87.6046837H741/M 4/1 361.3 3.950 100.000 19.000 55.650 137.200 732.050 95.4006837H747/M 4/1 365.8 4.530 100.000 20.434 54.507 154.460 759.226 81.4546837H749/M 4/1 328.0 2.683 100.000 14.878 53.268 127.902 579.122 92.146M e a n: 357.0+ 3.514 100.000 20.867 55.188 148.569% 753.744 103.390Standard deviation: 28.4 0.509 0.000 4.369 3.448 16.102 140.921 26.354Number of observ. : (19) (19) (19) (19) (19) (19) (19) (19)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 4Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) SpleenM a l e A n i m a l s6831E407/M 1/1 403.2 54.828 178.7196831E413/M 1/1 379.5 84.880 268.8186831E415/M 1/1 395.5 217.746 686.1876831E418/M 1/1 398.8 107.011 224.5396831E422/M 1/1 384.3 108.482 199.2296831E435/M 1/1 355.1 79.647 135.3606831E436/M 1/1 393.1 81.159 234.5676831E437/M 1/1 398.3 61.455 137.2306831E440/M 1/1 396.8 51.068 98.2916831E442/M 1/1 383.6 365.869 253.2796831E443/M 1/1 404.7 79.856 234.6636831E446/M 1/1 352.3 228.754 129.5886831E448/M 1/1 396.0 116.993 261.7536831E449/M 1/1 418.7 83.028 408.624M e a n: 390.0 122.912 246.489Standard deviation: 18.2 88.492 148.817Number of observ. : (14) (14) (14)6833F502/M 2/1 384.3 87.247 321.3186833F505/M 2/1 400.1 91.996 444.5226833F508/M 2/1 387.3 86.135 288.4066833F511/M 2/1 411.5 80.252 329.3186833F513/M 2/1 280.5 267.244 77.9326833F516/M 2/1 377.9 295.266 321.6696833F519/M 2/1 416.2 94.651 247.0396833F521/M 2/1 335.6 1021.832 156.5306833F523/M 2/1 408.3 146.786 253.6976833F525/M 2/1 393.6 185.312 208.4416833F526/M 2/1 362.5 240.911 205.7816833F535/M 2/1 409.1 209.908 257.0326833F536/M 2/1 340.7 45.742 205.8376833F542/M 2/1 365.4 91.963 229.0436833F547/M 2/1 366.3 60.612 191.7216833F550/M 2/1 368.4 100.971 430.257M e a n: 375.5 194.177 260.534Standard deviation: 35.2 233.918 94.668Number of observ. : (16) (16) (16)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 5Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6835G601/M 3/1 382.8 76.986 490.4676835G602/M 3/1 368.3 114.857 437.1436835G603/M 3/1 375.0 91.026 138.8566835G605/M 3/1 354.7 446.150 151.1856835G607/M 3/1 372.0 61.680 272.7546835G609/M 3/1 394.9 97.285 414.5886835G610/M 3/1 368.2 100.608 440.1036835G613/M 3/1 374.6 77.923 370.8216835G614/M 3/1 389.1 73.828 347.8956835G615/M 3/1 349.7 510.431 173.7326835G617/M 3/1 359.5 122.373 109.7546835G621/M 3/1 350.0 89.235 371.2136835G628/M 3/1 378.2 63.485 321.0476835G630/M 3/1 366.6 131.967 198.7466835G634/M 3/1 396.2 96.846 207.9576835G638/M 3/1 392.6 195.785 299.6726835G639/M 3/1 383.2 140.397 291.4146835G647/M 3/1 401.1 66.556 339.4956835G648/M 3/1 268.6 151.124 188.4566835G649/M 3/1 349.5 186.883 193.369M e a n: 368.7 144.771 287.933Standard deviation: 28.5 120.685 113.072Number of observ. : (20) (20) (20)6837H702/M 4/1 382.2 98.668 431.0186837H704/M 4/1 397.1 107.852 193.2086837H705/M 4/1 399.2 388.233 207.5226837H706/M 4/1 356.7 66.651 126.5946837H708/M 4/1 346.6 694.710 407.6816837H714/M 4/1 335.0 44.980 406.6936837H717/M 4/1 371.8 94.630 322.4426837H722/M 4/1 335.5 944.986 93.8776837H724/M 4/1 351.4 110.131 223.3116837H725/M 4/1 271.3 1014.839 102.1636837H726/M 4/1 376.6 74.112 527.0076837H728/M 4/1 348.4 69.060 460.7696837H729/M 4/1 355.9 191.867 319.7796837H735/M 4/1 357.6 81.951 342.1646837H736/M 4/1 371.5 37.352 363.785*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 6Scheduled Sacrifices FSRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6837H739/M 4/1 371.6 68.839 330.6716837H741/M 4/1 361.3 195.000 381.1506837H747/M 4/1 365.8 84.379 311.8926837H749/M 4/1 328.0 79.707 318.878M e a n: 357.0+ 234.102 308.979Standard deviation: 28.4 305.078 122.086Number of observ. : (19) (19) (19)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver OvariesF e m a l e A n i m a l s6832E451/F 1/1 290.9 3.682 100.000 55.016 103.095 550.694 77.481 4.9096832E452/F 1/1 265.5 4.008 100.000 47.996 101.002 461.551 67.300 6.8576832E456/F 1/1 272.8 3.789 100.000 51.016 100.000 513.619 75.069 4.7786832E458/F 1/1 257.4 2.906 100.000 46.986 93.219 463.886 64.909 5.9206832E460/F 1/1 277.6 3.505 100.000 49.549 97.716 514.923 71.907 4.9926832E461/F 1/1 300.6 3.887 100.000 58.056 103.683 540.256 67.928 4.9626832E462/F 1/1 304.3 3.655 100.000 44.543 108.982 644.282 99.582 5.4316832E463/F 1/1 277.1 3.689 100.000 47.797 97.387 540.779 95.953 4.7646832E464/F 1/1 217.4 3.328 100.000 51.173 98.691 361.702 110.475 3.8196832E467/F 1/1 301.9 3.590 100.000 47.677 100.211 492.344 75.396 6.0726832E472/F 1/1 165.8 4.296 100.000 50.458 196.850 375.773 71.592 4.9836832E475/F 1/1 260.0 3.029 100.000 41.735 92.094 409.343 67.864 5.8016832E478/F 1/1 263.4 2.924 100.000 42.141 98.433 449.295 67.467 5.2746832E483/F 1/1 271.8 3.407 100.000 44.348 93.294 478.691 67.658 6.5446832E486/F 1/1 265.4 3.122 100.000 45.856 100.377 465.070 71.313 5.2746832E489/F 1/1 263.9 3.498 100.000 44.136 95.165 436.728 62.449 4.8356832E490/F 1/1 223.6 2.740 100.000 48.736 95.416 624.658 155.479 3.7416832E493/F 1/1 230.8 3.289 100.000 50.925 103.032 517.832 151.490 1.7996832E495/F 1/1 301.6 4.192 100.000 53.586 105.152 496.566 75.808 27.7276832E497/F 1/1 269.1 3.479 100.000 50.193 96.080 538.874 80.508 5.1356832E498/F 1/1 254.1 3.169 100.000 43.964 89.638 365.241 61.720 5.3326832E500/F 1/1 303.6 3.316 100.000 54.947 104.895 489.211 74.368 5.526M e a n: 265.4 3.477 100.000 48.674 103.382 487.787 82.442 6.113Standard deviation: 33.3 0.411 0.000 4.349 21.414 73.459 25.995 4.937Number of observ. : (22) (22) (22) (22) (22) (22) (22) (22)6834F551/F 2/1 280.6 2.615 100.000 43.223 105.283 568.890 75.827 5.2836834F553/F 2/1 278.5 3.557 100.000 45.876 102.165 458.144 69.381 5.3616834F554/F 2/1 281.2 3.238 100.000 47.491 103.508 494.873 77.658 5.7206834F555/F 2/1 297.4 3.749 100.000 48.258 102.587 525.449 75.554 7.8146834F557/F 2/1 264.6 2.940 100.000 50.709 101.837 427.717 68.609 7.1396834F558/F 2/1 263.2 3.601 100.000 50.355 106.056 555.156 66.830 5.8376834F559/F 2/1 245.3 3.700 100.000 48.847 96.783 422.359 66.649 5.7376834F560/F 2/1 283.1 3.098 100.000 46.154 104.543 441.817 68.973 4.9566834F561/F 2/1 277.0 3.638 100.000 50.331 110.254 500.000 73.980 6.3406834F563/F 2/1 288.7 3.970 100.000 55.955 113.144 569.689 67.543 7.1356834F564/F 2/1 221.5 3.309 100.000 43.803 109.086 432.698 66.910 6.5626834F569/F 2/1 312.4 4.236 100.000 50.941 106.067 575.314 68.776 6.067*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6834F570/F 2/1 268.6 3.119 100.000 40.696 95.322 485.603 66.580 6.3416834F573/F 2/1 258.5 3.299 100.000 46.729 98.681 447.554 68.389 3.7936834F574/F 2/1 265.2 3.412 100.000 46.615 102.862 461.750 71.491 6.1096834F575/F 2/1 309.2 3.502 100.000 45.897 107.632 485.886 70.570 5.5936834F579/F 2/1 299.6 3.713 100.000 52.981 115.167 644.195 87.866 5.8586834F580/F 2/1 296.3 3.381 100.000 47.491 103.751 473.112 64.131 5.9176834F583/F 2/1 276.2 2.921 100.000 52.321 97.966 447.105 75.796 7.4076834F584/F 2/1 258.5 2.599 100.000 44.615 61.485 1225.252 82.175 9.7616834F585/F 2/1 234.6 3.014 100.000 50.978 94.553 456.795 97.885 5.1306834F586/F 2/1 286.9 3.929 100.000 44.187 99.516 482.939 71.367 5.5446834F587/F 2/1 282.6 3.227 100.000 50.286 101.562 457.887 68.662 6.1436834F588/F 2/1 267.6 2.822 100.000 57.613 103.880 509.112 79.953 7.4076834F591/F 2/1 256.1 3.251 100.000 47.037 100.787 449.712 71.159 5.7166834F592/F 2/1 274.7 3.050 100.000 48.154 99.893 431.728 73.141 5.7786834F596/F 2/1 262.2 3.491 100.000 44.576 101.450 600.591 68.260 23.3086834F597/F 2/1 280.2 3.499 100.000 44.698 97.667 463.574 72.057 7.0526834F598/F 2/1 252.7 3.071 100.000 43.588 102.802 458.459 66.433 4.7416834F600/F 2/1 280.6 3.237 100.000 40.493 95.272 512.025 82.374 6.783M e a n: 273.5 3.340 100.000 47.697 101.385 515.513 72.833 6.744Standard deviation: 20.4 0.388 0.000 4.042 9.040 145.286 7.328 3.318Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30)6836G651/F 3/1 262.8 3.421 100.000 46.947 109.474 480.053 69.211 4.2116836G652/F 3/1 277.7 3.491 100.000 43.095 100.886 516.936 72.486 6.5146836G654/F 3/1 238.3 3.550 100.000 46.696 112.288 544.675 65.101 3.3326836G655/F 3/1 259.9 3.930 100.000 44.981 111.365 551.514 74.243 4.0366836G656/F 3/1 277.7 3.391 100.000 45.694 105.059 464.047 67.546 4.4676836G657/F 3/1 263.5 3.208 100.000 49.538 105.003 463.458 67.809 6.0906836G658/F 3/1 274.9 3.231 100.000 48.676 104.714 479.025 64.407 4.6616836G660/F 3/1 295.8 4.579 100.000 51.384 112.087 1077.104 92.439 5.0056836G661/F 3/1 242.0 2.350 100.000 54.754 98.611 479.541 76.496 22.4896836G662/F 3/1 234.8 3.432 100.000 43.578 91.160 409.256 62.715 4.8886836G663/F 3/1 258.5 2.749 100.000 45.768 102.372 513.477 70.620 5.2836836G666/F 3/1 226.0 2.821 100.000 42.476 88.506 404.023 60.867 4.3366836G667/F 3/1 271.4 3.644 100.000 44.506 96.300 466.483 70.569 6.0746836G668/F 3/1 212.8 9.287 100.000 44.870 87.203 372.786 58.855 6.8576836G669/F 3/1 256.3 3.158 100.000 56.621 110.693 582.382 79.723 5.7066836G670/F 3/1 267.4 3.137 100.000 46.295 113.791 487.345 66.793 4.9226836G672/F 3/1 283.2 3.568 100.000 51.027 96.649 479.405 64.108 5.730*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6836G673/F 3/1 242.1 2.760 100.000 48.431 90.043 395.455 71.483 6.1156836G674/F 3/1 287.6 3.363 100.000 46.243 106.674 513.295 68.313 4.8346836G675/F 3/1 257.6 2.751 100.000 52.540 105.132 595.344 105.608 6.4556836G677/F 3/1 268.4 3.199 100.000 40.970 100.619 460.681 65.428 5.3156836G681/F 3/1 272.3 3.269 100.000 57.032 101.713 439.024 65.439 6.0726836G684/F 3/1 287.6 3.286 100.000 44.085 97.017 461.325 64.206 6.4716836G686/F 3/1 231.0 3.896 100.000 51.221 122.805 551.117 138.961 5.2996836G689/F 3/1 241.1 3.231 100.000 45.611 99.569 438.288 66.236 5.2236836G690/F 3/1 236.8 3.072 100.000 45.858 101.426 486.835 65.387 6.0346836G692/F 3/1 244.1 3.034 100.000 45.229 94.098 464.203 69.829 4.1376836G694/F 3/1 255.8 3.094 100.000 45.494 98.046 505.103 79.262 3.8006836G697/F 3/1 252.0 3.694 100.000 45.736 109.180 460.891 72.732 7.3336836G700/F 3/1 209.6 3.556 100.000 39.934 86.433 360.339 61.597 54.814M e a n: 256.3 3.505 100.000 47.176 101.964 496.780 72.616 7.550Standard deviation: 21.9 1.171 0.000 4.232 8.703 123.142 15.686 9.509Number of observ. : (30) (30) (30) (30) (30) (30) (30) (30)6838H754/F 4/1 267.9 2.949 100.000 58.231 104.290 501.984 70.563 6.6496838H755/F 4/1 229.6 2.744 100.000 43.393 132.475 431.747 62.038 5.3756838H756/F 4/1 250.7 3.161 100.000 50.194 100.333 448.419 63.006 4.9366838H758/F 4/1 247.8 3.332 100.000 48.576 116.282 473.563 69.694 6.6636838H759/F 4/1 230.5 3.959 100.000 44.516 104.548 478.117 75.602 9.3106838H760/F 4/1 245.1 3.183 100.000 48.223 100.371 473.263 70.716 5.5176838H761/F 4/1 244.4 3.708 100.000 46.663 101.695 504.767 72.034 6.2506838H762/F 4/1 237.7 3.116 100.000 48.879 104.975 472.717 71.296 4.2656838H765/F 4/1 259.5 2.640 100.000 53.801 105.597 486.167 80.570 4.5416838H767/F 4/1 251.5 3.117 100.000 41.944 100.106 456.101 74.115 4.7546838H768/F 4/1 242.4 3.324 100.000 49.866 101.930 542.574 70.563 4.8796838H769/F 4/1 232.5 2.653 100.000 42.175 92.573 419.576 63.183 5.1996838H771/F 4/1 217.7 2.750 100.000 40.825 88.366 402.010 62.295 5.8706838H773/F 4/1 256.8 3.270 100.000 42.616 103.106 510.300 67.302 5.5596838H776/F 4/1 261.4 3.956 100.000 50.755 108.798 482.093 66.476 4.5816838H777/F 4/1 242.5 3.404 100.000 52.230 108.744 472.477 68.016 6.2796838H778/F 4/1 218.1 2.982 100.000 55.715 101.380 456.046 130.536 5.9646838H779/F 4/1 265.1 3.268 100.000 48.802 109.858 461.220 69.771 5.6106838H780/F 4/1 236.3 3.191 100.000 47.713 101.011 661.649 81.702 8.2986838H781/F 4/1 244.3 2.662 100.000 49.734 100.692 464.324 68.158 5.8576838H782/F 4/1 240.3 3.812 100.000 51.547 101.768 477.403 63.315 6.3546838H784/F 4/1 202.7 3.152 100.000 43.101 87.287 265.478 65.323 4.651*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 4Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6838H787/F 4/1 266.0 3.856 100.000 42.957 117.729 611.462 92.501 6.2136838H788/F 4/1 244.1 2.974 100.000 42.985 104.321 515.376 65.600 6.0046838H789/F 4/1 247.7 2.905 100.000 49.637 103.579 441.805 70.851 7.6766838H790/F 4/1 238.2 1.397 100.000 56.368 100.322 465.395 70.983 5.6966838H791/F 4/1 265.6 3.011 100.000 52.139 113.154 626.836 115.055 3.9626838H793/F 4/1 231.8 2.776 100.000 46.434 106.478 652.096 91.072 4.8996838H794/F 4/1 258.7 3.575 100.000 45.666 106.446 466.143 65.710 6.0136838H796/F 4/1 240.6 2.963 100.000 45.690 105.496 436.261 67.511 5.3346838H798/F 4/1 256.0 3.035 100.000 43.024 102.236 487.327 63.685 5.2186838H799/F 4/1 215.8 3.169 100.000 41.192 86.144 412.460 64.071 4.0286838H800/F 4/1 247.9 3.384 100.000 45.688 116.812 612.336 88.210 5.131M e a n: 243.6$ 3.133$ 100.000 47.615 104.209 486.954 73.986 5.683Standard deviation: 15.7 0.483 0.000 4.625 8.959 77.866 14.988 1.154Number of observ. : (33) (33) (33) (33) (33) (33) (33) (33)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 5Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) SpleenF e m a l e A n i m a l s6832E451/F 1/1 290.9 47.812 31.5906832E452/F 1/1 265.5 52.004 32.8596832E456/F 1/1 272.8 136.079 53.9816832E458/F 1/1 257.4 31.862 34.7696832E460/F 1/1 277.6 69.995 212.2686832E461/F 1/1 300.6 39.079 37.2386832E462/F 1/1 304.3 93.420 39.3736832E463/F 1/1 277.1 222.541 37.5006832E464/F 1/1 217.4 232.624 33.2246832E467/F 1/1 301.9 39.282 30.2536832E472/F 1/1 165.8 31.615 42.1536832E475/F 1/1 260.0 30.801 26.1296832E478/F 1/1 263.4 34.987 42.2456832E483/F 1/1 271.8 32.504 32.8296832E486/F 1/1 265.4 38.805 29.8176832E489/F 1/1 263.9 27.572 41.7186832E490/F 1/1 223.6 223.709 31.3496832E493/F 1/1 230.8 797.431 26.5676832E495/F 1/1 301.6 33.586 49.2426832E497/F 1/1 269.1 110.271 46.4946832E498/F 1/1 254.1 25.151 41.3986832E500/F 1/1 303.6 86.053 27.737M e a n: 265.4 110.781 44.579Standard deviation: 33.3 167.421 38.179Number of observ. : (22) (22) (22)6834F551/F 2/1 280.6 71.718 36.1796834F553/F 2/1 278.5 46.340 29.6916834F554/F 2/1 281.2 27.901 28.9266834F555/F 2/1 297.4 45.459 35.9036834F557/F 2/1 264.6 31.076 68.5566834F558/F 2/1 263.2 43.372 39.6076834F559/F 2/1 245.3 43.271 31.6896834F560/F 2/1 283.1 32.731 31.8536834F561/F 2/1 277.0 44.928 50.9376834F563/F 2/1 288.7 34.818 70.2796834F564/F 2/1 221.5 32.081 27.3146834F569/F 2/1 312.4 40.324 41.893*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 6Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6834F570/F 2/1 268.6 112.058 36.8506834F573/F 2/1 258.5 34.415 42.5516834F574/F 2/1 265.2 33.957 54.2106834F575/F 2/1 309.2 53.842 76.3206834F579/F 2/1 299.6 240.220 33.2116834F580/F 2/1 296.3 66.561 38.7226834F583/F 2/1 276.2 31.768 45.9056834F584/F 2/1 258.5 140.955 46.9506834F585/F 2/1 234.6 77.684 40.7196834F586/F 2/1 286.9 42.142 32.0246834F587/F 2/1 282.6 44.456 32.4316834F588/F 2/1 267.6 40.976 43.7986834F591/F 2/1 256.1 63.293 34.9766834F592/F 2/1 274.7 38.577 30.6586834F596/F 2/1 262.2 39.151 40.0646834F597/F 2/1 280.2 33.457 35.3666834F598/F 2/1 252.7 28.125 45.2056834F600/F 2/1 280.6 106.578 31.860M e a n: 273.5 57.408 41.155Standard deviation: 20.4 43.752 12.323Number of observ. : (30) (30) (30)6836G651/F 3/1 262.8 33.947 59.9476836G652/F 3/1 277.7 79.990 32.0486836G654/F 3/1 238.3 46.313 31.8416836G655/F 3/1 259.9 74.615 31.0676836G656/F 3/1 277.7 38.644 46.1796836G657/F 3/1 263.5 33.442 33.7146836G658/F 3/1 274.9 51.006 28.2846836G660/F 3/1 295.8 135.463 39.0846836G661/F 3/1 242.0 51.015 165.3316836G662/F 3/1 234.8 31.981 38.0146836G663/F 3/1 258.5 37.844 37.6826836G666/F 3/1 226.0 20.533 35.3716836G667/F 3/1 271.4 35.229 71.7286836G668/F 3/1 212.8 18.251 59.1256836G669/F 3/1 256.3 37.119 76.0116836G670/F 3/1 267.4 37.263 44.8356836G672/F 3/1 283.2 62.000 30.757*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 7Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6836G673/F 3/1 242.1 28.680 62.1216836G674/F 3/1 287.6 36.626 46.2956836G675/F 3/1 257.6 179.524 37.4076836G677/F 3/1 268.4 39.112 34.8306836G681/F 3/1 272.3 30.566 47.2766836G684/F 3/1 287.6 41.962 31.3956836G686/F 3/1 231.0 134.390 39.7406836G689/F 3/1 241.1 44.588 49.1656836G690/F 3/1 236.8 34.833 59.1336836G692/F 3/1 244.1 28.020 29.9506836G694/F 3/1 255.8 94.354 39.6316836G697/F 3/1 252.0 34.818 51.5486836G700/F 3/1 209.6 25.328 174.562M e a n: 256.3 52.582 52.136Standard deviation: 21.9 37.585 34.443Number of observ. : (30) (30) (30)6838H754/F 4/1 267.9 30.992 36.1396838H755/F 4/1 229.6 40.705 36.8986838H756/F 4/1 250.7 38.048 32.4466838H758/F 4/1 247.8 40.838 45.9436838H759/F 4/1 230.5 56.822 51.3646838H760/F 4/1 245.1 35.385 38.6216838H761/F 4/1 244.4 116.208 41.5786838H762/F 4/1 237.7 65.555 37.9446838H765/F 4/1 259.5 29.778 51.2146838H767/F 4/1 251.5 222.715 64.4486838H768/F 4/1 242.4 63.753 34.7456838H769/F 4/1 232.5 29.920 106.5786838H771/F 4/1 217.7 25.542 35.0616838H773/F 4/1 256.8 35.858 46.4316838H776/F 4/1 261.4 43.779 36.0756838H777/F 4/1 242.5 46.948 32.6296838H778/F 4/1 218.1 470.348 38.9846838H779/F 4/1 265.1 47.113 30.6646838H780/F 4/1 236.3 156.489 112.8196838H781/F 4/1 244.3 30.671 36.1556838H782/F 4/1 240.3 28.453 32.8186838H784/F 4/1 202.7 22.997 30.904*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 8Scheduled Sacrifices FSRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6838H787/F 4/1 266.0 97.590 48.5276838H788/F 4/1 244.1 35.802 33.6146838H789/F 4/1 247.7 36.203 36.6186838H790/F 4/1 238.2 32.509 39.6566838H791/F 4/1 265.6 654.411 37.8246838H793/F 4/1 231.8 135.384 46.3266838H794/F 4/1 258.7 35.320 51.2466838H796/F 4/1 240.6 37.500 37.7166838H798/F 4/1 256.0 33.546 38.2326838H799/F 4/1 215.8 27.121 28.0346838H800/F 4/1 247.9 180.459 57.260M e a n: 243.6$ 90.447 44.409Standard deviation: 15.7 133.066 18.723Number of observ. : (33) (33) (33)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-4 Absolute Organ Weights, Male and Female, Euthanized RatsLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys LungsM a l e A n i m a l s6831E401/M 1/1 350.8 0.067 2.189 0.638 1.271 2.753 18.056 3.1016831E402/M 1/1 375.6 0.054 NT 1.014 1.285 2.751 13.564 3.0206831E403/M 1/1 276.1 0.064 2.003 0.423 1.119 2.426 10.792 3.1066831E404/M 1/1 494.2 0.071 2.094 0.881 1.380 2.824 15.373 2.8896831E405/M 1/1 311.3 0.056 2.075 0.357 1.718 2.595 10.311 3.0206831E406/M 1/1 224.4 0.095 1.974 0.731 0.976 1.930 4.063 1.3836831E408/M 1/1 312.1 0.051 2.105 0.816 0.866 2.157 7.247 1.1556831E409/M 1/1 300.4 0.069 2.094 0.554 0.842 2.464 11.069 2.2186831E410/M 1/1 369.2 0.118 2.087 0.567 1.358 3.031 19.129 3.0006831E411/M 1/1 339.4 0.064 2.078 0.440 1.098 2.920 19.761 3.9546831E412/M 1/1 331.9 0.077 1.994 0.350 0.961 2.031 8.317 1.3526831E414/M 1/1 255.3 0.109 2.105 0.536 1.181 2.465 7.873 3.6616831E416/M 1/1 385.4 0.079 2.057 0.507 1.151 2.962 17.859 4.1396831E417/M 1/1 372.5 0.072 2.055 0.902 1.257 2.590 10.233 1.7646831E419/M 1/1 359.2 0.066 2.189 0.315 1.495 3.114 15.481 4.9366831E420/M 1/1 355.4 0.065 1.983 0.472 1.066 2.720 12.879 2.6066831E421/M 1/1 385.2 0.064 2.098 0.797 1.336 3.013 12.585 4.0926831E423/M 1/1 381.1 0.061 2.135 0.834 1.203 2.721 13.786 3.2666831E424/M 1/1 365.0 0.106 2.132 0.547 1.186 2.756 14.755 3.1136831E426/M 1/1 282.1 0.077 2.076 0.413 1.363 2.563 9.207 3.2736831E427/M 1/1 294.9 0.072 2.110 0.468 1.461 2.745 16.057 5.8446831E428/M 1/1 355.2 0.071 2.023 0.562 1.232 2.457 10.804 2.0046831E429/M 1/1 352.3 0.077 2.159 0.471 1.402 2.836 15.320 3.0526831E430/M 1/1 327.7 0.074 2.083 0.466 1.240 2.340 7.638 2.5306831E431/M 1/1 346.8 0.056 2.255 0.931 1.166 2.429 8.002 1.4336831E432/M 1/1 379.0 0.047 2.047 0.505 1.439 2.869 17.505 3.2556831E433/M 1/1 311.2 0.061 2.011 0.569 1.033 2.400 9.705 1.5566831E434/M 1/1 317.5 0.093 2.020 0.594 1.221 3.216 12.553 1.6816831E438/M 1/1 331.8 0.074 2.135 0.500 1.286 3.117 18.231 3.1836831E439/M 1/1 417.3 0.029 1.965 1.138 1.053 2.513 13.050 1.4736831E441/M 1/1 366.9 0.064 2.177 0.869 1.338 2.953 11.189 3.0816831E444/M 1/1 331.1 0.085 2.011 0.574 1.072 2.575 16.132 3.3946831E445/M 1/1 369.9 0.061 2.067 0.452 1.477 2.811 12.286 3.4996831E447/M 1/1 353.4 0.062 2.044 0.521 1.174 2.587 19.636 3.6006831E450/M 1/1 440.7 0.052 2.011 1.033 1.214 2.759 15.438 2.210M e a n: 346.4 0.070 2.078 0.621 1.226 2.668 13.025 2.881Standard deviation: 50.7 0.018 0.068 0.215 0.186 0.299 3.997 1.053Number of observ. : (35) (35) (34) (35) (35) (35) (35) (35)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6833F504/M 2/1 344.8 0.408 2.188 0.369 1.283 2.980 20.773 3.6036833F506/M 2/1 299.2 0.050 2.124 0.358 1.267 2.799 13.412 3.6706833F507/M 2/1 367.4 0.067 2.048 0.615 1.392 2.877 16.133 3.1896833F509/M 2/1 503.4 0.100 2.054 1.178 1.334 2.646 10.207 1.7096833F510/M 2/1 314.7 0.079 2.057 0.433 1.220 2.539 8.993 1.6146833F512/M 2/1 306.8 0.055 2.079 0.567 1.393 2.774 10.773 3.0156833F514/M 2/1 395.1 0.040 1.986 0.810 1.134 2.886 13.112 1.8606833F515/M 2/1 352.0 0.069 2.111 0.706 1.064 2.731 14.976 2.7896833F517/M 2/1 408.0 0.047 2.142 0.735 1.344 2.979 18.906 3.3486833F518/M 2/1 407.4 0.083 2.155 0.421 1.410 3.064 16.277 2.7846833F520/M 2/1 324.1 0.112 2.056 0.518 1.441 4.755 16.535 2.5876833F522/M 2/1 377.2 0.082 2.086 0.428 1.299 2.893 17.617 2.8546833F527/M 2/1 357.5 0.072 1.972 0.903 1.193 2.994 15.175 2.0086833F528/M 2/1 309.8 0.044 1.911 0.616 1.159 2.571 9.672 2.7356833F529/M 2/1 444.5 0.066 2.055 0.909 1.257 2.697 12.470 1.6406833F530/M 2/1 329.6 0.055 2.077 0.593 1.306 3.177 11.588 2.1806833F531/M 2/1 355.2 0.082 2.117 0.621 1.323 2.640 10.398 1.6856833F532/M 2/1 314.7 0.061 2.076 0.870 1.235 2.563 16.010 6.4476833F533/M 2/1 388.3 0.054 2.036 0.820 1.861 3.611 23.559 2.3726833F534/M 2/1 247.0 0.047 1.993 0.431 1.332 2.378 11.087 2.8226833F537/M 2/1 338.3 0.062 2.130 0.432 0.967 2.901 10.246 4.1236833F538/M 2/1 369.0 0.066 2.087 0.514 1.345 2.805 9.488 3.8116833F539/M 2/1 259.2 0.093 2.088 0.445 1.041 2.184 5.004 1.4756833F540/M 2/1 300.4 0.066 2.155 1.029 1.285 2.863 9.134 2.9126833F543/M 2/1 325.3 0.061 1.990 0.338 0.924 3.166 14.003 7.3266833F544/M 2/1 352.7 0.115 1.957 0.432 1.957 2.719 19.204 2.9626833F545/M 2/1 367.1 0.105 2.015 0.716 1.555 2.832 20.436 3.3466833F546/M 2/1 350.7 0.077 1.994 0.341 1.168 4.144 14.791 2.8556833F548/M 2/1 472.7 0.103 2.231 0.500 1.443 3.444 20.929 2.750M e a n: 354.6 0.083 2.068 0.609 1.308 2.952% 14.169 2.982Standard deviation: 56.9 0.066 0.073 0.222 0.220 0.511 4.439 1.294Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29)6835G604/M 3/1 334.8 0.086 2.045 0.383 1.183 4.068 14.831 12.1926835G606/M 3/1 411.5 0.077 2.164 0.657 1.414 3.384 17.916 3.2966835G608/M 3/1 319.0 0.065 2.109 0.339 1.925 3.072 14.188 3.4256835G611/M 3/1 290.7 0.096 2.132 0.671 1.229 2.722 9.697 2.8376835G612/M 3/1 317.1 0.097 2.133 0.379 1.240 2.696 13.715 3.837*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6835G616/M 3/1 350.1 0.079 2.093 0.381 1.426 3.154 18.545 2.9126835G618/M 3/1 333.2 0.064 2.105 0.519 1.405 3.009 15.624 3.6456835G619/M 3/1 321.5 0.106 2.126 0.399 1.376 2.973 14.882 2.4556835G620/M 3/1 334.6 0.060 2.102 0.326 1.374 3.046 18.077 3.9616835G622/M 3/1 312.8 0.101 2.094 0.343 1.206 2.920 13.806 3.5016835G623/M 3/1 381.3 0.056 1.963 0.932 0.996 2.589 10.735 1.7536835G624/M 3/1 310.6 0.054 2.011 0.376 1.100 2.539 11.563 2.4756835G626/M 3/1 347.1 0.054 2.126 0.416 1.218 3.293 15.272 2.5136835G629/M 3/1 316.6 0.097 2.117 0.498 1.191 2.823 12.467 2.6386835G631/M 3/1 362.6 0.079 2.103 0.395 1.502 3.095 18.217 3.6816835G632/M 3/1 323.8 0.062 2.065 0.366 1.207 2.672 11.730 2.6276835G633/M 3/1 420.2 0.064 2.032 0.450 1.102 2.977 16.475 1.9076835G635/M 3/1 307.0 0.097 2.150 0.389 1.368 2.718 12.549 1.9556835G637/M 3/1 326.4 0.068 1.963 0.420 1.020 2.620 13.268 3.3506835G640/M 3/1 291.4 0.068 2.026 0.515 1.137 2.628 13.620 3.8046835G641/M 3/1 349.9 0.070 2.088 0.459 1.381 3.146 17.440 2.4266835G642/M 3/1 334.1 0.085 2.077 0.503 1.493 3.088 19.408 3.4706835G643/M 3/1 407.3 0.070 2.182 0.661 1.126 2.832 14.897 1.6396835G644/M 3/1 353.4 0.062 2.064 0.768 1.358 2.640 14.950 2.9476835G645/M 3/1 323.0 0.079 2.079 0.539 1.212 2.698 11.354 1.5996835G646/M 3/1 356.0 0.228 2.023 0.389 1.325 3.409 20.089 3.3836835G650/M 3/1 341.9 0.094 1.979 0.848 1.291 2.893 11.282 1.549M e a n: 339.9 0.082 2.080 0.493* 1.289 2.952$ 14.689 3.177Standard deviation: 33.5 0.033 0.058 0.162 0.187 0.332 2.837 1.951Number of observ. : (27) (27) (27) (27) (27) (27) (27) (27)6837H701/M 4/1 253.6 0.099 1.936 0.319 1.277 3.963 12.811 2.7536837H703/M 4/1 435.2 0.089 2.047 0.634 1.172 2.976 16.387 1.8106837H707/M 4/1 353.8 0.176 2.044 0.464 1.667 3.290 16.235 2.6366837H709/M 4/1 362.3 0.049 2.046 0.430 1.249 3.339 21.619 2.8196837H710/M 4/1 305.8 0.070 2.057 0.511 1.184 2.892 10.710 2.3186837H711/M 4/1 358.8 0.104 2.001 0.690 1.232 2.941 13.089 1.7756837H712/M 4/1 348.6 0.058 2.063 0.627 0.913 10.570 12.507 1.6666837H713/M 4/1 301.4 0.119 1.993 0.587 1.245 4.506 16.514 2.5286837H715/M 4/1 365.1 0.074 2.149 0.408 1.340 3.469 22.555 3.1046837H716/M 4/1 411.5 0.071 2.070 1.033 1.004 3.006 14.766 1.8096837H719/M 4/1 365.4 0.050 1.977 0.784 1.272 3.029 15.246 2.6306837H720/M 4/1 301.7 0.053 2.074 0.331 1.158 2.740 14.915 2.5076837H721/M 4/1 362.5 0.083 2.077 0.425 1.150 3.121 13.846 1.613*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 4Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6837H723/M 4/1 333.5 0.066 2.025 0.596 0.999 2.869 15.792 3.1206837H727/M 4/1 304.8 0.068 1.962 0.334 1.612 2.935 13.028 2.6486837H730/M 4/1 334.0 0.073 2.111 0.461 1.408 2.720 10.924 1.8436837H731/M 4/1 304.6 0.028 2.045 0.475 0.981 2.743 14.176 3.2626837H733/M 4/1 298.5 0.056 2.048 0.621 1.038 2.505 16.073 3.2046837H734/M 4/1 316.5 0.096 2.031 0.382 1.172 3.114 21.333 3.2716837H737/M 4/1 323.8 0.069 2.024 0.311 1.456 2.932 16.198 3.1446837H738/M 4/1 330.4 0.062 2.052 0.596 1.392 2.903 13.475 2.7086837H740/M 4/1 315.5 0.080 2.193 0.357 1.255 2.660 15.411 2.8116837H742/M 4/1 307.8 0.058 1.978 0.472 1.108 2.727 21.298 3.6056837H743/M 4/1 301.2 0.066 2.094 0.438 1.304 3.120 11.742 2.7436837H744/M 4/1 296.4 0.055 1.943 0.698 1.243 2.833 13.204 3.2946837H745/M 4/1 273.9 0.082 2.029 0.389 1.282 2.520 7.694 2.5336837H746/M 4/1 287.8 0.606 2.016 0.636 1.120 2.866 12.264 4.1456837H748/M 4/1 364.1 0.080 1.997 0.713 1.361 3.308 19.882 2.8146837H750/M 4/1 305.6 0.077 2.046 0.390 1.113 3.146 16.136 3.436M e a n: 328.4 0.094 2.039 0.521 1.231 3.301% 15.167 2.709Standard deviation: 39.6 0.102 0.056 0.167 0.175 1.457 3.519 0.626Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 5Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) SpleenM a l e A n i m a l s6831E401/M 1/1 350.8 9.782 3.2606831E402/M 1/1 375.6 17.452 3.0166831E403/M 1/1 276.1 15.750 2.9036831E404/M 1/1 494.2 2.033 4.2666831E405/M 1/1 311.3 7.921 1.6526831E406/M 1/1 224.4 0.477 2.3136831E408/M 1/1 312.1 0.654 3.0086831E409/M 1/1 300.4 3.669 2.3156831E410/M 1/1 369.2 20.943 2.5466831E411/M 1/1 339.4 11.696 1.6426831E412/M 1/1 331.9 0.602 2.2126831E414/M 1/1 255.3 0.492 1.9716831E416/M 1/1 385.4 22.346 2.1316831E417/M 1/1 372.5 1.489 2.9746831E419/M 1/1 359.2 11.185 2.0856831E420/M 1/1 355.4 8.490 4.6176831E421/M 1/1 385.2 15.749 2.5666831E423/M 1/1 381.1 13.603 2.6516831E424/M 1/1 365.0 8.662 2.6876831E426/M 1/1 282.1 10.465 2.3156831E427/M 1/1 294.9 9.566 1.0056831E428/M 1/1 355.2 2.000 2.7836831E429/M 1/1 352.3 14.355 2.5186831E430/M 1/1 327.7 0.798 2.3556831E431/M 1/1 346.8 0.772 3.1616831E432/M 1/1 379.0 24.221 1.9856831E433/M 1/1 311.2 1.702 4.6916831E434/M 1/1 317.5 0.726 2.2046831E438/M 1/1 331.8 9.366 1.2466831E439/M 1/1 417.3 0.919 3.4176831E441/M 1/1 366.9 10.929 2.6666831E444/M 1/1 331.1 13.234 1.9086831E445/M 1/1 369.9 13.445 3.3306831E447/M 1/1 353.4 11.908 1.7046831E450/M 1/1 440.7 3.734 3.036M e a n: 346.4 8.604 2.604Standard deviation: 50.7 6.952 0.828Number of observ. : (35) (35) (35)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 6Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6833F504/M 2/1 344.8 17.111 1.9366833F506/M 2/1 299.2 15.090 2.3746833F507/M 2/1 367.4 15.252 2.2956833F509/M 2/1 503.4 1.672 2.5706833F510/M 2/1 314.7 1.005 3.0366833F512/M 2/1 306.8 6.982 1.5506833F514/M 2/1 395.1 4.743 2.6306833F515/M 2/1 352.0 9.800 2.1886833F517/M 2/1 408.0 24.850 3.3786833F518/M 2/1 407.4 2.709 3.2376833F520/M 2/1 324.1 4.522 2.7176833F522/M 2/1 377.2 12.163 2.4056833F527/M 2/1 357.5 19.662 2.5276833F528/M 2/1 309.8 8.750 2.1836833F529/M 2/1 444.5 1.324 4.6586833F530/M 2/1 329.6 1.585 2.3296833F531/M 2/1 355.2 0.925 2.0406833F532/M 2/1 314.7 6.546 2.7386833F533/M 2/1 388.3 20.713 2.9256833F534/M 2/1 247.0 1.669 2.0566833F537/M 2/1 338.3 9.728 1.8486833F538/M 2/1 369.0 20.739 2.7196833F539/M 2/1 259.2 0.550 2.6676833F540/M 2/1 300.4 12.451 2.4146833F543/M 2/1 325.3 1.195 2.0896833F544/M 2/1 352.7 19.119 4.0196833F545/M 2/1 367.1 25.728 2.2096833F546/M 2/1 350.7 5.966 3.4926833F548/M 2/1 472.7 5.726 6.463M e a n: 354.6 9.596 2.748Standard deviation: 56.9 7.945 0.972Number of observ. : (29) (29) (29)6835G604/M 3/1 334.8 4.439 3.4006835G606/M 3/1 411.5 11.745 3.4636835G608/M 3/1 319.0 10.677 5.4366835G611/M 3/1 290.7 9.603 2.5556835G612/M 3/1 317.1 10.715 3.569*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 7Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6835G616/M 3/1 350.1 15.014 2.0176835G618/M 3/1 333.2 13.403 2.2206835G619/M 3/1 321.5 6.475 2.8286835G620/M 3/1 334.6 13.601 1.7336835G622/M 3/1 312.8 9.584 3.8106835G623/M 3/1 381.3 1.134 2.7956835G624/M 3/1 310.6 9.125 2.0896835G626/M 3/1 347.1 3.818 4.0926835G629/M 3/1 316.6 13.756 1.5916835G631/M 3/1 362.6 5.476 3.1386835G632/M 3/1 323.8 7.594 2.1256835G633/M 3/1 420.2 3.558 6.8316835G635/M 3/1 307.0 1.077 NT6835G637/M 3/1 326.4 4.382 2.4276835G640/M 3/1 291.4 21.296 2.4676835G641/M 3/1 349.9 16.627 3.2946835G642/M 3/1 334.1 7.449 3.7086835G643/M 3/1 407.3 1.308 5.1816835G644/M 3/1 353.4 10.510 2.7546835G645/M 3/1 323.0 0.887 4.9916835G646/M 3/1 356.0 21.891 2.8936835G650/M 3/1 341.9 0.995 2.911M e a n: 339.9 8.746 3.243Standard deviation: 33.5 5.964 1.244Number of observ. : (27) (27) (26)6837H701/M 4/1 253.6 1.142 4.1866837H703/M 4/1 435.2 2.411 2.0426837H707/M 4/1 353.8 24.826 1.4436837H709/M 4/1 362.3 16.549 1.9396837H710/M 4/1 305.8 1.664 4.0556837H711/M 4/1 358.8 1.350 4.2106837H712/M 4/1 348.6 1.084 3.0256837H713/M 4/1 301.4 3.950 1.9466837H715/M 4/1 365.1 13.526 2.6016837H716/M 4/1 411.5 1.018 3.5986837H719/M 4/1 365.4 19.724 2.9656837H720/M 4/1 301.7 10.114 2.5276837H721/M 4/1 362.5 1.269 6.211*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 8Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6837H723/M 4/1 333.5 15.525 1.6586837H727/M 4/1 304.8 12.195 2.3466837H730/M 4/1 334.0 1.369 5.8126837H731/M 4/1 304.6 5.152 2.3466837H733/M 4/1 298.5 11.018 1.9616837H734/M 4/1 316.5 5.461 4.2326837H737/M 4/1 323.8 15.703 1.3466837H738/M 4/1 330.4 7.892 2.6076837H740/M 4/1 315.5 8.076 2.4146837H742/M 4/1 307.8 15.130 1.6856837H743/M 4/1 301.2 7.466 4.2136837H744/M 4/1 296.4 11.692 2.0496837H745/M 4/1 273.9 0.465 2.9346837H746/M 4/1 287.8 7.929 1.2686837H748/M 4/1 364.1 14.579 2.4526837H750/M 4/1 305.6 9.684 NTM e a n: 328.4 8.550 2.860Standard deviation: 39.6 6.573 1.275Number of observ. : (29) (29) (28)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver OvariesF e m a l e A n i m a l s6832E453/F 1/1 219.3 0.059 1.874 0.827 1.761 13.580 2.049 0.1496832E455/F 1/1 279.2 0.070 1.901 0.969 1.877 9.411 1.419 0.1266832E457/F 1/1 201.2 0.077 1.949 0.952 1.881 7.826 1.869 0.0646832E459/F 1/1 223.0 0.070 1.931 0.942 1.698 19.564 2.491 0.0696832E465/F 1/1 192.6 0.065 1.859 0.855 1.557 4.828 0.969 0.0546832E466/F 1/1 237.0 0.053 1.911 1.010 1.737 9.505 1.871 0.1316832E468/F 1/1 260.6 0.057 1.977 1.064 1.824 7.881 1.378 0.1116832E469/F 1/1 201.9 0.071 1.832 0.950 2.041 6.956 1.640 0.0936832E470/F 1/1 239.4 0.055 1.913 0.825 1.680 11.924 3.381 0.0866832E471/F 1/1 236.9 0.057 1.866 1.141 1.880 11.599 2.997 0.0826832E474/F 1/1 189.3 0.054 2.018 0.993 1.765 8.193 2.036 0.0626832E476/F 1/1 259.5 0.067 1.903 1.038 2.028 13.141 2.965 0.0356832E479/F 1/1 263.3 0.071 1.949 1.282 1.950 9.869 2.131 0.1036832E481/F 1/1 203.4 0.066 1.854 0.809 1.589 7.212 1.228 0.1846832E482/F 1/1 250.2 0.071 1.974 1.192 2.257 14.427 2.649 0.0776832E484/F 1/1 212.8 0.055 1.912 1.196 2.219 10.267 2.731 0.0486832E485/F 1/1 211.2 0.068 1.813 1.027 1.876 12.211 2.263 0.1026832E487/F 1/1 226.0 0.067 1.930 0.825 1.687 12.808 2.153 0.0586832E488/F 1/1 220.2 0.074 1.839 0.999 1.962 7.663 1.148 0.0796832E491/F 1/1 217.6 0.085 1.993 1.018 2.167 11.452 2.390 0.0606832E492/F 1/1 186.5 0.055 1.831 0.691 1.382 5.019 0.959 0.0666832E494/F 1/1 276.5 0.053 1.899 1.071 1.779 8.133 1.179 0.0836832E496/F 1/1 200.1 0.057 1.839 1.127 1.996 8.842 2.402 0.0926832E499/F 1/1 248.6 0.049 1.819 0.798 1.670 10.709 1.434 0.097M e a n: 227.4 0.064 1.899 0.983 1.844 10.126 1.989 0.088Standard deviation: 27.6 0.009 0.058 0.146 0.212 3.277 0.685 0.034Number of observ. : (24) (24) (24) (24) (24) (24) (24) (24)6834F552/F 2/1 229.7 0.067 1.930 1.130 1.933 9.866 2.547 0.0666834F556/F 2/1 225.7 0.085 1.866 1.061 1.720 7.343 1.389 0.0376834F562/F 2/1 238.4 0.054 1.035 0.777 1.838 6.790 1.191 0.0956834F565/F 2/1 268.4 0.056 1.932 0.963 1.846 10.202 1.160 0.1376834F566/F 2/1 226.8 0.085 1.904 0.870 1.786 7.510 1.300 0.1046834F567/F 2/1 282.2 0.078 1.913 1.008 2.171 11.802 1.476 0.1386834F568/F 2/1 203.6 0.070 1.835 0.764 1.454 12.199 1.823 0.5556834F571/F 2/1 211.9 0.060 1.874 1.226 1.906 9.289 2.661 0.0586834F572/F 2/1 256.4 0.051 1.827 0.995 2.014 8.841 1.613 0.1256834F577/F 2/1 248.1 0.094 1.953 0.933 1.941 9.489 2.334 0.097*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6834F578/F 2/1 218.3 0.068 1.826 0.797 1.758 6.495 1.209 0.0746834F581/F 2/1 207.5 0.064 1.943 1.193 2.040 8.358 2.150 0.0986834F582/F 2/1 248.6 0.074 1.847 0.837 1.666 7.649 1.170 0.0626834F589/F 2/1 267.9 0.077 1.991 1.121 1.991 9.316 2.582 0.1526834F590/F 2/1 234.0 0.076 1.947 0.831 2.019 8.314 1.247 0.1526834F594/F 2/1 299.0 0.054 1.885 0.911 1.845 10.570 1.171 0.1086834F595/F 2/1 214.2 0.091 1.977 0.710 1.650 6.592 1.210 0.1016834F599/F 2/1 200.0 0.073 1.777 1.151 1.967 6.822 3.218 0.153M e a n: 237.8 0.071 1.848 0.960 1.864 8.747 1.747 0.128Standard deviation: 28.3 0.013 0.211 0.160 0.172 1.739 0.660 0.112Number of observ. : (18) (18) (18) (18) (18) (18) (18) (18)6836G653/F 3/1 207.9 0.084 1.879 0.892 1.416 6.856 1.277 0.1166836G659/F 3/1 232.0 0.049 1.922 1.057 2.088 9.467 3.251 0.0726836G664/F 3/1 223.0 0.044 1.870 0.862 1.850 7.449 1.315 0.0566836G676/F 3/1 232.8 0.069 1.942 1.005 1.988 11.130 2.743 0.0926836G678/F 3/1 235.4 0.066 1.882 0.787 1.970 8.714 1.668 0.1276836G679/F 3/1 217.4 0.064 1.851 0.769 1.824 7.610 1.214 0.0656836G680/F 3/1 213.1 0.055 1.951 1.283 2.137 9.056 2.880 0.0266836G682/F 3/1 223.1 0.069 1.866 0.952 1.736 15.168 3.080 0.3006836G683/F 3/1 240.7 0.053 1.916 0.970 1.747 7.473 1.190 0.1636836G685/F 3/1 186.6 0.064 1.891 0.932 1.676 7.213 1.881 0.0376836G687/F 3/1 223.0 0.079 1.962 1.012 2.142 11.239 1.869 0.0656836G688/F 3/1 246.4 0.060 1.920 0.938 2.104 10.718 2.452 0.1096836G691/F 3/1 156.8 0.093 1.743 0.612 1.265 5.034 1.090 0.0836836G695/F 3/1 204.4 0.067 2.060 0.894 1.937 8.129 1.209 0.0726836G696/F 3/1 175.2 0.065 1.665 0.590 1.302 6.162 0.935 0.0876836G698/F 3/1 226.0 0.052 1.842 0.845 1.926 8.064 1.731 0.0846836G699/F 3/1 153.9 0.054 1.777 0.516 1.195 4.320 0.982 0.089M e a n: 211.6 0.064 1.879 0.877 1.783 8.459 1.810 0.097Standard deviation: 27.9 0.013 0.090 0.187 0.314 2.594 0.781 0.062Number of observ. : (17) (17) (17) (17) (17) (17) (17) (17)6838H751/F 4/1 197.9 0.066 1.902 0.774 2.111 24.354 4.074 0.0646838H752/F 4/1 216.2 0.074 1.853 0.904 2.156 17.154 3.248 0.3316838H753/F 4/1 188.8 0.088 1.853 0.734 2.636 6.476 3.319 0.0616838H757/F 4/1 183.6 0.023 1.845 1.032 1.807 6.749 1.962 0.1206838H763/F 4/1 229.8 0.076 1.859 0.715 1.770 6.901 1.105 0.0926838H764/F 4/1 186.0 0.060 1.930 0.856 1.590 8.068 2.123 0.086*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6838H766/F 4/1 198.3 0.065 1.847 1.230 1.743 13.194 2.328 0.0566838H770/F 4/1 198.8 0.051 1.804 1.192 2.158 9.384 2.238 0.0266838H772/F 4/1 185.1 0.041 1.869 0.930 1.978 7.823 1.963 0.0466838H774/F 4/1 190.1 0.048 1.815 0.743 1.445 8.637 2.081 0.0516838H775/F 4/1 191.6 0.068 1.902 0.933 2.167 7.998 1.965 0.0546838H783/F 4/1 196.1 0.069 1.744 0.754 2.072 9.072 1.145 0.0806838H785/F 4/1 230.0 0.061 1.886 0.854 1.888 10.372 2.524 0.1286838H792/F 4/1 199.7 0.050 1.865 1.077 2.085 9.105 2.394 0.0666838H797/F 4/1 223.3 0.171 1.816 0.987 1.916 11.415 2.662 0.110M e a n: 201.0+ 0.067 1.853% 0.914 1.968 10.447 2.342 0.091Standard deviation: 16.0 0.033 0.046 0.164 0.286 4.747 0.776 0.072Number of observ. : (15) (15) (15) (15) (15) (15) (15) (15)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 4Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) SpleenF e m a l e A n i m a l s6832E453/F 1/1 219.3 3.201 2.8386832E455/F 1/1 279.2 1.025 NT6832E457/F 1/1 201.2 7.608 0.5206832E459/F 1/1 223.0 22.379 0.8796832E465/F 1/1 192.6 0.489 0.8656832E466/F 1/1 237.0 7.533 0.8966832E468/F 1/1 260.6 1.389 0.6946832E469/F 1/1 201.9 6.239 1.2796832E470/F 1/1 239.4 8.409 0.4616832E471/F 1/1 236.9 8.992 0.4376832E474/F 1/1 189.3 4.961 0.4516832E476/F 1/1 259.5 14.677 0.5976832E479/F 1/1 263.3 7.731 0.5796832E481/F 1/1 203.4 1.085 NT6832E482/F 1/1 250.2 12.009 0.4736832E484/F 1/1 212.8 1.819 0.5256832E485/F 1/1 211.2 7.873 1.5026832E487/F 1/1 226.0 18.072 0.8266832E488/F 1/1 220.2 0.641 0.4526832E491/F 1/1 217.6 12.931 0.8106832E492/F 1/1 186.5 0.454 0.7176832E494/F 1/1 276.5 0.857 0.5376832E496/F 1/1 200.1 6.146 0.7436832E499/F 1/1 248.6 10.111 0.639M e a n: 227.4 6.943 0.805Standard deviation: 27.6 5.928 0.528Number of observ. : (24) (24) (22)6834F552/F 2/1 229.7 6.415 0.7246834F556/F 2/1 225.7 1.951 15.6186834F562/F 2/1 238.4 0.571 1.1446834F565/F 2/1 268.4 0.669 0.6636834F566/F 2/1 226.8 1.357 7.5446834F567/F 2/1 282.2 3.049 0.6366834F568/F 2/1 203.6 7.143 0.6726834F571/F 2/1 211.9 7.282 0.4826834F572/F 2/1 256.4 16.685 0.7596834F577/F 2/1 248.1 0.833 0.996*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 5Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6834F578/F 2/1 218.3 0.614 0.7176834F581/F 2/1 207.5 7.529 0.5636834F582/F 2/1 248.6 1.668 28.0776834F589/F 2/1 267.9 6.510 9.4926834F590/F 2/1 234.0 0.639 NT6834F594/F 2/1 299.0 0.546 0.5126834F595/F 2/1 214.2 0.411 1.7236834F599/F 2/1 200.0 6.733 0.663M e a n: 237.8 3.923 4.176Standard deviation: 28.3 4.281 7.468Number of observ. : (18) (18) (17)6836G653/F 3/1 207.9 0.631 0.7056836G659/F 3/1 232.0 14.041 0.4946836G664/F 3/1 223.0 1.283 1.1176836G676/F 3/1 232.8 10.824 1.3516836G678/F 3/1 235.4 1.174 1.4716836G679/F 3/1 217.4 0.532 0.4486836G680/F 3/1 213.1 9.238 0.7926836G682/F 3/1 223.1 6.951 1.0956836G683/F 3/1 240.7 0.478 19.3076836G685/F 3/1 186.6 6.049 0.5746836G687/F 3/1 223.0 6.402 0.5706836G688/F 3/1 246.4 6.811 0.7316836G691/F 3/1 156.8 0.346 0.5466836G695/F 3/1 204.4 0.427 0.4476836G696/F 3/1 175.2 0.372 0.4086836G698/F 3/1 226.0 4.538 1.1156836G699/F 3/1 153.9 0.410 0.250M e a n: 211.6 4.147 1.848Standard deviation: 27.9 4.363 4.513Number of observ. : (17) (17) (17)6838H751/F 4/1 197.9 1.322 0.5776838H752/F 4/1 216.2 8.120 2.5706838H753/F 4/1 188.8 0.899 10.7516838H757/F 4/1 183.6 5.112 0.7106838H763/F 4/1 229.8 0.589 21.3526838H764/F 4/1 186.0 2.415 0.680*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary statistics for absolute organ weights (g) Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 6Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6838H766/F 4/1 198.3 12.559 0.6686838H770/F 4/1 198.8 4.392 1.0046838H772/F 4/1 185.1 2.453 0.6206838H774/F 4/1 190.1 5.702 0.6816838H775/F 4/1 191.6 3.654 0.7326838H783/F 4/1 196.1 0.678 0.4506838H785/F 4/1 230.0 5.651 0.7186838H792/F 4/1 199.7 13.648 0.5776838H797/F 4/1 223.3 7.103 0.578M e a n: 201.0+ 4.953 2.845Standard deviation: 16.0 4.060 5.746Number of observ. : (15) (15) (15)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-5 Percent Organ to Body Weight , Male and Female, Euthanized RatsLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys LungsM a l e A n i m a l s6831E401/M 1/1 350.8 0.019 0.624 0.182 0.362 0.785 5.147 0.8846831E402/M 1/1 375.6 0.014 NT 0.270 0.342 0.732 3.611 0.8046831E403/M 1/1 276.1 0.023 0.725 0.153 0.405 0.879 3.908 1.1256831E404/M 1/1 494.2 0.014 0.424 0.178 0.279 0.571 3.110 0.5856831E405/M 1/1 311.3 0.018 0.667 0.115 0.552 0.834 3.312 0.9706831E406/M 1/1 224.4 0.042 0.880 0.326 0.435 0.860 1.811 0.6166831E408/M 1/1 312.1 0.016 0.674 0.261 0.277 0.691 2.322 0.3706831E409/M 1/1 300.4 0.023 0.697 0.184 0.280 0.820 3.685 0.7386831E410/M 1/1 369.2 0.032 0.565 0.154 0.368 0.821 5.181 0.8126831E411/M 1/1 339.4 0.019 0.612 0.130 0.324 0.860 5.823 1.1656831E412/M 1/1 331.9 0.023 0.601 0.105 0.290 0.612 2.506 0.4076831E414/M 1/1 255.3 0.043 0.825 0.210 0.463 0.966 3.084 1.4346831E416/M 1/1 385.4 0.020 0.534 0.132 0.299 0.768 4.633 1.0746831E417/M 1/1 372.5 0.019 0.552 0.242 0.337 0.695 2.747 0.4746831E419/M 1/1 359.2 0.018 0.609 0.088 0.416 0.867 4.310 1.3746831E420/M 1/1 355.4 0.018 0.558 0.133 0.300 0.765 3.624 0.7336831E421/M 1/1 385.2 0.017 0.545 0.207 0.347 0.782 3.267 1.0626831E423/M 1/1 381.1 0.016 0.560 0.219 0.316 0.714 3.617 0.8576831E424/M 1/1 365.0 0.029 0.584 0.150 0.325 0.755 4.042 0.8536831E426/M 1/1 282.1 0.027 0.736 0.146 0.483 0.908 3.263 1.1606831E427/M 1/1 294.9 0.024 0.716 0.159 0.495 0.931 5.445 1.9826831E428/M 1/1 355.2 0.020 0.570 0.158 0.347 0.692 3.042 0.5646831E429/M 1/1 352.3 0.022 0.613 0.134 0.398 0.805 4.348 0.8666831E430/M 1/1 327.7 0.023 0.636 0.142 0.378 0.714 2.331 0.7726831E431/M 1/1 346.8 0.016 0.650 0.268 0.336 0.700 2.307 0.4136831E432/M 1/1 379.0 0.012 0.540 0.133 0.380 0.757 4.618 0.8596831E433/M 1/1 311.2 0.020 0.646 0.183 0.332 0.771 3.118 0.5006831E434/M 1/1 317.5 0.029 0.636 0.187 0.385 1.013 3.953 0.5296831E438/M 1/1 331.8 0.022 0.643 0.151 0.388 0.939 5.494 0.9596831E439/M 1/1 417.3 0.007 0.471 0.273 0.252 0.602 3.127 0.3536831E441/M 1/1 366.9 0.017 0.593 0.237 0.365 0.805 3.050 0.8406831E444/M 1/1 331.1 0.026 0.607 0.173 0.324 0.778 4.873 1.0256831E445/M 1/1 369.9 0.016 0.559 0.122 0.399 0.760 3.321 0.9466831E447/M 1/1 353.4 0.018 0.578 0.147 0.332 0.732 5.557 1.0196831E450/M 1/1 440.7 0.012 0.456 0.234 0.275 0.626 3.503 0.501M e a n: 346.4 0.021 0.614 0.180 0.360 0.780 3.745 0.846Standard deviation: 50.7 0.007 0.094 0.056 0.068 0.103 1.045 0.341Number of observ. : (35) (35) (34) (35) (35) (35) (35) (35)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6833F504/M 2/1 344.8 0.118 0.635 0.107 0.372 0.864 6.025 1.0456833F506/M 2/1 299.2 0.017 0.710 0.120 0.423 0.935 4.483 1.2276833F507/M 2/1 367.4 0.018 0.557 0.167 0.379 0.783 4.391 0.8686833F509/M 2/1 503.4 0.020 0.408 0.234 0.265 0.526 2.028 0.3396833F510/M 2/1 314.7 0.025 0.654 0.138 0.388 0.807 2.858 0.5136833F512/M 2/1 306.8 0.018 0.678 0.185 0.454 0.904 3.512 0.9836833F514/M 2/1 395.1 0.010 0.503 0.205 0.287 0.730 3.319 0.4716833F515/M 2/1 352.0 0.020 0.600 0.201 0.302 0.776 4.255 0.7926833F517/M 2/1 408.0 0.012 0.525 0.180 0.329 0.730 4.634 0.8216833F518/M 2/1 407.4 0.020 0.529 0.103 0.346 0.752 3.995 0.6836833F520/M 2/1 324.1 0.035 0.634 0.160 0.445 1.467 5.102 0.7986833F522/M 2/1 377.2 0.022 0.553 0.113 0.344 0.767 4.670 0.7576833F527/M 2/1 357.5 0.020 0.552 0.253 0.334 0.837 4.245 0.5626833F528/M 2/1 309.8 0.014 0.617 0.199 0.374 0.830 3.122 0.8836833F529/M 2/1 444.5 0.015 0.462 0.205 0.283 0.607 2.806 0.3696833F530/M 2/1 329.6 0.017 0.630 0.180 0.396 0.964 3.516 0.6626833F531/M 2/1 355.2 0.023 0.596 0.175 0.372 0.743 2.927 0.4746833F532/M 2/1 314.7 0.019 0.660 0.276 0.392 0.815 5.088 2.0496833F533/M 2/1 388.3 0.014 0.524 0.211 0.479 0.930 6.067 0.6116833F534/M 2/1 247.0 0.019 0.807 0.175 0.539 0.963 4.489 1.1436833F537/M 2/1 338.3 0.018 0.630 0.128 0.286 0.858 3.029 1.2196833F538/M 2/1 369.0 0.018 0.566 0.139 0.364 0.760 2.571 1.0336833F539/M 2/1 259.2 0.036 0.805 0.172 0.402 0.842 1.930 0.5696833F540/M 2/1 300.4 0.022 0.717 0.343 0.428 0.953 3.041 0.9696833F543/M 2/1 325.3 0.019 0.612 0.104 0.284 0.973 4.304 2.2526833F544/M 2/1 352.7 0.033 0.555 0.122 0.555 0.771 5.445 0.8406833F545/M 2/1 367.1 0.029 0.549 0.195 0.424 0.771 5.567 0.9116833F546/M 2/1 350.7 0.022 0.569 0.097 0.333 1.182 4.217 0.8146833F548/M 2/1 472.7 0.022 0.472 0.106 0.305 0.729 4.427 0.582M e a n: 354.6 0.024 0.597 0.172 0.375 0.847 4.002 0.870Standard deviation: 56.9 0.019 0.092 0.058 0.074 0.172 1.117 0.428Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29)6835G604/M 3/1 334.8 0.026 0.611 0.114 0.353 1.215 4.429 3.6416835G606/M 3/1 411.5 0.019 0.526 0.160 0.344 0.822 4.354 0.8016835G608/M 3/1 319.0 0.020 0.661 0.106 0.603 0.963 4.448 1.0746835G611/M 3/1 290.7 0.033 0.733 0.231 0.423 0.936 3.336 0.9766835G612/M 3/1 317.1 0.031 0.673 0.120 0.391 0.850 4.325 1.210*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6835G616/M 3/1 350.1 0.023 0.598 0.109 0.407 0.901 5.297 0.8326835G618/M 3/1 333.2 0.019 0.632 0.156 0.422 0.903 4.689 1.0946835G619/M 3/1 321.5 0.033 0.661 0.124 0.428 0.925 4.628 0.7646835G620/M 3/1 334.6 0.018 0.628 0.097 0.411 0.910 5.403 1.1846835G622/M 3/1 312.8 0.032 0.669 0.110 0.386 0.934 4.414 1.1196835G623/M 3/1 381.3 0.015 0.515 0.244 0.261 0.679 2.815 0.4606835G624/M 3/1 310.6 0.017 0.647 0.121 0.354 0.817 3.723 0.7976835G626/M 3/1 347.1 0.016 0.613 0.120 0.351 0.949 4.400 0.7246835G629/M 3/1 316.6 0.031 0.669 0.157 0.376 0.892 3.937 0.8336835G631/M 3/1 362.6 0.022 0.580 0.109 0.414 0.854 5.024 1.0156835G632/M 3/1 323.8 0.019 0.638 0.113 0.373 0.825 3.623 0.8116835G633/M 3/1 420.2 0.015 0.484 0.107 0.262 0.708 3.921 0.4546835G635/M 3/1 307.0 0.032 0.700 0.127 0.446 0.885 4.088 0.6376835G637/M 3/1 326.4 0.021 0.601 0.129 0.313 0.803 4.065 1.0266835G640/M 3/1 291.4 0.023 0.695 0.177 0.390 0.902 4.674 1.3056835G641/M 3/1 349.9 0.020 0.597 0.131 0.395 0.899 4.985 0.6936835G642/M 3/1 334.1 0.025 0.622 0.151 0.447 0.924 5.809 1.0396835G643/M 3/1 407.3 0.017 0.536 0.162 0.276 0.695 3.658 0.4026835G644/M 3/1 353.4 0.018 0.584 0.217 0.384 0.747 4.230 0.8346835G645/M 3/1 323.0 0.024 0.644 0.167 0.375 0.835 3.515 0.4956835G646/M 3/1 356.0 0.064 0.568 0.109 0.372 0.957 5.642 0.9506835G650/M 3/1 341.9 0.027 0.579 0.248 0.378 0.846 3.300 0.453M e a n: 339.9 0.024 0.617 0.145* 0.383 0.873$ 4.323 0.949Standard deviation: 33.5 0.010 0.059 0.044 0.066 0.105 0.736 0.594Number of observ. : (27) (27) (27) (27) (27) (27) (27) (27)6837H701/M 4/1 253.6 0.039 0.763 0.126 0.504 1.563 5.052 1.0866837H703/M 4/1 435.2 0.020 0.470 0.146 0.269 0.684 3.765 0.4166837H707/M 4/1 353.8 0.050 0.578 0.131 0.471 0.930 4.588 0.7456837H709/M 4/1 362.3 0.014 0.565 0.119 0.345 0.922 5.968 0.7786837H710/M 4/1 305.8 0.023 0.673 0.167 0.387 0.946 3.502 0.7586837H711/M 4/1 358.8 0.029 0.558 0.192 0.343 0.820 3.647 0.4956837H712/M 4/1 348.6 0.017 0.592 0.180 0.262 3.032 3.588 0.4786837H713/M 4/1 301.4 0.039 0.661 0.195 0.413 1.495 5.480 0.8396837H715/M 4/1 365.1 0.020 0.589 0.112 0.367 0.950 6.177 0.8506837H716/M 4/1 411.5 0.017 0.503 0.251 0.244 0.731 3.589 0.4406837H719/M 4/1 365.4 0.014 0.541 0.215 0.348 0.829 4.173 0.7206837H720/M 4/1 301.7 0.018 0.687 0.110 0.384 0.908 4.944 0.8316837H721/M 4/1 362.5 0.023 0.573 0.117 0.317 0.861 3.820 0.445*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 4Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6837H723/M 4/1 333.5 0.020 0.607 0.179 0.300 0.860 4.736 0.9366837H727/M 4/1 304.8 0.022 0.644 0.110 0.529 0.963 4.275 0.8696837H730/M 4/1 334.0 0.022 0.632 0.138 0.422 0.814 3.271 0.5526837H731/M 4/1 304.6 0.009 0.671 0.156 0.322 0.901 4.654 1.0716837H733/M 4/1 298.5 0.019 0.686 0.208 0.348 0.839 5.385 1.0736837H734/M 4/1 316.5 0.030 0.642 0.121 0.370 0.984 6.740 1.0336837H737/M 4/1 323.8 0.021 0.625 0.096 0.450 0.905 5.002 0.9716837H738/M 4/1 330.4 0.019 0.621 0.180 0.421 0.879 4.079 0.8206837H740/M 4/1 315.5 0.025 0.695 0.113 0.398 0.843 4.884 0.8916837H742/M 4/1 307.8 0.019 0.643 0.153 0.360 0.886 6.920 1.1716837H743/M 4/1 301.2 0.022 0.695 0.145 0.433 1.036 3.899 0.9116837H744/M 4/1 296.4 0.019 0.656 0.236 0.419 0.956 4.455 1.1116837H745/M 4/1 273.9 0.030 0.741 0.142 0.468 0.920 2.809 0.9256837H746/M 4/1 287.8 0.211 0.700 0.221 0.389 0.996 4.261 1.4406837H748/M 4/1 364.1 0.022 0.548 0.196 0.374 0.908 5.460 0.7736837H750/M 4/1 305.6 0.025 0.670 0.128 0.364 1.030 5.281 1.125M e a n: 328.4 0.030 0.629 0.158 0.380 1.013$ 4.635+ 0.847Standard deviation: 39.6 0.036 0.069 0.043 0.069 0.428 1.019 0.249Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 5Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) SpleenM a l e A n i m a l s6831E401/M 1/1 350.8 2.788 0.9296831E402/M 1/1 375.6 4.646 0.8036831E403/M 1/1 276.1 5.703 1.0516831E404/M 1/1 494.2 0.411 0.8636831E405/M 1/1 311.3 2.544 0.5316831E406/M 1/1 224.4 0.213 1.0316831E408/M 1/1 312.1 0.210 0.9646831E409/M 1/1 300.4 1.221 0.7716831E410/M 1/1 369.2 5.672 0.6906831E411/M 1/1 339.4 3.446 0.4846831E412/M 1/1 331.9 0.181 0.6666831E414/M 1/1 255.3 0.193 0.7726831E416/M 1/1 385.4 5.798 0.5536831E417/M 1/1 372.5 0.400 0.7986831E419/M 1/1 359.2 3.114 0.5816831E420/M 1/1 355.4 2.389 1.2996831E421/M 1/1 385.2 4.089 0.6666831E423/M 1/1 381.1 3.569 0.6966831E424/M 1/1 365.0 2.373 0.7366831E426/M 1/1 282.1 3.709 0.8216831E427/M 1/1 294.9 3.244 0.3416831E428/M 1/1 355.2 0.563 0.7836831E429/M 1/1 352.3 4.075 0.7156831E430/M 1/1 327.7 0.244 0.7196831E431/M 1/1 346.8 0.223 0.9116831E432/M 1/1 379.0 6.390 0.5246831E433/M 1/1 311.2 0.547 1.5076831E434/M 1/1 317.5 0.229 0.6946831E438/M 1/1 331.8 2.823 0.3756831E439/M 1/1 417.3 0.220 0.8196831E441/M 1/1 366.9 2.979 0.7276831E444/M 1/1 331.1 3.997 0.5766831E445/M 1/1 369.9 3.634 0.9006831E447/M 1/1 353.4 3.370 0.4826831E450/M 1/1 440.7 0.847 0.689M e a n: 346.4 2.459 0.756Standard deviation: 50.7 1.937 0.235Number of observ. : (35) (35) (35)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 6Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6833F504/M 2/1 344.8 4.963 0.5626833F506/M 2/1 299.2 5.043 0.7936833F507/M 2/1 367.4 4.151 0.6256833F509/M 2/1 503.4 0.332 0.5116833F510/M 2/1 314.7 0.319 0.9656833F512/M 2/1 306.8 2.276 0.5056833F514/M 2/1 395.1 1.200 0.6666833F515/M 2/1 352.0 2.784 0.6226833F517/M 2/1 408.0 6.091 0.8286833F518/M 2/1 407.4 0.665 0.7956833F520/M 2/1 324.1 1.395 0.8386833F522/M 2/1 377.2 3.224 0.6386833F527/M 2/1 357.5 5.500 0.7076833F528/M 2/1 309.8 2.824 0.7056833F529/M 2/1 444.5 0.298 1.0486833F530/M 2/1 329.6 0.481 0.7076833F531/M 2/1 355.2 0.260 0.5746833F532/M 2/1 314.7 2.080 0.8706833F533/M 2/1 388.3 5.334 0.7536833F534/M 2/1 247.0 0.676 0.8326833F537/M 2/1 338.3 2.876 0.5466833F538/M 2/1 369.0 5.620 0.7376833F539/M 2/1 259.2 0.212 1.0296833F540/M 2/1 300.4 4.145 0.8046833F543/M 2/1 325.3 0.367 0.6426833F544/M 2/1 352.7 5.421 1.1406833F545/M 2/1 367.1 7.008 0.6026833F546/M 2/1 350.7 1.701 0.9966833F548/M 2/1 472.7 1.211 1.367M e a n: 354.6 2.706 0.773Standard deviation: 56.9 2.166 0.203Number of observ. : (29) (29) (29)6835G604/M 3/1 334.8 1.326 1.0156835G606/M 3/1 411.5 2.854 0.8426835G608/M 3/1 319.0 3.347 1.7046835G611/M 3/1 290.7 3.303 0.8796835G612/M 3/1 317.1 3.379 1.126*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 7Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6835G616/M 3/1 350.1 4.288 0.5766835G618/M 3/1 333.2 4.023 0.6666835G619/M 3/1 321.5 2.014 0.8806835G620/M 3/1 334.6 4.065 0.5186835G622/M 3/1 312.8 3.064 1.2186835G623/M 3/1 381.3 0.297 0.7336835G624/M 3/1 310.6 2.938 0.6736835G626/M 3/1 347.1 1.100 1.1796835G629/M 3/1 316.6 4.344 0.5026835G631/M 3/1 362.6 1.510 0.8656835G632/M 3/1 323.8 2.345 0.6566835G633/M 3/1 420.2 0.847 1.6266835G635/M 3/1 307.0 0.351 NT6835G637/M 3/1 326.4 1.343 0.7446835G640/M 3/1 291.4 7.308 0.8476835G641/M 3/1 349.9 4.752 0.9416835G642/M 3/1 334.1 2.230 1.1106835G643/M 3/1 407.3 0.321 1.2726835G644/M 3/1 353.4 2.974 0.7796835G645/M 3/1 323.0 0.275 1.5456835G646/M 3/1 356.0 6.148 0.8136835G650/M 3/1 341.9 0.291 0.851M e a n: 339.9 2.631 0.945%Standard deviation: 33.5 1.842 0.324Number of observ. : (27) (27) (26)6837H701/M 4/1 253.6 0.450 1.6516837H703/M 4/1 435.2 0.554 0.4696837H707/M 4/1 353.8 7.016 0.4086837H709/M 4/1 362.3 4.568 0.5356837H710/M 4/1 305.8 0.544 1.3266837H711/M 4/1 358.8 0.376 1.1736837H712/M 4/1 348.6 0.311 0.8686837H713/M 4/1 301.4 1.311 0.6466837H715/M 4/1 365.1 3.704 0.7126837H716/M 4/1 411.5 0.247 0.8746837H719/M 4/1 365.4 5.398 0.8116837H720/M 4/1 301.7 3.352 0.8386837H721/M 4/1 362.5 0.350 1.714*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 8Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6837H723/M 4/1 333.5 4.656 0.4976837H727/M 4/1 304.8 4.001 0.7706837H730/M 4/1 334.0 0.410 1.7406837H731/M 4/1 304.6 1.691 0.7706837H733/M 4/1 298.5 3.691 0.6576837H734/M 4/1 316.5 1.725 1.3376837H737/M 4/1 323.8 4.849 0.4166837H738/M 4/1 330.4 2.389 0.7896837H740/M 4/1 315.5 2.560 0.7656837H742/M 4/1 307.8 4.916 0.5486837H743/M 4/1 301.2 2.479 1.3996837H744/M 4/1 296.4 3.945 0.6916837H745/M 4/1 273.9 0.170 1.0716837H746/M 4/1 287.8 2.755 0.4416837H748/M 4/1 364.1 4.004 0.6736837H750/M 4/1 305.6 3.169 NTM e a n: 328.4 2.607 0.878Standard deviation: 39.6 1.916 0.398Number of observ. : (29) (29) (28)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver OvariesF e m a l e A n i m a l s6832E453/F 1/1 219.3 0.027 0.855 0.377 0.803 6.193 0.934 0.0686832E455/F 1/1 279.2 0.025 0.681 0.347 0.672 3.371 0.508 0.0456832E457/F 1/1 201.2 0.038 0.969 0.473 0.935 3.889 0.929 0.0326832E459/F 1/1 223.0 0.031 0.866 0.422 0.761 8.774 1.117 0.0316832E465/F 1/1 192.6 0.034 0.965 0.444 0.808 2.506 0.503 0.0286832E466/F 1/1 237.0 0.022 0.806 0.426 0.733 4.010 0.789 0.0556832E468/F 1/1 260.6 0.022 0.759 0.408 0.700 3.024 0.529 0.0436832E469/F 1/1 201.9 0.035 0.907 0.470 1.011 3.445 0.812 0.0466832E470/F 1/1 239.4 0.023 0.799 0.345 0.702 4.980 1.412 0.0366832E471/F 1/1 236.9 0.024 0.788 0.482 0.793 4.895 1.265 0.0356832E474/F 1/1 189.3 0.029 1.066 0.525 0.933 4.329 1.076 0.0336832E476/F 1/1 259.5 0.026 0.733 0.400 0.781 5.063 1.142 0.0136832E479/F 1/1 263.3 0.027 0.740 0.487 0.741 3.748 0.809 0.0396832E481/F 1/1 203.4 0.032 0.911 0.398 0.781 3.545 0.604 0.0906832E482/F 1/1 250.2 0.028 0.789 0.476 0.902 5.766 1.059 0.0316832E484/F 1/1 212.8 0.026 0.898 0.562 1.043 4.824 1.283 0.0236832E485/F 1/1 211.2 0.032 0.858 0.486 0.888 5.780 1.071 0.0486832E487/F 1/1 226.0 0.030 0.854 0.365 0.746 5.667 0.953 0.0266832E488/F 1/1 220.2 0.034 0.835 0.454 0.891 3.480 0.521 0.0366832E491/F 1/1 217.6 0.039 0.916 0.468 0.996 5.262 1.098 0.0286832E492/F 1/1 186.5 0.029 0.982 0.371 0.741 2.692 0.514 0.0356832E494/F 1/1 276.5 0.019 0.687 0.387 0.643 2.942 0.426 0.0306832E496/F 1/1 200.1 0.028 0.919 0.563 0.997 4.419 1.200 0.0466832E499/F 1/1 248.6 0.020 0.732 0.321 0.672 4.308 0.577 0.039M e a n: 227.4 0.028 0.846 0.436 0.820 4.455 0.881 0.039Standard deviation: 27.6 0.005 0.099 0.066 0.119 1.391 0.298 0.016Number of observ. : (24) (24) (24) (24) (24) (24) (24) (24)6834F552/F 2/1 229.7 0.029 0.840 0.492 0.841 4.294 1.109 0.0296834F556/F 2/1 225.7 0.038 0.827 0.470 0.762 3.253 0.615 0.0166834F562/F 2/1 238.4 0.023 0.434 0.326 0.771 2.848 0.500 0.0406834F565/F 2/1 268.4 0.021 0.720 0.359 0.688 3.802 0.432 0.0516834F566/F 2/1 226.8 0.037 0.840 0.384 0.788 3.312 0.573 0.0466834F567/F 2/1 282.2 0.028 0.678 0.357 0.769 4.182 0.523 0.0496834F568/F 2/1 203.6 0.034 0.901 0.375 0.714 5.991 0.895 0.2736834F571/F 2/1 211.9 0.028 0.884 0.578 0.899 4.383 1.256 0.0276834F572/F 2/1 256.4 0.020 0.713 0.388 0.786 3.448 0.629 0.0496834F577/F 2/1 248.1 0.038 0.787 0.376 0.782 3.825 0.941 0.039*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6834F578/F 2/1 218.3 0.031 0.836 0.365 0.805 2.975 0.554 0.0346834F581/F 2/1 207.5 0.031 0.937 0.575 0.983 4.029 1.036 0.0476834F582/F 2/1 248.6 0.030 0.743 0.337 0.670 3.077 0.471 0.0256834F589/F 2/1 267.9 0.029 0.743 0.418 0.743 3.477 0.964 0.0576834F590/F 2/1 234.0 0.032 0.832 0.355 0.863 3.553 0.533 0.0656834F594/F 2/1 299.0 0.018 0.630 0.305 0.617 3.535 0.392 0.0366834F595/F 2/1 214.2 0.042 0.923 0.331 0.770 3.078 0.565 0.0476834F599/F 2/1 200.0 0.037 0.889 0.576 0.984 3.412 1.609 0.077M e a n: 237.8 0.030 0.786 0.409 0.791 3.693% 0.755 0.056Standard deviation: 28.3 0.007 0.124 0.090 0.097 0.730 0.335 0.056Number of observ. : (18) (18) (18) (18) (18) (18) (18) (18)6836G653/F 3/1 207.9 0.040 0.904 0.429 0.681 3.298 0.614 0.0566836G659/F 3/1 232.0 0.021 0.829 0.456 0.900 4.081 1.401 0.0316836G664/F 3/1 223.0 0.020 0.838 0.387 0.830 3.340 0.590 0.0256836G676/F 3/1 232.8 0.030 0.834 0.432 0.854 4.780 1.178 0.0406836G678/F 3/1 235.4 0.028 0.799 0.334 0.837 3.701 0.708 0.0546836G679/F 3/1 217.4 0.029 0.851 0.354 0.839 3.500 0.558 0.0306836G680/F 3/1 213.1 0.026 0.915 0.602 1.003 4.249 1.351 0.0126836G682/F 3/1 223.1 0.031 0.836 0.427 0.778 6.798 1.380 0.1346836G683/F 3/1 240.7 0.022 0.796 0.403 0.726 3.105 0.494 0.0686836G685/F 3/1 186.6 0.034 1.013 0.499 0.898 3.865 1.008 0.0206836G687/F 3/1 223.0 0.035 0.880 0.454 0.961 5.040 0.838 0.0296836G688/F 3/1 246.4 0.024 0.779 0.381 0.854 4.349 0.995 0.0446836G691/F 3/1 156.8 0.059 1.111 0.390 0.807 3.210 0.695 0.0536836G695/F 3/1 204.4 0.033 1.008 0.437 0.948 3.977 0.591 0.0356836G696/F 3/1 175.2 0.037 0.951 0.337 0.743 3.518 0.534 0.0506836G698/F 3/1 226.0 0.023 0.815 0.374 0.852 3.569 0.766 0.0376836G699/F 3/1 153.9 0.035 1.155 0.335 0.776 2.807 0.638 0.058M e a n: 211.6 0.031 0.901 0.414 0.840 3.952 0.844 0.046Standard deviation: 27.9 0.009 0.112 0.068 0.085 0.943 0.315 0.027Number of observ. : (17) (17) (17) (17) (17) (17) (17) (17)6838H751/F 4/1 197.9 0.033 0.961 0.391 1.067 12.308 2.059 0.0326838H752/F 4/1 216.2 0.034 0.857 0.418 0.997 7.934 1.502 0.1536838H753/F 4/1 188.8 0.047 0.981 0.389 1.396 3.429 1.758 0.0326838H757/F 4/1 183.6 0.013 1.005 0.562 0.984 3.676 1.069 0.0656838H763/F 4/1 229.8 0.033 0.809 0.311 0.770 3.003 0.481 0.0406838H764/F 4/1 186.0 0.032 1.038 0.460 0.855 4.337 1.141 0.046*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6838H766/F 4/1 198.3 0.033 0.931 0.620 0.879 6.652 1.174 0.0286838H770/F 4/1 198.8 0.026 0.907 0.600 1.085 4.720 1.126 0.0136838H772/F 4/1 185.1 0.022 1.010 0.502 1.069 4.226 1.061 0.0256838H774/F 4/1 190.1 0.025 0.955 0.391 0.760 4.543 1.095 0.0276838H775/F 4/1 191.6 0.035 0.993 0.487 1.131 4.174 1.026 0.0286838H783/F 4/1 196.1 0.035 0.889 0.385 1.057 4.626 0.584 0.0416838H785/F 4/1 230.0 0.027 0.820 0.371 0.821 4.510 1.097 0.0566838H792/F 4/1 199.7 0.025 0.934 0.539 1.044 4.560 1.199 0.0336838H797/F 4/1 223.3 0.077 0.813 0.442 0.858 5.112 1.192 0.049M e a n: 201.0+ 0.033 0.927 0.458 0.985$ 5.187 1.171* 0.045Standard deviation: 16.0 0.014 0.075 0.091 0.167 2.315 0.389 0.033Number of observ. : (15) (15) (15) (15) (15) (15) (15) (15)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 4Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) SpleenF e m a l e A n i m a l s6832E453/F 1/1 219.3 1.460 1.2946832E455/F 1/1 279.2 0.367 NT6832E457/F 1/1 201.2 3.781 0.2586832E459/F 1/1 223.0 10.036 0.3946832E465/F 1/1 192.6 0.254 0.4496832E466/F 1/1 237.0 3.178 0.3786832E468/F 1/1 260.6 0.533 0.2666832E469/F 1/1 201.9 3.090 0.6336832E470/F 1/1 239.4 3.512 0.1936832E471/F 1/1 236.9 3.795 0.1846832E474/F 1/1 189.3 2.621 0.2386832E476/F 1/1 259.5 5.655 0.2306832E479/F 1/1 263.3 2.936 0.2206832E481/F 1/1 203.4 0.533 NT6832E482/F 1/1 250.2 4.799 0.1896832E484/F 1/1 212.8 0.855 0.2476832E485/F 1/1 211.2 3.727 0.7116832E487/F 1/1 226.0 7.996 0.3656832E488/F 1/1 220.2 0.291 0.2056832E491/F 1/1 217.6 5.942 0.3726832E492/F 1/1 186.5 0.243 0.3856832E494/F 1/1 276.5 0.310 0.1946832E496/F 1/1 200.1 3.071 0.3716832E499/F 1/1 248.6 4.067 0.257M e a n: 227.4 3.044 0.365Standard deviation: 27.6 2.575 0.250Number of observ. : (24) (24) (22)6834F552/F 2/1 229.7 2.792 0.3156834F556/F 2/1 225.7 0.864 6.9206834F562/F 2/1 238.4 0.239 0.4806834F565/F 2/1 268.4 0.249 0.2476834F566/F 2/1 226.8 0.598 3.3276834F567/F 2/1 282.2 1.080 0.2256834F568/F 2/1 203.6 3.508 0.3306834F571/F 2/1 211.9 3.436 0.2276834F572/F 2/1 256.4 6.507 0.2966834F577/F 2/1 248.1 0.336 0.401*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 5Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6834F578/F 2/1 218.3 0.281 0.3286834F581/F 2/1 207.5 3.629 0.2716834F582/F 2/1 248.6 0.671 11.2946834F589/F 2/1 267.9 2.430 3.5436834F590/F 2/1 234.0 0.273 NT6834F594/F 2/1 299.0 0.183 0.1716834F595/F 2/1 214.2 0.192 0.8046834F599/F 2/1 200.0 3.367 0.332M e a n: 237.8 1.702 1.736Standard deviation: 28.3 1.810 3.058Number of observ. : (18) (18) (17)6836G653/F 3/1 207.9 0.303 0.3396836G659/F 3/1 232.0 6.053 0.2136836G664/F 3/1 223.0 0.575 0.5016836G676/F 3/1 232.8 4.649 0.5806836G678/F 3/1 235.4 0.499 0.6256836G679/F 3/1 217.4 0.245 0.2066836G680/F 3/1 213.1 4.335 0.3726836G682/F 3/1 223.1 3.115 0.4916836G683/F 3/1 240.7 0.199 8.0216836G685/F 3/1 186.6 3.242 0.3086836G687/F 3/1 223.0 2.871 0.2566836G688/F 3/1 246.4 2.764 0.2976836G691/F 3/1 156.8 0.221 0.3486836G695/F 3/1 204.4 0.209 0.2196836G696/F 3/1 175.2 0.212 0.2336836G698/F 3/1 226.0 2.008 0.4936836G699/F 3/1 153.9 0.266 0.162M e a n: 211.6 1.869 0.804Standard deviation: 27.9 1.917 1.865Number of observ. : (17) (17) (17)6838H751/F 4/1 197.9 0.668 0.2926838H752/F 4/1 216.2 3.756 1.1896838H753/F 4/1 188.8 0.476 5.6936838H757/F 4/1 183.6 2.784 0.3876838H763/F 4/1 229.8 0.256 9.2926838H764/F 4/1 186.0 1.298 0.366*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Body Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 6Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6838H766/F 4/1 198.3 6.332 0.3376838H770/F 4/1 198.8 2.209 0.5056838H772/F 4/1 185.1 1.325 0.3356838H774/F 4/1 190.1 2.999 0.3586838H775/F 4/1 191.6 1.907 0.3826838H783/F 4/1 196.1 0.346 0.2296838H785/F 4/1 230.0 2.457 0.3126838H792/F 4/1 199.7 6.836 0.2896838H797/F 4/1 223.3 3.181 0.259M e a n: 201.0+ 2.455 1.348Standard deviation: 16.0 2.004 2.596Number of observ. : (15) (15) (15)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-6 Percent Organ to Brain Wei ght, Male and Female, Euthanized RatsLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys LungsM a l e A n i m a l s6831E401/M 1/1 350.8 3.061 100.000 29.146 58.063 125.765 824.852 141.6636831E402/M 1/1 375.6 NT6831E403/M 1/1 276.1 3.195 100.000 21.118 55.866 121.118 538.792 155.0676831E404/M 1/1 494.2 3.391 100.000 42.073 65.903 134.862 734.145 137.9666831E405/M 1/1 311.3 2.699 100.000 17.205 82.795 125.060 496.916 145.5426831E406/M 1/1 224.4 4.813 100.000 37.031 49.443 97.771 205.826 70.0616831E408/M 1/1 312.1 2.423 100.000 38.765 41.140 102.470 344.276 54.8696831E409/M 1/1 300.4 3.295 100.000 26.457 40.210 117.670 528.606 105.9226831E410/M 1/1 369.2 5.654 100.000 27.168 65.069 145.232 916.579 143.7476831E411/M 1/1 339.4 3.080 100.000 21.174 52.839 140.520 950.962 190.2796831E412/M 1/1 331.9 3.862 100.000 17.553 48.195 101.856 417.101 67.8036831E414/M 1/1 255.3 5.178 100.000 25.463 56.105 117.102 374.014 173.9196831E416/M 1/1 385.4 3.841 100.000 24.648 55.955 143.996 868.206 201.2156831E417/M 1/1 372.5 3.504 100.000 43.893 61.168 126.034 497.956 85.8396831E419/M 1/1 359.2 3.015 100.000 14.390 68.296 142.257 707.218 225.4916831E420/M 1/1 355.4 3.278 100.000 23.802 53.757 137.166 649.471 131.4176831E421/M 1/1 385.2 3.051 100.000 37.989 63.680 143.613 599.857 195.0436831E423/M 1/1 381.1 2.857 100.000 39.063 56.347 127.447 645.714 152.9746831E424/M 1/1 365.0 4.972 100.000 25.657 55.629 129.268 692.073 146.0136831E426/M 1/1 282.1 3.709 100.000 19.894 65.655 123.459 443.497 157.6596831E427/M 1/1 294.9 3.412 100.000 22.180 69.242 130.095 760.995 276.9676831E428/M 1/1 355.2 3.510 100.000 27.781 60.900 121.453 534.058 99.0616831E429/M 1/1 352.3 3.566 100.000 21.816 64.937 131.357 709.588 141.3626831E430/M 1/1 327.7 3.553 100.000 22.372 59.530 112.338 366.683 121.4596831E431/M 1/1 346.8 2.483 100.000 41.286 51.707 107.716 354.856 63.5486831E432/M 1/1 379.0 2.296 100.000 24.670 70.298 140.156 855.154 159.0136831E433/M 1/1 311.2 3.033 100.000 28.294 51.367 119.344 482.596 77.3746831E434/M 1/1 317.5 4.604 100.000 29.406 60.446 159.208 621.436 83.2186831E438/M 1/1 331.8 3.466 100.000 23.419 60.234 145.995 853.911 149.0876831E439/M 1/1 417.3 1.476 100.000 57.913 53.588 127.888 664.122 74.9626831E441/M 1/1 366.9 2.940 100.000 39.917 61.461 135.645 513.964 141.5256831E444/M 1/1 331.1 4.227 100.000 28.543 53.307 128.046 802.188 168.7726831E445/M 1/1 369.9 2.951 100.000 21.867 71.456 135.994 594.388 169.2796831E447/M 1/1 353.4 3.033 100.000 25.489 57.436 126.566 960.665 176.1256831E450/M 1/1 440.7 2.586 100.000 51.367 60.368 137.195 767.678 109.896M e a n: 346.4 3.412 100.000 29.377 58.894 128.284 625.834 138.063Standard deviation: 50.7 0.867 0.000 10.095 8.553 13.808 193.580 49.938Number of observ. : (35) (34) (34) (34) (34) (34) (34) (34)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6833F504/M 2/1 344.8 18.647 100.000 16.865 58.638 136.197 949.406 164.6716833F506/M 2/1 299.2 2.354 100.000 16.855 59.652 131.780 631.450 172.7876833F507/M 2/1 367.4 3.271 100.000 30.029 67.969 140.479 787.744 155.7136833F509/M 2/1 503.4 4.869 100.000 57.352 64.946 128.822 496.933 83.2046833F510/M 2/1 314.7 3.841 100.000 21.050 59.310 123.432 437.190 78.4646833F512/M 2/1 306.8 2.646 100.000 27.273 67.003 133.430 518.182 145.0226833F514/M 2/1 395.1 2.014 100.000 40.786 57.100 145.317 660.222 93.6566833F515/M 2/1 352.0 3.269 100.000 33.444 50.403 129.370 709.427 132.1176833F517/M 2/1 408.0 2.194 100.000 34.314 62.745 139.076 882.633 156.3036833F518/M 2/1 407.4 3.852 100.000 19.536 65.429 142.181 755.313 129.1886833F520/M 2/1 324.1 5.447 100.000 25.195 70.088 231.274 804.232 125.8276833F522/M 2/1 377.2 3.931 100.000 20.518 62.272 138.686 844.535 136.8176833F527/M 2/1 357.5 3.651 100.000 45.791 60.497 151.826 769.523 101.8266833F528/M 2/1 309.8 2.302 100.000 32.234 60.649 134.537 506.122 143.1196833F529/M 2/1 444.5 3.212 100.000 44.234 61.168 131.241 606.813 79.8056833F530/M 2/1 329.6 2.648 100.000 28.551 62.879 152.961 557.920 104.9596833F531/M 2/1 355.2 3.873 100.000 29.334 62.494 124.705 491.167 79.5946833F532/M 2/1 314.7 2.938 100.000 41.908 59.489 123.459 771.195 310.5496833F533/M 2/1 388.3 2.652 100.000 40.275 91.405 177.358 1157.122 116.5036833F534/M 2/1 247.0 2.358 100.000 21.626 66.834 119.318 556.297 141.5966833F537/M 2/1 338.3 2.911 100.000 20.282 45.399 136.197 481.033 193.5686833F538/M 2/1 369.0 3.162 100.000 24.629 64.447 134.403 454.624 182.6076833F539/M 2/1 259.2 4.454 100.000 21.312 49.856 104.598 239.655 70.6426833F540/M 2/1 300.4 3.063 100.000 47.749 59.629 132.854 423.852 135.1286833F543/M 2/1 325.3 3.065 100.000 16.985 46.432 159.095 703.668 368.1416833F544/M 2/1 352.7 5.876 100.000 22.075 100.000 138.937 981.298 151.3546833F545/M 2/1 367.1 5.211 100.000 35.534 77.171 140.546 1014.194 166.0556833F546/M 2/1 350.7 3.862 100.000 17.101 58.576 207.824 741.775 143.1806833F548/M 2/1 472.7 4.617 100.000 22.411 64.680 154.370 938.100 123.263M e a n: 354.6 4.007 100.000 29.491 63.350 142.906$ 685.228 144.333Standard deviation: 56.9 2.992 0.000 10.890 11.255 25.374 212.442 63.668Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29)6835G604/M 3/1 334.8 4.205 100.000 18.729 57.848 198.924 725.232 596.1866835G606/M 3/1 411.5 3.558 100.000 30.360 65.342 156.377 827.911 152.3116835G608/M 3/1 319.0 3.082 100.000 16.074 91.275 145.661 672.736 162.3996835G611/M 3/1 290.7 4.503 100.000 31.473 57.645 127.674 454.831 133.0686835G612/M 3/1 317.1 4.548 100.000 17.768 58.134 126.395 642.991 179.887*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6835G616/M 3/1 350.1 3.774 100.000 18.204 68.132 150.693 886.049 139.1306835G618/M 3/1 333.2 3.040 100.000 24.656 66.746 142.945 742.233 173.1596835G619/M 3/1 321.5 4.986 100.000 18.768 64.722 139.840 700.000 115.4756835G620/M 3/1 334.6 2.854 100.000 15.509 65.366 144.910 859.991 188.4406835G622/M 3/1 312.8 4.823 100.000 16.380 57.593 139.446 659.312 167.1926835G623/M 3/1 381.3 2.853 100.000 47.478 50.739 131.890 546.867 89.3026835G624/M 3/1 310.6 2.685 100.000 18.697 54.699 126.256 574.988 123.0736835G626/M 3/1 347.1 2.540 100.000 19.567 57.291 154.892 718.344 118.2036835G629/M 3/1 316.6 4.582 100.000 23.524 56.259 133.349 588.899 124.6106835G631/M 3/1 362.6 3.757 100.000 18.783 71.422 147.171 866.239 175.0366835G632/M 3/1 323.8 3.002 100.000 17.724 58.450 129.395 568.039 127.2156835G633/M 3/1 420.2 3.150 100.000 22.146 54.232 146.506 810.778 93.8486835G635/M 3/1 307.0 4.512 100.000 18.093 63.628 126.419 583.674 90.9306835G637/M 3/1 326.4 3.464 100.000 21.396 51.961 133.469 675.904 170.6576835G640/M 3/1 291.4 3.356 100.000 25.420 56.120 129.714 672.261 187.7596835G641/M 3/1 349.9 3.352 100.000 21.983 66.140 150.671 835.249 116.1886835G642/M 3/1 334.1 4.092 100.000 24.218 71.883 148.676 934.425 167.0686835G643/M 3/1 407.3 3.208 100.000 30.293 51.604 129.789 682.722 75.1156835G644/M 3/1 353.4 3.004 100.000 37.209 65.795 127.907 724.322 142.7816835G645/M 3/1 323.0 3.800 100.000 25.926 58.297 129.774 546.128 76.9126835G646/M 3/1 356.0 11.270 100.000 19.229 65.497 168.512 993.030 167.2276835G650/M 3/1 341.9 4.750 100.000 42.850 65.235 146.185 570.086 78.272M e a n: 339.9 3.954 100.000 23.795 61.928 141.979$ 706.046 153.016Standard deviation: 33.5 1.632 0.000 8.155 8.381 15.940 134.204 95.551Number of observ. : (27) (27) (27) (27) (27) (27) (27) (27)6837H701/M 4/1 253.6 5.114 100.000 16.477 65.961 204.700 661.725 142.2006837H703/M 4/1 435.2 4.348 100.000 30.972 57.255 145.383 800.537 88.4226837H707/M 4/1 353.8 8.611 100.000 22.701 81.556 160.959 794.276 128.9636837H709/M 4/1 362.3 2.395 100.000 21.017 61.046 163.196 1056.647 137.7816837H710/M 4/1 305.8 3.403 100.000 24.842 57.560 140.593 520.661 112.6886837H711/M 4/1 358.8 5.197 100.000 34.483 61.569 146.977 654.123 88.7066837H712/M 4/1 348.6 2.811 100.000 30.393 44.256 512.361 606.253 80.7566837H713/M 4/1 301.4 5.971 100.000 29.453 62.469 226.091 828.600 126.8446837H715/M 4/1 365.1 3.443 100.000 18.986 62.355 161.424 1049.558 144.4396837H716/M 4/1 411.5 3.430 100.000 49.903 48.502 145.217 713.333 87.3916837H719/M 4/1 365.4 2.529 100.000 39.656 64.340 153.212 771.169 133.0306837H720/M 4/1 301.7 2.555 100.000 15.960 55.834 132.112 719.142 120.8786837H721/M 4/1 362.5 3.996 100.000 20.462 55.368 150.265 666.635 77.660*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 4Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Heart LiverNo/sex Subgroup Body wt. (g) Adrenal glands Epididymis Kidneys Lungs6837H723/M 4/1 333.5 3.259 100.000 29.432 49.333 141.679 779.852 154.0746837H727/M 4/1 304.8 3.466 100.000 17.023 82.161 149.592 664.016 134.9646837H730/M 4/1 334.0 3.458 100.000 21.838 66.698 128.849 517.480 87.3056837H731/M 4/1 304.6 1.369 100.000 23.227 47.971 134.132 693.203 159.5116837H733/M 4/1 298.5 2.734 100.000 30.322 50.684 122.314 784.814 156.4456837H734/M 4/1 316.5 4.727 100.000 18.808 57.706 153.324 1050.369 161.0546837H737/M 4/1 323.8 3.409 100.000 15.366 71.937 144.862 800.297 155.3366837H738/M 4/1 330.4 3.021 100.000 29.045 67.836 141.472 656.676 131.9696837H740/M 4/1 315.5 3.648 100.000 16.279 57.228 121.295 702.736 128.1816837H742/M 4/1 307.8 2.932 100.000 23.862 56.016 137.867 1076.744 182.2556837H743/M 4/1 301.2 3.152 100.000 20.917 62.273 148.997 560.745 130.9936837H744/M 4/1 296.4 2.831 100.000 35.924 63.973 145.805 679.568 169.5326837H745/M 4/1 273.9 4.041 100.000 19.172 63.184 124.199 379.202 124.8406837H746/M 4/1 287.8 30.060 100.000 31.548 55.556 142.163 608.333 205.6056837H748/M 4/1 364.1 4.006 100.000 35.704 68.152 165.648 995.594 140.9116837H750/M 4/1 305.6 3.763 100.000 19.062 54.399 153.763 788.661 167.937M e a n: 328.4 4.610 100.000 25.615 60.454 162.016% 744.171* 133.127Standard deviation: 39.6 5.072 0.000 8.330 8.911 70.816 172.255 31.712Number of observ. : (29) (29) (29) (29) (29) (29) (29) (29)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 5Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) SpleenM a l e A n i m a l s6831E401/M 1/1 350.8 446.871 148.9266831E402/M 1/1 375.66831E403/M 1/1 276.1 786.320 144.9336831E404/M 1/1 494.2 97.087 203.7256831E405/M 1/1 311.3 381.735 79.6146831E406/M 1/1 224.4 24.164 117.1736831E408/M 1/1 312.1 31.069 142.8986831E409/M 1/1 300.4 175.215 110.5546831E410/M 1/1 369.2 1003.498 121.9936831E411/M 1/1 339.4 562.849 79.0186831E412/M 1/1 331.9 30.191 110.9336831E414/M 1/1 255.3 23.373 93.6346831E416/M 1/1 385.4 1086.339 103.5976831E417/M 1/1 372.5 72.457 144.7206831E419/M 1/1 359.2 510.964 95.2496831E420/M 1/1 355.4 428.139 232.8296831E421/M 1/1 385.2 750.667 122.3076831E423/M 1/1 381.1 637.143 124.1696831E424/M 1/1 365.0 406.285 126.0326831E426/M 1/1 282.1 504.094 111.5136831E427/M 1/1 294.9 453.365 47.6306831E428/M 1/1 355.2 98.863 137.5686831E429/M 1/1 352.3 664.891 116.6286831E430/M 1/1 327.7 38.310 113.0586831E431/M 1/1 346.8 34.235 140.1776831E432/M 1/1 379.0 1183.244 96.9716831E433/M 1/1 311.2 84.635 233.2676831E434/M 1/1 317.5 35.941 109.1096831E438/M 1/1 331.8 438.689 58.3616831E439/M 1/1 417.3 46.768 173.8936831E441/M 1/1 366.9 502.021 122.4626831E444/M 1/1 331.1 658.081 94.8786831E445/M 1/1 369.9 650.460 161.1036831E447/M 1/1 353.4 582.583 83.3666831E450/M 1/1 440.7 185.679 150.970M e a n: 346.4 400.477 125.096Standard deviation: 50.7 332.180 41.734Number of observ. : (35) (34) (34)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 6Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6833F504/M 2/1 344.8 782.038 88.4836833F506/M 2/1 299.2 710.452 111.7706833F507/M 2/1 367.4 744.727 112.0616833F509/M 2/1 503.4 81.402 125.1226833F510/M 2/1 314.7 48.858 147.5946833F512/M 2/1 306.8 335.835 74.5556833F514/M 2/1 395.1 238.822 132.4276833F515/M 2/1 352.0 464.235 103.6486833F517/M 2/1 408.0 1160.131 157.7036833F518/M 2/1 407.4 125.708 150.2096833F520/M 2/1 324.1 219.942 132.1506833F522/M 2/1 377.2 583.078 115.2926833F527/M 2/1 357.5 997.059 128.1446833F528/M 2/1 309.8 457.876 114.2336833F529/M 2/1 444.5 64.428 226.6676833F530/M 2/1 329.6 76.312 112.1336833F531/M 2/1 355.2 43.694 96.3636833F532/M 2/1 314.7 315.318 131.8886833F533/M 2/1 388.3 1017.338 143.6646833F534/M 2/1 247.0 83.743 103.1616833F537/M 2/1 338.3 456.714 86.7616833F538/M 2/1 369.0 993.723 130.2836833F539/M 2/1 259.2 26.341 127.7306833F540/M 2/1 300.4 577.773 112.0196833F543/M 2/1 325.3 60.050 104.9756833F544/M 2/1 352.7 976.955 205.3656833F545/M 2/1 367.1 1276.824 109.6286833F546/M 2/1 350.7 299.198 175.1256833F548/M 2/1 472.7 256.656 289.691M e a n: 354.6 464.663 132.719Standard deviation: 56.9 386.620 44.754Number of observ. : (29) (29) (29)6835G604/M 3/1 334.8 217.066 166.2596835G606/M 3/1 411.5 542.745 160.0286835G608/M 3/1 319.0 506.259 257.7536835G611/M 3/1 290.7 450.422 119.8416835G612/M 3/1 317.1 502.344 167.323*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 7Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6835G616/M 3/1 350.1 717.344 96.3696835G618/M 3/1 333.2 636.722 105.4636835G619/M 3/1 321.5 304.563 133.0206835G620/M 3/1 334.6 647.050 82.4456835G622/M 3/1 312.8 457.689 181.9486835G623/M 3/1 381.3 57.769 142.3846835G624/M 3/1 310.6 453.754 103.8796835G626/M 3/1 347.1 179.586 192.4746835G629/M 3/1 316.6 649.787 75.1546835G631/M 3/1 362.6 260.390 149.2156835G632/M 3/1 323.8 367.748 102.9066835G633/M 3/1 420.2 175.098 336.1716835G635/M 3/1 307.0 50.093 NT6835G637/M 3/1 326.4 223.230 123.6376835G640/M 3/1 291.4 1051.135 121.7676835G641/M 3/1 349.9 796.312 157.7596835G642/M 3/1 334.1 358.642 178.5276835G643/M 3/1 407.3 59.945 237.4436835G644/M 3/1 353.4 509.205 133.4306835G645/M 3/1 323.0 42.665 240.0676835G646/M 3/1 356.0 1082.106 143.0056835G650/M 3/1 341.9 50.278 147.095M e a n: 339.9 420.368 155.975Standard deviation: 33.5 289.464 59.301Number of observ. : (27) (27) (26)6837H701/M 4/1 253.6 58.988 216.2196837H703/M 4/1 435.2 117.782 99.7566837H707/M 4/1 353.8 1214.579 70.5976837H709/M 4/1 362.3 808.847 94.7706837H710/M 4/1 305.8 80.895 197.1326837H711/M 4/1 358.8 67.466 210.3956837H712/M 4/1 348.6 52.545 146.6316837H713/M 4/1 301.4 198.194 97.6426837H715/M 4/1 365.1 629.409 121.0336837H716/M 4/1 411.5 49.179 173.8166837H719/M 4/1 365.4 997.673 149.9756837H720/M 4/1 301.7 487.657 121.8426837H721/M 4/1 362.5 61.098 299.037*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 8Unscheduled Sacrifices U2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal TestesNo/sex Subgroup Body wt. (g) Spleen6837H723/M 4/1 333.5 766.667 81.8776837H727/M 4/1 304.8 621.560 119.5726837H730/M 4/1 334.0 64.851 275.3206837H731/M 4/1 304.6 251.932 114.7196837H733/M 4/1 298.5 537.988 95.7526837H734/M 4/1 316.5 268.882 208.3706837H737/M 4/1 323.8 775.840 66.5026837H738/M 4/1 330.4 384.600 127.0476837H740/M 4/1 315.5 368.263 110.0786837H742/M 4/1 307.8 764.914 85.1876837H743/M 4/1 301.2 356.543 201.1946837H744/M 4/1 296.4 601.750 105.4556837H745/M 4/1 273.9 22.918 144.6036837H746/M 4/1 287.8 393.304 62.8976837H748/M 4/1 364.1 730.045 122.7846837H750/M 4/1 305.6 473.314 NTM e a n: 328.4 420.954 140.007Standard deviation: 39.6 325.797 61.350Number of observ. : (29) (29) (28)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver OvariesF e m a l e A n i m a l s6832E453/F 1/1 219.3 3.148 100.000 44.130 93.970 724.653 109.338 7.9516832E455/F 1/1 279.2 3.682 100.000 50.973 98.738 495.055 74.645 6.6286832E457/F 1/1 201.2 3.951 100.000 48.846 96.511 401.539 95.895 3.2846832E459/F 1/1 223.0 3.625 100.000 48.783 87.934 1013.154 129.001 3.5736832E465/F 1/1 192.6 3.497 100.000 45.992 83.755 259.710 52.125 2.9056832E466/F 1/1 237.0 2.773 100.000 52.852 90.895 497.384 97.907 6.8556832E468/F 1/1 260.6 2.883 100.000 53.819 92.261 398.634 69.702 5.6156832E469/F 1/1 201.9 3.876 100.000 51.856 111.408 379.694 89.520 5.0766832E470/F 1/1 239.4 2.875 100.000 43.126 87.820 623.314 176.738 4.4966832E471/F 1/1 236.9 3.055 100.000 61.147 100.750 621.597 160.611 4.3946832E474/F 1/1 189.3 2.676 100.000 49.207 87.463 405.996 100.892 3.0726832E476/F 1/1 259.5 3.521 100.000 54.545 106.569 690.541 155.807 1.8396832E479/F 1/1 263.3 3.643 100.000 65.777 100.051 506.362 109.338 5.2856832E481/F 1/1 203.4 3.560 100.000 43.635 85.707 388.997 66.235 9.9246832E482/F 1/1 250.2 3.597 100.000 60.385 114.336 730.851 134.195 3.9016832E484/F 1/1 212.8 2.877 100.000 62.552 116.057 536.977 142.835 2.5106832E485/F 1/1 211.2 3.751 100.000 56.646 103.475 673.525 124.821 5.6266832E487/F 1/1 226.0 3.472 100.000 42.746 87.409 663.627 111.554 3.0056832E488/F 1/1 220.2 4.024 100.000 54.323 106.688 416.694 62.425 4.2966832E491/F 1/1 217.6 4.265 100.000 51.079 108.731 574.611 119.920 3.0116832E492/F 1/1 186.5 3.004 100.000 37.739 75.478 274.113 52.376 3.6056832E494/F 1/1 276.5 2.791 100.000 56.398 93.681 428.278 62.085 4.3716832E496/F 1/1 200.1 3.100 100.000 61.283 108.537 480.805 130.614 5.0036832E499/F 1/1 248.6 2.694 100.000 43.870 91.809 588.730 78.835 5.333M e a n: 227.4 3.347 100.000 51.738 97.085 532.285 104.476 4.648Standard deviation: 27.6 0.468 0.000 7.308 10.670 169.006 35.502 1.852Number of observ. : (24) (24) (24) (24) (24) (24) (24) (24)6834F552/F 2/1 229.7 3.472 100.000 58.549 100.155 511.192 131.969 3.4206834F556/F 2/1 225.7 4.555 100.000 56.860 92.176 393.516 74.437 1.9836834F562/F 2/1 238.4 5.217 100.000 75.072 177.585 656.039 115.072 9.1796834F565/F 2/1 268.4 2.899 100.000 49.845 95.549 528.054 60.041 7.0916834F566/F 2/1 226.8 4.464 100.000 45.693 93.803 394.433 68.277 5.4626834F567/F 2/1 282.2 4.077 100.000 52.692 113.487 616.937 77.156 7.2146834F568/F 2/1 203.6 3.815 100.000 41.635 79.237 664.796 99.346 30.2456834F571/F 2/1 211.9 3.202 100.000 65.422 101.708 495.678 141.996 3.0956834F572/F 2/1 256.4 2.791 100.000 54.461 110.235 483.908 88.287 6.8426834F577/F 2/1 248.1 4.813 100.000 47.773 99.386 485.868 119.508 4.967*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6834F578/F 2/1 218.3 3.724 100.000 43.647 96.276 355.696 66.210 4.0536834F581/F 2/1 207.5 3.294 100.000 61.400 104.992 430.160 110.654 5.0446834F582/F 2/1 248.6 4.006 100.000 45.317 90.200 414.131 63.346 3.3576834F589/F 2/1 267.9 3.867 100.000 56.303 100.000 467.906 129.684 7.6346834F590/F 2/1 234.0 3.903 100.000 42.681 103.698 427.016 64.047 7.8076834F594/F 2/1 299.0 2.865 100.000 48.329 97.878 560.743 62.122 5.7296834F595/F 2/1 214.2 4.603 100.000 35.913 83.460 333.435 61.204 5.1096834F599/F 2/1 200.0 4.108 100.000 64.772 110.692 383.906 181.092 8.610M e a n: 237.8 3.871% 100.000 52.576 102.806 477.967 95.247 7.047Standard deviation: 28.3 0.697 0.000 9.979 20.664 98.416 35.306 6.133Number of observ. : (18) (18) (18) (18) (18) (18) (18) (18)6836G653/F 3/1 207.9 4.470 100.000 47.472 75.359 364.875 67.962 6.1736836G659/F 3/1 232.0 2.549 100.000 54.995 108.637 492.560 169.147 3.7466836G664/F 3/1 223.0 2.353 100.000 46.096 98.930 398.342 70.321 2.9956836G676/F 3/1 232.8 3.553 100.000 51.751 102.369 573.121 141.246 4.7376836G678/F 3/1 235.4 3.507 100.000 41.817 104.676 463.018 88.629 6.7486836G679/F 3/1 217.4 3.458 100.000 41.545 98.541 411.129 65.586 3.5126836G680/F 3/1 213.1 2.819 100.000 65.761 109.534 464.172 147.617 1.3336836G682/F 3/1 223.1 3.698 100.000 51.018 93.033 812.862 165.059 16.0776836G683/F 3/1 240.7 2.766 100.000 50.626 91.180 390.031 62.109 8.5076836G685/F 3/1 186.6 3.384 100.000 49.286 88.630 381.438 99.471 1.9576836G687/F 3/1 223.0 4.027 100.000 51.580 109.174 572.834 95.260 3.3136836G688/F 3/1 246.4 3.125 100.000 48.854 109.583 558.229 127.708 5.6776836G691/F 3/1 156.8 5.336 100.000 35.112 72.576 288.812 62.536 4.7626836G695/F 3/1 204.4 3.252 100.000 43.398 94.029 394.612 58.689 3.4956836G696/F 3/1 175.2 3.904 100.000 35.435 78.198 370.090 56.156 5.2256836G698/F 3/1 226.0 2.823 100.000 45.874 104.560 437.785 93.974 4.5606836G699/F 3/1 153.9 3.039 100.000 29.038 67.248 243.106 55.262 5.008M e a n: 211.6 3.415 100.000 46.451 94.486 448.060 95.690 5.166Standard deviation: 27.9 0.741 0.000 8.522 13.862 130.829 39.674 3.311Number of observ. : (17) (17) (17) (17) (17) (17) (17) (17)6838H751/F 4/1 197.9 3.470 100.000 40.694 110.988 1280.442 214.196 3.3656838H752/F 4/1 216.2 3.994 100.000 48.786 116.352 925.742 175.283 17.8636838H753/F 4/1 188.8 4.749 100.000 39.611 142.256 349.487 179.115 3.2926838H757/F 4/1 183.6 1.247 100.000 55.935 97.940 365.799 106.341 6.5046838H763/F 4/1 229.8 4.088 100.000 38.462 95.212 371.221 59.441 4.9496838H764/F 4/1 186.0 3.109 100.000 44.352 82.383 418.031 110.000 4.456*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal Brain Kidneys LungsNo/sex Subgroup Body wt. (g) Adrenal glands Heart Liver Ovaries6838H766/F 4/1 198.3 3.519 100.000 66.594 94.369 714.348 126.042 3.0326838H770/F 4/1 198.8 2.827 100.000 66.075 119.623 520.177 124.058 1.4416838H772/F 4/1 185.1 2.194 100.000 49.759 105.832 418.566 105.029 2.4616838H774/F 4/1 190.1 2.645 100.000 40.937 79.614 475.868 114.656 2.8106838H775/F 4/1 191.6 3.575 100.000 49.054 113.933 420.505 103.312 2.8396838H783/F 4/1 196.1 3.956 100.000 43.234 118.807 520.184 65.654 4.5876838H785/F 4/1 230.0 3.234 100.000 45.281 100.106 549.947 133.828 6.7876838H792/F 4/1 199.7 2.681 100.000 57.748 111.796 488.204 128.365 3.5396838H797/F 4/1 223.3 9.416 100.000 54.350 105.507 628.579 146.586 6.057M e a n: 201.0+ 3.647 100.000 49.392 106.315 563.140 126.127 4.932Standard deviation: 16.0 1.811 0.000 9.081 15.804 249.853 40.813 3.897Number of observ. : (15) (15) (15) (15) (15) (15) (15) (15)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 4Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) SpleenF e m a l e A n i m a l s6832E453/F 1/1 219.3 170.811 151.4416832E455/F 1/1 279.2 53.919 NT6832E457/F 1/1 201.2 390.354 26.6806832E459/F 1/1 223.0 1158.933 45.5206832E465/F 1/1 192.6 26.304 46.5306832E466/F 1/1 237.0 394.192 46.8866832E468/F 1/1 260.6 70.258 35.1046832E469/F 1/1 201.9 340.557 69.8146832E470/F 1/1 239.4 439.571 24.0986832E471/F 1/1 236.9 481.886 23.4196832E474/F 1/1 189.3 245.837 22.3496832E476/F 1/1 259.5 771.256 31.3726832E479/F 1/1 263.3 396.665 29.7086832E481/F 1/1 203.4 58.522 NT6832E482/F 1/1 250.2 608.359 23.9626832E484/F 1/1 212.8 95.136 27.4586832E485/F 1/1 211.2 434.253 82.8466832E487/F 1/1 226.0 936.373 42.7986832E488/F 1/1 220.2 34.856 24.5796832E491/F 1/1 217.6 648.821 40.6426832E492/F 1/1 186.5 24.795 39.1596832E494/F 1/1 276.5 45.129 28.2786832E496/F 1/1 200.1 334.203 40.4026832E499/F 1/1 248.6 555.855 35.129M e a n: 227.4 363.202 42.644Standard deviation: 27.6 307.168 28.581Number of observ. : (24) (24) (22)6834F552/F 2/1 229.7 332.383 37.5136834F556/F 2/1 225.7 104.555 836.9786834F562/F 2/1 238.4 55.169 110.5316834F565/F 2/1 268.4 34.627 34.3176834F566/F 2/1 226.8 71.271 396.2196834F567/F 2/1 282.2 159.383 33.2466834F568/F 2/1 203.6 389.264 36.6216834F571/F 2/1 211.9 388.581 25.7206834F572/F 2/1 256.4 913.246 41.5446834F577/F 2/1 248.1 42.652 50.998*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 5Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6834F578/F 2/1 218.3 33.625 39.2666834F581/F 2/1 207.5 387.494 28.9766834F582/F 2/1 248.6 90.309 1520.1416834F589/F 2/1 267.9 326.971 476.7456834F590/F 2/1 234.0 32.820 NT6834F594/F 2/1 299.0 28.966 27.1626834F595/F 2/1 214.2 20.789 87.1526834F599/F 2/1 200.0 378.897 37.310M e a n: 237.8 210.611 224.732Standard deviation: 28.3 231.151 400.890Number of observ. : (18) (18) (17)6836G653/F 3/1 207.9 33.582 37.5206836G659/F 3/1 232.0 730.541 25.7026836G664/F 3/1 223.0 68.610 59.7336836G676/F 3/1 232.8 557.364 69.5676836G678/F 3/1 235.4 62.380 78.1626836G679/F 3/1 217.4 28.741 24.2036836G680/F 3/1 213.1 473.501 40.5956836G682/F 3/1 223.1 372.508 58.6826836G683/F 3/1 240.7 24.948 1007.6726836G685/F 3/1 186.6 319.884 30.3546836G687/F 3/1 223.0 326.300 29.0526836G688/F 3/1 246.4 354.740 38.0736836G691/F 3/1 156.8 19.851 31.3256836G695/F 3/1 204.4 20.728 21.6996836G696/F 3/1 175.2 22.342 24.5056836G698/F 3/1 226.0 246.363 60.5326836G699/F 3/1 153.9 23.073 14.069M e a n: 211.6 216.791 97.144Standard deviation: 27.9 225.928 235.368Number of observ. : (17) (17) (17)6838H751/F 4/1 197.9 69.506 30.3366838H752/F 4/1 216.2 438.208 138.6946838H753/F 4/1 188.8 48.516 580.1946838H757/F 4/1 183.6 277.073 38.4826838H763/F 4/1 229.8 31.684 1148.5756838H764/F 4/1 186.0 125.130 35.233*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significanceLovelace Respiratory Summary Statistics for % Organ to Brain Weight Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 6Unscheduled Sacrifices U2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicAnimal Group/ Terminal UterusNo/sex Subgroup Body wt. (g) Spleen6838H766/F 4/1 198.3 679.968 36.1676838H770/F 4/1 198.8 243.459 55.6546838H772/F 4/1 185.1 131.247 33.1736838H774/F 4/1 190.1 314.160 37.5216838H775/F 4/1 191.6 192.114 38.4866838H783/F 4/1 196.1 38.876 25.8036838H785/F 4/1 230.0 299.629 38.0706838H792/F 4/1 199.7 731.796 30.9386838H797/F 4/1 223.3 391.134 31.828M e a n: 201.0+ 267.500 153.277Standard deviation: 16.0 219.343 309.239Number of observ. : (15) (15) (15)*(+) = mean value of group was significantly different from control at P = 0.05(0.01) with Dunnett’s test of significance%($) = mean value of group was significantly different from control at P = 0.05(0.01) with Modified T test of significance

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

K-7 Organ Weights for Animals that DiedLovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 1Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicTerminal Organ Relative RelativeAnimal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of BrainNo/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status6831E425/M 1/1 10-Feb-03 629/# 11-Feb-03 11:03 10-Feb-03 8 Adrenal glands 434.1 0.100 0.023 4.42 HIGH11-Feb-03 11:04 10-Feb-03 8 Brain 2.262 0.521 100.00 OK11-Feb-03 11:04 10-Feb-03 8 Epididymis 0.667 0.154 29.49 OK11-Feb-03 11:04 10-Feb-03 8 Heart 1.971 0.454 87.14 OK11-Feb-03 11:04 10-Feb-03 8 Kidneys 3.767 0.868 166.53 OK11-Feb-03 11:04 10-Feb-03 8 Liver 18.034 4.155 797.26 HIGH11-Feb-03 11:04 10-Feb-03 8 Lungs 2.140 0.493 94.61 OK11-Feb-03 11:04 10-Feb-03 8 Spleen 1.925 0.443 85.10 OK11-Feb-03 11:04 10-Feb-03 8 Testes 3.742 0.862 165.43 HIGH6833F501/M 2/1 24-Feb-03 643/# 27-Feb-03 16:49 24-Feb-03 128 Adrenal glands 357.8 0.041 0.011 1.88 OK27-Feb-03 16:49 24-Feb-03 128 Brain 2.183 0.610 100.00 OK27-Feb-03 16:52 24-Feb-03 128 Epididymis 0.481 0.134 22.03 OK27-Feb-03 16:52 24-Feb-03 128 Heart 1.581 0.442 72.42 OK27-Feb-03 16:52 24-Feb-03 128 Kidneys 3.835 1.072 175.68 OK27-Feb-03 16:52 24-Feb-03 128 Liver 15.500 4.332 710.03 HIGH27-Feb-03 16:52 24-Feb-03 128 Lungs 7.447 2.081 341.14 OK27-Feb-03 16:52 24-Feb-03 128 Spleen 10.926 3.054 500.50 HIGH27-Feb-03 16:52 24-Feb-03 128 Testes 3.181 0.889 145.72 HIGH6833F503/M 2/1 20-May-03 728/# 20-May-03 12:06 20-May-03 128 Adrenal glands 328.8 0.054 0.016 2.49 OK20-May-03 12:06 20-May-03 128 Brain 2.171 0.660 100.00 OK20-May-03 12:06 20-May-03 128 Epididymis 0.434 0.132 19.99 OK20-May-03 12:06 20-May-03 128 Heart 1.477 0.449 68.03 OK20-May-03 12:06 20-May-03 128 Kidneys 3.483 1.059 160.43 OK20-May-03 12:06 20-May-03 128 Liver 23.078 7.019 1063.01 HIGH20-May-03 12:06 20-May-03 128 Lungs 5.920 1.801 272.69 OK20-May-03 12:06 20-May-03 128 Spleen 13.861 4.216 638.46 HIGH20-May-03 12:06 20-May-03 128 Testes 2.396 0.729 110.36 HIGH6833F524/M 2/1 21-Jun-02 395/# 25-Jun-02 14:28 21-Jun-02 128 Adrenal glands 479.0 0.143 0.030 6.75 HIGH25-Jun-02 14:28 21-Jun-02 128 Brain 2.117 0.442 100.00 LOW25-Jun-02 14:29 21-Jun-02 128 Epididymis 1.730 0.361 81.72 OK25-Jun-02 14:28 21-Jun-02 128 Heart 1.534 0.320 72.46 OK25-Jun-02 14:28 21-Jun-02 128 Kidneys 3.981 0.831 188.05 OK25-Jun-02 14:29 21-Jun-02 128 Liver 18.813 3.927 888.66 OK25-Jun-02 14:29 21-Jun-02 128 Lungs 3.045 0.636 143.84 OK25-Jun-02 14:29 21-Jun-02 128 Spleen 0.969 0.202 45.77 OK25-Jun-02 14:29 21-Jun-02 128 Testes 3.615 0.755 170.76 HIGH6833F541/M 2/1 07-Mar-03 654/# 17-Mar-03 16:50 07-Mar-03 128 Adrenal glands 379.4 0.070 0.018 3.22 OK17-Mar-03 16:50 07-Mar-03 128 Brain 2.173 0.573 100.00 OK17-Mar-03 16:50 07-Mar-03 128 Epididymis 0.527 0.139 24.25 OK17-Mar-03 16:50 07-Mar-03 128 Heart 1.490 0.393 68.57 OK17-Mar-03 16:50 07-Mar-03 128 Kidneys 3.740 0.986 172.11 OK17-Mar-03 16:50 07-Mar-03 128 Liver 19.169 5.052 882.14 HIGH17-Mar-03 16:50 07-Mar-03 128 Lungs 3.196 0.842 147.08 OKNote: ! = Quarantine phase; " = Pretest phase; # = Dosing phaseLovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 2Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicTerminal Organ Relative RelativeAnimal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of BrainNo/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status6833F541/M 2/1 07-Mar-03 654/# 17-Mar-03 16:50 07-Mar-03 128 Spleen 379.4 2.829 0.746 130.19 HIGH17-Mar-03 16:50 07-Mar-03 128 Testes 5.559 1.465 255.82 HIGH6833F549/M 2/1 20-Feb-03 639/# 21-Feb-03 16:32 20-Feb-03 128 Adrenal glands 288.9 0.085 0.029 4.00 HIGH21-Feb-03 16:32 20-Feb-03 128 Brain 2.125 0.736 100.00 OK21-Feb-03 16:32 20-Feb-03 128 Epididymis 0.535 0.185 25.18 OK21-Feb-03 16:32 20-Feb-03 128 Heart 1.361 0.471 64.05 OK21-Feb-03 16:32 20-Feb-03 128 Kidneys 3.486 1.207 164.05 HIGH21-Feb-03 16:32 20-Feb-03 128 Liver 13.182 4.563 620.33 HIGH21-Feb-03 16:32 20-Feb-03 128 Lungs 4.343 1.503 204.38 OK21-Feb-03 16:32 20-Feb-03 128 Spleen 7.839 2.713 368.89 HIGH21-Feb-03 16:32 20-Feb-03 128 Testes 3.276 1.134 154.16 HIGH6835G625/M 3/1 04-Mar-03 651/# 10-Mar-03 17:00 04-Mar-03 128 Adrenal glands 323.9 0.118 0.036 5.60 HIGH10-Mar-03 17:00 04-Mar-03 128 Brain 2.106 0.650 100.00 OK10-Mar-03 17:00 04-Mar-03 128 Epididymis 0.476 0.147 22.60 OK10-Mar-03 17:00 04-Mar-03 128 Heart 1.402 0.433 66.57 OK10-Mar-03 17:00 04-Mar-03 128 Kidneys 3.784 1.168 179.68 OK10-Mar-03 17:00 04-Mar-03 128 Liver 20.970 6.474 995.73 HIGH10-Mar-03 17:00 04-Mar-03 128 Lungs 5.059 1.562 240.22 OK10-Mar-03 17:01 04-Mar-03 128 Spleen 9.653 2.980 458.36 HIGH10-Mar-03 17:01 04-Mar-03 128 Testes 1.968 0.608 93.45 OK6835G627/M 3/1 05-Apr-03 683/# 12-May-03 11:30 05-Apr-03 -1 Adrenal glands 372.8 0.180 0.048 8.38 HIGH12-May-03 11:30 05-Apr-03 -1 Brain 2.147 0.576 100.00 OK12-May-03 11:31 05-Apr-03 -1 Epididymis 0.483 0.130 22.50 OK12-May-03 11:31 05-Apr-03 -1 Heart 1.926 0.517 89.71 OK12-May-03 11:31 05-Apr-03 -1 Kidneys 5.269 1.414 245.41 HIGH12-May-03 11:31 05-Apr-03 -1 Liver 22.671 6.082 1055.94 HIGH12-May-03 11:31 05-Apr-03 -1 Lungs 3.727 1.000 173.59 OK12-May-03 11:31 05-Apr-03 -1 Spleen 2.248 0.603 104.70 HIGH12-May-03 11:31 05-Apr-03 -1 Testes 2.340 0.628 108.99 HIGH6835G636/M 3/1 02-Feb-03 621/# 03-Feb-03 09:12 02-Feb-03 8 Adrenal glands 297.7 0.133 0.045 6.33 HIGH03-Feb-03 09:12 02-Feb-03 8 Brain 2.100 0.705 100.00 OK03-Feb-03 09:12 02-Feb-03 8 Epididymis 0.471 0.158 22.43 OK03-Feb-03 09:12 02-Feb-03 8 Heart 1.897 0.637 90.33 HIGH03-Feb-03 09:12 02-Feb-03 8 Kidneys 3.635 1.221 173.10 HIGH03-Feb-03 09:12 02-Feb-03 8 Liver 15.909 5.344 757.57 HIGH03-Feb-03 09:12 02-Feb-03 8 Lungs 4.159 1.397 198.05 OK03-Feb-03 09:12 02-Feb-03 8 Spleen 5.744 1.929 273.52 HIGH03-Feb-03 09:12 02-Feb-03 8 Testes 2.518 0.846 119.90 HIGH6837H718/M 4/1 19-May-03 727/# 20-May-03 12:52 19-May-03 8 Adrenal glands 349.8 0.112 0.032 5.53 HIGH20-May-03 12:52 19-May-03 8 Brain 2.027 0.579 100.00 OK20-May-03 12:52 19-May-03 8 Epididymis 0.572 0.164 28.22 OK20-May-03 12:52 19-May-03 8 Heart 1.625 0.464 80.17 OK20-May-03 12:53 19-May-03 8 Kidneys 4.258 1.217 210.06 HIGHNote: ! = Quarantine phase; " = Pretest phase; # = Dosing phaseLovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04Research Institute Study number: FY01013M Page: 3Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/ChronicTerminal Organ Relative RelativeAnimal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of BrainNo/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status6837H718/M 4/1 19-May-03 727/# 20-May-03 12:53 19-May-03 8 Liver 349.8 18.253 5.217 900.49 HIGH20-May-03 12:53 19-May-03 8 Lungs 2.694 0.770 132.91 OK20-May-03 12:53 19-May-03 8 Spleen 0.548 0.157 27.04 LOW20-May-03 12:54 19-May-03 8 Testes 7.728 2.209 381.25 HIGH6837H732/M 4/1 30-Dec-02 587/# 06-Jan-03 15:52 30-Dec-02 -1 Adrenal glands 378.8 0.580 0.153 27.19 HIGH06-Jan-03 15:52 30-Dec-02 -1 Brain 2.133 0.563 100.00 OK06-Jan-03 15:52 30-Dec-02 -1 Epididymis 0.823 0.217 38.58 OK06-Jan-03 15:52 30-Dec-02 -1 Heart 1.184 0.313 55.51 OK06-Jan-03 15:52 30-Dec-02 -1 Kidneys 3.589 0.948 168.26 OK06-Jan-03 15:52 30-Dec-02 -1 Liver 15.375 4.059 720.82 HIGH06-Jan-03 15:52 30-Dec-02 -1 Lungs 6.445 1.702 302.16 OK06-Jan-03 15:52 30-Dec-02 -1 Spleen 1.123 0.296 52.65 OK06-Jan-03 15:52 30-Dec-02 -1 Testes 4.587 1.211 215.05 HIGHNote: ! = Quarantine phase; " = Pretest phase; # = Dosing phaseLovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 1Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicTerminal Organ Relative RelativeAnimal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of BrainNo/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status6832E454/F 1/1 31-Jan-03 612/# 03-Feb-03 10:43 31-Jan-03 8 Adrenal glands 273.6 0.066 0.024 3.63 HIGH03-Feb-03 10:43 31-Jan-03 8 Brain 1.816 0.664 100.00 OK03-Feb-03 10:43 31-Jan-03 8 Heart 1.058 0.387 58.26 OK03-Feb-03 10:43 31-Jan-03 8 Kidneys 1.820 0.665 100.22 OK03-Feb-03 10:43 31-Jan-03 8 Liver 10.435 3.814 574.61 OK03-Feb-03 10:43 31-Jan-03 8 Lungs 1.948 0.712 107.27 OK03-Feb-03 10:43 31-Jan-03 8 Ovaries 0.025 0.009 1.38 LOW03-Feb-03 10:43 31-Jan-03 8 Spleen 5.293 1.934 291.46 HIGH03-Feb-03 10:43 31-Jan-03 8 Uterus 0.520 0.190 28.63 OK6832E473/F 1/1 17-Mar-03 657/# 25-Mar-03 13:15 17-Mar-03 128 Adrenal glands 227.3 0.053 0.023 2.76 HIGH25-Mar-03 13:15 17-Mar-03 128 Brain 1.921 0.845 100.00 OK25-Mar-03 13:15 17-Mar-03 128 Heart 0.703 0.309 36.60 OK25-Mar-03 13:15 17-Mar-03 128 Kidneys 1.989 0.875 103.54 OK25-Mar-03 13:15 17-Mar-03 128 Liver 9.117 4.011 474.60 HIGH25-Mar-03 13:15 17-Mar-03 128 Lungs 1.887 0.830 98.23 OK25-Mar-03 13:15 17-Mar-03 128 Ovaries 0.041 0.018 2.13 LOW25-Mar-03 13:15 17-Mar-03 128 Spleen 0.435 0.191 22.64 LOW25-Mar-03 13:15 17-Mar-03 128 Uterus 0.568 0.250 29.57 OK6832E477/F 1/1 07-Jan-03 588/# 10-Jan-03 16:53 07-Jan-03 128 Adrenal glands 187.7 0.089 0.047 4.57 HIGH10-Jan-03 16:53 07-Jan-03 128 Brain 1.947 1.037 100.00 HIGH10-Jan-03 16:53 07-Jan-03 128 Heart 1.270 0.677 65.23 HIGH10-Jan-03 16:53 07-Jan-03 128 Kidneys 2.133 1.136 109.55 OK10-Jan-03 16:53 07-Jan-03 128 Liver 8.492 4.524 436.16 HIGH10-Jan-03 16:53 07-Jan-03 128 Lungs 2.651 1.412 136.16 OK10-Jan-03 16:53 07-Jan-03 128 Ovaries 0.148 0.079 7.60 HIGH10-Jan-03 16:54 07-Jan-03 128 Spleen 4.814 2.564 247.25 HIGH10-Jan-03 16:54 07-Jan-03 128 Uterus 0.596 0.317 30.61 OK6832E480/F 1/1 29-Mar-03 669/# 01-Apr-03 12:10 29-Mar-03 128 Adrenal glands 225.3 0.065 0.029 3.47 HIGH01-Apr-03 12:10 29-Mar-03 128 Brain 1.871 0.830 100.00 OK01-Apr-03 12:11 29-Mar-03 128 Heart 0.850 0.377 45.43 OK01-Apr-03 12:11 29-Mar-03 128 Kidneys 1.895 0.841 101.28 OK01-Apr-03 12:11 29-Mar-03 128 Liver 7.095 3.149 379.21 OK01-Apr-03 12:11 29-Mar-03 128 Lungs 1.998 0.887 106.79 OK01-Apr-03 12:11 29-Mar-03 128 Ovaries 0.085 0.038 4.54 OK01-Apr-03 12:11 29-Mar-03 128 Spleen 0.618 0.274 33.03 OK01-Apr-03 12:11 29-Mar-03 128 Uterus 0.996 0.442 53.23 OK6834F576/F 2/1 14-Apr-03 685/# 16-Apr-03 17:32 14-Apr-03 128 Adrenal glands 212.6 0.307 0.144 16.68 HIGH16-Apr-03 17:32 14-Apr-03 128 Brain 1.841 0.866 100.00 OK16-Apr-03 17:32 14-Apr-03 128 Heart 1.162 0.547 63.12 OK16-Apr-03 17:32 14-Apr-03 128 Kidneys 2.148 1.010 116.68 OK16-Apr-03 17:32 14-Apr-03 128 Liver 12.450 5.856 676.26 HIGH16-Apr-03 17:32 14-Apr-03 128 Lungs 2.801 1.317 152.15 OK16-Apr-03 17:32 14-Apr-03 128 Ovaries 0.089 0.042 4.83 OKNote: ! = Quarantine phase; " = Pretest phase; # = Dosing phaseLovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 2Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicTerminal Organ Relative RelativeAnimal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of BrainNo/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status6834F576/F 2/1 14-Apr-03 685/# 16-Apr-03 17:32 14-Apr-03 128 Spleen 212.6 5.653 2.659 307.06 HIGH16-Apr-03 17:32 14-Apr-03 128 Uterus 1.437 0.676 78.06 OK6834F593/F 2/1 24-May-03 725/# 28-May-03 16:49 24-May-03 128 Adrenal glands 257.4 0.088 0.034 4.55 HIGH28-May-03 16:49 24-May-03 128 Brain 1.936 0.752 100.00 OK28-May-03 16:49 24-May-03 128 Heart 0.943 0.366 48.71 OK28-May-03 16:49 24-May-03 128 Kidneys 2.335 0.907 120.61 OK28-May-03 16:49 24-May-03 128 Liver 11.281 4.383 582.70 HIGH28-May-03 16:49 24-May-03 128 Lungs 1.948 0.757 100.62 OK28-May-03 16:49 24-May-03 128 Ovaries 0.073 0.028 3.77 LOW28-May-03 16:49 24-May-03 128 Spleen 0.543 0.211 28.05 OK28-May-03 16:49 24-May-03 128 Uterus 0.617 0.240 31.87 OK6836G665/F 3/1 22-Oct-02 511/# 07-Nov-02 14:00 22-Oct-02 -1 Adrenal glands 191.0 0.049 0.026 2.36 HIGH07-Nov-02 14:00 22-Oct-02 -1 Brain 2.078 1.088 100.00 HIGH07-Nov-02 14:00 22-Oct-02 -1 Heart 0.718 0.376 34.55 OK07-Nov-02 14:00 22-Oct-02 -1 Kidneys 1.758 0.921 84.60 OK07-Nov-02 14:00 22-Oct-02 -1 Liver 8.383 4.390 403.42 HIGH07-Nov-02 14:01 22-Oct-02 -1 Lungs 1.958 1.025 94.23 OK07-Nov-02 14:01 22-Oct-02 -1 Ovaries 0.109 0.057 5.25 OK07-Nov-02 14:01 22-Oct-02 -1 Spleen 0.355 0.186 17.08 LOW13-Nov-02 10:26 22-Oct-02 -1 Uterus 0.425 0.223 20.45 OK6836G671/F 3/1 28-Nov-02 548/# 12-Dec-02 13:42 28-Nov-02 128 Adrenal glands 240.6 0.057 0.024 3.06 HIGH12-Dec-02 13:42 28-Nov-02 128 Brain 1.865 0.775 100.00 OK12-Dec-02 13:42 28-Nov-02 128 Heart 0.757 0.315 40.59 OK12-Dec-02 13:42 28-Nov-02 128 Kidneys 1.615 0.671 86.60 OK12-Dec-02 13:42 28-Nov-02 128 Liver 9.343 3.883 500.97 OK12-Dec-02 13:42 28-Nov-02 128 Lungs 1.155 0.480 61.93 OK12-Dec-02 13:42 28-Nov-02 128 Ovaries 0.080 0.033 4.29 OK12-Dec-02 13:42 28-Nov-02 128 Spleen 0.740 0.308 39.68 OK12-Dec-02 13:42 28-Nov-02 128 Uterus 17.380 7.224 931.90 OK6836G693/F 3/1 18-Mar-03 658/# 25-Mar-03 13:12 18-Mar-03 128 Adrenal glands 260.8 6.989 2.679 359.89 HIGH25-Mar-03 13:12 18-Mar-03 128 Brain 1.942 0.745 100.00 OK25-Mar-03 13:12 18-Mar-03 128 Heart 0.965 0.370 49.69 OK25-Mar-03 13:12 18-Mar-03 128 Kidneys 2.331 0.894 120.03 OK25-Mar-03 13:12 18-Mar-03 128 Liver 9.754 3.740 502.27 OK25-Mar-03 13:12 18-Mar-03 128 Lungs 3.655 1.401 188.21 OK25-Mar-03 13:12 18-Mar-03 128 Ovaries 0.093 0.036 4.79 OK25-Mar-03 13:12 18-Mar-03 128 Spleen 0.471 0.181 24.25 LOW25-Mar-03 13:13 18-Mar-03 128 Uterus 0.677 0.260 34.86 OK6838H786/F 4/1 15-May-03 716/# 19-May-03 16:24 15-May-03 128 Adrenal glands 240.4 0.071 0.030 3.79 HIGH19-May-03 16:24 15-May-03 128 Brain 1.872 0.779 100.00 OK19-May-03 16:24 15-May-03 128 Heart 1.175 0.489 62.77 OK19-May-03 16:24 15-May-03 128 Kidneys 1.803 0.750 96.31 OK19-May-03 16:24 15-May-03 128 Liver 7.592 3.158 405.56 OKNote: ! = Quarantine phase; " = Pretest phase; # = Dosing phaseLovelace Respiratory Raw Data Listing of Animal Organ Weights Printed: 21-Jul-04Research Institute Study number: FY01013F Page: 3Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/ChronicTerminal Organ Relative RelativeAnimal Group/ Date of Day of Date and Time Date Data Oper. Body Weight % of Body % of BrainNo/sex Subgroup Death Phase Data was Entered Taken No. Organ name wt(g) (g) Weight Weight Status6838H786/F 4/1 15-May-03 716/# 19-May-03 16:24 15-May-03 128 Lungs 240.4 1.793 0.746 95.78 OK19-May-03 16:24 15-May-03 128 Ovaries 0.106 0.044 5.66 OK19-May-03 16:24 15-May-03 128 Spleen 1.116 0.464 59.62 OK19-May-03 16:24 15-May-03 128 Uterus 32.243 13.412 1722.38 OK6838H795/F 4/1 15-May-03 716/# 19-May-03 16:22 15-May-03 128 Adrenal glands 219.8 0.068 0.031 3.51 HIGH19-May-03 16:22 15-May-03 128 Brain 1.938 0.882 100.00 OK19-May-03 16:22 15-May-03 128 Heart 0.857 0.390 44.22 OK19-May-03 16:22 15-May-03 128 Kidneys 2.363 1.075 121.93 OK19-May-03 16:22 15-May-03 128 Liver 9.829 4.472 507.17 HIGH19-May-03 16:22 15-May-03 128 Lungs 2.250 1.024 116.10 OK19-May-03 16:22 15-May-03 128 Ovaries 0.077 0.035 3.97 OK19-May-03 16:22 15-May-03 128 Spleen 0.457 0.208 23.58 OK19-May-03 16:22 15-May-03 128 Uterus 0.555 0.253 28.64 OKNote: ! = Quarantine phase; " = Pretest phase; # = Dosing phase

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

L-1 APPENDIX L

DIFFERENTIAL CELL COUNTS AND

WHITE BLOOD CELL COUNT ESTIMATES

L-1 12-Month Males

L-2 12-Month Females

L-3 18-Month Males

L-4 18-Month Females

L-5 24-Month Males

L-6 24-Month Females

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

L-1 12-Month MalesLRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103 cells/μl)CONTROL E401-6831 38 0 55 4 3 0 0 0014.0 5.3CONTROL E402-6831 30 0 67 1 2 0 0 0018.0 5.4CONTROL E403-6831 21 0 74 4 1 0 0 0110.0 2.1CONTROL E404-6831 22 0 73 4 1 0 0 007.0 1.5CONTROL E405-6831 16 0 82 2 0 0 0 006.0 1.0CONTROL E406-6831 29 0 65 4 2 0 0 008.0 2.3CONTROL E407-6831 33 1 59 4 3 0 0 0110.0 3.3CONTROL E409-6831 21 0 78 1 0 0 0 027.0 1.5CONTROLE410-6831220752100016 01 3CONTROLE410-6831220752100016.01.3CONTROL E411-6831 28 0 71 0 1 0 0 0110.0 2.8CONTROL E412-6831 31 0 67 1 1 0 0 004.0 1.2CONTROL E413-6831 26 0 72 2 0 0 0 027.0 1.8CONTROL E414-6831 33 0 61 4 2 0 0 0010.0 3.3CONTROL E415-6831 26 0 67 5 2 0 0 004.0 1.0CONTROL E416-6831 41 0 56 3 0 0 0 008.0 3.3CONTROL E417-6831 24 0 72 1 3 0 0 007.0 1.7CONTROL E418-6831 44 0 51 3 2 0 0 008.0 3.5CONTROL E419-6831 38 0 59 0 3 0 0 00CONTROL E420-6831 36 0 61 3 0 0 0 0020.0 7.2CONTROL E421-6831 44 0 47 4 4 1 0 006.0 2.6CONTROL E422-6831 27 0 71 1 1 0 0 008.0 2.2CONTROL E423-6831 29 0 62 4 5 0 0 0012.0 3.5CONTROL E424-6831 47 0 45 5 3 0 0 0015.0 7.1CONTROL E425-6831 27 0 68 4 1 0 0 026.0 1.61 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALCONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831CONTROLE410-6831ABSOLUTEBANDNEUTROPHILS(nX103 cells/μl)ABSOLUTELYMPHOCYTES(nX103 cells/μl)ABSOLUTEMONOCYTES(nX103 cells/μl)ABSOLUTEEOSINOPHILS(nX103 cells/μl)ABSOLUTEBASOPHILS(nX103 cells/μl)ABSOLUTEATYPICALLYMPHS(nX103 cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.07.70.60.40.00.00.0200.012.10.20.40.00.00.0200.07.40.40.10.00.00.0200.05.10.30.10.00.00.0200.04.90.10.00.00.00.0200.05.20.30.20.00.00.0200.15.90.40.30.00.00.0200.05.50.10.00.00.00.0200 04 50 10 10 00 00 020CONTROLE410-6831CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-68310.04.50.10.10.00.00.0200.07.10.00.10.00.00.0200.02.70.00.00.00.00.0200.05.00.10.00.00.00.0200.06.10.40.20.00.00.0200.02.70.20.10.00.00.0200.04.50.20.00.00.00.0100.05.00.10.20.00.00.0200.04.10.20.20.00.00.0102 00.012.20.60.00.00.00.0100.02.80.20.20.10.00.0100.05.70.10.10.00.00.0200.07.40.50.60.00.00.0100.06.80.80.50.00.00.0100.04.10.20.10.00.00.0102 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALCONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831CONTROLE410-6831PlateletEstimate(adequate,increased,decreased)CommentsADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATECONTROLE410-6831CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-6831ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE The smear was too thick for a WBC estimate to be madeADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE3 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103 cells/μl)CONTROL E426-6831 21 0 69 8 2 0 0 018.0 1.7CONTROL E427-6831 40 0 54 6 0 0 0 0010.4 4.2CONTROL E428-6831 44 0 50 5 1 0 0 009.2 4.0CONTROL E429-6831 25 0 70 4 1 0 0 0010.0 2.5CONTROL E430-6831 22 0 75 3 0 0 0 0010.0 2.2CONTROL E431-6831 46 0 46 5 3 0 0 0019.3 8.9CONTROL E432-6831 28 0 68 3 1 0 0 0012.0 3.4CONTROL E433-6831 31 0 66 2 1 0 0 0214.0 4.3CONTROL E434-6831 32 0 61 2 5 0 0 0014.5 4.6CONTROL E435-6831 34 0 60 4 2 0 0 0014.4 4.9CONTROL E436-6831 27 0 66 5 2 0 0 0014.0 3.8CONTROL E437-6831 31 0 64 4 1 0 0 0010.4 3.2CONTROL E439-6831 36 0 59 4 1 0 0 0012.8 4.6CONTROL E440-6831 30 0 62 4 4 0 0 0014.4 4.3CONTROL E441-6831 21 0 72 4 3 0 0 026.0 1.3CONTROL E442-6831 22 0 75 3 0 0 0 019.2 2.0CONTROL E443-6831 37 0 57 3 3 0 0 0012.8 4.7CONTROL E444-6831 28 0 69 2 1 0 0 0014.8 4.1CONTROL E445-6831 27 0 69 3 1 0 0 0010.5 2.8CONTROL E446-6831 35 0 59 5 1 0 0 009.6 3.4CONTROL E447-6831 28 0 65 5 2 0 0 008.0 2.2CONTROL E448-6831 36 0 61 3 0 0 0 0010.4 3.7CONTROL E449-6831 27 0 65 3 4 1 0 0015.2 4.1CONTROL E450-6831 41 0 54 4 1 0 0 0010.4 4.3HIGH H701-6837 48 1 44 4 3 0 0 0013.2 6.34 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALCONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E431-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831ABSOLUTEBANDNEUTROPHILS(nX103 cells/μl)ABSOLUTELYMPHOCYTES(nX103 cells/μl)ABSOLUTEMONOCYTES(nX103 cells/μl)ABSOLUTEEOSINOPHILS(nX103 cells/μl)ABSOLUTEBASOPHILS(nX103 cells/μl)ABSOLUTEATYPICALLYMPHS(nX103 cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.05.50.60.20.00.00.0100.05.60.60.00.00.00.0100.04.60.50.10.00.00.0100.07.00.40.10.00.00.0100.07.50.30.00.00.00.0100.08.91.00.60.00.00.0100.08.20.40.10.00.00.0100.09.20.30.10.00.00.0100.08.80.30.70.00.00.010CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E439-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831HIGH H701-68370.08.60.60.30.00.00.0100.09.20.70.30.00.00.0100.06.70.40.10.00.00.0100.07.60.50.10.00.00.0100.08.90.60.60.00.00.0100.04.30.20.20.00.00.0100.06.90.30.00.00.00.0100.07.30.40.40.00.00.0100.010.20.30.10.00.00.0100.07.20.30.10.00.00.0100.05.70.50.10.00.00.0100.05.20.40.20.00.00.0100.06.30.30.00.00.00.0100.09.90.50.60.20.00.0100.05.60.40.10.00.00.0100.15.80.50.40.00.00.0105 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALCONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E431-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831PlateletEstimate(adequate,increased,decreased)CommentsADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATECONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E439-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831HIGH H701-6837ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE 1 macrophage was observed.ADEQUATEADEQUATE6 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103 cells/μl)HIGH H702-6837 45 0 51 2 2 0 0 0019.2 8.6HIGH H703-6837 22 0 70 3 5 0 0 0011.2 2.5HIGH H704-6837 34 0 62 1 2 1 0 0114.0 4.8HIGH H705-6837 39 1 57 3 0 0 0 0017.2 6.7HIGH H706-6837 44 0 49 2 4 1 0 0018.8 8.3HIGH H707-6837 35 0 55 3 6 1 0 0122.4 7.8HIGH H708-6837 29 0 65 3 3 0 0 0122.8 6.6HIGH H709-6837 41 1 51 3 4 0 0 0023.6 9.7HIGH H710-6837 26 0 68 4 1 1 0 0019.2 5.0HIGH H711-6837 34 0 64 2 0 0 0 0115.2 5.2HIGH H712-6837 27 0 68 2 3 0 0 0020.8 5.6HIGH H713-6837 44 1 50 3 2 0 0 0029.6 13.0HIGH H714-6837 35 0 62 3 0 0 0 0022.0 7.7HIGH H715-6837 43 0 50 4 3 0 0 008.8 3.8HIGH H716-6837 42 0 53 2 3 0 0 0020.4 8.6HIGH H717-6837 39 0 55 3 3 0 0 0115.6 6.1HIGH H718-6837 42 2 51 1 4 0 0 0017.6 7.4HIGH H719-6837 42 0 53 2 3 0 0 0016.8 7.1HIGH H720-6837 32 0 61 6 1 0 0 0013.2 4.2HIGH H721-6837 38 0 55 4 3 0 0 0115.6 5.9HIGH H722-6837 47 0 47 5 1 0 0 0017.6 8.3HIGH H723-6837 46 0 50 3 1 0 0 0221.2 9.8HIGH H724-6837 43 0 54 1 2 0 0 0016.8 7.2HIGH H725-6837 37 0 57 5 1 0 0 0016.0 5.9HIGH H726-6837 41 0 51 3 4 1 0 0018.8 7.77 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALHIGH H702-6837HIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837ABSOLUTEBANDNEUTROPHILS(nX103 cells/μl)ABSOLUTELYMPHOCYTES(nX103 cells/μl)ABSOLUTEMONOCYTES(nX103 cells/μl)ABSOLUTEEOSINOPHILS(nX103 cells/μl)ABSOLUTEBASOPHILS(nX103 cells/μl)ABSOLUTEATYPICALLYMPHS(nX103 cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.09.80.40.40.00.00.0100.07.80.30.60.00.00.0100.08.70.10.30.10.00.0100.29.80.50.00.00.00.0100.09.20.40.80.20.00.0100.012.30.71.30.20.00.0100.014.80.70.70.00.00.0100.212.00.70.90.00.00.0100.013.10.80.20.20.00.010HIGH H711-6837HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H716-6837HIGH H717-6837HIGH H718-6837HIGH H719-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-68370.09.70.30.00.00.00.0100.014.10.40.60.00.00.0100.314.80.90.60.00.00.0100.013.60.70.00.00.00.0100.04.40.40.30.00.00.0100.010.80.40.60.00.00.0100.08.60.50.50.00.00.0100.49.00.20.70.00.00.0100.08.90.30.50.00.00.0100.08.10.80.10.00.00.0100.08.60.60.50.00.00.0100.08.30.90.20.00.00.0100.010.60.60.20.00.00.0100.09.10.20.30.00.00.0100.09.10.80.20.00.00.0100.09.60.60.80.20.00.0108 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALHIGH H702-6837HIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837PlateletEstimate(adequate,increased,decreased)CommentsADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEHIGH H711-6837HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H716-6837HIGH H717-6837HIGH H718-6837HIGH H719-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE9 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103 cells/μl)HIGH H727-6837 42 0 54 4 0 0 0 0022.0 9.2HIGH H728-6837 31 1 59 6 3 0 0 0011.6 3.6HIGH H729-6837 41 0 52 2 5 0 0 0014.8 6.1HIGH H730-6837 57 0 37 3 3 0 0 0020.0 11.4HIGH H731-6837 52 0 46 1 1 0 0 0012.0 6.2HIGH H732-6837 42 0 52 5 1 0 0 0016.0 6.7HIGH H733-6837 28 0 67 2 3 0 0 0022.8 6.4HIGH H734-6837 42 0 48 7 2 1 0 0122.4 9.4HIGHH735-68374604932000018 88 6HIGHH735-68374604932000018.88.6HIGH H736-6837 41 0 56 2 1 0 0 0017.6 7.2HIGH H737-6837 34 0 63 3 0 0 0 0010.8 3.7HIGH H738-6837 45 0 50 3 2 0 0 0016.0 7.2HIGH H739-6837 38 1 54 3 4 0 0 0019.2 7.3HIGH H740-6837 28 2 63 5 2 0 0 0016.0 4.5HIGH H741-6837 34 0 63 3 0 0 0 0016.8 5.7HIGH H742-6837 31 0 63 5 1 0 0 0015.6 4.8HIGH H743-6837 26 0 67 5 2 0 0 0015.2 4.0HIGH H744-6837 32 0 60 6 2 0 0 0015.0 4.8HIGH H745-6837 42 0 50 5 3 0 0 0014.8 6.2HIGH H746-6837 31 0 62 7 0 0 0 0115.4 4.8HIGH H747-6837 47 0 41 7 5 0 0 0026.2 12.3HIGH H748-6837 57 0 37 4 2 0 0 0023.2 13.2HIGH H749-6837 29 0 62 9 0 0 0 0214.0 4.1HIGH H750-6837 34 0 61 4 1 0 0 0013.2 4.510 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALHIGH H727-6837HIGH H728-6837HIGH H729-6837HIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGHH735-6837ABSOLUTEBANDNEUTROPHILS(nX103 cells/μl)ABSOLUTELYMPHOCYTES(nX103 cells/μl)ABSOLUTEMONOCYTES(nX103 cells/μl)ABSOLUTEEOSINOPHILS(nX103 cells/μl)ABSOLUTEBASOPHILS(nX103 cells/μl)ABSOLUTEATYPICALLYMPHS(nX103 cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.011.90.90.00.00.00.0100.16.80.70.30.00.00.0100.07.70.30.70.00.00.0100.07.40.60.60.00.00.0100.05.50.10.10.00.00.0100.08.30.80.20.00.00.0100.015.30.50.70.00.00.0100.010.81.60.40.20.00.0100 09 20 60 40 00 00 010HIGHH735-6837HIGH H736-6837HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H744-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-68370.09.20.60.40.00.00.0100.09.90.40.20.00.00.0100.06.80.30.00.00.00.0100.08.00.50.30.00.00.0100.210.40.60.80.00.00.0100.310.10.80.30.00.00.0100.010.60.50.00.00.00.0100.09.80.80.20.00.00.0100.010.20.80.30.00.00.0100.09.00.90.30.00.00.0100.07.40.70.40.00.00.0100.09.51.10.00.00.00.0100.010.71.81.30.00.00.0100.08.60.90.50.00.00.0110.08.71.30.00.00.00.0100.08.10.50.10.00.00.01011 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for Male RatsGROUP ANIMALHIGH H727-6837HIGH H728-6837HIGH H729-6837HIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGHH735-6837PlateletEstimate(adequate,increased,decreased)CommentsADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEHIGHH735-6837HIGH H736-6837HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H744-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-6837ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE12 of 12

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

L-2 12-Month FemalesLRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E451-683216 0 79 4 1 0 0 008.01.3CONTROL E452-683320 0 73 5 2 0 0 0011.22.2CONTROL E453-6832 23 0 73 2 2 0 0 029.6 2.2CONTROL E454-6832 16 0 83 0 1 0 0 0112.7 2.0CONTROL E455-6832 19 0 75 4 1 1 0 008.8 1.7CONTROL E456-6832 18 0 75 7 0 0 0 016.8 1.2CONTROL E457-6832 21 0 78 1 0 0 0 008.6 1.8CONTROL E458-6832 31 0 67 2 0 0 0 008.4 2.6CONTROL E459-6832 18 0 79 1 2 0 0 005.2 0.9CONTROL E460-6832 35 0 57 6 2 0 0 008.0 2.8CONTROL E461-6832 24 0 72 2 2 0 0 0012.4 3.0CONTROL E462-6832 8 0 90 2 0 0 0 004.4 0.4CONTROL E463-6832 24 0 70 4 2 0 0 025.8 1.4CONTROL E464-6832 18 0 78 3 1 0 0 006.4 1.2CONTROL E465-6832 27 0 64 7 2 0 0 018.4 2.3CONTROL E466-6832 28 0 65 6 1 0 0 009.6 2.7CONTROL E467-6832 26 0 66 5 2 1 0 008.0 2.1CONTROL E468-6832 21 0 74 4 1 0 0 006.6 1.4CONTROL E469-6832 15 0 76 5 4 0 0 008.4 1.3CONTROL E470-6832 26 0 69 1 4 0 0 008.8 2.3CONTROL E471-6832 40 0 56 3 1 0 0 009.2 3.7CONTROL E472-6832 36 0 62 2 0 0 0 017.6 2.7CONTROL E473-6832 24 0 65 4 6 1 0 008.4 2.0CONTROL E474-6832 23 0 72 2 2 1 0 008.0 1.81 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALCONTROL E451-6832CONTROL E452-6833CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E471-6832CONTROL E472-6832CONTROL E473-6832CONTROL E474-6832ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.06.30.30.10.00.00.01 00.08.20.60.20.00.00.01 00.07.00.20.20.00.00.01 00.010.50.00.10.00.00.01 00.06.60.40.10.10.00.01 00.05.10.50.00.00.00.01 00.06.70.10.00.00.00.01 00.05.60.20.00.00.00.01 00.04.10.10.10.00.00.01 00.04.60.50.20.00.00.01 00.08.90.20.20.00.00.01 00.04.00.10.00.00.00.01 00.04.10.20.10.00.00.01 00.05.00.20.10.00.00.01 00.05.40.60.20.00.00.01 00.06.20.60.10.00.00.01 00.05.30.40.20.10.00.01 00.04.90.30.10.00.00.01 00.06.40.40.30.00.00.01 00.06.10.40.40.00.00.01 00.05.20.30.10.00.00.01 00.04.70.20.00.00.00.01 00.05.50.30.50.10.00.00 00.05.80.20.20.10.00.01 02 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALCONTROL E451-6832CONTROL E452-6833CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E471-6832CONTROL E472-6832CONTROL E473-6832CONTROL E474-6832PlateletEstimate(adequate,increased,decreased)ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEDECREASEDADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE3 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E475-6832 34 0 63 1 2 0 0 008.0 2.7CONTROL E476-6832 21 0 70 6 3 0 0 0011.2 2.4CONTROL E477-6832 18 0 78 3 1 0 0 009.6 1.7CONTROL E478-6832 32 0 64 3 1 0 0 0010.0 3.2CONTROL E479-6832 18 0 76 5 1 0 0 0011.2 2.0CONTROL E480-6832 17 0 75 6 2 0 0 0010.8 1.8CONTROL E482-6832 17 0 77 6 0 0 0 008.4 1.4CONTROL E483-6832 20 0 73 5 2 0 0 008.8 1.8CONTROL E484-6832 14 0 78 6 1 1 0 0111.6 1.6CONTROL E485-6832 20 0 77 3 0 0 0 008.8 1.8CONTROL E486-6832 21 0 76 2 1 0 0 009.6 2.0CONTROL E487-6832 28 0 68 2 2 0 0 006.8 1.9CONTROL E488-6832 20 0 76 2 2 0 0 016.8 1.4CONTROL E489-6832 15 0 81 4 0 0 0 008.0 1.2CONTROL E490-6832 22 0 72 4 1 1 0 0010.0 2.2CONTROL E491-6832 28 0 70 2 0 0 0 007.2 2.0CONTROL E492-6832 12 0 86 1 1 0 0 044.8 0.6CONTROL E493-6832 35 0 58 5 2 0 0 0012.0 4.2CONTROL E494-6832 18 0 75 7 0 0 0 016.8 1.2CONTROL E495-6832 37 0 55 7 1 0 0 0011.2 4.1CONTROL E496-6832 25 0 70 3 1 1 0 0013.6 3.4CONTROL E497-6832 35 0 58 4 3 0 0 008.8 3.1CONTROL E498-6832 38 0 58 3 0 1 0 0013.2 5.0CONTROL E499-6832 23 0 71 4 2 0 0 0012.0 2.8CONTROL E500-6832 15 0 79 2 4 0 0 008.4 1.34 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALCONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROL E480-6832CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E485-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E492-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E497-6832CONTROL E498-6832CONTROL E499-6832CONTROL E500-6832ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.05.00.10.20.00.00.000.07.80.70.30.00.00.01 00.07.50.30.10.00.00.01 00.06.40.30.10.00.00.01 00.08.50.60.10.00.00.01 00.08.10.60.20.00.00.01 00.06.50.50.00.00.00.01 00.06.40.40.20.00.00.01 00.09.00.70.10.10.00.01 00.06.80.30.00.00.00.01 00.07.30.20.10.00.00.01 00.04.60.10.10.00.00.01 00.05.20.10.10.00.00.01 00.06.50.30.00.00.00.01 00.07.20.40.10.10.00.01 00.05.00.10.00.00.00.01 00.04.10.00.00.00.00.0100.07.00.60.20.00.00.0100.05.10.50.00.00.00.0100.06.20.80.10.00.00.0100.09.50.40.10.10.00.0100.05.10.40.30.00.00.0100.07.70.40.00.10.00.0100.08.50.50.20.00.00.0100.06.60.20.30.00.00.0105 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALCONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROL E480-6832CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E485-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E492-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E497-6832CONTROL E498-6832CONTROL E499-6832CONTROL E500-6832PlateletEstimate(adequate,increased,decreased)ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEDECREASEDADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE6 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H751-6838 26 0 70 1 3 0 0 006.8 1.8HIGH H752-6838 21 0 74 3 2 0 0 026.0 1.3HIGH H753-6838 27 0 67 5 1 0 0 007.6 2.1HIGH H754-6838 31 0 65 3 1 0 0 009.2 2.9HIGH H755-6838 33 2 61 3 1 0 0 0010.8 3.6HIGH H756-6838 22 0 71 3 3 1 0 008.8 1.9HIGH H757-6838 31 0 59 7 3 0 0 005.6 1.7HIGH H758-6838 27 0 67 5 1 0 0 0010.8 2.9HIGH H759-6838 24 0 74 0 2 0 0 004.8 1.2HIGH H760-6838 18 0 74 6 2 0 0 017.6 1.4HIGH H761-6838 22 0 70 6 2 0 0 006.8 1.5HIGH H762-6838 28 0 65 5 2 0 0 007.2 2.0HIGH H763-6838 29 0 64 4 3 0 0 005.2 1.5HIGH H764-6838 26 0 69 4 1 0 0 0010.8 2.8HIGH H765-6838 21 0 71 4 4 0 0 005.4 1.1HIGH H766-6838 22 0 72 3 3 0 0 008.8 1.9HIGH H767-6838 20 0 74 6 0 0 0 007.2 1.4HIGH H768-6838 21 0 74 4 1 0 0 006.0 1.3HIGH H769-6838 27 0 72 0 1 0 0 0011.2 3.0HIGH H770-6838 41 0 58 1 0 0 0 017.6 3.1HIGH H771-6838 37 0 61 1 1 0 0 008.0 3.0HIGH H772-6838 21 0 73 5 1 0 0 00HIGH H773-6838 29 0 65 5 1 0 0 0010.0 2.9HIGH H774-6838 34 0 58 4 4 0 0 019.6 3.3HIGH H775-6838 21 0 73 4 2 0 0 0010.0 2.17 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALHIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838HIGH H756-6838HIGH H757-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H763-6838HIGH H764-6838HIGH H765-6838HIGH H766-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H774-6838HIGH H775-6838ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.04.80.10.20.00.00.0100.04.40.20.10.00.00.0100.05.10.40.10.00.00.0100.06.00.30.10.00.00.0100.26.60.30.10.00.00.0100.06.20.30.30.10.00.0100.03.30.40.20.00.00.0100.07.20.50.10.00.00.0100.03.60.00.10.00.00.0100.05.60.50.20.00.00.0100.04.80.40.10.00.00.0100.04.70.40.10.00.00.0100.03.30.20.20.00.00.0100.07.50.40.10.00.00.0100.03.80.20.20.00.00.0100.06.30.30.30.00.00.0100.05.30.40.00.00.00.0100.04.40.20.10.00.00.0100.08.10.00.10.00.00.0100.04.40.10.00.00.00.0100.04.90.10.10.00.00.0101 00.06.50.50.10.00.00.0100.05.60.40.40.00.00.0100.07.30.40.20.00.00.0108 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALHIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838HIGH H756-6838HIGH H757-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H763-6838HIGH H764-6838HIGH H765-6838HIGH H766-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H774-6838HIGH H775-6838PlateletEstimate(adequate,increased,decreased)ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE9 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H776-6838 18 0 74 4 4 0 0 009.6 1.7HIGH H777-6838 26 0 66 7 1 0 0 007.8 2.0HIGH H778-6838 22 0 74 3 1 0 0 006.8 1.5HIGH H779-6838 31 0 64 0 5 0 0 008.2 2.5HIGH H780-6838 33 0 56 6 5 0 0 0010.4 3.4HIGH H781-6838 18 0 77 5 0 0 0 0010.0 1.8HIGH H782-6838 17 0 77 4 2 0 0 008.4 1.4HIGH H783-6838 27 0 70 2 1 0 0 009.6 2.6HIGH H784-6838 17 0 82 0 1 0 0 008.8 1.5HIGH H785-6838 30 0 65 3 2 0 0 0010.2 3.1HIGH H786-6838 25 0 70 4 1 0 0 008.0 2.0HIGH H787-6838 39 0 55 5 1 0 0 0010.8 4.2HIGH H788-6838 22 0 70 4 4 0 0 017.2 1.6HIGH H789-6838 31 0 59 9 1 0 0 0110.2 3.2HIGH H790-6838 20 0 76 1 3 0 0 018.8 1.8HIGH H791-6838 36 0 55 5 4 0 0 0012.0 4.3HIGH H792-6838 21 0 75 1 3 0 0 0010.0 2.1HIGH H793-6838 15 0 76 7 2 0 0 008.8 1.3HIGH H794-6838 24 0 73 3 0 0 0 018.0 1.9HIGH H795-6838 34 0 56 8 2 0 0 0210.8 3.7HIGH H796-6838 38 0 53 5 4 0 0 018.8 3.3HIGH H797-6838 29 0 68 3 0 0 0 008.0 2.3HIGH H798-6838 29 0 68 2 1 0 0 008.8 2.6HIGH H799-6838 25 0 65 7 3 0 0 008.4 2.1HIGH H800-6838 26 0 68 4 2 0 0 019.8 2.510 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALHIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838HIGH H784-6838HIGH H785-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H794-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.07.10.40.40.00.00.0100.05.10.50.10.00.00.0100.05.00.20.10.00.00.0100.05.20.00.40.00.00.0100.05.80.60.50.00.00.0100.07.70.50.00.00.00.0100.06.50.30.20.00.00.0100.06.70.20.10.00.00.0100.07.20.00.10.00.00.0100.06.60.30.20.00.00.0100.05.60.30.10.00.00.0100.05.90.50.10.00.00.0100.05.00.30.30.00.00.0100.06.00.90.10.00.00.0100.06.70.10.30.00.00.0100.06.60.60.50.00.00.0100.07.50.10.30.00.00.0100.06.70.60.20.00.00.0100.05.80.20.00.00.00.0100.06.00.90.20.00.00.0100.04.70.40.40.00.00.0100.05.40.20.00.00.00.0100.06.00.20.10.00.00.0100.05.50.60.30.00.00.0100.06.70.40.20.00.00.01011 of 12LRRI Protocol FY01-01312 Month Differential Cell Counts for FemalesGROUP ANIMALHIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838HIGH H784-6838HIGH H785-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H794-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838PlateletEstimate(adequate,increased,decreased)ADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATEADEQUATE12 of 12

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

L-3 18-Month MalesLRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E401-6831 34 0 56 6 4 0 0 0 0 14.4 4.9CONTROL E402-6831 17 0 80 2 1 0 0 01028.4 4.8CONTROL E403-6831 18 0 72 6 4 0 0 027.6 1.4CONTROL E404-6831 37 0 58 4 1 0 0 0310.8 4.0CONTROL E405-6831 21 0 74 3 2 0 0 028.4 1.8CONTROL E406-6831 44 1 46 6 3 0 0 0318.8 8.3CONTROL E407-6831 41 0 51 7 1 0 0 0212.0 4.9CONTROL E409-6831 35 0 58 5 2 0 0 019.2 3.2CONTROLE410 6831330631300038 02 6CONTROLE410-6831330631300038.02.6CONTROL E411-6831 38 0 58 3 1 0 0 0110.8 4.1CONTROL E412-6831 37 0 51 6 6 0 0 0014.4 5.3CONTROL E413-6831 25 0 70 2 3 0 0 027.2 1.8CONTROL E414-6831 25 0 70 4 1 0 0 0019.2 4.8CONTROL E415-6831 20 0 76 1 3 0 0 018.0 1.6CONTROL E416-6831 30 0 59 6 4 1 0 0810.0 3.0CONTROL E417-6831 51 0 47 2 0 0 0 0110.0 5.1CONTROL E418-6831 34 0 57 7 2 0 0 0014.0 4.8CONTROL E419-6831 28 1 65 4 2 0 0 0010.4 2.9CONTROL E420-6831 44 0 49 5 2 0 0 0211.2 4.9CONTROL E421-6831 12 0 79 5 4 0 0 0018.4 2.2CONTROL E422-6831 39 0 54 6 1 0 0 0115.2 5.9CONTROL E423-6831 26 0 66 4 4 0 0 0211.2 2.9CONTROL E424-6831 60 0 30 9 1 0 0 0029.6 17.8CONTROL E425-6831 37 0 56 4 3 0 0 0013.2 4.91 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALCONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831CONTROLE410 6831ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.0 8.1 0.9 0.6 0.0 0.0 0.0 1+ 00.022.70.60.30.00.00.03+2+0.05.50.50.30.00.00.01+00.06.30.40.10.00.00.01+00.06.20.30.20.00.00.01+00.28.61.10.60.00.00.01+00.06.10.80.10.00.00.01+00.05.30.50.20.00.00.01+00 05 00 10 20 00 00 01+0CONTROLE410-6831CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-68310.05.00.10.20.00.00.01+00.06.30.30.10.00.00.01+00.07.30.90.90.00.00.01+00.05.00.10.20.00.00.01+00.013.40.80.20.00.00.01+00.06.10.10.20.00.00.01+00.05.90.60.40.10.00.01+00.04.70.20.00.00.00.01+00.08.01.00.30.00.00.01+00.16.80.40.20.00.00.01+00.05.50.60.20.00.00.01+00.014.50.90.70.00.00.03+00.08.20.90.20.00.00.02+00.07.40.40.40.00.00.01+00.08.92.70.30.00.00.01+00.07.40.50.40.00.00.01+02 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALCONTROL E401-6831CONTROL E402-6831CONTROL E403-6831CONTROL E404-6831CONTROL E405-6831CONTROL E406-6831CONTROL E407-6831CONTROL E409-6831CONTROLE410 6831PlateletEstimate(adequate,increased,decreased)CommentsadequatedecreasedadequateadequateadequateadequateadequateadequateadequateCONTROLE410-6831CONTROL E411-6831CONTROL E412-6831CONTROL E413-6831CONTROL E414-6831CONTROL E415-6831CONTROL E416-6831CONTROL E417-6831CONTROL E418-6831CONTROL E419-6831CONTROL E420-6831CONTROL E421-6831CONTROL E422-6831CONTROL E423-6831CONTROL E424-6831CONTROL E425-6831adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate3 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E426-6831 24 0 69 1 6 0 0 0214.8 3.6CONTROL E427-6831 20 0 78 1 1 0 0 0210.4 2.1CONTROL E428-6831 34 0 57 3 6 0 0 027.2 2.4CONTROL E429-6831 27 1 64 4 4 0 0 0010.8 2.9CONTROL E430-6831 52 0 42 3 3 0 0 0110.8 5.6CONTROL E432-6831 23 0 73 3 1 0 0 0010.0 2.3CONTROL E433-6831 33 0 61 5 1 0 0 0212.4 4.1CONTROL E434-6831 20 0 72 4 4 0 0 0018.0 3.6CONTROL E435-6831 32 0 66 2 0 0 0 0412.8 4.1CONTROL E436-6831 47 0 47 4 2 0 0 0013.0 6.1CONTROL E437-6831 33 0 65 1 1 0 0 0012.0 4.0CONTROL E438-6831 17 0 74 6 3 0 0 026.8 1.2CONTROL E440-6831 34 0 61 5 0 0 0 0117.6 6.0CONTROL E441-6831 28 0 64 5 3 0 0 0214.0 3.9CONTROL E442-6831 39 0 60 1 0 0 0 0116.8 6.6CONTROL E443-6831 46 0 48 3 3 0 0 0010.8 5.0CONTROL E444-6831 32 0 61 4 3 0 0 0012.4 4.0CONTROL E445-6831 42 0 48 5 5 0 0 0113.6 5.7CONTROL E446-6831 24 0 70 5 1 0 0 038.4 2.0CONTROL E447-6831 35 0 59 2 4 0 0 0311.2 3.9CONTROL E448-6831 31 0 64 3 2 0 0 0217.2 5.3CONTROL E449-6831 35 0 58 5 2 0 0 0213.2 4.6CONTROL E450-6831 34 0 62 1 3 0 0 0121.2 7.2HIGH H701-6837 35 0 58 4 3 0 0 0115.2 5.3HIGH H702-6837 52 1 43 1 3 0 0 0510.0 5.24 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALCONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831CONTROL E435-6831ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.010.20.10.90.00.00.01+00.08.10.10.10.00.00.01+00.04.10.20.40.00.00.01+00.16.90.40.40.00.00.01+00.04.50.30.30.00.00.01+00.07.30.30.10.00.00.01+00.07.60.60.10.00.00.01+00.013.00.70.70.00.00.01+00.08.40.30.00.00.00.01+0CONTROL E436-6831CONTROL E437-6831CONTROL E438-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831HIGH H701-6837HIGH H702-68370.06.10.50.30.00.00.01+00.07.80.10.10.00.00.01+00.05.00.40.20.00.00.01+00.010.70.90.00.00.00.01+00.09.00.70.40.00.00.01+00.010.10.20.00.00.00.01+00.05.20.30.30.00.00.01+00.07.60.50.40.00.00.01+00.06.50.70.70.00.00.01+00.05.90.40.10.00.00.01+00.06.60.20.40.00.00.01+00.011.00.50.30.00.00.01+00.07.70.70.30.00.00.01+00.013.10.20.60.00.00.01+00.08.80.60.50.00.00.01+00.14.30.10.30.00.00.01+05 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALCONTROL E426-6831CONTROL E427-6831CONTROL E428-6831CONTROL E429-6831CONTROL E430-6831CONTROL E432-6831CONTROL E433-6831CONTROL E434-6831CONTROL E435-6831PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateadequateadequateadequateCONTROL E436-6831CONTROL E437-6831CONTROL E438-6831CONTROL E440-6831CONTROL E441-6831CONTROL E442-6831CONTROL E443-6831CONTROL E444-6831CONTROL E445-6831CONTROL E446-6831CONTROL E447-6831CONTROL E448-6831CONTROL E449-6831CONTROL E450-6831HIGH H701-6837HIGH H702-6837adequateadequatedecreased ss fibrin strands seen on slide. This would decrease the number of platelets seen on the slide.adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate6 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H703-6837 49 0 47 4 0 0 0 0113.2 6.5HIGH H704-6837 50 0 45 3 2 0 0 0113.0 6.5HIGH H705-6837 34 0 59 4 3 0 0 018.8 3.0HIGH H706-6837 46 0 47 4 3 0 0 0117.2 7.9HIGH H707-6837 23 0 71 5 1 0 0 0014.4 3.3HIGH H708-6837 55 0 42 1 2 0 0 0113.2 7.3HIGH H709-6837 22 0 69 5 4 0 0 0216.8 3.7HIGH H710-6837 40 0 51 7 2 0 0 0127.6 11.0HIGH H711-6837 30 0 63 1 6 0 0 029.6 2.9HIGH H712-6837 45 0 48 5 2 0 0 0013.2 5.9HIGH H713-6837 40 0 52 6 2 0 0 0016.8 6.7HIGH H714-6837 35 0 61 1 3 0 0 0015.2 5.3HIGH H715-6837 27 0 60 9 4 0 0 0121.6 5.8HIGH H717-6837 45 0 53 2 0 0 0 0310.0 4.5HIGH H718-6837 28 0 67 3 2 0 0 029.2 2.6HIGH H720-6837 25 0 70 3 2 0 0 0022.0 5.5HIGH H721-6837 17 0 76 4 3 0 0 0014.8 2.5HIGH H722-6837 66 0 30 3 1 0 0 0236.4 24.0HIGH H723-6837 34 0 57 8 1 0 0 0114.8 5.0HIGH H724-6837 37 0 59 4 0 0 0 029.6 3.6HIGH H725-6837 28 0 67 2 3 0 0 037.6 2.1HIGH H726-6837 36 0 59 3 2 0 0 017.2 2.6HIGH H727-6837 44 0 49 4 3 0 0 067.6 3.3HIGH H728-6837 26 0 66 5 3 0 0 0014.4 3.7HIGH H729-6837 47 0 49 2 2 0 0 038.0 3.87 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALHIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837HIGH H711-6837ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.06.20.50.00.00.00.01+00.05.90.40.30.00.00.01+00.05.20.40.30.00.00.01+00.08.10.70.50.00.00.01+00.010.20.70.10.00.00.01+00.05.50.10.30.00.00.01+00.011.60.80.70.00.00.01+00.014.11.90.60.00.00.01+00.06.00.10.60.00.00.01+0HIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H717-6837HIGH H718-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H727-6837HIGH H728-6837HIGH H729-68370.06.30.70.30.00.00.01+00.08.71.00.30.00.00.01+00.09.30.20.50.00.00.01+00.013.01.90.90.00.00.01+00.05.30.20.00.00.00.01+00.06.20.30.20.00.00.01+00.015.40.70.40.00.00.01+00.011.20.60.40.00.00.01+00.010.91.10.40.00.00.01+00.08.41.20.10.00.00.01+00.05.70.40.00.00.00.01+00.05.10.20.20.00.00.01+00.04.20.20.10.00.00.01+00.03.70.30.20.00.00.01+00.09.50.70.40.00.00.01+00.03.90.20.20.00.00.01+08 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALHIGH H703-6837HIGH H704-6837HIGH H705-6837HIGH H706-6837HIGH H707-6837HIGH H708-6837HIGH H709-6837HIGH H710-6837HIGH H711-6837PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateadequateadequateadequateHIGH H712-6837HIGH H713-6837HIGH H714-6837HIGH H715-6837HIGH H717-6837HIGH H718-6837HIGH H720-6837HIGH H721-6837HIGH H722-6837HIGH H723-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H727-6837HIGH H728-6837HIGH H729-6837adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate9 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H730-6837 31 0 64 1 4 0 0 0110.0 3.1HIGH H731-6837 27 0 66 4 3 0 0 0113.6 3.7HIGH H732-6837 51 0 45 3 1 0 0 0012.4 6.3HIGH H733-6837 30 0 60 5 5 0 0 0012.8 3.8HIGH H734-6837 49 0 44 4 3 0 0 027.6 3.7HIGH H735-6837 36 0 60 2 2 0 0 029.6 3.5HIGHH736 68373605743000017 66 3HIGHH736-68373605743000017.66.3HIGH H737-6837 71 0 27 2 0 0 0 0122.8 16.2HIGH H738-6837 29 0 64 6 1 0 0 009.2 2.7HIGH H739-6837 38 0 59 2 1 0 0 0011.2 4.3HIGH H740-6837 33 0 60 5 2 0 0 0114.8 4.9HIGH H741-6837 52 0 39 5 4 0 0 046.0 3.1HIGH H742-6837 22 0 69 4 5 0 0 0614.8 3.3HIGH H743-6837 48 0 46 5 1 0 0 0010.8 5.2HIGH H745-6837 32 0 61 4 3 0 0 016.0 1.9HIGH H746-6837 32 0 61 4 3 0 0 029.6 3.1HIGH H747-6837 51 0 46 2 1 0 0 018.8 4.5HIGH H748-6837 35 0 64 0 1 0 0 025.6 2.0HIGH H749-6837 34 0 58 4 4 0 0 034.6 1.6HIGH H750-6837 40 0 53 2 5 0 0 044.4 1.810 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALHIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGH H735-6837HIGHH736 6837ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.06.40.10.40.00.00.01+00.09.00.50.40.00.00.01+00.05.60.40.10.00.00.01+00.07.70.60.60.00.00.01+00.03.30.30.20.00.00.01+00.05.80.20.20.00.00.01+00 010 00 70 50 00 00 01+0HIGHH736-6837HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-68370.010.00.70.50.00.00.01+00.06.20.50.00.00.00.01+00.05.90.60.10.00.00.01+00.06.60.20.10.00.00.01+00.08.90.70.30.00.00.01+00.02.30.30.20.00.00.01+00.010.20.60.70.00.00.01+00.05.00.50.10.00.00.01+00.03.70.20.20.00.00.01+00.05.90.40.30.00.00.01+00.04.00.20.10.00.00.01+00.03.60.00.10.00.00.01+00.02.70.20.20.00.00.01+00.02.30.10.20.00.00.01+011 of 12LRRI Protocol FY01-01318 Month Differential Counts for Male RatsGROUP ANIMALHIGH H730-6837HIGH H731-6837HIGH H732-6837HIGH H733-6837HIGH H734-6837HIGH H735-6837HIGHH736 6837PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateadequateHIGHH736-6837HIGH H737-6837HIGH H738-6837HIGH H739-6837HIGH H740-6837HIGH H741-6837HIGH H742-6837HIGH H743-6837HIGH H745-6837HIGH H746-6837HIGH H747-6837HIGH H748-6837HIGH H749-6837HIGH H750-6837adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequatedecreased ss fibrin strands seen on slide. This would decrease the number of platelets seen on the slide.adequate12 of 12

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

L-4 18-Month FemalesLRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E451-6832 19 0 77 3 1 0 0 0 0 4.0 0.8CONTROL E452-6832 37 0 58 3 2 0 0 024.0 1.5CONTROL E453-6832 29 0 64 4 3 0 0 014.0 1.2CONTROL E454-6832 14 0 84 0 2 0 0 062.0 0.3CONTROL E455-6832 24 0 68 5 3 0 0 065.6 1.3CONTROL E456-6832 24 0 75 0 1 0 0 013.4 0.8CONTROL E457-6832 19 0 75 3 2 0 1 024.8 0.9CONTROL E458-6832 29 0 64 3 3 0 1 019.2 2.7CONTROL E459-6832 24 0 72 2 1 0 1 012.4 0.6CONTROL E460-6832 24 0 72 2 2 0 0 043.2 0.8CONTROL E461-6832 27 0 69 2 2 0 0 022.0 0.5CONTROL E462-6832 28 0 66 1 5 0 0 026.0 1.7CONTROL E463-6832 30 0 66 2 2 0 0 027.2 2.2CONTROL E464-6832 28 0 69 2 1 0 0 024.4 1.2CONTROL E465-6832 28 0 70 0 0 0 2 013.2 0.9CONTROL E466-6832 34 0 61 1 3 0 1 042.8 1.0CONTROL E467-6832 32 0 65 2 1 0 0 022.0 0.6CONTROL E468-6832 23 0 74 1 2 0 0 016.0 1.4CONTROL E469-6832 29 0 69 1 1 0 0 036.4 1.9CONTROL E470-6832 6 1 74 1 0 0 17 114CONTROL E472-6832 35 0 59 4 2 0 0 015.6 2.01 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALCONTROL E451-6832CONTROL E452-6832CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.03.10.10.00.00.00.01+ 00.02.30.10.10.00.00.01+ 2+0.02.60.20.10.00.00.01+ 00.01.70.00.00.00.00.01+ 00.03.80.30.20.00.00.01+ 00.02.60.00.00.00.00.01+ 00.03.60.10.10.00.00.01+ 0CONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E472-68320.05.90.30.30.00.10.01+ 00.01.70.00.00.00.00.01+ 00.02.30.10.10.00.00.01+ 00.01.40.00.00.00.00.01+ 00.04.00.10.30.00.00.01+ 00.04.80.10.10.00.00.01+ 00.03.00.10.00.00.00.01+ 00.02.20.00.00.00.10.01+ 00.01.70.00.10.00.00.01+ 00.01.30.00.00.00.00.01+ 00.04.40.10.10.00.00.01+ 00.04.40.10.10.00.00.01+ 02+ 1+0.03.30.20.10.00.00.01+ 02 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALCONTROL E451-6832CONTROL E452-6832CONTROL E453-6832CONTROL E454-6832CONTROL E455-6832CONTROL E456-6832CONTROL E457-6832PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateadequateCONTROL E458-6832CONTROL E459-6832CONTROL E460-6832CONTROL E461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E465-6832CONTROL E466-6832CONTROL E467-6832CONTROL E468-6832CONTROL E469-6832CONTROL E470-6832CONTROL E472-6832adequatedecreased Gross fibrin clots on slide. This would decrease the number ofplatelets seen on slide.adequateadequateadequateadequateadequateadequateadequateadequateadequateadequatedecreased Poor smear quality. Proper countingarea for WBC estimate not present on slide.adequate3 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E473-6832 18 0 78 2 1 0 1 016.8 1.2CONTROL E474-6832 24 0 73 1 2 0 0 093.6 0.9CONTROL E475-6832 27 0 71 1 1 0 0 023.6 1.0CONTROL E476-6832 32 0 64 2 2 0 0 024.8 1.5CONTROL E477-6832 21 0 78 0 1 0 0 054.4 0.9CONTROL E478-6832 36 0 58 2 4 0 0 02CONTROL E479-6832 26 0 71 1 2 0 0 037.2 1.9CONTROLE480 6832270681301006 81 8CONTROLE480-6832270681301006.81.8CONTROL E482-6832 25 0 71 2 0 0 2 054.0 1.0CONTROL E483-6832 37 0 60 0 3 0 0 0123.2 1.2CONTROL E484-6832 17 0 80 3 0 0 0 034.0 0.7CONTROL E486-6832 24 0 74 1 1 0 0 048.0 1.9CONTROL E487-6832 18 0 75 3 1 0 3 029.2 1.7CONTROL E488-6832 28 0 68 2 2 0 0 017.6 2.1CONTROL E489-6832 29 0 64 3 4 0 0 026.4 1.9CONTROL E490-6832 38 0 58 1 3 0 0 094.4 1.7CONTROL E491-6832 22 0 74 2 2 0 0 005.4 1.2CONTROL E493-6832 35 0 58 4 3 0 0 033.2 1.1CONTROL E494-6832 45 3 47 4 1 0 0 044.8 2.2CONTROL E495-6832 31 0 64 4 1 0 0 035.2 1.6CONTROL E496-6832 46 0 48 5 1 0 0 094.4 2.0CONTROL E498-6832 40 0 58 1 1 0 0 012.6 1.04 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALCONTROL E473-6832CONTROL E474-6832CONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROLE480 6832ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.05.30.10.10.00.10.01+ 00.02.60.00.10.00.00.01+ 00.02.60.00.00.00.00.01+ 00.03.10.10.10.00.00.01+ 00.03.40.00.00.00.00.01+ 01+ 00.05.10.10.10.00.00.01+ 00 04 60 10 20 00 10 01+0CONTROLE480-6832CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E498-68320.04.60.10.20.00.10.01+00.02.80.10.00.00.10.01+ 00.01.90.00.10.00.00.01+ 00.03.20.10.00.00.00.01+ 00.05.90.10.10.00.00.01+ 00.06.90.30.10.00.30.01+ 00.05.20.20.20.00.00.01+ 00.04.10.20.30.00.00.01+ 00.02.60.00.10.00.00.01+ 00.04.00.10.10.00.00.01+ 00.01.90.10.10.00.00.01+ 00.12.30.20.00.00.00.02+ 00.03.30.20.10.00.00.01+ 00.02.10.20.00.00.00.01+ 00.01.50.00.00.00.00.01+ 05 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALCONTROL E473-6832CONTROL E474-6832CONTROL E475-6832CONTROL E476-6832CONTROL E477-6832CONTROL E478-6832CONTROL E479-6832CONTROLE480 6832PlateletEstimate(adequate,increased,decreased)Commentsadequateadequateadequateadequateadequateadequate Poor smear quality. Proper counting areafor WBC estimate not present on slide.adequateadequateCONTROLE480-6832CONTROL E482-6832CONTROL E483-6832CONTROL E484-6832CONTROL E486-6832CONTROL E487-6832CONTROL E488-6832CONTROL E489-6832CONTROL E490-6832CONTROL E491-6832CONTROL E493-6832CONTROL E494-6832CONTROL E495-6832CONTROL E496-6832CONTROL E498-6832adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate6 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E499-6832 53 0 45 0 2 0 0 0105.2 2.8CONTROL E500-6832 16 0 77 2 5 0 0 034.0 0.6HIGH H751-6838 31 0 67 0 0 0 2 055.2 1.6HIGH H752-6838 32 0 65 3 0 0 0 024.8 1.5HIGH H753-6838 26 0 71 2 1 0 0 004.4 1.1HIGH H754-6838 16 0 78 2 4 0 0 013.0 0.5HIGH H755-6838 27 0 70 2 0 0 1 005.2 1.4HIGHH756 6838250703101034 61 2HIGHH756-6838250703101034.61.2HIGH H758-6838 16 0 79 3 2 0 0 044.6 0.7HIGH H759-6838 41 0 56 2 1 0 0 038.0 3.3HIGH H760-6838 18 0 79 2 0 0 1 025.0 0.9HIGH H761-6838 36 0 60 3 1 0 0 074.2 1.5HIGH H762-6838 32 0 65 2 0 0 1 006.4 2.0HIGH H765-6838 37 0 53 7 1 0 2 024.0 1.5HIGH H767-6838 31 0 63 3 3 0 0 073.6 1.1HIGH H768-6838 33 0 63 1 3 0 0 013.0 1.0HIGH H769-6838 22 0 74 3 1 0 0 053.4 0.7HIGH H770-6838 30 0 66 2 2 0 0 025.2 1.6HIGH H771-6838 29 0 61 4 4 0 2 023.2 0.9HIGH H772-6838 24 0 73 2 1 0 0 041.8 0.4HIGH H773-6838 23 0 74 2 1 0 0 012.8 0.6HIGH H775-6838 21 0 76 1 1 0 1 025.2 1.17 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALCONTROL E499-6832CONTROL E500-6832HIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838HIGHH756 6838ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.02.30.00.10.00.00.02+ 00.03.10.10.20.00.00.01+ 00.03.50.00.00.00.10.01+ 00.03.10.10.00.00.00.01+ 00.03.10.10.00.00.00.01+ 00.02.30.10.10.00.00.01+ 00.03.60.10.00.00.10.01+ 00 03 20 10 00 00 00 01+0HIGHH756-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H775-68380.03.20.10.00.00.00.01+00.03.60.10.10.00.00.01+ 00.04.50.20.10.00.00.01+ 00.04.00.10.00.00.10.01+ 00.02.50.10.00.00.00.01+ 00.04.20.10.00.00.10.01+ 00.02.10.30.00.00.10.01+ 00.02.30.10.10.00.00.01+ 00.01.90.00.10.00.00.01+ 00.02.50.10.00.00.00.01+ 00.03.40.10.10.00.00.01+ 00.02.00.10.10.00.10.01+ 00.01.30.00.00.00.00.01+ 00.02.10.10.00.00.00.01+ 00.04.00.10.10.00.10.01+ 08 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALCONTROL E499-6832CONTROL E500-6832HIGH H751-6838HIGH H752-6838HIGH H753-6838HIGH H754-6838HIGH H755-6838HIGHH756 6838PlateletEstimate(adequate,increased,decreased)CommentsdecreasedadequateadequateadequateadequateadequateadequateadequateHIGHH756-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H770-6838HIGH H771-6838HIGH H772-6838HIGH H773-6838HIGH H775-6838adequatedecreasedadequateadequateadequateadequatedecreasedadequateadequateadequateadequateadequateadequateadequateadequate9 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H776-6838 18 0 81 1 0 0 0 025.5 1.0HIGH H777-6838 34 0 63 3 0 0 0 074.8 1.6HIGH H778-6838 32 1 62 4 0 0 1 028.2 2.6HIGH H779-6838 37 0 58 4 0 0 1 024.4 1.6HIGH H780-6838 26 0 66 5 3 0 0 016.0 1.6HIGH H781-6838 34 0 60 2 4 0 0 003.8 1.3HIGH H782-6838 24 0 72 4 0 0 0 065.4 1.3HIGH H783-6838 35 0 59 3 3 0 0 063.8 1.3HIGH H784-6838 45 0 52 2 1 0 0 044.2 1.9HIGH H786-6838 23 0 70 4 3 0 0 027.0 1.6HIGH H787-6838 22 0 70 6 2 0 0 023.2 0.7HIGH H788-6838 28 0 66 4 2 0 0 043.8 1.1HIGH H789-6838 29 0 65 2 2 0 2 015.0 1.5HIGH H790-6838 35 0 62 3 0 0 0 052.6 0.9HIGH H791-6838 30 0 63 4 2 0 1 037.6 2.3HIGH H792-6838 27 0 63 8 1 0 1 016.0 1.6HIGH H793-6838 20 0 70 7 3 0 0 024.4 0.9HIGH H795-6838 37 0 60 1 2 0 0 015.0 1.9HIGH H796-6838 40 0 57 2 1 0 0 017.2 2.9HIGH H797-6838 30 1 62 3 3 0 1 066.8 2.0HIGH H798-6838 16 0 76 7 0 0 1 016.0 1.0HIGH H799-6838 28 0 70 2 0 0 0 094.2 1.2HIGH H800-6838 24 0 73 2 1 0 0 014.6 1.110 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALHIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.04.50.10.00.00.00.01+ 00.03.00.10.00.00.00.03+ 2+0.15.10.30.00.00.10.01+ 00.02.60.20.00.00.00.01+ 00.04.00.30.20.00.00.01+ 00.02.30.10.20.00.00.01+ 00.03.90.20.00.00.00.01+ 00.02.20.10.10.00.00.01+ 0HIGH H784-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-68380.02.20.10.00.00.00.01+ 00.04.90.30.20.00.00.01+ 00.02.20.20.10.00.00.01+ 00.02.50.20.10.00.00.01+ 00.03.30.10.10.00.10.01+ 00.01.60.10.00.00.00.01+ 00.04.80.30.20.00.10.01+ 00.03.80.50.10.00.10.01+ 00.03.10.30.10.00.00.01+ 00.03.00.10.10.00.00.01+ 00.04.10.10.10.00.00.01+ 00.14.20.20.20.00.10.01+ 00.04.60.40.00.00.10.01+ 00.02.90.10.00.00.00.01+ 00.03.40.10.00.00.00.01+ 011 of 12LRRI Protocol FY01-01318 Month Differential Cell Counts for Female RatsGROUP ANIMALHIGH H776-6838HIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGH H782-6838HIGH H783-6838PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateadequateadequateHIGH H784-6838HIGH H786-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H792-6838HIGH H793-6838HIGH H795-6838HIGH H796-6838HIGH H797-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate12 of 12

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

L-5 24-Month MalesLRRI Protocol FY01-013Final Differential Cell Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E407-6831 59 0 30 6 1 0 4 0 1 3.6 2.1CONTROL E413-6831 63 0 30 6 1 0 0 073.0 1.9CONTROL E415-6831 24 0 59 4 1 0 12 0222.6 5.4CONTROL E418-6831 55 0 32 5 5 0 3 072.2 1.2CONTROL E422-6831 49 0 42 6 2 0 1 003.8 1.9CONTROL E435-6831 54 0 40 3 0 0 3 002.8 1.5CONTROL E436-6831 59 0 30 5 0 0 6 025.4 3.2CONTROL E437-6831 37 0 53 5 1 0 4 004.2 1.6CONTROL E440-6831 57 0 33 4 0 0 6 012.0 1.1CONTROL E442-6831 14 0 68 2 0 0 16 0519.8 2.8CONTROL E443-6831 54 0 39 1 1 0 5 024.2 2.3CONTROL E446-6831 4 0 75 2 0 0 19 0068.8 2.8CONTROL E448-6831 43 0 49 1 0 0 7 043.2 1.4CONTROL E449-6831 60 0 27 1 4 0 8 002.1 1.3HIGH H702-6837 50 0 44 0 0 0 6 045.8 2.9HIGH H704-6837 42 0 44 3 1 0 10 042.6 1.11 of 6LRRI Protocol FY01-013Final Differential Cell Counts for Male RatsGROUP ANIMALCONTROL E407-6831CONTROL E413-6831CONTROL E415-6831CONTROL E418-6831CONTROL E422-6831CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E440-6831CONTROL E442-6831CONTROL E443-6831CONTROL E446-6831CONTROL E448-6831CONTROL E449-6831HIGH H702-6837HIGH H704-6837ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.01.10.20.00.00.10.01+ 00.00.90.20.00.00.00.01+ 00.013.30.90.20.02.70.01+ 00.00.70.10.10.00.10.01+ 00.01.60.20.10.00.00.01+ 00.01.10.10.00.00.10.01+ 00.01.60.30.00.00.30.01+ 00.02.20.20.00.00.20.01+ 00.00.70.10.00.00.10.01+ 00.013.50.40.00.03.20.02+ 2+0.01.60.00.00.00.20.01+ 00.051.61.40.00.013.10.02+ 2+0.01.60.00.00.00.20.01+ 00.00.60.00.10.00.20.01+ 00.02.60.00.00.00.30.01+ 00.01.10.10.00.00.30.01+ 02 of 6LRRI Protocol FY01-013Final Differential Cell Counts for Male RatsGROUP ANIMALCONTROL E407-6831CONTROL E413-6831CONTROL E415-6831CONTROL E418-6831CONTROL E422-6831CONTROL E435-6831CONTROL E436-6831CONTROL E437-6831CONTROL E440-6831CONTROL E442-6831CONTROL E443-6831CONTROL E446-6831CONTROL E448-6831CONTROL E449-6831HIGH H702-6837HIGH H704-6837PlateletEstimate(adequate,increased,decreased)Commentsadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequatedecreasedadequateadequateadequateadequate3 of 6LRRI Protocol FY01-013Final Differential Cell Counts for Male RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H705-6837 29 0 57 2 0 0 11 179.3 2.7HIGH H706-6837 60 0 34 1 1 0 4 003.6 2.2HIGH H708-6837 5 0 84 1 0 0 7 3040.7 2.0HIGH H714-6837 54 0 41 2 1 0 2 014.1 2.2HIGH H717-6837 51 0 35 4 3 0 7 033.4 1.7HIGH H722-6837 6 0 84 0 0 0 10 0048.8 2.9HIGH H724-6837 17 0 80 0 0 0 3 0110.8 1.8HIGH H725-6837 7 0 85 0 0 0 7 14362.0 25.3HIGH H726-6837 32 0 59 4 1 0 4 0114.4 1.4HIGH H728-6837 47 0 49 1 0 0 3 012.8 1.3HIGH H729-6837 38 0 55 0 1 0 6 0121.8 0.7HIGH H735-6837 46 0 47 0 1 0 6 051.6 0.7HIGH H736-6837 45 0 46 2 0 0 7 052.2 1.0HIGH H739-6837 62 0 27 2 2 0 7 064.0 2.5HIGH H741-6837 41 0 46 1 3 0 9 083.6 1.5HIGH H747-6837 64 0 28 3 3 0 2 063.0 1.9HIGH H749-6837 48 0 47 1 2 0 2 052.8 1.34 of 6LRRI Protocol FY01-013Final Differential Cell Counts for Male RatsGROUP ANIMALHIGH H705-6837HIGH H706-6837HIGH H708-6837HIGH H714-6837HIGH H717-6837HIGH H722-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H728-6837HIGH H729-6837HIGH H735-6837HIGH H736-6837HIGH H739-6837HIGH H741-6837HIGH H747-6837HIGH H749-6837ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.05.30.20.00.01.00.12+ 2+0.01.20.00.00.00.10.01+ 00.034.20.40.00.02.81.22+ 2+0.01.70.10.00.00.10.01+ 00.01.20.10.10.00.20.01+ 00.041.00.00.00.04.90.02+ 2+0.08.60.00.00.00.30.01+ 00.0307.70.00.00.025.33.62+ 2+0.02.60.20.00.00.20.01+ 00.01.40.00.00.00.10.01+ 00.01.00.00.00.00.10.01+ 00.00.80.00.00.00.10.01+ 00.01.00.00.00.00.20.01+ 00.01.10.10.10.00.30.01+ 00.01.70.00.10.00.30.01+ 00.00.80.10.10.00.10.01+ 00.01.30.00.10.00.10.01+ 05 of 6LRRI Protocol FY01-013Final Differential Cell Counts for Male RatsGROUP ANIMALHIGH H705-6837HIGH H706-6837HIGH H708-6837HIGH H714-6837HIGH H717-6837HIGH H722-6837HIGH H724-6837HIGH H725-6837HIGH H726-6837HIGH H728-6837HIGH H729-6837HIGH H735-6837HIGH H736-6837HIGH H739-6837HIGH H741-6837HIGH H747-6837HIGH H749-6837PlateletEstimate(adequate,increased,decreased)Commentsadequateadequatedecreasedadequateadequatedecreasedadequatedecreasedadequateadequateadequateadequateadequateadequateadequateadequateadequate6 of 6

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

L-6 24-Month FemalesLRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E451-6832 24 0 64 5 1 0 6 0 3 4.8 1.2CONTROL E452-6832 35 0 51 4 1 0 9 053.8 1.3CONTROL E456-6832 38 0 50 1 2 0 9 013.1 1.2CONTROL E458-6832 36 0 59 0 0 0 5 082.2 0.8CONTROL E460-6832 22 0 70 3 1 0 4 023.6 0.8CONTROLE461 6832240642406034 21 0CONTROLE461-6832240642406034.21.0CONTROL E462-6832 12 0 55 3 0 0 30 0312.0 1.4CONTROL E463-6832 22 1 68 3 2 0 4 0388.0 1.8CONTROL E464-6832 22 1 66 0 0 0 11 04223.6 5.2CONTROL E467-6832 31 0 58 1 1 0 9 032.0 0.6CONTROL E472-6832 47 0 41 2 0 0 10 014.0 1.9CONTROL E475-6832 43 0 48 1 2 0 6 072.4 1.0CONTROL E478-6832 28 0 64 1 2 0 5 034.0 1.1CONTROL E483-6832 35 0 52 4 1 0 8 052.8 1.0CONTROL E486-6832 49 0 43 2 2 0 4 041.8 0.9CONTROL E489-6832 33 0 57 4 3 0 3 012.8 0.9CONTROL E490-6832 8 0 82 2 0 0 8 0540.0 3.2CONTROL E493-6832 5 1 75 0 0 0 16 314130.0 6.51 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALCONTROL E451-6832CONTROL E452-6832CONTROL E456-6832CONTROL E458-6832CONTROL E460-6832CONTROLE461 6832ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.03.10.20.00.00.30.01+ 00.01.90.20.00.00.30.01+ 00.01.60.00.10.00.30.01+ 00.01.30.00.00.00.10.01+ 00.02.50.10.00.00.10.02+ 00 02 70 10 20 00 30 01+0CONTROLE461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E467-6832CONTROL E472-6832CONTROL E475-6832CONTROL E478-6832CONTROL E483-6832CONTROL E486-6832CONTROL E489-6832CONTROL E490-6832CONTROL E493-68320.02.70.10.20.00.30.01+00.06.60.40.00.03.60.01+ 00.15.40.20.20.00.30.03+ 2+0.215.60.00.00.02.60.03+ 2+0.01.20.00.00.00.20.01+ 00.01.60.10.00.00.40.01+ 00.01.20.00.00.00.10.01+ 00.02.60.00.10.00.20.01+ 00.01.50.10.00.00.20.01+ 00.00.80.00.00.00.10.01+ 00.01.60.10.10.00.10.01+ 00.032.80.80.00.03.20.03+ 2+1.397.50.00.00.020.83.93+ 2+2 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALCONTROL E451-6832CONTROL E452-6832CONTROL E456-6832CONTROL E458-6832CONTROL E460-6832CONTROLE461 6832PlateletEstimate(adequate,increased,decreased)Commentsadequatedecreased Platelet decrease is dueto miniclots in the sample.adequateadequateadequateadequateCONTROLE461-6832CONTROL E462-6832CONTROL E463-6832CONTROL E464-6832CONTROL E467-6832CONTROL E472-6832CONTROL E475-6832CONTROL E478-6832CONTROL E483-6832CONTROL E486-6832CONTROL E489-6832CONTROL E490-6832CONTROL E493-6832adequateadequateadequatedecreasedadequateadequateadequateadequateadequateadequateadequateadequatedecreased3 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)CONTROL E495-6832 28 0 60 1 1 0 10 064.0 1.1CONTROL E497-6832 40 0 46 4 2 0 8 062.8 1.1CONTROL E498-6832 34 0 59 0 3 0 4 091.8 0.6CONTROL E500-6832 46 0 43 0 1 0 10 012.6 1.2HIGH H754-6838 49 0 41 2 0 1 7 073.0 1.5HIGH H755-6838 33 0 56 2 2 0 7 062.4 0.8HIGH H756-6838 23 0 67 3 3 0 4 052.2 0.5HIGH H758-6838 47 1 47 1 0 0 4 002.4 1.1HIGH H759-6838 62 0 27 5 3 0 3 024.6 2.9HIGH H760-6838 49 0 42 3 2 0 4 043.0 1.5HIGH H761-6838 10 0 62 4 0 0 21 324.0 0.4HIGH H762-6838 44 0 48 1 1 0 6 012.8 1.2HIGH H765-6838 40 0 54 0 2 0 4 073.2 1.3HIGH H767-6838 24 0 66 3 0 0 7 0134.4 1.1HIGH H768-6838 33 0 60 1 1 0 5 033.2 1.1HIGH H769-6838 27 0 66 2 1 0 4 043.0 0.8HIGH H771-6838 38 0 58 3 0 0 1 051.6 0.6HIGH H773-6838 36 0 63 0 0 0 1 012.0 0.7HIGH H776-6838 50 0 48 1 1 0 0 021.4 0.74 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALCONTROL E495-6832CONTROL E497-6832CONTROL E498-6832CONTROL E500-6832HIGH H754-6838HIGH H755-6838ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.02.40.00.00.00.40.01+ 00.01.30.10.10.00.20.01+ 00.01.10.00.10.00.10.01+ 00.01.10.00.00.00.30.01+ 00.01.20.10.00.00.20.01+ 00.01.30.00.00.00.20.01+ 0HIGH H756-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H771-6838HIGH H773-6838HIGH H776-68380.01.50.10.10.00.10.01+ 00.01.10.00.00.00.10.01+ 00.01.20.20.10.00.10.01+ 00.01.30.10.10.00.10.01+ 00.02.50.20.00.00.80.12+ 1+0.01.30.00.00.00.20.01+ 00.01.70.00.10.00.10.01+ 00.02.90.10.00.00.30.01+ 00.01.90.00.00.00.20.01+ 00.02.00.10.00.00.10.01+ 00.00.90.00.00.00.00.01+ 00.01.30.00.00.00.00.01+ 00.00.70.00.00.00.00.01+ 05 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALCONTROL E495-6832CONTROL E497-6832CONTROL E498-6832CONTROL E500-6832HIGH H754-6838HIGH H755-6838PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateHIGH H756-6838HIGH H758-6838HIGH H759-6838HIGH H760-6838HIGH H761-6838HIGH H762-6838HIGH H765-6838HIGH H767-6838HIGH H768-6838HIGH H769-6838HIGH H771-6838HIGH H773-6838HIGH H776-6838adequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequateadequate6 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALNEUTROPHILS(%)BANDNEUTROPHILS(%)LYMPHOCYTES(%)MONOCYTES(%)EOSINOPHILS(%)BASOPHILS(%)ATYPICALLYMPHS(%)BLASTS(%)NUCLEATED RBC(#/100 WBC)WBCESTIMATE(nX103cells/μl)ABSOLUTENEUTROPHILS(nX103cells/μl)HIGH H777-6838 33 0 60 3 1 0 3 042.6 0.9HIGH H778-6838 7 0 79 0 0 0 11 3940.0 2.8HIGH H779-6838 33 0 64 0 0 0 3 012.4 0.8HIGH H780-6838 24 0 62 2 1 0 11 036.6 1.6HIGH H781-6838 32 0 60 2 0 0 6 012.0 0.6HIGHH782 6838400561102031 60 6HIGHH782-6838400561102031.60.6HIGH H784-6838 71 0 25 2 0 0 2 012.8 2.0HIGH H787-6838 29 0 61 1 0 0 9 033.0 0.9HIGH H788-6838 46 0 46 2 0 0 6 034.0 1.8HIGH H789-6838 49 0 42 3 3 0 3 061.8 0.9HIGH H790-6838 61 0 31 6 0 0 2 053.0 1.8HIGH H791-6838 15 0 64 1 0 0 19 169.6 1.4HIGH H793-6838 26 0 52 7 0 0 12 3168.8 2.3HIGH H794-6838 44 0 49 2 3 0 2 072.8 1.2HIGH H796-6838 36 0 58 0 0 0 6 032.0 0.7HIGH H798-6838 55 0 42 0 2 0 1 033.0 1.7HIGH H799-6838 49 1 48 1 0 0 1 061.8 0.9HIGH H800-6838 30 0 54 0 1 0 15 004.4 1.37 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALHIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGHH782 6838ABSOLUTEBANDNEUTROPHILS(nX103cells/μl)ABSOLUTELYMPHOCYTES(nX103cells/μl)ABSOLUTEMONOCYTES(nX103cells/μl)ABSOLUTEEOSINOPHILS(nX103cells/μl)ABSOLUTEBASOPHILS(nX103cells/μl)ABSOLUTEATYPICALLYMPHS(nX103cells/μl)ABSOLUTEBLASTS(nX103cells/μl)POLYCHROMASIA(1+ - 4+)ANISOCYTOSIS(0 - 4+)0.01.60.10.00.00.10.01+ 00.031.60.00.00.04.41.22+ 2+0.01.50.00.00.00.10.01+ 00.04.10.10.10.00.70.01+ 00.01.20.00.00.00.10.01+ 00 00 90 00 00 00 00 01+0HIGHH782-6838HIGH H784-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H793-6838HIGH H794-6838HIGH H796-6838HIGH H798-6838HIGH H799-6838HIGH H800-68380.00.90.00.00.00.00.01+00.00.70.10.00.00.10.01+ 00.01.80.00.00.00.30.01+ 00.01.80.10.00.00.20.01+ 00.00.80.10.10.00.10.01+ 00.00.90.20.00.00.10.01+ 00.06.10.10.00.01.80.12+ 2+0.04.60.60.00.01.10.31+ 00.01.40.10.10.00.10.01+ 00.01.20.00.00.00.10.01+ 00.01.30.00.10.00.00.01+ 00.00.90.00.00.00.00.01+ 00.02.40.00.00.00.70.01+ 08 of 9LRRI Protocol FY01-013Final Differential Counts for Female RatsGROUP ANIMALHIGH H777-6838HIGH H778-6838HIGH H779-6838HIGH H780-6838HIGH H781-6838HIGHH782 6838PlateletEstimate(adequate,increased,decreased)CommentsadequateadequateadequateadequateadequateadequateHIGHH782-6838HIGH H784-6838HIGH H787-6838HIGH H788-6838HIGH H789-6838HIGH H790-6838HIGH H791-6838HIGH H793-6838HIGH H794-6838HIGH H796-6838HIGH H798-6838HIGH H799-6838HIGH H800-6838adequateadequateadequateadequateadequateadequateadequate 1 lymphocyte in the 100 cell differential demonstrated erythro-phagocytosisadequateadequateadequateadequateadequateadequate 2 lymphocytes in the 100 cell differential demonstrated erythro-phagocytosis9 of 9

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

M-1 APPENDIX M

NEOPLASTIC AND NON-NEOPLASTIC LESIONS AND

GROSS NECROPSY OBSERVATIONS IN MALE RATS

M-1 Gross Necropsy Observations

M-2 Lesion Incidence by Animal Number for Microscopic Observations

M-3 Incidence Summary (with percentages) of Microscopic Observations

M-4 Tabulated Incidence Su mmary of Non-neoplastic Lesions

M-5 Lesion Incidence Summar y with Average Severity Grades

M-6 Raw Data

M-7 Individual Animal Report of Co rrelated Gross and Mi croscopic Diagnoses

M-8 Histological Comments on Tissue

M-9 Summary of Missing Tissues

M-10 Lesion Incidence Summary w ith K-S (comparison > control)

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-1 Gross Necropsy ObservationsLovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013M Page: 1All SacrificesRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Males --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------Adrenal glandsCyst ........................... 1 0 0 0Discolored ..................... 1 0 0 1Enlarged ....................... 2 2 5 4Mass ........................... 0 1 0 0AortaEnlarged ....................... 0 0 0 1BrainDeformity ...................... 6 1 2 3Discolored ..................... 0 0 1 0CecumDiscolored ..................... 0 1 0 0ColonMass ........................... 0 0 0 1DuodenumDiscolored ..................... 0 0 0 1Eyes/optic nerveCrust .......................... 0 1 1 0Small .......................... 1 0 0 0Discolored ..................... 0 0 4 1HeartDiscolored ..................... 0 1 0 0IleumMass ........................... 1 0 0 0Discolored ..................... 0 1 0 0JejunumMass ........................... 2 0 0 0KidneysCyst ........................... 0 0 1 1Enlarged ....................... 0 1 0 1Mass ........................... 0 1 1 1Nodule ......................... 0 1 2 0Discolored ..................... 7 5 6 14Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013M Page: 2All SacrificesRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Males --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------KidneysMineralization ................. 0 0 0 1LiverCyst ........................... 0 0 1 1Deformity ...................... 0 1 0 0Enlarged ....................... 0 2 1 2Hernia ......................... 1 0 0 2Mass ........................... 2 1 2 0Nodule ......................... 2 2 2 1Thick .......................... 9 6 6 12Discolored ..................... 9 13 13 11Pituitary glandCyst ........................... 0 1 2 0Deformity ...................... 0 0 1 0Enlarged ....................... 3 0 0 4Mass ........................... 4 3 0 1Nodule ......................... 1 3 3 0Discolored ..................... 7 4 7 4ParathyroidEnlarged ....................... 0 1 0 0Salivary glandEnlarged ....................... 0 0 1 0SkinAlopecia ....................... 0 1 0 0Crust .......................... 1 3 3 1Mass ........................... 2 3 4 1Scar ........................... 0 1 0 0SpleenCyst ........................... 0 1 0 0Deformity ...................... 0 1 3 0Discolored ..................... 6 2 2 5Enlarged ....................... 25 28 29 25Mass ........................... 0 0 1 1Nodule ......................... 0 1 1 1StomachRupture ........................ 1 0 0 0Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013M Page: 3All SacrificesRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Males --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------TestesCyst ........................... 1 0 0 0Enlarged ....................... 2 8 12 14Fluid .......................... 0 1 0 0Mass ........................... 6 7 2 5Small .......................... 2 6 4 6Discolored ..................... 37 34 47 38Thyroid glandsEnlarged ....................... 1 1 3 2Mass ........................... 0 3 1 1Nodule ......................... 1 0 0 0Discolored ..................... 1 1 1 0Urinary bladderEnlarged ....................... 0 0 0 1Mass ........................... 1 0 0 0LungsDiscolored ..................... 17 23 17 15Focus .......................... 0 1 0 0Mass ........................... 1 3 0 1Nodule ......................... 1 1 3 3EpididymisEnlarged ....................... 0 0 1 0Nodule ......................... 0 0 0 1Small .......................... 1 5 1 2Discolored ..................... 0 1 1 1ProstateEnlarged ....................... 0 0 0 2Discolored ..................... 0 1 0 0Seminal vesicleEnlarged ....................... 0 1 1 1Mass ........................... 1 0 0 0Small .......................... 5 2 9 6Thick .......................... 0 0 1 0TailAmputation ..................... 1 0 0 0Crust .......................... 0 0 1 0Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013M Page: 4All SacrificesRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Males --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------TailMass ........................... 0 1 0 0Nodule ......................... 0 1 0 0Bronchial (TBLN)Enlarged ....................... 6 3 4 6Discolored ..................... 1 2 0 2Mandibular LNEnlarged ....................... 6 2 4 2Discolored ..................... 0 2 0 0Mediastinal LNEnlarged ....................... 7 3 8 2Mass ........................... 1 0 0 0Discolored ..................... 1 1 1 0Mesenteric LNEnlarged ....................... 1 2 2 1Mammary glandMass ........................... 2 4 4 4Discolored ..................... 0 0 1 1Tiss.not specifiAdhesion ....................... 0 1 0 0Enlarged ....................... 0 0 0 1Mass ........................... 1 1 2 3Nodule ......................... 0 0 0 3Perforation .................... 1 0 0 0Thick .......................... 0 1 0 0Discolored ..................... 0 0 1 1Harderian glandEnlarged ....................... 1 0 0 0Discolored ..................... 0 1 0 0Preputial glandEnlarged ....................... 4 0 2 2Mass ........................... 0 1 1 0Pancreatic LNEnlarged ....................... 5 2 2 4Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013M Page: 5All SacrificesRat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Males --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------Iliac LNEnlarged ....................... 3 2 4 2Lymph node otherEnlarged ....................... 6 6 10 7Discolored ..................... 0 0 0 1CavitiesFluid .......................... 1 1 1 2Popliteal LNEnlarged ....................... 3 0 2 1Discolored ..................... 0 0 0 1ThymusMass ........................... 1 0 0 1Discolored ..................... 0 0 0 2MediastinumMass ........................... 1 0 0 0MesenteryMass ........................... 0 1 0 0Nodule ......................... 0 0 1 1Muscle, skeletalMass ........................... 0 2 0 0Discolored ..................... 0 0 1 0Bone, otherEnlarged ....................... 0 0 0 1Mass ........................... 0 1 0 0Zymbal's glandMass ........................... 0 0 0 1

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 1

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Adrenal glands

Cyst 6831E440

Discolored 6831E434 6837H732

Enlarged 6831E424 6833F504 6835G619 6837H707

- 6831E444 6833F509 6835G625 6837H712

- 6835G627 6837H734

- 6835G636 6837H746

- 6835G646

Mass 6833F525

Aorta Enlarged 6837H701

Brain Deformity 6831E409 6833F531 6835G647 6837H711

- 6831E414 6835G650 6837H713

- 6831E417 6837H735

- 6831E427

- 6831E434

- 6831E435

Discolored 6835G611

Cecum

Discolored 6833F530

Colon

Mass 6837H706

Duodenum

Discolored 6837H703

Eyes/optic nerve

Crust 6833F539 6835G615

Small 6831E430

Discolored 6835G601 6837H725

- 6835G611

- 6835G636

- 6835G648

Heart

Discolored 6833F530

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 2

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Ileum

Mass 6831E428

Discolored 6833F530

Jejunum

Mass 6831E412

- 6831E428

Kidneys

Cyst 6835G609 6837H747 Enlarged 6833F520 6837H712

Mass 6833F546 6835G604 6837H724

Nodule 6833F543 6835G605

- 6835G608

Discolored 6831E417 6833F530 6835G602 6837H703

- 6831E424 6833F540 6835G634 6837H705

- 6831E424 6833F543 6835G636 6837H706

- 6831E434 6833F545 6835G639 6837H708

- 6831E435 6833F550 6835G647 6837H708

- 6831E442 6835G648 6837H712

- 6831E444 6837H713

- 6837H714

- 6837H722

- 6837H725

- 6837H734

- 6837H735

- 6837H736

- 6837H740

Mineralization 6837H701

Liver

Cyst 6835G618 6837H724 Deformity 6833F545

Enlarged 6833F503 6835G606 6837H732

- 6833F533 6837H748

Hernia 6831E418 6837H703

- 6837H718

Mass 6831E415 6833F520 6835G614

- 6831E442 6835G631

Nodule 6831E423 6833F511 6835G606 6837H712

- 6831E427 6833F543 6835G607

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 3

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Liver

Thick 6831E401 6833F501 6835G616 6837H705

- 6831E416 6833F517 6835G620 6837H708

- 6831E425 6833F521 6835G625 6837H709

- 6831E427 6833F541 6835G627 6837H713

- 6831E432 6833F544 6835G642 6837H715

- 6831E438 6833F548 6835G646 6837H718

- 6831E442 6837H720

- 6831E444 6837H722

- 6831E447 6837H733

- 6837H734

- 6837H742

- 6837H746

Discolored 6831E405 6833F506 6835G605 6837H701

- 6831E410 6833F513 6835G611 6837H703

- 6831E421 6833F518 6835G615 6837H713

- 6831E428 6833F527 6835G622 6837H723

- 6831E431 6833F530 6835G629 6837H724

- 6831E434 6833F534 6835G632 6837H725

- 6831E435 6833F535 6835G634 6837H731

- 6831E445 6833F537 6835G637 6837H739

- 6831E450 6833F538 6835G639 6837H740

- 6833F542 6835G640 6837H743

- 6833F544 6835G647 6837H747

- 6833F549 6835G649

- 6833F550 6835G649

Pituitary gland

Cyst 6833F503 6835G627

- 6835G630 Deformity 6835G650

Enlarged 6831E414 6837H711

- 6831E425 6837H713

- 6831E427 6837H715

- 6837H742

Mass 6831E409 6833F520 6837H735

- 6831E417 6833F531

- 6831E434 6833F546

- 6831E435

Nodule 6831E407 6833F537 6835G625

- 6833F547 6835G636

- 6833F549 6835G644

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 4

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Pituitary gland

Discolored 6831E403 6833F507 6835G620 6837H704

- 6831E410 6833F511 6835G627 6837H714

- 6831E419 6833F516 6835G634 6837H725

- 6831E420 6833F530 6835G637 6837H746

- 6831E441 6835G638

- 6831E447 6835G641

- 6831E448 6835G647

Parathyroid

Enlarged 6833F550

Salivary gland

Enlarged 6835G604

Skin

Alopecia 6833F546

Crust 6831E438 6833F502 6835G615 6837H710

- 6833F518 6835G623

- 6833F546 6835G631

Mass 6831E439 6833F510 6835G605 6837H740

- 6831E440 6833F511 6835G607

- 6833F543 6835G614

- 6835G635

Scar 6833F519

Spleen

Cyst 6833F538 Deformity 6833F546 6835G605

- 6835G615

- 6835G630

Discolored 6831E410 6833F521 6835G631 6837H703

- 6831E417 6833F544 6835G642 6837H717

- 6831E422 6837H720

- 6831E425 6837H726

- 6831E426 6837H747

- 6831E432 Enlarged 6831E401 6833F501 6835G605 6837H705

- 6831E402 6833F503 6835G606 6837H707

- 6831E403 6833F504 6835G608 6837H708

- 6831E403 6833F506 6835G611 6837H709

- 6831E405 6833F507 6835G612 6837H713

- 6831E410 6833F512 6835G615 6837H715

- 6831E411 6833F513 6835G616 6837H719

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 5

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Spleen

Enlarged 6831E415 6833F514 6835G617 6837H720

- 6831E416 6833F515 6835G618 6837H722

- 6831E419 6833F516 6835G619 6837H723

- 6831E420 6833F517 6835G620 6837H725

- 6831E421 6833F520 6835G622 6837H727

- 6831E423 6833F521 6835G624 6837H731

- 6831E424 6833F522 6835G625 6837H733

- 6831E426 6833F526 6835G626 6837H734

- 6831E427 6833F527 6835G629 6837H737

- 6831E429 6833F528 6835G632 6837H738

- 6831E432 6833F532 6835G633 6837H740

- 6831E438 6833F533 6835G636 6837H741

- 6831E441 6833F535 6835G637 6837H742

- 6831E442 6833F537 6835G638 6837H743

- 6831E444 6833F538 6835G639 6837H744

- 6831E445 6833F540 6835G640 6837H746

- 6831E446 6833F544 6835G641 6837H748

- 6831E447 6833F545 6835G642 6837H750

- 6833F546 6835G644

- 6833F548 6835G646

- 6833F549 6835G648

- 6835G649

Mass 6835G604 6837H736

Nodule 6833F545 6835G640 6837H712

Stomach

Rupture 6831E434

Testes

Cyst 6831E415 Enlarged 6831E418 6833F505 6835G601 6837H702

- 6831E449 6833F510 6835G610 6837H704

- 6833F511 6835G613 6837H708

- 6833F516 6835G621 6837H711

- 6833F519 6835G628 6837H714

- 6833F536 6835G634 6837H717

- 6833F544 6835G635 6837H718

- 6833F550 6835G638 6837H724

- 6835G645 6837H726

- 6835G646 6837H730

- 6835G647 6837H736

- 6835G649 6837H741

- 6837H747

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 6

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Testes Enlarged 6837H749

Fluid 6833F538

Mass 6831E402 6833F509 6835G606 6837H723

- 6831E403 6833F515 6835G643 6837H732

- 6831E421 6833F527 6837H742

- 6831E421 6833F528 6837H748

- 6831E423 6833F533 6837H748

- 6831E441 6833F533

- 6833F545

Small 6831E415 6833F513 6835G604 6837H718

- 6831E419 6833F519 6835G616 6837H723

- 6833F520 6835G642 6837H727

- 6833F525 6835G648 6837H733

- 6833F531 6837H737

- 6833F538 6837H742

Discolored 6831E401 6833F501 6835G601 6837H701

- 6831E404 6833F501 6835G602 6837H702

- 6831E405 6833F502 6835G603 6837H703

- 6831E406 6833F503 6835G604 6837H704

- 6831E407 6833F504 6835G605 6837H705

- 6831E410 6833F506 6835G607 6837H706

- 6831E411 6833F507 6835G608 6837H707

- 6831E412 6833F508 6835G609 6837H709

- 6831E413 6833F511 6835G612 6837H710

- 6831E414 6833F514 6835G613 6837H710

- 6831E416 6833F516 6835G614 6837H711

- 6831E419 6833F517 6835G615 6837H712

- 6831E420 6833F518 6835G616 6837H713

- 6831E420 6833F521 6835G617 6837H714

- 6831E422 6833F522 6835G618 6837H715

- 6831E424 6833F523 6835G619 6837H719

- 6831E425 6833F523 6835G620 6837H720

- 6831E426 6833F525 6835G622 6837H721

- 6831E428 6833F526 6835G623 6837H722

- 6831E429 6833F529 6835G624 6837H724

- 6831E430 6833F534 6835G624 6837H725

- 6831E432 6833F535 6835G625 6837H727

- 6831E433 6833F536 6835G626 6837H728

- 6831E433 6833F537 6835G627 6837H729

- 6831E435 6833F538 6835G628 6837H730

- 6831E436 6833F539 6835G629 6837H731

- 6831E437 6833F541 6835G630 6837H734

- 6831E440 6833F542 6835G631 6837H735

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 7

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Testes

Discolored 6831E442 6833F543 6835G632 6837H736

- 6831E443 6833F544 6835G632 6837H737

- 6831E444 6833F546 6835G633 6837H738

- 6831E445 6833F547 6835G635 6837H739

- 6831E446 6833F548 6835G636 6837H740

- 6831E447 6833F549 6835G636 6837H743

- 6831E448 6835G637 6837H745

- 6831E449 6835G638 6837H746

- 6831E450 6835G639 6837H749

- 6835G640 6837H750

- 6835G640

- 6835G642

- 6835G644

- 6835G645

- 6835G646

- 6835G647

- 6835G648

- 6835G649

- 6835G650

Thyroid glands

Enlarged 6831E430 6833F530 6835G614 6837H710

- 6835G641 6837H720

- 6835G646

Mass 6833F520 6835G637 6837H735

- 6833F526

- 6833F550

Nodule 6831E422

Discolored 6831E446 6833F544 6835G632

Urinary bladder

Enlarged 6837H718

Mass 6831E409

Lungs

Discolored 6831E401 6833F503 6835G601 6837H702

- 6831E402 6833F504 6835G603 6837H709

- 6831E402 6833F506 6835G606 6837H714

- 6831E403 6833F507 6835G607 6837H719

- 6831E410 6833F508 6835G610 6837H720

- 6831E411 6833F514 6835G611 6837H723

- 6831E414 6833F518 6835G613 6837H725

- 6831E416 6833F521 6835G616 6837H726

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 8

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Lungs

Discolored 6831E420 6833F523 6835G620 6837H727

- 6831E424 6833F524 6835G621 6837H728

- 6831E429 6833F527 6835G624 6837H732

- 6831E430 6833F530 6835G625 6837H739

- 6831E439 6833F532 6835G636 6837H743

- 6831E440 6833F535 6835G637 6837H748

- 6831E441 6833F541 6835G639 6837H750

- 6831E448 6833F544 6835G640

- 6831E450 6833F545 6835G644

- 6833F545

- 6833F546

- 6833F548

- 6833F549

- 6833F550

- 6833F550

Focus 6833F515

Mass 6831E427 6833F511 6837H732

- 6833F518

- 6833F536

Nodule 6831E441 6833F543 6835G604 6837H712

- 6835G615 6837H724

- 6835G641 6837H747

Epididymis

Enlarged 6835G645

Nodule 6837H703

Small 6831E413 6833F506 6835G630 6837H735

- 6833F525 6837H740

- 6833F531

- 6833F539

- 6833F550

Discolored 6833F509 6835G625 6837H712

Prostate Enlarged 6837H713

- 6837H718

Discolored 6833F546

Seminal vesicle

Enlarged 6833F536 6835G648 6837H718

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 9

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Seminal vesicle

Mass 6831E427

Small 6831E415 6833F516 6835G603 6837H717

- 6831E418 6833F527 6835G605 6837H726

- 6831E436 6835G607 6837H732

- 6831E439 6835G610 6837H733

- 6831E440 6835G615 6837H747

- 6835G617 6837H748

- 6835G621

- 6835G622

- 6835G643

Thick 6835G604

Tail

Amputation 6831E436

Crust 6835G602

Mass 6833F521

Nodule 6833F505

Bronchial (TBLN)

Enlarged 6831E405 6833F501 6835G616 6837H705

- 6831E411 6833F507 6835G631 6837H709

- 6831E420 6833F515 6835G636 6837H722

- 6831E421 6835G646 6837H723

- 6831E429 6837H746

- 6831E442 6837H750

Discolored 6831E427 6833F532 6837H714

- 6833F536 6837H728

Mandibular LN

Enlarged 6831E407 6833F510 6835G604 6837H722

- 6831E409 6833F515 6835G616 6837H740

- 6831E420 6835G631

- 6831E422 6835G635

- 6831E427

- 6831E429

Discolored 6833F506

- 6833F541

Mediastinal LN

Enlarged 6831E410 6833F501 6835G602 6837H705

- 6831E411 6833F515 6835G604 6837H750

- 6831E420 6833F543 6835G612

- 6831E429 6835G616

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 10

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Mediastinal LN

Enlarged 6831E442 6835G636

- 6831E444 6835G637

- 6831E446 6835G641

- 6835G644

Mass 6831E427

Discolored 6831E438 6833F509 6835G620

Mesenteric LN Enlarged 6831E420 6833F515 6835G604 6837H723

- 6833F543 6835G644

Mammary gland

Mass 6831E404 6833F518 6835G617 6837H704

- 6831E435 6833F529 6835G633 6837H711

- 6833F543 6835G643 6837H714

- 6833F548 6835G649 6837H718

Discolored 6835G631 6837H732

Tiss.not specifi

Adhesion 6833F543

Enlarged 6837H718

Mass 6831E406 6833F543 6835G602 6837H712

- 6835G636 6837H728

- 6837H742

Nodule 6837H703

- 6837H712

- 6837H736

Perforation 6831E406

Thick 6833F546

Discolored 6835G625 6837H724

Harderian gland

Enlarged 6831E406

Discolored 6833F546

Preputial gland

Enlarged 6831E410 6835G605 6837H736

- 6831E418 6835G621 6837H747

- 6831E422

- 6831E443

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 30-May-05

Research Institute Study number: FY01013M Page: 11

All Sacrifices

Rat/F344/N Study start date: 23-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- M a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Preputial gland

Mass 6833F513 6835G608

Pancreatic LN Enlarged 6831E411 6833F501 6835G604 6837H709

- 6831E416 6833F533 6835G631 6837H722

- 6831E424 6837H742

- 6831E442 6837H750

- 6831E447

Iliac LN

Enlarged 6831E411 6833F501 6835G629 6837H709

- 6831E420 6833F515 6835G636 6837H733

- 6831E442 6835G641

- 6835G644

Lymph node other

Enlarged 6831E416 6833F501 6835G602 6837H705

- 6831E420 6833F515 6835G604 6837H707

- 6831E420 6833F515 6835G604 6837H709

- 6831E427 6833F515 6835G619 6837H713

- 6831E429 6833F525 6835G620 6837H723

- 6831E442 6833F531 6835G625 6837H727

- 6835G629 6837H733

- 6835G636

- 6835G641

- 6835G644

Discolored 6837H746

Cavities

Fluid 6831E420 6833F530 6835G614 6837H703

- 6837H718

Popliteal LN

Enlarged 6831E420 6835G604 6837H707

- 6831E435 6835G636

- 6831E442

Discolored 6837H733

Thymus

Mass 6831E427 6837H723

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-2 Lesion Incidence by Animal Number for Microscopic Observations

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Proliferative (includi ng Neoplastic) LesionsLovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Hyperplasia, alveolar epithelial, focal 6831E402 6833F504 6835G624 6837H7116831E410 6833F511 6835G629 6837H7166831E429 6833F518 6837H7246831E437 6833F520 6837H7286831E441 6833F5276831E444 6833F5366831E446 6833F5376831E448Hyperplasia, alveolar epithelial, widespread 6831E416 6833F546B-Adenoma, bronchiolo-alveolar 6831E441 6835G615N-Sarcoma, histiocytic 6833F5186833F543N-Leukemia, mononuclear - capillary involvement 6831E401 6833F501 6835G605 6837H7056831E402 6833F503 6835G606 6837H7076831E403 6833F504 6835G608 6837H7096831E405 6833F506 6835G610 6837H7126831E409 6833F507 6835G611 6837H7136831E410 6833F512 6835G612 6837H7156831E411 6833F513 6835G615 6837H7196831E415 6833F515 6835G616 6837H7206831E416 6833F516 6835G618 6837H7226831E419 6833F517 6835G619 6837H7236831E420 6833F518 6835G620 6837H7246831E421 6833F520 6835G622 6837H7256831E423 6833F521 6835G624 6837H7276831E424 6833F522 6835G625 6837H7296831E426 6833F523 6835G626 6837H7336831E429 6833F525 6835G627 6837H7346831E438 6833F526 6835G629 6837H7376831E441 6833F528 6835G630 6837H7386831E442 6833F530 6835G631 6837H7406831E444 6833F533 6835G632 6837H7426831E445 6833F534 6835G633 6837H7436831E446 6833F535 6835G636 6837H7446831E447 6833F537 6835G637 6837H7466831E450 6833F538 6835G638 6837H7486833F540 6835G639 6837H7506833F544 6835G6406833F545 6835G6416833F546 6835G6426833F548 6835G644All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 506833F549 6835G6466833F550 6835G6486835G649N-Leukemia, mononuclear - invasive involvement 6831E427 6833F532 6835G604 6837H708Trachea ........................................Number examined: 50 49 50 50Hyperplasia, epithelial 6831E430 6833F520N-Leukemia, mononuclear 6831E420 6835G6046831E438Bronchial (TBLN) ...............................Number examined: 49 33 28 47N-Sarcoma, histiocytic 6833F543N-Leukemia, mononuclear 6831E405 6833F501 6835G604 6837H7056831E411 6833F507 6835G616 6837H7096831E416 6833F515 6835G626 6837H7226831E420 6833F532 6835G631 6837H7236831E421 6833F533 6835G636 6837H7256831E427 6833F534 6835G644 6837H7466831E429 6833F537 6835G646 6837H7506831E442 6833F5456831E446 6833F5466831E447Thyroid glands .................................Number examined: 50 35 31 50Hyperplasia, C-cell, focal 6831E416 6833F538 6837H7076831E417 6833F546 6837H7146831E427 6837H7266831E446 6837H7296837H7416837H7466837H750Hyperplasia, follicular cell 6835G614B-Adenoma, C-cell 6831E403 6833F526 6835G616 6837H7136831E432 6833F529 6835G632 6837H7286831E442 6833F544 6835G641 6837H7346833F550 6835G646All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thyroid glands .................................Number examined: 50 35 31 50B-Adenoma, follicular cell 6831E430 6837H7186831E448 6837H7356837H743M-Carcinoma, C-cell 6833F5206833F530M-Carcinoma, follicular cell 6831E422 6835G637 6837H7106837H7206837H735Parathyroid ....................................Number examined: 45 33 30 46Hyperplasia, diffuse 6837H701Hyperplasia, focal 6837H7406837H743Aorta ..........................................Number examined: 50 34 30 50N-Leukemia, mononuclear - invasive involvement 6831E427Esophagus ......................................Number examined: 50 33 30 50Larynx .........................................Number examined: 50 49 50 50Hyperplasia, epithelial 6831E401 6833F501 6835G604 6837H7016831E402 6833F504 6835G608 6837H7026831E403 6833F508 6835G613 6837H7036831E404 6833F511 6835G614 6837H7046831E409 6833F513 6835G618 6837H7056831E410 6833F517 6835G619 6837H7066831E411 6833F518 6835G620 6837H7076831E413 6833F520 6835G622 6837H7086831E417 6833F525 6835G626 6837H7096831E418 6833F527 6835G627 6837H7136831E420 6833F531 6835G632 6837H7146831E421 6833F538 6835G635 6837H7226831E423 6833F546 6835G636 6837H7236831E426 6833F547 6835G649 6837H7246831E431 6833F548 6835G650 6837H7306831E432 6837H7346831E434 6837H7386831E435 6837H7406831E437 6837H741All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Larynx .........................................Number examined: 50 49 50 506831E438 6837H7426831E444 6837H7436831E446 6837H7466831E447 6837H7476831E448 6837H749Salivary gland .................................Number examined: 50 34 30 50M-Leukemia, mononuclear 6835G604 6837H7506835G627Mandibular LN ..................................Number examined: 40 32 30 48Hyperplasia, lymphoid 6831E409 6835G635N-Leukemia, mononuclear 6831E410 6833F501 6835G604 6837H7086831E411 6833F506 6835G608 6837H7096831E415 6833F515 6835G616 6837H7126831E416 6833F517 6835G622 6837H7226831E420 6833F532 6835G627 6837H7236831E424 6833F534 6835G631 6837H7246831E427 6833F537 6835G636 6837H7256831E429 6833F540 6835G641 6837H7336831E438 6833F545 6835G644 6837H7406831E442 6833F5466831E4446831E4466831E447Liver ..........................................Number examined: 50 40 38 50Hyperplasia, biliary 6831E401 6833F501 6835G604 6837H7016831E402 6833F503 6835G605 6837H7026831E403 6833F504 6835G606 6837H7046831E405 6833F506 6835G607 6837H7056831E406 6833F509 6835G608 6837H7066831E407 6833F510 6835G611 6837H7076831E409 6833F511 6835G612 6837H7086831E410 6833F512 6835G614 6837H7096831E411 6833F514 6835G615 6837H7106831E412 6833F515 6835G616 6837H7116831E413 6833F517 6835G618 6837H7136831E414 6833F518 6835G619 6837H7156831E415 6833F521 6835G620 6837H7166831E416 6833F522 6835G622 6837H717All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 506831E417 6833F524 6835G623 6837H7186831E418 6833F527 6835G624 6837H7196831E419 6833F528 6835G625 6837H7206831E420 6833F529 6835G626 6837H7216831E421 6833F530 6835G627 6837H7226831E422 6833F531 6835G629 6837H7236831E423 6833F532 6835G631 6837H7256831E424 6833F533 6835G632 6837H7266831E425 6833F535 6835G633 6837H7276831E426 6833F537 6835G634 6837H7286831E427 6833F538 6835G635 6837H7296831E428 6833F539 6835G636 6837H7306831E429 6833F540 6835G637 6837H7316831E430 6833F541 6835G639 6837H7326831E431 6833F542 6835G640 6837H7336831E432 6833F545 6835G641 6837H7346831E433 6833F546 6835G642 6837H7356831E434 6833F548 6835G643 6837H7366831E436 6833F549 6835G644 6837H7376831E437 6833F550 6835G645 6837H7386831E438 6835G646 6837H7396831E440 6835G647 6837H7406831E441 6835G650 6837H7416831E442 6837H7426831E443 6837H7436831E444 6837H7446831E445 6837H7456831E446 6837H7466831E447 6837H7476831E448 6837H7486831E449 6837H7496837H750Hyperplasia, hepatocellular, regenerative 6831E423 6833F513 6835G606 6837H7236833F541 6835G645 6837H7246833F544 6835G649B-Adenoma, hepatocellular 6831E415 6835G631 6837H747M-Carcinoma, hepatocellular 6831E442M-Sarcoma, histiocytic 6833F543 6837H712All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 50M-Sarcoma, undifferentiated 6835G607M-Leukemia, mononuclear 6831E401 6833F501 6835G604 6837H7036831E402 6833F503 6835G605 6837H7056831E403 6833F504 6835G606 6837H7076831E405 6833F506 6835G608 6837H7086831E409 6833F507 6835G611 6837H7096831E410 6833F512 6835G612 6837H7126831E411 6833F513 6835G615 6837H7136831E415 6833F514 6835G616 6837H7156831E416 6833F515 6835G618 6837H7176831E419 6833F517 6835G619 6837H7196831E420 6833F518 6835G620 6837H7206831E421 6833F520 6835G622 6837H7226831E423 6833F521 6835G624 6837H7236831E424 6833F522 6835G625 6837H7246831E426 6833F527 6835G626 6837H7256831E427 6833F528 6835G627 6837H7266831E429 6833F532 6835G629 6837H7276831E432 6833F533 6835G631 6837H7296831E438 6833F534 6835G632 6837H7316831E441 6833F535 6835G633 6837H7336831E442 6833F537 6835G634 6837H7346831E444 6833F538 6835G636 6837H7376831E445 6833F540 6835G637 6837H7386831E446 6833F541 6835G640 6837H7406831E447 6833F544 6835G641 6837H7416831E448 6833F545 6835G642 6837H7426831E450 6833F546 6835G644 6837H7436833F548 6835G646 6837H7446833F549 6835G649 6837H7466837H7486837H750Spleen .........................................Number examined: 50 39 38 50M-Fibrosarcoma 6837H736M-Leukemia, mononuclear 6831E401 6833F501 6835G604 6837H7036831E402 6833F503 6835G605 6837H7056831E403 6833F504 6835G606 6837H7076831E405 6833F506 6835G608 6837H7086831E409 6833F507 6835G611 6837H7096831E410 6833F512 6835G612 6837H7126831E411 6833F513 6835G615 6837H713All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spleen .........................................Number examined: 50 39 38 506831E415 6833F514 6835G616 6837H7156831E416 6833F515 6835G618 6837H7176831E419 6833F516 6835G619 6837H7196831E420 6833F517 6835G620 6837H7206831E421 6833F518 6835G622 6837H7226831E423 6833F520 6835G624 6837H7236831E424 6833F521 6835G625 6837H7246831E426 6833F522 6835G626 6837H7256831E427 6833F526 6835G627 6837H7266831E429 6833F527 6835G629 6837H7276831E432 6833F528 6835G631 6837H7296831E438 6833F532 6835G632 6837H7316831E441 6833F533 6835G633 6837H7336831E442 6833F534 6835G636 6837H7346831E444 6833F535 6835G637 6837H7376831E445 6833F537 6835G638 6837H7386831E446 6833F538 6835G639 6837H7406831E447 6833F540 6835G640 6837H7416831E448 6833F541 6835G641 6837H7426831E450 6833F544 6835G642 6837H7436833F545 6835G644 6837H7446833F546 6835G646 6837H7466833F548 6835G648 6837H7486833F549 6835G649 6837H750N-Sarcoma, histiocytic 6837H712Kidneys ........................................Number examined: 50 50 50 50B-Adenoma, renal tubule 6835G604 6837H7276835G605 6837H7476835G6086835G6096835G6336835G648M-Carcinoma, renal tubule 6833F546 6837H724M-Leukemia, mononuclear 6831E411 6833F532 6835G604 6837H7256831E420 6833F5336831E427 6833F5346831E429All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Heart ..........................................Number examined: 50 34 30 50M-Leukemia, mononuclear 6831E405 6833F504 6835G604 6837H7086831E411 6833F507 6835G618 6837H7226831E420 6833F517 6835G631 6837H7246831E427 6833F532 6837H7256833F534 6837H742Stomach ........................................Number examined: 50 34 30 49Hyperplasia, squamous epithelial 6831E4176831E434Cecum ..........................................Number examined: 50 34 30 48N-Leukemia, mononuclear 6831E4116831E427Urinary bladder ................................Number examined: 50 33 29 50B-Papilloma, transitional cell 6831E409M-Leukemia, mononuclear 6831E427 6833F518 6837H708Duodenum .......................................Number examined: 50 34 30 49Jejunum ........................................Number examined: 50 34 30 48M-Adenocarcinoma 6831E4126831E428Ileum ..........................................Number examined: 50 34 30 49Hyperplasia, lymphoid 6831E4256831E439B-Fibroma 6831E428N-Leukemia, mononuclear 6833F515All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Colon ..........................................Number examined: 50 34 30 49B-Leiomyoma 6837H706Pancreas .......................................Number examined: 50 34 30 49M-Carcinoma, ductal cell 6837H712M-Leukemia, mononuclear 6831E427Rectum .........................................Number examined: 50 34 30 50Adrenal glands .................................Number examined: 49 35 30 50Hyperplasia, cortical, diffuse 6835G625Hyperplasia, medullary, focal 6831E403 6833F517 6835G608 6837H7036831E407 6833F520 6835G616 6837H7056831E413 6835G620 6837H7086831E419 6835G631 6837H7136831E429 6835G633 6837H7146831E432 6837H7156831E446 6837H7176831E449 6837H7186837H7206837H7246837H7276837H7296837H7346837H7386837H7396837H7446837H745B-Pheochromocytoma, benign 6831E401 6833F504 6835G619 6837H7086831E416 6833F520 6835G622 6837H7146831E426 6833F544 6835G627 6837H7176831E429 6833F546 6835G642 6837H7346831E442 6835G646 6837H7376831E443 6837H7416831E444 6837H747B-Pheochromocytoma, complex, benign 6831E424 6833F525M-Pheochromocytoma, malignant 6831E416 6837H7466831E4406831E442All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Adrenal glands .................................Number examined: 49 35 30 50M-Leukemia, mononuclear 6831E405 6833F538 6835G611 6837H7226831E411 6835G618 6837H7256831E447 6835G6326835G636Prostate .......................................Number examined: 50 33 29 50Hyperplasia 6835G624Epididymis .....................................Number examined: 50 36 31 50M-Mesothelioma, malignant 6833F509 6837H7036837H736Seminal vesicle ................................Number examined: 50 35 37 50Hyperplasia 6833F536M-Leukemia, mononuclear 6831E427 6835G604Mesenteric LN ..................................Number examined: 50 34 30 50N-Sarcoma, histiocytic 6833F543N-Leukemia, mononuclear 6831E410 6833F506 6835G604 6837H7206831E411 6833F515 6835G606 6837H7226831E420 6833F533 6835G631 6837H7236831E424 6835G636 6837H7256831E446 6835G644 6837H7406831E447 6837H742Testes .........................................Number examined: 50 50 50 50Hyperplasia, interstitial cell 6831E417 6833F512 6835G611 6837H7186831E427 6833F514 6835G644 6837H7446831E431 6833F530 6835G6506831E439 6833F5326831E444 6833F5386833F540B-Adenoma, interstitial cell 6831E401 6833F501 6835G601 6837H7016831E402 6833F502 6835G602 6837H7026831E403 6833F503 6835G603 6837H7036831E404 6833F504 6835G604 6837H7046831E405 6833F505 6835G605 6837H705All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Testes .........................................Number examined: 50 50 50 506831E406 6833F506 6835G606 6837H7066831E407 6833F507 6835G607 6837H7076831E410 6833F508 6835G608 6837H7086831E411 6833F509 6835G609 6837H7096831E412 6833F510 6835G610 6837H7106831E413 6833F511 6835G612 6837H7116831E414 6833F513 6835G613 6837H7126831E415 6833F514 6835G614 6837H7136831E416 6833F515 6835G615 6837H7146831E418 6833F516 6835G616 6837H7156831E419 6833F517 6835G617 6837H7166831E420 6833F518 6835G618 6837H7176831E421 6833F519 6835G619 6837H7186831E422 6833F520 6835G620 6837H7196831E423 6833F521 6835G621 6837H7206831E424 6833F522 6835G622 6837H7216831E425 6833F523 6835G623 6837H7226831E426 6833F524 6835G624 6837H7236831E428 6833F525 6835G625 6837H7246831E429 6833F526 6835G626 6837H7256831E430 6833F527 6835G627 6837H7266831E432 6833F528 6835G628 6837H7276831E433 6833F529 6835G629 6837H7286831E435 6833F531 6835G630 6837H7296831E436 6833F532 6835G631 6837H7306831E437 6833F533 6835G632 6837H7316831E438 6833F534 6835G633 6837H7326831E440 6833F535 6835G634 6837H7336831E441 6833F536 6835G635 6837H7346831E442 6833F537 6835G636 6837H7356831E443 6833F538 6835G637 6837H7366831E444 6833F539 6835G638 6837H7376831E445 6833F541 6835G639 6837H7386831E446 6833F542 6835G640 6837H7396831E447 6833F543 6835G641 6837H7406831E448 6833F544 6835G642 6837H7416831E449 6833F545 6835G643 6837H7426831E450 6833F546 6835G644 6837H7436833F547 6835G645 6837H7446833F548 6835G646 6837H7456833F549 6835G647 6837H7466833F550 6835G648 6837H7476835G649 6837H7486837H7496837H750All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Testes .........................................Number examined: 50 50 50 50M-Mesothelioma, malignant 6833F509 6835G614 6837H7036837H736Sciatic nerve ..................................Number examined: 50 34 30 50N-Leukemia, mononuclear 6831E429Muscle, skeletal ...............................Number examined: 50 34 30 50N-Sarcoma, histiocytic 6833F5186833F543M-Leukemia, mononuclear 6835G604Mammary gland ..................................Number examined: 36 31 29 47Hyperplasia, lobular 6833F520 6837H7066837H7146837H7186837H7356837H749B-Fibroadenoma 6837H718B-Fibroma 6831E404 6833F529 6835G633 6837H7046831E435 6833F548 6835G6436835G649N-Sarcoma, histiocytic 6833F5186833F543Skin ...........................................Number examined: 49 37 35 50B-Fibroma 6831E439 6835G6176831E440B-Keratoacanthoma 6837H714B-Tumor, basal cell, benign 6837H710B-Tumor, hair follicle, benign 6835G607M-Carcinoma, sebaceous cell 6833F502All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 13Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Skin ...........................................Number examined: 49 37 35 50M-Sarcoma, undifferentiated 6833F511 6835G6146835G623N-Sarcoma, histiocytic 6833F5186833F543Brain ..........................................Number examined: 50 34 31 50M-Astrocytoma, malignant 6833F518 6837H711Eyes/optic nerve ...............................Number examined: 50 34 33 50M-Leukemia, mononuclear 6831E420 6833F515Bone, femur ....................................Number examined: 50 50 50 50Spinal cord ....................................Number examined: 50 34 30 50Nose/Turbinate 1 ...............................Number examined: 50 50 50 50Hyperplasia - respiratory epithelium 6831E408 6835G614 6837H7016831E414 6835G638 6837H7196831E433 6835G644 6837H7216837H737M-Leukemia, mononuclear 6831E420Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Hyperplasia - respiratory epithelium 6833F517 6835G622 6837H7196833F533 6835G638 6837H7216837H746M-Carcinoma, squamous cell 6831E406M-Leukemia, mononuclear 6831E420Nose/Turbinate 3 ...............................Number examined: 50 50 50 50M-Carcinoma, squamous cell 6833F539 6837H730M-Leukemia, mononuclear 6831E420All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 14Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 4 ...............................Number examined: 50 50 50 50N-Carcinoma, squamous cell 6833F510 6837H7306833F539 6837H745M-Leukemia, mononuclear 6831E420Preputial gland ................................Number examined: 4 1 3 2Pancreatic LN ..................................Number examined: 5 2 2 4N-Leukemia, mononuclear 6831E411 6833F501 6835G604 6837H7096831E416 6833F533 6835G631 6837H7226831E424 6837H7426831E442 6837H7506831E447Iliac LN .......................................Number examined: 3 1 4 2N-Leukemia, mononuclear 6831E411 6833F501 6835G629 6837H7096831E420 6835G636 6837H7336831E442 6835G644Lymph node other ...............................Number examined: 6 4 9 7N-Leukemia, mononuclear 6831E416 6833F501 6835G604 6837H7056831E420 6833F515 6835G619 6837H7076831E427 6835G620 6837H7096831E429 6835G625 6837H7236831E442 6835G629 6837H7276835G636 6837H7336835G644Mediastinal LN .................................Number examined: 49 30 30 50N-Sarcoma, histiocytic 6833F543N-Leukemia, mononuclear 6831E410 6833F501 6835G604 6837H7056831E411 6833F515 6835G616 6837H7076831E420 6833F518 6835G631 6837H7086831E427 6833F532 6835G636 6837H7096831E429 6833F533 6835G644 6837H7226831E442 6833F534 6837H7236831E444 6833F545 6837H7256831E446 6837H7506831E447All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 15Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pituitary gland ................................Number examined: 49 37 34 50Hyperplasia, pars distalis, focal 6831E401 6833F509 6835G637 6837H7056831E405 6833F514 6835G641 6837H7126831E410 6833F516 6835G646 6837H7146831E417 6833F539 6837H7166831E427 6837H7186837H7196837H7456837H746B-Adenoma, pars distalis 6831E407 6833F504 6835G625 6837H7046831E409 6833F511 6835G634 6837H7116831E414 6833F516 6835G636 6837H7136831E417 6833F520 6835G644 6837H7166831E425 6833F530 6835G647 6837H7356831E430 6833F531 6835G6506831E434 6833F5466831E435 6833F5476831E441 6833F549M-Leukemia, mononuclear 6831E427 6833F503 6835G604 6837H725Tiss.not specifi ...............................Number examined: 1 2 3 5B-Fibroma 6835G602B-Lipoma 6831E406 6837H728M-Mesothelioma, malignant 6837H7036837H736N-Sarcoma, histiocytic 6833F543Harderian gland ................................Number examined: 1 0 0 0N-Carcinoma, squamous cell 6831E406Thymus .........................................Number examined: 1 0 0 2M-Leukemia, mononuclear 6831E427 6837H723All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 16Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mediastinum ....................................Number examined: 1 0 0 0N-Leukemia, mononuclear 6831E427Tail ...........................................Number examined: 1 2 1 0Hyperplasia/hyperkeratosis 6833F505 6835G6026833F521Popliteal LN ...................................Number examined: 2 0 2 2N-Leukemia, mononuclear 6831E420 6835G604 6837H7076831E442 6835G636 6837H733Bone, other ....................................Number examined: 0 1 0 1M-Sarcoma, NOS 6837H721Zymbal’s gland .................................Number examined: 0 0 0 1M-Carcinoma, squamous cell 6837H716Mesentery ......................................Number examined: 0 1 1 0M-Mesothelioma, malignant 6835G614All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Non-neoplastic LesionsLovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Alveolar histiocytosis 6831E415 6833F504 6835G602 6837H7016831E417 6833F509 6835G603 6837H7066831E420 6833F513 6835G609 6837H7096831E428 6833F525 6835G616 6837H7176831E433 6833F531 6835G622 6837H7226831E440 6833F539 6835G629 6837H7286831E449 6833F540 6835G632 6837H7306833F547 6835G633 6837H7376833F548 6835G646 6837H7406833F550 6835G649 6837H7416837H747Autolysis, marked 6837H732Congestion 6833F5246833F541Fibrosis, focal 6831E429 6837H724Hemorrhage 6831E402 6833F515 6835G607 6837H7406831E403 6833F521 6835G6106831E440 6833F523 6835G6116833F535 6835G6166833F544 6835G6246833F545 6835G6446833F550 6835G646Metaplasia, squamous - alveolar epithelium 6833F5256833F536Mineralization, uremic 6837H701Cyst, squamous cell, keratinizing 6837H732Inflammation, acute 6831E414 6835G636 6837H745Inflammation, mixed 6831E430 6833F520 6835G602 6837H7106835G607 6837H7116835G6096835G6336835G637Inflammation, granulomatous 6833F507 6835G634 6837H7496833F525 6835G635All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Trachea ........................................Number examined: 50 49 50 50Metaplasia, squamous 6831E414Inflammation, acute 6833F508Inflammation, mixed 6831E430 6833F520 6837H7016837H7036837H7106837H740Inflammation, chronic 6831E439 6833F539 6835G617 6837H7176833F541Bronchial (TBLN) ...............................Number examined: 49 33 28 47Hemorrhage 6833F536 6837H7146833F548 6837H7286833F549Thyroid glands .................................Number examined: 50 35 31 50Cyst, follicular 6831E407 6833F528 6835G608 6837H7216835G633 6837H7256835G637 6837H741Parathyroid ....................................Number examined: 45 33 30 46Aorta ..........................................Number examined: 50 34 30 50Dilatation 6837H701Esophagus ......................................Number examined: 50 33 30 50Larynx .........................................Number examined: 50 49 50 50Ulceration 6831E432Inflammation, mixed 6831E401 6833F501 6835G601 6837H7016831E402 6833F502 6835G602 6837H7026831E403 6833F503 6835G603 6837H7036831E404 6833F504 6835G604 6837H7046831E405 6833F505 6835G605 6837H7056831E407 6833F507 6835G606 6837H7066831E408 6833F508 6835G607 6837H7076831E409 6833F510 6835G608 6837H7086831E410 6833F511 6835G609 6837H709All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Larynx .........................................Number examined: 50 49 50 506831E411 6833F513 6835G610 6837H7106831E413 6833F514 6835G612 6837H7116831E414 6833F515 6835G613 6837H7126831E415 6833F516 6835G614 6837H7136831E416 6833F517 6835G615 6837H7146831E417 6833F518 6835G616 6837H7156831E418 6833F520 6835G618 6837H7166831E419 6833F521 6835G619 6837H7176831E420 6833F522 6835G620 6837H7196831E421 6833F523 6835G621 6837H7206831E423 6833F524 6835G622 6837H7216831E424 6833F525 6835G623 6837H7226831E426 6833F527 6835G624 6837H7236831E427 6833F528 6835G625 6837H7246831E430 6833F533 6835G626 6837H7256831E431 6833F534 6835G627 6837H7266831E432 6833F535 6835G628 6837H7276831E433 6833F538 6835G629 6837H7286831E435 6833F539 6835G630 6837H7296831E436 6833F541 6835G631 6837H7306831E437 6833F543 6835G632 6837H7326831E438 6833F544 6835G634 6837H7336831E440 6833F546 6835G635 6837H7346831E442 6833F547 6835G636 6837H7366831E443 6833F548 6835G637 6837H7376831E444 6833F550 6835G638 6837H7386831E445 6835G639 6837H7396831E446 6835G640 6837H7406831E447 6835G645 6837H7416831E448 6835G647 6837H7426831E449 6835G648 6837H7436835G649 6837H7456837H7466837H7476837H749Inflammation, chronic 6831E412 6833F506 6835G641 6837H7186831E422 6833F531 6835G642 6837H7316831E429 6835G646 6837H7486831E434 6835G650Metaplasia, squamous 6831E407 6833F523 6835G602 6837H7046831E414 6833F533 6835G625 6837H7106831E419 6833F535 6835G628 6837H7176831E427 6835G631 6837H721All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Larynx .........................................Number examined: 50 49 50 506831E428 6835G645 6837H7266831E430 6835G648 6837H7396831E4326831E442Salivary gland .................................Number examined: 50 34 30 50Degeneration 6837H715Inflamation, acute 6837H701Mandibular LN ..................................Number examined: 40 32 30 48Hemorrhage 6831E422Sinus plasmacytosis 6831E407Liver ..........................................Number examined: 50 40 38 50Angiectasis 6831E402 6833F509 6835G605 6837H7016831E409 6833F535 6835G608 6837H7046831E411 6833F548 6835G620 6837H7066831E416 6833F550 6835G622 6837H7106831E419 6835G625 6837H7136831E424 6835G626 6837H7176831E426 6835G627 6837H7226831E432 6835G631 6837H7236831E436 6837H7246831E438 6837H7256831E442 6837H7266831E445 6837H7286831E446 6837H7336831E447 6837H7346831E449 6837H7406837H7416837H7426837H748Congestion 6837H732Cyst 6835G618Fatty Change 6831E434 6833F511 6835G6346831E435All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 50Foci of cellular alteration, basophilic 6831E437 6833F529Hepatodiaphragmatic nodule 6831E418 6833F520 6835G614 6837H7036837H745Necrosis 6831E403 6833F512 6835G608 6837H7236831E414 6833F530 6835G619 6837H7276831E415 6833F538 6837H7406833F546 6837H743Thrombus 6837H750Vaculolization, cytoplasmic 6831E427 6833F514 6835G649 6837H7046833F530 6837H7266833F540 6837H730Inflammation, chronic 6831E404 6833F548 6837H7176831E407 6837H7266831E417 6837H7286831E428 6837H7306831E430 6837H7366831E433 6837H7496831E440Spleen .........................................Number examined: 50 39 38 50Congestion 6833F514 6835G617Fibrosis 6831E410 6833F517 6835G6056831E425 6833F546 6835G6156831E432 6835G6306835G6386835G640Hemorrhage 6833F538Necrosis 6831E403 6833F521 6835G615 6837H7206831E426 6833F528All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 50 50 50Cyst 6833F528 6835G6056835G634Degeneration, hyaline droplet 6833F543Infarct 6835G6116835G627Nephropathy, chronic 6831E401 6833F501 6835G601 6837H7016831E402 6833F502 6835G602 6837H7026831E403 6833F503 6835G603 6837H7036831E404 6833F504 6835G604 6837H7046831E405 6833F505 6835G605 6837H7056831E406 6833F506 6835G606 6837H7066831E407 6833F507 6835G607 6837H7076831E409 6833F508 6835G608 6837H7086831E410 6833F509 6835G609 6837H7096831E411 6833F510 6835G610 6837H7106831E412 6833F511 6835G611 6837H7116831E413 6833F512 6835G612 6837H7126831E415 6833F513 6835G613 6837H7136831E416 6833F514 6835G614 6837H7146831E417 6833F515 6835G615 6837H7166831E418 6833F516 6835G616 6837H7186831E419 6833F517 6835G617 6837H7196831E420 6833F518 6835G618 6837H7206831E421 6833F519 6835G619 6837H7216831E422 6833F520 6835G620 6837H7226831E424 6833F521 6835G621 6837H7236831E425 6833F522 6835G622 6837H7246831E426 6833F523 6835G623 6837H7256831E428 6833F525 6835G624 6837H7266831E429 6833F526 6835G625 6837H7276831E432 6833F527 6835G626 6837H7286831E433 6833F528 6835G627 6837H7296831E434 6833F530 6835G628 6837H7316831E435 6833F531 6835G629 6837H7326831E436 6833F532 6835G630 6837H7336831E437 6833F533 6835G631 6837H7346831E438 6833F534 6835G632 6837H7356831E439 6833F535 6835G633 6837H7366831E440 6833F536 6835G634 6837H7386831E441 6833F537 6835G635 6837H7396831E442 6833F538 6835G636 6837H7406831E443 6833F539 6835G637 6837H741All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 50 50 506831E444 6833F541 6835G638 6837H7426831E445 6833F542 6835G639 6837H7436831E446 6833F543 6835G640 6837H7446831E447 6833F544 6835G641 6837H7456831E448 6833F545 6835G642 6837H7466831E449 6833F546 6835G643 6837H7476831E450 6833F547 6835G644 6837H7486833F548 6835G645 6837H7496833F549 6835G646 6837H7506833F550 6835G6476835G6486835G6496835G650Pigment accumulation, tubular epithelium 6831E403 6833F506 6835G646 6837H7036831E426 6833F509 6837H7196831E438 6833F540 6837H746Inflamation, acute 6833F539 6835G6256835G636Heart ..........................................Number examined: 50 34 30 50Degeneration, myocyte 6831E420 6833F546 6835G608 6837H7016831E432 6835G616 6837H7066835G624 6837H733Fibrosis 6831E407 6833F517 6835G625 6837H7016831E414 6833F518 6835G642 6837H7096831E421 6833F522 6837H7176831E437 6833F538 6837H7426831E442 6833F541Thrombus 6833F530 6835G608 6837H7316835G625 6837H746Inflamation, acute 6835G636Inflammation, focal, chronic 6831E401 6833F509 6835G606 6837H7016831E404 6833F520 6835G622 6837H7026831E408 6833F522 6835G626 6837H7046831E410 6833F527 6835G627 6837H7056831E413 6833F529 6835G632 6837H7146831E416 6833F530 6835G633 6837H7156831E418 6833F531 6835G641 6837H716All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Heart ..........................................Number examined: 50 34 30 506831E421 6833F544 6835G643 6837H7196831E423 6833F545 6835G644 6837H7216831E424 6835G645 6837H7266831E425 6837H7286831E428 6837H7296831E431 6837H7306831E438 6837H7316831E439 6837H7416831E441 6837H7476831E444 6837H7486831E448 6837H7496831E450 6837H750Stomach ........................................Number examined: 50 34 30 49Inflammation, mixed 6831E417 6833F5396831E434Cecum ..........................................Number examined: 50 34 30 48Urinary bladder ................................Number examined: 50 33 29 50Hemorrhage 6837H718Inflammation, mixed 6837H725Inflammation, chronic 6831E404 6837H7046831E447 6837H7396831E449 6837H741Duodenum .......................................Number examined: 50 34 30 49Jejunum ........................................Number examined: 50 34 30 48Ileum ..........................................Number examined: 50 34 30 49Colon ..........................................Number examined: 50 34 30 49Inflammation, mixed 6831E450All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pancreas .......................................Number examined: 50 34 30 49Rectum .........................................Number examined: 50 34 30 50Adrenal glands .................................Number examined: 49 35 30 50Cyst 6837H718Degeneration, cytoplasmic vacuolization 6831E409 6833F507 6835G619 6837H7046831E415 6833F534 6835G625 6837H7246831E418 6837H7266831E435 6837H7376831E436Necrosis 6835G611 6837H725Thrombus 6831E426 6833F537 6835G612 6837H7076831E445 6833F544 6835G629 6837H7186835G636 6837H7346837H7416837H743Prostate .......................................Number examined: 50 33 29 50Atrophy 6831E419 6837H7056831E436 6837H7086831E440 6837H7226837H7266837H729Hemorrhage 6837H718Mineralization 6831E445Inflamation, acute 6831E402 6833F5406831E406Inflammation, mixed 6831E407 6833F504 6835G608 6837H7016831E410 6833F512 6835G611 6837H7026831E415 6833F520 6835G616 6837H7036831E417 6833F522 6835G618 6837H7046831E421 6833F530 6835G619 6837H7056831E427 6833F531 6835G625 6837H7116831E430 6833F533 6835G626 6837H7136831E431 6833F538 6835G627 6837H7186831E434 6833F539 6835G632 6837H7196831E435 6833F545 6835G636 6837H725All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Prostate .......................................Number examined: 50 33 29 506831E437 6833F546 6835G640 6837H7276831E442 6833F549 6835G641 6837H7356831E443 6835G642 6837H7386831E444 6835G6436831E447 6835G6456835G650Epididymis .....................................Number examined: 50 36 31 50Atrophy 6831E413 6833F506 6835G630 6837H7056831E419 6833F525 6837H7226831E436 6833F531 6837H7266831E440 6833F539 6837H7286833F550 6837H7296837H7356837H740Granuloma, sperm 6833F537Inflammation, chronic 6831E433 6835G6426831E442Seminal vesicle ................................Number examined: 50 35 37 50Atrophy 6831E413 6833F516 6835G603 6837H7056831E414 6833F527 6835G605 6837H7086831E415 6835G607 6837H7106831E418 6835G610 6837H7176831E419 6835G615 6837H7226831E420 6835G617 6837H7246831E422 6835G621 6837H7256831E426 6835G643 6837H7266831E427 6837H7286831E436 6837H7296831E439 6837H7336831E440 6837H7346831E442 6837H7356831E443 6837H7366831E446 6837H7416837H7436837H7476837H748All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Seminal vesicle ................................Number examined: 50 35 37 50Dilatation 6833F536 6835G648 6837H718Mesenteric LN ..................................Number examined: 50 34 30 50Hemorrhage 6831E437Histiocytosis, sinus 6831E428Testes .........................................Number examined: 50 50 50 50Atrophy 6831E446 6833F513 6835G604 6837H7186833F519 6835G616 6837H7236833F531 6835G642 6837H7276833F538 6837H7376837H742Hemorrhage 6833F508 6837H716Sciatic nerve ..................................Number examined: 50 34 30 50Muscle, skeletal ...............................Number examined: 50 34 30 50Inflammation, chronic 6835G623Mammary gland ..................................Number examined: 36 31 29 47Cyst 6835G631Ectasia 6831E414 6837H711Skin ...........................................Number examined: 49 37 35 50Cyst, epithelial inclusion 6837H740Fibrosis 6831E435 6833F5106833F519Hyperkeratosis 6831E438 6833F519 6835G6156835G631Necrosis 6833F518Inflammation, mixed 6833F510 6835G6056833F519 6835G6356833F546All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Skin ...........................................Number examined: 49 37 35 50Inflammation, chronic 6831E437Brain ..........................................Number examined: 50 34 31 50Compression 6831E409 6833F531 6835G647 6837H7046831E414 6833F546 6835G650 6837H7116831E417 6837H7136831E427 6837H7356831E4346831E435Ectasia, ventricular system 6831E4276831E434Edema 6837H720Gliosis 6831E431Hemorrhage 6831E403 6835G6116835G625Mineralization 6837H724Necrosis 6837H733Inflamation, acute 6835G6256835G636Inflammation, chronic 6831E431Eyes/optic nerve ...............................Number examined: 50 34 33 50Atrophy 6831E430Atrophy, retinal, unilateral 6831E445 6835G601 6837H7256835G6456835G648Cataract 6831E445 6835G601 6837H7256835G6456835G648Degeneration 6831E430All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 13Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Eyes/optic nerve ...............................Number examined: 50 34 33 50Metaplasia, osseous, scleral 6831E4036831E4126831E436Mineralization, corneal stromal 6831E402 6835G636 6837H7476831E422 6835G6486831E448Mineralization, scleral 6831E405 6833F522 6835G618 6837H7256831E424 6835G620 6837H7306831E429 6835G622 6837H7386835G641 6837H7506835G6466835G650Neovascularization, corneal 6831E415 6835G6456831E422 6835G6486831E448Inflamation, acute 6835G636 6837H718Inflammation, mixed 6831E422 6833F5106833F539Inflammation, chronic 6835G635Bone, femur ....................................Number examined: 50 50 50 50New bone formation, endosteal 6831E402 6833F534 6837H743Inflamation, acute 6837H743Spinal cord ....................................Number examined: 50 34 30 50Degeneration, white matter 6831E427Hemorrhage 6831E403 6835G611Inflamation, acute 6835G636All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 14Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 1 ...............................Number examined: 50 50 50 50Degeneration - respiratory epithelium 6831E433Degeneration, hyaline - respiratory epithelium 6833F532 6835G615 6837H7076833F534 6835G617 6837H7106833F549 6835G622 6837H7486835G6256835G641Metaplasia, squamous - respiratory epithelium 6831E427 6833F521 6835G6386831E444 6833F5316831E446Metaplasia, squamous - transitional epithelium 6831E418Inflammation, mixed 6831E406 6833F504 6835G610 6837H7076831E412 6833F521 6835G622 6837H7186831E414 6833F531 6835G629 6837H7196831E427 6833F539 6835G635 6837H7216831E430 6833F541 6835G636 6837H7376831E432 6835G638 6837H7416831E446 6835G6476835G649Inflammation - nasolacrimal duct 6831E407 6833F502 6835G602 6837H7076831E410 6833F504 6835G609 6837H7186831E416 6833F510 6835G610 6837H7216831E422 6833F514 6835G611 6837H7236831E424 6833F521 6835G612 6837H7286831E431 6833F527 6835G615 6837H7296831E433 6833F531 6835G622 6837H7316831E440 6833F539 6835G625 6837H7416831E443 6833F542 6835G629 6837H7446831E444 6833F546 6835G631 6837H7466831E449 6833F547 6835G635 6837H7486835G637 6837H7496835G6416835G6436835G644Inflammation - respiratory epithelium 6831E444 6837H701All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 15Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 6831E433Degeneration, hyaline - olfactory epithelium 6833F512 6835G606 6837H7126833F517 6835G615 6837H7306833F531 6835G617 6837H7366833F532 6835G622 6837H7416833F534 6835G625 6837H7486835G629 6837H7506835G630Degeneration - respiratory epithelium 6835G610Degeneration, hyaline - respiratory epithelium 6833F549 6835G617 6837H7106835G625 6837H7416837H745Metaplasia, secretory - olfactory epithelium 6833F531Metaplasia, squamous - olfactory epithelium 6833F542Metaplasia, squamous - respiratory epithelium 6835G638Inflammation, mixed 6831E414 6833F517 6835G610 6837H7016831E430 6833F518 6835G622 6837H7196831E442 6833F531 6835G638 6837H7216831E446 6833F540 6837H7366833F542 6837H7466833F546Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 6831E402 6833F534 6835G610 6837H7106831E405 6835G617 6837H7146835G621 6837H7216835G625 6837H7266835G629 6837H7416835G641 6837H7456835G642 6837H748Inflammation, mixed 6831E414 6833F539 6835G638 6837H7016831E430 6837H7366831E435 6837H7476831E446All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 16Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 6835G638Degeneration, hyaline - olfactory epithelium 6835G617 6837H741Inflammation, mixed 6831E414 6835G638 6837H7016831E430 6837H747Preputial gland ................................Number examined: 4 1 3 2Cyst, epithelial inclusion 6835G608Ectasia 6831E410 6833F513 6835G605 6837H7366831E443 6835G621 6837H747Inflammation, chronic 6831E422 6837H747Inflammation, mixed 6831E410 6837H7366831E4186831E443Pancreatic LN ..................................Number examined: 5 2 2 4Iliac LN .......................................Number examined: 3 1 4 2Dilatation, sinusoidal 6835G641Lymph node other ...............................Number examined: 6 4 9 7Dilatation, sinusoidal 6833F531Infiltration, histiocytic 6833F525 6835G602Sinus plasmacytosis 6831E435 6837H713Mediastinal LN .................................Number examined: 49 30 30 50Hemorrhage 6831E412 6833F548 6835G602 6837H7266831E438 6835G620 6837H728Pigmentation 6833F509All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 17Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pituitary gland ................................Number examined: 49 37 34 50Angiectasis 6831E404 6837H7116831E406 6837H7406837H746Cyst 6831E419 6833F512 6835G616 6837H7076831E426 6833F515 6835G620 6837H7096831E437 6833F517 6835G622 6837H7246831E447 6833F534 6835G627 6837H7386833F537 6835G638 6837H7396833F538 6835G641 6837H7426833F544 6835G645Hemorrhage 6831E403 6837H7146831E419 6837H7426831E438Inflammation, chronic 6837H750Tiss.not specifi ...............................Number examined: 1 2 3 5Cyst 6837H718Mammary tissue 6835G625Myodegeneration 6833F546Inflammation, mixed 6835G636Splenic tissue, "accessory" 6837H742Harderian gland ................................Number examined: 1 0 0 0Thymus .........................................Number examined: 1 0 0 2Hemorrhage 6837H712Mediastinum ....................................Number examined: 1 0 0 0All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 18Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Tail ...........................................Number examined: 1 2 1 0Cyst, epithelial inclusion 6833F505Inflammation, acute 6831E436Inflammation, mixed 6833F505 6835G6026833F521Popliteal LN ...................................Number examined: 2 0 2 2Bone, other ....................................Number examined: 0 1 0 1Hyperostosis 6833F543Zymbal’s gland .................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 0 1 1 0Inflammation, mixed 6833F505All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-3 Incidence Summary (with percentages) of Microscopic Observations

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Proliferative (includi ng Neoplastic) LesionsLovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Hyperplasia, alveolar epithelial, focal 8 7 2 416% 14% 4% 8%Hyperplasia, alveolar epithelial, widespread 1 1 0 02% 2% 0% 0%B-Adenoma, bronchiolo-alveolar 1 0 1 02% 0% 2% 0%N-Sarcoma, histiocytic 0 2 0 00% 4% 0% 0%N-Leukemia, mononuclear - capillary involvement 24 31 32 2548% 62% 64% 50%N-Leukemia, mononuclear - invasive involvement 1 1 1 12% 2% 2% 2%Trachea ........................................Number examined: 50 49 50 50Hyperplasia, epithelial 1 1 0 02% 2% 0% 0%N-Leukemia, mononuclear 2 0 1 04% 0% 2% 0%Bronchial (TBLN) ...............................Number examined: 49 33 28 47N-Sarcoma, histiocytic 0 1 0 00% 3% 0% 0%N-Leukemia, mononuclear 10 9 7 720% 27% 25% 15%Thyroid glands .................................Number examined: 50 35 31 50Hyperplasia, C-cell, focal 4 2 0 78% 6% 0% 14%Hyperplasia, follicular cell 0 0 1 00% 0% 3% 0%B-Adenoma, C-cell 3 4 4 36% 11% 13% 6%B-Adenoma, follicular cell 2 0 0 34% 0% 0% 6%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thyroid glands .................................Number examined: 50 35 31 50M-Carcinoma, C-cell 0 2 0 00% 6% 0% 0%M-Carcinoma, follicular cell 1 0 1 32% 0% 3% 6%Parathyroid ....................................Number examined: 45 33 30 46Hyperplasia, diffuse 0 0 0 10% 0% 0% 2%Hyperplasia, focal 0 0 0 20% 0% 0% 4%Aorta ..........................................Number examined: 50 34 30 50N-Leukemia, mononuclear - invasive involvement 1 0 0 02% 0% 0% 0%Esophagus ......................................Number examined: 50 33 30 50Larynx .........................................Number examined: 50 49 50 50Hyperplasia, epithelial 24 15 15 2448% 31% 30% 48%Salivary gland .................................Number examined: 50 34 30 50M-Leukemia, mononuclear 0 0 2 10% 0% 7% 2%Mandibular LN ..................................Number examined: 40 32 30 48Hyperplasia, lymphoid 1 0 1 03% 0% 3% 0%N-Leukemia, mononuclear 13 10 9 933% 31% 30% 19%Liver ..........................................Number examined: 50 40 38 50Hyperplasia, biliary 45 34 37 4690% 85% 97% 92%Hyperplasia, hepatocellular, regenerative 1 3 3 22% 8% 8% 4%B-Adenoma, hepatocellular 1 0 1 12% 0% 3% 2%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 50M-Carcinoma, hepatocellular 1 0 0 02% 0% 0% 0%M-Sarcoma, histiocytic 0 1 0 10% 3% 0% 2%M-Sarcoma, undifferentiated 0 0 1 00% 0% 3% 0%M-Leukemia, mononuclear 27 29 29 3154% 73% 76% 62%Spleen .........................................Number examined: 50 39 38 50M-Fibrosarcoma 0 0 0 10% 0% 0% 2%M-Leukemia, mononuclear 27 31 31 3154% 79% 82% 62%N-Sarcoma, histiocytic 0 0 0 10% 0% 0% 2%Kidneys ........................................Number examined: 50 50 50 50B-Adenoma, renal tubule 0 0 6 20% 0% 12% 4%M-Carcinoma, renal tubule 0 1 0 10% 2% 0% 2%M-Leukemia, mononuclear 4 3 1 18% 6% 2% 2%Heart ..........................................Number examined: 50 34 30 50M-Leukemia, mononuclear 4 5 3 58% 15% 10% 10%Stomach ........................................Number examined: 50 34 30 49Hyperplasia, squamous epithelial 2 0 0 04% 0% 0% 0%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Cecum ..........................................Number examined: 50 34 30 48N-Leukemia, mononuclear 2 0 0 04% 0% 0% 0%Urinary bladder ................................Number examined: 50 33 29 50B-Papilloma, transitional cell 1 0 0 02% 0% 0% 0%M-Leukemia, mononuclear 1 1 0 12% 3% 0% 2%Duodenum .......................................Number examined: 50 34 30 49Jejunum ........................................Number examined: 50 34 30 48M-Adenocarcinoma 2 0 0 04% 0% 0% 0%Ileum ..........................................Number examined: 50 34 30 49Hyperplasia, lymphoid 2 0 0 04% 0% 0% 0%B-Fibroma 1 0 0 02% 0% 0% 0%N-Leukemia, mononuclear 0 1 0 00% 3% 0% 0%Colon ..........................................Number examined: 50 34 30 49B-Leiomyoma 0 0 0 10% 0% 0% 2%Pancreas .......................................Number examined: 50 34 30 49M-Carcinoma, ductal cell 0 0 0 10% 0% 0% 2%M-Leukemia, mononuclear 1 0 0 02% 0% 0% 0%Rectum .........................................Number examined: 50 34 30 50All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Adrenal glands .................................Number examined: 49 35 30 50Hyperplasia, cortical, diffuse 0 0 1 00% 0% 3% 0%Hyperplasia, medullary, focal 8 2 5 1716% 6% 17% 34%B-Pheochromocytoma, benign 7 4 5 714% 11% 17% 14%B-Pheochromocytoma, complex, benign 1 1 0 02% 3% 0% 0%M-Pheochromocytoma, malignant 3 0 0 16% 0% 0% 2%M-Leukemia, mononuclear 3 1 4 26% 3% 13% 4%Prostate .......................................Number examined: 50 33 29 50Hyperplasia 0 0 1 00% 0% 3% 0%Epididymis .....................................Number examined: 50 36 31 50M-Mesothelioma, malignant 0 1 0 20% 3% 0% 4%Seminal vesicle ................................Number examined: 50 35 37 50Hyperplasia 0 1 0 00% 3% 0% 0%M-Leukemia, mononuclear 1 0 1 02% 0% 3% 0%Mesenteric LN ..................................Number examined: 50 34 30 50N-Sarcoma, histiocytic 0 1 0 00% 3% 0% 0%N-Leukemia, mononuclear 6 3 5 612% 9% 17% 12%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Testes .........................................Number examined: 50 50 50 50Hyperplasia, interstitial cell 5 6 3 210% 12% 6% 4%B-Adenoma, interstitial cell 43 47 48 5086% 94% 96% 100%M-Mesothelioma, malignant 0 1 1 20% 2% 2% 4%Sciatic nerve ..................................Number examined: 50 34 30 50N-Leukemia, mononuclear 1 0 0 02% 0% 0% 0%Muscle, skeletal ...............................Number examined: 50 34 30 50N-Sarcoma, histiocytic 0 2 0 00% 6% 0% 0%M-Leukemia, mononuclear 0 0 1 00% 0% 3% 0%Mammary gland ..................................Number examined: 36 31 29 47Hyperplasia, lobular 0 1 0 50% 3% 0% 11%B-Fibroadenoma 0 0 0 10% 0% 0% 2%B-Fibroma 2 2 3 16% 6% 10% 2%N-Sarcoma, histiocytic 0 2 0 00% 6% 0% 0%Skin ...........................................Number examined: 49 37 35 50B-Fibroma 2 0 1 04% 0% 3% 0%B-Keratoacanthoma 0 0 0 10% 0% 0% 2%B-Tumor, basal cell, benign 0 0 0 10% 0% 0% 2%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Skin ...........................................Number examined: 49 37 35 50B-Tumor, hair follicle, benign 0 0 1 00% 0% 3% 0%M-Carcinoma, sebaceous cell 0 1 0 00% 3% 0% 0%M-Sarcoma, undifferentiated 0 1 2 00% 3% 6% 0%N-Sarcoma, histiocytic 0 2 0 00% 5% 0% 0%Brain ..........................................Number examined: 50 34 31 50M-Astrocytoma, malignant 0 1 0 10% 3% 0% 2%Eyes/optic nerve ...............................Number examined: 50 34 33 50M-Leukemia, mononuclear 1 1 0 02% 3% 0% 0%Bone, femur ....................................Number examined: 50 50 50 50Spinal cord ....................................Number examined: 50 34 30 50Nose/Turbinate 1 ...............................Number examined: 50 50 50 50Hyperplasia - respiratory epithelium 3 0 3 46% 0% 6% 8%M-Leukemia, mononuclear 1 0 0 02% 0% 0% 0%Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Hyperplasia - respiratory epithelium 0 2 2 30% 4% 4% 6%M-Carcinoma, squamous cell 1 0 0 02% 0% 0% 0%M-Leukemia, mononuclear 1 0 0 02% 0% 0% 0%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 3 ...............................Number examined: 50 50 50 50M-Carcinoma, squamous cell 0 1 0 10% 2% 0% 2%M-Leukemia, mononuclear 1 0 0 02% 0% 0% 0%Nose/Turbinate 4 ...............................Number examined: 50 50 50 50N-Carcinoma, squamous cell 0 2 0 20% 4% 0% 4%M-Leukemia, mononuclear 1 0 0 02% 0% 0% 0%Preputial gland ................................Number examined: 4 1 3 2Pancreatic LN ..................................Number examined: 5 2 2 4N-Leukemia, mononuclear 5 2 2 4100% 100% 100% 100%Iliac LN .......................................Number examined: 3 1 4 2N-Leukemia, mononuclear 3 1 3 2100% 100% 75% 100%Lymph node other ...............................Number examined: 6 4 9 7N-Leukemia, mononuclear 5 2 7 683% 50% 78% 86%Mediastinal LN .................................Number examined: 49 30 30 50N-Sarcoma, histiocytic 0 1 0 00% 3% 0% 0%N-Leukemia, mononuclear 9 7 5 818% 23% 17% 16%Pituitary gland ................................Number examined: 49 37 34 50Hyperplasia, pars distalis, focal 5 4 3 810% 11% 9% 16%B-Adenoma, pars distalis 9 9 6 518% 24% 18% 10%M-Leukemia, mononuclear 1 1 1 12% 3% 3% 2%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Tiss.not specifi ...............................Number examined: 1 2 3 5B-Fibroma 0 0 1 00% 0% 33% 0%B-Lipoma 1 0 0 1100% 0% 0% 20%M-Mesothelioma, malignant 0 0 0 20% 0% 0% 40%N-Sarcoma, histiocytic 0 1 0 00% 50% 0% 0%Harderian gland ................................Number examined: 1 0 0 0N-Carcinoma, squamous cell 1 0 0 0100% 0% 0% 0%Thymus .........................................Number examined: 1 0 0 2M-Leukemia, mononuclear 1 0 0 1100% 0% 0% 50%Mediastinum ....................................Number examined: 1 0 0 0N-Leukemia, mononuclear 1 0 0 0100% 0% 0% 0%Tail ...........................................Number examined: 1 2 1 0Hyperplasia/hyperkeratosis 0 2 1 00% 100% 100% 0%Popliteal LN ...................................Number examined: 2 0 2 2N-Leukemia, mononuclear 2 0 2 2100% 0% 100% 100%Bone, other ....................................Number examined: 0 1 0 1M-Sarcoma, NOS 0 0 0 10% 0% 0% 100%Zymbal’s gland .................................Number examined: 0 0 0 1M-Carcinoma, squamous cell 0 0 0 10% 0% 0% 100%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mesentery ......................................Number examined: 0 1 1 0M-Mesothelioma, malignant 0 0 1 00% 0% 100% 0%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Non-neoplastic LesionsLovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Alveolar histiocytosis 7 10 10 1114% 20% 20% 22%Autolysis, marked 0 0 0 10% 0% 0% 2%Congestion 0 2 0 00% 4% 0% 0%Fibrosis, focal 1 0 0 12% 0% 0% 2%Hemorrhage 3 7 7 16% 14% 14% 2%Metaplasia, squamous - alveolar epithelium 0 2 0 00% 4% 0% 0%Mineralization, uremic 0 0 0 10% 0% 0% 2%Cyst, squamous cell, keratinizing 0 0 0 10% 0% 0% 2%Inflammation, acute 1 0 1 12% 0% 2% 2%Inflammation, mixed 1 1 5 22% 2% 10% 4%Inflammation, granulomatous 0 2 2 10% 4% 4% 2%Trachea ........................................Number examined: 50 49 50 50Metaplasia, squamous 1 0 0 02% 0% 0% 0%Inflammation, acute 0 1 0 00% 2% 0% 0%Inflammation, mixed 1 1 0 42% 2% 0% 8%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Trachea ........................................Number examined: 50 49 50 50Inflammation, chronic 1 2 1 12% 4% 2% 2%Bronchial (TBLN) ...............................Number examined: 49 33 28 47Hemorrhage 0 3 0 20% 9% 0% 4%Thyroid glands .................................Number examined: 50 35 31 50Cyst, follicular 1 1 3 32% 3% 10% 6%Parathyroid ....................................Number examined: 45 33 30 46Aorta ..........................................Number examined: 50 34 30 50Dilatation 0 0 0 10% 0% 0% 2%Esophagus ......................................Number examined: 50 33 30 50Larynx .........................................Number examined: 50 49 50 50Ulceration 1 0 0 02% 0% 0% 0%Inflammation, mixed 40 35 41 4480% 71% 82% 88%Inflammation, chronic 4 2 4 38% 4% 8% 6%Metaplasia, squamous 8 3 6 616% 6% 12% 12%Salivary gland .................................Number examined: 50 34 30 50Degeneration 0 0 0 10% 0% 0% 2%Inflamation, acute 0 0 0 10% 0% 0% 2%Mandibular LN ..................................Number examined: 40 32 30 48Hemorrhage 1 0 0 03% 0% 0% 0%Sinus plasmacytosis 1 0 0 03% 0% 0% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 50Angiectasis 15 4 8 1830% 10% 21% 36%Congestion 0 0 0 10% 0% 0% 2%Cyst 0 0 1 00% 0% 3% 0%Fatty Change 2 1 1 04% 3% 3% 0%Foci of cellular alteration, basophilic 1 1 0 02% 3% 0% 0%Hepatodiaphragmatic nodule 1 1 1 22% 3% 3% 4%Necrosis 3 4 2 46% 10% 5% 8%Thrombus 0 0 0 10% 0% 0% 2%Vaculolization, cytoplasmic 1 3 1 32% 8% 3% 6%Inflammation, chronic 7 1 0 614% 3% 0% 12%Spleen .........................................Number examined: 50 39 38 50Congestion 0 1 1 00% 3% 3% 0%Fibrosis 3 2 5 06% 5% 13% 0%Hemorrhage 0 1 0 00% 3% 0% 0%Necrosis 2 2 1 14% 5% 3% 2%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 50 50 50Cyst 0 1 2 00% 2% 4% 0%Degeneration, hyaline droplet 0 1 0 00% 2% 0% 0%Infarct 0 0 2 00% 0% 4% 0%Nephropathy, chronic 44 47 50 4688% 94% 100% 92%Pigment accumulation, tubular epithelium 3 3 1 36% 6% 2% 6%Inflamation, acute 0 1 2 00% 2% 4% 0%Heart ..........................................Number examined: 50 34 30 50Degeneration, myocyte 2 1 3 34% 3% 10% 6%Fibrosis 5 5 2 410% 15% 7% 8%Thrombus 0 1 2 20% 3% 7% 4%Inflamation, acute 0 0 1 00% 0% 3% 0%Inflammation, focal, chronic 19 9 10 1938% 26% 33% 38%Stomach ........................................Number examined: 50 34 30 49Inflammation, mixed 2 1 0 04% 3% 0% 0%Cecum ..........................................Number examined: 50 34 30 48All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Urinary bladder ................................Number examined: 50 33 29 50Hemorrhage 0 0 0 10% 0% 0% 2%Inflammation, mixed 0 0 0 10% 0% 0% 2%Inflammation, chronic 3 0 0 36% 0% 0% 6%Duodenum .......................................Number examined: 50 34 30 49Jejunum ........................................Number examined: 50 34 30 48Ileum ..........................................Number examined: 50 34 30 49Colon ..........................................Number examined: 50 34 30 49Inflammation, mixed 1 0 0 02% 0% 0% 0%Pancreas .......................................Number examined: 50 34 30 49Rectum .........................................Number examined: 50 34 30 50Adrenal glands .................................Number examined: 49 35 30 50Cyst 0 0 0 10% 0% 0% 2%Degeneration, cytoplasmic vacuolization 5 2 2 410% 6% 7% 8%Necrosis 0 0 1 10% 0% 3% 2%Thrombus 2 2 3 54% 6% 10% 10%Prostate .......................................Number examined: 50 33 29 50Atrophy 3 0 0 56% 0% 0% 10%Hemorrhage 0 0 0 10% 0% 0% 2%Mineralization 1 0 0 02% 0% 0% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Prostate .......................................Number examined: 50 33 29 50Inflamation, acute 2 1 0 04% 3% 0% 0%Inflammation, mixed 15 12 16 1330% 36% 55% 26%Epididymis .....................................Number examined: 50 36 31 50Atrophy 4 5 1 78% 14% 3% 14%Granuloma, sperm 0 1 0 00% 3% 0% 0%Inflammation, chronic 2 0 1 04% 0% 3% 0%Seminal vesicle ................................Number examined: 50 35 37 50Atrophy 15 2 8 1830% 6% 22% 36%Dilatation 0 1 1 10% 3% 3% 2%Mesenteric LN ..................................Number examined: 50 34 30 50Hemorrhage 1 0 0 02% 0% 0% 0%Histiocytosis, sinus 1 0 0 02% 0% 0% 0%Testes .........................................Number examined: 50 50 50 50Atrophy 1 4 3 52% 8% 6% 10%Hemorrhage 0 1 0 10% 2% 0% 2%Sciatic nerve ..................................Number examined: 50 34 30 50Muscle, skeletal ...............................Number examined: 50 34 30 50Inflammation, chronic 0 0 1 00% 0% 3% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mammary gland ..................................Number examined: 36 31 29 47Cyst 0 0 1 00% 0% 3% 0%Ectasia 1 0 0 13% 0% 0% 2%Skin ...........................................Number examined: 49 37 35 50Cyst, epithelial inclusion 0 0 0 10% 0% 0% 2%Fibrosis 1 2 0 02% 5% 0% 0%Hyperkeratosis 1 1 2 02% 3% 6% 0%Necrosis 0 1 0 00% 3% 0% 0%Inflammation, mixed 0 3 2 00% 8% 6% 0%Inflammation, chronic 1 0 0 02% 0% 0% 0%Brain ..........................................Number examined: 50 34 31 50Compression 6 2 2 412% 6% 6% 8%Ectasia, ventricular system 2 0 0 04% 0% 0% 0%Edema 0 0 0 10% 0% 0% 2%Gliosis 1 0 0 02% 0% 0% 0%Hemorrhage 1 0 2 02% 0% 6% 0%Mineralization 0 0 0 10% 0% 0% 2%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Brain ..........................................Number examined: 50 34 31 50Necrosis 0 0 0 10% 0% 0% 2%Inflamation, acute 0 0 2 00% 0% 6% 0%Inflammation, chronic 1 0 0 02% 0% 0% 0%Eyes/optic nerve ...............................Number examined: 50 34 33 50Atrophy 1 0 0 02% 0% 0% 0%Atrophy, retinal, unilateral 1 0 3 12% 0% 9% 2%Cataract 1 0 3 12% 0% 9% 2%Degeneration 1 0 0 02% 0% 0% 0%Metaplasia, osseous, scleral 3 0 0 06% 0% 0% 0%Mineralization, corneal stromal 3 0 2 16% 0% 6% 2%Mineralization, scleral 3 1 6 46% 3% 18% 8%Neovascularization, corneal 3 0 2 06% 0% 6% 0%Inflamation, acute 0 0 1 10% 0% 3% 2%Inflammation, mixed 1 2 0 02% 6% 0% 0%Inflammation, chronic 0 0 1 00% 0% 3% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Bone, femur ....................................Number examined: 50 50 50 50New bone formation, endosteal 1 1 0 12% 2% 0% 2%Inflamation, acute 0 0 0 10% 0% 0% 2%Spinal cord ....................................Number examined: 50 34 30 50Degeneration, white matter 1 0 0 02% 0% 0% 0%Hemorrhage 1 0 1 02% 0% 3% 0%Inflamation, acute 0 0 1 00% 0% 3% 0%Nose/Turbinate 1 ...............................Number examined: 50 50 50 50Degeneration - respiratory epithelium 1 0 0 02% 0% 0% 0%Degeneration, hyaline - respiratory epithelium 0 3 5 30% 6% 10% 6%Metaplasia, squamous - respiratory epithelium 3 2 1 06% 4% 2% 0%Metaplasia, squamous - transitional epithelium 1 0 0 02% 0% 0% 0%Inflammation, mixed 7 5 8 614% 10% 16% 12%Inflammation - nasolacrimal duct 11 11 15 1222% 22% 30% 24%Inflammation - respiratory epithelium 1 0 0 12% 0% 0% 2%Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 1 0 0 02% 0% 0% 0%Degeneration, hyaline - olfactory epithelium 0 5 7 60% 10% 14% 12%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration - respiratory epithelium 0 0 1 00% 0% 2% 0%Degeneration, hyaline - respiratory epithelium 0 1 2 30% 2% 4% 6%Metaplasia, secretory - olfactory epithelium 0 1 0 00% 2% 0% 0%Metaplasia, squamous - olfactory epithelium 0 1 0 00% 2% 0% 0%Metaplasia, squamous - respiratory epithelium 0 0 1 00% 0% 2% 0%Inflammation, mixed 4 6 3 58% 12% 6% 10%Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 2 1 7 74% 2% 14% 14%Inflammation, mixed 4 1 1 38% 2% 2% 6%Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 0 0 1 00% 0% 2% 0%Degeneration, hyaline - olfactory epithelium 0 0 1 10% 0% 2% 2%Inflammation, mixed 2 0 1 24% 0% 2% 4%Preputial gland ................................Number examined: 4 1 3 2Cyst, epithelial inclusion 0 0 1 00% 0% 33% 0%Ectasia 2 1 2 250% 100% 67% 100%Inflammation, chronic 1 0 0 125% 0% 0% 50%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Preputial gland ................................Number examined: 4 1 3 2Inflammation, mixed 3 0 0 175% 0% 0% 50%Pancreatic LN ..................................Number examined: 5 2 2 4Iliac LN .......................................Number examined: 3 1 4 2Dilatation, sinusoidal 0 0 1 00% 0% 25% 0%Lymph node other ...............................Number examined: 6 4 9 7Dilatation, sinusoidal 0 1 0 00% 25% 0% 0%Infiltration, histiocytic 0 1 1 00% 25% 11% 0%Sinus plasmacytosis 1 0 0 117% 0% 0% 14%Mediastinal LN .................................Number examined: 49 30 30 50Hemorrhage 2 1 2 24% 3% 7% 4%Pigmentation 0 1 0 00% 3% 0% 0%Pituitary gland ................................Number examined: 49 37 34 50Angiectasis 2 0 0 34% 0% 0% 6%Cyst 4 7 7 68% 19% 21% 12%Hemorrhage 3 0 0 26% 0% 0% 4%Inflammation, chronic 0 0 0 10% 0% 0% 2%Tiss.not specifi ...............................Number examined: 1 2 3 5Cyst 0 0 0 10% 0% 0% 20%Mammary tissue 0 0 1 00% 0% 33% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013M Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Tiss.not specifi ...............................Number examined: 1 2 3 5Myodegeneration 0 1 0 00% 50% 0% 0%Inflammation, mixed 0 0 1 00% 0% 33% 0%Splenic tissue, "accessory" 0 0 0 10% 0% 0% 20%Harderian gland ................................Number examined: 1 0 0 0Thymus .........................................Number examined: 1 0 0 2Hemorrhage 0 0 0 10% 0% 0% 50%Mediastinum ....................................Number examined: 1 0 0 0Tail ...........................................Number examined: 1 2 1 0Cyst, epithelial inclusion 0 1 0 00% 50% 0% 0%Inflammation, acute 1 0 0 0100% 0% 0% 0%Inflammation, mixed 0 2 1 00% 100% 100% 0%Popliteal LN ...................................Number examined: 2 0 2 2Bone, other ....................................Number examined: 0 1 0 1Hyperostosis 0 1 0 00% 100% 0% 0%Zymbal’s gland .................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 0 1 1 0Inflammation, mixed 0 1 0 00% 100% 0% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-4 Tabulated Incidence Su mmary of Non-neoplastic LesionsLovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Hyperplasia, alveolar epithelial, focal, Minimal. 6 4 1 2Hyperplasia, alveolar epithelial, focal, Mild. 2 3 1 2Congestion, Mild. 0 1 0 0Congestion, Moderate. 0 1 0 0Alveolar histiocytosis, Minimal. 7 10 10 11Hyperplasia, alveolar epithelial, widespread, Mild. 1 1 0 0Fibrosis, focal, Mild. 1 0 0 1Inflammation, mixed, Minimal. 0 0 3 2Inflammation, mixed, Mild. 0 1 2 0Inflammation, mixed, Moderate. 1 0 0 0Hemorrhage, Minimal. 3 4 5 1Hemorrhage, Mild. 0 2 2 0Hemorrhage, Moderate. 0 1 0 0Inflammation, acute, Minimal. 0 0 1 0Inflammation, acute, Moderate. 0 0 0 1Inflammation, acute, Marked. 1 0 0 0Inflammation, granulomatous, Minimal. 0 2 2 0Inflammation, granulomatous, Moderate. 0 0 0 1Mineralization, uremic, Moderate. 0 0 0 1Cyst, squamous cell, keratinizing, Present. 0 0 0 1Autolysis, marked, Present. 0 0 0 1Metaplasia, squamous - alveolar epithelium, Minimal. 0 1 0 0Metaplasia, squamous - alveolar epithelium, Moderate. 0 1 0 0Trachea ........................................Number examined: 50 49 50 50Inflammation, acute, Minimal. 0 1 0 0Inflammation, mixed, Minimal. 0 0 0 1Inflammation, mixed, Mild. 1 1 0 3Hyperplasia, epithelial, Mild. 1 0 0 0Hyperplasia, epithelial, Moderate. 0 1 0 0Inflammation, chronic, Minimal. 1 1 0 1Inflammation, chronic, Mild. 0 1 1 0Metaplasia, squamous, Moderate. 1 0 0 0Bronchial (TBLN) ...............................Number examined: 49 33 28 47Hemorrhage, Minimal. 0 0 0 1Hemorrhage, Mild. 0 3 0 1Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thyroid glands .................................Number examined: 50 35 31 50Hyperplasia, C-cell, focal, Minimal. 1 1 0 5Hyperplasia, C-cell, focal, Mild. 2 1 0 2Hyperplasia, C-cell, focal, Moderate. 1 0 0 0Cyst, follicular, Present. 1 1 3 3Hyperplasia, follicular cell, Moderate. 0 0 1 0Parathyroid ....................................Number examined: 45 33 30 46Hyperplasia, focal, Minimal. 0 0 0 1Hyperplasia, focal, Moderate. 0 0 0 1Hyperplasia, diffuse, Moderate. 0 0 0 1Aorta ..........................................Number examined: 50 34 30 50Dilatation, Present. 0 0 0 1Esophagus ......................................Number examined: 50 33 30 50Larynx .........................................Number examined: 50 49 50 50Hyperplasia, epithelial, Minimal. 15 5 8 10Hyperplasia, epithelial, Mild. 9 10 7 14Metaplasia, squamous, Minimal. 4 1 6 2Metaplasia, squamous, Mild. 3 2 0 4Metaplasia, squamous, Moderate. 1 0 0 0Inflammation, mixed, Minimal. 14 10 11 5Inflammation, mixed, Mild. 25 23 30 36Inflammation, mixed, Moderate. 1 2 0 3Inflammation, chronic, Minimal. 3 2 2 2Inflammation, chronic, Mild. 1 0 2 1Ulceration, Mild. 1 0 0 0Salivary gland .................................Number examined: 50 34 30 50Degeneration, Minimal. 0 0 0 1Inflamation, acute, Minimal. 0 0 0 1Mandibular LN ..................................Number examined: 40 32 30 48Hyperplasia, lymphoid, Mild. 1 0 1 0Sinus plasmacytosis, Moderate. 1 0 0 0Hemorrhage, Mild. 1 0 0 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 50Necrosis, Minimal. 2 3 2 1Necrosis, Mild. 1 1 0 3Vaculolization, cytoplasmic, Minimal. 1 1 0 2Vaculolization, cytoplasmic, Mild. 0 1 1 1Vaculolization, cytoplasmic, Moderate. 0 1 0 0Angiectasis, Minimal. 9 3 6 12Angiectasis, Mild. 6 0 2 6Angiectasis, Marked. 0 1 0 0Hyperplasia, biliary, Minimal. 6 1 1 3Hyperplasia, biliary, Mild. 23 19 16 25Hyperplasia, biliary, Moderate. 14 13 19 16Hyperplasia, biliary, Marked. 2 1 1 2Hyperplasia, hepatocellular, regenerative, Minimal. 0 0 1 1Hyperplasia, hepatocellular, regenerative, Mild. 1 3 2 1Inflammation, chronic, Minimal. 7 1 0 5Inflammation, chronic, Mild. 0 0 0 1Fatty Change, Minimal. 0 1 1 0Fatty Change, Mild. 1 0 0 0Fatty Change, Moderate. 1 0 0 0Hepatodiaphragmatic nodule, Present. 1 1 1 2Foci of cellular alteration, basophilic, Minimal. 1 0 0 0Foci of cellular alteration, basophilic, Mild. 0 1 0 0Congestion, Moderate. 0 0 0 1Thrombus, Mild. 0 0 0 1Cyst, Moderate. 0 0 1 0Spleen .........................................Number examined: 50 39 38 50Fibrosis, Minimal. 0 0 1 0Fibrosis, Mild. 2 1 4 0Fibrosis, Moderate. 1 0 0 0Fibrosis, Marked. 0 1 0 0Necrosis, Mild. 0 1 1 0Necrosis, Moderate. 0 1 0 1Necrosis, Marked. 2 0 0 0Hemorrhage, Moderate. 0 1 0 0Congestion, Mild. 0 0 1 0Congestion, Moderate. 0 1 0 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 50 50 50Nephropathy, chronic, Minimal. 7 8 2 0Nephropathy, chronic, Mild. 23 23 17 8Nephropathy, chronic, Moderate. 13 14 29 34Nephropathy, chronic, Marked. 1 2 2 4Pigment accumulation, tubular epithelium, Moderate. 2 3 1 2Pigment accumulation, tubular epithelium, Marked. 1 0 0 1Cyst, Minimal. 0 1 1 0Cyst, Mild. 0 0 1 0Degeneration, hyaline droplet, Marked. 0 1 0 0Infarct, Mild. 0 0 2 0Inflamation, acute, Minimal. 0 1 0 0Inflamation, acute, Moderate. 0 0 2 0Heart ..........................................Number examined: 50 34 30 50Inflammation, focal, chronic, Minimal. 17 9 10 18Inflammation, focal, chronic, Mild. 2 0 0 1Degeneration, myocyte, Minimal. 2 1 3 2Degeneration, myocyte, Mild. 0 0 0 1Fibrosis, Minimal. 2 3 2 2Fibrosis, Mild. 3 1 0 2Fibrosis, Moderate. 0 1 0 0Thrombus, Minimal. 0 0 1 0Thrombus, Mild. 0 0 1 1Thrombus, Moderate. 0 1 0 1Inflamation, acute, Moderate. 0 0 1 0Stomach ........................................Number examined: 50 34 30 49Hyperplasia, squamous epithelial, Marked. 2 0 0 0Inflammation, mixed, Mild. 1 1 0 0Inflammation, mixed, Moderate. 1 0 0 0Cecum ..........................................Number examined: 50 34 30 48Urinary bladder ................................Number examined: 50 33 29 50Inflammation, chronic, Minimal. 3 0 0 3Hemorrhage, Marked. 0 0 0 1Inflammation, mixed, Marked. 0 0 0 1Duodenum .......................................Number examined: 50 34 30 49Jejunum ........................................Number examined: 50 34 30 48Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Ileum ..........................................Number examined: 50 34 30 49Hyperplasia, lymphoid, Mild. 1 0 0 0Hyperplasia, lymphoid, Moderate. 1 0 0 0Colon ..........................................Number examined: 50 34 30 49Inflammation, mixed, Marked. 1 0 0 0Pancreas .......................................Number examined: 50 34 30 49Rectum .........................................Number examined: 50 34 30 50Adrenal glands .................................Number examined: 49 35 30 50Hyperplasia, medullary, focal, Present. 8 2 5 17Degeneration, cytoplasmic vacuolization, Minimal. 4 1 1 4Degeneration, cytoplasmic vacuolization, Mild. 1 0 1 0Degeneration, cytoplasmic vacuolization, Moderate. 0 1 0 0Thrombus, Minimal. 1 0 0 3Thrombus, Mild. 1 1 1 1Thrombus, Moderate. 0 1 2 0Thrombus, Marked. 0 0 0 1Cyst, Moderate. 0 0 0 1Necrosis, Mild. 0 0 1 0Necrosis, Moderate. 0 0 0 1Hyperplasia, cortical, diffuse, Moderate. 0 0 1 0Prostate .......................................Number examined: 50 33 29 50Inflammation, mixed, Minimal. 5 1 4 3Inflammation, mixed, Mild. 8 6 8 4Inflammation, mixed, Moderate. 2 4 4 4Inflammation, mixed, Marked. 0 1 0 2Inflamation, acute, Minimal. 2 0 0 0Inflamation, acute, Moderate. 0 1 0 0Mineralization, Minimal. 1 0 0 0Atrophy, Minimal. 0 0 0 4Atrophy, Mild. 3 0 0 0Atrophy, Moderate. 0 0 0 1Hemorrhage, Mild. 0 0 0 1Hyperplasia, Minimal. 0 0 1 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Epididymis .....................................Number examined: 50 36 31 50Inflammation, chronic, Mild. 2 0 0 0Inflammation, chronic, Moderate. 0 0 1 0Atrophy, Minimal. 0 1 0 2Atrophy, Mild. 2 3 1 5Atrophy, Moderate. 2 1 0 0Granuloma, sperm, Mild. 0 1 0 0Seminal vesicle ................................Number examined: 50 35 37 50Atrophy, Minimal. 1 0 0 3Atrophy, Mild. 10 1 5 13Atrophy, Moderate. 4 1 3 2Dilatation, Mild. 0 1 0 0Dilatation, Moderate. 0 0 0 1Dilatation, Marked. 0 0 1 0Hyperplasia, Moderate. 0 1 0 0Mesenteric LN ..................................Number examined: 50 34 30 50Histiocytosis, sinus, Moderate. 1 0 0 0Hemorrhage, Mild. 1 0 0 0Testes .........................................Number examined: 50 50 50 50Hyperplasia, interstitial cell, Present. 5 6 3 2Atrophy, Mild. 0 0 2 1Atrophy, Moderate. 0 1 1 1Atrophy, Marked. 1 3 0 3Hemorrhage, Moderate. 0 1 0 1Sciatic nerve ..................................Number examined: 50 34 30 50Muscle, skeletal ...............................Number examined: 50 34 30 50Inflammation, chronic, Mild. 0 0 1 0Mammary gland ..................................Number examined: 36 31 29 47Hyperplasia, lobular, Minimal. 0 0 0 1Hyperplasia, lobular, Mild. 0 1 0 1Hyperplasia, lobular, Moderate. 0 0 0 1Hyperplasia, lobular, Marked. 0 0 0 2Ectasia, Moderate. 1 0 0 0Ectasia, Marked. 0 0 0 1Cyst, Present. 0 0 1 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Skin ...........................................Number examined: 49 37 35 50Fibrosis, Mild. 1 0 0 0Fibrosis, Moderate. 0 2 0 0Inflammation, chronic, Minimal. 1 0 0 0Hyperkeratosis, Moderate. 0 1 1 0Hyperkeratosis, Marked. 1 0 1 0Cyst, epithelial inclusion, Present. 0 0 0 1Inflammation, mixed, Moderate. 0 2 1 0Inflammation, mixed, Marked. 0 1 1 0Necrosis, Marked. 0 1 0 0Brain ..........................................Number examined: 50 34 31 50Compression, Minimal. 0 0 1 0Compression, Mild. 1 2 0 2Compression, Moderate. 5 0 0 2Compression, Marked. 0 0 1 0Necrosis, Mild. 0 0 0 1Ectasia, ventricular system, Mild. 1 0 0 0Ectasia, ventricular system, Moderate. 1 0 0 0Hemorrhage, Mild. 1 0 1 0Hemorrhage, Moderate. 0 0 1 0Gliosis, Marked. 1 0 0 0Inflammation, chronic, Marked. 1 0 0 0Mineralization, Minimal. 0 0 0 1Edema, Moderate. 0 0 0 1Inflamation, acute, Minimal. 0 0 1 0Inflamation, acute, Mild. 0 0 1 0Eyes/optic nerve ...............................Number examined: 50 34 33 50Mineralization, corneal stromal, Minimal. 2 0 2 1Mineralization, corneal stromal, Mild. 1 0 0 0Mineralization, scleral, Minimal. 3 1 5 4Mineralization, scleral, Mild. 0 0 1 0Atrophy, Marked. 1 0 0 0Degeneration, Marked. 1 0 0 0Atrophy, retinal, unilateral, Moderate. 1 0 2 0Atrophy, retinal, unilateral, Marked. 0 0 1 1Cataract, Present. 1 0 3 1Neovascularization, corneal, Minimal. 2 0 0 0Neovascularization, corneal, Mild. 1 0 1 0Neovascularization, corneal, Moderate. 0 0 1 0Inflammation, mixed, Minimal. 1 0 0 0Inflammation, mixed, Moderate. 0 1 0 0Inflammation, mixed, Marked. 0 1 0 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Eyes/optic nerve ...............................Number examined: 50 34 33 50Metaplasia, osseous, scleral, Minimal. 3 0 0 0Inflamation, acute, Minimal. 0 0 1 0Inflamation, acute, Mild. 0 0 0 1Inflammation, chronic, Moderate. 0 0 1 0Bone, femur ....................................Number examined: 50 50 50 50New bone formation, endosteal, Minimal. 1 0 0 0New bone formation, endosteal, Mild. 0 0 0 1New bone formation, endosteal, Marked. 0 1 0 0Inflamation, acute, Mild. 0 0 0 1Spinal cord ....................................Number examined: 50 34 30 50Degeneration, white matter, Minimal. 1 0 0 0Hemorrhage, Mild. 1 0 1 0Inflamation, acute, Minimal. 0 0 1 0Nose/Turbinate 1 ...............................Number examined: 50 50 50 50Inflammation - nasolacrimal duct, Minimal. 0 0 4 0Inflammation - nasolacrimal duct, Mild. 6 5 5 4Inflammation - nasolacrimal duct, Moderate. 5 6 6 6Inflammation - nasolacrimal duct, Marked. 0 0 0 2Inflammation, mixed, Minimal. 1 2 6 2Inflammation, mixed, Mild. 3 1 1 2Inflammation, mixed, Moderate. 2 1 1 2Inflammation, mixed, Marked. 1 1 0 0Metaplasia, squamous - respiratory epithelium, Minimal. 1 0 1 0Metaplasia, squamous - respiratory epithelium, Mild. 1 1 0 0Metaplasia, squamous - respiratory epithelium, Moderate. 1 1 0 0Inflammation - respiratory epithelium, Minimal. 1 0 0 0Inflammation - respiratory epithelium, Mild. 0 0 0 1Metaplasia, squamous - transitional epithelium, Minimal. 1 0 0 0Hyperplasia - respiratory epithelium, Minimal. 0 0 2 0Hyperplasia - respiratory epithelium, Mild. 1 0 0 1Hyperplasia - respiratory epithelium, Moderate. 2 0 1 3Degeneration, hyaline - respiratory epithelium, Minimal. 0 2 2 1Degeneration, hyaline - respiratory epithelium, Mild. 0 0 3 2Degeneration, hyaline - respiratory epithelium, Moderate. 0 1 0 0Degeneration - respiratory epithelium, Minimal. 1 0 0 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium, Minimal. 0 3 3 3Degeneration, hyaline - olfactory epithelium, Mild. 0 1 4 1Degeneration, hyaline - olfactory epithelium, Moderate. 0 1 0 2Inflammation, mixed, Minimal. 0 2 1 0Inflammation, mixed, Mild. 1 3 2 4Inflammation, mixed, Moderate. 2 1 0 1Inflammation, mixed, Marked. 1 0 0 0Degeneration - olfactory epithelium, Minimal. 1 0 0 0Degeneration, hyaline - respiratory epithelium, Minimal. 0 1 0 0Degeneration, hyaline - respiratory epithelium, Mild. 0 0 2 2Degeneration, hyaline - respiratory epithelium, Moderate. 0 0 0 1Metaplasia, secretory - olfactory epithelium, Moderate. 0 1 0 0Hyperplasia - respiratory epithelium, Minimal. 0 1 1 0Hyperplasia - respiratory epithelium, Mild. 0 1 1 1Hyperplasia - respiratory epithelium, Moderate. 0 0 0 2Degeneration - respiratory epithelium, Minimal. 0 0 1 0Metaplasia, squamous - olfactory epithelium, Minimal. 0 1 0 0Metaplasia, squamous - respiratory epithelium, Minimal. 0 0 1 0Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium, Minimal. 2 0 3 2Degeneration, hyaline - olfactory epithelium, Mild. 0 1 4 3Degeneration, hyaline - olfactory epithelium, Moderate. 0 0 0 2Inflammation, mixed, Minimal. 0 1 1 2Inflammation, mixed, Minimal, Focal. 1 0 0 0Inflammation, mixed, Mild. 1 0 0 1Inflammation, mixed, Moderate. 1 0 0 0Inflammation, mixed, Marked. 1 0 0 0Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Inflammation, mixed, Minimal. 0 0 0 2Inflammation, mixed, Mild. 0 0 1 0Inflammation, mixed, Moderate. 2 0 0 0Degeneration, hyaline - olfactory epithelium, Minimal. 0 0 1 1Degeneration - olfactory epithelium, Mild. 0 0 1 0Preputial gland ................................Number examined: 4 1 3 2Ectasia, Moderate. 1 0 2 2Ectasia, Marked. 1 1 0 0Inflammation, mixed, Mild. 0 0 0 1Inflammation, mixed, Moderate. 2 0 0 0Inflammation, mixed, Marked. 1 0 0 0Inflammation, chronic, Minimal. 0 0 0 1Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Preputial gland ................................Number examined: 4 1 3 2Inflammation, chronic, Mild. 1 0 0 0Cyst, epithelial inclusion, Present. 0 0 1 0Pancreatic LN ..................................Number examined: 5 2 2 4Iliac LN .......................................Number examined: 3 1 4 2Dilatation, sinusoidal, Mild. 0 0 1 0Lymph node other ...............................Number examined: 6 4 9 7Sinus plasmacytosis, Marked. 1 0 0 1Infiltration, histiocytic, Moderate. 0 0 1 0Infiltration, histiocytic, Marked. 0 1 0 0Dilatation, sinusoidal, Marked. 0 1 0 0Mediastinal LN .................................Number examined: 49 30 30 50Hemorrhage, Minimal. 1 0 0 0Hemorrhage, Mild. 1 1 2 2Pigmentation, Marked. 0 1 0 0Pituitary gland ................................Number examined: 49 37 34 50Cyst, Minimal. 1 5 4 3Cyst, Mild. 2 2 3 2Cyst, Moderate. 1 0 0 0Cyst, Marked. 0 0 0 1Hyperplasia, pars distalis, focal, Minimal. 3 3 3 5Hyperplasia, pars distalis, focal, Mild. 2 1 0 0Hyperplasia, pars distalis, focal, Moderate. 0 0 0 3Hemorrhage, Minimal. 1 0 0 0Hemorrhage, Mild. 2 0 0 0Hemorrhage, Moderate. 0 0 0 1Hemorrhage, Marked. 0 0 0 1Angiectasis, Minimal. 2 0 0 1Angiectasis, Mild. 0 0 0 1Angiectasis, Moderate. 0 0 0 1Inflammation, chronic, Minimal. 0 0 0 1Tiss.not specifi ...............................Number examined: 1 2 3 5Cyst, Moderate. 0 0 0 1Mammary tissue, Present. 0 0 1 0Inflammation, mixed, Marked. 0 0 1 0Myodegeneration, Mild. 0 1 0 0Splenic tissue, "accessory", Present. 0 0 0 1Harderian gland ................................Number examined: 1 0 0 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:14-Jun-04Research Institute Study Number:FY01013M Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thymus .........................................Number examined: 1 0 0 2Hemorrhage, Mild. 0 0 0 1Mediastinum ....................................Number examined: 1 0 0 0Tail ...........................................Number examined: 1 2 1 0Inflammation, acute, Marked. 1 0 0 0Inflammation, mixed, Moderate. 0 2 0 0Inflammation, mixed, Marked. 0 0 1 0Hyperplasia/hyperkeratosis, Moderate. 0 1 1 0Hyperplasia/hyperkeratosis, Marked. 0 1 0 0Cyst, epithelial inclusion, Present. 0 1 0 0Popliteal LN ...................................Number examined: 2 0 2 2Bone, other ....................................Number examined: 0 1 0 1Hyperostosis, Mild. 0 1 0 0Zymbal’s gland .................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 0 1 1 0Inflammation, mixed, Marked. 0 1 0 0Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-5 Lesion Incidence Summar y with Average Severity GradesLovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Alveolar histiocytosis 7 10 10 11Average severity: 0.1 0.2 0.2 0.2Autolysis, marked 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Congestion 0 2 0 0Average severity: 0.0 0.1 0.0 0.0Fibrosis, focal 1 0 0 1Average severity: 0.0 0.0 0.0 0.0Hemorrhage 3 7 7 1Average severity: 0.1 0.2 0.2 0.0Metaplasia, squamous - alveolar epithelium 0 2 0 0Average severity: 0.0 0.1 0.0 0.0Mineralization, uremic 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Cyst, squamous cell, keratinizing 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Inflammation, acute 1 0 1 1Average severity: 0.1 0.0 0.0 0.1Inflammation, mixed 1 1 5 2Average severity: 0.1 0.0 0.1 0.0Inflammation, granulomatous 0 2 2 1Average severity: 0.0 0.0 0.0 0.1Hyperplasia, alveolar epithelial, focal 8 7 2 4Average severity: 0.2 0.2 0.1 0.1Hyperplasia, alveolar epithelial, widespread 1 1 0 0Average severity: 0.0 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Trachea ........................................Number examined: 50 49 50 50Metaplasia, squamous 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Inflammation, acute 0 1 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 1 1 0 4Average severity: 0.0 0.0 0.0 0.1Inflammation, chronic 1 2 1 1Average severity: 0.0 0.1 0.0 0.0Hyperplasia, epithelial 1 1 0 0Average severity: 0.0 0.1 0.0 0.0Bronchial (TBLN) ...............................Number examined: 49 33 28 47Hemorrhage 0 3 0 2Average severity: 0.0 0.2 0.0 0.1Thyroid glands .................................Number examined: 50 35 31 50Cyst, follicular 1 1 3 3Average severity: 0.0 0.0 0.1 0.1Hyperplasia, C-cell, focal 4 2 0 7Average severity: 0.2 0.1 0.0 0.2Hyperplasia, follicular cell 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Parathyroid ....................................Number examined: 45 33 30 46Hyperplasia, diffuse 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Hyperplasia, focal 0 0 0 2Average severity: 0.0 0.0 0.0 0.1Aorta ..........................................Number examined: 50 34 30 50Dilatation 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Esophagus ......................................Number examined: 50 33 30 50Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Larynx .........................................Number examined: 50 49 50 50Ulceration 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 40 35 41 44Average severity: 1.3 1.3 1.4 1.7Inflammation, chronic 4 2 4 3Average severity: 0.1 0.0 0.1 0.1Metaplasia, squamous 8 3 6 6Average severity: 0.3 0.1 0.1 0.2Hyperplasia, epithelial 24 15 15 24Average severity: 0.7 0.5 0.4 0.8Salivary gland .................................Number examined: 50 34 30 50Degeneration 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Inflamation, acute 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Mandibular LN ..................................Number examined: 40 32 30 48Hemorrhage 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Sinus plasmacytosis 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Hyperplasia, lymphoid 1 0 1 0Average severity: 0.1 0.0 0.1 0.0Liver ..........................................Number examined: 50 40 38 50Angiectasis 15 4 8 18Average severity: 0.4 0.2 0.3 0.5Congestion 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Cyst 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 40 38 50Fatty Change 2 1 1 0Average severity: 0.1 0.0 0.0 0.0Foci of cellular alteration, basophilic 1 1 0 0Average severity: 0.0 0.1 0.0 0.0Hepatodiaphragmatic nodule 1 1 1 2Average severity: 0.0 0.0 0.0 0.0Necrosis 3 4 2 4Average severity: 0.1 0.1 0.1 0.1Thrombus 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Vaculolization, cytoplasmic 1 3 1 3Average severity: 0.0 0.2 0.1 0.1Inflammation, chronic 7 1 0 6Average severity: 0.1 0.0 0.0 0.1Hyperplasia, biliary 45 34 37 46Average severity: 2.0 2.1 2.5 2.2Hyperplasia, hepatocellular, regenerative 1 3 3 2Average severity: 0.0 0.2 0.1 0.1Spleen .........................................Number examined: 50 39 38 50Congestion 0 1 1 0Average severity: 0.0 0.1 0.1 0.0Fibrosis 3 2 5 0Average severity: 0.1 0.2 0.2 0.0Hemorrhage 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Necrosis 2 2 1 1Average severity: 0.2 0.1 0.1 0.1Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 50 50 50Cyst 0 1 2 0Average severity: 0.0 0.0 0.1 0.0Degeneration, hyaline droplet 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Infarct 0 0 2 0Average severity: 0.0 0.0 0.1 0.0Nephropathy, chronic 44 47 50 46Average severity: 1.9 2.1 2.6 2.7Pigment accumulation, tubular epithelium 3 3 1 3Average severity: 0.2 0.2 0.1 0.2Inflamation, acute 0 1 2 0Average severity: 0.0 0.0 0.1 0.0Heart ..........................................Number examined: 50 34 30 50Degeneration, myocyte 2 1 3 3Average severity: 0.0 0.0 0.1 0.1Fibrosis 5 5 2 4Average severity: 0.2 0.2 0.1 0.1Thrombus 0 1 2 2Average severity: 0.0 0.1 0.1 0.1Inflamation, acute 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Inflammation, focal, chronic 19 9 10 19Average severity: 0.4 0.3 0.3 0.4Stomach ........................................Number examined: 50 34 30 49Inflammation, mixed 2 1 0 0Average severity: 0.1 0.1 0.0 0.0Hyperplasia, squamous epithelial 2 0 0 0Average severity: 0.2 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Cecum ..........................................Number examined: 50 34 30 48Urinary bladder ................................Number examined: 50 33 29 50Hemorrhage 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Inflammation, mixed 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Inflammation, chronic 3 0 0 3Average severity: 0.1 0.0 0.0 0.1Duodenum .......................................Number examined: 50 34 30 49Jejunum ........................................Number examined: 50 34 30 48Ileum ..........................................Number examined: 50 34 30 49Hyperplasia, lymphoid 2 0 0 0Average severity: 0.1 0.0 0.0 0.0Colon ..........................................Number examined: 50 34 30 49Inflammation, mixed 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Pancreas .......................................Number examined: 50 34 30 49Rectum .........................................Number examined: 50 34 30 50Adrenal glands .................................Number examined: 49 35 30 50Cyst 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Degeneration, cytoplasmic vacuolization 5 2 2 4Average severity: 0.1 0.1 0.1 0.1Necrosis 0 0 1 1Average severity: 0.0 0.0 0.1 0.1Thrombus 2 2 3 5Average severity: 0.1 0.1 0.3 0.2Hyperplasia, cortical, diffuse 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Adrenal glands .................................Number examined: 49 35 30 50Hyperplasia, medullary, focal 8 2 5 17Average severity: 0.2 0.1 0.2 0.3Prostate .......................................Number examined: 50 33 29 50Atrophy 3 0 0 5Average severity: 0.1 0.0 0.0 0.1Hemorrhage 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Mineralization 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Hyperplasia 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Inflamation, acute 2 1 0 0Average severity: 0.0 0.1 0.0 0.0Inflammation, mixed 15 12 16 13Average severity: 0.5 0.9 1.1 0.6Epididymis .....................................Number examined: 50 36 31 50Atrophy 4 5 1 7Average severity: 0.2 0.3 0.1 0.2Granuloma, sperm 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Inflammation, chronic 2 0 1 0Average severity: 0.1 0.0 0.1 0.0Seminal vesicle ................................Number examined: 50 35 37 50Atrophy 15 2 8 18Average severity: 0.7 0.1 0.5 0.7Dilatation 0 1 1 1Average severity: 0.0 0.1 0.1 0.1Hyperplasia 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mesenteric LN ..................................Number examined: 50 34 30 50Hemorrhage 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Histiocytosis, sinus 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Testes .........................................Number examined: 50 50 50 50Atrophy 1 4 3 5Average severity: 0.1 0.3 0.1 0.3Hemorrhage 0 1 0 1Average severity: 0.0 0.1 0.0 0.1Hyperplasia, interstitial cell 5 6 3 2Average severity: 0.1 0.1 0.1 0.0Sciatic nerve ..................................Number examined: 50 34 30 50Muscle, skeletal ...............................Number examined: 50 34 30 50Inflammation, chronic 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Mammary gland ..................................Number examined: 36 31 29 47Cyst 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Ectasia 1 0 0 1Average severity: 0.1 0.0 0.0 0.1Hyperplasia, lobular 0 1 0 5Average severity: 0.0 0.1 0.0 0.3Skin ...........................................Number examined: 49 37 35 50Cyst, epithelial inclusion 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Fibrosis 1 2 0 0Average severity: 0.0 0.2 0.0 0.0Hyperkeratosis 1 1 2 0Average severity: 0.1 0.1 0.2 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Skin ...........................................Number examined: 49 37 35 50Necrosis 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Inflammation, mixed 0 3 2 0Average severity: 0.0 0.3 0.2 0.0Inflammation, chronic 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Brain ..........................................Number examined: 50 34 31 50Compression 6 2 2 4Average severity: 0.3 0.1 0.2 0.2Ectasia, ventricular system 2 0 0 0Average severity: 0.1 0.0 0.0 0.0Edema 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Gliosis 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Hemorrhage 1 0 2 0Average severity: 0.0 0.0 0.2 0.0Mineralization 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Necrosis 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Inflamation, acute 0 0 2 0Average severity: 0.0 0.0 0.1 0.0Inflammation, chronic 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Eyes/optic nerve ...............................Number examined: 50 34 33 50Atrophy 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Atrophy, retinal, unilateral 1 0 3 1Average severity: 0.1 0.0 0.3 0.1Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Eyes/optic nerve ...............................Number examined: 50 34 33 50Cataract 1 0 3 1Average severity: 0.0 0.0 0.1 0.0Degeneration 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Metaplasia, osseous, scleral 3 0 0 0Average severity: 0.1 0.0 0.0 0.0Mineralization, corneal stromal 3 0 2 1Average severity: 0.1 0.0 0.1 0.0Mineralization, scleral 3 1 6 4Average severity: 0.1 0.0 0.2 0.1Neovascularization, corneal 3 0 2 0Average severity: 0.1 0.0 0.2 0.0Inflamation, acute 0 0 1 1Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 1 2 0 0Average severity: 0.0 0.2 0.0 0.0Inflammation, chronic 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Bone, femur ....................................Number examined: 50 50 50 50New bone formation, endosteal 1 1 0 1Average severity: 0.0 0.1 0.0 0.0Inflamation, acute 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Spinal cord ....................................Number examined: 50 34 30 50Degeneration, white matter 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Hemorrhage 1 0 1 0Average severity: 0.0 0.0 0.1 0.0Inflamation, acute 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 1 ...............................Number examined: 50 50 50 50Degeneration - respiratory epithelium 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Degeneration, hyaline - respiratory epithelium 0 3 5 3Average severity: 0.0 0.1 0.2 0.1Metaplasia, squamous - respiratory epithelium 3 2 1 0Average severity: 0.1 0.1 0.0 0.0Metaplasia, squamous - transitional epithelium 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 7 5 8 6Average severity: 0.3 0.2 0.2 0.2Inflammation - nasolacrimal duct 11 11 15 12Average severity: 0.5 0.6 0.6 0.7Inflammation - respiratory epithelium 1 0 0 1Average severity: 0.0 0.0 0.0 0.0Hyperplasia - respiratory epithelium 3 0 3 4Average severity: 0.2 0.0 0.1 0.2Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Degeneration, hyaline - olfactory epithelium 0 5 7 6Average severity: 0.0 0.2 0.2 0.2Degeneration - respiratory epithelium 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Degeneration, hyaline - respiratory epithelium 0 1 2 3Average severity: 0.0 0.0 0.1 0.1Metaplasia, secretory - olfactory epithelium 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Metaplasia, squamous - olfactory epithelium 0 1 0 0Average severity: 0.0 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Metaplasia, squamous - respiratory epithelium 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 4 6 3 5Average severity: 0.2 0.2 0.1 0.2Hyperplasia - respiratory epithelium 0 2 2 3Average severity: 0.0 0.1 0.1 0.2Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 2 1 7 7Average severity: 0.0 0.0 0.2 0.3Inflammation, mixed 4 1 1 3Average severity: 0.2 0.0 0.0 0.1Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Degeneration, hyaline - olfactory epithelium 0 0 1 1Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 2 0 1 2Average severity: 0.1 0.0 0.0 0.0Preputial gland ................................Number examined: 4 1 3 2Cyst, epithelial inclusion 0 0 1 0Average severity: 0.0 0.0 0.3 0.0Ectasia 2 1 2 2Average severity: 1.8 4.0 2.0 3.0Inflammation, chronic 1 0 0 1Average severity: 0.5 0.0 0.0 0.5Inflammation, mixed 3 0 0 1Average severity: 2.5 0.0 0.0 1.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 13Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pancreatic LN ..................................Number examined: 5 2 2 4Iliac LN .......................................Number examined: 3 1 4 2Dilatation, sinusoidal 0 0 1 0Average severity: 0.0 0.0 0.5 0.0Lymph node other ...............................Number examined: 6 4 9 7Dilatation, sinusoidal 0 1 0 0Average severity: 0.0 1.0 0.0 0.0Infiltration, histiocytic 0 1 1 0Average severity: 0.0 1.0 0.3 0.0Sinus plasmacytosis 1 0 0 1Average severity: 0.7 0.0 0.0 0.6Mediastinal LN .................................Number examined: 49 30 30 50Hemorrhage 2 1 2 2Average severity: 0.1 0.1 0.1 0.1Pigmentation 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Pituitary gland ................................Number examined: 49 37 34 50Angiectasis 2 0 0 3Average severity: 0.0 0.0 0.0 0.1Cyst 4 7 7 6Average severity: 0.2 0.2 0.3 0.2Hemorrhage 3 0 0 2Average severity: 0.1 0.0 0.0 0.1Inflammation, chronic 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Hyperplasia, pars distalis, focal 5 4 3 8Average severity: 0.1 0.1 0.1 0.3Tiss.not specifi ...............................Number examined: 1 2 3 5Cyst 0 0 0 1Average severity: 0.0 0.0 0.0 0.6Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 14Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Tiss.not specifi ...............................Number examined: 1 2 3 5Mammary tissue 0 0 1 0Average severity: 0.0 0.0 0.3 0.0Myodegeneration 0 1 0 0Average severity: 0.0 1.0 0.0 0.0Inflammation, mixed 0 0 1 0Average severity: 0.0 0.0 1.3 0.0Splenic tissue, "accessory" 0 0 0 1Average severity: 0.0 0.0 0.0 0.2Harderian gland ................................Number examined: 1 0 0 0Thymus .........................................Number examined: 1 0 0 2Hemorrhage 0 0 0 1Average severity: 0.0 0.0 0.0 1.0Mediastinum ....................................Number examined: 1 0 0 0Tail ...........................................Number examined: 1 2 1 0Cyst, epithelial inclusion 0 1 0 0Average severity: 0.0 0.5 0.0 0.0Inflammation, acute 1 0 0 0Average severity: 4.0 0.0 0.0 0.0Inflammation, mixed 0 2 1 0Average severity: 0.0 3.0 4.0 0.0Hyperplasia/hyperkeratosis 0 2 1 0Average severity: 0.0 3.5 3.0 0.0Popliteal LN ...................................Number examined: 2 0 2 2Bone, other ....................................Number examined: 0 1 0 1Hyperostosis 0 1 0 0Average severity: 0.0 2.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 15Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Zymbal’s gland .................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 0 1 1 0Inflammation, mixed 0 1 0 0Average severity: 0.0 4.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-6 Raw DataLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 1Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSLungs (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - - - - - - - - - - - - - - 1299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - 1= 1 - - - - - - - - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - 4= -84-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - 2= - - - - - - - 1 - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol 1= 2 2= - 2 - - - 2 2= 2= - - - 2131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - 3 -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -9-N-Leukemia, monuc - - - - 1= - - - - - 1= - - - -Thyroid glands (7) Status > mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - P - - - - - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -10-B-Adenoma, C-cell - - 1 - - - - - - - - - - - -87-B-Adenoma, follicular cell - - - - - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 2Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSParathyroid (2) Status > m mH mH mH m mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -325-Dilatation p - - - - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 2 2 2 2 1 - 1 1 2 2 2 - 2 2 119-Inflammation, chronic s - - - - - - - - - - - 1 - - -16-Metaplasia, squamous s - - - - - - 1 - - - - - - 2 -15-Hyperplasia, epithelial s 1 1 2 1 - - - - 1 1 1 - 1 - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (4) Status > *H *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - 3= - - - - - - -60-Hyperplasia, lymphoid s - - - - - - 2= - - - - - -21-N-Leukemia, monuc - - - - - - - 1 1 - - - 1Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - 2 - - - - - - 1 - 1 - - - -160-Congestion s - - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - - -99-Fatty Change s - - - - - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - - -123-Hdn p - - - - - - - - - - - - - - -22-Necrosis s - - 2 - - - - - - - - - - 1 1231-Thrombus s - - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - - - - - -29-Inflammation, chronic s - - - 1 - - 1 - - - - - - - -27-Hyperplasia, biliary s 3 3 3 - 3 2 2 - 2 3 3 1 2 1 328-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 3Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSLiver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -24-M-Leukemia, monuc 2= 2 2 - 2= - - - 2 2= 1 - - - 2Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - - -63-Fibrosis s - - - - - - - - - 2= - - - - -247-Hemorrhage s - - - - - - - - - - - - - - -129-Necrosis s - - 4= - - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - - - -30-M-Leukemia, monuc 2= 2= 2= - 2= - - - 2 2= 2= - - - 2=326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 2 1 2 2 2 2 3 - 3 3 3 1 3 - 2130-Pigment, tubular epithelium s - - 3 - - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - 1 - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - - - - - - - - - - - -116-Fibrosis s - - - - - - 1 - - - - - - 1 -206-Thrombus s - - - - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - - - - -34-Inflammation, focal, chronic s 1 - - 1 - - - 1 - 1 - - 1 - -35-M-Leukemia, monuc - - - - 1 - - - - - 1 - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - 1 - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 4Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSUrinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - - - - -37-Inflammation, chronic s - - - 1 - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - 1= - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - 2= - - -Ileum (3) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - - - - - - 1 - - - - - 1194-Necrosis s - - - - - - - - - - - - - - -108-Thrombus s - - - - - - - - - - - - - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - - P - - - P - - - - - P - -77-B-Pheochrom, bgn 1 - - - - - - - - - - - - - -305-B-Pheochro, complex, benign - - - - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - -57-M-Leukemia, monuc - - - - 1 - - - - - 1 - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 5Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSProstate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - - - - - - - - -179-Hemorrhage s - - - - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - - - - -88-Inflammation, acute s - 1 - - - 1 - - - - - - - - -64-Inflammation, mixed s - - - - - - 3 - - 1 - - - - 2Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - - - - - - - - - 3= - -242-Granuloma, sperm s - - - - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - - - - -198-M-Mesothelio, mal - - - - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - - - - - - - - - - - 3 2 3=182-Dilatation s - - - - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -43-N-Leukemia, monuc - - - - - - - - - 1 1 - - - -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= - - 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 6Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSMammary gland (6) Status > * * * *H * * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - -166-Ectasia s - - - - - - 3 -155-Hyperplasia, lobular s - - - - - - - -165-B-Fibroadenoma - - - - - - - -55-B-Fibroma - 1= - - - - - -266-N-Sarcoma, histiocytic - - - - - - - -Skin (13) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - - - - - - 3= - - - - 2= -103-Ectasia, ventricular sys s - - - - - - - - - - - - - - -226-Edema s - - - - - - - - - - - - - - -189-Gliosis s - - - - - - - - - - - - - - -183-Hemorrhage s - - 2 - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - - - - -45-Necrosis s - - - - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -111-Cataract p - - - - - - - - - - - - - - -90-Degen s - - - - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - 1 - - - - - - - - 1 - - -46-Mineralization, corneal str s - 2 - - - - - - - - - - - - -59-Mineralization, scleral s - - - - 1 - - - - - - - - - -121-Neovascularization, corneal s - - - - - - - - - - - - - - 2180-Inflammation, acute s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 7Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSEyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - 1 - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - - - - -184-Hemorrhage s - - 2 - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - - 2 - - - - - 1 - 3 -49-Inflammation-nasolac duct s - - - - - - 3 - - 2 - - - - -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - 3 - - - - - 3 -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - - - - - - - - - 3 -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - 2= - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status > H HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - 1 - - 1 - - - - - - - - - -93-Inflammation, mixed s - - - - - - - - - - - - - 3 -195-M-Carcinoma, squamous cell - - - - - 2 - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 8Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSNose/Turbinate 4 (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - 3 -196-N-Carcinoma, squamous cell - - - - - 2= - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator > 142283-Cyst, epithelial inclusion p -66-Ectasia s 3=128-Inflammation, chronic s -67-Inflammation, mixed s 3Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator >270-Dilatation, sinusoidal s169-Infiltration, histiocytic s142-Sinus plasmacytosis s75-N-Leukemia, monucMediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - - - 2 - - -171-Pigmentation s - - - - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-N-Leukemia, monuc - - - - - - - - - 1= 1= - - - -Pituitary gland (7) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - 1 - 1 - - - - - - - - -40-Cyst s - - - - - - - - - - - - - - -172-Hemorrhage s - - 2= - - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s 2 - - - 1 - - - - 1 - - - - -39-B-Adenoma, pars distalis - - - - - - 1= - 1= - - - - 1= -138-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 9Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSTiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142181-Cyst s -276-Mammary tissue p -286-Myodegeneration s -281-Inflammation, mixed s -308-B-Fibroma -113-B-Lipoma 1=200-M-Mesothelio, mal -328-N-Sarcoma, histiocytic -331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator > 142114-N-Carcinoma, squamous cell 2NT.Thymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 10Rat/F344/NGroup Sex Dosage Animal > 6831E402 6831E404 6831E406 6831E408 6831E410 6831E412 6831E4141 M 0 g/m3 Animal > 6831E401 6831E403 6831E405 6831E407 6831E409 6831E411 6831E413 6831E415Tissue/diagnosis Death code > U2 U2 U2 U2 U2 U2 FS U2 U2 U2 U2 U2 FS U2 FSMesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 11Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Lungs (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - 1 - - 1 - - - - - - - 1 - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - 2 -154-Hemorrhage s - - - - - - - - - - - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - - - - - - 3=214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - 1 -5-Hyperplasia, alv epi, wdsprd s 2 - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol 2= - - 2 2= 2 - 2 2= - 2 - - 2= -131-N-Leukemia,monuc - inv invol - - - - - - - - - - - 2= - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - 2177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - 2215-N-Leukemia, mononuclear - - - - 1 - - - - - - - - - -Bronchial (TBLN) (3) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -9-N-Leukemia, monuc 1 - - - 1= 1= - - - - - 2= - 1= -Thyroid glands (7) Status > mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - - - - - - - -73-Hyperplasia, C-cell, focal s 2 3 - - - - - - - - - 1 - - -153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -10-B-Adenoma, C-cell - - - - - - - - - - - - - - -87-B-Adenoma, follicular cell - - - - - - - - - - - - - - 2=204-M-Carcinoma, C-cell - - - - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - 1= - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 12Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Parathyroid (2) Status > *H H mH mH *H m m *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - 2 - - -325-Dilatation p - - - - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 1 2 2 1 2 2 - 2 2 - 1 1 - - 3=19-Inflammation, chronic s - - - - - - 2 - - - - - - 1 -16-Metaplasia, squamous s - - - 1 - - - - - - - 1 1 - 315-Hyperplasia, epithelial s - 1 2 - 2 1 - 2 - - 2 - - - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (4) Status > * * * *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - 2= - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - -21-N-Leukemia, monuc 1 - - 1= - - 1 - 1= 1= -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s 2 - - 1 - - - - 1 - 2 - - - -160-Congestion s - - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - - -99-Fatty Change s - - - - - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - - -123-Hdn p - - P= - - - - - - - - - - - -22-Necrosis s - - - - - - - - - - - - - - -231-Thrombus s - - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - - 1 - - -29-Inflammation, chronic s - 1 - - - - - - - - - - 1 - 127-Hyperplasia, biliary s 3 2 2 4 3 3 2 3 4 2 2 1 2 2 128-Hyperplasia, hepato, regen s - - - - - - - 2= - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 13Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -24-M-Leukemia, monuc 2= - - 2 2 2= - 2 2 - 2 2= - 2 -Spleen (7) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - - -63-Fibrosis s - - - - - - - - - 2= - - - - -247-Hemorrhage s - - - - - - - - - - - - - - -129-Necrosis s - - - - - - - - - - 4= - - - -201-M-Fibrosarc - - - - - - - - - - - - - - -30-M-Leukemia, monuc 2= - - 2= 2= 2= - 2= 2= - 2= 2= - 2= -326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 3 3= 2 2 2 2 2 - 3= 2 1 - 1 2 -130-Pigment, tubular epithelium s - - - - - - - - - - 4 - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - 1 - - - - - - 1 - 1 -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - 1 - - - - - - - - - -116-Fibrosis s - - - - - 2 - - - - - - - - -206-Thrombus s - - - - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - - - - -34-Inflammation, focal, chronic s 1 - 1 - - 1 - 1 2 1 - - 1 - -35-M-Leukemia, monuc - - - - 1 - - - - - - 1 - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - 2 - - - - - - - - - - - - -100-Hyperplasia, sq epi s - 4 - - - - - - - - - - - - -Cecum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - 1 - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 14Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - 1 - - -Duodenum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - - 2= - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - 3 - - - - -81-B-Fibroma - - - - - - - - - - - - 1= - -207-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon (2) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - 1 - - -Rectum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - - - -62-Degen, cytopl vacuol s - - 1 - - - - - - - - - - -194-Necrosis s - - - - - - - - - - - - - -108-Thrombus s - - - - - - - - - - 2 - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - - - P - - - - - - - - P -77-B-Pheochrom, bgn 1 - - - - - - - - - 1 - 1 -305-B-Pheochro, complex, benign - - - - - - - - 1= - - - - -74-M-Pheochromocytoma, malig 1 - - - - - - - - - - - - -57-M-Leukemia, monuc - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 15Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - 2 - - - - - - - - - - -179-Hemorrhage s - - - - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - - - - - - -64-Inflammation, mixed s - 1 - - - 1 - - - - - 2 - - 2=Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - 2 - - - - - - - - - - -242-Granuloma, sperm s - - - - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - - - - -198-M-Mesothelio, mal - - - - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - 3= 2 2 - 2 - - - 2 2 - - -182-Dilatation s - - - - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - 1= - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - - 3 - -257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -43-N-Leukemia, monuc - - - - 1= - - - 1 - - - - - -Testes (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - P - - - - - - - - - P - - -54-B-Adenoma, interstitial 1= - 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - - - 1 -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 16Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Mammary gland (6) Status > * * * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - -166-Ectasia s - - - - - - - - - - -155-Hyperplasia, lobular s - - - - - - - - - - -165-B-Fibroadenoma - - - - - - - - - - -55-B-Fibroma - - - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - 3= - - - - - - - - - 3= - - -103-Ectasia, ventricular sys s - - - - - - - - - - - 3 - - -226-Edema s - - - - - - - - - - - - - - -189-Gliosis s - - - - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - - - - -45-Necrosis s - - - - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - - - - 4=110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -111-Cataract p - - - - - - - - - - - - - - -90-Degen s - - - - - - - - - - - - - - 4144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -46-Mineralization, corneal str s - - - - - - 1 - - - - - - - -59-Mineralization, scleral s - - - - - - - - 1 - - - - 1 -121-Neovascularization, corneal s - - - - - - 1 - - - - - - - -180-Inflammation, acute s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 17Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - 1 - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - - - - - -216-M-Leukemia, monuc - - - - 1= - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - 1 - - -184-Hemorrhage s - - - - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - 3 - - -124-Metaplasia, squ-trans epith s - - 1 - - - - - - - - - - - -91-Inflammation, mixed s - - - - - - - - - - - 2 - - 449-Inflammation-nasolac duct s 2 - - - - - 2 - 3 - - - - - -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - - - - - - - - -217-M-Leukemia, monuc - - - - 1 - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - - - - - - - - - - 4227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - 1 - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -93-Inflammation, mixed s - - - - - - - - - - - - - - 4195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - 1 - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 18Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - 3196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - 1 - - - - - - - - - -Preputial gland (4) Status > M M MH M M M M M M M M M M M MOperator > 142 142283-Cyst, epithelial inclusion p - -66-Ectasia s - -128-Inflammation, chronic s - 2=67-Inflammation, mixed s 4= -Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 142 14271-N-Leukemia, monuc 1= 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142 142 142270-Dilatation, sinusoidal s - - - -169-Infiltration, histiocytic s - - - -142-Sinus plasmacytosis s - - - -75-N-Leukemia, monuc 1= 1= 1= 1=Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - - - - - - -171-Pigmentation s - - - - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-N-Leukemia, monuc - - - - 1= - - - - - - 1= - 1= -Pituitary gland (7) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - - - - - -40-Cyst s - - - 2= - - - - - - 1 - - - -172-Hemorrhage s - - - 2 - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - 1 - - - - - - - - - 2 - - -39-B-Adenoma, pars distalis - 1= - - - - - - - 1 - - - - 1=138-M-Leukemia, monuc - - - - - - - - - - - 2= - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 19Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator > 142324-Hemorrhage s -137-M-Leukemia, monuc 1=Mediastinum (1) Status > M M M M M M M M M M M M M M MOperator > 142139-N-Leukemia, monuc 1=Tail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 142151-N-Leukemia, monuc 1=Bone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 20Rat/F344/NGroup Sex Dosage Animal > 6831E417 6831E419 6831E421 6831E423 6831E425 6831E427 6831E4291 M 0 g/m3 Animal > 6831E416 6831E418 6831E420 6831E422 6831E424 6831E426 6831E428 6831E430Tissue/diagnosis Death code > U2 U2 FS U2 U2 U2 FS U2 U2 U1 U2 U2 U2 U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 21Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Lungs (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - - 1 - - - - - - 1 - - - - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - - - - - 1= - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - 2 - - - 1= - - 1 -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - 1= - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol - - - - - - - 2 - - 2 2 - 2 2131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - - - - - - - - 1 - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - 1 - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -9-N-Leukemia, monuc - - - - - - - - - - - 1= - - -Thyroid glands (7) Status > m mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - - - - - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -10-B-Adenoma, C-cell - 1 - - - - - - - - - 1 - - -87-B-Adenoma, follicular cell - - - - - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 22Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Parathyroid (2) Status > m m mH m m mH *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -325-Dilatation p - - - - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - 2 - - - - - - - - - - - - -18-Inflammation, mixed s 1 2 2 - 2 1 1 2 - 2 - 2 1 2 119-Inflammation, chronic s - - - 1 - - - - - - - - - - -16-Metaplasia, squamous s - 2 - - - - - - - - - 2 - - -15-Hyperplasia, epithelial s 1 2 - 1 2 - 1 1 - - - - - 2 -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (4) Status > *H * * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - -21-N-Leukemia, monuc - - - - - 1 - - 1 - 1Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - 1 - - - 1 - 2 - - - 1 - - 2160-Congestion s - - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - - -99-Fatty Change s - - - 3= 2= - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - 1 - - - - - - - -123-Hdn p - - - - - - - - - - - - - - -22-Necrosis s - - - - - - - - - - - - - - -231-Thrombus s - - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - - - - - -29-Inflammation, chronic s - - 1 - - - - - - 1 - - - - -27-Hyperplasia, biliary s 2 3 1 1 - 2 2 3 - 2 2 2 2 3 228-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 23Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - 2= - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -24-M-Leukemia, monuc - 2= - - - - - 2= - - 2 2= - 2= 2=Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - - -63-Fibrosis s - 3= - - - - - - - - - - - - -247-Hemorrhage s - - - - - - - - - - - - - - -129-Necrosis s - - - - - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - - - -30-M-Leukemia, monuc - 2= - - - - - 2= - - 2= 2= - 2= 2=326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s - 2 2 3= 3= 2 1 2 1 2 1 4= 2 3= 2130-Pigment, tubular epithelium s - - - - - - - 3 - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - 1 - - - - - - - - - - - - -116-Fibrosis s - - - - - - 2 - - - - 2 - - -206-Thrombus s - - - - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - - - - -34-Inflammation, focal, chronic s 1 - - - - - - 2 1 - 1 - - 1 -35-M-Leukemia, monuc - - - - - - - - - - - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - 3= - - - - - - - - - - -100-Hyperplasia, sq epi s - - - 4 - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 24Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - 2 - - - - - -81-B-Fibroma - - - - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon (2) Status > a HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - - 2 1 - - - - - - - - -194-Necrosis s - - - - - - - - - - - - - - -108-Thrombus s - - - - - - - - - - - - - - 1277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - P - - - - - - - - - - - - -77-B-Pheochrom, bgn - - - - - - - - - - - 1 1 1= -305-B-Pheochro, complex, benign - - - - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - 1= - 1= - - -57-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 25Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - 2 - - - 2 - - - - -179-Hemorrhage s - - - - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - - - - 1273-Hyperplasia s - - - - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - - - - - - -64-Inflammation, mixed s 2 - - 2 3 - 2 - - - - 2 1 2 -Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - - 3 - - - 2 - - - - -242-Granuloma, sperm s - - - - - - - - - - - - - - -97-Inflammation, chronic s - - 2 - - - - - - - - 2 - - -198-M-Mesothelio, mal - - - - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - - - - 3= - - 2= 2= - 2 2 - -182-Dilatation s - - - - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - 2 - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -43-N-Leukemia, monuc - - - - - - - - - - - - - - -Testes (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p P - - - - - - - P - - - - P -54-B-Adenoma, interstitial - 1= 1= - 1= 1= 1= 1= - 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 26Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Mammary gland (6) Status > * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - - - -166-Ectasia s - - - - - - - - - - - - -155-Hyperplasia, lobular s - - - - - - - - - - - - -165-B-Fibroadenoma - - - - - - - - - - - - -55-B-Fibroma - - - 1= - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - - - - -140-Fibrosis s - - - - 2 - - - - - - - - - -221-Hyperkeratosis s - - - - - - - 4= - - - - - - -241-Necrosis s - - - - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - 1 - - - - - - - -149-B-Fibroma - - - - - - - - 1= 1= - - - - -176-B-Keratoacanthoma - - - - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Brain (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - 3= 3= - - - - - - - - - -103-Ectasia, ventricular sys s - - - 2 - - - - - - - - - - -226-Edema s - - - - - - - - - - - - - - -189-Gliosis s 4 - - - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - - - - -45-Necrosis s - - - - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - - - - -190-Inflammation, chronic s 4 - - - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - 3111-Cataract p - - - - - - - - - - - - - - P90-Degen s - - - - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - 1 - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - - - - - - -59-Mineralization, scleral s - - - - - - - - - - - - - - -121-Neovascularization, corneal s - - - - - - - - - - - - - - -180-Inflammation, acute s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 27Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - 1 - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - 1 -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - 2 - - - - - - - - - - - - -49-Inflammation-nasolac duct s 2 - 2 - - - - - - 3 - - 2 3 -107-Inflammation-resp epith s - - - - - - - - - - - - - 1 -186-Hyperplasia-resp epith s - - 2 - - - - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - 1 - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - - - - - - - 2 - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -93-Inflammation, mixed s - - - - 1F - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 28Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator > 142283-Cyst, epithelial inclusion p -66-Ectasia s 4=128-Inflammation, chronic s -67-Inflammation, mixed s 3Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142270-Dilatation, sinusoidal s - -169-Infiltration, histiocytic s - -142-Sinus plasmacytosis s 4= -75-N-Leukemia, monuc - 1=Mediastinal LN (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - 1= - - - - - -171-Pigmentation s - - - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - - - -14-N-Leukemia, monuc - - - - - - - - - - 1= - 2= -Pituitary gland (7) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - - - - - -40-Cyst s - - - - - - 2 - - - - - - - -172-Hemorrhage s - - - - - - - 1 - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - - - - - - - - - - - -39-B-Adenoma, pars distalis - - - 1= 1= - - - - - 1= - - - -138-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 29Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator > 142302-Cyst, epi inclusion p -145-Inflammation, acute s 4=174-Inflammation, mixed s -175-Hyperplasia/hyperkeratosis s -Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 142151-N-Leukemia, monuc 1=Bone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 30Rat/F344/NGroup Sex Dosage Animal > 6831E432 6831E434 6831E436 6831E438 6831E440 6831E442 6831E4441 M 0 g/m3 Animal > 6831E431 6831E433 6831E435 6831E437 6831E439 6831E441 6831E443 6831E445Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS FS U2 U2 FS U2 FS FS U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 31Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Lungs (17) Status >Operator > 142 142 142 142 1424-Alveolar histiocytosis s - - - 1 -299-Autolysis, marked p - - - - -3-Congestion s - - - - -82-Fibrosis, focal s - - - - -154-Hemorrhage s - - - - -306-Metaplasia, squam - alv epi s - - - - -233-Mineralization, uremic s - - - - -298-Cyst, squamous, keratiniz p - - - - -187-Inflammation, acute s - - - - -84-Inflammation, mixed s - - - - -214-Inflammation, granulomatous s - - - - -1-Hyperplasia, alv epi, focal s 1 - 1 - -5-Hyperplasia, alv epi, wdsprd s - - - - -104-B-Adenoma, bronchiolo-alv - - - - -240-N-Sarcoma, histiocytic - - - - -2-N-Leukemia,monuc - cap invol 2 2 - - 1131-N-Leukemia,monuc - inv invol - - - - -Trachea (6) Status >Operator > 142 142 142 142 142188-Metaplasia, squamous s - - - - -7-Inflammation, acute s - - - - -85-Inflammation, mixed s - - - - -177-Inflammation, chronic s - - - - -86-Hyperplasia, epithelial s - - - - -215-N-Leukemia, mononuclear - - - - -Bronchial (TBLN) (3) Status > *Operator > 142 142 142 142 1428-Hemorrhage s - - - -243-N-Sarcoma, histiocytic - - - -9-N-Leukemia, monuc 1 1 - -Thyroid glands (7) Status >Operator > 142 142 142 142 142115-Cyst, follicular p - - - - -73-Hyperplasia, C-cell, focal s 2 - - - -153-Hyperplasia, follicular cell s - - - - -10-B-Adenoma, C-cell - - - - -87-B-Adenoma, follicular cell - - 1 - -204-M-Carcinoma, C-cell - - - - -125-M-Carcinoma, follicular cell - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 32Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Parathyroid (2) Status > mH * mHOperator > 142 142 142 142 142235-Hyperplasia, diffuse s - - - -203-Hyperplasia, focal s - - - -Aorta (2) Status >Operator > 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - -325-Dilatation p - - - - -Esophagus Status > U U U U UOperator > 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 14295-Ulceration s - - - - -18-Inflammation, mixed s 2 2 2 1 -19-Inflammation, chronic s - - - - -16-Metaplasia, squamous s - - - - -15-Hyperplasia, epithelial s 2 1 1 - -Salivary gland (3) Status >Operator > 142 142 142 142 142225-Degen s - - - - -236-Inflammation, acute s - - - - -20-M-Leukemia, monuc - - - - -Mandibular LN (4) Status >Operator > 142 142 142 142 142126-Hemorrhage s - - - - -118-Sinus plasmacytosis s - - - - -60-Hyperplasia, lymphoid s - - - - -21-N-Leukemia, monuc 1 1 - - -Liver (17) Status >Operator > 142 142 142 142 14226-Angiectasis s 2 1 - 1 -160-Congestion s - - - - -272-Cyst s - - - - -99-Fatty Change s - - - - -158-Foci cell alter, basophilic s - - - - -123-Hdn p - - - - -22-Necrosis s - - - - -231-Thrombus s - - - - -23-Vaculoliz, cyto s - - - - -29-Inflammation, chronic s - - - - -27-Hyperplasia, biliary s 2 2 2 2 -28-Hyperplasia, hepato, regen s - - - - -122-B-Adenoma, hepatocellular - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 33Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Liver (17) Status >Operator > 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - -246-M-Sarcoma, histiocytic - - - - -310-M-Sarcoma, undifferentiated - - - - -24-M-Leukemia, monuc 2 2= 1 - 2=Spleen (7) Status >Operator > 142 142 142 142 142285-Congestion s - - - - -63-Fibrosis s - - - - -247-Hemorrhage s - - - - -129-Necrosis s - - - - -201-M-Fibrosarc - - - - -30-M-Leukemia, monuc 2= 2= 1 - 1326-N-Sarcoma, histiocytic - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142161-Cyst s - - - - -248-Degen, hyaline droplet s - - - - -251-Infarct s - - - - -33-Nephropathy, chronic s 3 2 2 3 2130-Pigment, tubular epithelium s - - - - -274-Inflammation, acute s - - - - -213-B-Adenoma, renal tubule - - - - -191-M-Carcinoma, renal tubule - - - - -68-M-Leukemia, monuc - - - - -Heart (6) Status >Operator > 142 142 142 142 14296-Degen, myocyte s - - - - -116-Fibrosis s - - - - -206-Thrombus s - - - - -279-Inflammation, acute s - - - - -34-Inflammation, focal, chronic s - - 1 - 135-M-Leukemia, monuc - - - - -Stomach (2) Status >Operator > 142 142 142 142 142101-Inflammation, mixed s - - - - -100-Hyperplasia, sq epi s - - - - -Cecum (1) Status >Operator > 142 142 142 142 14269-N-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 34Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Urinary bladder (5) Status >Operator > 142 142 142 142 142178-Hemorrhage s - - - - -193-Inflammation, mixed s - - - - -37-Inflammation, chronic s - 1 - 1 -61-B-Papilloma, transitional - - - - -134-M-Leukemia, monuc - - - - -Duodenum Status > U U U U UOperator > 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 14280-M-Adenocarcinoma - - - - -Ileum (3) Status >Operator > 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - -81-B-Fibroma - - - - -207-N-Leukemia, monuc - - - - -Colon (2) Status >Operator > 142 142 142 142 142197-Inflammation, mixed s - - - - 4156-B-Leiomyoma - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - -135-M-Leukemia, monuc - - - - -Rectum Status > U U U U UOperator > 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142164-Cyst s - - - - -62-Degen, cytopl vacuol s - - - - -194-Necrosis s - - - - -108-Thrombus s - - - - -277-Hyperplasia, cort, diffuse s - - - - -38-Hyperplasia, medulla, focal p P - - P= -77-B-Pheochrom, bgn - - - - -305-B-Pheochro, complex, benign - - - - -74-M-Pheochromocytoma, malig - - - - -57-M-Leukemia, monuc - 1 - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 35Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Prostate (6) Status >Operator > 142 142 142 142 142143-Atrophy s - - - - -179-Hemorrhage s - - - - -109-Mineralization s - - - - -273-Hyperplasia s - - - - -88-Inflammation, acute s - - - - -64-Inflammation, mixed s - 1 - - -Epididymis (4) Status >Operator > 142 142 142 142 142119-Atrophy s - - - - -242-Granuloma, sperm s - - - - -97-Inflammation, chronic s - - - - -198-M-Mesothelio, mal - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142120-Atrophy s 1 - - - -182-Dilatation s - - - - -307-Hyperplasia s - - - - -136-M-Leukemia, monuc - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142147-Hemorrhage s - - - - -79-Histiocytosis, sinus s - - - - -257-N-Sarcoma, histiocytic - - - - -43-N-Leukemia, monuc 2 2 - - -Testes (5) Status >Operator > 142 142 142 142 142152-Atrophy s 4 - - - -287-Hemorrhage s - - - - -105-Hyperplasia, interst cell p - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 14283-N-Leukemia, monuc - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142304-Inflammation, chronic s - - - - -258-N-Sarcoma, histiocytic - - - - -271-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 36Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Mammary gland (6) Status > *Operator > 142 142 142 142 142284-Cyst p - - - -166-Ectasia s - - - -155-Hyperplasia, lobular s - - - -165-B-Fibroadenoma - - - -55-B-Fibroma - - - -266-N-Sarcoma, histiocytic - - - -Skin (13) Status >Operator > 142 142 142 142 142229-Cyst, epith inc p - - - - -140-Fibrosis s - - - - -221-Hyperkeratosis s - - - - -241-Necrosis s - - - - -237-Inflammation, mixed s - - - - -148-Inflammation, chronic s - - - - -149-B-Fibroma - - - - -176-B-Keratoacanthoma - - - - -223-B-Tumor, basal cell, benign - - - - -309-B-Tumor, hair follicle, ben - - - - -300-M-Carcinoma, sebaceous cell - - - - -303-M-Sarcoma, undifferentiated - - - - -327-N-Sarcoma, histiocytic - - - - -Brain (10) Status >Operator > 142 142 142 142 14244-Compression s - - - - -103-Ectasia, ventricular sys s - - - - -226-Edema s - - - - -189-Gliosis s - - - - -183-Hemorrhage s - - - - -192-Mineralization s - - - - -45-Necrosis s - - - - -275-Inflammation, acute s - - - - -190-Inflammation, chronic s - - - - -224-M-Astrocytoma, malignant - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 14289-Atrophy s - - - - -110-Atrophy, retinal, unilat s - - - - -111-Cataract p - - - - -90-Degen s - - - - -144-Metaplasia, osseous, sclera s - - - - -46-Mineralization, corneal str s - - 1 - -59-Mineralization, scleral s - - - - -121-Neovascularization, corneal s - - 1 - -180-Inflammation, acute s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 37Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142127-Inflammation, mixed s - - - - -278-Inflammation, chronic s - - - - -216-M-Leukemia, monuc - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142209-New bone, endosteal s - - - - -212-Inflammation, acute s - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 14248-Degen, white matter s - - - - -184-Hemorrhage s - - - - -280-Inflammation, acute s - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142261-Degeneration-resp epith s - - - - -222-Degeneration,hyal-Resp Epith s - - - - -106-Metaplasia, squ-resp epith s 2 - - - -124-Metaplasia, squ-trans epith s - - - - -91-Inflammation, mixed s 3 - - - -49-Inflammation-nasolac duct s - - - 3 -107-Inflammation-resp epith s - - - - -186-Hyperplasia-resp epith s - - - - -217-M-Leukemia, monuc - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 14298-Degeneration-olfact epith s - - - - -51-Degeneration,hyaline-olf epi s - - - - -262-Degeneration-resp epith s - - - - -202-Degeneration, hyal-resp epit s - - - - -210-Metaplasia, sec-olfact epith s - - - - -292-Metaplasia, squ-olfact epith s - - - - -312-Metaplasia, squ-resp epith s - - - - -92-Inflammation, mixed s 3 - - - -227-Hyperplasia-resp epith s - - - - -112-M-Carcinoma, squamous cell - - - - -218-M-Leukemia, monuc - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - -93-Inflammation, mixed s 2 - - - -195-M-Carcinoma, squamous cell - - - - -219-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 38Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142313-Degeneration-olfact epith s - - - - -168-Degeneration, hyal-olf epi s - - - - -94-Inflammation, mixed s - - - - -196-N-Carcinoma, squamous cell - - - - -220-M-Leukemia, monuc - - - - -Preputial gland (4) Status > M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M MOperator >270-Dilatation, sinusoidal s169-Infiltration, histiocytic s142-Sinus plasmacytosis s75-N-Leukemia, monucMediastinal LN (4) Status >Operator > 142 142 142 142 14213-Hemorrhage s - - - - -171-Pigmentation s - - - - -267-N-Sarcoma, histiocytic - - - - -14-N-Leukemia, monuc 1= 2 - - -Pituitary gland (7) Status > H *HOperator > 142 142 142 142 142173-Angiectasis s - - - -40-Cyst s - 3= - -172-Hemorrhage s - - - -232-Inflammation, chronic s - - - -42-Hyperplasia, pars dist, fcl s - - - -39-B-Adenoma, pars distalis - - - -138-M-Leukemia, monuc - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 39Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Tiss.not specifi (9) Status > M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 40Rat/F344/NGroup Sex Dosage Animal > 6831E447 6831E4491 M 0 g/m3 Animal > 6831E446 6831E448 6831E450Tissue/diagnosis Death code > FS U2 FS FS U2Mesentery (2) Status > M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 41Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Lungs (17) Status > a aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - - - 1 - - - - 1 - - - 1 - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - - - - - - - - - - 1=306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - 1 - - - - - - - -1-Hyperplasia, alv epi, focal s - - - 2= - - - - - - 2= - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol 2 - 2= 2 - 2= 2= - - - - 2 2 - 2131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - 1 - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - -9-N-Leukemia, monuc 1= - - 1= - - - - 1=Thyroid glands (7) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - -10-B-Adenoma, C-cell - - - - - - - - -87-B-Adenoma, follicular cell - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 42Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Parathyroid (2) Status > mH mH *H mH m m mOperator > 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - -325-Dilatation p - - - - - - - - - -Esophagus Status > U U U U U *H U U U UOperator > 142 142 142 142 142 142 142 142 142 142Larynx (5) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - -18-Inflammation, mixed s 2 2 1 2 1 - 2 3 2 2 - 2 2 219-Inflammation, chronic s - - - - - 1 - - - - - - - -16-Metaplasia, squamous s - - - - - - - - - - - - - -15-Hyperplasia, epithelial s 1 - - 2 - - - 2 - 1 - 2 - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - -Mandibular LN (4) Status > mOperator > 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - -21-N-Leukemia, monuc 1 - - 1= - - - - - 1=Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - - - - - 1 - - - - - -160-Congestion s - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - -99-Fatty Change s - - - - - - - 1= - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - -123-Hdn p - - - - - - - - - - - -22-Necrosis s - - - - - - - - 1 - - -231-Thrombus s - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - 1 -29-Inflammation, chronic s - - - - - - - - - - - -27-Hyperplasia, biliary s 3 3 3 3 - 2 2 2 2 - 2 228-Hyperplasia, hepato, regen s - - - - - - - - - 2= - -122-B-Adenoma, hepatocellular - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 43Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - -24-M-Leukemia, monuc 2= 2= 2 2= 2 - - - 2 2 2 2Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - 3= -63-Fibrosis s - - - - - - - - - - -247-Hemorrhage s - - - - - - - - - - -129-Necrosis s - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - -30-M-Leukemia, monuc 2= 2= 2= 2= 2= - - 2= 2= 1 2=326-N-Sarcoma, histiocytic - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 2 2 2 3 3 2 2 3 1 1 3 1 3 2 1130-Pigment, tubular epithelium s - - - - - 3 - - 3 - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - - - - - - -116-Fibrosis s - - - - - - - - - -206-Thrombus s - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - -34-Inflammation, focal, chronic s - - - - - 1 - - - -35-M-Leukemia, monuc - - 1 - 1 - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 44Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - -Duodenum Status > U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - -81-B-Fibroma - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - 1Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - -Rectum Status > U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - -62-Degen, cytopl vacuol s - - - - 1 - - - - -194-Necrosis s - - - - - - - - - -108-Thrombus s - - - - - - - - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - -38-Hyperplasia, medulla, focal p - - - - - - - - - -77-B-Pheochrom, bgn - - 1= - - - - - - -305-B-Pheochro, complex, benign - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - -57-M-Leukemia, monuc - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 45Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - - - -179-Hemorrhage s - - - - - - - - - -109-Mineralization s - - - - - - - - - -273-Hyperplasia s - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - -64-Inflammation, mixed s - - 2 - - - - 4 - -Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - 2= - - - - - -242-Granuloma, sperm s - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - -198-M-Mesothelio, mal - - - - - 2= - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - - - - - - - - -182-Dilatation s - - - - - - - - - -307-Hyperplasia s - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - -43-N-Leukemia, monuc - - - 1 - - - - - 1=Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - - - - - - - 3= - -287-Hemorrhage s - - - - - - - 3 - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - P - P -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - 2 - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 46Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Mammary gland (6) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - -166-Ectasia s - - - - - - - - -155-Hyperplasia, lobular s - - - - - - - - -165-B-Fibroadenoma - - - - - - - - -55-B-Fibroma - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - -140-Fibrosis s - - - - - - - 3 - - - -221-Hyperkeratosis s - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - 4= - - - -148-Inflammation, chronic s - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - 1= - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - 2= - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 14244-Compression s - - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - - -226-Edema s - - - - - - - - - -189-Gliosis s - - - - - - - - - -183-Hemorrhage s - - - - - - - - - -192-Mineralization s - - - - - - - - - -45-Necrosis s - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - -Eyes/optic nerve (12) Status > mHOperator > 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - -111-Cataract p - - - - - - - - - -90-Degen s - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - -59-Mineralization, scleral s - - - - - - - - - -121-Neovascularization, corneal s - - - - - - - - - -180-Inflammation, acute s - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 47Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Eyes/optic nerve (12) Status > mHOperator > 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - 3 - - -278-Inflammation, chronic s - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - 1Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - -184-Hemorrhage s - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - 3 - - - - - - - - - - -49-Inflammation-nasolac duct s - 3 - 3 - - - - - 3 - - - 2 -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - 1 - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -93-Inflammation, mixed s - - - - - - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 48Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Nose/Turbinate 4 (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - 2 - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator > 142283-Cyst, epithelial inclusion p -66-Ectasia s 4=128-Inflammation, chronic s -67-Inflammation, mixed s -Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M *MHOperator > 142 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142270-Dilatation, sinusoidal s - -169-Infiltration, histiocytic s - -142-Sinus plasmacytosis s - -75-N-Leukemia, monuc 1= 1=Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - -171-Pigmentation s - - - - - 4= - - - -267-N-Sarcoma, histiocytic - - - - - - - - - -14-N-Leukemia, monuc 1= - - - - - - - - 1=Pituitary gland (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - -40-Cyst s - - - - - - - - 1 - 1172-Hemorrhage s - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - - 2 - - - 1 -39-B-Adenoma, pars distalis - - 1 - - - - 1= - - -138-M-Leukemia, monuc - 1 - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 49Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator > 142302-Cyst, epi inclusion p P=145-Inflammation, acute s -174-Inflammation, mixed s 3175-Hyperplasia/hyperkeratosis s 3=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 50Rat/F344/NGroup Sex Dosage Animal > 6833F502 6833F504 6833F506 6833F508 6833F510 6833F512 6833F5142 M 2 g/m3 Animal > 6833F501 6833F503 6833F505 6833F507 6833F509 6833F511 6833F513 6833F515Tissue/diagnosis Death code > U1 FS U1 U2 FS U2 U2 FS U2 U2 FS U2 FS U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator > 142301-Inflammation, mixed s 4=311-M-Mesothelio, mal -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 51Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Lungs (17) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - - - - - - - - - 1 - - - - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - 3= - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - 1= - 1= - - - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - 1 - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - 2 - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - 1 - - - - -1-Hyperplasia, alv epi, focal s - - 1= - 1 - - - - - - 1= - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - 2 - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol 2 2 2= - 1 2 2 2 - 2 2 - 2 - 2=131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - 2 - - - - - - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - 3 - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *HOperator > 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - -9-N-Leukemia, monuc - - - - - - - -Thyroid glands (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - P - -73-Hyperplasia, C-cell, focal s - - - - - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - - -10-B-Adenoma, C-cell - - - - - 1= - - 1 -87-B-Adenoma, follicular cell - - - - - - - - - -204-M-Carcinoma, C-cell - - 2= - - - - - - 1=125-M-Carcinoma, follicular cell - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 52Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Parathyroid (2) Status > m mOperator > 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - -325-Dilatation p - - - - - - - - -Esophagus Status > U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 1 3 2 - 2 2 1 2 1 2 - 2 2 - -19-Inflammation, chronic s - - - - - - - - - - - - - - -16-Metaplasia, squamous s - - - - - - - 2 - - - - - - -15-Hyperplasia, epithelial s - 2 2 - 2 - - - - 2 - 2 - - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - -236-Inflammation, acute s - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - -Mandibular LN (4) Status > *Operator > 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - -118-Sinus plasmacytosis s - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - -21-N-Leukemia, monuc 1 - - - - - - -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - - - - - - - - - -160-Congestion s - - - - - - - - - -272-Cyst s - - - - - - - - - -99-Fatty Change s - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - 2 -123-Hdn p - - P= - - - - - - -22-Necrosis s - - - - - - - - - 2=231-Thrombus s - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - 3=29-Inflammation, chronic s - - - - - - - - - -27-Hyperplasia, biliary s 3 2 - 2 3 2 2 2 1 328-Hyperplasia, hepato, regen s - - - - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 53Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - -24-M-Leukemia, monuc 2= 1= 1 2= 2 - 1= 2 - -Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - -63-Fibrosis s - 2 - - - - - - - - - -247-Hemorrhage s - - - - - - - - - - - -129-Necrosis s - - - - 3= - - - - 2 - -201-M-Fibrosarc - - - - - - - - - - - -30-M-Leukemia, monuc 2= 2= 1 1= 2= 2= - 1= 1= 2= - -326-N-Sarcoma, histiocytic - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - 1 - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 3 2 1 3 3= 3 2 2 - 4 4 2 1 - 2=130-Pigment, tubular epithelium s - - - - - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - - - - - -116-Fibrosis s 1 1 - 1 - - - - -206-Thrombus s - - - - - - - - 3=279-Inflammation, acute s - - - - - - - - -34-Inflammation, focal, chronic s - - 1 1 - 1 - 1 135-M-Leukemia, monuc 1 - - - - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 54Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Urinary bladder (5) Status > *HOperator > 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - -193-Inflammation, mixed s - - - - - - - -37-Inflammation, chronic s - - - - - - - -61-B-Papilloma, transitional - - - - - - - -134-M-Leukemia, monuc 1 - - - - - - -Duodenum Status > U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - -81-B-Fibroma - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - -156-B-Leiomyoma - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - -Rectum Status > U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - -62-Degen, cytopl vacuol s - - - - - - - - - -194-Necrosis s - - - - - - - - - -108-Thrombus s - - - - - - - - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - -38-Hyperplasia, medulla, focal p P - P - - - - - - -77-B-Pheochrom, bgn - - 1= - - - - - - -305-B-Pheochro, complex, benign - - - - - 1= - - - -74-M-Pheochromocytoma, malig - - - - - - - - - -57-M-Leukemia, monuc - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 55Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Prostate (6) Status > *HOperator > 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - -179-Hemorrhage s - - - - - - - -109-Mineralization s - - - - - - - -273-Hyperplasia s - - - - - - - -88-Inflammation, acute s - - - - - - - -64-Inflammation, mixed s - 3 2 - - - - 3Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - - 2= - - - -242-Granuloma, sperm s - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - -198-M-Mesothelio, mal - - - - - - - - - -Seminal vesicle (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142120-Atrophy s 3= - - - - 2= - - -182-Dilatation s - - - - - - - - -307-Hyperplasia s - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - -43-N-Leukemia, monuc - - - - - - - - -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - 4= - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - - - - P54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= -199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - -258-N-Sarcoma, histiocytic - 1= - - - - - - -271-M-Leukemia, monuc - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 56Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Mammary gland (6) Status > *HOperator > 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - -166-Ectasia s - - - - - - - -155-Hyperplasia, lobular s - - 2 - - - - -165-B-Fibroadenoma - - - - - - - -55-B-Fibroma - - - - - - 1= -266-N-Sarcoma, histiocytic - 1 - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - -140-Fibrosis s - - 3= - - - - - - -221-Hyperkeratosis s - - 3 - - - - - - -241-Necrosis s - 4= - - - - - - - -237-Inflammation, mixed s - - 3 - - - - - - -148-Inflammation, chronic s - - - - - - - - - -149-B-Fibroma - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - -327-N-Sarcoma, histiocytic - 1= - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 14244-Compression s - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - -226-Edema s - - - - - - - - -189-Gliosis s - - - - - - - - -183-Hemorrhage s - - - - - - - - -192-Mineralization s - - - - - - - - -45-Necrosis s - - - - - - - - -275-Inflammation, acute s - - - - - - - - -190-Inflammation, chronic s - - - - - - - - -224-M-Astrocytoma, malignant - 2= - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - -111-Cataract p - - - - - - - - -90-Degen s - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - -59-Mineralization, scleral s - - - 1 - - - - -121-Neovascularization, corneal s - - - - - - - - -180-Inflammation, acute s - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 57Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - -278-Inflammation, chronic s - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - -184-Hemorrhage s - - - - - - - - -280-Inflammation, acute s - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - 3 - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - - 4 - - - - - - - - -49-Inflammation-nasolac duct s - - - - - 3 - - - - - 3 - - -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - 2 - - - - - - - - - - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - 2 2 - - - - - - - - - - - -227-Hyperplasia-resp epith s - 2 - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -93-Inflammation, mixed s - - - - - - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 58Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >71-N-Leukemia, monucIliac LN (2) Status > M M M M M M M M M M M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142270-Dilatation, sinusoidal s -169-Infiltration, histiocytic s 4=142-Sinus plasmacytosis s -75-N-Leukemia, monuc -Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - -171-Pigmentation s - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - -14-N-Leukemia, monuc - 1 - - - - - - -Pituitary gland (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - -40-Cyst s - 1 - - - - - - - -172-Hemorrhage s - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - -42-Hyperplasia, pars dist, fcl s 1 - - - - - - - - -39-B-Adenoma, pars distalis 1= - - 1= - - - - - 1=138-M-Leukemia, monuc - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 59Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator > 142302-Cyst, epi inclusion p -145-Inflammation, acute s -174-Inflammation, mixed s 3=175-Hyperplasia/hyperkeratosis s 4=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 60Rat/F344/NGroup Sex Dosage Animal > 6833F517 6833F519 6833F521 6833F523 6833F525 6833F527 6833F5292 M 2 g/m3 Animal > 6833F516 6833F518 6833F520 6833F522 6833F524 6833F526 6833F528 6833F530Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 FS U1 FS FS U2 U2 U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 61Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Lungs (17) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s 1 - - - - - - - 1 1 - - - - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - 2= - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - 2= - - - - - - - - 3= 2=306-Metaplasia, squam - alv epi s - - - - - 3= - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - 1 2 - - - - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - 2= - -2-N-Leukemia,monuc - cap invol - - 2 2 1 - 2 2 - 2 - - - 2 2=131-N-Leukemia,monuc - inv invol - 2 - - - - - - - - - - - - -Trachea (6) Status > * HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - -177-Inflammation, chronic s - - - - - - - 1 - 2 - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - 2= - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - - 1 - -9-N-Leukemia, monuc - 1= 1 1 - 1 - - - - - - 1Thyroid glands (7) Status > mOperator > 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - - - - -73-Hyperplasia, C-cell, focal s - - - - - 1 - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - - - - -10-B-Adenoma, C-cell - - - - - - - - - - 1= -87-B-Adenoma, follicular cell - - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 62Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Parathyroid (2) Status > mH m m m m m mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - -325-Dilatation p - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s - - 2 1 2 - - 2 1 - 1 - 2 1 -19-Inflammation, chronic s 1 - - - - - - - - - - - - - -16-Metaplasia, squamous s - - 2 - 1 - - - - - - - - - -15-Hyperplasia, epithelial s 1 - - - - - - 1 - - - - - - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - -Mandibular LN (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - -21-N-Leukemia, monuc - 1 - 1 1 - - 1 - - 1Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - - - - 1 - - - - - - - - -160-Congestion s - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - -99-Fatty Change s - - - - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - -123-Hdn p - - - - - - - - - - - - - -22-Necrosis s - - - - - - 1 - - - - - - -231-Thrombus s - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - 2 - - - - -29-Inflammation, chronic s - - - - - - - - - - - - - -27-Hyperplasia, biliary s 2 2 3 - 2 4 3 2 3 2 3 - - 228-Hyperplasia, hepato, regen s - - - - - - - - - 2 - - 2= -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 63Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - 1= - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - -24-M-Leukemia, monuc - 2 2= 2= 1= 2= 2= - 2 1= - - 2= 2=Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - -63-Fibrosis s - - - - - - - - - - - - -247-Hemorrhage s - - - - - - 3= - - - - - -129-Necrosis s - - - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - -30-M-Leukemia, monuc - 2= 2= 1 1= 2= 2= - 2= 1 - 2= 2=326-N-Sarcoma, histiocytic - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - 4= - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 2 1 2 2 3 3 2 2 3 - 2 2 1 2 2130-Pigment, tubular epithelium s - - - - - - - - - 3= - - - - -274-Inflammation, acute s - - - - - - - - 1 - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - 1 1 1 - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - - - - - - - - -116-Fibrosis s - - - - - 2 - - 3= - - -206-Thrombus s - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - -34-Inflammation, focal, chronic s 1 - - - - - - - - - 1 135-M-Leukemia, monuc - 1 - 2 - - - - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - 2 - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 64Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - -Duodenum Status > U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - -Rectum Status > U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - 3 - - - - - - - -194-Necrosis s - - - - - - - - - - - -108-Thrombus s - - - - 2 - - - - - 3 -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - - - - - - - - - - - -77-B-Pheochrom, bgn - - - - - - - - - - 1 -305-B-Pheochro, complex, benign - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - - -57-M-Leukemia, monuc - - - - - 1 - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 65Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - - - - - -179-Hemorrhage s - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - 3 - - - -64-Inflammation, mixed s 3 - 1 - - 2 2 - - - - 2Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s 1= - - - - - 2= - - - - -242-Granuloma, sperm s - - - - 2 - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - -198-M-Mesothelio, mal - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - - - - - - - - - - - -182-Dilatation s - - - - 2= - - - - - - - -307-Hyperplasia s - - - - 3 - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - 1= - -43-N-Leukemia, monuc - - 1 - - - - - - - - -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s 4= - - - - - - 4= - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - P - - - - - P - P - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - 1= - -271-M-Leukemia, monuc - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 66Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Mammary gland (6) Status > mH *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - -166-Ectasia s - - - - - - - - - - -155-Hyperplasia, lobular s - - - - - - - - - - -165-B-Fibroadenoma - - - - - - - - - - -55-B-Fibroma - - - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - 1= - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - 1= - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s 2= - - - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - - - - -226-Edema s - - - - - - - - - - - -189-Gliosis s - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - -45-Necrosis s - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - - -111-Cataract p - - - - - - - - - - - -90-Degen s - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - - - -59-Mineralization, scleral s - - - - - - - - - - - -121-Neovascularization, corneal s - - - - - - - - - - - -180-Inflammation, acute s - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 67Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - 4= - - - - -278-Inflammation, chronic s - - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - 4 - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - -Nose/Turbinate 1 (9) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - 1 - 3 - - - - - - - - - - -106-Metaplasia, squ-resp epith s 2 - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s 2 - - - - - - - 1 - 1 - - - -49-Inflammation-nasolac duct s 3 - - - - - - - 2 - - 2 - - -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s 1 1 - 3 - - - - - - - - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s 3 - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - 1 - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s 3 - - - - - - - - 2 - 1 - - -227-Hyperplasia-resp epith s - - 1 - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status > a HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - 2 - - - - - - - - - - -93-Inflammation, mixed s - - - - - - - - 1 - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - 2 - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 68Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Nose/Turbinate 4 (5) Status > a HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - 2 - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142270-Dilatation, sinusoidal s 4=169-Infiltration, histiocytic s -142-Sinus plasmacytosis s -75-N-Leukemia, monuc -Mediastinal LN (4) Status > *H *H *HOperator > 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - -171-Pigmentation s - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - 1= - -14-N-Leukemia, monuc - 1 1 1 - - - - 1Pituitary gland (7) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - - -40-Cyst s - - - 2 2= 1 - - - - 1 -172-Hemorrhage s - - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - - - 1 - - - - -39-B-Adenoma, pars distalis 1= - - - - - - - - - - -138-M-Leukemia, monuc - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 69Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142181-Cyst s -276-Mammary tissue p -286-Myodegeneration s -281-Inflammation, mixed s -308-B-Fibroma -113-B-Lipoma -200-M-Mesothelio, mal -328-N-Sarcoma, histiocytic 1=331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M M M M M M M M M M M MOperator > 142269-Hyperostosis s 2=228-M-Sarcoma, NOS -Zymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 70Rat/F344/NGroup Sex Dosage Animal > 6833F532 6833F534 6833F536 6833F538 6833F540 6833F542 6833F5442 M 2 g/m3 Animal > 6833F531 6833F533 6833F535 6833F537 6833F539 6833F541 6833F543 6833F545Tissue/diagnosis Death code > U2 U2 U2 U2 FS FS U2 U2 U2 U2 U1 FS U2 U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 71Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSLungs (17) Status > aOperator > 142 142 142 142 1424-Alveolar histiocytosis s - 1 1 - 1299-Autolysis, marked p - - - - -3-Congestion s - - - - -82-Fibrosis, focal s - - - - -154-Hemorrhage s - - - - 1=306-Metaplasia, squam - alv epi s - - - - -233-Mineralization, uremic s - - - - -298-Cyst, squamous, keratiniz p - - - - -187-Inflammation, acute s - - - - -84-Inflammation, mixed s - - - - -214-Inflammation, granulomatous s - - - - -1-Hyperplasia, alv epi, focal s - - - - -5-Hyperplasia, alv epi, wdsprd s 2 - - - -104-B-Adenoma, bronchiolo-alv - - - - -240-N-Sarcoma, histiocytic - - - - -2-N-Leukemia,monuc - cap invol 2= - 2= 2= 1131-N-Leukemia,monuc - inv invol - - - - -Trachea (6) Status >Operator > 142 142 142 142 142188-Metaplasia, squamous s - - - - -7-Inflammation, acute s - - - - -85-Inflammation, mixed s - - - - -177-Inflammation, chronic s - - - - -86-Hyperplasia, epithelial s - - - - -215-N-Leukemia, mononuclear - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 1428-Hemorrhage s - 2 2243-N-Sarcoma, histiocytic - - -9-N-Leukemia, monuc 1 - -Thyroid glands (7) Status >Operator > 142 142 142 142115-Cyst, follicular p - - - -73-Hyperplasia, C-cell, focal s 2 - - -153-Hyperplasia, follicular cell s - - - -10-B-Adenoma, C-cell - - - 1=87-B-Adenoma, follicular cell - - - -204-M-Carcinoma, C-cell - - - -125-M-Carcinoma, follicular cell - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 72Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSParathyroid (2) Status > *HOperator > 142 142 142 142235-Hyperplasia, diffuse s - - -203-Hyperplasia, focal s - - -Aorta (2) Status >Operator > 142 142 142132-N-Leukemia,monuc - inv invol - - -325-Dilatation p - - -Esophagus Status > U U UOperator > 142 142 142Larynx (5) Status >Operator > 142 142 142 142 14295-Ulceration s - - - - -18-Inflammation, mixed s 2 2 2 - 119-Inflammation, chronic s - - - - -16-Metaplasia, squamous s - - - - -15-Hyperplasia, epithelial s 2 1 2 - -Salivary gland (3) Status >Operator > 142 142 142225-Degen s - - -236-Inflammation, acute s - - -20-M-Leukemia, monuc - - -Mandibular LN (4) Status >Operator > 142 142 142126-Hemorrhage s - - -118-Sinus plasmacytosis s - - -60-Hyperplasia, lymphoid s - - -21-N-Leukemia, monuc 1 - -Liver (17) Status >Operator > 142 142 142 14226-Angiectasis s - 1 - 4=160-Congestion s - - - -272-Cyst s - - - -99-Fatty Change s - - - -158-Foci cell alter, basophilic s - - - -123-Hdn p - - - -22-Necrosis s 1 - - -231-Thrombus s - - - -23-Vaculoliz, cyto s - - - -29-Inflammation, chronic s - 1 - -27-Hyperplasia, biliary s 3 2 2 328-Hyperplasia, hepato, regen s - - - -122-B-Adenoma, hepatocellular - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 73Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSLiver (17) Status >Operator > 142 142 142 142150-M-Carcinoma, hepatocellular - - - -246-M-Sarcoma, histiocytic - - - -310-M-Sarcoma, undifferentiated - - - -24-M-Leukemia, monuc 2 2= 2= -Spleen (7) Status >Operator > 142 142 142285-Congestion s - - -63-Fibrosis s 4= - -247-Hemorrhage s - - -129-Necrosis s - - -201-M-Fibrosarc - - -30-M-Leukemia, monuc 2= 2= 2=326-N-Sarcoma, histiocytic - - -Kidneys (9) Status >Operator > 142 142 142 142 142161-Cyst s - - - - -248-Degen, hyaline droplet s - - - - -251-Infarct s - - - - -33-Nephropathy, chronic s 2 2 3 2 3=130-Pigment, tubular epithelium s - - - - -274-Inflammation, acute s - - - - -213-B-Adenoma, renal tubule - - - - -191-M-Carcinoma, renal tubule 1= - - - -68-M-Leukemia, monuc - - - - -Heart (6) Status >Operator > 142 142 14296-Degen, myocyte s 1 - -116-Fibrosis s - - -206-Thrombus s - - -279-Inflammation, acute s - - -34-Inflammation, focal, chronic s - - -35-M-Leukemia, monuc - - -Stomach (2) Status >Operator > 142 142 142101-Inflammation, mixed s - - -100-Hyperplasia, sq epi s - - -Cecum (1) Status >Operator > 142 142 14269-N-Leukemia, monuc - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 74Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSUrinary bladder (5) Status >Operator > 142 142 142178-Hemorrhage s - - -193-Inflammation, mixed s - - -37-Inflammation, chronic s - - -61-B-Papilloma, transitional - - -134-M-Leukemia, monuc - - -Duodenum Status > U U UOperator > 142 142 142Jejunum (1) Status >Operator > 142 142 14280-M-Adenocarcinoma - - -Ileum (3) Status >Operator > 142 142 14278-Hyperplasia, lymphoid s - - -81-B-Fibroma - - -207-N-Leukemia, monuc - - -Colon (2) Status >Operator > 142 142 142197-Inflammation, mixed s - - -156-B-Leiomyoma - - -Pancreas (2) Status >Operator > 142 142 142323-M-Carcinoma, ductal cell - - -135-M-Leukemia, monuc - - -Rectum Status > U U UOperator > 142 142 142Adrenal glands (10) Status >Operator > 142 142 142164-Cyst s - - -62-Degen, cytopl vacuol s - - -194-Necrosis s - - -108-Thrombus s - - -277-Hyperplasia, cort, diffuse s - - -38-Hyperplasia, medulla, focal p - - -77-B-Pheochrom, bgn 1 - -305-B-Pheochro, complex, benign - - -74-M-Pheochromocytoma, malig - - -57-M-Leukemia, monuc - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 75Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSProstate (6) Status >Operator > 142 142 142143-Atrophy s - - -179-Hemorrhage s - - -109-Mineralization s - - -273-Hyperplasia s - - -88-Inflammation, acute s - - -64-Inflammation, mixed s 3= - 2Epididymis (4) Status >Operator > 142 142 142 142119-Atrophy s - - - 3=242-Granuloma, sperm s - - - -97-Inflammation, chronic s - - - -198-M-Mesothelio, mal - - - -Seminal vesicle (4) Status >Operator > 142 142 142120-Atrophy s - - -182-Dilatation s - - -307-Hyperplasia s - - -136-M-Leukemia, monuc - - -Mesenteric LN (4) Status >Operator > 142 142 142147-Hemorrhage s - - -79-Histiocytosis, sinus s - - -257-N-Sarcoma, histiocytic - - -43-N-Leukemia, monuc - - -Testes (5) Status >Operator > 142 142 142 142 142152-Atrophy s - - - - -287-Hemorrhage s - - - - -105-Hyperplasia, interst cell p - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - -Sciatic nerve (1) Status >Operator > 142 142 14283-N-Leukemia, monuc - - -Muscle, skeletal (3) Status >Operator > 142 142 142304-Inflammation, chronic s - - -258-N-Sarcoma, histiocytic - - -271-M-Leukemia, monuc - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 76Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSMammary gland (6) Status >Operator > 142 142 142284-Cyst p - - -166-Ectasia s - - -155-Hyperplasia, lobular s - - -165-B-Fibroadenoma - - -55-B-Fibroma - 1= -266-N-Sarcoma, histiocytic - - -Skin (13) Status >Operator > 142 142 142229-Cyst, epith inc p - - -140-Fibrosis s - - -221-Hyperkeratosis s - - -241-Necrosis s - - -237-Inflammation, mixed s 3= - -148-Inflammation, chronic s - - -149-B-Fibroma - - -176-B-Keratoacanthoma - - -223-B-Tumor, basal cell, benign - - -309-B-Tumor, hair follicle, ben - - -300-M-Carcinoma, sebaceous cell - - -303-M-Sarcoma, undifferentiated - - -327-N-Sarcoma, histiocytic - - -Brain (10) Status >Operator > 142 142 14244-Compression s 2 - -103-Ectasia, ventricular sys s - - -226-Edema s - - -189-Gliosis s - - -183-Hemorrhage s - - -192-Mineralization s - - -45-Necrosis s - - -275-Inflammation, acute s - - -190-Inflammation, chronic s - - -224-M-Astrocytoma, malignant - - -Eyes/optic nerve (12) Status >Operator > 142 142 14289-Atrophy s - - -110-Atrophy, retinal, unilat s - - -111-Cataract p - - -90-Degen s - - -144-Metaplasia, osseous, sclera s - - -46-Mineralization, corneal str s - - -59-Mineralization, scleral s - - -121-Neovascularization, corneal s - - -180-Inflammation, acute s - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 77Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSEyes/optic nerve (12) Status >Operator > 142 142 142127-Inflammation, mixed s - - -278-Inflammation, chronic s - - -216-M-Leukemia, monuc - - -Bone, femur (2) Status >Operator > 142 142 142 142 142209-New bone, endosteal s - - - - -212-Inflammation, acute s - - - - -Spinal cord (3) Status >Operator > 142 142 14248-Degen, white matter s - - -184-Hemorrhage s - - -280-Inflammation, acute s - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142261-Degeneration-resp epith s - - - - -222-Degeneration,hyal-Resp Epith s - - - 1 -106-Metaplasia, squ-resp epith s - - - - -124-Metaplasia, squ-trans epith s - - - - -91-Inflammation, mixed s - - - - -49-Inflammation-nasolac duct s 2 2 - - -107-Inflammation-resp epith s - - - - -186-Hyperplasia-resp epith s - - - - -217-M-Leukemia, monuc - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 14298-Degeneration-olfact epith s - - - - -51-Degeneration,hyaline-olf epi s - - - - -262-Degeneration-resp epith s - - - - -202-Degeneration, hyal-resp epit s - - - 1 -210-Metaplasia, sec-olfact epith s - - - - -292-Metaplasia, squ-olfact epith s - - - - -312-Metaplasia, squ-resp epith s - - - - -92-Inflammation, mixed s 1 - - - -227-Hyperplasia-resp epith s - - - - -112-M-Carcinoma, squamous cell - - - - -218-M-Leukemia, monuc - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - -93-Inflammation, mixed s - - - - -195-M-Carcinoma, squamous cell - - - - -219-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 78Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSNose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142313-Degeneration-olfact epith s - - - - -168-Degeneration, hyal-olf epi s - - - - -94-Inflammation, mixed s - - - - -196-N-Carcinoma, squamous cell - - - - -220-M-Leukemia, monuc - - - - -Preputial gland (4) Status > M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M MOperator >71-N-Leukemia, monucIliac LN (2) Status > M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M MOperator >270-Dilatation, sinusoidal s169-Infiltration, histiocytic s142-Sinus plasmacytosis s75-N-Leukemia, monucMediastinal LN (4) Status > *Operator > 142 142 14213-Hemorrhage s 2 -171-Pigmentation s - -267-N-Sarcoma, histiocytic - -14-N-Leukemia, monuc - -Pituitary gland (7) Status >Operator > 142 142 142 142173-Angiectasis s - - - -40-Cyst s - - - -172-Hemorrhage s - - - -232-Inflammation, chronic s - - - -42-Hyperplasia, pars dist, fcl s - - - -39-B-Adenoma, pars distalis 1= 1= - 1=138-M-Leukemia, monuc - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 79Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSTiss.not specifi (9) Status > M M M M MOperator > 142181-Cyst s -276-Mammary tissue p -286-Myodegeneration s 2281-Inflammation, mixed s -308-B-Fibroma -113-B-Lipoma -200-M-Mesothelio, mal -328-N-Sarcoma, histiocytic -331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 80Rat/F344/NGroup Sex Dosage Animal > 6833F547 6833F5492 M 2 g/m3 Animal > 6833F546 6833F548 6833F550Tissue/diagnosis Death code > U2 FS U2 U1 FSMesentery (2) Status > M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 81Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSLungs (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - 1 1 - - - - - 1 - - - - - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - - 1 - - 1= 1= - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - 1 - - - - 1 - 2 - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - 1=240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol - - - - 1 1= - 2 - 1 2 2 - - 1131-N-Leukemia,monuc - inv invol - - - 2= - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - 2 - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 1428-Hemorrhage s - - - - -243-N-Sarcoma, histiocytic - - - - -9-N-Leukemia, monuc 2 - - - -Thyroid glands (7) Status >Operator > 142 142 142 142 142 142115-Cyst, follicular p - - P - - -73-Hyperplasia, C-cell, focal s - - - - - -153-Hyperplasia, follicular cell s - - - - - 3=10-B-Adenoma, C-cell - - - - - -87-B-Adenoma, follicular cell - - - - - -204-M-Carcinoma, C-cell - - - - - -125-M-Carcinoma, follicular cell - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 82Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSParathyroid (2) Status > m mHOperator > 142 142 142 142 142235-Hyperplasia, diffuse s - - - - -203-Hyperplasia, focal s - - - - -Aorta (2) Status >Operator > 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - -325-Dilatation p - - - - -Esophagus Status > U U U U UOperator > 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 2 2 1 2 2 1 2 2 1 2 - 1 2 2 119-Inflammation, chronic s - - - - - - - - - - - - - - -16-Metaplasia, squamous s - 1 - - - - - - - - - - - - -15-Hyperplasia, epithelial s - - - 2 - - - 2 - - - - 1 1 -Salivary gland (3) Status >Operator > 142 142 142 142 142225-Degen s - - - - -236-Inflammation, acute s - - - - -20-M-Leukemia, monuc 1= - - - -Mandibular LN (4) Status >Operator > 142 142 142 142 142126-Hemorrhage s - - - - -118-Sinus plasmacytosis s - - - - -60-Hyperplasia, lymphoid s - - - - -21-N-Leukemia, monuc 2= - 1 - -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 14226-Angiectasis s - 2 - - 1 - - - -160-Congestion s - - - - - - - - -272-Cyst s - - - - - - - - -99-Fatty Change s - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - -123-Hdn p - - - - - - - P= -22-Necrosis s - - - - 1 - - - -231-Thrombus s - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - -29-Inflammation, chronic s - - - - - - - - -27-Hyperplasia, biliary s 2 3 3 1 3 2 2 2 328-Hyperplasia, hepato, regen s - - 1= - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 83Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSLiver (17) Status >Operator > 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - -310-M-Sarcoma, undifferentiated - - - 1= - - - - -24-M-Leukemia, monuc 2 1= 2= - 2 2 2 - 1=Spleen (7) Status >Operator > 142 142 142 142 142 142 142285-Congestion s - - - - - - -63-Fibrosis s - 2= - - - - 2=247-Hemorrhage s - - - - - - -129-Necrosis s - - - - - - 2=201-M-Fibrosarc - - - - - - -30-M-Leukemia, monuc 2= 1= 2= 2= 2= 2= 1=326-N-Sarcoma, histiocytic - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - 1 - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - 2 - - - -33-Nephropathy, chronic s 3 4= 2 2 3 3 3 3 3 2 3 3 2 3 3130-Pigment, tubular epithelium s - - - - - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - 1 1= - - 1= 1= - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - 2= - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 14296-Degen, myocyte s - - 1 - -116-Fibrosis s - - - - -206-Thrombus s - - 2 - -279-Inflammation, acute s - - - - -34-Inflammation, focal, chronic s - 1 - - -35-M-Leukemia, monuc 1 - - - -Stomach (2) Status >Operator > 142 142 142 142 142101-Inflammation, mixed s - - - - -100-Hyperplasia, sq epi s - - - - -Cecum (1) Status >Operator > 142 142 142 142 14269-N-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 84Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSUrinary bladder (5) Status >Operator > 142 142 142 142 142178-Hemorrhage s - - - - -193-Inflammation, mixed s - - - - -37-Inflammation, chronic s - - - - -61-B-Papilloma, transitional - - - - -134-M-Leukemia, monuc - - - - -Duodenum Status > U U U U UOperator > 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 14280-M-Adenocarcinoma - - - - -Ileum (3) Status >Operator > 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - -81-B-Fibroma - - - - -207-N-Leukemia, monuc - - - - -Colon (2) Status >Operator > 142 142 142 142 142197-Inflammation, mixed s - - - - -156-B-Leiomyoma - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - -135-M-Leukemia, monuc - - - - -Rectum Status > U U U U UOperator > 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142164-Cyst s - - - - -62-Degen, cytopl vacuol s - - - - -194-Necrosis s - - - 2 -108-Thrombus s - - - - 3277-Hyperplasia, cort, diffuse s - - - - -38-Hyperplasia, medulla, focal p - - P - -77-B-Pheochrom, bgn - - - - -305-B-Pheochro, complex, benign - - - - -74-M-Pheochromocytoma, malig - - - - -57-M-Leukemia, monuc - - - 2 -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 85Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSProstate (6) Status >Operator > 142 142 142 142 142143-Atrophy s - - - - -179-Hemorrhage s - - - - -109-Mineralization s - - - - -273-Hyperplasia s - - - - -88-Inflammation, acute s - - - - -64-Inflammation, mixed s - - 2 3 -Epididymis (4) Status >Operator > 142 142 142 142 142119-Atrophy s - - - - -242-Granuloma, sperm s - - - - -97-Inflammation, chronic s - - - - -198-M-Mesothelio, mal - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142120-Atrophy s 3= - 2= - 2= - 3= - - 2=182-Dilatation s - - - - - - - - - -307-Hyperplasia s - - - - - - - - - -136-M-Leukemia, monuc - 1= - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142147-Hemorrhage s - - - - -79-Histiocytosis, sinus s - - - - -257-N-Sarcoma, histiocytic - - - - -43-N-Leukemia, monuc 1= 1 - - -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - 2= - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - P - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= - 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - 1 -Sciatic nerve (1) Status >Operator > 142 142 142 142 14283-N-Leukemia, monuc - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142304-Inflammation, chronic s - - - - -258-N-Sarcoma, histiocytic - - - - -271-M-Leukemia, monuc 1= - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 86Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSMammary gland (6) Status >Operator > 142 142 142 142 142284-Cyst p - - - - -166-Ectasia s - - - - -155-Hyperplasia, lobular s - - - - -165-B-Fibroadenoma - - - - -55-B-Fibroma - - - - -266-N-Sarcoma, histiocytic - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - -140-Fibrosis s - - - - - - - - -221-Hyperkeratosis s - - - - - - - - 3=241-Necrosis s - - - - - - - - -237-Inflammation, mixed s - 4= - - - - - - -148-Inflammation, chronic s - - - - - - - - -149-B-Fibroma - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - -309-B-Tumor, hair follicle, ben - - - 1= - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - 1= -327-N-Sarcoma, histiocytic - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 14244-Compression s - - - - -103-Ectasia, ventricular sys s - - - - -226-Edema s - - - - -189-Gliosis s - - - - -183-Hemorrhage s - - - 3= -192-Mineralization s - - - - -45-Necrosis s - - - - -275-Inflammation, acute s - - - - -190-Inflammation, chronic s - - - - -224-M-Astrocytoma, malignant - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 14289-Atrophy s - - - - - - -110-Atrophy, retinal, unilat s 3 - - - - - -111-Cataract p P= - - - - - -90-Degen s - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - -46-Mineralization, corneal str s - - - - - - -59-Mineralization, scleral s - - - - - - -121-Neovascularization, corneal s - - - - - - -180-Inflammation, acute s - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 87Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSEyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - -278-Inflammation, chronic s - - - - - - -216-M-Leukemia, monuc - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 14248-Degen, white matter s - - - - -184-Hemorrhage s - - - 2 -280-Inflammation, acute s - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - 2106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - - - - - - 2 - - - - -49-Inflammation-nasolac duct s - 1 - - - - - - 3 2 2 3 - - 3107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - - - - - - - 1 -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - 1 - - - - - - - - 1262-Degeneration-resp epith s - - - - - - - - - 1 - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - - - - - 2 - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - 1 - - - - -93-Inflammation, mixed s - - - - - - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 88Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSNose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator > 142 142283-Cyst, epithelial inclusion p - P=66-Ectasia s 3= -128-Inflammation, chronic s - -67-Inflammation, mixed s - -Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142270-Dilatation, sinusoidal s - -169-Infiltration, histiocytic s 3= -142-Sinus plasmacytosis s - -75-N-Leukemia, monuc - 1=Mediastinal LN (4) Status >Operator > 142 142 142 142 142 14213-Hemorrhage s 2= - - - - -171-Pigmentation s - - - - - -267-N-Sarcoma, histiocytic - - - - - -14-N-Leukemia, monuc - 1= - - - -Pituitary gland (7) Status >Operator > 142 142 142 142 142173-Angiectasis s - - - - -40-Cyst s - - - - -172-Hemorrhage s - - - - -232-Inflammation, chronic s - - - - -42-Hyperplasia, pars dist, fcl s - - - - -39-B-Adenoma, pars distalis - - - - -138-M-Leukemia, monuc 1 - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 89Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSTiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142181-Cyst s -276-Mammary tissue p -286-Myodegeneration s -281-Inflammation, mixed s -308-B-Fibroma 1=113-B-Lipoma -200-M-Mesothelio, mal -328-N-Sarcoma, histiocytic -331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator > 142302-Cyst, epi inclusion p -145-Inflammation, acute s -174-Inflammation, mixed s 4=175-Hyperplasia/hyperkeratosis s 3=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 142151-N-Leukemia, monuc 1=Bone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 90Rat/F344/NGroup Sex Dosage Animal > 6835G602 6835G604 6835G606 6835G608 6835G610 6835G612 6835G6143 M 10 g/m3 Animal > 6835G601 6835G603 6835G605 6835G607 6835G609 6835G611 6835G613 6835G615Tissue/diagnosis Death code > FS FS FS U2 FS U2 FS U2 FS FS U2 U2 FS FS FSMesentery (2) Status > M M M M M M M M M M M M M M MOperator > 142301-Inflammation, mixed s -311-M-Mesothelio, mal 2=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 91Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSLungs (17) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s 1 - - - - - 1 - - - - - - 1 -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s 1= - - - - - - - 2= - - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - - - 2 - - - - 1 -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol 2 - 2 2 2= - 2 - 2 2= 2 2 - 2 1131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - 2 - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - - -9-N-Leukemia, monuc 1= - - - - - - - 1 - -Thyroid glands (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - - - -10-B-Adenoma, C-cell 1 - - - - - - - - - -87-B-Adenoma, follicular cell - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 92Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSParathyroid (2) Status > mH mH m m mOperator > 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - -325-Dilatation p - - - - - - - - - - -Esophagus Status > U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 2 - 2 2 2 2 1 2 2 1 2 2 2 1 119-Inflammation, chronic s - - - - - - - - - - - - - - -16-Metaplasia, squamous s - - - - - - - - - 1 - - 1 - -15-Hyperplasia, epithelial s - - 1 2 2 - 1 - - - 2 1 - - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - 2 -Mandibular LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - -21-N-Leukemia, monuc 1= - - - 1 - - - - 1 -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - - - 1 1 - - 1 1 2 -160-Congestion s - - - - - - - - - - -272-Cyst s - 3= - - - - - - - - -99-Fatty Change s - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - -123-Hdn p - - - - - - - - - - -22-Necrosis s - - 1 - - - - - - - -231-Thrombus s - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - -29-Inflammation, chronic s - - - - - - - - - - -27-Hyperplasia, biliary s 2 3 3 2 3 2 3 3 3 3 328-Hyperplasia, hepato, regen s - - - - - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 93Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSLiver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - -24-M-Leukemia, monuc 2= 2 2 2= 2= - 2 2= 2 2= 2=Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - 2= - - - - - - - - - - -63-Fibrosis s - - - - - - - - - - - - 2=247-Hemorrhage s - - - - - - - - - - - - -129-Necrosis s - - - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - -30-M-Leukemia, monuc 2= - 2= 2= 2= 2= - 2= 2= 2= 2 2= -326-N-Sarcoma, histiocytic - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - 2 - - -33-Nephropathy, chronic s 3 3 2 2 2 3 3 1 2 2 3 2 3 2 3130-Pigment, tubular epithelium s - - - - - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - 3= - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s 1 - - - - - 1 - - - -116-Fibrosis s - - - - - - - 1 - - -206-Thrombus s - - - - - - - 1 - - -279-Inflammation, acute s - - - - - - - - - - -34-Inflammation, focal, chronic s - - - - 1 - - - 1 1 -35-M-Leukemia, monuc - 1 - - - - - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 94Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSUrinary bladder (5) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - -Duodenum Status > U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - -Rectum Status > U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - -62-Degen, cytopl vacuol s - - 2 - - - - 1 - - -194-Necrosis s - - - - - - - - - - -108-Thrombus s - - - - - - - - - - 2277-Hyperplasia, cort, diffuse s - - - - - - - 3= - - -38-Hyperplasia, medulla, focal p P - - P - - - - - - -77-B-Pheochrom, bgn - - 1= - 1 - - - - 1= -305-B-Pheochro, complex, benign - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - -57-M-Leukemia, monuc - 1 - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 95Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSProstate (6) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - - - -179-Hemorrhage s - - - - - - - - - -109-Mineralization s - - - - - - - - - -273-Hyperplasia s - - - - - 1 - - - -88-Inflammation, acute s - - - - - - - - - -64-Inflammation, mixed s 1 3 2 - - - 2 1 2 -Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - - - - - - - - 2=242-Granuloma, sperm s - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - -198-M-Mesothelio, mal - - - - - - - - - - - -Seminal vesicle (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - 2= - - - 3= - - - - - -182-Dilatation s - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - -43-N-Leukemia, monuc - - - - - - - - - - -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s 3= - - - - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - 2 - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 96Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSMammary gland (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - -166-Ectasia s - - - - - - - - - - -155-Hyperplasia, lobular s - - - - - - - - - - -165-B-Fibroadenoma - - - - - - - - - - -55-B-Fibroma - - - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - -149-B-Fibroma - 1= - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - 2= - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - - - -226-Edema s - - - - - - - - - - -189-Gliosis s - - - - - - - - - - -183-Hemorrhage s - - - - - - - 2 - - -192-Mineralization s - - - - - - - - - - -45-Necrosis s - - - - - - - - - - -275-Inflammation, acute s - - - - - - - 2= - - -190-Inflammation, chronic s - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - -111-Cataract p - - - - - - - - - - -90-Degen s - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - - -59-Mineralization, scleral s - 1 - 1 2 - - - - - -121-Neovascularization, corneal s - - - - - - - - - - -180-Inflammation, acute s - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 97Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSEyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - 1 - - - - 2 - - 2 - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - - - 1 - - - - - - 3 -49-Inflammation-nasolac duct s - - - - - - 3 - - 1 - - - 2 -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - 2 - - - - 2 - - 2 - - - 2 1262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - 2 - - - - - - - 2 - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - - 2 - - - - - - - -227-Hyperplasia-resp epith s - - - - - - 2 - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - 2 - - - 1 - - - 2 - - - 2 -93-Inflammation, mixed s - - - - - - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 98Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSNose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - 1 - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator > 142283-Cyst, epithelial inclusion p -66-Ectasia s 3=128-Inflammation, chronic s -67-Inflammation, mixed s -Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >71-N-Leukemia, monucIliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142 142 142270-Dilatation, sinusoidal s - - - -169-Infiltration, histiocytic s - - - -142-Sinus plasmacytosis s - - - -75-N-Leukemia, monuc 1= 1= 1= 1=Mediastinal LN (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - 2= - - - - - -171-Pigmentation s - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - -14-N-Leukemia, monuc 1= - - - - - - - - -Pituitary gland (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - - -40-Cyst s 2 - - 2= 1 - - - - 1= - -172-Hemorrhage s - - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - - - - - - - - -39-B-Adenoma, pars distalis - - - - - - - 1= - - - -138-M-Leukemia, monuc - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 99Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSTiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142181-Cyst s -276-Mammary tissue p P=286-Myodegeneration s -281-Inflammation, mixed s -308-B-Fibroma -113-B-Lipoma -200-M-Mesothelio, mal -328-N-Sarcoma, histiocytic -331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:100Rat/F344/NGroup Sex Dosage Animal > 6835G617 6835G619 6835G621 6835G623 6835G625 6835G627 6835G6293 M 10 g/m3 Animal > 6835G616 6835G618 6835G620 6835G622 6835G624 6835G626 6835G628 6835G630Tissue/diagnosis Death code > U2 FS U2 U2 U2 FS U2 U2 U2 U1 U2 U1 FS U2 FSMesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:101Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Lungs (17) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - 1 1 - - - - - - - - - - - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - - - - - - - - - 2= -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - 1= - - - - - - - - -84-Inflammation, mixed s - - 1 - - - 2 - - - - - - - -214-Inflammation, granulomatous s - - - 1 1 - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol 2 2 1 - - 2 1= 1 1= 2= 1 2 - 2 -131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *H *HOperator > 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - -9-N-Leukemia, monuc 1= - - 1= - - - - 1 -Thyroid glands (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - P - - P - - - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - - - - -153-Hyperplasia, follicular cell s - - - - - - - - - - - -10-B-Adenoma, C-cell - 1= - - - - - 1= - - - -87-B-Adenoma, follicular cell - - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - 1= - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:102Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Parathyroid (2) Status > m m mH m mOperator > 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - -325-Dilatation p - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 2 2 - 2 2 1 2 2 2 1 - - - - 219-Inflammation, chronic s - - - - - - - - - - 2 1 - - -16-Metaplasia, squamous s 1 - - - - - - - - - - - - - 115-Hyperplasia, epithelial s - 1 - - 1 1 - - - - - - - - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - -Mandibular LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - 2= - - - - - - - -21-N-Leukemia, monuc 1= - - - 1 - - 1 - - 1 -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s 1 - - - - - - - - - - - - -160-Congestion s - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - -99-Fatty Change s - - - 1 - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - -123-Hdn p - - - - - - - - - - - - - -22-Necrosis s - - - - - - - - - - - - - -231-Thrombus s - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - - - - -29-Inflammation, chronic s - - - - - - - - - - - - - -27-Hyperplasia, biliary s 3 3 2 2 2 4 3 2= 2 2 3 2 3 228-Hyperplasia, hepato, regen s - - - - - - - - - - - - - 2122-B-Adenoma, hepatocellular 1= - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:103Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - -24-M-Leukemia, monuc 1 2= 1 1= - 2 2= - 2= 2 2= - 2 -Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - -63-Fibrosis s - - - - - - 2 - 1= - - - - -247-Hemorrhage s - - - - - - - - - - - - - -129-Necrosis s - - - - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - - -30-M-Leukemia, monuc 2= 2= 1= - 2= 2= 1= 1= 2= 2= 2= - 2= -326-N-Sarcoma, histiocytic - - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - 2 - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 3 2 3 3= 2 2 3 3 3= 2 2 3 2 1 3130-Pigment, tubular epithelium s - - - - - - - - - - - - - - -274-Inflammation, acute s - - - - - 3= - - - - - - - - -213-B-Adenoma, renal tubule - - 1 - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - - - - - - - - -116-Fibrosis s - - - - - - - - 1 - - -206-Thrombus s - - - - - - - - - - - -279-Inflammation, acute s - - - - 3 - - - - - - -34-Inflammation, focal, chronic s - 1 1 - - - - 1 - 1 1 135-M-Leukemia, monuc 1 - - - - - - - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:104Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - -Duodenum Status > U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - -Rectum Status > U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - - - - - - - - - -194-Necrosis s - - - - - - - - - - - -108-Thrombus s - - - - 3 - - - - - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - -38-Hyperplasia, medulla, focal p P - P - - - - - - - - -77-B-Pheochrom, bgn - - - - - - - - 1 - - -305-B-Pheochro, complex, benign - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - - -57-M-Leukemia, monuc - 1 - - 2= - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:105Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - - - - - -179-Hemorrhage s - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - - - -64-Inflammation, mixed s - 2 - - 2 - 2 1 2 1 - 3Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - - - - - - - - -242-Granuloma, sperm s - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - 3 - - -198-M-Mesothelio, mal - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - - - - - - - - 2= - -182-Dilatation s - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - - -43-N-Leukemia, monuc 1 - - - 1 - - - - - 1= -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - - - - - - 2= - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - - - P -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:106Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Mammary gland (6) Status > *H *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p P= - - - - - - - - -166-Ectasia s - - - - - - - - - -155-Hyperplasia, lobular s - - - - - - - - - -165-B-Fibroadenoma - - - - - - - - - -55-B-Fibroma - - 1= - - - - 1= - -266-N-Sarcoma, histiocytic - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - -221-Hyperkeratosis s 4= - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - -237-Inflammation, mixed s - - - 3= - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - - - - -226-Edema s - - - - - - - - - - - -189-Gliosis s - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - -45-Necrosis s - - - - - - - - - - - -275-Inflammation, acute s - - - - 1 - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - - 4111-Cataract p - - - - - - - - - - - P90-Degen s - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - - - -46-Mineralization, corneal str s - - - - 1= - - - - - - -59-Mineralization, scleral s - - - - - - - 1 - - - -121-Neovascularization, corneal s - - - - - - - - - - - 3180-Inflammation, acute s - - - - 1 - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:107Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - - -278-Inflammation, chronic s - - - 3 - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - - -280-Inflammation, acute s - - - - 1 - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - 1 - - - -106-Metaplasia, squ-resp epith s - - - - - - - 1 - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - 1 1 - 1 - - - - - - -49-Inflammation-nasolac duct s 1 - - - 2 - 2 - - - 1 - 3 3 -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - - 1 - - - - - 3 -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - 1 - - - - - - -92-Inflammation, mixed s - - - - - - - 1 - - - - - - -227-Hyperplasia-resp epith s - - - - - - - 1 - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - - 2 1 - - -93-Inflammation, mixed s - - - - - - - 1 - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:108Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - 2 - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - 2 - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142 142 142282-Dilatation, sinusoidal s - 2= -72-N-Leukemia, monuc 2= - 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142 142270-Dilatation, sinusoidal s - - -169-Infiltration, histiocytic s - - -142-Sinus plasmacytosis s - - -75-N-Leukemia, monuc 2= - 1=Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - - - -171-Pigmentation s - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - -14-N-Leukemia, monuc 1 - - - 1= - - - - - 1= -Pituitary gland (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - - - - -40-Cyst s - - - - - - - 2= - 1= - - - 1172-Hemorrhage s - - - - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - - - 1 - - 1 - - - -39-B-Adenoma, pars distalis - - - 1= - 1= - - - - - - 1= -138-M-Leukemia, monuc - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:109Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142181-Cyst s -276-Mammary tissue p -286-Myodegeneration s -281-Inflammation, mixed s 4=308-B-Fibroma -113-B-Lipoma -200-M-Mesothelio, mal -328-N-Sarcoma, histiocytic -331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 142151-N-Leukemia, monuc 1=Bone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:110Rat/F344/NGroup Sex Dosage Animal > 6835G632 6835G634 6835G636 6835G638 6835G640 6835G642 6835G6443 M 10 g/m3 Animal > 6835G631 6835G633 6835G635 6835G637 6835G639 6835G641 6835G643 6835G645Tissue/diagnosis Death code > U2 U2 U2 FS U2 U1 U2 FS FS U2 U2 U2 U2 U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:111Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Lungs (17) Status >Operator > 142 142 142 142 1424-Alveolar histiocytosis s 1 - - 1 -299-Autolysis, marked p - - - - -3-Congestion s - - - - -82-Fibrosis, focal s - - - - -154-Hemorrhage s 1 - - - -306-Metaplasia, squam - alv epi s - - - - -233-Mineralization, uremic s - - - - -298-Cyst, squamous, keratiniz p - - - - -187-Inflammation, acute s - - - - -84-Inflammation, mixed s - - - - -214-Inflammation, granulomatous s - - - - -1-Hyperplasia, alv epi, focal s - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - -104-B-Adenoma, bronchiolo-alv - - - - -240-N-Sarcoma, histiocytic - - - - -2-N-Leukemia,monuc - cap invol 2 - 1 1 -131-N-Leukemia,monuc - inv invol - - - - -Trachea (6) Status >Operator > 142 142 142 142 142188-Metaplasia, squamous s - - - - -7-Inflammation, acute s - - - - -85-Inflammation, mixed s - - - - -177-Inflammation, chronic s - - - - -86-Hyperplasia, epithelial s - - - - -215-N-Leukemia, mononuclear - - - - -Bronchial (TBLN) (3) Status >Operator > 142 1428-Hemorrhage s - -243-N-Sarcoma, histiocytic - -9-N-Leukemia, monuc 1= -Thyroid glands (7) Status >Operator > 142 142115-Cyst, follicular p - -73-Hyperplasia, C-cell, focal s - -153-Hyperplasia, follicular cell s - -10-B-Adenoma, C-cell 1= -87-B-Adenoma, follicular cell - -204-M-Carcinoma, C-cell - -125-M-Carcinoma, follicular cell - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:112Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Parathyroid (2) Status >Operator > 142 142235-Hyperplasia, diffuse s - -203-Hyperplasia, focal s - -Aorta (2) Status >Operator > 142 142132-N-Leukemia,monuc - inv invol - -325-Dilatation p - -Esophagus Status > U UOperator > 142 142Larynx (5) Status >Operator > 142 142 142 142 14295-Ulceration s - - - - -18-Inflammation, mixed s - 2 2 2 -19-Inflammation, chronic s 1 - - - 216-Metaplasia, squamous s - - 1 - -15-Hyperplasia, epithelial s - - - 2 2Salivary gland (3) Status >Operator > 142 142225-Degen s - -236-Inflammation, acute s - -20-M-Leukemia, monuc - -Mandibular LN (4) Status >Operator > 142 142126-Hemorrhage s - -118-Sinus plasmacytosis s - -60-Hyperplasia, lymphoid s - -21-N-Leukemia, monuc - -Liver (17) Status >Operator > 142 142 142 14226-Angiectasis s - - - -160-Congestion s - - - -272-Cyst s - - - -99-Fatty Change s - - - -158-Foci cell alter, basophilic s - - - -123-Hdn p - - - -22-Necrosis s - - - -231-Thrombus s - - - -23-Vaculoliz, cyto s - - 2 -29-Inflammation, chronic s - - - -27-Hyperplasia, biliary s 3 2 - 328-Hyperplasia, hepato, regen s - - 2= -122-B-Adenoma, hepatocellular - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:113Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Liver (17) Status >Operator > 142 142 142 142150-M-Carcinoma, hepatocellular - - - -246-M-Sarcoma, histiocytic - - - -310-M-Sarcoma, undifferentiated - - - -24-M-Leukemia, monuc 2= - 1= -Spleen (7) Status >Operator > 142 142 142 142285-Congestion s - - - -63-Fibrosis s - - - -247-Hemorrhage s - - - -129-Necrosis s - - - -201-M-Fibrosarc - - - -30-M-Leukemia, monuc 2= 1= 1= -326-N-Sarcoma, histiocytic - - - -Kidneys (9) Status >Operator > 142 142 142 142 142161-Cyst s - - - - -248-Degen, hyaline droplet s - - - - -251-Infarct s - - - - -33-Nephropathy, chronic s 3 3= 4= 3 3130-Pigment, tubular epithelium s 3 - - - -274-Inflammation, acute s - - - - -213-B-Adenoma, renal tubule - - 1 - -191-M-Carcinoma, renal tubule - - - - -68-M-Leukemia, monuc - - - - -Heart (6) Status >Operator > 142 14296-Degen, myocyte s - -116-Fibrosis s - -206-Thrombus s - -279-Inflammation, acute s - -34-Inflammation, focal, chronic s - -35-M-Leukemia, monuc - -Stomach (2) Status >Operator > 142 142101-Inflammation, mixed s - -100-Hyperplasia, sq epi s - -Cecum (1) Status >Operator > 142 14269-N-Leukemia, monuc - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:114Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Urinary bladder (5) Status >Operator > 142 142178-Hemorrhage s - -193-Inflammation, mixed s - -37-Inflammation, chronic s - -61-B-Papilloma, transitional - -134-M-Leukemia, monuc - -Duodenum Status > U UOperator > 142 142Jejunum (1) Status >Operator > 142 14280-M-Adenocarcinoma - -Ileum (3) Status >Operator > 142 14278-Hyperplasia, lymphoid s - -81-B-Fibroma - -207-N-Leukemia, monuc - -Colon (2) Status >Operator > 142 142197-Inflammation, mixed s - -156-B-Leiomyoma - -Pancreas (2) Status >Operator > 142 142323-M-Carcinoma, ductal cell - -135-M-Leukemia, monuc - -Rectum Status > U UOperator > 142 142Adrenal glands (10) Status >Operator > 142 142164-Cyst s - -62-Degen, cytopl vacuol s - -194-Necrosis s - -108-Thrombus s - -277-Hyperplasia, cort, diffuse s - -38-Hyperplasia, medulla, focal p - -77-B-Pheochrom, bgn 1= -305-B-Pheochro, complex, benign - -74-M-Pheochromocytoma, malig - -57-M-Leukemia, monuc - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:115Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Prostate (6) Status >Operator > 142 142143-Atrophy s - -179-Hemorrhage s - -109-Mineralization s - -273-Hyperplasia s - -88-Inflammation, acute s - -64-Inflammation, mixed s - 3Epididymis (4) Status >Operator > 142 142119-Atrophy s - -242-Granuloma, sperm s - -97-Inflammation, chronic s - -198-M-Mesothelio, mal - -Seminal vesicle (4) Status >Operator > 142 142 142120-Atrophy s - - -182-Dilatation s - 4= -307-Hyperplasia s - - -136-M-Leukemia, monuc - - -Mesenteric LN (4) Status >Operator > 142 142147-Hemorrhage s - -79-Histiocytosis, sinus s - -257-N-Sarcoma, histiocytic - -43-N-Leukemia, monuc - -Testes (5) Status >Operator > 142 142 142 142 142152-Atrophy s - - - - -287-Hemorrhage s - - - - -105-Hyperplasia, interst cell p - - - - P=54-B-Adenoma, interstitial 1= 1= 1= 1= -199-M-Mesothelioma, malig - - - - -Sciatic nerve (1) Status >Operator > 142 14283-N-Leukemia, monuc - -Muscle, skeletal (3) Status >Operator > 142 142304-Inflammation, chronic s - -258-N-Sarcoma, histiocytic - -271-M-Leukemia, monuc - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:116Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Mammary gland (6) Status >Operator > 142 142 142284-Cyst p - - -166-Ectasia s - - -155-Hyperplasia, lobular s - - -165-B-Fibroadenoma - - -55-B-Fibroma - 1= -266-N-Sarcoma, histiocytic - - -Skin (13) Status >Operator > 142 142229-Cyst, epith inc p - -140-Fibrosis s - -221-Hyperkeratosis s - -241-Necrosis s - -237-Inflammation, mixed s - -148-Inflammation, chronic s - -149-B-Fibroma - -176-B-Keratoacanthoma - -223-B-Tumor, basal cell, benign - -309-B-Tumor, hair follicle, ben - -300-M-Carcinoma, sebaceous cell - -303-M-Sarcoma, undifferentiated - -327-N-Sarcoma, histiocytic - -Brain (10) Status >Operator > 142 142 14244-Compression s - 1= 4=103-Ectasia, ventricular sys s - - -226-Edema s - - -189-Gliosis s - - -183-Hemorrhage s - - -192-Mineralization s - - -45-Necrosis s - - -275-Inflammation, acute s - - -190-Inflammation, chronic s - - -224-M-Astrocytoma, malignant - - -Eyes/optic nerve (12) Status >Operator > 142 142 14289-Atrophy s - - -110-Atrophy, retinal, unilat s - 3 -111-Cataract p - P= -90-Degen s - - -144-Metaplasia, osseous, sclera s - - -46-Mineralization, corneal str s - 1 -59-Mineralization, scleral s 1 - 1121-Neovascularization, corneal s - 2 -180-Inflammation, acute s - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:117Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Eyes/optic nerve (12) Status >Operator > 142 142 142127-Inflammation, mixed s - - -278-Inflammation, chronic s - - -216-M-Leukemia, monuc - - -Bone, femur (2) Status >Operator > 142 142 142 142 142209-New bone, endosteal s - - - - -212-Inflammation, acute s - - - - -Spinal cord (3) Status >Operator > 142 14248-Degen, white matter s - -184-Hemorrhage s - -280-Inflammation, acute s - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142261-Degeneration-resp epith s - - - - -222-Degeneration,hyal-Resp Epith s - - - - -106-Metaplasia, squ-resp epith s - - - - -124-Metaplasia, squ-trans epith s - - - - -91-Inflammation, mixed s - 1 - 1 -49-Inflammation-nasolac duct s - - - - -107-Inflammation-resp epith s - - - - -186-Hyperplasia-resp epith s - - - - -217-M-Leukemia, monuc - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 14298-Degeneration-olfact epith s - - - - -51-Degeneration,hyaline-olf epi s - - - - -262-Degeneration-resp epith s - - - - -202-Degeneration, hyal-resp epit s - - - - -210-Metaplasia, sec-olfact epith s - - - - -292-Metaplasia, squ-olfact epith s - - - - -312-Metaplasia, squ-resp epith s - - - - -92-Inflammation, mixed s - - - - -227-Hyperplasia-resp epith s - - - - -112-M-Carcinoma, squamous cell - - - - -218-M-Leukemia, monuc - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - -93-Inflammation, mixed s - - - - -195-M-Carcinoma, squamous cell - - - - -219-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:118Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142313-Degeneration-olfact epith s - - - - -168-Degeneration, hyal-olf epi s - - - - -94-Inflammation, mixed s - - - - -196-N-Carcinoma, squamous cell - - - - -220-M-Leukemia, monuc - - - - -Preputial gland (4) Status > M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M MOperator >71-N-Leukemia, monucIliac LN (2) Status > M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M MOperator >270-Dilatation, sinusoidal s169-Infiltration, histiocytic s142-Sinus plasmacytosis s75-N-Leukemia, monucMediastinal LN (4) Status >Operator > 142 14213-Hemorrhage s - -171-Pigmentation s - -267-N-Sarcoma, histiocytic - -14-N-Leukemia, monuc - -Pituitary gland (7) Status >Operator > 142 142 142173-Angiectasis s - - -40-Cyst s - - -172-Hemorrhage s - - -232-Inflammation, chronic s - - -42-Hyperplasia, pars dist, fcl s 1 - -39-B-Adenoma, pars distalis - 1= 1=138-M-Leukemia, monuc - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:119Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Tiss.not specifi (9) Status > M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:120Rat/F344/NGroup Sex Dosage Animal > 6835G647 6835G6493 M 10 g/m3 Animal > 6835G646 6835G648 6835G650Tissue/diagnosis Death code > U2 FS FS FS U2Mesentery (2) Status > M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:121Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Lungs (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s 1 - - - - 1 - - 1 - - - - - -299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - - - - - - - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s 3 - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - 1 1 - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - - - - - 1 - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol - - - - 2 - 2 - 2= - - 1 2 - 2131-N-Leukemia,monuc - inv invol - - - - - - - 2 - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s 2 - 2 - - - - - - 2 - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - - 2= -243-N-Sarcoma, histiocytic - - - - - - - - - - - - -9-N-Leukemia, monuc - - 1= - - - 1= - - - - - -Thyroid glands (7) Status > mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - - - - - - - -73-Hyperplasia, C-cell, focal s - - - - - - 1 - - - - - - 1 -153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -10-B-Adenoma, C-cell - - - - - - - - - - - - 1 - -87-B-Adenoma, follicular cell - - - - - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - - - - - - 1= - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:122Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Parathyroid (2) Status > * mH *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s 3 - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -325-Dilatation p P= - - - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 3 2 2 2 2 2 3 2 3 2 2 2 2 2 219-Inflammation, chronic s - - - - - - - - - - - - - - -16-Metaplasia, squamous s - - - 2 - - - - - 2 - - - - -15-Hyperplasia, epithelial s 2 1 2 2 1 2 2 2 2 - - - 1 2 -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - - - - 1236-Inflammation, acute s 1 - - - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - - - - - -21-N-Leukemia, monuc - - - - - - - 1 1 - - 1 - - -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s 2 - - 1 - 2 - - - 1 - - 1 - -160-Congestion s - - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - - -99-Fatty Change s - - - - - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - - -123-Hdn p - - P= - - - - - - - - - - - -22-Necrosis s - - - - - - - - - - - - - - -231-Thrombus s - - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - 2 - - - - - - - - - - -29-Inflammation, chronic s - - - - - - - - - - - - - - -27-Hyperplasia, biliary s 3= 2 - 2 3 2 3 3 3 2 2 - 1 - 428-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:123Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - 2 - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -24-M-Leukemia, monuc - - 2= - 2= - 2 2= 2= - - 1 2= - 2=Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - - -63-Fibrosis s - - - - - - - - - - - - - - -247-Hemorrhage s - - - - - - - - - - - - - - -129-Necrosis s - - - - - - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - - - -30-M-Leukemia, monuc - - 1 - 2= - 2= 2= 2= - - 1 2= - 2=326-N-Sarcoma, histiocytic - - - - - - - - - - - 2 - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 4= 3 3= 3 3= 3= 2 3= 3 3 3 2= 4= 4= -130-Pigment, tubular epithelium s - - 3 - - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s 2 - - - - 1 - - - - - - - - -116-Fibrosis s 2 - - - - - - - 1= - - - - - -206-Thrombus s - - - - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - - - - -34-Inflammation, focal, chronic s 1 1 - 1 1 - - - - - - - - 1 135-M-Leukemia, monuc - - - - - - - 1 - - - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - - - - - -Cecum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:124Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - - - - -37-Inflammation, chronic s - - - 1 - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - 1 - - - - - - -Duodenum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - - - - -156-B-Leiomyoma - - - - - 1= - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - 2= - - -135-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - 1 - - - - - - - - - - -194-Necrosis s - - - - - - - - - - - - - - -108-Thrombus s - - - - - - 4= - - - - - - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - - P= - P - - P - - - - P P P77-B-Pheochrom, bgn - - - - - - - 1 - - - - - 1 -305-B-Pheochro, complex, benign - - - - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - -57-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:125Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - 1 - - 1 - - - - - - -179-Hemorrhage s - - - - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - - - - - - -64-Inflammation, mixed s 3 1 2 3 1 - - - - - 2 - 4= - -Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - 1 - - - - - - - - - -242-Granuloma, sperm s - - - - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - - - - -198-M-Mesothelio, mal - - 2= - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - - - 1 - - 3 - 1 - - - - -182-Dilatation s - - - - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -43-N-Leukemia, monuc - - - - - - - - - - - - - - -Testes (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - - - - - - - - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - 2 - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:126Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Mammary gland (6) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - - - - -166-Ectasia s - - - - - - - - - - 4= - - -155-Hyperplasia, lobular s - - - - - 3 - - - - - - 2 -165-B-Fibroadenoma - - - - - - - - - - - - - -55-B-Fibroma - - - 1= - - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - - - 1= -223-B-Tumor, basal cell, benign - - - - - - - - - 1= - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - 2 - - - - - - 2= - 3= - -103-Ectasia, ventricular sys s - - - - - - - - - - - - - - -226-Edema s - - - - - - - - - - - - - - -189-Gliosis s - - - - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - - - - -45-Necrosis s - - - - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - 2 - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -111-Cataract p - - - - - - - - - - - - - - -90-Degen s - - - - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - - - - - - -59-Mineralization, scleral s - - - - - - - - - - - - - - -121-Neovascularization, corneal s - - - - - - - - - - - - - - -180-Inflammation, acute s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:127Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - 1 - - 2 - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - - - 1 - - - - - - - -49-Inflammation-nasolac duct s - - - - - - 3 - - - - - - - -107-Inflammation-resp epith s 2 - - - - - - - - - - - - - -186-Hyperplasia-resp epith s 2 - - - - - - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - 1 - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - 2 - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s 2 - - - - - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - 2 - - - 2 -93-Inflammation, mixed s 1 - - - - - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:128Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s 1 - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142 142 142270-Dilatation, sinusoidal s - - - -169-Infiltration, histiocytic s - - - -142-Sinus plasmacytosis s - - - 4=75-N-Leukemia, monuc 1= 1= 1= -Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - - - - - - -171-Pigmentation s - - - - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-N-Leukemia, monuc - - - - 1= - 1 1 1 - - - - - -Pituitary gland (7) Status > H HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - 3 - - - -40-Cyst s - - - - - - 1 - 1 - - - - - -172-Hemorrhage s - - - - - - - - - - - - - 3= -232-Inflammation, chronic s - - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - 1 - - - - - - 1 - 3 -39-B-Adenoma, pars distalis - - - 1= - - - - - - 1= - 1= - -138-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:129Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Tiss.not specifi (9) Status > M M MH M M M M M M M M M M M MOperator > 142181-Cyst s -276-Mammary tissue p -286-Myodegeneration s -281-Inflammation, mixed s -308-B-Fibroma -113-B-Lipoma -200-M-Mesothelio, mal 2=328-N-Sarcoma, histiocytic -331-Splenic tissue, "accessory" p -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator > 142324-Hemorrhage s 2=137-M-Leukemia, monuc -Mediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 142151-N-Leukemia, monuc 1=Bone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:130Rat/F344/NGroup Sex Dosage Animal > 6837H702 6837H704 6837H706 6837H708 6837H710 6837H712 6837H7144 M 20 g/m3 Animal > 6837H701 6837H703 6837H705 6837H707 6837H709 6837H711 6837H713 6837H715Tissue/diagnosis Death code > U2 FS U2 FS FS FS U2 FS U2 U2 U2 U2 U2 FS U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:131Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Lungs (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - 1 - - - - 1 - - - - - 1= - 1299-Autolysis, marked p - - - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - 2 - - - - - -154-Hemorrhage s - - - - - - - - - - - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - - - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - -84-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s 2 - - - - - - - 2= - - - 1 - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol - - - 2= 2= - 2 2= 2 2= - 2= - 1 -131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - - - - - - -177-Inflammation, chronic s - 1 - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - - - 1= - -243-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -9-N-Leukemia, monuc - - - - - - 1= 1= - 1 - - - - -Thyroid glands (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - P - - - P - - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - - - 2 - - 1 -153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -10-B-Adenoma, C-cell - - - - - - - - - - - - 1 - -87-B-Adenoma, follicular cell - - 1= - - - - - - - - - - - -204-M-Carcinoma, C-cell - - - - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - 1= - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:132Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Parathyroid (2) Status > mH mH *H mH m mH mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - - - - - - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -325-Dilatation p - - - - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s 1 2 - 1 2 2 2 2 2 2 2 2 2 2 219-Inflammation, chronic s - - 2 - - - - - - - - - - - -16-Metaplasia, squamous s - 1 - - - 1 - - - - 2 - - - -15-Hyperplasia, epithelial s - - - - - - 2 1 2 - - - - - 2Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - - - - -21-N-Leukemia, monuc - - - - - 1= 1 1 1 - - - - -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - 1 - - - - 2 1 2= 1 1 - 1 - -160-Congestion s - - - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - - -99-Fatty Change s - - - - - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - - -123-Hdn p - - - - - - - - - - - - - - -22-Necrosis s - - - - - - - 1 - - - 2 - - -231-Thrombus s - - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - 1 - - - 129-Inflammation, chronic s - 1 - - - - - - - - 2 - 1 - 127-Hyperplasia, biliary s 2 1 2 2 3 2 3 2 - 4 2 3 2 2 228-Hyperplasia, hepato, regen s - - - - - - - 1 2 - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:133Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -24-M-Leukemia, monuc - 1 - 2 2= - 2= 2= 2= 2= 1 2 - 1 -Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - - -63-Fibrosis s - - - - - - - - - - - - - - -247-Hemorrhage s - - - - - - - - - - - - - - -129-Necrosis s - - - - 3= - - - - - - - - - -201-M-Fibrosarc - - - - - - - - - - - - - - -30-M-Leukemia, monuc - 1 - 2= 2= - 2= 2= 2 2= 1 2= - 1 -326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 2 - 3 2 2 3 3= 3 3 3= 3 3 3 3 -130-Pigment, tubular epithelium s - - - 3 - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - 1= - - -191-M-Carcinoma, renal tubule - - - - - - - - 2= - - - - - -68-M-Leukemia, monuc - - - - - - - - - 1 - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - - - - - - - - - - - - - -116-Fibrosis s - 2 - - - - - - - - - - - - -206-Thrombus s - - - - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - - - - -34-Inflammation, focal, chronic s 1 - - 1 - 1 - - - - 1 - 1 1 135-M-Leukemia, monuc - - - - - - 1 - 2 1 - - - - -Stomach (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - - - - - -Cecum (1) Status > A aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:134Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - 4= - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - 4 - - - - -37-Inflammation, chronic s - - - - - - - - - - - - - - -61-B-Papilloma, transitional - - - - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum Status > U U Ua U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - - - -Ileum (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - 3 - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - - - - - - 1 - 1 - - - -194-Necrosis s - - - - - - - - - 3 - - - - -108-Thrombus s - - 1 - - - - - - - - - - - -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - P P - P - - - P - - P - P -77-B-Pheochrom, bgn - 1 - - - - - - - - - - - - -305-B-Pheochro, complex, benign - - - - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - -57-M-Leukemia, monuc - - - - - - 1 - - 2 - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:135Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - 3 - - - 1 - - 1 -179-Hemorrhage s - - 2 - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - - - - - - -64-Inflammation, mixed s - - 3= 1 - - - - - 4 - 2 - - -Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - - - 2 - - - 2 - 2 1 -242-Granuloma, sperm s - - - - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - - - - -198-M-Mesothelio, mal - - - - - - - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - 3= - - - - 2 - 2 1 2= - 2 2 -182-Dilatation s - - 3= - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -43-N-Leukemia, monuc - - - - 1 - 1 1= - 1 - - - - -Testes (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - 3= - - - - 2= - - - 4= - - -287-Hemorrhage s 3 - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - P - - - - - - - - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - - - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:136Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Mammary gland (6) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - - - - -166-Ectasia s - - - - - - - - - - - - - -155-Hyperplasia, lobular s - - 4 - - - - - - - - - - -165-B-Fibroadenoma - - 1= - - - - - - - - - - -55-B-Fibroma - - - - - - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - - - - - - -140-Fibrosis s - - - - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - - - - - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - - - - - - - -226-Edema s - - - - 3 - - - - - - - - - -189-Gliosis s - - - - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - - - - -192-Mineralization s - - - - - - - - 1= - - - - - -45-Necrosis s - - - - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (12) Status > mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - 4 - - - - -111-Cataract p - - - - - - - - - P= - - - - -90-Degen s - - - - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - - - - - - -59-Mineralization, scleral s - - - - - - - - - 1 - - - - 1121-Neovascularization, corneal s - - - - - - - - - - - - - - -180-Inflammation, acute s - - 2 - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:137Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Eyes/optic nerve (12) Status > mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - - - -212-Inflammation, acute s - - - - - - - - - - - - - - -Spinal cord (3) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - 3 3 - 2 - - - - - - - - -49-Inflammation-nasolac duct s - - 3 - - 4 - 4 - - - - 2 2 -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - 3 - 3 - - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - 1262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - - - - - -210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - 3 - 2 - - - - - - - - -227-Hyperplasia-resp epith s - - - 2 - 3 - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - 1 - - - - 2 - - - -93-Inflammation, mixed s - - - - - - - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - 2219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:138Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Nose/Turbinate 4 (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - - - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - 2220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator >283-Cyst, epithelial inclusion p66-Ectasia s128-Inflammation, chronic s67-Inflammation, mixed sPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142 142270-Dilatation, sinusoidal s - -169-Infiltration, histiocytic s - -142-Sinus plasmacytosis s - -75-N-Leukemia, monuc 1= 1=Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - - 2 - 2 - -171-Pigmentation s - - - - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-N-Leukemia, monuc - - - - - - 1 1 - 1 - - - - -Pituitary gland (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - - - - - - -40-Cyst s - - - - - - - - 2 - - - - - -172-Hemorrhage s - - - - - - - - - - - - - - -232-Inflammation, chronic s - - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s 1 - 1= 3 - - - - - - - - - - -39-B-Adenoma, pars distalis 1 - - - - - - - - - - - - - -138-M-Leukemia, monuc - - - - - - - - - 1= - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:139Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142 142 142181-Cyst s 3= -276-Mammary tissue p - -286-Myodegeneration s - -281-Inflammation, mixed s - -308-B-Fibroma - -113-B-Lipoma - 1=200-M-Mesothelio, mal - -328-N-Sarcoma, histiocytic - -331-Splenic tissue, "accessory" p - -Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M M M M M M M M M M M MOperator > 142324-Hemorrhage s -137-M-Leukemia, monuc 1=Mediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M M M M M M M M M M M MOperator > 142269-Hyperostosis s -228-M-Sarcoma, NOS 1=Zymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator > 142297-M-Carcinoma, squamous cell 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:140Rat/F344/NGroup Sex Dosage Animal > 6837H717 6837H719 6837H721 6837H723 6837H725 6837H727 6837H7294 M 20 g/m3 Animal > 6837H716 6837H718 6837H720 6837H722 6837H724 6837H726 6837H728 6837H730Tissue/diagnosis Death code > U2 FS U1 U2 U2 U2 FS U2 FS FS FS U2 FS FS U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:141Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Lungs (17) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1424-Alveolar histiocytosis s - - - - - - 1 - - 1 1= - - - -299-Autolysis, marked p - P= - - - - - - - - - - - - -3-Congestion s - - - - - - - - - - - - - - -82-Fibrosis, focal s - - - - - - - - - - - - - - -154-Hemorrhage s - - - - - - - - - 1 - - - - -306-Metaplasia, squam - alv epi s - - - - - - - - - - - - - - -233-Mineralization, uremic s - - - - - - - - - - - - - - -298-Cyst, squamous, keratiniz p - P= - - - - - - - - - - - - -187-Inflammation, acute s - - - - - - - - - - - - - - 384-Inflammation, mixed s - - - - - - - - - - - - - - -214-Inflammation, granulomatous s - - - - - - - - - - - - - - -1-Hyperplasia, alv epi, focal s - - - - - - - - - - - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - - - - - - - - - - - -104-B-Adenoma, bronchiolo-alv - - - - - - - - - - - - - - -240-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -2-N-Leukemia,monuc - cap invol - - 2 2 - - 2 2 - 2 - 2 2= 2 -131-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Trachea (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142188-Metaplasia, squamous s - - - - - - - - - - - - - - -7-Inflammation, acute s - - - - - - - - - - - - - - -85-Inflammation, mixed s - - - - - - - - - 1 - - - - -177-Inflammation, chronic s - - - - - - - - - - - - - - -86-Hyperplasia, epithelial s - - - - - - - - - - - - - - -215-N-Leukemia, mononuclear - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 1428-Hemorrhage s - - - - - - - - - - - - - -243-N-Sarcoma, histiocytic - - - - - - - - - - - - - -9-N-Leukemia, monuc - - - - - - - - - - - - - -Thyroid glands (7) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142115-Cyst, follicular p - - - - - - - - - - P - - - -73-Hyperplasia, C-cell, focal s - - - - - - - - - - 1 - - - -153-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -10-B-Adenoma, C-cell - - - 1 - - - - - - - - - - -87-B-Adenoma, follicular cell - - - - 1= - - - - - - - 1 - -204-M-Carcinoma, C-cell - - - - - - - - - - - - - - -125-M-Carcinoma, follicular cell - - - - 1 - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:142Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Parathyroid (2) Status > m *H m mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142235-Hyperplasia, diffuse s - - - - - - - - - - - - - -203-Hyperplasia, focal s - - - - - - - - 3 - - 1 - -Aorta (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -325-Dilatation p - - - - - - - - - - - - - - -Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14295-Ulceration s - - - - - - - - - - - - - - -18-Inflammation, mixed s - 1 2 2 - 2 1 2 2 2 2 2 2 - 119-Inflammation, chronic s 1 - - - - - - - - - - - - - -16-Metaplasia, squamous s - - - - - - - - 2 - - - - - -15-Hyperplasia, epithelial s - - - 2 - - - 1 - 2 1 1 1 - -Salivary gland (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142225-Degen s - - - - - - - - - - - - - - -236-Inflammation, acute s - - - - - - - - - - - - - - -20-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (4) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142126-Hemorrhage s - - - - - - - - - - - - - -118-Sinus plasmacytosis s - - - - - - - - - - - - - -60-Hyperplasia, lymphoid s - - - - - - - - - - - - - -21-N-Leukemia, monuc - 1 - - - - - - 1= - - - - -Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Angiectasis s - - 1 2 - - - - - 2 1 1 - - -160-Congestion s - 3= - - - - - - - - - - - - -272-Cyst s - - - - - - - - - - - - - - -99-Fatty Change s - - - - - - - - - - - - - - -158-Foci cell alter, basophilic s - - - - - - - - - - - - - - -123-Hdn p - - - - - - - - - - - - - - P22-Necrosis s - - - - - - - - - 2 - - 2 - -231-Thrombus s - - - - - - - - - - - - - - -23-Vaculoliz, cyto s - - - - - - - - - - - - - - -29-Inflammation, chronic s - - - - - 1 - - - - - - - - -27-Hyperplasia, biliary s 3 2 2 3 1 2 2 3 2 2 2 2 3 3 228-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -122-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:143Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Liver (17) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - - - - - - - - - - - -246-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -310-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -24-M-Leukemia, monuc 2= - 2= 2= - - 2 2 - 2= 1 2= 2= 2 -Spleen (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Congestion s - - - - - - - - - - - - - - -63-Fibrosis s - - - - - - - - - - - - - - -247-Hemorrhage s - - - - - - - - - - - - - - -129-Necrosis s - - - - - - - - - - - - - - -201-M-Fibrosarc - - - - - 1= - - - - - - - - -30-M-Leukemia, monuc 2= - 2= 2= - - 2= 2= - 2= 1= 2= 1= 2= -326-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Kidneys (9) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -248-Degen, hyaline droplet s - - - - - - - - - - - - - - -251-Infarct s - - - - - - - - - - - - - - -33-Nephropathy, chronic s 2 2 3 3= 3= 4= - 3 3 3= 3 3 3 2 3130-Pigment, tubular epithelium s - - - - - - - - - - - - - - -274-Inflammation, acute s - - - - - - - - - - - - - - -213-B-Adenoma, renal tubule - - - - - - - - - - - - - - -191-M-Carcinoma, renal tubule - - - - - - - - - - - - - - -68-M-Leukemia, monuc - - - - - - - - - - - - - - -Heart (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Degen, myocyte s - - 1 - - - - - - - - - - - -116-Fibrosis s - - - - - - - - - - - 1 - - -206-Thrombus s 3= - - - - - - - - - - - - - -279-Inflammation, acute s - - - - - - - - - - - - - - -34-Inflammation, focal, chronic s 2 - - - - - - - - - 1 - - - -35-M-Leukemia, monuc - - - - - - - - - - - 1 - - -Stomach (2) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142101-Inflammation, mixed s - - - - - - - - - - - - - -100-Hyperplasia, sq epi s - - - - - - - - - - - - - -Cecum (1) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14269-N-Leukemia, monuc - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:144Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Urinary bladder (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142178-Hemorrhage s - - - - - - - - - - - - - - -193-Inflammation, mixed s - - - - - - - - - - - - - - -37-Inflammation, chronic s - - - - - - - - 1 - 1 - - - -61-B-Papilloma, transitional - - - - - - - - - - - - - - -134-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum Status > U A U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Jejunum (1) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14280-M-Adenocarcinoma - - - - - - - - - - - - - -Ileum (3) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - - - - - - - - - - -81-B-Fibroma - - - - - - - - - - - - - -207-N-Leukemia, monuc - - - - - - - - - - - - - -Colon (2) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142197-Inflammation, mixed s - - - - - - - - - - - - - -156-B-Leiomyoma - - - - - - - - - - - - - -Pancreas (2) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - - - - - - - - - - -135-M-Leukemia, monuc - - - - - - - - - - - - - -Rectum Status > U Ua U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142164-Cyst s - - - - - - - - - - - - - - -62-Degen, cytopl vacuol s - - - - - - 1 - - - - - - - -194-Necrosis s - - - - - - - - - - - - - - -108-Thrombus s - - - 1 - - - - - - 1 - 2 - -277-Hyperplasia, cort, diffuse s - - - - - - - - - - - - - - -38-Hyperplasia, medulla, focal p - - - P - - - P P - - - - P P77-B-Pheochrom, bgn - - - 1= - - 1 - - - 1 - - - -305-B-Pheochro, complex, benign - - - - - - - - - - - - - - -74-M-Pheochromocytoma, malig - - - - - - - - - - - - - - -57-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:145Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Prostate (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142143-Atrophy s - - - - - - - - - - - - - - -179-Hemorrhage s - - - - - - - - - - - - - - -109-Mineralization s - - - - - - - - - - - - - - -273-Hyperplasia s - - - - - - - - - - - - - - -88-Inflammation, acute s - - - - - - - - - - - - - - -64-Inflammation, mixed s - - - - 2 - - 3 - - - - - - -Epididymis (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142119-Atrophy s - - - - 2= - - - - 2= - - - - -242-Granuloma, sperm s - - - - - - - - - - - - - - -97-Inflammation, chronic s - - - - - - - - - - - - - - -198-M-Mesothelio, mal - - - - - 1 - - - - - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Atrophy s - - 2= 2 2 2 - - - - 2 - 2 - -182-Dilatation s - - - - - - - - - - - - - - -307-Hyperplasia s - - - - - - - - - - - - - - -136-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142147-Hemorrhage s - - - - - - - - - - - - - - -79-Histiocytosis, sinus s - - - - - - - - - - - - - - -257-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -43-N-Leukemia, monuc - - - - - - - - - 1 - 1 - - -Testes (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142152-Atrophy s - - - - - - 4= - - - - 4= - - -287-Hemorrhage s - - - - - - - - - - - - - - -105-Hyperplasia, interst cell p - - - - - - - - - - - - - P -54-B-Adenoma, interstitial 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - - 1 - - - - - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia, monuc - - - - - - - - - - - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142304-Inflammation, chronic s - - - - - - - - - - - - - - -258-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -271-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:146Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Mammary gland (6) Status > H *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Cyst p - - - - - - - - - - - - - -166-Ectasia s - - - - - - - - - - - - - -155-Hyperplasia, lobular s - - - - 1 - - - - - - - - -165-B-Fibroadenoma - - - - - - - - - - - - - -55-B-Fibroma - - - - - - - - - - - - - -266-N-Sarcoma, histiocytic - - - - - - - - - - - - - -Skin (13) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142229-Cyst, epith inc p - - - - - - - - - P= - - - - -140-Fibrosis s - - - - - - - - - - - - - - -221-Hyperkeratosis s - - - - - - - - - - - - - - -241-Necrosis s - - - - - - - - - - - - - - -237-Inflammation, mixed s - - - - - - - - - - - - - - -148-Inflammation, chronic s - - - - - - - - - - - - - - -149-B-Fibroma - - - - - - - - - - - - - - -176-B-Keratoacanthoma - - - - - - - - - - - - - - -223-B-Tumor, basal cell, benign - - - - - - - - - - - - - - -309-B-Tumor, hair follicle, ben - - - - - - - - - - - - - - -300-M-Carcinoma, sebaceous cell - - - - - - - - - - - - - - -303-M-Sarcoma, undifferentiated - - - - - - - - - - - - - - -327-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Brain (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14244-Compression s - - - - 3= - - - - - - - - - -103-Ectasia, ventricular sys s - - - - - - - - - - - - - - -226-Edema s - - - - - - - - - - - - - - -189-Gliosis s - - - - - - - - - - - - - - -183-Hemorrhage s - - - - - - - - - - - - - - -192-Mineralization s - - - - - - - - - - - - - - -45-Necrosis s - - 2= - - - - - - - - - - - -275-Inflammation, acute s - - - - - - - - - - - - - - -190-Inflammation, chronic s - - - - - - - - - - - - - - -224-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Atrophy s - - - - - - - - - - - - - - -110-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -111-Cataract p - - - - - - - - - - - - - - -90-Degen s - - - - - - - - - - - - - - -144-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -46-Mineralization, corneal str s - - - - - - - - - - - - - - -59-Mineralization, scleral s - - - - - - - 1 - - - - - - -121-Neovascularization, corneal s - - - - - - - - - - - - - - -180-Inflammation, acute s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:147Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Inflammation, mixed s - - - - - - - - - - - - - - -278-Inflammation, chronic s - - - - - - - - - - - - - - -216-M-Leukemia, monuc - - - - - - - - - - - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142209-New bone, endosteal s - - - - - - - - - - - - 2 - -212-Inflammation, acute s - - - - - - - - - - - - 2 - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14248-Degen, white matter s - - - - - - - - - - - - - - -184-Hemorrhage s - - - - - - - - - - - - - - -280-Inflammation, acute s - - - - - - - - - - - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142261-Degeneration-resp epith s - - - - - - - - - - - - - - -222-Degeneration,hyal-Resp Epith s - - - - - - - - - - - - - - -106-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -124-Metaplasia, squ-trans epith s - - - - - - - - - - - - - - -91-Inflammation, mixed s - - - - - - 2 - - - 1 - - - -49-Inflammation-nasolac duct s 3 - - - - - - - - - 3 - - 3 -107-Inflammation-resp epith s - - - - - - - - - - - - - - -186-Hyperplasia-resp epith s - - - - - - 3 - - - - - - - -217-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14298-Degeneration-olfact epith s - - - - - - - - - - - - - - -51-Degeneration,hyaline-olf epi s - - - - - 1 - - - - 3 - - - -262-Degeneration-resp epith s - - - - - - - - - - - - - - -202-Degeneration, hyal-resp epit s - - - - - - - - - - 3 - - - 2210-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -292-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -312-Metaplasia, squ-resp epith s - - - - - - - - - - - - - - -92-Inflammation, mixed s - - - - - 2 - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -112-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -218-M-Leukemia, monuc - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14252-Degeneration, hyal-olf epi s - - - - - - - - - - 3 - - - 193-Inflammation, mixed s - - - - - 2 - - - - - - - - -195-M-Carcinoma, squamous cell - - - - - - - - - - - - - - -219-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:148Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Nose/Turbinate 4 (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142313-Degeneration-olfact epith s - - - - - - - - - - - - - - -168-Degeneration, hyal-olf epi s - - - - - - - - - - 1 - - - -94-Inflammation, mixed s - - - - - - - - - - - - - - -196-N-Carcinoma, squamous cell - - - - - - - - - - - - - - 1220-M-Leukemia, monuc - - - - - - - - - - - - - - -Preputial gland (4) Status > M M M M M M M M M M M M M M MOperator > 142283-Cyst, epithelial inclusion p -66-Ectasia s 3=128-Inflammation, chronic s -67-Inflammation, mixed s 2Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M M M M M M M M M M M MOperator > 142282-Dilatation, sinusoidal s -72-N-Leukemia, monuc 1=Lymph node other (4) Status > M M M M M M M M M M M M M M MOperator > 142270-Dilatation, sinusoidal s -169-Infiltration, histiocytic s -142-Sinus plasmacytosis s -75-N-Leukemia, monuc 1=Mediastinal LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14213-Hemorrhage s - - - - - - - - - - - - - - -171-Pigmentation s - - - - - - - - - - - - - - -267-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-N-Leukemia, monuc - - - - - - - - - - - - - - -Pituitary gland (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142173-Angiectasis s - - - - - - - - - 1 - - - - -40-Cyst s - - - - - - - 2 1 - - 4= - - -172-Hemorrhage s - - - - - - - - - - - 4 - - -232-Inflammation, chronic s - - - - - - - - - - - - - - -42-Hyperplasia, pars dist, fcl s - - - - - - - - - - - - - - 139-B-Adenoma, pars distalis - - - - 1= - - - - - - - - - -138-M-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:149Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Tiss.not specifi (9) Status > M M M M M M M M M M M M M M MOperator > 142 142181-Cyst s - -276-Mammary tissue p - -286-Myodegeneration s - -281-Inflammation, mixed s - -308-B-Fibroma - -113-B-Lipoma - -200-M-Mesothelio, mal 1= -328-N-Sarcoma, histiocytic - -331-Splenic tissue, "accessory" p - P=Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M MH M M M M M M M M M M M M MOperator > 142324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M M M M M M M M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 142151-N-Leukemia, monuc 1=Bone, other (2) Status > M M M M M M M M M M M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:150Rat/F344/NGroup Sex Dosage Animal > 6837H732 6837H734 6837H736 6837H738 6837H740 6837H742 6837H7444 M 20 g/m3 Animal > 6837H731 6837H733 6837H735 6837H737 6837H739 6837H741 6837H743 6837H745Tissue/diagnosis Death code > U2 U1 U2 U2 FS FS U2 U2 FS U2 FS U2 U2 U2 U2Mesentery (2) Status > M M M M M M M M M M M M M M MOperator > 142301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:151Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Lungs (17) Status > HOperator > 142 142 142 142 1424-Alveolar histiocytosis s - 1= - - -299-Autolysis, marked p - - - - -3-Congestion s - - - - -82-Fibrosis, focal s - - - - -154-Hemorrhage s - - - - -306-Metaplasia, squam - alv epi s - - - - -233-Mineralization, uremic s - - - - -298-Cyst, squamous, keratiniz p - - - - -187-Inflammation, acute s - - - - -84-Inflammation, mixed s - - - - -214-Inflammation, granulomatous s - - - 3 -1-Hyperplasia, alv epi, focal s - - - - -5-Hyperplasia, alv epi, wdsprd s - - - - -104-B-Adenoma, bronchiolo-alv - - - - -240-N-Sarcoma, histiocytic - - - - -2-N-Leukemia,monuc - cap invol 2 - 2= - 2=131-N-Leukemia,monuc - inv invol - - - - -Trachea (6) Status >Operator > 142 142 142 142 142188-Metaplasia, squamous s - - - - -7-Inflammation, acute s - - - - -85-Inflammation, mixed s - - - - -177-Inflammation, chronic s - - - - -86-Hyperplasia, epithelial s - - - - -215-N-Leukemia, mononuclear - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 1428-Hemorrhage s - - - - -243-N-Sarcoma, histiocytic - - - - -9-N-Leukemia, monuc 1= - - - 1=Thyroid glands (7) Status >Operator > 142 142 142 142 142115-Cyst, follicular p - - - - -73-Hyperplasia, C-cell, focal s 2 - - - 1153-Hyperplasia, follicular cell s - - - - -10-B-Adenoma, C-cell - - - - -87-B-Adenoma, follicular cell - - - - -204-M-Carcinoma, C-cell - - - - -125-M-Carcinoma, follicular cell - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:152Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Parathyroid (2) Status > mHOperator > 142 142 142 142 142235-Hyperplasia, diffuse s - - - - -203-Hyperplasia, focal s - - - - -Aorta (2) Status >Operator > 142 142 142 142 142132-N-Leukemia,monuc - inv invol - - - - -325-Dilatation p - - - - -Esophagus Status > U U U U UOperator > 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 14295-Ulceration s - - - - -18-Inflammation, mixed s 2 2 - 2 -19-Inflammation, chronic s - - 1 - -16-Metaplasia, squamous s - - - - -15-Hyperplasia, epithelial s 1 2 - 1 -Salivary gland (3) Status >Operator > 142 142 142 142 142225-Degen s - - - - -236-Inflammation, acute s - - - - -20-M-Leukemia, monuc - - - - 1Mandibular LN (4) Status >Operator > 142 142 142 142 142126-Hemorrhage s - - - - -118-Sinus plasmacytosis s - - - - -60-Hyperplasia, lymphoid s - - - - -21-N-Leukemia, monuc - - - - -Liver (17) Status >Operator > 142 142 142 142 14226-Angiectasis s - - 1 - -160-Congestion s - - - - -272-Cyst s - - - - -99-Fatty Change s - - - - -158-Foci cell alter, basophilic s - - - - -123-Hdn p - - - - -22-Necrosis s - - - - -231-Thrombus s - - - - 223-Vaculoliz, cyto s - - - - -29-Inflammation, chronic s - - - 1 -27-Hyperplasia, biliary s 3 2 3 2 328-Hyperplasia, hepato, regen s - - - - -122-B-Adenoma, hepatocellular - 1= - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:153Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Liver (17) Status >Operator > 142 142 142 142 142150-M-Carcinoma, hepatocellular - - - - -246-M-Sarcoma, histiocytic - - - - -310-M-Sarcoma, undifferentiated - - - - -24-M-Leukemia, monuc 2= - 2= - 2Spleen (7) Status >Operator > 142 142 142 142 142285-Congestion s - - - - -63-Fibrosis s - - - - -247-Hemorrhage s - - - - -129-Necrosis s - - - - -201-M-Fibrosarc - - - - -30-M-Leukemia, monuc 2= - 2= - 2=326-N-Sarcoma, histiocytic - - - - -Kidneys (9) Status >Operator > 142 142 142 142 142161-Cyst s - - - - -248-Degen, hyaline droplet s - - - - -251-Infarct s - - - - -33-Nephropathy, chronic s 3 3 3 3 3130-Pigment, tubular epithelium s 4 - - - -274-Inflammation, acute s - - - - -213-B-Adenoma, renal tubule - 1= - - -191-M-Carcinoma, renal tubule - - - - -68-M-Leukemia, monuc - - - - -Heart (6) Status >Operator > 142 142 142 142 14296-Degen, myocyte s - - - - -116-Fibrosis s - - - - -206-Thrombus s 2= - - - -279-Inflammation, acute s - - - - -34-Inflammation, focal, chronic s - 1 1 1 135-M-Leukemia, monuc - - - - -Stomach (2) Status >Operator > 142 142 142 142 142101-Inflammation, mixed s - - - - -100-Hyperplasia, sq epi s - - - - -Cecum (1) Status >Operator > 142 142 142 142 14269-N-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:154Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Urinary bladder (5) Status >Operator > 142 142 142 142 142178-Hemorrhage s - - - - -193-Inflammation, mixed s - - - - -37-Inflammation, chronic s - - - - -61-B-Papilloma, transitional - - - - -134-M-Leukemia, monuc - - - - -Duodenum Status > U U U U UOperator > 142 142 142 142 142Jejunum (1) Status >Operator > 142 142 142 142 14280-M-Adenocarcinoma - - - - -Ileum (3) Status >Operator > 142 142 142 142 14278-Hyperplasia, lymphoid s - - - - -81-B-Fibroma - - - - -207-N-Leukemia, monuc - - - - -Colon (2) Status >Operator > 142 142 142 142 142197-Inflammation, mixed s - - - - -156-B-Leiomyoma - - - - -Pancreas (2) Status >Operator > 142 142 142 142 142323-M-Carcinoma, ductal cell - - - - -135-M-Leukemia, monuc - - - - -Rectum Status > U U U U UOperator > 142 142 142 142 142Adrenal glands (10) Status >Operator > 142 142 142 142 142164-Cyst s - - - - -62-Degen, cytopl vacuol s - - - - -194-Necrosis s - - - - -108-Thrombus s - - - - -277-Hyperplasia, cort, diffuse s - - - - -38-Hyperplasia, medulla, focal p - - - - -77-B-Pheochrom, bgn - 1 - - -305-B-Pheochro, complex, benign - - - - -74-M-Pheochromocytoma, malig 1= - - - -57-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:155Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Prostate (6) Status >Operator > 142 142 142 142 142143-Atrophy s - - - - -179-Hemorrhage s - - - - -109-Mineralization s - - - - -273-Hyperplasia s - - - - -88-Inflammation, acute s - - - - -64-Inflammation, mixed s - - - - -Epididymis (4) Status >Operator > 142 142 142 142 142119-Atrophy s - - - - -242-Granuloma, sperm s - - - - -97-Inflammation, chronic s - - - - -198-M-Mesothelio, mal - - - - -Seminal vesicle (4) Status >Operator > 142 142 142 142 142120-Atrophy s - 2= 2= - -182-Dilatation s - - - - -307-Hyperplasia s - - - - -136-M-Leukemia, monuc - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142147-Hemorrhage s - - - - -79-Histiocytosis, sinus s - - - - -257-N-Sarcoma, histiocytic - - - - -43-N-Leukemia, monuc - - - - -Testes (5) Status >Operator > 142 142 142 142 142152-Atrophy s - - - - -287-Hemorrhage s - - - - -105-Hyperplasia, interst cell p - - - - -54-B-Adenoma, interstitial 1= 1= 1= 1= 1=199-M-Mesothelioma, malig - - - - -Sciatic nerve (1) Status >Operator > 142 142 142 142 14283-N-Leukemia, monuc - - - - -Muscle, skeletal (3) Status >Operator > 142 142 142 142 142304-Inflammation, chronic s - - - - -258-N-Sarcoma, histiocytic - - - - -271-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:156Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Mammary gland (6) Status >Operator > 142 142 142 142 142284-Cyst p - - - - -166-Ectasia s - - - - -155-Hyperplasia, lobular s - - - 4 -165-B-Fibroadenoma - - - - -55-B-Fibroma - - - - -266-N-Sarcoma, histiocytic - - - - -Skin (13) Status >Operator > 142 142 142 142 142229-Cyst, epith inc p - - - - -140-Fibrosis s - - - - -221-Hyperkeratosis s - - - - -241-Necrosis s - - - - -237-Inflammation, mixed s - - - - -148-Inflammation, chronic s - - - - -149-B-Fibroma - - - - -176-B-Keratoacanthoma - - - - -223-B-Tumor, basal cell, benign - - - - -309-B-Tumor, hair follicle, ben - - - - -300-M-Carcinoma, sebaceous cell - - - - -303-M-Sarcoma, undifferentiated - - - - -327-N-Sarcoma, histiocytic - - - - -Brain (10) Status >Operator > 142 142 142 142 14244-Compression s - - - - -103-Ectasia, ventricular sys s - - - - -226-Edema s - - - - -189-Gliosis s - - - - -183-Hemorrhage s - - - - -192-Mineralization s - - - - -45-Necrosis s - - - - -275-Inflammation, acute s - - - - -190-Inflammation, chronic s - - - - -224-M-Astrocytoma, malignant - - - - -Eyes/optic nerve (12) Status >Operator > 142 142 142 142 14289-Atrophy s - - - - -110-Atrophy, retinal, unilat s - - - - -111-Cataract p - - - - -90-Degen s - - - - -144-Metaplasia, osseous, sclera s - - - - -46-Mineralization, corneal str s - 1 - - -59-Mineralization, scleral s - - - - 1121-Neovascularization, corneal s - - - - -180-Inflammation, acute s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:157Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Eyes/optic nerve (12) Status >Operator > 142 142 142 142 142127-Inflammation, mixed s - - - - -278-Inflammation, chronic s - - - - -216-M-Leukemia, monuc - - - - -Bone, femur (2) Status >Operator > 142 142 142 142 142209-New bone, endosteal s - - - - -212-Inflammation, acute s - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 14248-Degen, white matter s - - - - -184-Hemorrhage s - - - - -280-Inflammation, acute s - - - - -Nose/Turbinate 1 (9) Status >Operator > 142 142 142 142 142261-Degeneration-resp epith s - - - - -222-Degeneration,hyal-Resp Epith s - - 2 - -106-Metaplasia, squ-resp epith s - - - - -124-Metaplasia, squ-trans epith s - - - - -91-Inflammation, mixed s - - - - -49-Inflammation-nasolac duct s 2 - 2 3 -107-Inflammation-resp epith s - - - - -186-Hyperplasia-resp epith s - - - - -217-M-Leukemia, monuc - - - - -Nose/Turbinate 2 (11) Status >Operator > 142 142 142 142 14298-Degeneration-olfact epith s - - - - -51-Degeneration,hyaline-olf epi s - - 3 - 2262-Degeneration-resp epith s - - - - -202-Degeneration, hyal-resp epit s - - - - -210-Metaplasia, sec-olfact epith s - - - - -292-Metaplasia, squ-olfact epith s - - - - -312-Metaplasia, squ-resp epith s - - - - -92-Inflammation, mixed s 2 - - - -227-Hyperplasia-resp epith s 3 - - - -112-M-Carcinoma, squamous cell - - - - -218-M-Leukemia, monuc - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 14252-Degeneration, hyal-olf epi s - - 3 - -93-Inflammation, mixed s - 1 - - -195-M-Carcinoma, squamous cell - - - - -219-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:158Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Nose/Turbinate 4 (5) Status >Operator > 142 142 142 142 142313-Degeneration-olfact epith s - - - - -168-Degeneration, hyal-olf epi s - - - - -94-Inflammation, mixed s - 1 - - -196-N-Carcinoma, squamous cell - - - - -220-M-Leukemia, monuc - - - - -Preputial gland (4) Status > M M M M MOperator > 142283-Cyst, epithelial inclusion p -66-Ectasia s 3=128-Inflammation, chronic s 167-Inflammation, mixed s -Pancreatic LN (1) Status > M M M M MOperator > 14271-N-Leukemia, monuc 1=Iliac LN (2) Status > M M M M MOperator >282-Dilatation, sinusoidal s72-N-Leukemia, monucLymph node other (4) Status > M M M M MOperator >270-Dilatation, sinusoidal s169-Infiltration, histiocytic s142-Sinus plasmacytosis s75-N-Leukemia, monucMediastinal LN (4) Status >Operator > 142 142 142 142 14213-Hemorrhage s - - - - -171-Pigmentation s - - - - -267-N-Sarcoma, histiocytic - - - - -14-N-Leukemia, monuc - - - - 1=Pituitary gland (7) Status >Operator > 142 142 142 142 142173-Angiectasis s 2= - - - -40-Cyst s - - - - -172-Hemorrhage s - - - - -232-Inflammation, chronic s - - - - 142-Hyperplasia, pars dist, fcl s 3= - - - -39-B-Adenoma, pars distalis - - - - -138-M-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:159Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Tiss.not specifi (9) Status > M M M M MOperator >181-Cyst s276-Mammary tissue p286-Myodegeneration s281-Inflammation, mixed s308-B-Fibroma113-B-Lipoma200-M-Mesothelio, mal328-N-Sarcoma, histiocytic331-Splenic tissue, "accessory" pHarderian gland (1) Status > M M M M MOperator >114-N-Carcinoma, squamous cellThymus (2) Status > M M M M MOperator >324-Hemorrhage s137-M-Leukemia, monucMediastinum (1) Status > M M M M MOperator >139-N-Leukemia, monucTail (4) Status > M M M M MOperator >302-Cyst, epi inclusion p145-Inflammation, acute s174-Inflammation, mixed s175-Hyperplasia/hyperkeratosis sPopliteal LN (1) Status > M M M M MOperator >151-N-Leukemia, monucBone, other (2) Status > M M M M MOperator >269-Hyperostosis s228-M-Sarcoma, NOSZymbal’s gland (1) Status > M M M M MOperator >297-M-Carcinoma, squamous cellLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:160Rat/F344/NGroup Sex Dosage Animal > 6837H747 6837H7494 M 20 g/m3 Animal > 6837H746 6837H748 6837H750Tissue/diagnosis Death code > U2 FS U2 FS U2Mesentery (2) Status > M M M M MOperator >301-Inflammation, mixed s311-M-Mesothelio, malLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:09-Mar-09Research Institute Study Number:FY01013M Page:161Rat/F344/NSYMBOLS, ABBREVIATIONS, AND CODES USED IN THE "MICROSCOPIC EVALUATION OF TISSUES"*** DISTRIBUTION OF FINDINGS *** *** NEOPLASTIC FINDINGS ***" " NO PARENTHESIS = NOT SPECIFIED " B- " = PRIMARY, BENIGN NEOPLASM IN ORGAN/TISSUE" M " M = FINDING MULTI-FOCAL " M- " = PRIMARY, MALIGNANT NEOPLASM IN ORGAN/TISSUE" F " F = FINDING FOCAL " X- " = MALIGNANT NEOPLASM - TISSUE OR ORIGIN UNKNOWN" D " D = FINDING DIFFUSE " N- " = METASTATIC NEOPLASM WITHIN ORGAN/TISSUE*** GRADES FOR DEFINING SEVERITY (DEGREE) OR AMOUNT OF CHANGE *** " I- " = LOCALLY INVASIVE NEOPLASM FROM NEARBY ORGAN" NON-NEOPLASMS " " NEOPLASMS " " + " = PRESENCE OF A NEOPLASTIC FINDING IN ORGAN/TISSUE" 1 " = MINIMUM " 1 " = INCIDENTAL " +AA" = SECONDARY NEOPLASM FROM ORGAN/TISSUE INDICATED BYTWO LETTER ABBREVIATION (FOR EXAMPLE, LI=LIVER)" 2 " = MILD " 2 " = CONTRIBUTORY" +N " = MORE THAN ONE NEOPLASM OF THE SAME TYPE IN THE" 3 " = MODERATE " 3 " = FATAL SAME ORGAN, N EQUALS THE NUMBER OBSERVED" 4 " = MARKED " / " = NEOPLASM PRESENT AND RELATED TO ANIMAL DEATH*** OTHER SYMBOLS *** *** ANIMAL DEATH CODES ***" U " = ORGAN/TISSUE HISTOLOGICALLY NOT REMARKABLE " Un " = USER DEFINDED UNSCHEDULED DEATH CODES" M " = MISCELLANEOUS TISSUE " I1 " = INTERIM SACRIFICE #1" - " = FINDING NOT PRESENT OR OBSERVED " I2 " = INTERIM SACRIFICE #2" P " = FINDINGS PRESENT OR CONFIRMED (GRADING INAPPROPRIATE) " I3 " = INTERIM SACRIFICE #3" * " = TISSUE NOT AVAILABLE FOR MICROSCOPIC EXAMINATION " I4 " = INTERIM SACRIFICE #4" H " = SPECIAL HISTOLOGICAL COMMENTS ON TISSUE " I5 " = INTERIM SACRIFICE #5" A " = TISSUE NOT READABLE - AUTOLYTIC " FS " = FINAL SACRIFICE" a " = TISSUE READABLE - AUTOLYTIC " R " = RE-CUT OF TISSUE REQUESTED" m " = ONE OF PAIRED ORGANS MISSING" I " = TISSUE INADEQUATE AND UNREADABLE

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-7 Individual Animal Report of Co rrelated Gross and Mi croscopic Diagnoses

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-8 Histological Comments on TissueLovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 1Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6831E404 M 1/1 12-Jan-04 09:08 142 Mandibular LN Tissue not represented on recut6831E406 M 1/1 24-Oct-03 14:54 142 Parathyroid One of pair not represented on slide.05-Mar-09 09:57 142 Nose/Turbinate 2 SCC is of oral origin.05-Mar-09 09:57 142 Nose/Turbinate 3 SCC is of oral origin.05-Mar-09 09:58 142 Nose/Turbinate 4 SCC is of oral origin.6831E408 M 1/1 30-Oct-03 10:24 142 Bronchial (TBLN) On slide 4.12-Jan-04 09:39 142 Parathyroid One of pair not represented on slide.03-Feb-04 14:34 142 Mandibular LN Not on recut 1 (R/C 1)6831E409 M 1/1 12-Jan-04 09:47 142 Parathyroid One of pair not represented on slide.23-Oct-03 11:25 142 Mammary gland Tissue not represented on slide, missing at trim.05-Feb-04 09:24 142 Skin Tissue not represented on slide, missing at trim.6831E410 M 1/1 03-Feb-04 14:37 142 Pituitary gland Grossly noted enlargement, nothing on recut 1, minimalhyperplasia on R/C 2.6831E414 M 1/1 30-Oct-03 12:36 142 Nose/Turbinate 3 Fragmented specimen.6831E415 M 1/1 24-Oct-03 16:23 142 Trachea Very poor tinctorial properties in section. Staining fine inslide 04.6831E417 M 1/1 24-Oct-03 16:57 142 Spleen Focal region without congestion.6831E418 M 1/1 03-Feb-04 14:38 142 Parathyroid Tissue not represented on R/C 1 or 2.27-Oct-03 11:04 142 Preputial gland Slide consists of necrotic debris mixed with bacteria.6831E419 M 1/1 13-Nov-03 10:03 142 Parathyroid One of pair not represented on slide.18-Feb-04 14:19 142 Testes Both testes largely effaced by adenomas, even small one.6831E420 M 1/1 17-Nov-03 12:47 142 Colon Submucosal/lamina propria rarefaction interpreted as artifactof formalin injection at necropsy.6831E423 M 1/1 30-Oct-03 14:02 142 Parathyroid One of pair not represented on slide.6831E424 M 1/1 23-Oct-03 12:48 142 Parathyroid One of pair not represented on slide.6831E425 M 1/1 03-Feb-04 14:44 142 Larynx Incomplete specimen on original and R/C 1 and 2.Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 2Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6831E425 M 1/1 10-Feb-04 09:27 142 Pituitary gland Fragmented lesion judged adenoma based primarily on compressionin original, less so in R/C 1 and 2.6831E426 M 1/1 03-Feb-04 14:48 142 Parathyroid Tissue not represented on slide, R/C 1 or 2.6831E427 M 1/1 27-Oct-03 11:56 142 Bronchial (TBLN) Leukemia/lymphoma effacing tissues.05-Feb-04 12:31 142 Adrenal glands Lost in processing.6831E428 M 1/1 03-Feb-04 14:50 142 Mandibular LN Tissue not represented on slide or recut6831E430 M 1/1 03-Feb-04 14:53 142 Parathyroid Tissue distortion due to thyroid mass, no parathyroids on slideor on recuts.6831E431 M 1/1 12-Jan-04 11:31 142 Mandibular LN Tissue not represented on slide or recut 1.30-Oct-03 14:40 142 Brain Focally extensive gliosis and granulomatous enephalitis withthrombosis, presumed infarct.6831E434 M 1/1 23-Oct-03 17:05 142 Sciatic nerve Scattered histiocyte like cells distributed through otherwiseunremarkable nerve.6831E435 M 1/1 27-Oct-03 14:02 142 Parathyroid One of pair not represented on slide.6831E439 M 1/1 30-Oct-03 15:37 142 Testes Unilateral03-Feb-04 14:55 142 Spinal cord Only 1 section available for evaluation.6831E440 M 1/1 03-Feb-04 14:57 142 Pituitary gland Pars distalis only on original and recut.6831E441 M 1/1 24-Oct-03 09:24 142 Mediastinal LN No tissue found at embedding.6831E442 M 1/1 27-Oct-03 17:00 142 Parathyroid One of pair not represented on slide.6831E443 M 1/1 27-Oct-03 17:24 142 Colon Rarefaction of l.p. and submucosa interpreted as artifact offormalin injection.6831E447 M 1/1 24-Oct-03 10:53 142 Parathyroid One of pair not represented on slide.6831E448 M 1/1 28-Oct-03 09:00 142 Pituitary gland Focal hemorrhage interpreted as artifact.6831E449 M 1/1 28-Oct-03 09:02 142 Parathyroid One of pair not represented on slide.6831E450 M 1/1 10-Feb-04 10:21 142 Pituitary gland Tissue not represented on slide, lymphoid tissue only present.6833F506 M 2/1 05-Feb-04 12:36 142 Parathyroid One of pair not represented on slide.6833F507 M 2/1 31-Dec-03 10:56 142 Parathyroid One of pair not represented on slide.6833F509 M 2/1 13-Jan-04 07:49 142 Thyroid glands Missing at trimLovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 3Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6833F509 M 2/1 05-Feb-04 12:38 142 Parathyroid Missing at trim05-Feb-04 12:38 142 Esophagus Missing at trim13-Jan-04 07:49 142 Larynx Missing at trim03-Feb-04 15:01 142 Mammary gland Tissue not represented on slide or recut.6833F510 M 2/1 31-Dec-03 11:07 142 Parathyroid One of pair not represented on slide.05-Mar-09 09:59 142 Nose/Turbinate 4 SCC of oral origin6833F512 M 2/1 13-Jan-04 09:02 142 Eyes/optic nerve One eye presumed missing at trim6833F515 M 2/1 13-Jan-04 09:57 142 Iliac LN Not recorded as trimmed. Gross enlargement presumed due toleukemia/lymphoma.6833F517 M 2/1 05-Jan-04 09:40 142 Urinary bladder Bladder missing at trim.05-Jan-04 09:43 142 Prostate Missing at trim.05-Jan-04 09:44 142 Seminal vesicle Missing at trim.6833F524 M 2/1 03-Feb-04 15:06 142 Bronchial (TBLN) Tissue not represented on slide or recut6833F528 M 2/1 04-Feb-04 12:16 142 Mammary gland Tissue not represented on slide or recut6833F531 M 2/1 08-Jan-04 08:58 142 Parathyroid One of pair not represented on slide.6833F537 M 2/1 03-Feb-04 15:14 142 Mammary gland Tissue not represented on slide or recut6833F539 M 2/1 05-Mar-09 10:01 142 Nose/Turbinate 3 SCC of oral origin.05-Mar-09 10:00 142 Nose/Turbinate 4 SCC oral origin.04-Feb-04 11:06 142 Mediastinal LN Tissue not represented on slide or recut6833F540 M 2/1 05-Feb-04 12:31 142 Mammary gland Missing at trim.13-Jan-04 12:15 142 Mediastinal LN Tissue trimmed as mediastinal node is pancreas.6833F541 M 2/1 06-Jan-04 13:09 142 Lungs Prominent deposition of birefringent pigment interpreted asacid hematin, often within macrophages.04-Feb-04 11:08 142 Mandibular LN Tissue not represented on slide or recut04-Feb-04 11:07 142 Mediastinal LN Tissue not represented on slide or recut6833F542 M 2/1 19-Jan-04 13:11 142 Trachea Extensive artifactual epithelial loss.Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 4Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6833F543 M 2/1 06-Jan-04 15:36 142 Parathyroid One of pair not represented on slide.6833F545 M 2/1 13-Jan-04 12:38 142 Pituitary gland Fragmented6833F550 M 2/1 19-Jan-04 13:33 142 Parathyroid Distortion due to bilateral thyroid C-cell adenomas.6835G612 M 3/1 08-Jan-04 11:01 142 Parathyroid Tissue not represented on slide.6835G619 M 3/1 08-Jan-04 11:29 142 Parathyroid One of pair missing6835G620 M 3/1 08-Jan-04 11:45 142 Parathyroid One of pair not represented on slide.6835G622 M 3/1 14-Jan-04 08:18 142 Urinary bladder Missing at trim14-Jan-04 08:21 142 Prostate Missing at trim13-Feb-04 08:43 142 Seminal vesicle Missing at trim, small size described grossly presumed due toatrophy.6835G623 M 3/1 04-Feb-04 11:20 142 Trachea Lost in processing, evaluated on slide 4.6835G629 M 3/1 04-Feb-04 11:21 142 Mediastinal LN Tissue not represented on slide or recut6835G635 M 3/1 04-Feb-04 11:24 142 Bronchial (TBLN) Tissue not represented on slide or recut04-Feb-04 11:26 142 Mammary gland Tissue not represented on slide or recut6835G637 M 3/1 04-Feb-04 11:29 142 Mammary gland Tissue not represented on slide or recut6835G641 M 3/1 04-Feb-04 11:31 142 Lungs Grossly described nodule not present on slide or recut6835G642 M 3/1 09-Jan-04 10:39 142 Parathyroid One of pair not represented on slide.6835G643 M 3/1 04-Feb-04 11:34 142 Bronchial (TBLN) Tissue not represented on slide or recut6837H703 M 4/1 07-Jan-04 12:18 142 Tiss.not specifi Malignant mesothelioma widespread on mesothelial surfaces6837H705 M 4/1 29-Oct-03 10:55 142 Spinal cord Focus of hematopoietic cells interpreted as artifact (from bonemarrow).6837H708 M 4/1 29-Oct-03 11:29 142 Parathyroid One of pair not represented on slide.6837H710 M 4/1 20-Nov-03 10:18 142 Parathyroid Thyroid mass interferes, no recut.6837H713 M 4/1 29-Oct-03 12:00 142 Testes Unilateral6837H714 M 4/1 29-Oct-03 16:03 142 Pituitary gland Hemorrhage within cystic spaces in proliferative area.6837H715 M 4/1 20-Nov-03 15:13 142 Pituitary gland Slide 22 fragment of pituitary, slide 23 good section.Lovelace Respiratory Histological Comments on Tissues Printed:09-Mar-09Research Institute Study Number:FY01013M Page: 5Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6837H716 M 4/1 04-Feb-04 11:40 142 Mandibular LN Tissue not represented on slide or recut6837H717 M 4/1 29-Oct-03 16:32 142 Parathyroid One of pair not represented on slide.6837H718 M 4/1 29-Oct-03 17:12 142 Parathyroid One of pair not represented on slide.29-Oct-03 17:24 142 Jejunum No recut based on autolysis in other GI sections.29-Oct-03 17:31 142 Testes Unilateral6837H719 M 4/1 04-Feb-04 11:42 142 Mammary gland Tissue not represented on slide or recut6837H720 M 4/1 04-Feb-04 11:44 142 Parathyroid Tissue not represented on slide recut. Distorted by thyroidmass.21-Nov-03 09:59 142 Eyes/optic nerve One eye missing at trim6837H722 M 4/1 30-Oct-03 16:12 142 Parathyroid One of pair not represented on slide.6837H724 M 4/1 30-Oct-03 16:33 142 Parathyroid One of pair not represented on slide.6837H729 M 4/1 04-Feb-04 12:00 142 Parathyroid Tissue not represented on slide or recut 1, small amount onrecut 2.12-Jan-04 12:56 142 Spinal cord Scattered spheroid-like bodies.6837H730 M 4/1 05-Mar-09 10:02 142 Nose/Turbinate 3 Carcinoma is likely of oral origin.05-Mar-09 10:02 142 Nose/Turbinate 4 Carcinoma likely of oral origin.6837H732 M 4/1 04-Feb-04 12:03 142 Mandibular LN Tissue not represented on slide or recut20-Feb-04 10:02 142 Thymus Gross findings correlated to autolysis (widespread autolysisnoted in lungs only due to software constraints).6837H735 M 4/1 07-Nov-03 12:16 142 Thyroid glands Follicular carcinoma arising within follicular adenoma.12-Jan-04 12:58 142 Parathyroid Parathyroids not present on slide, distortion due to thyroidlesion.07-Nov-03 14:25 142 Mammary gland Mammary tissue on slide 66837H745 M 4/1 04-Feb-04 12:15 142 Mammary gland Tissue not represented on slide or recut05-Mar-09 10:03 142 Nose/Turbinate 4 SCC likely of oral origin.6837H748 M 4/1 07-Jan-04 14:08 142 Parathyroid One of pair not represented on slide.6837H749 M 4/1 11-Nov-03 15:10 142 Lungs Multifocal granulomatous inflammation often associated withforeign material (interpreted as plant material).

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-9 Summary of Missing TissuesLovelace Respiratory Summary Table of Missing Tissues Printed:14-Jun-04Research Institute Study number:FY01013M Page: 1Rat/F344/NTissue AnimalsTrachea 6833F536Bronchial (TBLN) 6831E450 6833F504 6833F524 6835G635 6835G643 6837H703 6837H704 6837H736Thyroid glands 6831E412* 6831E428* 6831E432* 6831E437* 6833F509 6833F537* 6837H709*Parathyroid 6831E404* 6831E406* 6831E408* 6831E409* 6831E412* 6831E413* 6831E418 6831E423* 6831E424* 6831E426 6831E427*Parathyroid 6831E428* 6831E430 6831E432* 6831E433* 6831E435* 6831E437* 6831E441* 6831E442* 6831E443 6831E447* 6831E448Parathyroid 6831E449* 6833F506* 6833F507* 6833F509 6833F510* 6833F512* 6833F514* 6833F515* 6833F518* 6833F528* 6833F531*Parathyroid 6833F533* 6833F534* 6833F537* 6833F538* 6833F541* 6833F543* 6833F550 6835G608* 6835G612* 6835G619* 6835G620*Parathyroid 6835G622* 6835G623* 6835G626* 6835G632* 6835G640* 6835G642* 6835G643* 6835G644* 6837H706 6837H708* 6837H710Parathyroid 6837H717* 6837H718* 6837H720 6837H722* 6837H723* 6837H724* 6837H729* 6837H731* 6837H735 6837H736* 6837H742*Parathyroid 6837H748*Esophagus 6833F509Larynx 6833F509Mandibular LN 6831E404 6831E408 6831E417 6831E421 6831E425 6831E428 6831E431 6831E432 6831E439 6831E445 6833F507*Mandibular LN 6833F520 6833F541 6837H716 6837H732Urinary bladder 6833F517 6835G622Jejunum 6837H718Adrenal glands 6831E427Prostate 6833F517 6835G622Seminal vesicle 6833F517 6835G622Mammary gland 6831E401 6831E402 6831E407 6831E409 6831E410 6831E412 6831E413 6831E421 6831E424 6831E429 6831E430Mammary gland 6831E432 6831E437 6831E449 6833F509 6833F528 6833F537* 6833F540 6835G635 6835G637 6837H713 6837H719Mammary gland 6837H745Skin 6831E409Eyes/optic nerve 6833F512* 6837H720*Iliac LN 6833F515Mediastinal LN 6831E441 6833F539 6833F540 6833F541 6833F546 6835G629Pituitary gland 6831E450* Only one of the pair is missing

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

M-10 Lesion Incidence Summary with K-S (comparison > control)Lovelace Respiratory Lesion incidence summary with K-S (comparison > control) Printed:30-Jun-04Research Institute Study Number:FY01013M Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- M a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 50 50 50Cyst 0 1 2 0Degeneration, hyaline droplet 0 1 0 0Infarct 0 0 2 0Nephropathy, chronic 44 47 -50 -46Pigment accumulation, tubular epithelium 3 3 1 3Inflamation, acute 0 1 2 0Note: Entries flagged with a - (minus) are significantly higher than control at the 0.05 level using the Kolmogorov-Smirnovone-tailed test.All Graded Diagnoses; Phases: All; Death types: All; Date of death range: 17-Dec-01 To 30-May-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

N-1 APPENDIX N

NEOPLASTIC AND NON-NEOPLASTIC LESIONS AND

GROSS NECROPYS OBSERVATIONS IN FEMALE RATS

N-1 Gross Necropsy Observations

N-2 Lesion Incidence by Animal Number for Microscopic Observations

N-3 Incidence Summary (with percentages) of Microscopic Observations

N-4 Tabulated Incidence Su mmary of Non-neoplastic Lesions

N-5 Lesion Incidence Summar y with Average Severity Grades

N-6 Raw Data

N-7 Individual Animal Report of Co rrelated Gross and Mi croscopic Diagnoses

N-8 Histological Comments on Tissue

N-9 Summary of Missing Tissues

N-10 Lesion Incidence Summary with K-S (comparison > control)

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-1 Gross Necropsy ObservationsLovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013F Page: 1All SacrificesRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Females --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------Adrenal glandsDiscolored ..................... 1 2 0 1Enlarged ....................... 0 1 1 0Mass ........................... 0 0 1 0BrainDeformity ...................... 2 8 9 8Discolored ..................... 1 2 1 0DuodenumDiscolored ..................... 0 0 1 0EsophagusDiscolored ..................... 0 0 1 0Eyes/optic nerveCrust .......................... 3 0 3 3Small .......................... 0 0 1 1Discolored ..................... 1 3 1 5IleumDiscolored ..................... 0 0 1 1JejunumDiscolored ..................... 0 0 1 0KidneysCyst ........................... 2 0 0 3Discolored ..................... 1 1 1 1LiverDeformity ...................... 1 0 0 0Enlarged ....................... 0 0 0 1Hernia ......................... 0 5 0 3Mass ........................... 2 1 0 1Nodule ......................... 1 0 2 0Small .......................... 1 0 0 0Thick .......................... 0 2 1 2Discolored ..................... 18 14 8 9PancreasSmall .......................... 0 0 0 1Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013F Page: 2All SacrificesRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Females --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------Pituitary glandCyst ........................... 1 1 0 1Enlarged ....................... 4 3 6 4Focus .......................... 0 0 0 1Mass ........................... 1 5 4 4Nodule ......................... 1 2 0 1Discolored ..................... 18 7 15 4Salivary glandDiscolored ..................... 0 1 0 0SkinCrust .......................... 0 0 1 0Mass ........................... 0 2 0 0SpleenAdhesion ....................... 1 0 0 0Discolored ..................... 3 2 1 2Enlarged ....................... 23 11 11 19Mass ........................... 1 1 0 0Nodule ......................... 1 1 0 0Small .......................... 1 1 1 0StomachMass ........................... 0 0 0 1Thyroid glandsCyst ........................... 1 0 0 0Enlarged ....................... 2 1 2 3Mass ........................... 0 0 1 0Nodule ......................... 0 1 0 0Discolored ..................... 0 0 0 1Urinary bladderFluid .......................... 1 0 0 0Discolored ..................... 1 0 0 0LungsDiscolored ..................... 15 5 8 14Mass ........................... 0 0 0 1Nodule ......................... 2 1 2 1TailAmputation ..................... 0 1 0 0Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013F Page: 3All SacrificesRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Females --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------TailCrust .......................... 0 0 1 1Bronchial (TBLN)Enlarged ....................... 6 1 3 1Discolored ..................... 1 1 0 0Mandibular LNEnlarged ....................... 4 3 3 2Mediastinal LNEnlarged ....................... 8 3 4 4Discolored ..................... 1 0 0 1Mesenteric LNEnlarged ....................... 7 1 1 1Discolored ..................... 1 0 0 0UterusCyst ........................... 1 0 1 0Dilatation ..................... 0 1 1 1Enlarged ....................... 2 3 2 2Focus .......................... 0 0 0 1Intussusception ................ 0 0 0 1Mass ........................... 2 8 9 8Nodule ......................... 1 1 1 0Prolapse ....................... 2 1 0 0Thick .......................... 0 0 1 0Discolored ..................... 1 3 3 2OvariesCyst ........................... 1 0 2 1Enlarged ....................... 0 2 0 1Mass ........................... 0 1 0 0Small .......................... 0 0 0 2Discolored ..................... 1 0 2 1Mammary glandMass ........................... 2 5 3 5Discolored ..................... 0 0 1 0CervixEnlarged ....................... 1 5 3 2Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013F Page: 4All SacrificesRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Females --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------CervixMass ........................... 1 0 0 1Thick .......................... 1 1 0 0MesenteryNodule ......................... 1 0 0 0MediastinumMass ........................... 1 0 0 0Lymph node otherEnlarged ....................... 5 2 4 2Bone, vertebraeMass ........................... 1 0 0 0Pancreatic LNEnlarged ....................... 2 2 2 1Iliac LNEnlarged ....................... 2 2 2 0Discolored ..................... 0 0 1 0Zymbal's glandMass ........................... 1 0 0 0Clitoral glandMass ........................... 1 1 3 0Popliteal LNEnlarged ....................... 1 1 0 0VaginaMass ........................... 0 1 0 0Harderian glandDiscolored ..................... 0 0 1 0Tiss.not specifiMass ........................... 0 0 1 0Malocclusion ................... 0 0 1 0Bone, otherDeformity ...................... 0 0 1 0Lovelace Respiratory Incidence Summary Report for Gross Necropsy Observations by Animal Printed: 22-Aug-08Research Institute Study number: FY01013F Page: 5All SacrificesRat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic+___________________________________________________________________________________________________________________________________-- Females --Group: 1 2 3 4Number in group: 50 50 50 50-----------------------------------------------------------------------------------------------------------------------------------CavitiesFluid .......................... 0 0 1 1Bone, ribMass ........................... 0 0 0 1

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 1

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Adrenal glands

Discolored 6832E487 6834F552 6838H786

- 6834F599 Enlarged 6834F576 6836G668

Mass 6836G693

Brain Deformity 6832E473 6834F563 6836G654 6838H754

- 6832E488 6834F564 6836G655 6838H762

- 6834F565 6836G665 6838H769

- 6834F569 6836G666 6838H783

- 6834F576 6836G669 6838H787

- 6834F579 6836G679 6838H790

- 6834F584 6836G687 6838H799

- 6834F593 6836G692 6838H800

- 6836G695

Discolored 6832E474 6834F564 6836G695

- 6834F584

Duodenum

Discolored 6836G671

Esophagus

Discolored 6836G653

Eyes/optic nerve

Crust 6832E468 6836G654 6838H755

- 6832E478 6836G655 6838H762

- 6832E489 6836G689 6838H776

Small 6836G666 6838H782

Discolored 6832E476 6834F555 6836G699 6838H767

- 6834F572 6838H777

- 6834F585 6838H785

- 6838H786

- 6838H798

Ileum

Discolored 6836G671 6838H772

Jejunum

Discolored 6836G671

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 2

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Kidneys

Cyst 6832E472 6838H755

- 6832E472 6838H757

- 6838H762

Discolored 6832E474 6834F599 6836G660 6838H787

Liver Deformity 6832E468

Enlarged 6838H785

Hernia 6834F566 6838H756

- 6834F575 6838H771

- 6834F577 6838H786

- 6834F578

- 6834F596

Mass 6832E484 6834F584 6838H751

- 6832E497

Nodule 6832E453 6836G653

- 6836G660

Small 6832E464

Thick 6834F576 6836G682 6838H768

- 6834F584 6838H800

Discolored 6832E452 6834F551 6836G655 6838H758

- 6832E454 6834F552 6836G659 6838H762

- 6832E457 6834F553 6836G660 6838H763

- 6832E462 6834F556 6836G676 6838H772

- 6832E464 6834F558 6836G680 6838H775

- 6832E469 6834F562 6836G682 6838H783

- 6832E470 6834F566 6836G685 6838H787

- 6832E474 6834F571 6836G687 6838H791

- 6832E476 6834F579 6838H797

- 6832E477 6834F581

- 6832E480 6834F589

- 6832E485 6834F589

- 6832E490 6834F591

- 6832E491 6834F599

- 6832E493

- 6832E496

- 6832E499

- 6832E500

Pancreas

Small 6838H785

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 3

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Pituitary gland

Cyst 6832E496 6834F563 6838H759 Enlarged 6832E452 6834F577 6836G654 6838H762

- 6832E474 6834F579 6836G655 6838H769

- 6832E488 6834F593 6836G669 6838H790

- 6832E493 6836G678 6838H799

- 6836G692

- 6836G695

Focus 6838H757

Mass 6832E473 6834F564 6836G665 6838H754

- 6834F565 6836G666 6838H783

- 6834F569 6836G679 6838H787

- 6834F576 6836G687 6838H800

- 6834F584

Nodule 6832E482 6834F561 6838H779

- 6834F594

Discolored 6832E451 6834F558 6836G652 6838H768

- 6832E454 6834F573 6836G653 6838H770

- 6832E455 6834F580 6836G657 6838H788

- 6832E456 6834F582 6836G663 6838H791

- 6832E457 6834F585 6836G664

- 6832E458 6834F596 6836G672

- 6832E460 6834F600 6836G675

- 6832E461 6836G676

- 6832E462 6836G680

- 6832E463 6836G681

- 6832E471 6836G683

- 6832E475 6836G684

- 6832E479 6836G685

- 6832E483 6836G689

- 6832E484 6836G694

- 6832E489

- 6832E496

- 6832E497

Salivary gland

Discolored 6834F562

Skin

Crust 6836G666

Mass 6834F551

- 6834F576

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 4

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Spleen

Adhesion 6832E466

Discolored 6832E456 6834F572 6836G660 6838H772

- 6832E479 6834F576 6838H778

- 6832E490 Enlarged 6832E453 6834F552 6836G659 6838H751

- 6832E454 6834F556 6836G660 6838H752

- 6832E456 6834F567 6836G675 6838H757

- 6832E457 6834F568 6836G676 6838H761

- 6832E459 6834F571 6836G680 6838H764

- 6832E463 6834F572 6836G682 6838H766

- 6832E464 6834F576 6836G685 6838H767

- 6832E466 6834F579 6836G686 6838H770

- 6832E469 6834F581 6836G687 6838H774

- 6832E470 6834F589 6836G688 6838H775

- 6832E471 6834F599 6836G698 6838H778

- 6832E474 6838H780

- 6832E476 6838H785

- 6832E477 6838H787

- 6832E479 6838H791

- 6832E482 6838H792

- 6832E484 6838H793

- 6832E485 6838H797

- 6832E487 6838H800

- 6832E491

- 6832E493

- 6832E496

- 6832E499

Mass 6832E470 6834F568

Nodule 6832E453 6834F577

Small 6832E483 6834F575 6836G700

Stomach

Mass 6838H753

Thyroid glands

Cyst 6832E479 Enlarged 6832E462 6834F570 6836G686 6838H753

- 6832E482 6836G694 6838H786

- 6838H791

Mass 6836G653

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 5

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Thyroid glands

Nodule 6834F557

Discolored 6838H776

Urinary bladder

Fluid 6832E468

Discolored 6832E491

Lungs

Discolored 6832E459 6834F566 6836G660 6838H751

- 6832E466 6834F568 6836G665 6838H753

- 6832E469 6834F576 6836G667 6838H756

- 6832E470 6834F586 6836G673 6838H766

- 6832E470 6834F599 6836G676 6838H771

- 6832E471 6836G677 6838H772

- 6832E473 6836G682 6838H774

- 6832E474 6836G693 6838H776

- 6832E476 6838H785

- 6832E477 6838H785

- 6832E480 6838H786

- 6832E482 6838H791

- 6832E485 6838H795

- 6832E491 6838H797

- 6832E494

Mass 6838H753

Nodule 6832E453 6834F592 6836G686 6838H753

- 6832E490 6836G692

Tail

Amputation 6834F559

Crust 6836G689 6838H759

Bronchial (TBLN)

Enlarged 6832E453 6834F568 6836G682 6838H752

- 6832E459 6836G686

- 6832E470 6836G698

- 6832E485

- 6832E493

- 6832E496

Discolored 6832E473 6834F562

Mandibular LN

Enlarged 6832E459 6834F568 6836G666 6838H752

- 6832E487 6834F569 6836G672 6838H761

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 6

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Mandibular LN

Enlarged 6832E491 6834F596 6836G682

- 6832E496

Mediastinal LN

Enlarged 6832E453 6834F568 6836G660 6838H752

- 6832E459 6834F572 6836G682 6838H753

- 6832E466 6834F577 6836G688 6838H770

- 6832E487 6836G698 6838H778

- 6832E490

- 6832E491

- 6832E493

- 6832E496

Discolored 6832E473 6838H792

Mesenteric LN Enlarged 6832E453 6834F568 6836G682 6838H752

- 6832E459

- 6832E485

- 6832E487

- 6832E491

- 6832E493

- 6832E496

Discolored 6832E485

Uterus

Cyst 6832E495 6836G674

Dilatation 6834F595 6836G683 6838H753

Enlarged 6832E456 6834F557 6836G673 6838H763

- 6832E485 6834F562 6836G676 6838H798

- 6834F589

Focus 6838H757

Intussusception 6838H769

Mass 6832E453 6834F556 6836G651 6838H752

- 6832E460 6834F561 6836G661 6838H753

- 6834F562 6836G666 6838H767

- 6834F563 6836G667 6838H770

- 6834F566 6836G670 6838H772

- 6834F573 6836G671 6838H780

- 6834F576 6836G683 6838H786

- 6834F582 6836G690 6838H791

- 6836G700

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 7

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Uterus

Nodule 6832E489 6834F594 6836G659

Prolapse 6832E455 6834F590

- 6832E481

Thick 6836G669

Discolored 6832E480 6834F552 6836G660 6838H770

- 6834F562 6836G665 6838H795

- 6834F565 6836G669

Ovaries

Cyst 6832E495 6836G661 6838H759

- 6836G675 Enlarged 6834F562 6838H752

- 6834F568

Mass 6834F596

Small 6838H770

- 6838H772

Discolored 6832E473 6836G657 6838H795

- 6836G665

Mammary gland

Mass 6832E459 6834F563 6836G672 6838H756

- 6832E499 6834F565 6836G687 6838H761

- 6834F565 6836G697 6838H773

- 6834F567 6838H782

- 6834F571 6838H798

Discolored 6836G679

Cervix Enlarged 6832E489 6834F569 6836G657 6838H771

- 6834F570 6836G668 6838H799

- 6834F574 6836G673

- 6834F575

- 6834F576

Mass 6832E454 6838H769

Thick 6832E473 6834F595

Lymph node other

Enlarged 6832E491 6834F568 6836G653 6838H752

- 6832E491 6834F568 6836G680 6838H752

- 6832E491 6836G682

- 6832E494 6836G682

- 6832E496

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 8

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Mesentery

Nodule 6832E477

Mediastinum

Mass 6832E490

Bone, vertebrae

Mass 6832E491

Pancreatic LN Enlarged 6832E491 6834F572 6836G682 6838H752

- 6832E496 6834F577 6836G688

Iliac LN

Enlarged 6832E491 6834F568 6836G682

- 6832E496 6834F577 6836G688

Discolored 6836G682

Zymbal's gland

Mass 6832E492

Clitoral gland

Mass 6832E494 6834F594 6836G669

- 6836G678

- 6836G687

Popliteal LN

Enlarged 6832E496 6834F568

Vagina

Mass 6834F561

Harderian gland

Discolored 6836G683

Tiss.not specifi

Mass 6836G684

Malocclusion 6836G699

Bone, other

Deformity 6836G688

# Lovelace Respiratory Gross Necropsy Observations Incidence Report by Animal Number Printed: 20-May-05

Research Institute Study number: FY01013F Page: 9

All Sacrifices

Rat/F344/N Study start date: 30-May-01 Inhalation/whole-bdy/Chronic

+___________________________________________________________________________________________________________________________________ Controls from group(s): 1 -- F e m a l e s --

Group: Ctls 2 3 4

Number in group: 50 50 50 50

----------------------------------------------------------------------------------------------------------------------------------- Cavities

Fluid 6836G693 6838H757

Bone, rib

Mass 6838H761

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-2 Lesion Incidence by Animal Number for Microscopic Observations

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Proliferative (includi ng Neoplastic) LesionsLovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Hyperplasia, alveolar epithelial, focal 6832E459 6834F592 6836G700 6838H7726832E4606832E4626832E4696832E4766832E4876832E494N-Carcinoma, metastatic 6838H753N-Leukemia, mononuclear - capillary involvement 6832E454 6834F551 6836G652 6838H7576832E456 6834F552 6836G655 6838H7616832E459 6834F556 6836G659 6838H7646832E462 6834F568 6836G675 6838H7666832E463 6834F571 6836G676 6838H7676832E464 6834F572 6836G678 6838H7686832E466 6834F574 6836G680 6838H7706832E469 6834F576 6836G685 6838H7726832E471 6834F579 6836G687 6838H7746832E474 6834F581 6836G688 6838H7756832E476 6834F584 6836G694 6838H7786832E477 6834F585 6836G698 6838H7806832E479 6834F589 6838H7856832E480 6834F591 6838H7876832E482 6834F599 6838H7916832E484 6834F600 6838H7926832E485 6838H7936832E487 6838H7976832E491 6838H8006832E4936832E4966832E499N-Leukemia, mononuclear - invasive involvement 6832E453 6834F577 6836G682 6838H7526832E470 6836G6866832E490N-Sarcoma, histiocytic 6836G660 6838H751All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Trachea ........................................Number examined: 50 50 50 50Hyperplasia 6836G653N-Leukemia, mononuclear 6834F577 6836G682Bronchial (TBLN) ...............................Number examined: 48 19 20 48N-Leukemia, mononuclear 6832E453 6834F568 6836G676 6838H7526832E459 6834F571 6836G678 6838H7856832E470 6834F599 6836G6826832E476 6836G6866832E485 6836G6876832E490 6836G6886832E491 6836G6986832E4936832E496Thyroid glands .................................Number examined: 50 22 22 50Hyperplasia, C-cell, focal 6832E455 6834F570 6836G685 6838H7616832E460 6834F572 6838H7676832E461 6834F589 6838H7736834F594 6838H7766838H7816838H788Hyperplasia, follicular cell 6832E479B-Adenoma, C-cell 6832E482 6834F557 6836G659 6838H7596834F570 6836G686 6838H7916836G694B-Adenoma, follicular cell 6838H7706838H791M-Carcinoma, C-cell 6832E462M-Carcinoma, follicular cell 6832E454 6836G653M-Leukemia, mononuclear 6838H770All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Parathyroid ....................................Number examined: 47 20 20 50Hyperplasia, focal 6832E497B-Adenoma 6832E494Aorta ..........................................Number examined: 49 20 20 50N-Leukemia, mononuclear - invasive involvement 6832E490Esophagus ......................................Number examined: 50 20 20 50Larynx .........................................Number examined: 50 50 50 50Hyperplasia 6832E451 6834F553 6836G655 6838H7526832E452 6834F560 6836G656 6838H7546832E453 6834F563 6836G670 6838H7636832E455 6834F567 6836G672 6838H7656832E457 6834F571 6836G676 6838H7686832E462 6834F572 6838H7706832E464 6834F582 6838H7716832E470 6834F585 6838H7726832E471 6834F593 6838H7756832E473 6834F595 6838H7766832E476 6838H7916832E479 6838H7926832E480 6838H7966832E482 6838H7976832E488 6838H8006832E4896832E500Salivary gland .................................Number examined: 50 20 20 50M-Leukemia, mononuclear 6832E484 6838H7646832E485Mandibular LN ..................................Number examined: 44 19 21 47N-Leukemia, mononuclear 6832E459 6834F552 6836G659 6838H7526832E464 6834F568 6836G678 6838H7616832E470 6834F571 6836G682 6838H7706832E471 6834F572 6836G685 6838H7726832E476 6834F589 6836G688 6838H7856832E477 6834F5966832E4846832E487All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mandibular LN ..................................Number examined: 44 19 21 476832E4906832E4916832E4936832E496Liver ..........................................Number examined: 50 28 22 50Hyperplasia, biliary 6832E451 6834F551 6836G653 6838H7546832E453 6834F553 6836G655 6838H7556832E454 6834F556 6836G659 6838H7566832E455 6834F565 6836G664 6838H7576832E456 6834F566 6836G665 6838H7596832E458 6834F571 6836G676 6838H7606832E460 6834F576 6836G678 6838H7626832E463 6834F578 6836G679 6838H7656832E466 6834F579 6836G680 6838H7686832E467 6834F581 6836G682 6838H7706832E468 6834F582 6836G683 6838H7716832E470 6834F589 6836G685 6838H7746832E471 6834F593 6836G687 6838H7756832E472 6834F594 6836G688 6838H7766832E475 6834F595 6836G693 6838H7796832E476 6834F599 6836G695 6838H7826832E478 6836G698 6838H7836832E479 6838H7876832E480 6838H7886832E483 6838H7906832E484 6838H7926832E485 6838H7936832E486 6838H7966832E487 6838H8006832E4886832E4896832E4906832E4916832E4926832E4936832E4946832E4966832E4986832E4996832E500All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 28 22 50Hyperplasia, hepatocellular, regenerative 6832E484 6834F584 6836G659 6838H772B-Adenoma, hepatocellular 6832E497M-Sarcoma. histiocytic 6836G660 6838H751M-Leukemia, mononuclear 6832E452 6834F551 6836G655 6838H7526832E453 6834F552 6836G659 6838H7536832E454 6834F553 6836G676 6838H7576832E456 6834F556 6836G678 6838H7596832E457 6834F567 6836G680 6838H7606832E459 6834F568 6836G682 6838H7616832E462 6834F571 6836G685 6838H7646832E463 6834F572 6836G687 6838H7666832E464 6834F576 6836G688 6838H7676832E466 6834F577 6836G698 6838H7686832E468 6834F579 6838H7706832E469 6834F581 6838H7726832E470 6834F584 6838H7746832E471 6834F589 6838H7756832E474 6834F591 6838H7786832E476 6834F596 6838H7806832E477 6834F599 6838H7856832E479 6838H7876832E482 6838H7916832E485 6838H7926832E487 6838H7936832E490 6838H7976832E491 6838H8006832E4936832E4966832E4976832E499Spleen .........................................Number examined: 50 22 24 50M-Leukemia, mononuclear 6832E453 6834F552 6836G659 6838H7526832E454 6834F556 6836G675 6838H7536832E456 6834F567 6836G676 6838H7576832E457 6834F568 6836G678 6838H7596832E459 6834F571 6836G680 6838H7606832E462 6834F572 6836G682 6838H7616832E463 6834F576 6836G685 6838H7646832E464 6834F577 6836G686 6838H7666832E466 6834F579 6836G687 6838H767All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spleen .........................................Number examined: 50 22 24 506832E468 6834F581 6836G688 6838H7686832E469 6834F589 6836G698 6838H7706832E470 6834F599 6838H7726832E471 6838H7746832E474 6838H7756832E476 6838H7786832E477 6838H7806832E479 6838H7856832E482 6838H7876832E484 6838H7916832E485 6838H7926832E487 6838H7936832E490 6838H7976832E491 6838H8006832E4936832E4966832E4976832E499N-Sarcoma, histiocytic 6836G660Kidneys ........................................Number examined: 50 20 21 50M-Leukemia, mononuclear 6832E491 6834F568 6836G682 6838H7526838H766N-Sarcoma, histiocytic 6836G660Heart ..........................................Number examined: 50 20 20 50M-Leukemia, mononuclear 6832E453 6834F568 6838H7526832E459 6834F577 6838H7646832E4846832E4906832E496Stomach ........................................Number examined: 50 20 20 50M-Carcinoma, metastatic 6838H753M-Leukemia, mononuclear 6832E491 6834F577 6836G682All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Cecum ..........................................Number examined: 49 20 20 49N-Leukemia, mononuclear 6832E485 6834F5686832E491Urinary bladder ................................Number examined: 50 20 19 50Hyperplasia, papillary 6832E456M-Leukemia, mononuclear 6832E453 6836G676Duodenum .......................................Number examined: 50 20 20 50Jejunum ........................................Number examined: 50 20 20 50Ileum ..........................................Number examined: 50 20 19 50N-Leukemia, mononuclear 6832E485 6838H772Colon ..........................................Number examined: 50 20 20 50Pancreas .......................................Number examined: 50 18 20 50M-Leukemia, mononuclear 6834F568Rectum .........................................Number examined: 50 20 20 50Adrenal glands .................................Number examined: 49 20 21 50Hyperplasia, cortical, focal 6832E454 6838H7916832E476Hyperplasia, focal 6832E496 6836G653 6838H7826836G698 6838H792B-Pheochromocytoma, benign 6832E487 6834F576 6836G668 6838H7576836G693M-Carcinoma, metastatic 6838H753M-Leukemia, mononuclear 6832E453 6834F599 6838H7526832E457 6838H7746832E491 6838H793All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Uterus .........................................Number examined: 50 24 31 50Hyperplasia, cystic endometrial 6832E456 6834F552 6836G670 6838H7596832E458 6834F556 6836G674 6838H7606832E459 6834F572 6836G679 6838H7676832E468 6834F582 6836G690 6838H7786832E469 6838H7796832E472 6838H7816832E478 6838H7876832E483 6838H7896832E489 6838H7916832E491 6838H7926832E497 6838H794B-Adenoma, endometrial 6834F561B-Polyp, endometrial stromal 6832E455 6834F552 6836G651 6838H7576832E460 6834F556 6836G660 6838H7636832E485 6834F562 6836G661 6838H7676832E492 6834F563 6836G665 6838H7696832E495 6834F565 6836G666 6838H7706834F566 6836G667 6838H7726834F573 6836G669 6838H7806834F582 6836G676 6838H7816834F589 6836G683 6838H7906834F594 6836G698 6838H7916834F595 6836G700 6838H798M-Adenocarcinoma, endometrial 6834F576 6836G667 6838H7536836G670M-Leiomyosarcoma 6834F562 6836G671M-Leukemia, mononuclear 6832E453 6834F568 6838H7526832E470 6834F5766834F577Mesenteric LN ..................................Number examined: 50 19 20 50N-Sarcoma, histiocytic 6838H751N-Leukemia, mononuclear 6832E453 6834F552 6836G659 6838H7526832E459 6834F568 6836G676 6838H7646832E462 6834F581 6836G680 6838H7706832E470 6836G682 6838H7746832E474 6836G6856832E476 6836G687All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mesenteric LN ..................................Number examined: 50 19 20 506832E477 6836G6886832E4846832E4856832E4876832E4916832E4936832E496Ovaries ........................................Number examined: 49 21 23 50N-Sarcoma, histiocytic 6838H751M-Leukemia, mononuclear 6832E453 6834F568 6836G682 6838H752Sciatic nerve ..................................Number examined: 50 20 19 50Muscle, skeletal ...............................Number examined: 50 20 20 50N-Sarcoma, histiocytic 6838H751Mammary gland ..................................Number examined: 49 20 22 47Hyperplasia, lobular 6832E500 6836G695 6838H7726838H787B-Fibroadenoma 6834F563 6836G672 6838H7566834F567 6836G684 6838H7616834F594 6838H7736838H7826838H798B-Fibroma 6832E459 6834F551 6836G6976834F571M-Adenocarcinoma 6834F565 6836G687M-Adenocarcinoma arising in fibroadenoma 6832E499All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Skin ...........................................Number examined: 50 19 20 49Brain ..........................................Number examined: 50 25 25 50M-Astrocytoma, malignant 6834F578Eyes/optic nerve ...............................Number examined: 50 22 24 50Bone, femur ....................................Number examined: 50 20 19 50Spinal cord ....................................Number examined: 50 20 19 50Nose/Turbinate 1 ...............................Number examined: 50 50 49 50Hyperplasia - respiratory epithelium 6834F585 6836G664 6838H7766836G700 6838H788Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Hyperplasia - respiratory epithelium 6834F568 6838H7836834F569Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Cervix .........................................Number examined: 2 5 3 2B-Polyp, endometrial stromal 6838H769M-Leiomyosarcoma 6834F570N-Adenocarcinoma, endometrial 6834F576Clitoral gland .................................Number examined: 1 0 3 0B-Adenoma 6836G669M-Carcinoma, squamous cell 6832E494N-Adenocarcinoma 6836G6786836G687All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lymph node other ...............................Number examined: 3 1 3 1N-Leukemia, mononuclear 6832E491 6834F568 6836G680 6838H7526832E496 6836G682Popliteal LN ...................................Number examined: 1 1 0 0N-Leukemia, mononuclear 6832E496 6834F568Iliac LN .......................................Number examined: 2 2 2 0N-Leukemia, mononuclear 6832E491 6834F568 6836G6826832E496 6834F577 6836G688Pancreatic LN ..................................Number examined: 2 1 2 1N-Leukemia, mononuclear 6832E491 6834F572 6836G682 6838H7526832E496 6836G688Mediastinal LN .................................Number examined: 50 20 20 47B-Thymoma 6836G688M-Carcinoma, metastatic 6838H753N-Sarcoma, histiocytic 6836G660N-Leukemia, mononuclear 6832E453 6834F552 6836G676 6838H7526832E459 6834F567 6836G678 6838H7666832E470 6834F568 6836G682 6838H7706832E476 6834F572 6836G685 6838H7726832E477 6834F577 6836G698 6838H7786832E4846832E4856832E4876832E4906832E4916832E4936832E496All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pituitary gland ................................Number examined: 50 32 34 50Hyperplasia, focal 6832E455 6834F567 6836G653 6838H7626832E460 6834F585 6836G663 6838H7686832E461 6834F596 6836G664 6838H7706832E471 6836G675 6838H7776832E479 6836G6766832E489 6836G6846832E494 6836G6896832E496 6836G693B-Adenoma, pars distalis 6832E458 6834F558 6836G654 6838H7546832E463 6834F561 6836G655 6838H7696832E473 6834F565 6836G657 6838H7706832E474 6834F569 6836G663 6838H7796832E484 6834F573 6836G665 6838H7836832E488 6834F576 6836G666 6838H7876832E493 6834F577 6836G669 6838H7886834F579 6836G672 6838H7906834F580 6836G678 6838H7916834F584 6836G679 6838H7996834F593 6836G687 6838H8006834F594 6836G6926834F600 6836G6946836G695B-Adenoma, pars intermedia 6836G695M-Carcinoma 6834F564M-Leukemia, mononuclear 6834F577 6838H772Tail ...........................................Number examined: 0 0 1 1Hyperplasia/hyperkeratosis 6836G689 6838H759Bone, rib ......................................Number examined: 0 0 0 1M-Osteosarcoma 6838H761All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 13Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mesentery ......................................Number examined: 1 0 0 1M-Carcinoma, metastatic 6838H753Bone, vertebrae ................................Number examined: 1 0 0 0N-Leukemia, mononuclear 6832E491Zymbal’s gland .................................Number examined: 1 0 0 0M-Carcinoma, squamous cell 6832E492Mediastinum ....................................Number examined: 1 0 0 0N-Leukemia, mononuclear 6832E490Bone, other ....................................Number examined: 0 0 1 0Harderian gland ................................Number examined: 0 0 1 0Vagina .........................................Number examined: 0 1 0 0M-Leiomoysarcoma 6834F561Tiss.not specifi ...............................Number examined: 0 0 0 0All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Non-neoplastic LesionsLovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Alveolar histiocytosis 6832E456 6834F566 6836G651 6838H7606832E460 6834F568 6836G657 6838H7626832E461 6834F575 6836G692 6838H7716832E463 6838H7726832E479 6838H7766832E484 6838H7776832E485 6838H7796832E488 6838H7826832E492 6838H789Congestion 6832E473 6836G660 6838H7956836G665Fibrosis, focal 6834F592Hemorrhage 6832E466 6834F576 6836G660 6838H7666832E479 6838H7746832E485 6838H7916832E4876832E491Inflammation, acute 6832E467 6834F578Inflammation, mixed 6836G653Inflammation, granulomatous 6836G654Trachea ........................................Number examined: 50 50 50 50Inflammation, acute 6832E4676832E473Inflammation, mixed 6832E495 6838H764Bronchial (TBLN) ...............................Number examined: 48 19 20 48Hemorrhage 6832E473 6834F552 6838H7606834F562 6838H7766834F576 6838H7816838H798Inflammation, mixed 6836G686All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thyroid glands .................................Number examined: 50 22 22 50Cyst, follicular 6836G693Parathyroid ....................................Number examined: 47 20 20 50Aorta ..........................................Number examined: 49 20 20 50Esophagus ......................................Number examined: 50 20 20 50Larynx .........................................Number examined: 50 50 50 50Metaplasia, squamous 6832E458 6834F554 6836G651 6838H7556832E472 6834F561 6836G654 6838H7596832E484 6834F564 6836G655 6838H7606832E495 6834F574 6836G657 6838H7626832E496 6834F580 6836G665 6838H7666834F583 6836G666 6838H7686834F588 6836G669 6838H7786834F591 6836G677 6838H7846834F592 6836G684 6838H7876834F600 6836G700Inflammation, acute 6832E459 6836G6966832E460Inflammation, mixed 6832E451 6834F551 6836G654 6838H7526832E452 6834F553 6836G655 6838H7546832E453 6834F554 6836G656 6838H7576832E455 6834F555 6836G658 6838H7596832E457 6834F556 6836G659 6838H7606832E458 6834F559 6836G660 6838H7616832E461 6834F561 6836G662 6838H7626832E462 6834F563 6836G665 6838H7646832E464 6834F564 6836G667 6838H7666832E467 6834F565 6836G668 6838H7686832E470 6834F567 6836G670 6838H7696832E471 6834F568 6836G672 6838H7706832E473 6834F570 6836G674 6838H7716832E476 6834F571 6836G675 6838H7726832E477 6834F572 6836G678 6838H7736832E478 6834F574 6836G679 6838H7756832E479 6834F575 6836G680 6838H7776832E480 6834F577 6836G684 6838H7786832E483 6834F578 6836G685 6838H7796832E484 6834F580 6836G688 6838H7836832E487 6834F581 6836G689 6838H784All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Larynx .........................................Number examined: 50 50 50 506832E488 6834F582 6836G693 6838H7866832E489 6834F583 6836G695 6838H7876832E493 6834F584 6838H7886832E495 6834F585 6838H7916832E496 6834F586 6838H7926832E499 6834F588 6838H7936832E500 6834F589 6838H7946834F591 6838H7956834F592 6838H7966834F593 6838H7976834F596 6838H7996834F598 6838H8006834F5996834F600Inflammation, chronic 6832E456 6834F594 6836G657 6838H7556832E465 6836G669 6838H7766832E472 6836G676 6838H7806832E475 6836G677 6838H7816832E490 6836G682 6838H7826832E491 6836G687 6838H7896832E492 6838H7906832E494Salivary gland .................................Number examined: 50 20 20 50Mandibular LN ..................................Number examined: 44 19 21 47Hemorrhage 6834F576Liver ..........................................Number examined: 50 28 22 50Angiectasis 6832E482 6838H791Congestion 6832E452 6836G665Fatty Change 6834F571 6836G655 6838H7586836G660 6838H7836838H787Foci of cellular alteration, basophilic 6832E478 6838H758Hepatodiaphragmatic nodule 6834F566 6838H7566834F575 6838H7716834F577 6838H786All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 28 22 506834F5786834F596Necrosis 6832E452 6834F566 6836G660 6838H7636832E474 6834F582 6838H7686832E480 6834F589 6838H7786838H7816838H785Thrombus 6838H793Vaculolization cytoplasmic 6832E452 6834F581 6836G687 6838H8006832E4576832E4646832E4696832E477Inflammation, acute 6832E473Inflammation, chronic 6832E458 6834F558 6836G671 6838H7546832E461 6834F565 6836G679 6838H7556832E467 6834F567 6836G695 6838H7566832E468 6834F578 6838H7606832E472 6834F582 6838H7656832E475 6838H7736832E481 6838H7766832E483 6838H7796832E486 6838H7816832E489 6838H7826832E494 6838H7836832E495 6838H7886832E498 6838H7896838H7906838H7946838H7986838H800Spleen .........................................Number examined: 50 22 24 50Fibrosis 6832E466 6836G6856832E4796832E490All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spleen .........................................Number examined: 50 22 24 50Hemorrhage 6838H778Necrosis 6832E491 6834F572 6838H7726838H778Kidneys ........................................Number examined: 50 20 21 50Atrophy 6838H753Cyst 6832E472 6838H7556838H7576838H762Degeneration, hyaline droplet 6838H751Dilatation 6838H753Infarct 6838H784Nephropathy, chronic 6832E451 6834F552 6836G653 6838H7516832E452 6834F556 6836G659 6838H7526832E453 6834F562 6836G660 6838H7536832E456 6834F565 6836G664 6838H7546832E457 6834F567 6836G665 6838H7556832E458 6834F568 6836G676 6838H7576832E460 6834F571 6836G678 6838H7586832E461 6834F572 6836G679 6838H7596832E462 6834F576 6836G680 6838H7606832E463 6834F577 6836G682 6838H7616832E465 6834F578 6836G683 6838H7626832E466 6834F581 6836G685 6838H7646832E467 6834F582 6836G687 6838H7676832E468 6834F589 6836G693 6838H7686832E469 6834F593 6836G695 6838H7706832E470 6834F594 6838H7716832E471 6834F599 6838H7726832E472 6838H7736832E473 6838H7746832E474 6838H7766832E475 6838H7776832E476 6838H7786832E478 6838H7796832E480 6838H7806832E481 6838H7816832E482 6838H782All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 20 21 506832E483 6838H7836832E484 6838H7846832E485 6838H7856832E486 6838H7876832E487 6838H7886832E488 6838H7896832E489 6838H7906832E490 6838H7916832E491 6838H7926832E493 6838H7936832E494 6838H7946832E495 6838H7956832E496 6838H7966832E497 6838H7976832E499 6838H7986832E500 6838H7996838H800Pigment accumulation, tubular epithelium 6834F581 6838H7636834F599 6838H792Heart ..........................................Number examined: 50 20 20 50Degeneration, myocyte 6832E452 6838H7586832E472 6838H7596832E483 6838H790Fibrosis 6832E500Thrombus 6832E464Inflammation, focal, chronic 6832E451 6834F562 6836G664 6838H7516832E454 6834F565 6836G665 6838H7546832E455 6834F566 6836G671 6838H7556832E460 6834F567 6836G678 6838H7566832E461 6834F576 6836G687 6838H7586832E462 6834F581 6836G688 6838H7606832E463 6834F589 6836G695 6838H7616832E465 6836G696 6838H7696832E467 6838H7706832E468 6838H7746832E470 6838H7756832E475 6838H7766832E482 6838H7776832E484 6838H779All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Heart ..........................................Number examined: 50 20 20 506832E486 6838H7806832E487 6838H7846832E488 6838H7876832E492 6838H7886832E494 6838H7896832E495 6838H7916832E497 6838H7926832E498 6838H7936832E499 6838H7946832E500 6838H7966838H7996838H800Stomach ........................................Number examined: 50 20 20 50Ulcer 6834F576Inflammation, mixed 6834F576Cecum ..........................................Number examined: 49 20 20 49Urinary bladder ................................Number examined: 50 20 19 50Hemorrhage 6832E491Inflammation, chronic 6832E455 6838H7516832E494 6838H7546838H773Duodenum .......................................Number examined: 50 20 20 50Inflamation, acute 6834F581Jejunum ........................................Number examined: 50 20 20 50Ileum ..........................................Number examined: 50 20 19 50Colon ..........................................Number examined: 50 20 20 50All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pancreas .......................................Number examined: 50 18 20 50Fibrosis 6838H753Rectum .........................................Number examined: 50 20 20 50Metaplasia, squamous 6834F581Adrenal glands .................................Number examined: 49 20 21 50Cyst 6836G653 6838H765Degeneration, cytoplasmic vacuolization 6832E452 6834F593 6838H7546832E458 6838H7586832E462 6838H7626832E464 6838H7666832E467 6838H7676832E477 6838H7696832E478 6838H7726832E483 6838H7736832E487 6838H7816832E490 6838H7846832E495 6838H7896832E500 6838H7936838H7966838H800Necrosis 6832E457Thrombus 6832E457Uterus .........................................Number examined: 50 24 31 50Angiectasis 6836G659Dilatation 6834F557 6836G669 6838H7526836G673 6838H7536836G678 6838H7636836G683Intussusception 6832E481 6834F590 6838H7696838H786Inflammation, mixed 6832E4536832E4556832E460All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Uterus .........................................Number examined: 50 24 31 50Inflammation, chronic 6832E4666832E4846832E496Mesenteric LN ..................................Number examined: 50 19 20 50Hemorrhage 6832E472 6836G693Inflammation, chronic 6832E481 6836G659Ovaries ........................................Number examined: 49 21 23 50Congestion 6836G665Cyst, bursa 6836G675 6838H759Cyst, epithelial 6832E495 6834F556Cyst, follicular 6836G661Cyst, rete ovarii 6836G657Hemorrhage 6832E473Necrosis, mesenteric fat 6834F596Sciatic nerve ..................................Number examined: 50 20 19 50Muscle, skeletal ...............................Number examined: 50 20 20 50Mammary gland ..................................Number examined: 49 20 22 47Ectasia 6832E452 6838H7696832E4766832E490Skin ...........................................Number examined: 50 19 20 49Cyst, epithelial inclusion 6834F576Fibrosis 6836G666Inflammation, mixed 6836G699All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Brain ..........................................Number examined: 50 25 25 50Compression 6832E473 6834F563 6836G654 6838H7546832E488 6834F564 6836G655 6838H7626834F565 6836G665 6838H7696834F569 6836G666 6838H7836834F576 6836G669 6838H7876834F579 6836G679 6838H7886834F584 6836G687 6838H7906834F593 6836G692 6838H7996836G695 6838H800Hemorrhage 6832E473 6834F584Metaplasia, osseous, meninges 6838H761Necrosis 6832E474Inflammation, chronic 6838H755Eyes/optic nerve ...............................Number examined: 50 22 24 50Atrophy 6832E476 6834F572 6838H7676838H777Atrophy, retinal, unilateral 6834F555 6836G6996834F585Cataract 6832E476 6834F555 6836G699 6838H7776834F572 6838H7986834F585Metaplasia, osseous, scleral 6832E463Mineralization, corneal stromal 6832E453 6838H7546832E459 6838H7596832E476 6838H7676832E494 6838H785Mineralization, scleral 6832E480 6834F576 6836G682 6838H7526832E498 6834F589 6836G693 6838H7656838H7806838H782Neovascularization, corneal 6832E453 6838H7596838H760All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Bone, femur ....................................Number examined: 50 20 19 50New bone formation, endosteal 6838H770Spinal cord ....................................Number examined: 50 20 19 50Degeneration, white matter 6832E473 6838H792Hemorrhage 6832E491 6836G682Necrosis, neuronal 6838H785Nose/Turbinate 1 ...............................Number examined: 50 50 49 50Degeneration, hyaline - respiratory epithelium 6832E482 6834F552 6836G657 6838H7666832E487 6834F563 6836G680 6838H7826832E492 6834F572 6836G6906834F582 6836G6936834F585 6836G6976834F589 6836G6986834F590Inflammation, mixed 6832E457 6834F557 6836G664 6838H7526832E464 6834F561 6836G666 6838H7536832E472 6834F569 6836G671 6838H7576832E477 6834F571 6836G691 6838H7836832E486 6834F593Inflammation - nasolacrimal duct 6832E451 6834F556 6836G653 6838H7516832E452 6834F557 6836G654 6838H7526832E456 6834F559 6836G655 6838H7536832E457 6834F561 6836G657 6838H7546832E465 6834F563 6836G659 6838H7556832E471 6834F571 6836G663 6838H7576832E472 6834F578 6836G664 6838H7586832E474 6834F584 6836G665 6838H7596832E475 6834F585 6836G669 6838H7606832E476 6834F593 6836G670 6838H7626832E477 6834F594 6836G671 6838H7676832E478 6834F596 6836G674 6838H7706832E480 6834F597 6836G678 6838H7726832E484 6834F598 6836G679 6838H7766832E485 6834F599 6836G680 6838H7806832E489 6836G686 6838H7836832E490 6836G691 6838H7856832E494 6836G693 6838H7886832E495 6836G695 6838H789All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 1 ...............................Number examined: 50 50 49 506832E496 6836G697 6838H7906832E497 6838H7936838H796Inflammation - respiratory epithelium 6832E486 6838H788Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 6832E453 6834F552 6836G651 6838H7516832E465 6834F576 6836G657 6838H7546832E468 6834F581 6836G659 6838H7666832E469 6834F585 6836G664 6838H7686834F590 6836G695 6838H7696836G697 6838H7766838H7776838H7826838H7846838H789Degeneration, hyaline - respiratory epithelium 6834F582 6836G654 6838H7766836G657 6838H7796836G660 6838H7886836G662 6838H7916836G679 6838H7926836G680 6838H7976836G697Metaplasia, secretory - olfactory epithelium 6832E464Metaplasia, squamous - olfactory epithelium 6836G687Inflammation, mixed 6832E464 6834F557 6836G655 6838H7526832E477 6834F568 6836G685 6838H7836832E486 6834F5696834F593Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 6834F561Degeneration, hyaline - olfactory epithelium 6832E453 6834F556 6836G652 6838H7526832E465 6834F576 6836G655 6838H7536832E469 6836G657 6838H7696832E472 6836G659 6838H7766836G662 6838H782All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 13Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 3 ...............................Number examined: 50 50 50 506836G664 6838H7856836G679 6838H7916836G680 6838H7926836G6956836G697Degeneration - respiratory epithelium 6834F557 6838H7976834F588Inflammation, mixed 6832E477 6834F557 6836G6666834F5616834F588Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 6834F557Degeneration, hyaline - olfactory epithelium 6832E453 6838H7536832E472 6838H7686832E475 6838H791Inflammation, mixed 6832E477 6834F557Cervix .........................................Number examined: 2 5 3 2Clitoral gland .................................Number examined: 1 0 3 0Lymph node other ...............................Number examined: 3 1 3 1Hemorrhage 6832E494Infiltration, histiocytic 6832E494Popliteal LN ...................................Number examined: 1 1 0 0Iliac LN .......................................Number examined: 2 2 2 0Pancreatic LN ..................................Number examined: 2 1 2 1All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 14Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mediastinal LN .................................Number examined: 50 20 20 47Hemorrhage 6832E465 6834F582 6836G653 6838H7996832E4666832E4736832E480Infiltration, histiocytic 6838H763Pigmentation 6838H763Pituitary gland ................................Number examined: 50 32 34 50Angiectasis 6832E455 6834F596 6836G676 6838H7626832E457 6836G683 6838H7646832E460 6836G685 6838H7686832E471 6838H7696832E479 6838H7796832E483 6838H7826832E4886832E4906832E497Cyst 6832E451 6834F556 6836G652 6838H7516832E452 6834F558 6836G653 6838H7526832E453 6834F561 6836G663 6838H7576832E454 6834F563 6836G664 6838H7596832E456 6834F567 6836G675 6838H7616832E457 6834F568 6836G680 6838H7756832E461 6834F573 6836G681 6838H7766832E462 6834F590 6836G682 6838H7806832E464 6834F595 6836G689 6838H7816832E466 6836G694 6838H7916832E467 6838H7976832E470 6838H7986832E4756832E4766832E4786832E4796832E4826832E4866832E4896832E4906832E4916832E4966832E4986832E500All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 15Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pituitary gland ................................Number examined: 50 32 34 50Degeneration 6832E482Hemorrhage 6832E465 6838H7546832E475 6838H7576832E489 6838H7616832E493 6838H7836832E497 6838H7876838H7886838H7906838H7916838H7996838H800Necrosis 6838H772Tail ...........................................Number examined: 0 0 1 1Inflammation, acute 6836G689Inflammation, mixed 6838H759Bone, rib ......................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 1 0 0 1Splenic tissue, "accessory" 6832E477Bone, vertebrae ................................Number examined: 1 0 0 0Zymbal’s gland .................................Number examined: 1 0 0 0Mediastinum ....................................Number examined: 1 0 0 0Bone, other ....................................Number examined: 0 0 1 0Fracture 6836G688Harderian gland ................................Number examined: 0 0 1 0Pigment 6836G683All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion Incidence by Animal Number for Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 16Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Vagina .........................................Number examined: 0 1 0 0Tiss.not specifi ...............................Number examined: 0 0 0 0All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-3 Incidence Summary (with percentages) of Microscopic Observations

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Proliferative (includi ng Neoplastic) LesionsLovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Hyperplasia, alveolar epithelial, focal 7 1 1 114% 2% 2% 2%N-Carcinoma, metastatic 0 0 0 10% 0% 0% 2%N-Leukemia, mononuclear - capillary involvement 22 16 12 1944% 32% 24% 38%N-Leukemia, mononuclear - invasive involvement 3 1 2 16% 2% 4% 2%N-Sarcoma, histiocytic 0 0 1 10% 0% 2% 2%Trachea ........................................Number examined: 50 50 50 50Hyperplasia 0 0 1 00% 0% 2% 0%N-Leukemia, mononuclear 0 1 1 00% 2% 2% 0%Bronchial (TBLN) ...............................Number examined: 48 19 20 48N-Leukemia, mononuclear 9 3 7 219% 16% 35% 4%Thyroid glands .................................Number examined: 50 22 22 50Hyperplasia, C-cell, focal 3 4 1 66% 18% 5% 12%Hyperplasia, follicular cell 1 0 0 02% 0% 0% 0%B-Adenoma, C-cell 1 2 3 22% 9% 14% 4%B-Adenoma, follicular cell 0 0 0 20% 0% 0% 4%M-Carcinoma, C-cell 1 0 0 02% 0% 0% 0%M-Carcinoma, follicular cell 1 0 1 02% 0% 5% 0%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thyroid glands .................................Number examined: 50 22 22 50M-Leukemia, mononuclear 0 0 0 10% 0% 0% 2%Parathyroid ....................................Number examined: 47 20 20 50Hyperplasia, focal 1 0 0 02% 0% 0% 0%B-Adenoma 1 0 0 02% 0% 0% 0%Aorta ..........................................Number examined: 49 20 20 50N-Leukemia, mononuclear - invasive involvement 1 0 0 02% 0% 0% 0%Esophagus ......................................Number examined: 50 20 20 50Larynx .........................................Number examined: 50 50 50 50Hyperplasia 17 10 5 1534% 20% 10% 30%Salivary gland .................................Number examined: 50 20 20 50M-Leukemia, mononuclear 2 0 0 14% 0% 0% 2%Mandibular LN ..................................Number examined: 44 19 21 47N-Leukemia, mononuclear 12 6 5 527% 32% 24% 11%Liver ..........................................Number examined: 50 28 22 50Hyperplasia, biliary 35 16 17 2470% 57% 77% 48%Hyperplasia, hepatocellular, regenerative 1 1 1 12% 4% 5% 2%B-Adenoma, hepatocellular 1 0 0 02% 0% 0% 0%M-Sarcoma. histiocytic 0 0 1 10% 0% 5% 2%M-Leukemia, mononuclear 27 17 10 2354% 61% 45% 46%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spleen .........................................Number examined: 50 22 24 50M-Leukemia, mononuclear 27 12 11 2354% 55% 46% 46%N-Sarcoma, histiocytic 0 0 1 00% 0% 4% 0%Kidneys ........................................Number examined: 50 20 21 50M-Leukemia, mononuclear 1 1 1 22% 5% 5% 4%N-Sarcoma, histiocytic 0 0 1 00% 0% 5% 0%Heart ..........................................Number examined: 50 20 20 50M-Leukemia, mononuclear 5 2 0 210% 10% 0% 4%Stomach ........................................Number examined: 50 20 20 50M-Carcinoma, metastatic 0 0 0 10% 0% 0% 2%M-Leukemia, mononuclear 1 1 1 02% 5% 5% 0%Cecum ..........................................Number examined: 49 20 20 49N-Leukemia, mononuclear 2 1 0 04% 5% 0% 0%Urinary bladder ................................Number examined: 50 20 19 50Hyperplasia, papillary 1 0 0 02% 0% 0% 0%M-Leukemia, mononuclear 1 0 1 02% 0% 5% 0%Duodenum .......................................Number examined: 50 20 20 50Jejunum ........................................Number examined: 50 20 20 50Ileum ..........................................Number examined: 50 20 19 50N-Leukemia, mononuclear 1 0 0 12% 0% 0% 2%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Colon ..........................................Number examined: 50 20 20 50Pancreas .......................................Number examined: 50 18 20 50M-Leukemia, mononuclear 0 1 0 00% 6% 0% 0%Rectum .........................................Number examined: 50 20 20 50Adrenal glands .................................Number examined: 49 20 21 50Hyperplasia, cortical, focal 2 0 0 14% 0% 0% 2%Hyperplasia, focal 1 0 2 22% 0% 10% 4%B-Pheochromocytoma, benign 1 1 2 12% 5% 10% 2%M-Carcinoma, metastatic 0 0 0 10% 0% 0% 2%M-Leukemia, mononuclear 3 1 0 36% 5% 0% 6%Uterus .........................................Number examined: 50 24 31 50Hyperplasia, cystic endometrial 11 4 4 1122% 17% 13% 22%B-Adenoma, endometrial 0 1 0 00% 4% 0% 0%B-Polyp, endometrial stromal 5 11 11 1110% 46% 35% 22%M-Adenocarcinoma, endometrial 0 1 2 10% 4% 6% 2%M-Leiomyosarcoma 0 1 1 00% 4% 3% 0%M-Leukemia, mononuclear 2 3 0 14% 13% 0% 2%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mesenteric LN ..................................Number examined: 50 19 20 50N-Sarcoma, histiocytic 0 0 0 10% 0% 0% 2%N-Leukemia, mononuclear 13 3 7 426% 16% 35% 8%Ovaries ........................................Number examined: 49 21 23 50N-Sarcoma, histiocytic 0 0 0 10% 0% 0% 2%M-Leukemia, mononuclear 1 1 1 12% 5% 4% 2%Sciatic nerve ..................................Number examined: 50 20 19 50Muscle, skeletal ...............................Number examined: 50 20 20 50N-Sarcoma, histiocytic 0 0 0 10% 0% 0% 2%Mammary gland ..................................Number examined: 49 20 22 47Hyperplasia, lobular 1 0 1 22% 0% 5% 4%B-Fibroadenoma 0 3 2 50% 15% 9% 11%B-Fibroma 1 2 1 02% 10% 5% 0%M-Adenocarcinoma 0 1 1 00% 5% 5% 0%M-Adenocarcinoma arising in fibroadenoma 1 0 0 02% 0% 0% 0%Skin ...........................................Number examined: 50 19 20 49Brain ..........................................Number examined: 50 25 25 50M-Astrocytoma, malignant 0 1 0 00% 4% 0% 0%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Eyes/optic nerve ...............................Number examined: 50 22 24 50Bone, femur ....................................Number examined: 50 20 19 50Spinal cord ....................................Number examined: 50 20 19 50Nose/Turbinate 1 ...............................Number examined: 50 50 49 50Hyperplasia - respiratory epithelium 0 1 2 20% 2% 4% 4%Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Hyperplasia - respiratory epithelium 0 2 0 10% 4% 0% 2%Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Cervix .........................................Number examined: 2 5 3 2B-Polyp, endometrial stromal 0 0 0 10% 0% 0% 50%M-Leiomyosarcoma 0 1 0 00% 20% 0% 0%N-Adenocarcinoma, endometrial 0 1 0 00% 20% 0% 0%Clitoral gland .................................Number examined: 1 0 3 0B-Adenoma 0 0 1 00% 0% 33% 0%M-Carcinoma, squamous cell 1 0 0 0100% 0% 0% 0%N-Adenocarcinoma 0 0 2 00% 0% 67% 0%Lymph node other ...............................Number examined: 3 1 3 1N-Leukemia, mononuclear 2 1 2 167% 100% 67% 100%Popliteal LN ...................................Number examined: 1 1 0 0N-Leukemia, mononuclear 1 1 0 0100% 100% 0% 0%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Iliac LN .......................................Number examined: 2 2 2 0N-Leukemia, mononuclear 2 2 2 0100% 100% 100% 0%Pancreatic LN ..................................Number examined: 2 1 2 1N-Leukemia, mononuclear 2 1 2 1100% 100% 100% 100%Mediastinal LN .................................Number examined: 50 20 20 47B-Thymoma 0 0 1 00% 0% 5% 0%M-Carcinoma, metastatic 0 0 0 10% 0% 0% 2%N-Sarcoma, histiocytic 0 0 1 00% 0% 5% 0%N-Leukemia, mononuclear 12 5 5 524% 25% 25% 11%Pituitary gland ................................Number examined: 50 32 34 50Hyperplasia, focal 8 3 8 416% 9% 24% 8%B-Adenoma, pars distalis 7 13 14 1114% 41% 41% 22%B-Adenoma, pars intermedia 0 0 1 00% 0% 3% 0%M-Carcinoma 0 1 0 00% 3% 0% 0%M-Leukemia, mononuclear 0 1 0 10% 3% 0% 2%Tail ...........................................Number examined: 0 0 1 1Hyperplasia/hyperkeratosis 0 0 1 10% 0% 100% 100%All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Bone, rib ......................................Number examined: 0 0 0 1M-Osteosarcoma 0 0 0 10% 0% 0% 100%Mesentery ......................................Number examined: 1 0 0 1M-Carcinoma, metastatic 0 0 0 10% 0% 0% 100%Bone, vertebrae ................................Number examined: 1 0 0 0N-Leukemia, mononuclear 1 0 0 0100% 0% 0% 0%Zymbal’s gland .................................Number examined: 1 0 0 0M-Carcinoma, squamous cell 1 0 0 0100% 0% 0% 0%Mediastinum ....................................Number examined: 1 0 0 0N-Leukemia, mononuclear 1 0 0 0100% 0% 0% 0%Bone, other ....................................Number examined: 0 0 1 0Harderian gland ................................Number examined: 0 0 1 0Vagina .........................................Number examined: 0 1 0 0M-Leiomoysarcoma 0 1 0 00% 100% 0% 0%Tiss.not specifi ...............................Number examined: 0 0 0 0All Proliferative Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

Non-neoplastic LesionsLovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Alveolar histiocytosis 9 3 3 918% 6% 6% 18%Congestion 1 0 2 12% 0% 4% 2%Fibrosis, focal 0 1 0 00% 2% 0% 0%Hemorrhage 5 1 1 310% 2% 2% 6%Inflammation, acute 1 1 0 02% 2% 0% 0%Inflammation, mixed 0 0 1 00% 0% 2% 0%Inflammation, granulomatous 0 0 1 00% 0% 2% 0%Trachea ........................................Number examined: 50 50 50 50Inflammation, acute 2 0 0 04% 0% 0% 0%Inflammation, mixed 1 0 0 12% 0% 0% 2%Bronchial (TBLN) ...............................Number examined: 48 19 20 48Hemorrhage 1 3 0 42% 16% 0% 8%Inflammation, mixed 0 0 1 00% 0% 5% 0%Thyroid glands .................................Number examined: 50 22 22 50Cyst, follicular 0 0 1 00% 0% 5% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Parathyroid ....................................Number examined: 47 20 20 50Aorta ..........................................Number examined: 49 20 20 50Esophagus ......................................Number examined: 50 20 20 50Larynx .........................................Number examined: 50 50 50 50Metaplasia, squamous 5 10 10 910% 20% 20% 18%Inflammation, acute 2 0 1 04% 0% 2% 0%Inflammation, mixed 28 35 23 3356% 70% 46% 66%Inflammation, chronic 8 1 6 716% 2% 12% 14%Salivary gland .................................Number examined: 50 20 20 50Mandibular LN ..................................Number examined: 44 19 21 47Hemorrhage 0 1 0 00% 5% 0% 0%Liver ..........................................Number examined: 50 28 22 50Angiectasis 1 0 0 12% 0% 0% 2%Congestion 1 0 1 02% 0% 5% 0%Fatty Change 0 1 2 30% 4% 9% 6%Foci of cellular alteration, basophilic 1 0 0 12% 0% 0% 2%Hepatodiaphragmatic nodule 0 5 0 30% 18% 0% 6%Necrosis 3 3 1 56% 11% 5% 10%Thrombus 0 0 0 10% 0% 0% 2%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 28 22 50Vaculolization cytoplasmic 5 1 1 110% 4% 5% 2%Inflammation, acute 1 0 0 02% 0% 0% 0%Inflammation, chronic 13 5 3 1726% 18% 14% 34%Spleen .........................................Number examined: 50 22 24 50Fibrosis 3 0 1 06% 0% 4% 0%Hemorrhage 0 0 0 10% 0% 0% 2%Necrosis 1 1 0 22% 5% 0% 4%Kidneys ........................................Number examined: 50 20 21 50Atrophy 0 0 0 10% 0% 0% 2%Cyst 1 0 0 32% 0% 0% 6%Degeneration, hyaline droplet 0 0 0 10% 0% 0% 2%Dilatation 0 0 0 10% 0% 0% 2%Infarct 0 0 0 10% 0% 0% 2%Nephropathy, chronic 42 17 15 4384% 85% 71% 86%Pigment accumulation, tubular epithelium 0 2 0 20% 10% 0% 4%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Heart ..........................................Number examined: 50 20 20 50Degeneration, myocyte 3 0 0 36% 0% 0% 6%Fibrosis 1 0 0 02% 0% 0% 0%Thrombus 1 0 0 02% 0% 0% 0%Inflammation, focal, chronic 24 7 8 2648% 35% 40% 52%Stomach ........................................Number examined: 50 20 20 50Ulcer 0 1 0 00% 5% 0% 0%Inflammation, mixed 0 1 0 00% 5% 0% 0%Cecum ..........................................Number examined: 49 20 20 49Urinary bladder ................................Number examined: 50 20 19 50Hemorrhage 1 0 0 02% 0% 0% 0%Inflammation, chronic 2 0 0 34% 0% 0% 6%Duodenum .......................................Number examined: 50 20 20 50Inflamation, acute 0 1 0 00% 5% 0% 0%Jejunum ........................................Number examined: 50 20 20 50Ileum ..........................................Number examined: 50 20 19 50Colon ..........................................Number examined: 50 20 20 50Pancreas .......................................Number examined: 50 18 20 50Fibrosis 0 0 0 10% 0% 0% 2%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Rectum .........................................Number examined: 50 20 20 50Metaplasia, squamous 0 1 0 00% 5% 0% 0%Adrenal glands .................................Number examined: 49 20 21 50Cyst 0 0 1 10% 0% 5% 2%Degeneration, cytoplasmic vacuolization 12 1 0 1424% 5% 0% 28%Necrosis 1 0 0 02% 0% 0% 0%Thrombus 1 0 0 02% 0% 0% 0%Uterus .........................................Number examined: 50 24 31 50Angiectasis 0 0 1 00% 0% 3% 0%Dilatation 0 1 4 30% 4% 13% 6%Intussusception 1 1 0 22% 4% 0% 4%Inflammation, mixed 3 0 0 06% 0% 0% 0%Inflammation, chronic 3 0 0 06% 0% 0% 0%Mesenteric LN ..................................Number examined: 50 19 20 50Hemorrhage 1 0 1 02% 0% 5% 0%Inflammation, chronic 1 0 1 02% 0% 5% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Ovaries ........................................Number examined: 49 21 23 50Congestion 0 0 1 00% 0% 4% 0%Cyst, bursa 0 0 1 10% 0% 4% 2%Cyst, epithelial 1 1 0 02% 5% 0% 0%Cyst, follicular 0 0 1 00% 0% 4% 0%Cyst, rete ovarii 0 0 1 00% 0% 4% 0%Hemorrhage 1 0 0 02% 0% 0% 0%Necrosis, mesenteric fat 0 1 0 00% 5% 0% 0%Sciatic nerve ..................................Number examined: 50 20 19 50Muscle, skeletal ...............................Number examined: 50 20 20 50Mammary gland ..................................Number examined: 49 20 22 47Ectasia 3 0 0 16% 0% 0% 2%Skin ...........................................Number examined: 50 19 20 49Cyst, epithelial inclusion 0 1 0 00% 5% 0% 0%Fibrosis 0 0 1 00% 0% 5% 0%Inflammation, mixed 0 0 1 00% 0% 5% 0%Brain ..........................................Number examined: 50 25 25 50Compression 2 8 9 94% 32% 36% 18%Hemorrhage 1 1 0 02% 4% 0% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Brain ..........................................Number examined: 50 25 25 50Metaplasia, osseous, meninges 0 0 0 10% 0% 0% 2%Necrosis 1 0 0 02% 0% 0% 0%Inflammation, chronic 0 0 0 10% 0% 0% 2%Eyes/optic nerve ...............................Number examined: 50 22 24 50Atrophy 1 1 0 22% 5% 0% 4%Atrophy, retinal, unilateral 0 2 1 00% 9% 4% 0%Cataract 1 3 1 22% 14% 4% 4%Metaplasia, osseous, scleral 1 0 0 02% 0% 0% 0%Mineralization, corneal stromal 4 0 0 48% 0% 0% 8%Mineralization, scleral 2 2 2 44% 9% 8% 8%Neovascularization, corneal 1 0 0 22% 0% 0% 4%Bone, femur ....................................Number examined: 50 20 19 50New bone formation, endosteal 0 0 0 10% 0% 0% 2%Spinal cord ....................................Number examined: 50 20 19 50Degeneration, white matter 1 0 0 12% 0% 0% 2%Hemorrhage 1 0 1 02% 0% 5% 0%Necrosis, neuronal 0 0 0 10% 0% 0% 2%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 1 ...............................Number examined: 50 50 49 50Degeneration, hyaline - respiratory epithelium 3 7 6 26% 14% 12% 4%Inflammation, mixed 5 5 4 410% 10% 8% 8%Inflammation - nasolacrimal duct 21 15 20 2242% 30% 41% 44%Inflammation - respiratory epithelium 1 0 0 12% 0% 0% 2%Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 4 5 6 108% 10% 12% 20%Degeneration, hyaline - respiratory epithelium 0 1 7 60% 2% 14% 12%Metaplasia, secretory - olfactory epithelium 1 0 0 02% 0% 0% 0%Metaplasia, squamous - olfactory epithelium 0 0 1 00% 0% 2% 0%Inflammation, mixed 3 4 2 26% 8% 4% 4%Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 0 1 0 00% 2% 0% 0%Degeneration, hyaline - olfactory epithelium 4 2 10 88% 4% 20% 16%Degeneration - respiratory epithelium 0 2 0 10% 4% 0% 2%Inflammation, mixed 1 3 1 02% 6% 2% 0%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 0 1 0 00% 2% 0% 0%Degeneration, hyaline - olfactory epithelium 3 0 0 36% 0% 0% 6%Inflammation, mixed 1 1 0 02% 2% 0% 0%Cervix .........................................Number examined: 2 5 3 2Clitoral gland .................................Number examined: 1 0 3 0Lymph node other ...............................Number examined: 3 1 3 1Hemorrhage 1 0 0 033% 0% 0% 0%Infiltration, histiocytic 1 0 0 033% 0% 0% 0%Popliteal LN ...................................Number examined: 1 1 0 0Iliac LN .......................................Number examined: 2 2 2 0Pancreatic LN ..................................Number examined: 2 1 2 1Mediastinal LN .................................Number examined: 50 20 20 47Hemorrhage 4 1 1 18% 5% 5% 2%Infiltration, histiocytic 0 0 0 10% 0% 0% 2%Pigmentation 0 0 0 10% 0% 0% 2%Pituitary gland ................................Number examined: 50 32 34 50Angiectasis 9 1 3 618% 3% 9% 12%Cyst 24 9 10 1248% 28% 29% 24%Degeneration 1 0 0 02% 0% 0% 0%Hemorrhage 5 0 0 1010% 0% 0% 20%All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Incidence Summary (with percentages) of Microscopic Observations Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Pituitary gland ................................Number examined: 50 32 34 50Necrosis 0 0 0 10% 0% 0% 2%Tail ...........................................Number examined: 0 0 1 1Inflammation, acute 0 0 1 00% 0% 100% 0%Inflammation, mixed 0 0 0 10% 0% 0% 100%Bone, rib ......................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 1 0 0 1Splenic tissue, "accessory" 1 0 0 0100% 0% 0% 0%Bone, vertebrae ................................Number examined: 1 0 0 0Zymbal’s gland .................................Number examined: 1 0 0 0Mediastinum ....................................Number examined: 1 0 0 0Bone, other ....................................Number examined: 0 0 1 0Fracture 0 0 1 00% 0% 100% 0%Harderian gland ................................Number examined: 0 0 1 0Pigment 0 0 1 00% 0% 100% 0%Vagina .........................................Number examined: 0 1 0 0Tiss.not specifi ...............................Number examined: 0 0 0 0All Nonneoplastic Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-4 Tabulated Incidence Su mmary of Non-neoplastic LesionsLovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Hyperplasia, alveolar epithelial, focal, Minimal. 4 0 0 0Hyperplasia, alveolar epithelial, focal, Mild. 2 1 1 1Hyperplasia, alveolar epithelial, focal, Moderate. 1 0 0 0Congestion, Minimal. 0 0 1 0Congestion, Mild. 1 0 1 1Alveolar histiocytosis, Minimal. 9 3 3 9Fibrosis, focal, Mild. 0 1 0 0Inflammation, mixed, Moderate. 0 0 1 0Inflammation, acute, Minimal. 1 1 0 0Hemorrhage, Minimal. 3 0 0 2Hemorrhage, Mild. 2 1 1 1Inflammation, granulomatous, Minimal. 0 0 1 0Trachea ........................................Number examined: 50 50 50 50Inflammation, acute, Mild. 2 0 0 0Inflammation, mixed, Mild. 1 0 0 1Hyperplasia, Moderate. 0 0 1 0Bronchial (TBLN) ...............................Number examined: 48 19 20 48Hemorrhage, Mild. 1 2 0 4Hemorrhage, Moderate. 0 1 0 0Inflammation, mixed, Minimal. 0 0 1 0Thyroid glands .................................Number examined: 50 22 22 50Hyperplasia, C-cell, focal, Minimal. 1 1 1 0Hyperplasia, C-cell, focal, Mild. 1 1 0 4Hyperplasia, C-cell, focal, Moderate. 1 1 0 2Hyperplasia, C-cell, focal, Marked. 0 1 0 0Cyst, follicular, Present. 0 0 1 0Hyperplasia, follicular cell, Mild. 1 0 0 0Parathyroid ....................................Number examined: 47 20 20 50Hyperplasia, focal, Mild. 1 0 0 0Aorta ..........................................Number examined: 49 20 20 50Esophagus ......................................Number examined: 50 20 20 50Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Larynx .........................................Number examined: 50 50 50 50Hyperplasia, Minimal. 12 8 5 7Hyperplasia, Mild. 5 2 0 8Metaplasia, squamous, Minimal. 1 5 7 9Metaplasia, squamous, Mild. 3 5 3 0Metaplasia, squamous, Moderate. 1 0 0 0Inflammation, acute, Minimal. 2 0 1 0Inflammation, mixed, Minimal. 10 20 14 17Inflammation, mixed, Mild. 17 15 9 16Inflammation, mixed, Moderate. 1 0 0 0Inflammation, chronic, Minimal. 8 1 4 5Inflammation, chronic, Mild. 0 0 2 2Salivary gland .................................Number examined: 50 20 20 50Mandibular LN ..................................Number examined: 44 19 21 47Hemorrhage, Mild. 0 1 0 0Liver ..........................................Number examined: 50 28 22 50Necrosis, Minimal. 2 1 0 3Necrosis, Mild. 0 1 1 1Necrosis, Moderate. 1 1 0 1Vaculolization cytoplasmic, Minimal. 1 0 0 0Vaculolization cytoplasmic, Mild. 1 1 1 1Vaculolization cytoplasmic, Moderate. 3 0 0 0Inflammation, acute, Mild. 1 0 0 0Angiectasis, Minimal. 1 0 0 1Hyperplasia, biliary, Minimal. 12 8 9 19Hyperplasia, biliary, Mild. 22 8 7 5Hyperplasia, biliary, Moderate. 1 0 1 0Hyperplasia, hepatocellular, regenerative, Minimal. 0 0 0 1Hyperplasia, hepatocellular, regenerative, Mild. 0 1 1 0Hyperplasia, hepatocellular, regenerative, Moderate. 1 0 0 0Inflammation, chronic, Minimal. 10 4 2 16Inflammation, chronic, Mild. 3 1 1 1Fatty Change, Minimal. 0 1 1 1Fatty Change, Mild. 0 0 1 2Hepatodiaphragmatic nodule, Present. 0 5 0 3Foci of cellular alteration, basophilic, Mild. 0 0 0 1Foci of cellular alteration, basophilic, Moderate. 1 0 0 0Congestion, Mild. 1 0 1 0Thrombus, Mild. 0 0 0 1Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spleen .........................................Number examined: 50 22 24 50Fibrosis, Minimal. 1 0 1 0Fibrosis, Mild. 1 0 0 0Fibrosis, Moderate. 1 0 0 0Necrosis, Mild. 1 0 0 0Necrosis, Moderate. 0 0 0 1Necrosis, Marked. 0 1 0 1Hemorrhage, Moderate. 0 0 0 1Kidneys ........................................Number examined: 50 20 21 50Pigment accumulation, tubular epithelium, Minimal. 0 0 0 1Pigment accumulation, tubular epithelium, Moderate. 0 2 0 1Nephropathy, chronic, Minimal. 32 14 11 16Nephropathy, chronic, Mild. 10 3 3 20Nephropathy, chronic, Moderate. 0 0 1 7Cyst, Mild. 0 0 0 1Cyst, Moderate. 1 0 0 2Degeneration, hyaline droplet, Marked. 0 0 0 1Dilatation, Moderate. 0 0 0 1Atrophy, Marked. 0 0 0 1Infarct, Moderate. 0 0 0 1Heart ..........................................Number examined: 50 20 20 50Inflammation, focal, chronic, Minimal. 23 7 8 25Inflammation, focal, chronic, Mild. 1 0 0 1Degeneration, myocyte, Minimal. 2 0 0 3Degeneration, myocyte, Mild. 1 0 0 0Fibrosis, Minimal. 1 0 0 0Thrombus, Minimal. 1 0 0 0Stomach ........................................Number examined: 50 20 20 50Inflammation, mixed, Mild. 0 1 0 0Ulcer, Mild. 0 1 0 0Cecum ..........................................Number examined: 49 20 20 49Urinary bladder ................................Number examined: 50 20 19 50Inflammation, chronic, Minimal. 2 0 0 3Hyperplasia, papillary, Mild. 1 0 0 0Hemorrhage, Mild. 1 0 0 0Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Duodenum .......................................Number examined: 50 20 20 50Inflamation, acute, Moderate. 0 1 0 0Jejunum ........................................Number examined: 50 20 20 50Ileum ..........................................Number examined: 50 20 19 50Colon ..........................................Number examined: 50 20 20 50Pancreas .......................................Number examined: 50 18 20 50Fibrosis, Mild. 0 0 0 1Rectum .........................................Number examined: 50 20 20 50Metaplasia, squamous, Mild. 0 1 0 0Adrenal glands .................................Number examined: 49 20 21 50Hyperplasia, focal, Present. 1 0 2 2Degeneration, cytoplasmic vacuolization, Minimal. 10 0 0 12Degeneration, cytoplasmic vacuolization, Mild. 1 1 0 2Degeneration, cytoplasmic vacuolization, Moderate. 1 0 0 0Hyperplasia, cortical, focal, Minimal. 2 0 0 1Thrombus, Minimal. 1 0 0 0Cyst, Minimal. 0 0 0 1Cyst, Mild. 0 0 1 0Necrosis, Minimal. 1 0 0 0Uterus .........................................Number examined: 50 24 31 50Dilatation, Minimal. 0 0 1 0Dilatation, Mild. 0 1 2 0Dilatation, Moderate. 0 0 1 1Dilatation, Marked. 0 0 0 2Hyperplasia, cystic endometrial, Minimal. 5 0 0 6Hyperplasia, cystic endometrial, Mild. 4 3 2 3Hyperplasia, cystic endometrial, Moderate. 1 1 2 2Hyperplasia, cystic endometrial, Marked. 1 0 0 0Inflammation, chronic, Minimal. 3 0 0 0Inflammation, mixed, Minimal. 1 0 0 0Inflammation, mixed, Mild. 2 0 0 0Intussusception, Present. 1 1 0 2Angiectasis, Mild. 0 0 1 0Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mesenteric LN ..................................Number examined: 50 19 20 50Hemorrhage, Mild. 1 0 1 0Inflammation, chronic, Minimal. 0 0 1 0Inflammation, chronic, Moderate. 1 0 0 0Ovaries ........................................Number examined: 49 21 23 50Hemorrhage, Mild. 1 0 0 0Cyst, bursa, Present. 0 0 1 1Cyst, epithelial, Present. 1 1 0 0Congestion, Mild. 0 0 1 0Necrosis, mesenteric fat, Mild. 0 1 0 0Cyst, rete ovarii, Mild. 0 0 1 0Cyst, follicular, Present. 0 0 1 0Sciatic nerve ..................................Number examined: 50 20 19 50Muscle, skeletal ...............................Number examined: 50 20 20 50Mammary gland ..................................Number examined: 49 20 22 47Ectasia, Minimal. 2 0 0 0Ectasia, Mild. 0 0 0 1Ectasia, Moderate. 1 0 0 0Hyperplasia, lobular, Minimal. 1 0 0 1Hyperplasia, lobular, Mild. 0 0 1 1Skin ...........................................Number examined: 50 19 20 49Fibrosis, Moderate. 0 0 1 0Cyst, epithelial inclusion, Present. 0 1 0 0Inflammation, mixed, Minimal. 0 0 1 0Brain ..........................................Number examined: 50 25 25 50Compression, Minimal. 0 1 0 1Compression, Mild. 0 4 3 5Compression, Moderate. 1 3 4 3Compression, Marked. 1 0 2 0Necrosis, Mild. 1 0 0 0Metaplasia, osseous, meninges, Minimal. 0 0 0 1Hemorrhage, Mild. 1 1 0 0Inflammation, chronic, Marked. 0 0 0 1Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Eyes/optic nerve ...............................Number examined: 50 22 24 50Mineralization, corneal stromal, Minimal. 3 0 0 3Mineralization, corneal stromal, Mild. 1 0 0 1Mineralization, scleral, Minimal. 2 0 2 3Mineralization, scleral, Mild. 0 2 0 1Atrophy, Moderate. 1 0 0 0Atrophy, Marked. 0 1 0 2Atrophy, retinal, unilateral, Mild. 0 0 1 0Atrophy, retinal, unilateral, Marked. 0 2 0 0Cataract, Present. 1 3 1 2Neovascularization, corneal, Minimal. 1 0 0 2Metaplasia, osseous, scleral, Minimal. 1 0 0 0Bone, femur ....................................Number examined: 50 20 19 50New bone formation, endosteal, Minimal. 0 0 0 1Spinal cord ....................................Number examined: 50 20 19 50Degeneration, white matter, Minimal. 0 0 0 1Degeneration, white matter, Mild. 1 0 0 0Hemorrhage, Minimal. 0 0 1 0Hemorrhage, Mild. 1 0 0 0Necrosis, neuronal, Minimal. 0 0 0 1Nose/Turbinate 1 ...............................Number examined: 50 50 49 50Inflammation - nasolacrimal duct, Minimal. 4 2 1 1Inflammation - nasolacrimal duct, Mild. 9 6 5 6Inflammation - nasolacrimal duct, Moderate. 8 7 14 10Inflammation - nasolacrimal duct, Marked. 0 0 0 5Inflammation, mixed, Minimal. 0 2 1 1Inflammation, mixed, Mild. 1 2 1 3Inflammation, mixed, Moderate. 3 1 2 0Inflammation, mixed, Marked. 1 0 0 0Inflammation - respiratory epithelium, Mild. 0 0 0 1Inflammation - respiratory epithelium, Moderate. 1 0 0 0Hyperplasia - respiratory epithelium, Minimal. 0 1 0 0Hyperplasia - respiratory epithelium, Mild. 0 0 2 2Degeneration, hyaline - respiratory epithelium, Minimal. 1 5 4 1Degeneration, hyaline - respiratory epithelium, Mild. 0 2 1 1Degeneration, hyaline - respiratory epithelium, Moderate. 2 0 1 0Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium, Minimal. 3 2 3 5Degeneration, hyaline - olfactory epithelium, Mild. 1 3 2 5Degeneration, hyaline - olfactory epithelium, Moderate. 0 0 1 0Inflammation, mixed, Minimal. 0 2 1 1Inflammation, mixed, Mild. 1 2 1 0Inflammation, mixed, Moderate. 1 0 0 1Inflammation, mixed, Marked. 1 0 0 0Metaplasia, secretory - olfactory epithelium, Marked. 1 0 0 0Hyperplasia - respiratory epithelium, Mild. 0 2 0 0Hyperplasia - respiratory epithelium, Moderate. 0 0 0 1Degeneration, hyaline - respiratory epithelium, Minimal. 0 1 2 2Degeneration, hyaline - respiratory epithelium, Mild. 0 0 4 4Degeneration, hyaline - respiratory epithelium, Moderate. 0 0 1 0Metaplasia, squamous - olfactory epithelium, Minimal. 0 0 1 0Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium, Minimal. 3 1 4 2Degeneration, hyaline - olfactory epithelium, Mild. 0 1 3 4Degeneration, hyaline - olfactory epithelium, Moderate. 1 0 3 2Inflammation, mixed, Minimal. 0 1 0 0Inflammation, mixed, Mild. 0 2 1 0Inflammation, mixed, Moderate. 1 0 0 0Degeneration - respiratory epithelium, Mild. 0 2 0 1Degeneration - olfactory epithelium, Minimal. 0 1 0 0Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Inflammation, mixed, Mild. 1 1 0 0Degeneration, hyaline - olfactory epithelium, Minimal. 2 0 0 3Degeneration, hyaline - olfactory epithelium, Mild. 1 0 0 0Degeneration - olfactory epithelium, Mild. 0 1 0 0Cervix .........................................Number examined: 2 5 3 2Clitoral gland .................................Number examined: 1 0 3 0Lymph node other ...............................Number examined: 3 1 3 1Infiltration, histiocytic, Mild. 1 0 0 0Hemorrhage, Minimal. 1 0 0 0Popliteal LN ...................................Number examined: 1 1 0 0Iliac LN .......................................Number examined: 2 2 2 0Pancreatic LN ..................................Number examined: 2 1 2 1Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mediastinal LN .................................Number examined: 50 20 20 47Pigmentation, Moderate. 0 0 0 1Infiltration, histiocytic, Moderate. 0 0 0 1Hemorrhage, Mild. 3 1 1 1Hemorrhage, Moderate. 1 0 0 0Pituitary gland ................................Number examined: 50 32 34 50Cyst, Minimal. 8 2 2 6Cyst, Mild. 11 5 4 6Cyst, Moderate. 4 1 4 0Cyst, Marked. 1 1 0 0Degeneration, Mild. 1 0 0 0Hyperplasia, focal, Minimal. 1 1 2 1Hyperplasia, focal, Mild. 3 1 3 1Hyperplasia, focal, Moderate. 4 1 2 2Hyperplasia, focal, Marked. 0 0 1 0Hemorrhage, Minimal. 2 0 0 2Hemorrhage, Mild. 1 0 0 2Hemorrhage, Moderate. 2 0 0 6Angiectasis, Minimal. 2 0 0 2Angiectasis, Mild. 5 0 1 1Angiectasis, Moderate. 2 1 2 2Angiectasis, Marked. 0 0 0 1Necrosis, Moderate. 0 0 0 1Tail ...........................................Number examined: 0 0 1 1Inflammation, mixed, Moderate. 0 0 0 1Hyperplasia/hyperkeratosis, Moderate. 0 0 1 0Hyperplasia/hyperkeratosis, Marked. 0 0 0 1Inflammation, acute, Mild. 0 0 1 0Bone, rib ......................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 1 0 0 1Splenic tissue, "accessory", Present. 1 0 0 0Bone, vertebrae ................................Number examined: 1 0 0 0Zymbal’s gland .................................Number examined: 1 0 0 0Mediastinum ....................................Number examined: 1 0 0 0Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.Lovelace Respiratory Tabulated Incidence Summary of Nonneoplastic Lesions Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Bone, other ....................................Number examined: 0 0 1 0Fracture, Present. 0 0 1 0Harderian gland ................................Number examined: 0 0 1 0Pigment, Mild. 0 0 1 0Vagina .........................................Number examined: 0 1 0 0Tiss.not specifi ...............................Number examined: 0 0 0 0Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Diagnoses tabulated by: Tissue locators, Severity levels, Distribution, Duration.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-5 Lesion Incidence Summar y with Average Severity GradesLovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Lungs ..........................................Number examined: 50 50 50 50Alveolar histiocytosis 9 3 3 9Average severity: 0.2 0.1 0.1 0.2Congestion 1 0 2 1Average severity: 0.0 0.0 0.1 0.0Fibrosis, focal 0 1 0 0Average severity: 0.0 0.0 0.0 0.0Hemorrhage 5 1 1 3Average severity: 0.1 0.0 0.0 0.1Inflammation, acute 1 1 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Inflammation, granulomatous 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Hyperplasia, alveolar epithelial, focal 7 1 1 1Average severity: 0.2 0.0 0.0 0.0Trachea ........................................Number examined: 50 50 50 50Inflammation, acute 2 0 0 0Average severity: 0.1 0.0 0.0 0.0Inflammation, mixed 1 0 0 1Average severity: 0.0 0.0 0.0 0.0Hyperplasia 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Bronchial (TBLN) ...............................Number examined: 48 19 20 48Hemorrhage 1 3 0 4Average severity: 0.0 0.4 0.0 0.2Inflammation, mixed 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Thyroid glands .................................Number examined: 50 22 22 50Cyst, follicular 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Hyperplasia, C-cell, focal 3 4 1 6Average severity: 0.1 0.5 0.0 0.3Hyperplasia, follicular cell 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Parathyroid ....................................Number examined: 47 20 20 50Hyperplasia, focal 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Aorta ..........................................Number examined: 49 20 20 50Esophagus ......................................Number examined: 50 20 20 50Larynx .........................................Number examined: 50 50 50 50Metaplasia, squamous 5 10 10 9Average severity: 0.2 0.3 0.3 0.2Hyperplasia 17 10 5 15Average severity: 0.4 0.2 0.1 0.5Inflammation, acute 2 0 1 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 28 35 23 33Average severity: 0.9 1.0 0.6 1.0Inflammation, chronic 8 1 6 7Average severity: 0.2 0.0 0.2 0.2Salivary gland .................................Number examined: 50 20 20 50Mandibular LN ..................................Number examined: 44 19 21 47Hemorrhage 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Liver ..........................................Number examined: 50 28 22 50Angiectasis 1 0 0 1Average severity: 0.0 0.0 0.0 0.0Congestion 1 0 1 0Average severity: 0.0 0.0 0.1 0.0Fatty Change 0 1 2 3Average severity: 0.0 0.0 0.1 0.1Foci of cellular alteration, basophilic 1 0 0 1Average severity: 0.1 0.0 0.0 0.0Hepatodiaphragmatic nodule 0 5 0 3Average severity: 0.0 0.2 0.0 0.1Necrosis 3 3 1 5Average severity: 0.1 0.2 0.1 0.2Thrombus 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Vaculolization cytoplasmic 5 1 1 1Average severity: 0.2 0.1 0.1 0.0Inflammation, acute 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, chronic 13 5 3 17Average severity: 0.3 0.2 0.2 0.4Hyperplasia, biliary 35 16 17 24Average severity: 1.2 0.9 1.2 0.6Hyperplasia, hepatocellular, regenerative 1 1 1 1Average severity: 0.1 0.1 0.1 0.0Spleen .........................................Number examined: 50 22 24 50Fibrosis 3 0 1 0Average severity: 0.1 0.0 0.0 0.0Hemorrhage 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spleen .........................................Number examined: 50 22 24 50Necrosis 1 1 0 2Average severity: 0.0 0.2 0.0 0.1Kidneys ........................................Number examined: 50 20 21 50Atrophy 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Cyst 1 0 0 3Average severity: 0.1 0.0 0.0 0.2Degeneration, hyaline droplet 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Dilatation 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Infarct 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Nephropathy, chronic 42 17 15 43Average severity: 1.0 1.0 1.0 1.5Pigment accumulation, tubular epithelium 0 2 0 2Average severity: 0.0 0.3 0.0 0.1Heart ..........................................Number examined: 50 20 20 50Degeneration, myocyte 3 0 0 3Average severity: 0.1 0.0 0.0 0.1Fibrosis 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Thrombus 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, focal, chronic 24 7 8 26Average severity: 0.5 0.4 0.4 0.5Stomach ........................................Number examined: 50 20 20 50Ulcer 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Stomach ........................................Number examined: 50 20 20 50Inflammation, mixed 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Cecum ..........................................Number examined: 49 20 20 49Urinary bladder ................................Number examined: 50 20 19 50Hemorrhage 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, chronic 2 0 0 3Average severity: 0.0 0.0 0.0 0.1Hyperplasia, papillary 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Duodenum .......................................Number examined: 50 20 20 50Inflamation, acute 0 1 0 0Average severity: 0.0 0.2 0.0 0.0Jejunum ........................................Number examined: 50 20 20 50Ileum ..........................................Number examined: 50 20 19 50Colon ..........................................Number examined: 50 20 20 50Pancreas .......................................Number examined: 50 18 20 50Fibrosis 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Rectum .........................................Number examined: 50 20 20 50Metaplasia, squamous 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Adrenal glands .................................Number examined: 49 20 21 50Cyst 0 0 1 1Average severity: 0.0 0.0 0.1 0.0Degeneration, cytoplasmic vacuolization 12 1 0 14Average severity: 0.3 0.1 0.0 0.3Necrosis 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Adrenal glands .................................Number examined: 49 20 21 50Thrombus 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Hyperplasia, cortical, focal 2 0 0 1Average severity: 0.0 0.0 0.0 0.0Hyperplasia, focal 1 0 2 2Average severity: 0.0 0.0 0.1 0.0Uterus .........................................Number examined: 50 24 31 50Angiectasis 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Dilatation 0 1 4 3Average severity: 0.0 0.1 0.3 0.2Intussusception 1 1 0 2Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 3 0 0 0Average severity: 0.1 0.0 0.0 0.0Inflammation, chronic 3 0 0 0Average severity: 0.1 0.0 0.0 0.0Hyperplasia, cystic endometrial 11 4 4 11Average severity: 0.4 0.4 0.3 0.4Mesenteric LN ..................................Number examined: 50 19 20 50Hemorrhage 1 0 1 0Average severity: 0.0 0.0 0.1 0.0Inflammation, chronic 1 0 1 0Average severity: 0.1 0.0 0.1 0.0Ovaries ........................................Number examined: 49 21 23 50Congestion 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Cyst, bursa 0 0 1 1Average severity: 0.0 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Ovaries ........................................Number examined: 49 21 23 50Cyst, epithelial 1 1 0 0Average severity: 0.0 0.0 0.0 0.0Cyst, follicular 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Cyst, rete ovarii 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Hemorrhage 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Necrosis, mesenteric fat 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Sciatic nerve ..................................Number examined: 50 20 19 50Muscle, skeletal ...............................Number examined: 50 20 20 50Mammary gland ..................................Number examined: 49 20 22 47Ectasia 3 0 0 1Average severity: 0.1 0.0 0.0 0.0Hyperplasia, lobular 1 0 1 2Average severity: 0.0 0.0 0.1 0.1Skin ...........................................Number examined: 50 19 20 49Cyst, epithelial inclusion 0 1 0 0Average severity: 0.0 0.1 0.0 0.0Fibrosis 0 0 1 0Average severity: 0.0 0.0 0.2 0.0Inflammation, mixed 0 0 1 0Average severity: 0.0 0.0 0.1 0.0Brain ..........................................Number examined: 50 25 25 50Compression 2 8 9 9Average severity: 0.1 0.7 1.0 0.4Hemorrhage 1 1 0 0Average severity: 0.0 0.1 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Brain ..........................................Number examined: 50 25 25 50Metaplasia, osseous, meninges 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Necrosis 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Inflammation, chronic 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Eyes/optic nerve ...............................Number examined: 50 22 24 50Atrophy 1 1 0 2Average severity: 0.1 0.2 0.0 0.2Atrophy, retinal, unilateral 0 2 1 0Average severity: 0.0 0.4 0.1 0.0Cataract 1 3 1 2Average severity: 0.0 0.1 0.0 0.0Metaplasia, osseous, scleral 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Mineralization, corneal stromal 4 0 0 4Average severity: 0.1 0.0 0.0 0.1Mineralization, scleral 2 2 2 4Average severity: 0.0 0.2 0.1 0.1Neovascularization, corneal 1 0 0 2Average severity: 0.0 0.0 0.0 0.0Bone, femur ....................................Number examined: 50 20 19 50New bone formation, endosteal 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Spinal cord ....................................Number examined: 50 20 19 50Degeneration, white matter 1 0 0 1Average severity: 0.0 0.0 0.0 0.0Hemorrhage 1 0 1 0Average severity: 0.0 0.0 0.1 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 9Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Spinal cord ....................................Number examined: 50 20 19 50Necrosis, neuronal 0 0 0 1Average severity: 0.0 0.0 0.0 0.0Nose/Turbinate 1 ...............................Number examined: 50 50 49 50Degeneration, hyaline - respiratory epithelium 3 7 6 2Average severity: 0.1 0.2 0.2 0.1Inflammation, mixed 5 5 4 4Average severity: 0.3 0.2 0.2 0.1Inflammation - nasolacrimal duct 21 15 20 22Average severity: 0.9 0.7 1.1 1.3Inflammation - respiratory epithelium 1 0 0 1Average severity: 0.1 0.0 0.0 0.0Hyperplasia - respiratory epithelium 0 1 2 2Average severity: 0.0 0.0 0.1 0.1Nose/Turbinate 2 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 4 5 6 10Average severity: 0.1 0.2 0.2 0.3Degeneration, hyaline - respiratory epithelium 0 1 7 6Average severity: 0.0 0.0 0.3 0.2Metaplasia, secretory - olfactory epithelium 1 0 0 0Average severity: 0.1 0.0 0.0 0.0Metaplasia, squamous - olfactory epithelium 0 0 1 0Average severity: 0.0 0.0 0.0 0.0Inflammation, mixed 3 4 2 2Average severity: 0.2 0.1 0.1 0.1Hyperplasia - respiratory epithelium 0 2 0 1Average severity: 0.0 0.1 0.0 0.1Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 0 1 0 0Average severity: 0.0 0.0 0.0 0.0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 10Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Nose/Turbinate 3 ...............................Number examined: 50 50 50 50Degeneration, hyaline - olfactory epithelium 4 2 10 8Average severity: 0.1 0.1 0.4 0.3Degeneration - respiratory epithelium 0 2 0 1Average severity: 0.0 0.1 0.0 0.0Inflammation, mixed 1 3 1 0Average severity: 0.1 0.1 0.0 0.0Nose/Turbinate 4 ...............................Number examined: 50 50 50 50Degeneration - olfactory epithelium 0 1 0 0Average severity: 0.0 0.0 0.0 0.0Degeneration, hyaline - olfactory epithelium 3 0 0 3Average severity: 0.1 0.0 0.0 0.1Inflammation, mixed 1 1 0 0Average severity: 0.0 0.0 0.0 0.0Cervix .........................................Number examined: 2 5 3 2Clitoral gland .................................Number examined: 1 0 3 0Lymph node other ...............................Number examined: 3 1 3 1Hemorrhage 1 0 0 0Average severity: 0.3 0.0 0.0 0.0Infiltration, histiocytic 1 0 0 0Average severity: 0.7 0.0 0.0 0.0Popliteal LN ...................................Number examined: 1 1 0 0Iliac LN .......................................Number examined: 2 2 2 0Pancreatic LN ..................................Number examined: 2 1 2 1Mediastinal LN .................................Number examined: 50 20 20 47Hemorrhage 4 1 1 1Average severity: 0.2 0.1 0.1 0.0Infiltration, histiocytic 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 11Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Mediastinal LN .................................Number examined: 50 20 20 47Pigmentation 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Pituitary gland ................................Number examined: 50 32 34 50Angiectasis 9 1 3 6Average severity: 0.4 0.1 0.2 0.3Cyst 24 9 10 12Average severity: 0.9 0.6 0.6 0.4Degeneration 1 0 0 0Average severity: 0.0 0.0 0.0 0.0Hemorrhage 5 0 0 10Average severity: 0.2 0.0 0.0 0.5Necrosis 0 0 0 1Average severity: 0.0 0.0 0.0 0.1Hyperplasia, focal 8 3 8 4Average severity: 0.4 0.2 0.5 0.2Tail ...........................................Number examined: 0 0 1 1Inflammation, acute 0 0 1 0Average severity: 0.0 0.0 2.0 0.0Inflammation, mixed 0 0 0 1Average severity: 0.0 0.0 0.0 3.0Hyperplasia/hyperkeratosis 0 0 1 1Average severity: 0.0 0.0 3.0 4.0Bone, rib ......................................Number examined: 0 0 0 1Mesentery ......................................Number examined: 1 0 0 1Splenic tissue, "accessory" 1 0 0 0Average severity: 1.0 0.0 0.0 0.0Bone, vertebrae ................................Number examined: 1 0 0 0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03Lovelace Respiratory Lesion incidence summary with average severity grades Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 12Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Zymbal’s gland .................................Number examined: 1 0 0 0Mediastinum ....................................Number examined: 1 0 0 0Bone, other ....................................Number examined: 0 0 1 0Fracture 0 0 1 0Average severity: 0.0 0.0 1.0 0.0Harderian gland ................................Number examined: 0 0 1 0Pigment 0 0 1 0Average severity: 0.0 0.0 2.0 0.0Vagina .........................................Number examined: 0 1 0 0Tiss.not specifi ...............................Number examined: 0 0 0 0Nonneoplastic Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-6 Raw DataLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Lungs (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - 1 - - - 1 1 - 1 - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - 2 1 - 1 - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - - - 2 - 1 - - 2= - - 2 2 2 -74-N-Leukemia,monuc - inv invol - - 2= - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - - - - - - - - -297-Inflammation, mixed s - - - - - - - - - - - - - -62-N-Leukemia, monuc - - 1= - - - - 1= - - - - - -Thyroid glands (8) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - - - - - - - -77-Hyperplasia, C-cell, focal s - - - - 1 - - - - 3 2 - - - -81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -35-B-Adenoma, C-cell - - - - - - - - - - - - - - -78-B-Adenoma, follicular cell - - - - - - - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - - - - 1= - - -80-M-Carcinoma, follicular cell - - - 1= - - - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - - - - - - - -Parathyroid (2) Status > mH mH mH mH m m mH mH mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - - - - - - - - -296-B-Adenoma - - - - - - - - - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - - - - - 2 - - - - - - -1-Hyperplasia s 1 2 1 - 1 - 1 - - - - 1 - 2 -23-Inflammation, acute s - - - - - - - - 1 1 - - - - -42-Inflammation, mixed s 2 2 1 - 1 - 2 2 - - 2 2 - 2 -53-Inflammation, chronic s - - - - - 1 - - - - - - - - 1Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (2) Status > * * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - - - - - -44-N-Leukemia, monuc - - - - - - - 1= - - - 1Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - - - - - - - -158-Congestion s - 2= - - - - - - - - - - - - -90-Fatty Change s - - - - - - - - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - - - - - - - - -92-Hdn p - - - - - - - - - - - - - - -4-Necrosis s - 1 - - - - - - - - - - - - -230-Thrombus s - - - - - - - - - - - - - - -13-Vaculoliz cyto s - 1 - - - - 3 - - - - - - 3 -24-Inflammation, acute s - - - - - - - - - - - - - - -54-Inflammation, chronic s - - - - - - - 1 - - 1 - - - -46-Hyperplasia, biliary s 1 - 2 1 2 2 - 1 - 2 - - 2 - -47-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-M-Leukemia, monuc - 1 1= 2= - 1 2= - 2 - - 2= 2 2= -Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Fibrosis s - - - - - - - - - - - - - - -226-Hemorrhage s - - - - - - - - - - - - - - -97-Necrosis s - - - - - - - - - - - - - - -15-M-Leukemia, monuc - - 2= 2= - 1= 2= - 2= - - 1 2= 2= -298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Kidneys (9) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - - - - - - - - -149-Cyst s - - - - - - - - - - - - - - -209-Degen, hyaline droplet s - - - - - - - - - - - - - - -210-Dilatation s - - - - - - - - - - - - - - -228-Infarct s - - - - - - - - - - - - - - -16-Nephropathy, chronic s 1 1 1 - - 1 1 1 - 1 2 2 1 - 16-Pigment accum, tub epi s - - - - - - - - - - - - - - -98-M-Leukemia, monuc - - - - - - - - - - - - - - -299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142100-Degen, myocyte s - 2 - - - - - - - - - - - - -101-Fibrosis s - - - - - - - - - - - - - - -175-Thrombus s - - - - - - - - - - - - - 1= -36-Inflammation, focal, chronic s 1 - - 1 2 - - - - 1 1 1 1 - 148-M-Leukemia, monuc - - 1 - - - - - 1 - - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - - - - - - - - -103-Inflammation, mixed s - - - - - - - - - - - - - - -217-M-Carcinoma, metastatic - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - - - - - - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - - - - - - - - -56-Inflammation, chronic s - - - - 1 - - - - - - - - - -166-Hyperplasia, papillary s - - - - - 2 - - - - - - - - -106-M-Leukemia, monuc - - 1 - - - - - - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - - - - - - - - -Jejunum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Ileum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - - - - - - - - - -110-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - - - - - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -113-Degen, cytopl vacuol s - 1 - - - - - 1 - - - 1 - 1 -170-Necrosis s - - - - - - 1 - - - - - - - -118-Thrombus s - - - - - - 1 - - - - - - - -117-Hyperplasia, cortical, focal s - - - 1 - - - - - - - - - - -64-Hyperplasia, focal p - - - - - - - - - - - - - - -116-B-Pheochrom, bgn - - - - - - - - - - - - - - -216-M-Carcinoma, metastatic - - - - - - - - - - - - - - -112-M-Leukemia, monuc - - 1 - - - 1 - - - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - - - - - -7-Dilatation s - - - - - - - - - - - - - - -167-Intussusception p - - - - - - - - - - - - - - -162-Inflammation, mixed s - - 2 - 1 - - - - 2 - - - - -49-Inflammation, chronic s - - - - - - - - - - - - - - -20-Hyperplasia, cystic endom s - - - - - 4= - 1 1 - - - - - -286-B-Adenoma, endometrial - - - - - - - - - - - - - - -9-B-Polyp, endometrial stromal - - - - 1= - - - - 1= - - - - -213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - -279-M-Leiomyosar - - - - - - - - - - - - - - -165-M-Leukemia, monuc - - 2= - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - - - - - - - - - -173-Inflammation, chronic s - - - - - - - - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -32-N-Leukemia, monuc - - 1= - - - - - 1= - - 1 - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Ovaries (9) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - - - - - - - -154-Cyst, bursa p - - - - - - - - - - - - - -234-Cyst, epithelial p - - - - - - - - - - - - - -293-Cyst, follicular p - - - - - - - - - - - - - -291-Cyst, rete ovarii s - - - - - - - - - - - - - -25-Hemorrhage s - - - - - - - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - - - - - - - -163-M-Leukemia, monuc - - 1 - - - - - - - - - - -Sciatic nerve Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Mammary gland (6) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142159-Ectasia s - 3 - - - - - - - - - - - -190-Hyperplasia, lobular s - - - - - - - - - - - - - -156-B-Fibroadenoma - - - - - - - - - - - - - -70-B-Fibroma - - - - - - - - 1= - - - - -235-M-Adenocarcinoma - - - - - - - - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - - - - - - - - - -122-Fibrosis s - - - - - - - - - - - - - - -253-Inflammation, mixed s - - - - - - - - - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Compression s - - - - - - - - - - - - - - -192-Hemorrhage s - - - - - - - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - -33-Necrosis s - - - - - - - - - - - - - - -194-Inflammation, chronic s - - - - - - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - - - - - - - - -129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -130-Cataract p - - - - - - - - - - - - - - -133-Metaplasia, osseous, sclera s - - - - - - - - - - - - 1 - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 6Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - 1 - - - - - 1 - - - - - -126-Mineralization, scleral s - - - - - - - - - - - - - - -131-Neovascularization, corneal s - - 1 - - - - - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - - - - - - - - -197-Hemorrhage s - - - - - - - - - - - - - - -231-Necrosis, neuronal s - - - - - - - - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -134-Inflammation, mixed s - - - - - - 2 - - - - - - 3 -34-Inflammation-nasolac duct s 3 2 - - - 3 2 - - - - - - - 2136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - 2 - - - - - - - - - - - 1261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - 4= -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - - - - - - - - - 3 -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - 3 - - - - - - - - - - - 1232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - 2 - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 7Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Cervix (3) Status > M M M M M M M M M M M M M M MOperator > 142168-B-Polyp, endometrial stromal -289-M-Leiomyosarcoma -269-N-Adenocarcinoma, endometr -Clitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - - - - - - - - - 23-Infiltration, histiocytic s - - - - - - - - - - - - - - -2-Pigmentation s - - - - - - - - - - - - - - -273-B-Thymoma - - - - - - - - - - - - - - -219-M-Carcinoma, metastatic - - - - - - - - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -41-N-Leukemia, monuc - - 1= - - - - - 2= - - - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - 2= - 1 - - 2 - - - - -37-Cyst s 2= 4= 1 2= - 1= 1 - - - 3= 3= - 2 -38-Degen s - - - - - - - - - - - - - - -148-Hemorrhage s - - - - - - - - - - - - - - 1203-Necrosis s - - - - - - - - - - - - - - -57-Hyperplasia, focal s - - - - 2 - - - - 3= 3 - - - -31-B-Adenoma, pars distalis - - - - - - - 1= - - - - 1= - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 8Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 9Rat/F344/NGroup Sex Dosage Animal > 6832E452 6832E454 6832E456 6832E458 6832E460 6832E462 6832E4641 F 0 g/m3 Animal > 6832E451 6832E453 6832E455 6832E457 6832E459 6832E461 6832E463 6832E465Tissue/diagnosis Death code > FS FS U2 U1 U2 FS U2 FS U2 FS FS FS FS FS U2Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 10Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Lungs (12) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - - - - - - - - - 1 -30-Congestion s - - - - - - - 2= - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s 2= - - - - - - - - - - - - 1 -177-Inflammation, acute s - 1 - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - 1 - - - - - - 3 - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol 2 - - 2= - 2= - - 2= - 2= 2= - 1 1=74-N-Leukemia,monuc - inv invol - - - - 2= - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - 2 - - - - - 2 - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - - 2= - - - - - - -297-Inflammation, mixed s - - - - - - - - - - - - - - -62-N-Leukemia, monuc - - - - 1= - - - - - 1 - - - -Thyroid glands (8) Status > a aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - - - - - - - -77-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - -81-Hyperplasia, follicular cell s - - - - - - - - - - - - - 2= -35-B-Adenoma, C-cell - - - - - - - - - - - - - - -78-B-Adenoma, follicular cell - - - - - - - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - - - - - - - -Parathyroid (2) Status > m mH mH mH *H mH *H mH mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - - - - - - -296-B-Adenoma - - - - - - - - - - - - -Aorta (1) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 11Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - - - - 1 - - - - - - - -1-Hyperplasia s - - - - 1 1 - 1 - - 2 - - 2 123-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - 1 - - 1 2 - 2 - - 2 1 1 2 253-Inflammation, chronic s - - - - - - 1 - - 1 - - - - -Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (2) Status > *H *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - - - - - - -44-N-Leukemia, monuc - - - - 1 1 - - - 1 1 - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - - - - - - - -158-Congestion s - - - - - - - - - - - - - - -90-Fatty Change s - - - - - - - - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - - - - - - 3 - -92-Hdn p - - - - - - - - - - - - - - -4-Necrosis s - - - - - - - - 1 - - - - - 3=230-Thrombus s - - - - - - - - - - - - - - -13-Vaculoliz cyto s - - - 2 - - - - - - - 3 - - -24-Inflammation, acute s - - - - - - - 2 - - - - - - -54-Inflammation, chronic s - 1 2 - - - 1 - - 1 - - - - -46-Hyperplasia, biliary s 1 2 2 - 2 2 2 - - 2 2 - 1 1 147-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-M-Leukemia, monuc 2 - 1 2= 2= 2 - - 2= - 2= 2= - 2 -Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Fibrosis s 2= - - - - - - - - - - - - 1= -226-Hemorrhage s - - - - - - - - - - - - - - -97-Necrosis s - - - - - - - - - - - - - - -15-M-Leukemia, monuc 2= - 1 2= 2= 2= - - 2= - 2= 2= - 2= -298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 12Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Kidneys (9) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - - - - - - - - -149-Cyst s - - - - - - 3= - - - - - - - -209-Degen, hyaline droplet s - - - - - - - - - - - - - - -210-Dilatation s - - - - - - - - - - - - - - -228-Infarct s - - - - - - - - - - - - - - -16-Nephropathy, chronic s 1 1 1 2 2 1 2 1 1= 1 1 - 1 - 16-Pigment accum, tub epi s - - - - - - - - - - - - - - -98-M-Leukemia, monuc - - - - - - - - - - - - - - -299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - 1 - - - - - - - -101-Fibrosis s - - - - - - - - - - - - - - -175-Thrombus s - - - - - - - - - - - - - - -36-Inflammation, focal, chronic s - 1 1 - 1 - - - - 1 - - - - -48-M-Leukemia, monuc - - - - - - - - - - - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - - - - - - - - -103-Inflammation, mixed s - - - - - - - - - - - - - - -217-M-Carcinoma, metastatic - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Cecum (1) Status > a AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - - - - - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - - - - - - - - -56-Inflammation, chronic s - - - - - - - - - - - - - - -166-Hyperplasia, papillary s - - - - - - - - - - - - - - -106-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - - - - - - - - -Jejunum Status > U U U U U U U U U U U U U U UaOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 13Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Ileum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - - - - - - - - - -110-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum (1) Status > H aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - - - - - - - - -Adrenal glands (9) Status > AOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - -113-Degen, cytopl vacuol s - 1 - - - - - - - - - 1 1 -170-Necrosis s - - - - - - - - - - - - - -118-Thrombus s - - - - - - - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - - - - 1 - - -64-Hyperplasia, focal p - - - - - - - - - - - - - -116-B-Pheochrom, bgn - - - - - - - - - - - - - -216-M-Carcinoma, metastatic - - - - - - - - - - - - - -112-M-Leukemia, monuc - - - - - - - - - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - - - - - -7-Dilatation s - - - - - - - - - - - - - - -167-Intussusception p - - - - - - - - - - - - - - -162-Inflammation, mixed s - - - - - - - - - - - - - - -49-Inflammation, chronic s 1 - - - - - - - - - - - - - -20-Hyperplasia, cystic endom s - - 2= 2 - - 2 - - - - - 1 - -286-B-Adenoma, endometrial - - - - - - - - - - - - - - -9-B-Polyp, endometrial stromal - - - - - - - - - - - - - - -213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - -279-M-Leiomyosar - - - - - - - - - - - - - - -165-M-Leukemia, monuc - - - - 1 - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - 2 - - - - - - - -173-Inflammation, chronic s - - - - - - - - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -32-N-Leukemia, monuc - - - - 1 - - - 2 - 1 1 - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 14Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Ovaries (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - - - - - - - - -154-Cyst, bursa p - - - - - - - - - - - - - - -234-Cyst, epithelial p - - - - - - - - - - - - - - -293-Cyst, follicular p - - - - - - - - - - - - - - -291-Cyst, rete ovarii s - - - - - - - - - - - - - - -25-Hemorrhage s - - - - - - - 2= - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -163-M-Leukemia, monuc - - - - - - - - - - - - - - -Sciatic nerve Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142159-Ectasia s - - - - - - - - - - 1 - - - -190-Hyperplasia, lobular s - - - - - - - - - - - - - - -156-B-Fibroadenoma - - - - - - - - - - - - - - -70-B-Fibroma - - - - - - - - - - - - - - -235-M-Adenocarcinoma - - - - - - - - - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - - - - - - - - - -122-Fibrosis s - - - - - - - - - - - - - - -253-Inflammation, mixed s - - - - - - - - - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Compression s - - - - - - - 3= - - - - - - -192-Hemorrhage s - - - - - - - 2 - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - -33-Necrosis s - - - - - - - - 2= - - - - - -194-Inflammation, chronic s - - - - - - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (7) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - - - - 3 - - - -129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -130-Cataract p - - - - - - - - - - P= - - - -133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 15Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Eyes/optic nerve (7) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - - - - - - 2 - - - -126-Mineralization, scleral s - - - - - - - - - - - - - - 1131-Neovascularization, corneal s - - - - - - - - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - - - - - - - - -Spinal cord (3) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - 2 - - - - - - -197-Hemorrhage s - - - - - - - - - - - - - - -231-Necrosis, neuronal s - - - - - - - - - - - - - - -Nose/Turbinate 1 (5) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -134-Inflammation, mixed s - - - - - - 3 - - - - 4 - - -34-Inflammation-nasolac duct s - - - - - 3 3 - 3 2 2 2 2 - 2136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - 1 1 - - - - - - - - - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - - - - - - - 4 - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - 1 - - 1 - - - - - - - -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - 3 - - -Nose/Turbinate 4 (3) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - 1 - - 1 - - - - -144-Inflammation, mixed s - - - - - - - - - - - 2 - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 16Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Cervix (3) Status > M M M M M M M M M M M M M M MOperator > 142168-B-Polyp, endometrial stromal -289-M-Leiomyosarcoma -269-N-Adenocarcinoma, endometr -Clitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14229-Hemorrhage s 2= - - - - - - 3= - - - - - - 23-Infiltration, histiocytic s - - - - - - - - - - - - - - -2-Pigmentation s - - - - - - - - - - - - - - -273-B-Thymoma - - - - - - - - - - - - - - -219-M-Carcinoma, metastatic - - - - - - - - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -41-N-Leukemia, monuc - - - - 1 - - - - - 1 1 - - -Pituitary gland (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - 3= - - - - - - - 2= -37-Cyst s 2 1 - - 1 - - - - 2 1 - 1 2 -38-Degen s - - - - - - - - - - - - - - -148-Hemorrhage s - - - - - - - - - 1= - - - - -203-Necrosis s - - - - - - - - - - - - - - -57-Hyperplasia, focal s - - - - - 3 - - - - - - - 2 -31-B-Adenoma, pars distalis - - - - - - - 1= 1= - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 17Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Pituitary gland (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator > 142171-Splenic tissue, "accessory" p P=218-M-Carcinoma, metastatic -Bone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 18Rat/F344/NGroup Sex Dosage Animal > 6832E467 6832E469 6832E471 6832E473 6832E475 6832E477 6832E4791 F 0 g/m3 Animal > 6832E466 6832E468 6832E470 6832E472 6832E474 6832E476 6832E478 6832E480Tissue/diagnosis Death code > U2 FS U2 U2 U2 U2 FS U1 U2 FS U2 U1 FS U2 U1Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 19Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSLungs (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - 1 1 - - 1 - - - 1 - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - 1 - 1 - - - 2= - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - 1 - - - - - - 2= -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - 2= - 2 2= - 2 - - - 2 - 2 - -74-N-Leukemia,monuc - inv invol - - - - - - - - - 2= - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - 276-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - - - - - - - - - -297-Inflammation, mixed s - - - - - - - - - - - - - - -62-N-Leukemia, monuc - - - - 1= - - - - 1 1 - 1= - -Thyroid glands (8) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - - - - - - - -77-Hyperplasia, C-cell, focal s - - - - - - - - - - - - - - -81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -35-B-Adenoma, C-cell - 1= - - - - - - - - - - - - -78-B-Adenoma, follicular cell - - - - - - - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - - - - - - - -Parathyroid (2) Status > *H m m mH mH mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - - - - - - - -296-B-Adenoma - - - - - - - - - - - - 1= -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - - - 1 - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 20Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSEsophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - 3 - - - - - - - - - - 21-Hyperplasia s - 1 - - - - - 1 2 - - - - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - - 1 2 - - 2 2 2 - - - 1 - 253-Inflammation, chronic s - - - - - - - - - 1 1 1 - 1 -Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - 1 1 - - - - - - - - - -Mandibular LN (2) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - - - - - - - -44-N-Leukemia, monuc - - 1 - - 1= - - 1 1= - 1 - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - 1 - - - - - - - - - - - - -158-Congestion s - - - - - - - - - - - - - - -90-Fatty Change s - - - - - - - - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - - - - - - - - -92-Hdn p - - - - - - - - - - - - - - -4-Necrosis s - - - - - - - - - - - - - - -230-Thrombus s - - - - - - - - - - - - - - -13-Vaculoliz cyto s - - - - - - - - - - - - - - -24-Inflammation, acute s - - - - - - - - - - - - - - -54-Inflammation, chronic s 1 - 2 - - 1 - - 1 - - - - 1 246-Hyperplasia, biliary s - - 1 2 1 2 1 2 2 2 3 2 2 1 -47-Hyperplasia, hepato, regen s - - - 3= - - - - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-M-Leukemia, monuc - 2 - - 2= - 2 - - 2= 2= - 2= - -Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Fibrosis s - - - - - - - - - 3= - - - - -226-Hemorrhage s - - - - - - - - - - - - - - -97-Necrosis s - - - - - - - - - - 2 - - - -15-M-Leukemia, monuc - 1= - 2= 2= - 2= - - 2 2= - 2= - -298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 21Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSKidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - - - - - - - - -149-Cyst s - - - - - - - - - - - - - - -209-Degen, hyaline droplet s - - - - - - - - - - - - - - -210-Dilatation s - - - - - - - - - - - - - - -228-Infarct s - - - - - - - - - - - - - - -16-Nephropathy, chronic s 1 2 1 1 1 1 1 2 1 2 1 - 2 1 26-Pigment accum, tub epi s - - - - - - - - - - - - - - -98-M-Leukemia, monuc - - - - - - - - - - 1 - - - -299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142100-Degen, myocyte s - - 1 - - - - - - - - - - - -101-Fibrosis s - - - - - - - - - - - - - - -175-Thrombus s - - - - - - - - - - - - - - -36-Inflammation, focal, chronic s - 1 - 1 - 1 1 1 - - - 1 - 1 148-M-Leukemia, monuc - - - 1 - - - - - 1 - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - - - - - - - - -103-Inflammation, mixed s - - - - - - - - - - - - - - -217-M-Carcinoma, metastatic - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - 1 - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - 1 - - - - - 1 - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - - - - 2= - - - -56-Inflammation, chronic s - - - - - - - - - - - - - 1 -166-Hyperplasia, papillary s - - - - - - - - - - - - - - -106-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - - - - - - - - -Jejunum Status > U U U Ua U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 22Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSIleum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - 1 - - - - - - - - - -Colon Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - - - - - - - - - -110-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - - - - - - - - -Adrenal glands (9) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -113-Degen, cytopl vacuol s - - 1 - - - 3 - - 2 - - - - 1170-Necrosis s - - - - - - - - - - - - - - -118-Thrombus s - - - - - - - - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - - - - - - - - -64-Hyperplasia, focal p - - - - - - - - - - - - - - -116-B-Pheochrom, bgn - - - - - - 1= - - - - - - - -216-M-Carcinoma, metastatic - - - - - - - - - - - - - - -112-M-Leukemia, monuc - - - - - - - - - - 1 - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - - - - - -7-Dilatation s - - - - - - - - - - - - - - -167-Intussusception p P= - - - - - - - - - - - - - -162-Inflammation, mixed s - - - - - - - - - - - - - - -49-Inflammation, chronic s - - - 1 - - - - - - - - - - -20-Hyperplasia, cystic endom s - - 1 - - - - - 3= - 2 - - - -286-B-Adenoma, endometrial - - - - - - - - - - - - - - -9-B-Polyp, endometrial stromal - - - - 1= - - - - - - 1 - - 1=213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - -279-M-Leiomyosar - - - - - - - - - - - - - - -165-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - - - - - - - - - -173-Inflammation, chronic s 3 - - - - - - - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -32-N-Leukemia, monuc - - - 1 1= - 1= - - - 1= - 1= - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 23Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSOvaries (9) Status > mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - - - - - - - - -154-Cyst, bursa p - - - - - - - - - - - - - - -234-Cyst, epithelial p - - - - - - - - - - - - - - P=293-Cyst, follicular p - - - - - - - - - - - - - - -291-Cyst, rete ovarii s - - - - - - - - - - - - - - -25-Hemorrhage s - - - - - - - - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -163-M-Leukemia, monuc - - - - - - - - - - - - - - -Sciatic nerve Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142159-Ectasia s - - - - - - - - - 1 - - - - -190-Hyperplasia, lobular s - - - - - - - - - - - - - - -156-B-Fibroadenoma - - - - - - - - - - - - - - -70-B-Fibroma - - - - - - - - - - - - - - -235-M-Adenocarcinoma - - - - - - - - - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - - - - - - - - - -122-Fibrosis s - - - - - - - - - - - - - - -253-Inflammation, mixed s - - - - - - - - - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Compression s - - - - - - - 4= - - - - - - -192-Hemorrhage s - - - - - - - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - -33-Necrosis s - - - - - - - - - - - - - - -194-Inflammation, chronic s - - - - - - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - - - - - - - - -129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -130-Cataract p - - - - - - - - - - - - - - -133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 24Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSEyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - - - - - - - - - 1 -126-Mineralization, scleral s - - - - - - - - - - - - - - -131-Neovascularization, corneal s - - - - - - - - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - - - - - - - - -197-Hemorrhage s - - - - - - - - - - 2 - - - -231-Necrosis, neuronal s - - - - - - - - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - 3 - - - - 3 - - - - 1 - - -134-Inflammation, mixed s - - - - - 3 - - - - - - - - -34-Inflammation-nasolac duct s - - - 1 3 - - - 3 2 - - - 1 3136-Inflammation-resp epith s - - - - - 3 - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - 2 - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 25Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSCervix (3) Status > M M M M M M M M M M M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M M M M M M M M M M aM MOperator > 142294-B-Adenoma -61-M-Carcinoma, squamous cell 2=271-N-Adenocarcinoma -Lymph node other (3) Status > M M M M M M M M M M M M M M MOperator > 142 14260-Hemorrhage s - 1=59-Infiltration, histiocytic s - 265-N-Leukemia, monuc 1= -Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator > 14267-N-Leukemia, monuc 1=Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14268-N-Leukemia, monuc 1=Mediastinal LN (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - - - - - - - - - -3-Infiltration, histiocytic s - - - - - - - - - - - - - - -2-Pigmentation s - - - - - - - - - - - - - - -273-B-Thymoma - - - - - - - - - - - - - - -219-M-Carcinoma, metastatic - - - - - - - - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -41-N-Leukemia, monuc - - - 1 1 - 1= - - 1= 1= - 1= - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - 2= - - - - 3= - 1 - - - - -37-Cyst s - 2= - - - 2 - - 3 2 2 - - - -38-Degen s - 2 - - - - - - - - - - - - -148-Hemorrhage s - - - - - - - - 3= - - - 2 - -203-Necrosis s - - - - - - - - - - - - - - -57-Hyperplasia, focal s - - - - - - - - 2 - - - - 1 -31-B-Adenoma, pars distalis - - - 1= - - - 1 - - - - 1= - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 26Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSPituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator > 142221-N-Leukemia, monuc 1=Zymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator > 142223-M-Carcinoma, squamous cell 1=Mediastinum (1) Status > M M M M M M M M M M M M M M MOperator > 142233-N-Leukemia, monuc 2=Bone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 27Rat/F344/NGroup Sex Dosage Animal > 6832E482 6832E484 6832E486 6832E488 6832E490 6832E492 6832E4941 F 0 g/m3 Animal > 6832E481 6832E483 6832E485 6832E487 6832E489 6832E491 6832E493 6832E495Tissue/diagnosis Death code > U2 U2 FS U2 U2 FS U2 U2 FS FS U2 U2 FS U2 FSTiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 28Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSLungs (12) Status >Operator > 142 142 142 142 14240-Alveolar histiocytosis s - - - - -30-Congestion s - - - - -71-Fibrosis, focal s - - - - -182-Hemorrhage s - - - - -177-Inflammation, acute s - - - - -72-Inflammation, mixed s - - - - -236-Inflammation, granulomatous s - - - - -10-Hyperplasia, alv. epi. focal s - - - - -214-N-Carcinoma, metastatic - - - - -11-N-Leukemia,monuc - cap invol 2 - - 2 -74-N-Leukemia,monuc - inv invol - - - - -204-N-Sarcoma, histiocytic - - - - -Trachea (4) Status >Operator > 142 142 142 142 14222-Inflammation, acute s - - - - -75-Inflammation, mixed s - - - - -76-Hyperplasia s - - - - -238-N-Leukemia, monuc - - - - -Bronchial (TBLN) (3) Status > *HOperator > 142 142 142 142 14221-Hemorrhage s - - - -297-Inflammation, mixed s - - - -62-N-Leukemia, monuc 1= - - -Thyroid glands (8) Status > mOperator > 142 142 142 142 14279-Cyst, follicular p - - - - -77-Hyperplasia, C-cell, focal s - - - - -81-Hyperplasia, follicular cell s - - - - -35-B-Adenoma, C-cell - - - - -78-B-Adenoma, follicular cell - - - - -174-M-Carcinoma, C-cell - - - - -80-M-Carcinoma, follicular cell - - - - -178-M-Leukemia, monuc - - - - -Parathyroid (2) Status > mH mOperator > 142 142 142 142 142241-Hyperplasia, focal s - 2 - - -296-B-Adenoma - - - - -Aorta (1) Status >Operator > 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 29Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSEsophagus Status > U U U U UOperator > 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 14212-Metaplasia, squamous s 2 - - - -1-Hyperplasia s - - - - 123-Inflammation, acute s - - - - -42-Inflammation, mixed s 3 - - 1 153-Inflammation, chronic s - - - - -Salivary gland (1) Status >Operator > 142 142 142 142 14243-M-Leukemia, monuc - - - - -Mandibular LN (2) Status >Operator > 142 142 142 142 14289-Hemorrhage s - - - - -44-N-Leukemia, monuc 1= - - - -Liver (15) Status >Operator > 142 142 142 142 14245-Angiectasis s - - - - -158-Congestion s - - - - -90-Fatty Change s - - - - -150-Foci cell alter, basophilic s - - - - -92-Hdn p - - - - -4-Necrosis s - - - - -230-Thrombus s - - - - -13-Vaculoliz cyto s - - - - -24-Inflammation, acute s - - - - -54-Inflammation, chronic s - - 1 - -46-Hyperplasia, biliary s 1 - 2 2 247-Hyperplasia, hepato, regen s - - - - -91-B-Adenoma, hepatocellular - 1= - - -205-M-Sarcoma, histiocytic - - - - -14-M-Leukemia, monuc 2= 1 - 2= -Spleen (5) Status >Operator > 142 142 142 142 14296-Fibrosis s - - - - -226-Hemorrhage s - - - - -97-Necrosis s - - - - -15-M-Leukemia, monuc 1= 1 - 2= -298-N-Sarcoma, histiocytic - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 30Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSKidneys (9) Status >Operator > 142 142 142 142 142211-Atrophy s - - - - -149-Cyst s - - - - -209-Degen, hyaline droplet s - - - - -210-Dilatation s - - - - -228-Infarct s - - - - -16-Nephropathy, chronic s 1 1 - 1 16-Pigment accum, tub epi s - - - - -98-M-Leukemia, monuc - - - - -299-N-Sarcoma, histiocytic - - - - -Heart (5) Status >Operator > 142 142 142 142 142100-Degen, myocyte s - - - - -101-Fibrosis s - - - - 1175-Thrombus s - - - - -36-Inflammation, focal, chronic s - 1 1 1 148-M-Leukemia, monuc 1 - - - -Stomach (4) Status >Operator > 142 142 142 142 142268-Ulcer s - - - - -103-Inflammation, mixed s - - - - -217-M-Carcinoma, metastatic - - - - -220-M-Leukemia, monuc - - - - -Cecum (1) Status >Operator > 142 142 142 142 142104-N-Leukemia, monuc - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142186-Hemorrhage s - - - - -56-Inflammation, chronic s - - - - -166-Hyperplasia, papillary s - - - - -106-M-Leukemia, monuc - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142275-Inflammation, acute s - - - - -Jejunum Status > U U U U UOperator > 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 31Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSIleum (1) Status >Operator > 142 142 142 142 142181-N-Leukemia, monuc - - - - -Colon Status > U U U U UOperator > 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142212-Fibrosis s - - - - -110-M-Leukemia, monuc - - - - -Rectum (1) Status >Operator > 142 142 142 142 142276-Metaplasia, squamous s - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142161-Cyst s - - - - -113-Degen, cytopl vacuol s - - - - 1170-Necrosis s - - - - -118-Thrombus s - - - - -117-Hyperplasia, cortical, focal s - - - - -64-Hyperplasia, focal p P - - - -116-B-Pheochrom, bgn - - - - -216-M-Carcinoma, metastatic - - - - -112-M-Leukemia, monuc - - - - -Uterus (11) Status >Operator > 142 142 142 142 142277-Angiectasis s - - - - -7-Dilatation s - - - - -167-Intussusception p - - - - -162-Inflammation, mixed s - - - - -49-Inflammation, chronic s 1 - - - -20-Hyperplasia, cystic endom s - 1 - - -286-B-Adenoma, endometrial - - - - -9-B-Polyp, endometrial stromal - - - - -213-M-Adenocarcinoma, endometr - - - - -279-M-Leiomyosar - - - - -165-M-Leukemia, monuc - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142120-Hemorrhage s - - - - -173-Inflammation, chronic s - - - - -206-N-Sarcoma, histiocytic - - - - -32-N-Leukemia, monuc 1= - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 32Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSOvaries (9) Status >Operator > 142 142 142 142 142284-Congestion s - - - - -154-Cyst, bursa p - - - - -234-Cyst, epithelial p - - - - -293-Cyst, follicular p - - - - -291-Cyst, rete ovarii s - - - - -25-Hemorrhage s - - - - -290-Necrosis, mesenteric fat s - - - - -207-N-Sarcoma, histiocytic - - - - -163-M-Leukemia, monuc - - - - -Sciatic nerve Status > U U U U UOperator > 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142159-Ectasia s - - - - -190-Hyperplasia, lobular s - - - - 1=156-B-Fibroadenoma - - - - -70-B-Fibroma - - - - -235-M-Adenocarcinoma - - - - -224-M-AdenoCA arising in fibroAD - - - 2= -Skin (3) Status >Operator > 142 142 142 142 142252-Cyst, epith inc p - - - - -122-Fibrosis s - - - - -253-Inflammation, mixed s - - - - -Brain (6) Status >Operator > 142 142 142 142 14226-Compression s - - - - -192-Hemorrhage s - - - - -155-Metaplasia, osseous, meninge s - - - - -33-Necrosis s - - - - -194-Inflammation, chronic s - - - - -256-M-Astrocytoma, malignant - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142127-Atrophy s - - - - -129-Atrophy, retinal, unilat s - - - - -130-Cataract p - - - - -133-Metaplasia, osseous, sclera s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 33Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSEyes/optic nerve (7) Status >Operator > 142 142 142 142 14258-Mineralization, corneal str s - - - - -126-Mineralization, scleral s - - 1 - -131-Neovascularization, corneal s - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142179-New bone, endosteal s - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 14227-Degen, white matter s - - - - -197-Hemorrhage s - - - - -231-Necrosis, neuronal s - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - -134-Inflammation, mixed s - - - - -34-Inflammation-nasolac duct s 1 1 - - -136-Inflammation-resp epith s - - - - -199-Hyperplasia-resp epith s - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - -261-Degeneration,hyal-resp epith s - - - - -176-Metaplasia, sec-olfact epith s - - - - -270-Metaplasia, squ-olfact epith s - - - - -138-Inflammation, mixed s - - - - -227-Hyperplasia-resp epith s - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142295-Degeneration-olfact epith s - - - - -19-Degeneration,hyaline-olf epi s - - - - -232-Degeneration-resp epith s - - - - -142-Inflammation, mixed s - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142285-Degeneration-olfact epith s - - - - -164-Degeneration,hyaline-olf epi s - - - - -144-Inflammation, mixed s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 34Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSCervix (3) Status > M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M MOperator > 14260-Hemorrhage s -59-Infiltration, histiocytic s -65-N-Leukemia, monuc 1=Popliteal LN (1) Status > M M M M MOperator > 14266-N-Leukemia, monuc 1=Iliac LN (1) Status > M M M M MOperator > 14267-N-Leukemia, monuc 1=Pancreatic LN (1) Status > M M M M MOperator > 14268-N-Leukemia, monuc 1=Mediastinal LN (7) Status >Operator > 142 142 142 142 14229-Hemorrhage s - - - - -3-Infiltration, histiocytic s - - - - -2-Pigmentation s - - - - -273-B-Thymoma - - - - -219-M-Carcinoma, metastatic - - - - -265-N-Sarcoma, histiocytic - - - - -41-N-Leukemia, monuc 1= - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142160-Angiectasis s - 2 - - -37-Cyst s 2= - 3 - 138-Degen s - - - - -148-Hemorrhage s - 3= - - -203-Necrosis s - - - - -57-Hyperplasia, focal s 3 - - - -31-B-Adenoma, pars distalis - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 35Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSPituitary gland (10) Status >Operator > 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - -288-M-Carcinoma - - - - -146-M-Leukemia, monuc - - - - -Tail (3) Status > M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M MOperator >278-Pigment sVagina (1) Status > M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 36Rat/F344/NGroup Sex Dosage Animal > 6832E497 6832E4991 F 0 g/m3 Animal > 6832E496 6832E498 6832E500Tissue/diagnosis Death code > U2 FS FS U2 FSTiss.not specifi Status > M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 37Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Lungs (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - - - - - - - - - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol 1 2 - - - 1 - - - - - - - - -74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 14221-Hemorrhage s 2 - 3= -297-Inflammation, mixed s - - - -62-N-Leukemia, monuc - - - -Thyroid glands (8) Status >Operator > 142 142 142 142 14279-Cyst, follicular p - - - - -77-Hyperplasia, C-cell, focal s - - - - -81-Hyperplasia, follicular cell s - - - - -35-B-Adenoma, C-cell - - 1= - -78-B-Adenoma, follicular cell - - - - -174-M-Carcinoma, C-cell - - - - -80-M-Carcinoma, follicular cell - - - - -178-M-Leukemia, monuc - - - - -Parathyroid (2) Status > mHOperator > 142 142 142 142241-Hyperplasia, focal s - - - -296-B-Adenoma - - - -Aorta (1) Status >Operator > 142 142 142 14283-N-Leukemia,monuc - inv invol - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 38Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Esophagus Status > U U U UOperator > 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - 2 - - - - - - 1 - - 1 -1-Hyperplasia s - - 1 - - - - - - 1 - - 1 - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s 1 - 1 2 1 1 - - 1 - 2 - 2 2 153-Inflammation, chronic s - - - - - - - - - - - - - - -Salivary gland (1) Status >Operator > 142 142 142 14243-M-Leukemia, monuc - - - -Mandibular LN (2) Status > *HOperator > 142 142 142 14289-Hemorrhage s - - -44-N-Leukemia, monuc 1 - -Liver (15) Status >Operator > 142 142 142 142 142 142 14245-Angiectasis s - - - - - - -158-Congestion s - - - - - - -90-Fatty Change s - - - - - - -150-Foci cell alter, basophilic s - - - - - - -92-Hdn p - - - - - - -4-Necrosis s - - - - - - -230-Thrombus s - - - - - - -13-Vaculoliz cyto s - - - - - - -24-Inflammation, acute s - - - - - - -54-Inflammation, chronic s - - - - 1 - 246-Hyperplasia, biliary s 2 - 2 1 - - 147-Hyperplasia, hepato, regen s - - - - - - -91-B-Adenoma, hepatocellular - - - - - - -205-M-Sarcoma, histiocytic - - - - - - -14-M-Leukemia, monuc 1= 2= 1= 1= - - -Spleen (5) Status >Operator > 142 142 142 14296-Fibrosis s - - - -226-Hemorrhage s - - - -97-Necrosis s - - - -15-M-Leukemia, monuc 2= 1= - -298-N-Sarcoma, histiocytic - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 39Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Kidneys (9) Status >Operator > 142 142 142 142211-Atrophy s - - - -149-Cyst s - - - -209-Degen, hyaline droplet s - - - -210-Dilatation s - - - -228-Infarct s - - - -16-Nephropathy, chronic s 1 1 1 16-Pigment accum, tub epi s - - - -98-M-Leukemia, monuc - - - -299-N-Sarcoma, histiocytic - - - -Heart (5) Status >Operator > 142 142 142 142100-Degen, myocyte s - - - -101-Fibrosis s - - - -175-Thrombus s - - - -36-Inflammation, focal, chronic s - - 1 148-M-Leukemia, monuc - - - -Stomach (4) Status >Operator > 142 142 142 142268-Ulcer s - - - -103-Inflammation, mixed s - - - -217-M-Carcinoma, metastatic - - - -220-M-Leukemia, monuc - - - -Cecum (1) Status >Operator > 142 142 142 142104-N-Leukemia, monuc - - - -Urinary bladder (4) Status >Operator > 142 142 142 142186-Hemorrhage s - - - -56-Inflammation, chronic s - - - -166-Hyperplasia, papillary s - - - -106-M-Leukemia, monuc - - - -Duodenum (1) Status >Operator > 142 142 142 142275-Inflammation, acute s - - - -Jejunum Status > U U U UOperator > 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 40Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Ileum (1) Status >Operator > 142 142 142 142181-N-Leukemia, monuc - - - -Colon Status > U U U UOperator > 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142212-Fibrosis s - - - -110-M-Leukemia, monuc - - - -Rectum (1) Status >Operator > 142 142 142 142276-Metaplasia, squamous s - - - -Adrenal glands (9) Status >Operator > 142 142 142 142161-Cyst s - - - -113-Degen, cytopl vacuol s - - - -170-Necrosis s - - - -118-Thrombus s - - - -117-Hyperplasia, cortical, focal s - - - -64-Hyperplasia, focal p - - - -116-B-Pheochrom, bgn - - - -216-M-Carcinoma, metastatic - - - -112-M-Leukemia, monuc - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142277-Angiectasis s - - - - - - -7-Dilatation s - - 2= - - - -167-Intussusception p - - - - - - -162-Inflammation, mixed s - - - - - - -49-Inflammation, chronic s - - - - - - -20-Hyperplasia, cystic endom s 2 2 - - - - -286-B-Adenoma, endometrial - - - 1= - - -9-B-Polyp, endometrial stromal 1= 2= - - 1 1= 1=213-M-Adenocarcinoma, endometr - - - - - - -279-M-Leiomyosar - - - - 2= - -165-M-Leukemia, monuc - - - - - - -Mesenteric LN (4) Status > *HOperator > 142 142 142 142120-Hemorrhage s - - -173-Inflammation, chronic s - - -206-N-Sarcoma, histiocytic - - -32-N-Leukemia, monuc 1 - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 41Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Ovaries (9) Status >Operator > 142 142 142 142284-Congestion s - - - -154-Cyst, bursa p - - - -234-Cyst, epithelial p - P - -293-Cyst, follicular p - - - -291-Cyst, rete ovarii s - - - -25-Hemorrhage s - - - -290-Necrosis, mesenteric fat s - - - -207-N-Sarcoma, histiocytic - - - -163-M-Leukemia, monuc - - - -Sciatic nerve Status > U U U UOperator > 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142208-N-Sarcoma, histiocytic - - - -Mammary gland (6) Status > *HOperator > 142 142 142 142 142 142159-Ectasia s - - - - -190-Hyperplasia, lobular s - - - - -156-B-Fibroadenoma - - - 1= -70-B-Fibroma 1= - - - -235-M-Adenocarcinoma - - - - 1=224-M-AdenoCA arising in fibroAD - - - - -Skin (3) Status > *HOperator > 142 142 142 142252-Cyst, epith inc p - - -122-Fibrosis s - - -253-Inflammation, mixed s - - -Brain (6) Status >Operator > 142 142 142 142 142 14226-Compression s - - - 2= 2= 3=192-Hemorrhage s - - - - - -155-Metaplasia, osseous, meninge s - - - - - -33-Necrosis s - - - - - -194-Inflammation, chronic s - - - - - -256-M-Astrocytoma, malignant - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142127-Atrophy s - - - - -129-Atrophy, retinal, unilat s - 4 - - -130-Cataract p - P= - - -133-Metaplasia, osseous, sclera s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 42Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Eyes/optic nerve (7) Status >Operator > 142 142 142 142 14258-Mineralization, corneal str s - - - - -126-Mineralization, scleral s - - - - -131-Neovascularization, corneal s - - - - -Bone, femur (1) Status >Operator > 142 142 142 142179-New bone, endosteal s - - - -Spinal cord (3) Status >Operator > 142 142 142 14227-Degen, white matter s - - - -197-Hemorrhage s - - - -231-Necrosis, neuronal s - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - 1 - - - - - - - - - - 1 - -134-Inflammation, mixed s - - - - - - 1 - - - 2 - - - -34-Inflammation-nasolac duct s - - - - - 1 2 - 2 - 3 - 3 - -136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - 1 - - - - - - - - - - - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - - 1 - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - 1 - - - -19-Degeneration,hyaline-olf epi s - - - - - 1 - - - - - - - - -232-Degeneration-resp epith s - - - - - - 2 - - - - - - - -142-Inflammation, mixed s - - - - - - 2 - - - 1 - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - 2 - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - 2 - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 43Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Cervix (3) Status > M M M M M M M M M M M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 14229-Hemorrhage s - - - -3-Infiltration, histiocytic s - - - -2-Pigmentation s - - - -273-B-Thymoma - - - -219-M-Carcinoma, metastatic - - - -265-N-Sarcoma, histiocytic - - - -41-N-Leukemia, monuc 1 - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - - - -37-Cyst s - 2 2 2 - 4= - -38-Degen s - - - - - - - -148-Hemorrhage s - - - - - - - -203-Necrosis s - - - - - - - -57-Hyperplasia, focal s - - - - - - - -31-B-Adenoma, pars distalis - - 1= 1= - - - 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 44Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - -288-M-Carcinoma - - - - - - 1= -146-M-Leukemia, monuc - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator > 142287-M-Leiomyosarcoma 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 45Rat/F344/NGroup Sex Dosage Animal > 6834F552 6834F554 6834F556 6834F558 6834F560 6834F562 6834F5642 F 2 g/m3 Animal > 6834F551 6834F553 6834F555 6834F557 6834F559 6834F561 6834F563 6834F565Tissue/diagnosis Death code > FS U2 FS FS FS U2 FS FS FS FS FS U2 FS FS U2Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 46Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSLungs (12) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s 1 - 1 - - - - - - 1 - - - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - 2= - - - -177-Inflammation, acute s - - - - - - - - - - - - 1 - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - - 1= - - 2 1 - 1 - 2 - - 1 -74-N-Leukemia,monuc - inv invol - - - - - - - - - - - 2 - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - 1 - - -Bronchial (TBLN) (3) Status > *HOperator > 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - 2 -297-Inflammation, mixed s - - - - - - -62-N-Leukemia, monuc - - 1= 1 - - -Thyroid glands (8) Status >Operator > 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - -77-Hyperplasia, C-cell, focal s - - - 1 - 4 - - -81-Hyperplasia, follicular cell s - - - - - - - - -35-B-Adenoma, C-cell - - - 1= - - - - -78-B-Adenoma, follicular cell - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - -Parathyroid (2) Status > m mH mHOperator > 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - -296-B-Adenoma - - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 47Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSEsophagus Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - - - - - - 2 - - - - - 21-Hyperplasia s - 1 - - - 2 2 - - - - - - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - 2 2 - 1 2 2 - 2 1 - 1 1 - 253-Inflammation, chronic s - - - - - - - - - - - - - - -Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - -Mandibular LN (2) Status > *HOperator > 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - 2 -44-N-Leukemia, monuc - - 1= - 1 1 - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - - -158-Congestion s - - - - - - - - - -90-Fatty Change s - - - 1 - - - - - -150-Foci cell alter, basophilic s - - - - - - - - - -92-Hdn p P= - - - - P= - P= P= -4-Necrosis s 3= - - - - - - - - -230-Thrombus s - - - - - - - - - -13-Vaculoliz cyto s - - - - - - - - - -24-Inflammation, acute s - - - - - - - - - -54-Inflammation, chronic s - 1 - - - - - - 1 -46-Hyperplasia, biliary s 2 - - 2 - - 2 - 1 147-Hyperplasia, hepato, regen s - - - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - - -14-M-Leukemia, monuc - 1 2 2= 2 - 2= 2 - 1=Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 142 14296-Fibrosis s - - - - - - - - - -226-Hemorrhage s - - - - - - - - - -97-Necrosis s - - - - 4= - - - - -15-M-Leukemia, monuc - 1= 2= 2= 2= - 2= 2= - 1=298-N-Sarcoma, histiocytic - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 48Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSKidneys (9) Status >Operator > 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - -149-Cyst s - - - - - - - -209-Degen, hyaline droplet s - - - - - - - -210-Dilatation s - - - - - - - -228-Infarct s - - - - - - - -16-Nephropathy, chronic s - 1 1 2 1 1 2 16-Pigment accum, tub epi s - - - - - - - -98-M-Leukemia, monuc - - 1 - - - - -299-N-Sarcoma, histiocytic - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - - -101-Fibrosis s - - - - - - - -175-Thrombus s - - - - - - - -36-Inflammation, focal, chronic s 1 1 - - - 1 - -48-M-Leukemia, monuc - - 1 - - - 1 -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142268-Ulcer s - - - - - 2 - -103-Inflammation, mixed s - - - - - 2 - -217-M-Carcinoma, metastatic - - - - - - - -220-M-Leukemia, monuc - - - - - - 2 -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - 2 - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - -56-Inflammation, chronic s - - - - - - - -166-Hyperplasia, papillary s - - - - - - - -106-M-Leukemia, monuc - - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - -Jejunum Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 49Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSIleum (1) Status >Operator > 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - - -Colon Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Pancreas (2) Status > H *HOperator > 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - -110-M-Leukemia, monuc - - 2 - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - -Adrenal glands (9) Status > mOperator > 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - -113-Degen, cytopl vacuol s - - - - - - - -170-Necrosis s - - - - - - - -118-Thrombus s - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - -64-Hyperplasia, focal p - - - - - - - -116-B-Pheochrom, bgn - - - - - 1= - -216-M-Carcinoma, metastatic - - - - - - - -112-M-Leukemia, monuc - - - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - -7-Dilatation s - - - - - - - - -167-Intussusception p - - - - - - - - -162-Inflammation, mixed s - - - - - - - - -49-Inflammation, chronic s - - - - - - - - -20-Hyperplasia, cystic endom s - - - - 2 - - - -286-B-Adenoma, endometrial - - - - - - - - -9-B-Polyp, endometrial stromal 1= - - - - 1= - - -213-M-Adenocarcinoma, endometr - - - - - - 2= - -279-M-Leiomyosar - - - - - - - - -165-M-Leukemia, monuc - - 1 - - - 1 1 -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - - -173-Inflammation, chronic s - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - -32-N-Leukemia, monuc - - 1= - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 50Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSOvaries (9) Status >Operator > 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - -154-Cyst, bursa p - - - - - - - -234-Cyst, epithelial p - - - - - - - -293-Cyst, follicular p - - - - - - - -291-Cyst, rete ovarii s - - - - - - - -25-Hemorrhage s - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - -163-M-Leukemia, monuc - - 2= - - - - -Sciatic nerve Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - -Mammary gland (6) Status > *HOperator > 142 142 142 142 142 142 142 142159-Ectasia s - - - - - - -190-Hyperplasia, lobular s - - - - - - -156-B-Fibroadenoma - 1= - - - - -70-B-Fibroma - - 1= - - - -235-M-Adenocarcinoma - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - P= - -122-Fibrosis s - - - - - - - -253-Inflammation, mixed s - - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 142 14226-Compression s - - - 2= - - 3= - - 1=192-Hemorrhage s - - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - -33-Necrosis s - - - - - - - - - -194-Inflammation, chronic s - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - 2 -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142127-Atrophy s - - - - 4= - - -129-Atrophy, retinal, unilat s - - - - - - - -130-Cataract p - - - - P= - - -133-Metaplasia, osseous, sclera s - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 51Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSEyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - - - -126-Mineralization, scleral s - - - - - 2 - -131-Neovascularization, corneal s - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - -197-Hemorrhage s - - - - - - - -231-Necrosis, neuronal s - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - 1 - - - - - - - -134-Inflammation, mixed s - - - 1 - 2 - - - - - - - - -34-Inflammation-nasolac duct s - - - - - 1 - - - - - - 3 - -136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - - - - - - - 2 - - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - 2 2 - - - - - - - - - - -227-Hyperplasia-resp epith s - - 2 2 - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - - - - - - - - 2 - - - -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 52Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSCervix (3) Status > M M M M M M M M M M M M M M MOperator > 142 142 142 142 142168-B-Polyp, endometrial stromal - - - - -289-M-Leiomyosarcoma - 1= - - -269-N-Adenocarcinoma, endometr - - - - 1=Clitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator > 14260-Hemorrhage s -59-Infiltration, histiocytic s -65-N-Leukemia, monuc 1=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator > 14266-N-Leukemia, monuc 1=Iliac LN (1) Status > M M M M M M M M M M M M M M MOperator > 142 14267-N-Leukemia, monuc 1= 1=Pancreatic LN (1) Status > M M M M M M M M M M M *MH M M MOperator > 142 14268-N-Leukemia, monuc 1=Mediastinal LN (7) Status >Operator > 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - - -3-Infiltration, histiocytic s - - - - - - - -2-Pigmentation s - - - - - - - -273-B-Thymoma - - - - - - - -219-M-Carcinoma, metastatic - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - -41-N-Leukemia, monuc - 1 1= - 1= - 1= -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - - - - - - - -37-Cyst s - 2 1 - - - 3 - - - - -38-Degen s - - - - - - - - - - - -148-Hemorrhage s - - - - - - - - - - - -203-Necrosis s - - - - - - - - - - - -57-Hyperplasia, focal s - 1 - - - - - - - - - -31-B-Adenoma, pars distalis - - - 1= - - 1= 1= 1= - 1= 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 53Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSPituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - 1= - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 54Rat/F344/NGroup Sex Dosage Animal > 6834F567 6834F569 6834F571 6834F573 6834F575 6834F577 6834F5792 F 2 g/m3 Animal > 6834F566 6834F568 6834F570 6834F572 6834F574 6834F576 6834F578 6834F580Tissue/diagnosis Death code > U2 U2 U2 FS FS U2 U2 FS FS FS U1 U2 U2 FS FSTiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 55Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Lungs (12) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - - - - - - - - - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - 2= - - -182-Hemorrhage s - - - - - - - - - - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - 2= - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol 2 - - 1 1 - - - 2 - 1 - - - -74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - -297-Inflammation, mixed s - - - - - - -62-N-Leukemia, monuc - - - - - - -Thyroid glands (8) Status >Operator > 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - -77-Hyperplasia, C-cell, focal s - - 2 - - 3 -81-Hyperplasia, follicular cell s - - - - - - -35-B-Adenoma, C-cell - - - - - - -78-B-Adenoma, follicular cell - - - - - - -174-M-Carcinoma, C-cell - - - - - - -80-M-Carcinoma, follicular cell - - - - - - -178-M-Leukemia, monuc - - - - - - -Parathyroid (2) Status > m mOperator > 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - -296-B-Adenoma - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 56Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Esophagus Status > U U U U U U UOperator > 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - 1 - - - - 2 - - 1 1 - - -1-Hyperplasia s - 1 - - 1 - - - - - - - 1 - 123-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s 1 2 2 1 1 1 - 2 1 - 1 1 1 - -53-Inflammation, chronic s - - - - - - - - - - - - - 1 -Salivary gland (1) Status >Operator > 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - -Mandibular LN (2) Status > *Operator > 142 142 142 142 142 142 14289-Hemorrhage s - - - - - -44-N-Leukemia, monuc - 1 - - - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - -158-Congestion s - - - - - - - - -90-Fatty Change s - - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - - -92-Hdn p - - - - - - - - -4-Necrosis s - 1 - 2= - - - - -230-Thrombus s - - - - - - - - -13-Vaculoliz cyto s 2 - - - - - - - -24-Inflammation, acute s - - - - - - - - -54-Inflammation, chronic s - 1 - - - - - - -46-Hyperplasia, biliary s 2 1 - 2 - - 1 1 147-Hyperplasia, hepato, regen s - - 2= - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - -14-M-Leukemia, monuc 2= - 1= 2= - 1= - - -Spleen (5) Status >Operator > 142 142 142 142 142 142 14296-Fibrosis s - - - - - - -226-Hemorrhage s - - - - - - -97-Necrosis s - - - - - - -15-M-Leukemia, monuc 2= - 2= - - - -298-N-Sarcoma, histiocytic - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 57Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Kidneys (9) Status >Operator > 142 142 142 142 142 142 142211-Atrophy s - - - - - - -149-Cyst s - - - - - - -209-Degen, hyaline droplet s - - - - - - -210-Dilatation s - - - - - - -228-Infarct s - - - - - - -16-Nephropathy, chronic s 2 1 1 - 1 1 -6-Pigment accum, tub epi s 3 - - - - - -98-M-Leukemia, monuc - - - - - - -299-N-Sarcoma, histiocytic - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - -101-Fibrosis s - - - - - - -175-Thrombus s - - - - - - -36-Inflammation, focal, chronic s 1 - 1 - - - -48-M-Leukemia, monuc - - - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142268-Ulcer s - - - - - - -103-Inflammation, mixed s - - - - - - -217-M-Carcinoma, metastatic - - - - - - -220-M-Leukemia, monuc - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - -56-Inflammation, chronic s - - - - - - -166-Hyperplasia, papillary s - - - - - - -106-M-Leukemia, monuc - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142275-Inflammation, acute s 3 - - - - - -Jejunum Status > U U U U U U UOperator > 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 58Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Ileum (1) Status >Operator > 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - -Colon Status > U U U U U U UOperator > 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142212-Fibrosis s - - - - - - -110-M-Leukemia, monuc - - - - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142276-Metaplasia, squamous s 2 - - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142 142161-Cyst s - - - - - - -113-Degen, cytopl vacuol s - - - - 2 - -170-Necrosis s - - - - - - -118-Thrombus s - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - -64-Hyperplasia, focal p - - - - - - -116-B-Pheochrom, bgn - - - - - - -216-M-Carcinoma, metastatic - - - - - - -112-M-Leukemia, monuc - - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142277-Angiectasis s - - - - - - -7-Dilatation s - - - - - - -167-Intussusception p - - - P= - - -162-Inflammation, mixed s - - - - - - -49-Inflammation, chronic s - - - - - - -20-Hyperplasia, cystic endom s - 3 - - - - -286-B-Adenoma, endometrial - - - - - - -9-B-Polyp, endometrial stromal - 2= 1= - - 1= 1=213-M-Adenocarcinoma, endometr - - - - - - -279-M-Leiomyosar - - - - - - -165-M-Leukemia, monuc - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - -173-Inflammation, chronic s - - - - - - -206-N-Sarcoma, histiocytic - - - - - - -32-N-Leukemia, monuc 1 - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 59Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Ovaries (9) Status >Operator > 142 142 142 142 142 142 142284-Congestion s - - - - - - -154-Cyst, bursa p - - - - - - -234-Cyst, epithelial p - - - - - - -293-Cyst, follicular p - - - - - - -291-Cyst, rete ovarii s - - - - - - -25-Hemorrhage s - - - - - - -290-Necrosis, mesenteric fat s - - - - - - -207-N-Sarcoma, histiocytic - - - - - - -163-M-Leukemia, monuc - - - - - - -Sciatic nerve Status > U U U U U U UOperator > 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - -Mammary gland (6) Status > HOperator > 142 142 142 142 142 142 142159-Ectasia s - - - - - - -190-Hyperplasia, lobular s - - - - - - -156-B-Fibroadenoma - - - - - 2= -70-B-Fibroma - - - - - - -235-M-Adenocarcinoma - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - -122-Fibrosis s - - - - - - -253-Inflammation, mixed s - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 14226-Compression s - - 3= - - 2= - -192-Hemorrhage s - - 2= - - - - -155-Metaplasia, osseous, meninge s - - - - - - - -33-Necrosis s - - - - - - - -194-Inflammation, chronic s - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - -129-Atrophy, retinal, unilat s - - 4 - - - - -130-Cataract p - - P= - - - - -133-Metaplasia, osseous, sclera s - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 60Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - - - -126-Mineralization, scleral s - - - 2 - - - -131-Neovascularization, corneal s - - - - - - - -Bone, femur (1) Status > HOperator > 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - -197-Hemorrhage s - - - - - - -231-Necrosis, neuronal s - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - 1 - - 2 - - - 1 2 - - - - -134-Inflammation, mixed s - - - - - - - - - - - - 3 - -34-Inflammation-nasolac duct s - - - 3 2 - - - - - - - 3 2 -136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - 1 - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s 1 - - - 2 - - - - 2 - - - - -261-Degeneration,hyal-resp epith s - 1 - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - - - - - - - - 1 - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -232-Degeneration-resp epith s - - - - - - - 2 - - - - - - -142-Inflammation, mixed s - - - - - - - 2 - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 61Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Cervix (3) Status > M M M M M M M M M M M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 142 142 142 14229-Hemorrhage s - 2 - - - - -3-Infiltration, histiocytic s - - - - - - -2-Pigmentation s - - - - - - -273-B-Thymoma - - - - - - -219-M-Carcinoma, metastatic - - - - - - -265-N-Sarcoma, histiocytic - - - - - - -41-N-Leukemia, monuc - - - - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - - - - -37-Cyst s - - - - - 1 - - 238-Degen s - - - - - - - - -148-Hemorrhage s - - - - - - - - -203-Necrosis s - - - - - - - - -57-Hyperplasia, focal s - - - 3= - - - - -31-B-Adenoma, pars distalis - - 1= - - - 1= 1= -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 62Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - -288-M-Carcinoma - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 63Rat/F344/NGroup Sex Dosage Animal > 6834F582 6834F584 6834F586 6834F588 6834F590 6834F592 6834F5942 F 2 g/m3 Animal > 6834F581 6834F583 6834F585 6834F587 6834F589 6834F591 6834F593 6834F595Tissue/diagnosis Death code > U2 U2 FS FS FS FS FS FS U2 U2 FS FS U1 U2 U2Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 64Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSLungs (12) Status >Operator > 142 142 142 142 14240-Alveolar histiocytosis s - - - - -30-Congestion s - - - - -71-Fibrosis, focal s - - - - -182-Hemorrhage s - - - - -177-Inflammation, acute s - - - - -72-Inflammation, mixed s - - - - -236-Inflammation, granulomatous s - - - - -10-Hyperplasia, alv. epi. focal s - - - - -214-N-Carcinoma, metastatic - - - - -11-N-Leukemia,monuc - cap invol - - - 2= 174-N-Leukemia,monuc - inv invol - - - - -204-N-Sarcoma, histiocytic - - - - -Trachea (4) Status >Operator > 142 142 142 142 14222-Inflammation, acute s - - - - -75-Inflammation, mixed s - - - - -76-Hyperplasia s - - - - -238-N-Leukemia, monuc - - - - -Bronchial (TBLN) (3) Status >Operator > 14221-Hemorrhage s -297-Inflammation, mixed s -62-N-Leukemia, monuc 1Thyroid glands (8) Status >Operator > 14279-Cyst, follicular p -77-Hyperplasia, C-cell, focal s -81-Hyperplasia, follicular cell s -35-B-Adenoma, C-cell -78-B-Adenoma, follicular cell -174-M-Carcinoma, C-cell -80-M-Carcinoma, follicular cell -178-M-Leukemia, monuc -Parathyroid (2) Status > mOperator > 142241-Hyperplasia, focal s -296-B-Adenoma -Aorta (1) Status >Operator > 14283-N-Leukemia,monuc - inv invol -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 65Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSEsophagus Status > UOperator > 142Larynx (5) Status >Operator > 142 142 142 142 14212-Metaplasia, squamous s - - - - 21-Hyperplasia s - - - - -23-Inflammation, acute s - - - - -42-Inflammation, mixed s 2 - 1 1 253-Inflammation, chronic s - - - - -Salivary gland (1) Status >Operator > 14243-M-Leukemia, monuc -Mandibular LN (2) Status >Operator > 142 14289-Hemorrhage s - -44-N-Leukemia, monuc 1= -Liver (15) Status >Operator > 142 14245-Angiectasis s - -158-Congestion s - -90-Fatty Change s - -150-Foci cell alter, basophilic s - -92-Hdn p P= -4-Necrosis s - -230-Thrombus s - -13-Vaculoliz cyto s - -24-Inflammation, acute s - -54-Inflammation, chronic s - -46-Hyperplasia, biliary s - 247-Hyperplasia, hepato, regen s - -91-B-Adenoma, hepatocellular - -205-M-Sarcoma, histiocytic - -14-M-Leukemia, monuc 1 2=Spleen (5) Status >Operator > 14296-Fibrosis s -226-Hemorrhage s -97-Necrosis s -15-M-Leukemia, monuc 2=298-N-Sarcoma, histiocytic -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 66Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSKidneys (9) Status >Operator > 142211-Atrophy s -149-Cyst s -209-Degen, hyaline droplet s -210-Dilatation s -228-Infarct s -16-Nephropathy, chronic s 16-Pigment accum, tub epi s 3=98-M-Leukemia, monuc -299-N-Sarcoma, histiocytic -Heart (5) Status >Operator > 142100-Degen, myocyte s -101-Fibrosis s -175-Thrombus s -36-Inflammation, focal, chronic s -48-M-Leukemia, monuc -Stomach (4) Status >Operator > 142268-Ulcer s -103-Inflammation, mixed s -217-M-Carcinoma, metastatic -220-M-Leukemia, monuc -Cecum (1) Status >Operator > 142104-N-Leukemia, monuc -Urinary bladder (4) Status >Operator > 142186-Hemorrhage s -56-Inflammation, chronic s -166-Hyperplasia, papillary s -106-M-Leukemia, monuc -Duodenum (1) Status >Operator > 142275-Inflammation, acute s -Jejunum Status > UOperator > 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 67Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSIleum (1) Status >Operator > 142181-N-Leukemia, monuc -Colon Status > UOperator > 142Pancreas (2) Status > *HOperator > 142212-Fibrosis s110-M-Leukemia, monucRectum (1) Status >Operator > 142276-Metaplasia, squamous s -Adrenal glands (9) Status >Operator > 142161-Cyst s -113-Degen, cytopl vacuol s -170-Necrosis s -118-Thrombus s -117-Hyperplasia, cortical, focal s -64-Hyperplasia, focal p -116-B-Pheochrom, bgn -216-M-Carcinoma, metastatic -112-M-Leukemia, monuc 1=Uterus (11) Status >Operator > 142277-Angiectasis s -7-Dilatation s -167-Intussusception p -162-Inflammation, mixed s -49-Inflammation, chronic s -20-Hyperplasia, cystic endom s -286-B-Adenoma, endometrial -9-B-Polyp, endometrial stromal -213-M-Adenocarcinoma, endometr -279-M-Leiomyosar -165-M-Leukemia, monuc -Mesenteric LN (4) Status >Operator > 142120-Hemorrhage s -173-Inflammation, chronic s -206-N-Sarcoma, histiocytic -32-N-Leukemia, monuc -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 68Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSOvaries (9) Status >Operator > 142 142284-Congestion s - -154-Cyst, bursa p - -234-Cyst, epithelial p - -293-Cyst, follicular p - -291-Cyst, rete ovarii s - -25-Hemorrhage s - -290-Necrosis, mesenteric fat s 2= -207-N-Sarcoma, histiocytic - -163-M-Leukemia, monuc - -Sciatic nerve Status > UOperator > 142Muscle, skeletal (1) Status >Operator > 142208-N-Sarcoma, histiocytic -Mammary gland (6) Status >Operator > 142159-Ectasia s -190-Hyperplasia, lobular s -156-B-Fibroadenoma -70-B-Fibroma -235-M-Adenocarcinoma -224-M-AdenoCA arising in fibroAD -Skin (3) Status >Operator > 142252-Cyst, epith inc p -122-Fibrosis s -253-Inflammation, mixed s -Brain (6) Status >Operator > 14226-Compression s -192-Hemorrhage s -155-Metaplasia, osseous, meninge s -33-Necrosis s -194-Inflammation, chronic s -256-M-Astrocytoma, malignant -Eyes/optic nerve (7) Status >Operator > 142127-Atrophy s -129-Atrophy, retinal, unilat s -130-Cataract p -133-Metaplasia, osseous, sclera s -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 69Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSEyes/optic nerve (7) Status >Operator > 14258-Mineralization, corneal str s -126-Mineralization, scleral s -131-Neovascularization, corneal s -Bone, femur (1) Status >Operator > 142179-New bone, endosteal s -Spinal cord (3) Status >Operator > 14227-Degen, white matter s -197-Hemorrhage s -231-Necrosis, neuronal s -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - -134-Inflammation, mixed s - - - - -34-Inflammation-nasolac duct s 3 2 3 2 -136-Inflammation-resp epith s - - - - -199-Hyperplasia-resp epith s - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - -261-Degeneration,hyal-resp epith s - - - - -176-Metaplasia, sec-olfact epith s - - - - -270-Metaplasia, squ-olfact epith s - - - - -138-Inflammation, mixed s - - - - -227-Hyperplasia-resp epith s - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142295-Degeneration-olfact epith s - - - - -19-Degeneration,hyaline-olf epi s - - - - -232-Degeneration-resp epith s - - - - -142-Inflammation, mixed s - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142285-Degeneration-olfact epith s - - - - -164-Degeneration,hyaline-olf epi s - - - - -144-Inflammation, mixed s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 70Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSCervix (3) Status > M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 14229-Hemorrhage s -3-Infiltration, histiocytic s -2-Pigmentation s -273-B-Thymoma -219-M-Carcinoma, metastatic -265-N-Sarcoma, histiocytic -41-N-Leukemia, monuc -Pituitary gland (10) Status >Operator > 142 142 142160-Angiectasis s 3= - -37-Cyst s - - -38-Degen s - - -148-Hemorrhage s - - -203-Necrosis s - - -57-Hyperplasia, focal s 2 - -31-B-Adenoma, pars distalis - - 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 71Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSPituitary gland (10) Status >Operator > 142 142 142274-B-Adenoma, pars intermedia - - -288-M-Carcinoma - - -146-M-Leukemia, monuc - - -Tail (3) Status > M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M MOperator >278-Pigment sVagina (1) Status > M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 72Rat/F344/NGroup Sex Dosage Animal > 6834F597 6834F5992 F 2 g/m3 Animal > 6834F596 6834F598 6834F600Tissue/diagnosis Death code > FS FS FS U2 FSTiss.not specifi Status > M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 73Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Lungs (12) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s 1 - - - - - 1 - - - - - - - -30-Congestion s - - - - - - - - - 1 - - - - 2=71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - 2 - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - 3 - - - - - - - - - - - -236-Inflammation, granulomatous s - - - 1 - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - 1 - - 1 - - - 2 - - - - - -74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - 1= - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - 3 - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *HOperator > 142 142 142 14221-Hemorrhage s - - -297-Inflammation, mixed s - - -62-N-Leukemia, monuc - - -Thyroid glands (8) Status >Operator > 142 142 142 14279-Cyst, follicular p - - - -77-Hyperplasia, C-cell, focal s - - - -81-Hyperplasia, follicular cell s - - - -35-B-Adenoma, C-cell - 1 - -78-B-Adenoma, follicular cell - - - -174-M-Carcinoma, C-cell - - - -80-M-Carcinoma, follicular cell 2= - - -178-M-Leukemia, monuc - - - -Parathyroid (2) Status > m m mOperator > 142 142 142 142241-Hyperplasia, focal s - - - -296-B-Adenoma - - - -Aorta (1) Status >Operator > 142 142 142 14283-N-Leukemia,monuc - inv invol - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 74Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Esophagus Status > UH U U UOperator > 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s 1 - - 1 1 - 1 - - - - - - - 21-Hyperplasia s - - - - 1 1 - - - - - - - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - - - 2 2 2 - 1 2 2 - 1 - - 253-Inflammation, chronic s - - - - - - 1 - - - - - - - -Salivary gland (1) Status >Operator > 142 142 142 14243-M-Leukemia, monuc - - - -Mandibular LN (2) Status >Operator > 142 142 142 14289-Hemorrhage s - - - -44-N-Leukemia, monuc - 1 - -Liver (15) Status > HOperator > 142 142 142 142 142 142 14245-Angiectasis s - - - - - -158-Congestion s - - - - - 290-Fatty Change s - 1 - 2 - -150-Foci cell alter, basophilic s - - - - - -92-Hdn p - - - - - -4-Necrosis s - - - 2 - -230-Thrombus s - - - - - -13-Vaculoliz cyto s - - - - - -24-Inflammation, acute s - - - - - -54-Inflammation, chronic s - - - - - -46-Hyperplasia, biliary s 1 3 2 - 2 147-Hyperplasia, hepato, regen s - - 2 - - -91-B-Adenoma, hepatocellular - - - - - -205-M-Sarcoma, histiocytic - - - 1= - -14-M-Leukemia, monuc - 1= 2= - - -Spleen (5) Status >Operator > 142 142 142 142 14296-Fibrosis s - - - - -226-Hemorrhage s - - - - -97-Necrosis s - - - - -15-M-Leukemia, monuc - 2= - - -298-N-Sarcoma, histiocytic - - 1= - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 75Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Kidneys (9) Status >Operator > 142 142 142 142 142211-Atrophy s - - - - -149-Cyst s - - - - -209-Degen, hyaline droplet s - - - - -210-Dilatation s - - - - -228-Infarct s - - - - -16-Nephropathy, chronic s 1 1 3= 1 16-Pigment accum, tub epi s - - - - -98-M-Leukemia, monuc - - - - -299-N-Sarcoma, histiocytic - - 1= - -Heart (5) Status >Operator > 142 142 142 142100-Degen, myocyte s - - - -101-Fibrosis s - - - -175-Thrombus s - - - -36-Inflammation, focal, chronic s - - 1 148-M-Leukemia, monuc - - - -Stomach (4) Status >Operator > 142 142 142 142268-Ulcer s - - - -103-Inflammation, mixed s - - - -217-M-Carcinoma, metastatic - - - -220-M-Leukemia, monuc - - - -Cecum (1) Status >Operator > 142 142 142 142104-N-Leukemia, monuc - - - -Urinary bladder (4) Status >Operator > 142 142 142 142186-Hemorrhage s - - - -56-Inflammation, chronic s - - - -166-Hyperplasia, papillary s - - - -106-M-Leukemia, monuc - - - -Duodenum (1) Status >Operator > 142 142 142 142275-Inflammation, acute s - - - -Jejunum Status > U U U UOperator > 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 76Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Ileum (1) Status > *Operator > 142 142 142 142181-N-Leukemia, monuc - - -Colon Status > U U U UOperator > 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142212-Fibrosis s - - - -110-M-Leukemia, monuc - - - -Rectum (1) Status >Operator > 142 142 142 142276-Metaplasia, squamous s - - - -Adrenal glands (9) Status > mHOperator > 142 142 142 142161-Cyst s 2 - - -113-Degen, cytopl vacuol s - - - -170-Necrosis s - - - -118-Thrombus s - - - -117-Hyperplasia, cortical, focal s - - - -64-Hyperplasia, focal p P - - -116-B-Pheochrom, bgn - - - -216-M-Carcinoma, metastatic - - - -112-M-Leukemia, monuc - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142277-Angiectasis s - - 2= - - - -7-Dilatation s - - - - - - -167-Intussusception p - - - - - - -162-Inflammation, mixed s - - - - - - -49-Inflammation, chronic s - - - - - - -20-Hyperplasia, cystic endom s - - - - - - -286-B-Adenoma, endometrial - - - - - - -9-B-Polyp, endometrial stromal 1= - - 1= 1= - 1=213-M-Adenocarcinoma, endometr - - - - - - -279-M-Leiomyosar - - - - - - -165-M-Leukemia, monuc - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142120-Hemorrhage s - - - -173-Inflammation, chronic s - 1 - -206-N-Sarcoma, histiocytic - - - -32-N-Leukemia, monuc - 1 - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 77Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Ovaries (9) Status >Operator > 142 142 142 142 142 142 142284-Congestion s - - - - - 2=154-Cyst, bursa p - - - - - -234-Cyst, epithelial p - - - - - -293-Cyst, follicular p - - - P= - -291-Cyst, rete ovarii s - 2= - - - -25-Hemorrhage s - - - - - -290-Necrosis, mesenteric fat s - - - - - -207-N-Sarcoma, histiocytic - - - - - -163-M-Leukemia, monuc - - - - - -Sciatic nerve Status > U U U UOperator > 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142208-N-Sarcoma, histiocytic - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142159-Ectasia s - - - -190-Hyperplasia, lobular s - - - -156-B-Fibroadenoma - - - -70-B-Fibroma - - - -235-M-Adenocarcinoma - - - -224-M-AdenoCA arising in fibroAD - - - -Skin (3) Status >Operator > 142 142 142 142252-Cyst, epith inc p - - - -122-Fibrosis s - - - -253-Inflammation, mixed s - - - -Brain (6) Status >Operator > 142 142 142 142 142 14226-Compression s - 4= 2= - - 3=192-Hemorrhage s - - - - - -155-Metaplasia, osseous, meninge s - - - - - -33-Necrosis s - - - - - -194-Inflammation, chronic s - - - - - -256-M-Astrocytoma, malignant - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142127-Atrophy s - - - - - -129-Atrophy, retinal, unilat s - - - - - -130-Cataract p - - - - - -133-Metaplasia, osseous, sclera s - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 78Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - -126-Mineralization, scleral s - - - - - -131-Neovascularization, corneal s - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142179-New bone, endosteal s - - - -Spinal cord (3) Status >Operator > 142 142 142 14227-Degen, white matter s - - - -197-Hemorrhage s - - - -231-Necrosis, neuronal s - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - 2 - - - - - - - -134-Inflammation, mixed s - - - - - - - - - - - - - 2 -34-Inflammation-nasolac duct s - - 3 3 3 - 2 - 2 - - - 3 3 2136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - 2 -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s 1 - - - - - 2 - 1 - - - - 3 -261-Degeneration,hyal-resp epith s - - - 2 - - 2 - - 1 - 2 - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - 1 - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - 2 - - 1 - 2 - 3 - - 1 - 3 -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 79Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Cervix (3) Status > M M M M M M M M M M M M M M MOperator > 142168-B-Polyp, endometrial stromal -289-M-Leiomyosarcoma -269-N-Adenocarcinoma, endometr -Clitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M MH M M M M M M M M M M M MOperator > 14260-Hemorrhage s -59-Infiltration, histiocytic s -65-N-Leukemia, monuc -Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 142 14229-Hemorrhage s 2 - - - -3-Infiltration, histiocytic s - - - - -2-Pigmentation s - - - - -273-B-Thymoma - - - - -219-M-Carcinoma, metastatic - - - - -265-N-Sarcoma, histiocytic - - 1 - -41-N-Leukemia, monuc - - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - - - - -37-Cyst s 3= 2= - - - - 1 2= -38-Degen s - - - - - - - - -148-Hemorrhage s - - - - - - - - -203-Necrosis s - - - - - - - - -57-Hyperplasia, focal s - 3 - - - - 2 1 -31-B-Adenoma, pars distalis - - 1= 1= 1= - 1= - 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 80Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - -288-M-Carcinoma - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 81Rat/F344/NGroup Sex Dosage Animal > 6836G652 6836G654 6836G656 6836G658 6836G660 6836G662 6836G6643 F 10 g/m3 Animal > 6836G651 6836G653 6836G655 6836G657 6836G659 6836G661 6836G663 6836G665Tissue/diagnosis Death code > FS FS U2 FS FS FS FS FS U2 FS FS FS FS U2 U1Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 82Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Lungs (12) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - - - - - - - - - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - - - - - - - - - 1 2= - 2 - 274-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 14221-Hemorrhage s - - - - -297-Inflammation, mixed s - - - - -62-N-Leukemia, monuc - 1 1 - -Thyroid glands (8) Status >Operator > 142 142 142 142 14279-Cyst, follicular p - - - - -77-Hyperplasia, C-cell, focal s - - - - -81-Hyperplasia, follicular cell s - - - - -35-B-Adenoma, C-cell - - - - -78-B-Adenoma, follicular cell - - - - -174-M-Carcinoma, C-cell - - - - -80-M-Carcinoma, follicular cell - - - - -178-M-Leukemia, monuc - - - - -Parathyroid (2) Status > m mHOperator > 142 142 142 142 142241-Hyperplasia, focal s - - - - -296-B-Adenoma - - - - -Aorta (1) Status >Operator > 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 83Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Esophagus Status > U U U U UOperator > 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s 1 - - 1 - - - - - - - 2 - - -1-Hyperplasia s - - - - 1 - 1 - - - 1 - - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - 1 1 - 2 - 2 - 1 1 - - 1 1 153-Inflammation, chronic s - - - 1 - - - - - - 2 1 - - -Salivary gland (1) Status >Operator > 142 142 142 142 14243-M-Leukemia, monuc - - - - -Mandibular LN (2) Status >Operator > 142 142 142 142 142 14289-Hemorrhage s - - - - - -44-N-Leukemia, monuc - - - 1 - -Liver (15) Status >Operator > 142 142 142 142 14245-Angiectasis s - - - - -158-Congestion s - - - - -90-Fatty Change s - - - - -150-Foci cell alter, basophilic s - - - - -92-Hdn p - - - - -4-Necrosis s - - - - -230-Thrombus s - - - - -13-Vaculoliz cyto s - - - - -24-Inflammation, acute s - - - - -54-Inflammation, chronic s 1 - - 1 -46-Hyperplasia, biliary s - 1 1 2 247-Hyperplasia, hepato, regen s - - - - -91-B-Adenoma, hepatocellular - - - - -205-M-Sarcoma, histiocytic - - - - -14-M-Leukemia, monuc - 2= 2 - 2=Spleen (5) Status >Operator > 142 142 142 142 142 14296-Fibrosis s - - - - - -226-Hemorrhage s - - - - - -97-Necrosis s - - - - - -15-M-Leukemia, monuc - 1= 2= 2 - 2=298-N-Sarcoma, histiocytic - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 84Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Kidneys (9) Status >Operator > 142 142 142 142 142211-Atrophy s - - - - -149-Cyst s - - - - -209-Degen, hyaline droplet s - - - - -210-Dilatation s - - - - -228-Infarct s - - - - -16-Nephropathy, chronic s - 1 1 2 16-Pigment accum, tub epi s - - - - -98-M-Leukemia, monuc - - - - -299-N-Sarcoma, histiocytic - - - - -Heart (5) Status >Operator > 142 142 142 142 142100-Degen, myocyte s - - - - -101-Fibrosis s - - - - -175-Thrombus s - - - - -36-Inflammation, focal, chronic s 1 - 1 - -48-M-Leukemia, monuc - - - - -Stomach (4) Status >Operator > 142 142 142 142 142268-Ulcer s - - - - -103-Inflammation, mixed s - - - - -217-M-Carcinoma, metastatic - - - - -220-M-Leukemia, monuc - - - - -Cecum (1) Status >Operator > 142 142 142 142 142104-N-Leukemia, monuc - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142186-Hemorrhage s - - - - -56-Inflammation, chronic s - - - - -166-Hyperplasia, papillary s - - - - -106-M-Leukemia, monuc - 1 - - -Duodenum (1) Status >Operator > 142 142 142 142 142275-Inflammation, acute s - - - - -Jejunum Status > U U U U UOperator > 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 85Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Ileum (1) Status >Operator > 142 142 142 142 142181-N-Leukemia, monuc - - - - -Colon Status > U U U U UOperator > 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142212-Fibrosis s - - - - -110-M-Leukemia, monuc - - - - -Rectum (1) Status >Operator > 142 142 142 142 142276-Metaplasia, squamous s - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142161-Cyst s - - - - - -113-Degen, cytopl vacuol s - - - - - -170-Necrosis s - - - - - -118-Thrombus s - - - - - -117-Hyperplasia, cortical, focal s - - - - - -64-Hyperplasia, focal p - - - - - -116-B-Pheochrom, bgn 1= - - - - -216-M-Carcinoma, metastatic - - - - - -112-M-Leukemia, monuc - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - -7-Dilatation s - - 2 - - 1= - - 3 - -167-Intussusception p - - - - - - - - - - -162-Inflammation, mixed s - - - - - - - - - - -49-Inflammation, chronic s - - - - - - - - - - -20-Hyperplasia, cystic endom s - - - 3= - - 3= - - 2 -286-B-Adenoma, endometrial - - - - - - - - - - -9-B-Polyp, endometrial stromal 1= 1= 1= - - - - 1= - - -213-M-Adenocarcinoma, endometr - 1= - 1 - - - - - - -279-M-Leiomyosar - - - - 2= - - - - - -165-M-Leukemia, monuc - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142120-Hemorrhage s - - - - -173-Inflammation, chronic s - - - - -206-N-Sarcoma, histiocytic - - - - -32-N-Leukemia, monuc - 1 - - 1Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 86Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Ovaries (9) Status >Operator > 142 142 142 142 142 142284-Congestion s - - - - - -154-Cyst, bursa p - P= - - - -234-Cyst, epithelial p - - - - - -293-Cyst, follicular p - - - - - -291-Cyst, rete ovarii s - - - - - -25-Hemorrhage s - - - - - -290-Necrosis, mesenteric fat s - - - - - -207-N-Sarcoma, histiocytic - - - - - -163-M-Leukemia, monuc - - - - - -Sciatic nerve Status > U U U U UOperator > 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142 142159-Ectasia s - - - - - -190-Hyperplasia, lobular s - - - - - -156-B-Fibroadenoma - 1= - - - -70-B-Fibroma - - - - - -235-M-Adenocarcinoma - - - - - -224-M-AdenoCA arising in fibroAD - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142252-Cyst, epith inc p - - - - - -122-Fibrosis s 3= - - - - -253-Inflammation, mixed s - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 14226-Compression s 3= 2= - - - 3= -192-Hemorrhage s - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - -33-Necrosis s - - - - - - -194-Inflammation, chronic s - - - - - - -256-M-Astrocytoma, malignant - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142127-Atrophy s - - - - - -129-Atrophy, retinal, unilat s - - - - - -130-Cataract p - - - - - -133-Metaplasia, osseous, sclera s - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 87Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - -126-Mineralization, scleral s - - - - - -131-Neovascularization, corneal s - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142179-New bone, endosteal s - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 14227-Degen, white matter s - - - - -197-Hemorrhage s - - - - -231-Necrosis, neuronal s - - - - -Nose/Turbinate 1 (5) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - 1134-Inflammation, mixed s 1 - - - - 3 - - - - - - - -34-Inflammation-nasolac duct s - - - 3 2 3 - 3 - - - 3 3 1136-Inflammation-resp epith s - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - 1 3176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - 1 2232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s 2 - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 88Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Cervix (3) Status > M M M M M M M M M M M M M M MOperator > 142 142168-B-Polyp, endometrial stromal - -289-M-Leiomyosarcoma - -269-N-Adenocarcinoma, endometr - -Clitoral gland (3) Status > M M M M M M M M M M M M M M MOperator > 142 142294-B-Adenoma 1= -61-M-Carcinoma, squamous cell - -271-N-Adenocarcinoma - 1=Lymph node other (3) Status > M M M M M M M M M M M M M M MOperator > 14260-Hemorrhage s -59-Infiltration, histiocytic s -65-N-Leukemia, monuc 1=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 142 14229-Hemorrhage s - - - - -3-Infiltration, histiocytic s - - - - -2-Pigmentation s - - - - -273-B-Thymoma - - - - -219-M-Carcinoma, metastatic - - - - -265-N-Sarcoma, histiocytic - - - - -41-N-Leukemia, monuc - 1 1 - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - 3= - - -37-Cyst s - - - - 3= - - - 2=38-Degen s - - - - - - - - -148-Hemorrhage s - - - - - - - - -203-Necrosis s - - - - - - - - -57-Hyperplasia, focal s - - - - 1 3 - - -31-B-Adenoma, pars distalis 1= 1= - 1= - - 1= 1= -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 89Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - -288-M-Carcinoma - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 90Rat/F344/NGroup Sex Dosage Animal > 6836G667 6836G669 6836G671 6836G673 6836G675 6836G677 6836G6793 F 10 g/m3 Animal > 6836G666 6836G668 6836G670 6836G672 6836G674 6836G676 6836G678 6836G680Tissue/diagnosis Death code > FS FS FS FS FS U1 FS FS FS FS U2 FS U2 U2 U2Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 91Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Lungs (12) Status > H aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - - - - - - - 1 - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - - - - 2 - 2 2 - - - - - 1 -74-N-Leukemia,monuc - inv invol - 2= - - - 1= - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - 1 - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - - - -297-Inflammation, mixed s - - - 1= - - - - -62-N-Leukemia, monuc 1= - - 1 1 1 - - -Thyroid glands (8) Status >Operator > 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - P - -77-Hyperplasia, C-cell, focal s - - 1 - - - - - - -81-Hyperplasia, follicular cell s - - - - - - - - - -35-B-Adenoma, C-cell - - - 1= - - - - 1= -78-B-Adenoma, follicular cell - - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - - -Parathyroid (2) Status > mH m m mHOperator > 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - -296-B-Adenoma - - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 92Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Esophagus Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Larynx (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - 2 - - - - - - - - - - -1-Hyperplasia s - - - - - - - - - - - - - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - - - 1 1 - - 1 1 - - - 2 - 153-Inflammation, chronic s - 1 - - - - 2 - - - - - - - -Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - -Mandibular LN (2) Status >Operator > 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - -44-N-Leukemia, monuc 1= - 1 - 1 - - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - -158-Congestion s - - - - - - - -90-Fatty Change s - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - -92-Hdn p - - - - - - - -4-Necrosis s - - - - - - - -230-Thrombus s - - - - - - - -13-Vaculoliz cyto s - - - 2 - - - -24-Inflammation, acute s - - - - - - - -54-Inflammation, chronic s - - - - - - - 246-Hyperplasia, biliary s 1 1 2 2 1 - 1 247-Hyperplasia, hepato, regen s - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - -14-M-Leukemia, monuc 2= - 2= 2= 2 - - -Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 14296-Fibrosis s - - 1 - - - - - -226-Hemorrhage s - - - - - - - - -97-Necrosis s - - - - - - - - -15-M-Leukemia, monuc 2= - 2= 1= 2= 2= - - -298-N-Sarcoma, histiocytic - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 93Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Kidneys (9) Status >Operator > 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - -149-Cyst s - - - - - - - -209-Degen, hyaline droplet s - - - - - - - -210-Dilatation s - - - - - - - -228-Infarct s - - - - - - - -16-Nephropathy, chronic s 1 1 1 2 - - 1 26-Pigment accum, tub epi s - - - - - - - -98-M-Leukemia, monuc 1 - - - - - - -299-N-Sarcoma, histiocytic - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - - -101-Fibrosis s - - - - - - - -175-Thrombus s - - - - - - - -36-Inflammation, focal, chronic s - - - 1 1 - - 148-M-Leukemia, monuc - - - - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - -103-Inflammation, mixed s - - - - - - - -217-M-Carcinoma, metastatic - - - - - - - -220-M-Leukemia, monuc 1 - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - - -Urinary bladder (4) Status > *HOperator > 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - -56-Inflammation, chronic s - - - - - - -166-Hyperplasia, papillary s - - - - - - -106-M-Leukemia, monuc - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - -Jejunum Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 94Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Ileum (1) Status >Operator > 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - - -Colon Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - - -110-M-Leukemia, monuc - - - - - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - -113-Degen, cytopl vacuol s - - - - - - - -170-Necrosis s - - - - - - - -118-Thrombus s - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - -64-Hyperplasia, focal p - - - - - - - -116-B-Pheochrom, bgn - - - - - - 2= -216-M-Carcinoma, metastatic - - - - - - - -112-M-Leukemia, monuc - - - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - -7-Dilatation s - 2= - - - - - - -167-Intussusception p - - - - - - - - -162-Inflammation, mixed s - - - - - - - - -49-Inflammation, chronic s - - - - - - - - -20-Hyperplasia, cystic endom s - - - - - 2= - - -286-B-Adenoma, endometrial - - - - - - - - -9-B-Polyp, endometrial stromal - 1= - - - - - - -213-M-Adenocarcinoma, endometr - - - - - - - - -279-M-Leiomyosar - - - - - - - - -165-M-Leukemia, monuc - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - 2 -173-Inflammation, chronic s - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - -32-N-Leukemia, monuc 1= - 1 1 1 - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 95Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Ovaries (9) Status >Operator > 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - -154-Cyst, bursa p - - - - - - - -234-Cyst, epithelial p - - - - - - - -293-Cyst, follicular p - - - - - - - -291-Cyst, rete ovarii s - - - - - - - -25-Hemorrhage s - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - -163-M-Leukemia, monuc 1 - - - - - - -Sciatic nerve Status > U U U U U U U UOperator > 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - -Mammary gland (6) Status > *HOperator > 142 142 142 142 142 142 142 142 142159-Ectasia s - - - - - - - -190-Hyperplasia, lobular s - - - - - - - 2156-B-Fibroadenoma - 1= - - - - - -70-B-Fibroma - - - - - - - -235-M-Adenocarcinoma - - - 1= - - - -224-M-AdenoCA arising in fibroAD - - - - - - - -Skin (3) Status > *HOperator > 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - -122-Fibrosis s - - - - - - -253-Inflammation, mixed s - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 14226-Compression s - - - 3= - - 2= - 4=192-Hemorrhage s - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - -33-Necrosis s - - - - - - - - -194-Inflammation, chronic s - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - - -129-Atrophy, retinal, unilat s - - - - - - - - -130-Cataract p - - - - - - - - -133-Metaplasia, osseous, sclera s - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 96Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - - - - - - -126-Mineralization, scleral s 1 - - - - - - 1 -131-Neovascularization, corneal s - - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - -197-Hemorrhage s 1 - - - - - - -231-Necrosis, neuronal s - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - - - - 1 - - 1 - -134-Inflammation, mixed s - - - - - - - - - - 3 - - - -34-Inflammation-nasolac duct s - - - - - 3 - - - - 3 - 3 - 2136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - 1261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - 1 - - - - - - - -138-Inflammation, mixed s - - - - 2 - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - 1232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 97Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Cervix (3) Status > M M M M M M M M M M M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M M M M M M M M M M M MOperator > 142294-B-Adenoma -61-M-Carcinoma, squamous cell -271-N-Adenocarcinoma 1=Lymph node other (3) Status > M M M M M M M M M M M M M M MOperator > 14260-Hemorrhage s -59-Infiltration, histiocytic s -65-N-Leukemia, monuc 1=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator > 142 14267-N-Leukemia, monuc 1= 1=Pancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 142 14268-N-Leukemia, monuc 1= 1=Mediastinal LN (7) Status > H *HOperator > 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - -3-Infiltration, histiocytic s - - - - - - -2-Pigmentation s - - - - - - -273-B-Thymoma - - - - 1= - -219-M-Carcinoma, metastatic - - - - - - -265-N-Sarcoma, histiocytic - - - - - - -41-N-Leukemia, monuc 1= - 1 - - - -Pituitary gland (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - 2= - 3= - - - - - - - -37-Cyst s 1 2 - - - - - 3= - - - 3 -38-Degen s - - - - - - - - - - - - -148-Hemorrhage s - - - - - - - - - - - - -203-Necrosis s - - - - - - - - - - - - -57-Hyperplasia, focal s - - - 2= - - - 4 - - 2 - -31-B-Adenoma, pars distalis - - - - - 1= - - - 1= - 1= 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 98Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Pituitary gland (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - 2=288-M-Carcinoma - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator > 142202-Inflammation, acute s 2152-Inflammation, mixed s -153-Hyperplasia/hyperkeratosis s 3=Bone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator > 142272-Fracture p P=Harderian gland (1) Status > M M M M M M M M M M M M M M MOperator > 142278-Pigment s 2=Vagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page: 99Rat/F344/NGroup Sex Dosage Animal > 6836G682 6836G684 6836G686 6836G688 6836G690 6836G692 6836G6943 F 10 g/m3 Animal > 6836G681 6836G683 6836G685 6836G687 6836G689 6836G691 6836G693 6836G695Tissue/diagnosis Death code > FS U2 U2 FS U2 FS U2 U2 FS FS U2 FS U1 FS U2Tiss.not specifi Status > M M M MH M M M M M M M M M M MOperator > 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:100Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSLungs (12) Status >Operator > 142 142 142 142 14240-Alveolar histiocytosis s - - - - -30-Congestion s - - - - -71-Fibrosis, focal s - - - - -182-Hemorrhage s - - - - -177-Inflammation, acute s - - - - -72-Inflammation, mixed s - - - - -236-Inflammation, granulomatous s - - - - -10-Hyperplasia, alv. epi. focal s - - - - 2214-N-Carcinoma, metastatic - - - - -11-N-Leukemia,monuc - cap invol - - 2 - -74-N-Leukemia,monuc - inv invol - - - - -204-N-Sarcoma, histiocytic - - - - -Trachea (4) Status >Operator > 142 142 142 142 14222-Inflammation, acute s - - - - -75-Inflammation, mixed s - - - - -76-Hyperplasia s - - - - -238-N-Leukemia, monuc - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 14221-Hemorrhage s - - -297-Inflammation, mixed s - - -62-N-Leukemia, monuc - 1= -Thyroid glands (8) Status >Operator > 142 142 14279-Cyst, follicular p - - -77-Hyperplasia, C-cell, focal s - - -81-Hyperplasia, follicular cell s - - -35-B-Adenoma, C-cell - - -78-B-Adenoma, follicular cell - - -174-M-Carcinoma, C-cell - - -80-M-Carcinoma, follicular cell - - -178-M-Leukemia, monuc - - -Parathyroid (2) Status > mHOperator > 142 142 142241-Hyperplasia, focal s - - -296-B-Adenoma - - -Aorta (1) Status >Operator > 142 142 14283-N-Leukemia,monuc - inv invol - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:101Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSEsophagus Status > U U UOperator > 142 142 142Larynx (5) Status >Operator > 142 142 142 142 14212-Metaplasia, squamous s - - - - 11-Hyperplasia s - - - - -23-Inflammation, acute s 1 - - - -42-Inflammation, mixed s - - - - -53-Inflammation, chronic s - - - - -Salivary gland (1) Status >Operator > 142 142 14243-M-Leukemia, monuc - - -Mandibular LN (2) Status >Operator > 142 142 14289-Hemorrhage s - - -44-N-Leukemia, monuc - - -Liver (15) Status >Operator > 142 142 14245-Angiectasis s - - -158-Congestion s - - -90-Fatty Change s - - -150-Foci cell alter, basophilic s - - -92-Hdn p - - -4-Necrosis s - - -230-Thrombus s - - -13-Vaculoliz cyto s - - -24-Inflammation, acute s - - -54-Inflammation, chronic s - - -46-Hyperplasia, biliary s - 1 -47-Hyperplasia, hepato, regen s - - -91-B-Adenoma, hepatocellular - - -205-M-Sarcoma, histiocytic - - -14-M-Leukemia, monuc - 2 -Spleen (5) Status >Operator > 142 142 142 14296-Fibrosis s - - - -226-Hemorrhage s - - - -97-Necrosis s - - - -15-M-Leukemia, monuc - 2= - -298-N-Sarcoma, histiocytic - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:102Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSKidneys (9) Status >Operator > 142 142 142211-Atrophy s - - -149-Cyst s - - -209-Degen, hyaline droplet s - - -210-Dilatation s - - -228-Infarct s - - -16-Nephropathy, chronic s - - -6-Pigment accum, tub epi s - - -98-M-Leukemia, monuc - - -299-N-Sarcoma, histiocytic - - -Heart (5) Status >Operator > 142 142 142100-Degen, myocyte s - - -101-Fibrosis s - - -175-Thrombus s - - -36-Inflammation, focal, chronic s 1 - -48-M-Leukemia, monuc - - -Stomach (4) Status >Operator > 142 142 142268-Ulcer s - - -103-Inflammation, mixed s - - -217-M-Carcinoma, metastatic - - -220-M-Leukemia, monuc - - -Cecum (1) Status >Operator > 142 142 142104-N-Leukemia, monuc - - -Urinary bladder (4) Status >Operator > 142 142 142186-Hemorrhage s - - -56-Inflammation, chronic s - - -166-Hyperplasia, papillary s - - -106-M-Leukemia, monuc - - -Duodenum (1) Status >Operator > 142 142 142275-Inflammation, acute s - - -Jejunum Status > U U UOperator > 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:103Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSIleum (1) Status >Operator > 142 142 142181-N-Leukemia, monuc - - -Colon Status > U U UOperator > 142 142 142Pancreas (2) Status >Operator > 142 142 142212-Fibrosis s - - -110-M-Leukemia, monuc - - -Rectum (1) Status >Operator > 142 142 142276-Metaplasia, squamous s - - -Adrenal glands (9) Status >Operator > 142 142 142161-Cyst s - - -113-Degen, cytopl vacuol s - - -170-Necrosis s - - -118-Thrombus s - - -117-Hyperplasia, cortical, focal s - - -64-Hyperplasia, focal p - P -116-B-Pheochrom, bgn - - -216-M-Carcinoma, metastatic - - -112-M-Leukemia, monuc - - -Uterus (11) Status >Operator > 142 142 142 142277-Angiectasis s - - - -7-Dilatation s - - - -167-Intussusception p - - - -162-Inflammation, mixed s - - - -49-Inflammation, chronic s - - - -20-Hyperplasia, cystic endom s - - - -286-B-Adenoma, endometrial - - - -9-B-Polyp, endometrial stromal - 1 - 1=213-M-Adenocarcinoma, endometr - - - -279-M-Leiomyosar - - - -165-M-Leukemia, monuc - - - -Mesenteric LN (4) Status >Operator > 142 142 142120-Hemorrhage s - - -173-Inflammation, chronic s - - -206-N-Sarcoma, histiocytic - - -32-N-Leukemia, monuc - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:104Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSOvaries (9) Status >Operator > 142 142 142284-Congestion s - - -154-Cyst, bursa p - - -234-Cyst, epithelial p - - -293-Cyst, follicular p - - -291-Cyst, rete ovarii s - - -25-Hemorrhage s - - -290-Necrosis, mesenteric fat s - - -207-N-Sarcoma, histiocytic - - -163-M-Leukemia, monuc - - -Sciatic nerve Status > U *H UOperator > 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142208-N-Sarcoma, histiocytic - - -Mammary gland (6) Status >Operator > 142 142 142 142159-Ectasia s - - - -190-Hyperplasia, lobular s - - - -156-B-Fibroadenoma - - - -70-B-Fibroma - 1= - -235-M-Adenocarcinoma - - - -224-M-AdenoCA arising in fibroAD - - - -Skin (3) Status >Operator > 142 142 142252-Cyst, epith inc p - - -122-Fibrosis s - - -253-Inflammation, mixed s - - 1Brain (6) Status >Operator > 142 142 14226-Compression s - - -192-Hemorrhage s - - -155-Metaplasia, osseous, meninge s - - -33-Necrosis s - - -194-Inflammation, chronic s - - -256-M-Astrocytoma, malignant - - -Eyes/optic nerve (7) Status >Operator > 142 142 142127-Atrophy s - - -129-Atrophy, retinal, unilat s - - 2130-Cataract p - - P=133-Metaplasia, osseous, sclera s - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:105Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSEyes/optic nerve (7) Status >Operator > 142 142 14258-Mineralization, corneal str s - - -126-Mineralization, scleral s - - -131-Neovascularization, corneal s - - -Bone, femur (1) Status > *HOperator > 142 142 142179-New bone, endosteal s - -Spinal cord (3) Status > *HOperator > 142 142 14227-Degen, white matter s - -197-Hemorrhage s - -231-Necrosis, neuronal s - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142260-Degeneration,hyal-resp epith s - 3 1 - -134-Inflammation, mixed s - - - - -34-Inflammation-nasolac duct s - 3 - - -136-Inflammation-resp epith s - - - - -199-Hyperplasia-resp epith s - - - - 2Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 14218-Degeneration,hyaline-olf epi s - 2 - - -261-Degeneration,hyal-resp epith s - 2 - - -176-Metaplasia, sec-olfact epith s - - - - -270-Metaplasia, squ-olfact epith s - - - - -138-Inflammation, mixed s - - - - -227-Hyperplasia-resp epith s - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142295-Degeneration-olfact epith s - - - - -19-Degeneration,hyaline-olf epi s - 3 - - -232-Degeneration-resp epith s - - - - -142-Inflammation, mixed s - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142285-Degeneration-olfact epith s - - - - -164-Degeneration,hyaline-olf epi s - - - - -144-Inflammation, mixed s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:106Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSCervix (3) Status > M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 14229-Hemorrhage s - - -3-Infiltration, histiocytic s - - -2-Pigmentation s - - -273-B-Thymoma - - -219-M-Carcinoma, metastatic - - -265-N-Sarcoma, histiocytic - - -41-N-Leukemia, monuc - 1= -Pituitary gland (10) Status >Operator > 142 142 142160-Angiectasis s - - -37-Cyst s - - -38-Degen s - - -148-Hemorrhage s - - -203-Necrosis s - - -57-Hyperplasia, focal s - - -31-B-Adenoma, pars distalis - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:107Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSPituitary gland (10) Status >Operator > 142 142 142274-B-Adenoma, pars intermedia - - -288-M-Carcinoma - - -146-M-Leukemia, monuc - - -Tail (3) Status > M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M MOperator >278-Pigment sVagina (1) Status > M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:108Rat/F344/NGroup Sex Dosage Animal > 6836G697 6836G6993 F 10 g/m3 Animal > 6836G696 6836G698 6836G700Tissue/diagnosis Death code > U2 FS U2 U2 FSTiss.not specifi Status > M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:109Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSLungs (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - - - - - 1 - 1 - - -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - 2= - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - - - - - - 2 - - - 1 - - 2 -74-N-Leukemia,monuc - inv invol - 2 - - - - - - - - - - - - -204-N-Sarcoma, histiocytic 2= - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - 2 -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - - - - 2 - - - -297-Inflammation, mixed s - - - - - - - - - - - - - -62-N-Leukemia, monuc - 1= - - - - - - - - - - - -Thyroid glands (8) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - - - - - - - -77-Hyperplasia, C-cell, focal s - - - - - - - - - - 2 - - - -81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -35-B-Adenoma, C-cell - - - - - - - - 1 - - - - - -78-B-Adenoma, follicular cell - - - - - - - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - - - - - - - -Parathyroid (2) Status > mH mH m m m mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - - - - - - - - -296-B-Adenoma - - - - - - - - - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:110Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSEsophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - - 1 - - - 1 1 - 1 - - -1-Hyperplasia s - 2 - 2 - - - - - - - - 1 - 223-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - 2 - 2 - - 1 - 2 1 2 2 - 1 -53-Inflammation, chronic s - - - - 1 - - - - - - - - - -Salivary gland (1) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - - - - - - - 1 -Mandibular LN (2) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - - - - - - - -44-N-Leukemia, monuc 1= - - - - - - - - 1= - - - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - - - - - - - -158-Congestion s - - - - - - - - - - - - - - -90-Fatty Change s - - - - - - - 1 - - - - - - -150-Foci cell alter, basophilic s - - - - - - - 2 - - - - - - -92-Hdn p - - - - - P= - - - - - - - - -4-Necrosis s - - - - - - - - - - - - 3= - -230-Thrombus s - - - - - - - - - - - - - - -13-Vaculoliz cyto s - - - - - - - - - - - - - - -24-Inflammation, acute s - - - - - - - - - - - - - - -54-Inflammation, chronic s - - - 1 1 1 - - - 1 - - - - 146-Hyperplasia, biliary s - - - 1 1 1 1 - 1 1 - 1 - - 147-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -205-M-Sarcoma, histiocytic 2= - - - - - - - - - - - - - -14-M-Leukemia, monuc - 2 1 - - - 2 - 1 1 1 - - 2 -Spleen (5) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Fibrosis s - - - - - - - - - - - - - - -226-Hemorrhage s - - - - - - - - - - - - - - -97-Necrosis s - - - - - - - - - - - - - - -15-M-Leukemia, monuc - 2= 1 - - - 2= - 1 1 1= - - 2= -298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:111Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSKidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142211-Atrophy s - - 4= - - - - - - - - - - - -149-Cyst s - - - - 3= - 3= - - - - 2= - - -209-Degen, hyaline droplet s 4 - - - - - - - - - - - - - -210-Dilatation s - - 3= - - - - - - - - - - - -228-Infarct s - - - - - - - - - - - - - - -16-Nephropathy, chronic s 1 1 1 2 2 - 2 1 2 2 2 2 - 1 -6-Pigment accum, tub epi s - - - - - - - - - - - - 1 - -98-M-Leukemia, monuc - 1 - - - - - - - - - - - - -299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - - 1 1 - - - - - -101-Fibrosis s - - - - - - - - - - - - - - -175-Thrombus s - - - - - - - - - - - - - - -36-Inflammation, focal, chronic s 1 - - 1 1 2 - 1 - 1 1 - - - -48-M-Leukemia, monuc - 1 - - - - - - - - - - - 1 -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - - - - - - - - -103-Inflammation, mixed s - - - - - - - - - - - - - - -217-M-Carcinoma, metastatic - - 1= - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Cecum (1) Status > A a a aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - - - - - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - - - - - - - - -56-Inflammation, chronic s 1 - - 1 - - - - - - - - - - -166-Hyperplasia, papillary s - - - - - - - - - - - - - - -106-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - - - - - - - - -Jejunum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:112Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSIleum (1) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142212-Fibrosis s - - 2 - - - - - - - - - - - -110-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - - - - - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - 1113-Degen, cytopl vacuol s - - - 1 - - - 1 - - - 1 - - -170-Necrosis s - - - - - - - - - - - - - - -118-Thrombus s - - - - - - - - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - - - - - - - - -64-Hyperplasia, focal p - - - - - - - - - - - - - - -116-B-Pheochrom, bgn - - - - - - 1 - - - - - - - -216-M-Carcinoma, metastatic - - 1 - - - - - - - - - - - -112-M-Leukemia, monuc - 1 - - - - - - - - - - - - -Uterus (11) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - - - - - -7-Dilatation s - 4= 4= - - - - - - - - - 3 - -167-Intussusception p - - - - - - - - - - - - - - -162-Inflammation, mixed s - - - - - - - - - - - - - - -49-Inflammation, chronic s - - - - - - - - - - - - - - -20-Hyperplasia, cystic endom s - - - - - - - - 3 1 - - - - -286-B-Adenoma, endometrial - - - - - - - - - - - - - - -9-B-Polyp, endometrial stromal - - - - - - 1= - - - - - 2= - -213-M-Adenocarcinoma, endometr - - 2= - - - - - - - - - - - -279-M-Leiomyosar - - - - - - - - - - - - - - -165-M-Leukemia, monuc - 1 - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - - - - - - - - - -173-Inflammation, chronic s - - - - - - - - - - - - - - -206-N-Sarcoma, histiocytic 1 - - - - - - - - - - - - - -32-N-Leukemia, monuc - 1= - - - - - - - - - - - 1 -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:113Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSOvaries (9) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - - - - - - - - -154-Cyst, bursa p - - - - - - - - P= - - - - - -234-Cyst, epithelial p - - - - - - - - - - - - - - -293-Cyst, follicular p - - - - - - - - - - - - - - -291-Cyst, rete ovarii s - - - - - - - - - - - - - - -25-Hemorrhage s - - - - - - - - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - -207-N-Sarcoma, histiocytic 1 - - - - - - - - - - - - - -163-M-Leukemia, monuc - 1= - - - - - - - - - - - - -Sciatic nerve Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic 1 - - - - - - - - - - - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142159-Ectasia s - - - - - - - - - - - - - - -190-Hyperplasia, lobular s - - - - - - - - - - - - - - -156-B-Fibroadenoma - - - - - 1= - - - - 1= - - - -70-B-Fibroma - - - - - - - - - - - - - - -235-M-Adenocarcinoma - - - - - - - - - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - - - - - - - - - -122-Fibrosis s - - - - - - - - - - - - - - -253-Inflammation, mixed s - - - - - - - - - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Compression s - - - 2= - - - - - - - 2= - - -192-Hemorrhage s - - - - - - - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - - 1 - - - -33-Necrosis s - - - - - - - - - - - - - - -194-Inflammation, chronic s - - - - 4= - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - - - - - - - - -129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -130-Cataract p - - - - - - - - - - - - - - -133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:114Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSEyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - 1 - - - - 1 - - - - - -126-Mineralization, scleral s - 2 - - - - - - - - - - - - 1131-Neovascularization, corneal s - - - - - - - - 1 1 - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - - - - - - - - -197-Hemorrhage s - - - - - - - - - - - - - - -231-Necrosis, neuronal s - - - - - - - - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -134-Inflammation, mixed s - 2 2 - - - 2 - - - - - - - -34-Inflammation-nasolac duct s 3 2 2 1 3 - 4 3 3 3 - 4 - - -136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s 2 - - 2 - - - - - - - - - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - - - - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - 1 - - - - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - 2 2 - - - - - - - - - - - -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - 1 - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:115Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSCervix (3) Status > M M M M M M M M M M M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator > 14260-Hemorrhage s -59-Infiltration, histiocytic s -65-N-Leukemia, monuc 1=Popliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator > 14268-N-Leukemia, monuc 1=Mediastinal LN (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - - - - - - - - - -3-Infiltration, histiocytic s - - - - - - - - - - - - 3 - -2-Pigmentation s - - - - - - - - - - - - 3 - -273-B-Thymoma - - - - - - - - - - - - - - -219-M-Carcinoma, metastatic - - 1= - - - - - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -41-N-Leukemia, monuc - 1= - - - - - - - - - - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - - - - - - - - - - 4= - 1 -37-Cyst s 2 1 - - - - 2 - 2= - 1 - - - -38-Degen s - - - - - - - - - - - - - - -148-Hemorrhage s - - - 3 - - 1= - - - 1 - - - -203-Necrosis s - - - - - - - - - - - - - - -57-Hyperplasia, focal s - - - - - - - - - - - 3 - - -31-B-Adenoma, pars distalis - - - 1= - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:116Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSPituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator > 142202-Inflammation, acute s -152-Inflammation, mixed s 3153-Hyperplasia/hyperkeratosis s 4=Bone, rib (1) Status > M M M M M M M M M M M M M M MOperator > 142157-M-Osteosarcoma 1=Mesentery (2) Status > M M M M M M M M M M M M M M MOperator > 142171-Splenic tissue, "accessory" p -218-M-Carcinoma, metastatic 1Bone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:117Rat/F344/NGroup Sex Dosage Animal > 6838H752 6838H754 6838H756 6838H758 6838H760 6838H762 6838H7644 F 20 g/m3 Animal > 6838H751 6838H753 6838H755 6838H757 6838H759 6838H761 6838H763 6838H765Tissue/diagnosis Death code > U2 U2 U2 FS FS FS U2 FS FS FS FS FS U2 U2 FSTiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:118Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSLungs (12) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - - - - - 1= 1 - - - 1 1 - 1 -30-Congestion s - - - - - - - - - - - - - - -71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s 2= - - - - - - - 1= - - - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - 2= - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol 2 1 1 - 2 - 2 - 2= 2 - - 2 - 174-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14221-Hemorrhage s - - - - - - - - - - 2 - - -297-Inflammation, mixed s - - - - - - - - - - - - - -62-N-Leukemia, monuc - - - - - - - - - - - - - -Thyroid glands (8) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - - - - - - - -77-Hyperplasia, C-cell, focal s - 2 - - - - - 2 - - 3= - - - -81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -35-B-Adenoma, C-cell - - - - - - - - - - - - - - -78-B-Adenoma, follicular cell - - - - 1 - - - - - - - - - -174-M-Carcinoma, C-cell - - - - - - - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -178-M-Leukemia, monuc - - - - 1 - - - - - - - - - -Parathyroid (2) Status > m mH mH mH mH mHOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - - - - - - - - -296-B-Adenoma - - - - - - - - - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:119Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSEsophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s 1 - 1 - - - - - - - - - 1 - -1-Hyperplasia s - - 1 - 1 2 1 - - 2 2 - - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s 1 - 2 2 2 2 2 1 - 2 - 1 1 1 -53-Inflammation, chronic s - - - - - - - - - - 2 - - - 2Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (2) Status > * *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - - - - - - -44-N-Leukemia, monuc - - - 1 - 1 - - - - - - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - - - - - - - -158-Congestion s - - - - - - - - - - - - - - -90-Fatty Change s - - - - - - - - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - - - - - - - - -92-Hdn p - - - - - P= - - - - - - - - -4-Necrosis s - - 1 - - - - - - - - - 1 - -230-Thrombus s - - - - - - - - - - - - - - -13-Vaculoliz cyto s - - - - - - - - - - - - - - -24-Inflammation, acute s - - - - - - - - - - - - - - -54-Inflammation, chronic s - - - - - - - 1 - - 1 - - 1 -46-Hyperplasia, biliary s - - 1 - 2 2 - - 1 1 1 - - 1 -47-Hyperplasia, hepato, regen s - - - - - - 1 - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-M-Leukemia, monuc 2 1 1= - 2 - 2= - 2 2= - - 2 - 2Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Fibrosis s - - - - - - - - - - - - - - -226-Hemorrhage s - - - - - - - - - - - - 3 - -97-Necrosis s - - - - - - 4= - - - - - 3= - -15-M-Leukemia, monuc 2= 1= 1 - 2= - 2= - 2= 2= - - 2= - 2=298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:120Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSKidneys (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - - - - - - - - -149-Cyst s - - - - - - - - - - - - - - -209-Degen, hyaline droplet s - - - - - - - - - - - - - - -210-Dilatation s - - - - - - - - - - - - - - -228-Infarct s - - - - - - - - - - - - - - -16-Nephropathy, chronic s - 1 2 - 1 1 2 1 1 - 2 2 2 2 26-Pigment accum, tub epi s - - - - - - - - - - - - - - -98-M-Leukemia, monuc 1 - - - - - - - - - - - - - -299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - - - - - - - - - -101-Fibrosis s - - - - - - - - - - - - - - -175-Thrombus s - - - - - - - - - - - - - - -36-Inflammation, focal, chronic s - - - 1 1 - - - 1 1 1 1 - 1 148-M-Leukemia, monuc - - - - - - - - - - - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - - - - - - - - -103-Inflammation, mixed s - - - - - - - - - - - - - - -217-M-Carcinoma, metastatic - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Cecum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - - - - - - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - - - - - - - - -56-Inflammation, chronic s - - - - - - - 1 - - - - - - -166-Hyperplasia, papillary s - - - - - - - - - - - - - - -106-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - - - - - - - - -Jejunum Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:121Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSIleum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - 1= - - - - - - - -Colon Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - - - - - - - - - -110-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - - - - - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -113-Degen, cytopl vacuol s 1 1 - 2 - - 1 1 - - - - - - -170-Necrosis s - - - - - - - - - - - - - - -118-Thrombus s - - - - - - - - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - - - - - - - - -64-Hyperplasia, focal p - - - - - - - - - - - - - - -116-B-Pheochrom, bgn - - - - - - - - - - - - - - -216-M-Carcinoma, metastatic - - - - - - - - - - - - - - -112-M-Leukemia, monuc - - - - - - - - 1 - - - - - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - - - - - -7-Dilatation s - - - - - - - - - - - - - - -167-Intussusception p - - - P= - - - - - - - - - - -162-Inflammation, mixed s - - - - - - - - - - - - - - -49-Inflammation, chronic s - - - - - - - - - - - - - - -20-Hyperplasia, cystic endom s - 2 - - - - - - - - - - 1 1 -286-B-Adenoma, endometrial - - - - - - - - - - - - - - -9-B-Polyp, endometrial stromal - 1= - 1 1= - 1= - - - - - - - 1=213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - -279-M-Leiomyosar - - - - - - - - - - - - - - -165-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - - - - - - - - - -173-Inflammation, chronic s - - - - - - - - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -32-N-Leukemia, monuc - - - - 1 - - - 1 - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:122Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSOvaries (9) Status > H HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - - - - - - - - -154-Cyst, bursa p - - - - - - - - - - - - - - -234-Cyst, epithelial p - - - - - - - - - - - - - - -293-Cyst, follicular p - - - - - - - - - - - - - - -291-Cyst, rete ovarii s - - - - - - - - - - - - - - -25-Hemorrhage s - - - - - - - - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -163-M-Leukemia, monuc - - - - - - - - - - - - - - -Sciatic nerve Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Mammary gland (6) Status > *H *H *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142159-Ectasia s - - 2 - - - - - - - - -190-Hyperplasia, lobular s - - - - 2 - - - - - - -156-B-Fibroadenoma - - - - - 1= - - - - - -70-B-Fibroma - - - - - - - - - - - -235-M-Adenocarcinoma - - - - - - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - - - - - - -Skin (3) Status > *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - - - - - - - - -122-Fibrosis s - - - - - - - - - - - - - -253-Inflammation, mixed s - - - - - - - - - - - - - -Brain (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Compression s - - - 2= - - - - - - - - - - -192-Hemorrhage s - - - - - - - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - -33-Necrosis s - - - - - - - - - - - - - - -194-Inflammation, chronic s - - - - - - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Atrophy s - 4= - - - - - - - - - 4 - - -129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -130-Cataract p - - - - - - - - - - - P= - - -133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:123Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSEyes/optic nerve (7) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - 1 - - - - - - - - - - - - -126-Mineralization, scleral s - - - - - - - - - - - - - - 1131-Neovascularization, corneal s - - - - - - - - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - 1 - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - - - - - - - - -197-Hemorrhage s - - - - - - - - - - - - - - -231-Necrosis, neuronal s - - - - - - - - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s 2 - - - - - - - - - - - - - -134-Inflammation, mixed s - - - - - - - - - - - - - - -34-Inflammation-nasolac duct s - 4 - - 2 - 3 - - - 4 - - - 2136-Inflammation-resp epith s - - - - - - - - - - - - - - -199-Hyperplasia-resp epith s - - - - - - - - - - 2 - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s 1 - 2 1 - - - - - - 2 1 - - -261-Degeneration,hyal-resp epith s - - - - - - - - - - 1 - - 1 -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - - - - - - - - - - - - - -227-Hyperplasia-resp epith s - - - - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - - - 3 - - - - - - 2 - - - -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - 1 - - - - - - - - - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:124Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSCervix (3) Status > M M M M M M M M M M M M M M MOperator > 142 142168-B-Polyp, endometrial stromal 1= -289-M-Leiomyosarcoma - -269-N-Adenocarcinoma, endometr - -Clitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status > * *HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - - - - - - - -3-Infiltration, histiocytic s - - - - - - - - - - - - -2-Pigmentation s - - - - - - - - - - - - -273-B-Thymoma - - - - - - - - - - - - -219-M-Carcinoma, metastatic - - - - - - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - - - - - - -41-N-Leukemia, monuc 1 - - - 1= 1 - - - - - 1= -Pituitary gland (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - - 3= 2 - - - - - - - - - 3 -37-Cyst s - - - - - - - - - 1 1 - - - 238-Degen s - - - - - - - - - - - - - - -148-Hemorrhage s - - - - - - - - - - - - - - -203-Necrosis s - - - - - - 3 - - - - - - - -57-Hyperplasia, focal s - - 2 - 3 - - - - - - 1 - - -31-B-Adenoma, pars distalis - - - 1= 1= - - - - - - - - 1= -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:125Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSPituitary gland (10) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - 1 - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:126Rat/F344/NGroup Sex Dosage Animal > 6838H767 6838H769 6838H771 6838H773 6838H775 6838H777 6838H7794 F 20 g/m3 Animal > 6838H766 6838H768 6838H770 6838H772 6838H774 6838H776 6838H778 6838H780Tissue/diagnosis Death code > U2 FS FS FS U2 FS U2 FS U2 U2 FS FS FS FS FSTiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:127Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Lungs (12) Status > H aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14240-Alveolar histiocytosis s - 1 - - - - - - 1 - - - - - -30-Congestion s - - - - - - - - - - - - - - 2=71-Fibrosis, focal s - - - - - - - - - - - - - - -182-Hemorrhage s - - - - - - - - - - 1 - - - -177-Inflammation, acute s - - - - - - - - - - - - - - -72-Inflammation, mixed s - - - - - - - - - - - - - - -236-Inflammation, granulomatous s - - - - - - - - - - - - - - -10-Hyperplasia, alv. epi. focal s - - - - - - - - - - - - - - -214-N-Carcinoma, metastatic - - - - - - - - - - - - - - -11-N-Leukemia,monuc - cap invol - - - - 2= - 1 - - - 2= 2 1 - -74-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -204-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Trachea (4) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14222-Inflammation, acute s - - - - - - - - - - - - - - -75-Inflammation, mixed s - - - - - - - - - - - - - - -76-Hyperplasia s - - - - - - - - - - - - - - -238-N-Leukemia, monuc - - - - - - - - - - - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14221-Hemorrhage s 2 - - - - - - - - - - - - - -297-Inflammation, mixed s - - - - - - - - - - - - - - -62-N-Leukemia, monuc - - - - 1 - - - - - - - - - -Thyroid glands (8) Status > m mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14279-Cyst, follicular p - - - - - - - - - - - - - - -77-Hyperplasia, C-cell, focal s 3 - - - - - - 2 - - - - - - -81-Hyperplasia, follicular cell s - - - - - - - - - - - - - - -35-B-Adenoma, C-cell - - - - - - - - - - 1= - - - -78-B-Adenoma, follicular cell - - - - - - - - - - 1 - - - -174-M-Carcinoma, C-cell - - - - - - - - - - - - - - -80-M-Carcinoma, follicular cell - - - - - - - - - - - - - - -178-M-Leukemia, monuc - - - - - - - - - - - - - - -Parathyroid (2) Status > mH mH mH mH mH m m mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142241-Hyperplasia, focal s - - - - - - - - - - - - - - -296-B-Adenoma - - - - - - - - - - - - - - -Aorta (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:128Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Esophagus Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14212-Metaplasia, squamous s - - - 1 - - 1 - - - - - - - -1-Hyperplasia s - - - - - - - - - - 1 1 - - -23-Inflammation, acute s - - - - - - - - - - - - - - -42-Inflammation, mixed s - - 2 2 - 1 1 2= - - 1 2 1 1 153-Inflammation, chronic s 1 1 - - - - - - 1 1 - - - - -Salivary gland (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14243-M-Leukemia, monuc - - - - - - - - - - - - - - -Mandibular LN (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14289-Hemorrhage s - - - - - - - - - - - - - - -44-N-Leukemia, monuc - - - - 1 - - - - - - - - - -Liver (15) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14245-Angiectasis s - - - - - - - - - - 1 - - - -158-Congestion s - - - - - - - - - - - - - - -90-Fatty Change s - - 2= - - - 2 - - - - - - - -150-Foci cell alter, basophilic s - - - - - - - - - - - - - - -92-Hdn p - - - - - P= - - - - - - - - -4-Necrosis s 1 - - - 2 - - - - - - - - - -230-Thrombus s - - - - - - - - - - - - 2 - -13-Vaculoliz cyto s - - - - - - - - - - - - - - -24-Inflammation, acute s - - - - - - - - - - - - - - -54-Inflammation, chronic s 1 1 1 - - - - 1 1 1 - - - 1 -46-Hyperplasia, biliary s - 1 1 - - - 1 1 - 1 - 2 2 - -47-Hyperplasia, hepato, regen s - - - - - - - - - - - - - - -91-B-Adenoma, hepatocellular - - - - - - - - - - - - - - -205-M-Sarcoma, histiocytic - - - - - - - - - - - - - - -14-M-Leukemia, monuc - - - - 2= - 1= - - - 2= 2 2 - -Spleen (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14296-Fibrosis s - - - - - - - - - - - - - - -226-Hemorrhage s - - - - - - - - - - - - - - -97-Necrosis s - - - - - - - - - - - - - - -15-M-Leukemia, monuc - - - - 2= - 1= - - - 2= 2= 2= - -298-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:129Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Kidneys (9) Status > a aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142211-Atrophy s - - - - - - - - - - - - - - -149-Cyst s - - - - - - - - - - - - - - -209-Degen, hyaline droplet s - - - - - - - - - - - - - - -210-Dilatation s - - - - - - - - - - - - - - -228-Infarct s - - - 3 - - - - - - - - - - -16-Nephropathy, chronic s 3 2 3 3 1 - 3= 3 2 2 3 1 1 2 16-Pigment accum, tub epi s - - - - - - - - - - - 3 - - -98-M-Leukemia, monuc - - - - - - - - - - - - - - -299-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Heart (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142100-Degen, myocyte s - - - - - - - - - 1 - - - - -101-Fibrosis s - - - - - - - - - - - - - - -175-Thrombus s - - - - - - - - - - - - - - -36-Inflammation, focal, chronic s - - - 1 - - 1 1 1 - 1 1 1 1 -48-M-Leukemia, monuc - - - - - - - - - - - - - - -Stomach (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142268-Ulcer s - - - - - - - - - - - - - - -103-Inflammation, mixed s - - - - - - - - - - - - - - -217-M-Carcinoma, metastatic - - - - - - - - - - - - - - -220-M-Leukemia, monuc - - - - - - - - - - - - - - -Cecum (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142104-N-Leukemia, monuc - - - - - - - - - - - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142186-Hemorrhage s - - - - - - - - - - - - - - -56-Inflammation, chronic s - - - - - - - - - - - - - - -166-Hyperplasia, papillary s - - - - - - - - - - - - - - -106-M-Leukemia, monuc - - - - - - - - - - - - - - -Duodenum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142275-Inflammation, acute s - - - - - - - - - - - - - - -Jejunum Status > U U U U U U U U U U U U U U UaOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:130Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Ileum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142181-N-Leukemia, monuc - - - - - - - - - - - - - - -Colon Status > U U U U U U U U U U U U U U UaOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142212-Fibrosis s - - - - - - - - - - - - - - -110-M-Leukemia, monuc - - - - - - - - - - - - - - -Rectum (1) Status > aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142276-Metaplasia, squamous s - - - - - - - - - - - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142161-Cyst s - - - - - - - - - - - - - - -113-Degen, cytopl vacuol s 1 - - 2 - - - - 1 - - - 1 - -170-Necrosis s - - - - - - - - - - - - - - -118-Thrombus s - - - - - - - - - - - - - - -117-Hyperplasia, cortical, focal s - - - - - - - - - - 1 - - - -64-Hyperplasia, focal p - P - - - - - - - - - P - - -116-B-Pheochrom, bgn - - - - - - - - - - - - - - -216-M-Carcinoma, metastatic - - - - - - - - - - - - - - -112-M-Leukemia, monuc - - - - - - - - - - - - 1 - -Uterus (11) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142277-Angiectasis s - - - - - - - - - - - - - - -7-Dilatation s - - - - - - - - - - - - - - -167-Intussusception p - - - - - P= - - - - - - - - -162-Inflammation, mixed s - - - - - - - - - - - - - - -49-Inflammation, chronic s - - - - - - - - - - - - - - -20-Hyperplasia, cystic endom s 1 - - - - - 3 - 2 - 2 1 - 1 -286-B-Adenoma, endometrial - - - - - - - - - - - - - - -9-B-Polyp, endometrial stromal 1= - - - - - - - - 1 1= - - - -213-M-Adenocarcinoma, endometr - - - - - - - - - - - - - - -279-M-Leiomyosar - - - - - - - - - - - - - - -165-M-Leukemia, monuc - - - - - - - - - - - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142120-Hemorrhage s - - - - - - - - - - - - - - -173-Inflammation, chronic s - - - - - - - - - - - - - - -206-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -32-N-Leukemia, monuc - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:131Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Ovaries (9) Status > mOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142284-Congestion s - - - - - - - - - - - - - - -154-Cyst, bursa p - - - - - - - - - - - - - - -234-Cyst, epithelial p - - - - - - - - - - - - - - -293-Cyst, follicular p - - - - - - - - - - - - - - -291-Cyst, rete ovarii s - - - - - - - - - - - - - - -25-Hemorrhage s - - - - - - - - - - - - - - -290-Necrosis, mesenteric fat s - - - - - - - - - - - - - - -207-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -163-M-Leukemia, monuc - - - - - - - - - - - - - - -Sciatic nerve Status > U U U U U U U U U U U U U U UOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - - - - - - - - - - - -Mammary gland (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142159-Ectasia s - - - - - - - - - - - - - - -190-Hyperplasia, lobular s - - - - - - 1 - - - - - - - -156-B-Fibroadenoma - 1= - - - - - - - - - - - - -70-B-Fibroma - - - - - - - - - - - - - - -235-M-Adenocarcinoma - - - - - - - - - - - - - - -224-M-AdenoCA arising in fibroAD - - - - - - - - - - - - - - -Skin (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142252-Cyst, epith inc p - - - - - - - - - - - - - - -122-Fibrosis s - - - - - - - - - - - - - - -253-Inflammation, mixed s - - - - - - - - - - - - - - -Brain (6) Status > HOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14226-Compression s - - 3= - - - 2= 1 - 3= - - - - -192-Hemorrhage s - - - - - - - - - - - - - - -155-Metaplasia, osseous, meninge s - - - - - - - - - - - - - - -33-Necrosis s - - - - - - - - - - - - - - -194-Inflammation, chronic s - - - - - - - - - - - - - - -256-M-Astrocytoma, malignant - - - - - - - - - - - - - - -Eyes/optic nerve (7) Status > H aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142127-Atrophy s - - - - - - - - - - - - - - -129-Atrophy, retinal, unilat s - - - - - - - - - - - - - - -130-Cataract p - - - - - - - - - - - - - - -133-Metaplasia, osseous, sclera s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:132Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Eyes/optic nerve (7) Status > H aOperator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14258-Mineralization, corneal str s - - - - 2= - - - - - - - - - -126-Mineralization, scleral s - 1 - - - - - - - - - - - - -131-Neovascularization, corneal s - - - - - - - - - - - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142179-New bone, endosteal s - - - - - - - - - - - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14227-Degen, white matter s - - - - - - - - - - - 1 - - -197-Hemorrhage s - - - - - - - - - - - - - - -231-Necrosis, neuronal s - - - - 1 - - - - - - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142260-Degeneration,hyal-resp epith s - 1 - - - - - - - - - - - - -134-Inflammation, mixed s - - 1 - - - - - - - - - - - -34-Inflammation-nasolac duct s - - 4 - 2 - - 2 3 3 - - 3 - -136-Inflammation-resp epith s - - - - - - - 2 - - - - - - -199-Hyperplasia-resp epith s - - - - - - - 2 - - - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14218-Degeneration,hyaline-olf epi s - 2 - 1 - - - - 1 - - - - - -261-Degeneration,hyal-resp epith s - - - - - - - 2 - - 2 2 - - -176-Metaplasia, sec-olfact epith s - - - - - - - - - - - - - - -270-Metaplasia, squ-olfact epith s - - - - - - - - - - - - - - -138-Inflammation, mixed s - - 3 - - - - - - - - - - - -227-Hyperplasia-resp epith s - - 3 - - - - - - - - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142295-Degeneration-olfact epith s - - - - - - - - - - - - - - -19-Degeneration,hyaline-olf epi s - 1 - - 1 - - - - - 3 2 - - -232-Degeneration-resp epith s - - - - - - - - - - - - - - -142-Inflammation, mixed s - - - - - - - - - - - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142285-Degeneration-olfact epith s - - - - - - - - - - - - - - -164-Degeneration,hyaline-olf epi s - - - - - - - - - - 1 - - - -144-Inflammation, mixed s - - - - - - - - - - - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:133Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Cervix (3) Status > M M M M M M M M M M M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M M M M M M M M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M M M M M M M M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M M M M M M M M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M M M M M M M M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M M M M M M M M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status > *Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 14229-Hemorrhage s - - - - - - - - - - - - - -3-Infiltration, histiocytic s - - - - - - - - - - - - - -2-Pigmentation s - - - - - - - - - - - - - -273-B-Thymoma - - - - - - - - - - - - - -219-M-Carcinoma, metastatic - - - - - - - - - - - - - -265-N-Sarcoma, histiocytic - - - - - - - - - - - - - -41-N-Leukemia, monuc - - - - - - - - - - - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142160-Angiectasis s - 1 - - - - - - - - - - - - -37-Cyst s 1 - - - - - - - - - 1 - - - -38-Degen s - - - - - - - - - - - - - - -148-Hemorrhage s - - 3 - - - 3 3 - 3 2 - - - -203-Necrosis s - - - - - - - - - - - - - - -57-Hyperplasia, focal s - - - - - - - - - - - - - - -31-B-Adenoma, pars distalis - - 1= - - - 1= 1= - 1= 1= - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:134Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Pituitary gland (10) Status >Operator > 142 142 142 142 142 142 142 142 142 142 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - - - - - - - - - - - -288-M-Carcinoma - - - - - - - - - - - - - - -146-M-Leukemia, monuc - - - - - - - - - - - - - - -Tail (3) Status > M M M M M M M M M M M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M M M M M M M M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M M M M M M M M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M M M M M M M M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M M M M M M M M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M M M M M M M M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M M M M M M M M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M M M M M M M M M M M MOperator >278-Pigment sVagina (1) Status > M M M M M M M M M M M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:135Rat/F344/NGroup Sex Dosage Animal > 6838H782 6838H784 6838H786 6838H788 6838H790 6838H792 6838H7944 F 20 g/m3 Animal > 6838H781 6838H783 6838H785 6838H787 6838H789 6838H791 6838H793 6838H795Tissue/diagnosis Death code > FS FS U2 FS U2 U1 FS FS FS FS FS U2 FS FS U1Tiss.not specifi Status > M M M M M M M M M M M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:136Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSLungs (12) Status >Operator > 142 142 142 142 14240-Alveolar histiocytosis s - - - - -30-Congestion s - - - - -71-Fibrosis, focal s - - - - -182-Hemorrhage s - - - - -177-Inflammation, acute s - - - - -72-Inflammation, mixed s - - - - -236-Inflammation, granulomatous s - - - - -10-Hyperplasia, alv. epi. focal s - - - - -214-N-Carcinoma, metastatic - - - - -11-N-Leukemia,monuc - cap invol - 2= - - 274-N-Leukemia,monuc - inv invol - - - - -204-N-Sarcoma, histiocytic - - - - -Trachea (4) Status >Operator > 142 142 142 142 14222-Inflammation, acute s - - - - -75-Inflammation, mixed s - - - - -76-Hyperplasia s - - - - -238-N-Leukemia, monuc - - - - -Bronchial (TBLN) (3) Status >Operator > 142 142 142 142 14221-Hemorrhage s - - 2 - -297-Inflammation, mixed s - - - - -62-N-Leukemia, monuc - - - - -Thyroid glands (8) Status >Operator > 142 142 142 142 14279-Cyst, follicular p - - - - -77-Hyperplasia, C-cell, focal s - - - - -81-Hyperplasia, follicular cell s - - - - -35-B-Adenoma, C-cell - - - - -78-B-Adenoma, follicular cell - - - - -174-M-Carcinoma, C-cell - - - - -80-M-Carcinoma, follicular cell - - - - -178-M-Leukemia, monuc - - - - -Parathyroid (2) Status > m mOperator > 142 142 142 142 142241-Hyperplasia, focal s - - - - -296-B-Adenoma - - - - -Aorta (1) Status >Operator > 142 142 142 142 14283-N-Leukemia,monuc - inv invol - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:137Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSEsophagus Status > U U U U UOperator > 142 142 142 142 142Larynx (5) Status >Operator > 142 142 142 142 14212-Metaplasia, squamous s - - - - -1-Hyperplasia s 1 2 - - 223-Inflammation, acute s - - - - -42-Inflammation, mixed s 1 1 - 1 253-Inflammation, chronic s - - - - -Salivary gland (1) Status >Operator > 142 142 142 142 14243-M-Leukemia, monuc - - - - -Mandibular LN (2) Status >Operator > 142 142 142 142 14289-Hemorrhage s - - - - -44-N-Leukemia, monuc - - - - -Liver (15) Status >Operator > 142 142 142 142 14245-Angiectasis s - - - - -158-Congestion s - - - - -90-Fatty Change s - - - - -150-Foci cell alter, basophilic s - - - - -92-Hdn p - - - - -4-Necrosis s - - - - -230-Thrombus s - - - - -13-Vaculoliz cyto s - - - - 224-Inflammation, acute s - - - - -54-Inflammation, chronic s - - 1 - 246-Hyperplasia, biliary s 2 - - - 147-Hyperplasia, hepato, regen s - - - - -91-B-Adenoma, hepatocellular - - - - -205-M-Sarcoma, histiocytic - - - - -14-M-Leukemia, monuc - 2= - - 2=Spleen (5) Status >Operator > 142 142 142 142 14296-Fibrosis s - - - - -226-Hemorrhage s - - - - -97-Necrosis s - - - - -15-M-Leukemia, monuc - 2= - - 2=298-N-Sarcoma, histiocytic - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:138Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSKidneys (9) Status >Operator > 142 142 142 142 142211-Atrophy s - - - - -149-Cyst s - - - - -209-Degen, hyaline droplet s - - - - -210-Dilatation s - - - - -228-Infarct s - - - - -16-Nephropathy, chronic s 2 1 1 2 36-Pigment accum, tub epi s - - - - -98-M-Leukemia, monuc - - - - -299-N-Sarcoma, histiocytic - - - - -Heart (5) Status >Operator > 142 142 142 142 142100-Degen, myocyte s - - - - -101-Fibrosis s - - - - -175-Thrombus s - - - - -36-Inflammation, focal, chronic s 1 - - 1 148-M-Leukemia, monuc - - - - -Stomach (4) Status >Operator > 142 142 142 142 142268-Ulcer s - - - - -103-Inflammation, mixed s - - - - -217-M-Carcinoma, metastatic - - - - -220-M-Leukemia, monuc - - - - -Cecum (1) Status >Operator > 142 142 142 142 142104-N-Leukemia, monuc - - - - -Urinary bladder (4) Status >Operator > 142 142 142 142 142186-Hemorrhage s - - - - -56-Inflammation, chronic s - - - - -166-Hyperplasia, papillary s - - - - -106-M-Leukemia, monuc - - - - -Duodenum (1) Status >Operator > 142 142 142 142 142275-Inflammation, acute s - - - - -Jejunum Status > U U U U UOperator > 142 142 142 142 142Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:139Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSIleum (1) Status >Operator > 142 142 142 142 142181-N-Leukemia, monuc - - - - -Colon Status > U U U U UOperator > 142 142 142 142 142Pancreas (2) Status >Operator > 142 142 142 142 142212-Fibrosis s - - - - -110-M-Leukemia, monuc - - - - -Rectum (1) Status >Operator > 142 142 142 142 142276-Metaplasia, squamous s - - - - -Adrenal glands (9) Status >Operator > 142 142 142 142 142161-Cyst s - - - - -113-Degen, cytopl vacuol s 1 - - - 1170-Necrosis s - - - - -118-Thrombus s - - - - -117-Hyperplasia, cortical, focal s - - - - -64-Hyperplasia, focal p - - - - -116-B-Pheochrom, bgn - - - - -216-M-Carcinoma, metastatic - - - - -112-M-Leukemia, monuc - - - - -Uterus (11) Status >Operator > 142 142 142 142 142277-Angiectasis s - - - - -7-Dilatation s - - - - -167-Intussusception p - - - - -162-Inflammation, mixed s - - - - -49-Inflammation, chronic s - - - - -20-Hyperplasia, cystic endom s - - - - -286-B-Adenoma, endometrial - - - - -9-B-Polyp, endometrial stromal - - 1= - -213-M-Adenocarcinoma, endometr - - - - -279-M-Leiomyosar - - - - -165-M-Leukemia, monuc - - - - -Mesenteric LN (4) Status >Operator > 142 142 142 142 142120-Hemorrhage s - - - - -173-Inflammation, chronic s - - - - -206-N-Sarcoma, histiocytic - - - - -32-N-Leukemia, monuc - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:140Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSOvaries (9) Status >Operator > 142 142 142 142 142284-Congestion s - - - - -154-Cyst, bursa p - - - - -234-Cyst, epithelial p - - - - -293-Cyst, follicular p - - - - -291-Cyst, rete ovarii s - - - - -25-Hemorrhage s - - - - -290-Necrosis, mesenteric fat s - - - - -207-N-Sarcoma, histiocytic - - - - -163-M-Leukemia, monuc - - - - -Sciatic nerve Status > U U U U UOperator > 142 142 142 142 142Muscle, skeletal (1) Status >Operator > 142 142 142 142 142208-N-Sarcoma, histiocytic - - - - -Mammary gland (6) Status > HOperator > 142 142 142 142 142159-Ectasia s - - - - -190-Hyperplasia, lobular s - - - - -156-B-Fibroadenoma - - 1= - -70-B-Fibroma - - - - -235-M-Adenocarcinoma - - - - -224-M-AdenoCA arising in fibroAD - - - - -Skin (3) Status >Operator > 142 142 142 142 142252-Cyst, epith inc p - - - - -122-Fibrosis s - - - - -253-Inflammation, mixed s - - - - -Brain (6) Status >Operator > 142 142 142 142 14226-Compression s - - - 3= 2=192-Hemorrhage s - - - - -155-Metaplasia, osseous, meninge s - - - - -33-Necrosis s - - - - -194-Inflammation, chronic s - - - - -256-M-Astrocytoma, malignant - - - - -Eyes/optic nerve (7) Status >Operator > 142 142 142 142 142127-Atrophy s - - - - -129-Atrophy, retinal, unilat s - - - - -130-Cataract p - - P= - -133-Metaplasia, osseous, sclera s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:141Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSEyes/optic nerve (7) Status >Operator > 142 142 142 142 14258-Mineralization, corneal str s - - - - -126-Mineralization, scleral s - - - - -131-Neovascularization, corneal s - - - - -Bone, femur (1) Status >Operator > 142 142 142 142 142179-New bone, endosteal s - - - - -Spinal cord (3) Status >Operator > 142 142 142 142 14227-Degen, white matter s - - - - -197-Hemorrhage s - - - - -231-Necrosis, neuronal s - - - - -Nose/Turbinate 1 (5) Status >Operator > 142 142 142 142 142260-Degeneration,hyal-resp epith s - - - - -134-Inflammation, mixed s - - - - -34-Inflammation-nasolac duct s 3 - - - -136-Inflammation-resp epith s - - - - -199-Hyperplasia-resp epith s - - - - -Nose/Turbinate 2 (6) Status >Operator > 142 142 142 142 14218-Degeneration,hyaline-olf epi s - - - - -261-Degeneration,hyal-resp epith s - 2 - - -176-Metaplasia, sec-olfact epith s - - - - -270-Metaplasia, squ-olfact epith s - - - - -138-Inflammation, mixed s - - - - -227-Hyperplasia-resp epith s - - - - -Nose/Turbinate 3 (4) Status >Operator > 142 142 142 142 142295-Degeneration-olfact epith s - - - - -19-Degeneration,hyaline-olf epi s - - - - -232-Degeneration-resp epith s - 2 - - -142-Inflammation, mixed s - - - - -Nose/Turbinate 4 (3) Status >Operator > 142 142 142 142 142285-Degeneration-olfact epith s - - - - -164-Degeneration,hyaline-olf epi s - - - - -144-Inflammation, mixed s - - - - -Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:142Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSCervix (3) Status > M M M M MOperator >168-B-Polyp, endometrial stromal289-M-Leiomyosarcoma269-N-Adenocarcinoma, endometrClitoral gland (3) Status > M M M M MOperator >294-B-Adenoma61-M-Carcinoma, squamous cell271-N-AdenocarcinomaLymph node other (3) Status > M M M M MOperator >60-Hemorrhage s59-Infiltration, histiocytic s65-N-Leukemia, monucPopliteal LN (1) Status > M M M M MOperator >66-N-Leukemia, monucIliac LN (1) Status > M M M M MOperator >67-N-Leukemia, monucPancreatic LN (1) Status > M M M M MOperator >68-N-Leukemia, monucMediastinal LN (7) Status >Operator > 142 142 142 142 14229-Hemorrhage s - - - 2 -3-Infiltration, histiocytic s - - - - -2-Pigmentation s - - - - -273-B-Thymoma - - - - -219-M-Carcinoma, metastatic - - - - -265-N-Sarcoma, histiocytic - - - - -41-N-Leukemia, monuc - - - - -Pituitary gland (10) Status >Operator > 142 142 142 142 142160-Angiectasis s - - - - -37-Cyst s - 2 2 - -38-Degen s - - - - -148-Hemorrhage s - - - 3 2203-Necrosis s - - - - -57-Hyperplasia, focal s - - - - -31-B-Adenoma, pars distalis - - - 1= 1=Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:143Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSPituitary gland (10) Status >Operator > 142 142 142 142 142274-B-Adenoma, pars intermedia - - - - -288-M-Carcinoma - - - - -146-M-Leukemia, monuc - - - - -Tail (3) Status > M M M M MOperator >202-Inflammation, acute s152-Inflammation, mixed s153-Hyperplasia/hyperkeratosis sBone, rib (1) Status > M M M M MOperator >157-M-OsteosarcomaMesentery (2) Status > M M M M MOperator >171-Splenic tissue, "accessory" p218-M-Carcinoma, metastaticBone, vertebrae (1) Status > M M M M MOperator >221-N-Leukemia, monucZymbal’s gland (1) Status > M M M M MOperator >223-M-Carcinoma, squamous cellMediastinum (1) Status > M M M M MOperator >233-N-Leukemia, monucBone, other (1) Status > M M M M MOperator >272-Fracture pHarderian gland (1) Status > M M M M MOperator >278-Pigment sVagina (1) Status > M M M M MOperator >287-M-LeiomyosarcomaLovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:144Rat/F344/NGroup Sex Dosage Animal > 6838H797 6838H7994 F 20 g/m3 Animal > 6838H796 6838H798 6838H800Tissue/diagnosis Death code > FS U2 FS FS FSTiss.not specifi Status > M M M M MOperator >Lovelace Respiratory Raw Data Listing for Microscopic Tissue Evaluations Printed:25-Jun-04Research Institute Study Number:FY01013F Page:145Rat/F344/NSYMBOLS, ABBREVIATIONS, AND CODES USED IN THE "MICROSCOPIC EVALUATION OF TISSUES"*** DISTRIBUTION OF FINDINGS *** *** NEOPLASTIC FINDINGS ***" " NO PARENTHESIS = NOT SPECIFIED " B- " = PRIMARY, BENIGN NEOPLASM IN ORGAN/TISSUE" M " M = FINDING MULTI-FOCAL " M- " = PRIMARY, MALIGNANT NEOPLASM IN ORGAN/TISSUE" F " F = FINDING FOCAL " X- " = MALIGNANT NEOPLASM - TISSUE OR ORIGIN UNKNOWN" D " D = FINDING DIFFUSE " N- " = METASTATIC NEOPLASM WITHIN ORGAN/TISSUE*** GRADES FOR DEFINING SEVERITY (DEGREE) OR AMOUNT OF CHANGE *** " I- " = LOCALLY INVASIVE NEOPLASM FROM NEARBY ORGAN" NON-NEOPLASMS " " NEOPLASMS " " + " = PRESENCE OF A NEOPLASTIC FINDING IN ORGAN/TISSUE" 1 " = MINIMUM " 1 " = INCIDENTAL " +AA" = SECONDARY NEOPLASM FROM ORGAN/TISSUE INDICATED BYTWO LETTER ABBREVIATION (FOR EXAMPLE, LI=LIVER)" 2 " = MILD " 2 " = CONTRIBUTORY" +N " = MORE THAN ONE NEOPLASM OF THE SAME TYPE IN THE" 3 " = MODERATE " 3 " = FATAL SAME ORGAN, N EQUALS THE NUMBER OBSERVED" 4 " = MARKED " / " = NEOPLASM PRESENT AND RELATED TO ANIMAL DEATH*** OTHER SYMBOLS *** *** ANIMAL DEATH CODES ***" U " = ORGAN/TISSUE HISTOLOGICALLY NOT REMARKABLE " Un " = USER DEFINDED UNSCHEDULED DEATH CODES" M " = MISCELLANEOUS TISSUE " I1 " = INTERIM SACRIFICE #1" - " = FINDING NOT PRESENT OR OBSERVED " I2 " = INTERIM SACRIFICE #2" P " = FINDINGS PRESENT OR CONFIRMED (GRADING INAPPROPRIATE) " I3 " = INTERIM SACRIFICE #3" * " = TISSUE NOT AVAILABLE FOR MICROSCOPIC EXAMINATION " I4 " = INTERIM SACRIFICE #4" H " = SPECIAL HISTOLOGICAL COMMENTS ON TISSUE " I5 " = INTERIM SACRIFICE #5" A " = TISSUE NOT READABLE - AUTOLYTIC " FS " = FINAL SACRIFICE" a " = TISSUE READABLE - AUTOLYTIC " R " = RE-CUT OF TISSUE REQUESTED" m " = ONE OF PAIRED ORGANS MISSING" I " = TISSUE INADEQUATE AND UNREADABLE

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-7 Individual Animal Report of Co rrelated Gross and Mi croscopic DiagnosesLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:1Rat/F344/NAnimal: 6832E451 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 290.9Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Purple, +2/ 2 Round Cyst, Mild.Animal: 6832E452 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.5Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Enlarged, 3-5 mm, Black/ Single Round Cyst, Marked.Liver . . . . . . . Discolored, Diffuse, Mottled, +2 Congestion, Mild.Animal: 6832E453 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 707 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 219.3Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, Multiple, +1/ 2-6 N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory.Nodule, Confluent, +2/ 3-4 Raised M-Leukemia, mononuclear, Contributory.Bronchial (TBLN) . Enlarged, 3-5 mm, +1/ Diffuse N-Leukemia, mononuclear, Incidental.Lungs . . . . . . . Nodule, Right caudal, 3-5 mm, Pale, Firm, +1/ Round N-Leukemia, mononuclear - invasive involvement,Contributory.Uterus . . . . . . Mass, Right, 21-45 mm, Mottled, +2/ Irregular M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Nodule, Confluent, Mottled, +3/ 2-6 Raised M-Leukemia, mononuclear, Incidental.Mesenteric LN . . . Enlarged, Multiple, +4/ Irregular 6-10 N-Leukemia, mononuclear, Incidental.Animal: 6832E454 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 612 Dosing phase Status: Found Dead Terminal body weight (g): 273.6Tissue Gross observations / Comments Correlated microscopic observationsCervix . . . . . . Mass, 6-10 mm, Firm, +1 Examined; no correlation foundSpleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, 0-2 mm, Grey/ Focus, Round Cyst, Mild.Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:2Rat/F344/NAnimal: 6832E455 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 279.2Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark/ 1 Focus Round Angiectasis, Mild.Uterus . . . . . . Prolapse, 21-45 mm, +3 B-Polyp, endometrial stromal, Incidental.Animal: 6832E456 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 272.8Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Incidental.Discolored, 0-2 mm, Pale, Gritty/ Multifocal Round Examined; no correlation foundUterus . . . . . . Enlarged, Right, 11-15 mm, Soft/ Patchy Hyperplasia, cystic endometrial, Marked.Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus, round Cyst, Minimal.Animal: 6832E457 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 588 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 201.2Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, 0-2 mm, Red/ 1 Focus Round No correlation entry madeAnimal: 6832E458 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 257.4Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark Red, +2/ Focus Irregular B-Adenoma, pars distalis, Incidental.Animal: 6832E459 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 626 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 90-112 mm, Mottled, Friable, +3 M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, 0-2 mm, Dark Red, +2/ Multifocus Round N-Leukemia, mononuclear - capillary involvement,Contributory.Bronchial (TBLN) . Enlarged, 6-10 mm, +2/ Diffuse N-Leukemia, mononuclear, Incidental.Mammary gland . . . Mass, Left Thoracic, 16-20 mm, White, Firm, +3/ Round B-Fibroma, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:3Rat/F344/NAnimal: 6832E459 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 626 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0Tissue Gross observations / Comments Correlated microscopic observations(continued)Mediastinal LN . . Enlarged, 6-10 mm, +1/ Oval Diffuse N-Leukemia, mononuclear, Contributory.Mesenteric LN . . . Enlarged, 6-10 mm, +3/ Multiple Oval N-Leukemia, mononuclear, Incidental.Mandibular LN . . . Enlarged, 6-10 mm, +2/ Oval N-Leukemia, mononuclear, Incidental.Animal: 6832E460 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.6Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Dark, Soft/ Patchy Irregular Hyperplasia, focal, Moderate.Uterus . . . . . . Mass, Right, 21-45 mm, Dark, Firm/ Diffuse B-Polyp, endometrial stromal, Incidental.Animal: 6832E461 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 300.6Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Black, +2/ Foci Round Cyst, Moderate.Animal: 6832E462 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 304.3Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, 3-5 mm, Dark, +2/ Focus Irregular Cyst, Moderate.Thyroid glands . . Enlarged, Left, 6-10 mm, Dark, +1/ Diffuse M-Carcinoma, C-cell, Incidental.Animal: 6832E463 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.1Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, 0-2 mm, Dark, +1/ Irregular B-Adenoma, pars distalis, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:4Rat/F344/NAnimal: 6832E464 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 217.4Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, Friable, +3 M-Leukemia, mononuclear, Contributory.Small, +3 Examined; no correlation foundSpleen . . . . . . Enlarged, 46-67 mm, +2 M-Leukemia, mononuclear, Contributory.Animal: 6832E466 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 682 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 237.0Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 3-5 mm, Red, Firm, +2 Hemorrhage, Mild.Lungs . . . . . . . Discolored, 0-2 mm, Dark Red, Soft, +3/ Multifocal Hemorrhage, Mild.RoundSpleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory.Adhesion, 11-15 mm, Cloudy, +2/ Irregular Fibrosis, Mild.Animal: 6832E468 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 260.6Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Left, Diffuse, Pale/ Irregular No correlation entry madeLiver . . . . . . . Deformity, Diffuse, Mottled Examined; no correlation foundUrinary bladder . . Fluid, Diffuse, Cloudy, +2 No correlation entry madeAnimal: 6832E469 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 632 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 201.9Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round N-Leukemia, mononuclear - capillary involvement,Contributory.Spleen . . . . . . Enlarged, 46-67 mm, +2 M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:5Rat/F344/NAnimal: 6832E470 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 540 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 239.4Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Friable, +2/ Mottled Pale M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory.Mass, 16-20 mm, Firm/ Oval M-Leukemia, mononuclear, Contributory.Bronchial (TBLN) . Enlarged, 6-10 mm/ Pale Yellow Oval N-Leukemia, mononuclear, Incidental.Lungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round N-Leukemia, mononuclear - invasive involvement,Contributory.Discolored, Diffuse, +1/ Mottled Brown N-Leukemia, mononuclear - invasive involvement,Contributory.Animal: 6832E471 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 673 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 236.9Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Mottled, +1/ Focus Irregular Angiectasis, Moderate.Spleen . . . . . . Enlarged, 68-89 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, 0-2 mm, Red, +2/ Multifocus Round N-Leukemia, mononuclear - capillary involvement,Contributory.Animal: 6832E472 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 165.8Tissue Gross observations / Comments Correlated microscopic observationsKidneys . . . . . . Cyst, Left, 16-20 mm, Clear, Watery/ 1 Round Cyst, Moderate.Cyst, Right, 3-5 mm, Pale, +1/ Irregular, 1 Cyst, Moderate.Animal: 6832E473 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 657 Dosing phase Status: Found Dead Terminal body weight (g): 227.3Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Discolored, Dark Red, +4 Hemorrhage, Moderate.Lungs . . . . . . . Discolored, Diffuse, Mottled Red, +3 Congestion, Mild.Ovaries . . . . . . Discolored, Bilateral, Dark Red, +3 Hemorrhage, Mild.Cervix . . . . . . Thick, +3 Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:6Rat/F344/NAnimal: 6832E473 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 657 Dosing phase Status: Found Dead Terminal body weight (g): 227.3Tissue Gross observations / Comments Correlated microscopic observations(continued)Brain . . . . . . . Deformity, 6-10 mm, Soft, +2/ Depressed Compression, Moderate.Pituitary gland . . Mass, 6-10 mm, Dark Red, Soft, +2 B-Adenoma, pars distalis, Incidental.Bronchial (TBLN) . Discolored, Dark Red, +3 Hemorrhage, Mild.Animal: 6832E474 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 632 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 189.3Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Discolored, Left, 0-2 mm, Red, +1/ Focus Round Necrosis, Mild.Kidneys . . . . . . Discolored, Right, Patchy, Mottled, +1 Nephropathy, chronic, Minimal.Liver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory.Pituitary gland . . Enlarged, 3-5 mm, Dark Red, +2/ Oval B-Adenoma, pars distalis, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, Left Lobe, 0-2 mm, Red, +1/ Multifocus N-Leukemia, mononuclear - capillary involvement,Round Contributory.Animal: 6832E475 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 260.0Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Dark, +1/ Focus Irregular Hemorrhage, Minimal.Animal: 6832E476 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 723 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 259.5Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, All Lobes, Diffuse, Mottled Red, +2 N-Leukemia, mononuclear - capillary involvement,Contributory.Spleen . . . . . . Enlarged, 68-89 mm, +4 M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Friable, +2 M-Leukemia, mononuclear, Contributory.Eyes/optic nerve . Discolored, Right, Opaque, +2 Cataract, Present.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:7Rat/F344/NAnimal: 6832E477 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 588 Dosing phase Status: Found Dead Terminal body weight (g): 187.7Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Pale, Friable M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, Firm M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, All Lobes, Diffuse, Mottled, +3 N-Leukemia, mononuclear - capillary involvement,Contributory.Mesentery . . . . . Nodule, 3-5 mm, Dark Red, Rubbery/ Single Round Splenic tissue, "accessory", Present.Animal: 6832E478 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.4Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Left, Diffuse, Red, +1 No correlation entry madeAnimal: 6832E479 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 709 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 263.3Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Purple, +1/ Foci Round Angiectasis, Mild.Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Discolored, 0-2 mm, White, +1/ Foci Round Fibrosis, Minimal.Thyroid glands . . Cyst, Right, 3-5 mm, Yellow, +3/ Oval Hyperplasia, follicular cell, Mild.Animal: 6832E480 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 669 Dosing phase Status: Found Dead Terminal body weight (g): 225.3Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Pale, Friable, +3 Necrosis, Moderate.Lungs . . . . . . . Discolored, Left Lobe, Diffuse, Mottled Red, +2 N-Leukemia, mononuclear - capillary involvement,Incidental.Uterus . . . . . . Discolored, Bilateral, Diffuse, Dark, +3 Examined; no correlation foundAnimal: 6832E481 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 316 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 203.4Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Prolapse, Left, 6-10 mm, Dark Red, +4/ Round Intussusception, Present.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:8Rat/F344/NAnimal: 6832E482 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 647 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 250.2Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Nodule, 3-5 mm, Mottled/ Oval Cyst, Mild.Spleen . . . . . . Enlarged, 68-89 mm/ Diffuse M-Leukemia, mononuclear, Incidental.Thyroid glands . . Enlarged, Left, 6-10 mm, Dark/ Oval B-Adenoma, C-cell, Incidental.Lungs . . . . . . . Discolored, Diffuse, Mottled, +1 N-Leukemia, mononuclear - capillary involvement,Contributory.Animal: 6832E483 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 271.8Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark Red, Soft, +1/ Single Angiectasis, Mild.Spleen . . . . . . Small, 21-45 mm, +1 Examined; no correlation foundAnimal: 6832E484 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 659 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 212.8Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Mass, Left Lobe, 11-15 mm/ Round Hyperplasia, hepatocellular, regenerative, Moderate.Pituitary gland . . Discolored, Single, Dark/ Round, focus B-Adenoma, pars distalis, Incidental.Spleen . . . . . . Enlarged, 21-45 mm/ Diffuse M-Leukemia, mononuclear, Contributory.Animal: 6832E485 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 483 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 211.2Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Mottled, +1 M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, 0-2 mm, Mottled, +1/ Diffuse N-Leukemia, mononuclear - capillary involvement,Contributory.Bronchial (TBLN) . Enlarged, 6-10 mm N-Leukemia, mononuclear, Incidental.Uterus . . . . . . Enlarged, +2 B-Polyp, endometrial stromal, Incidental.Mesenteric LN . . . Discolored, Diffuse, Mottled, +3 N-Leukemia, mononuclear, Incidental.Enlarged, Multiple/ Oval N-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:9Rat/F344/NAnimal: 6832E487 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 589 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 226.0Tissue Gross observations / Comments Correlated microscopic observationsAdrenal glands . . Discolored, Left, 3-5 mm, Yellow B-Pheochromocytoma, benign, Incidental.Spleen . . . . . . Enlarged, 90-112 mm, Dark Red, +3/ Single M-Leukemia, mononuclear, Contributory.Mandibular LN . . . Enlarged, 6-10 mm, Pink/ Single Oval N-Leukemia, mononuclear, Incidental.Mediastinal LN . . Enlarged, 6-10 mm, Pale/ Multiple Oval N-Leukemia, mononuclear, Incidental.Mesenteric LN . . . Enlarged, 16-20 mm, Pale/ Multiple Oval N-Leukemia, mononuclear, Incidental.Animal: 6832E488 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 681 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 220.2Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 6-10 mm Compression, Marked.Pituitary gland . . Enlarged, 6-10 mm, Mottled Red, Firm, +3/ Diffuse Angiectasis, Moderate.IrregularAnimal: 6832E489 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.9Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Right, Diffuse, Red, +1 No correlation entry madePituitary gland . . Discolored, 0-2 mm, Dark, +2/ Single Round Tan Hemorrhage, Moderate.Uterus . . . . . . Nodule, Right, 3-5 mm, Firm/ Single Round Hyperplasia, cystic endometrial, Moderate.Cervix . . . . . . Enlarged, White, Firm, +2 Examined; no correlation foundAnimal: 6832E490 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 223.6Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 11-15 mm, Pale, +3/ Multiple Oval N-Leukemia, mononuclear, Incidental.Mediastinum . . . . Mass, 21-45 mm, Pale, +3/ Irregular N-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Nodule, All Lobes, 3-5 mm, Pale, Firm, +3/ Multiple N-Leukemia, mononuclear - invasive involvement,Round Contributory.Spleen . . . . . . Discolored, 6-10 mm, Pale, +1/ Focus Irregular Fibrosis, Moderate.Liver . . . . . . . Discolored, 3-5 mm, Pale, +3/ Mottled Foci Round M-Leukemia, mononuclear, Contributory.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:10Rat/F344/NAnimal: 6832E491 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 678 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 217.6Tissue Gross observations / Comments Correlated microscopic observationsMandibular LN . . . Enlarged, 16-20 mm, Dark, +3/ 2 Irregular N-Leukemia, mononuclear, Incidental.Mediastinal LN . . Enlarged, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental.Lymph node other . Enlarged, Submandibular, 11-15 mm, +3/ Quant 4 N-Leukemia, mononuclear, Incidental.Enlarged, Renal, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental.Enlarged, Cervical, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental.Lungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round Hemorrhage, Mild.Bone, vertebrae . . Mass, Thoracic, 11-15 mm, Pale, Firm/ Single Irregular N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 68-89 mm, +3 M-Leukemia, mononuclear, Contributory.Urinary bladder . . Discolored, 0-2 mm, Red/ Multifocal Round Hemorrhage, Mild.Pancreatic LN . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental.Mesenteric LN . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental.Liver . . . . . . . Discolored, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory.Iliac LN . . . . . Enlarged, 6-10 mm, +3 N-Leukemia, mononuclear, Incidental.Animal: 6832E492 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 512 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 186.5Tissue Gross observations / Comments Correlated microscopic observationsZymbal’s gland . . Mass, Right, 16-20 mm, Mottled, Firm/ Round M-Carcinoma, squamous cell, Incidental.Animal: 6832E493 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 230.8Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 68-89 mm, +4 M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Irregular M-Leukemia, mononuclear, Contributory.Pituitary gland . . Enlarged, 3-5 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental.Mediastinal LN . . Enlarged, 6-10 mm, +1/ Multiple, Irregular N-Leukemia, mononuclear, Incidental.Bronchial (TBLN) . Enlarged, 6-10 mm, +2/ Diffuse N-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:11Rat/F344/NAnimal: 6832E493 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 230.8Tissue Gross observations / Comments Correlated microscopic observations(continued)Mesenteric LN . . . Enlarged, 3-5 mm, Dark, +2/ Multiple, Irregular N-Leukemia, mononuclear, Incidental.Animal: 6832E494 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 637 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 276.5Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, Right cranial, 0-2 mm, Brown, +1/ Focus Hyperplasia, alveolar epithelial, focal, Mild.RoundClitoral gland . . Mass, Left, 21-45 mm, Firm, +4/ Diffuse Irregular M-Carcinoma, squamous cell, Contributory.Lymph node other . Enlarged, Renal, 3-5 mm, Dark, +1/ Diffuse Oval Hemorrhage, Minimal.Animal: 6832E495 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 301.6Tissue Gross observations / Comments Correlated microscopic observationsOvaries . . . . . . Cyst, Left, 6-10 mm, Yellow, Watery, +3/ Single Round Cyst, epithelial, Present.Uterus . . . . . . Cyst, Left, 3-5 mm, Clear, Watery, +2/ Single Round B-Polyp, endometrial stromal, Incidental.Left UpperAnimal: 6832E496 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 637 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 200.1Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, 3-5 mm, Red, +2/ Patchy Cyst, Mild.Cyst, 3-5 mm, Clear Cyst, Mild.Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Incidental.Bronchial (TBLN) . Enlarged, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental.Mandibular LN . . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental.Mediastinal LN . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental.Mesenteric LN . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental.Popliteal LN . . . Enlarged, 3-5 mm, +1 N-Leukemia, mononuclear, Incidental.Iliac LN . . . . . Enlarged, 11-15 mm, +3 N-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:12Rat/F344/NAnimal: 6832E496 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 637 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 200.1Tissue Gross observations / Comments Correlated microscopic observations(continued)Pancreatic LN . . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental.Lymph node other . Enlarged, Renal, 3-5 mm, +1 N-Leukemia, mononuclear, Incidental.Animal: 6832E497 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 269.1Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Mottled, Soft, +2/ Focus Hemorrhage, Moderate.Liver . . . . . . . Mass, Left Lobe, 11-15 mm, Mottled, +2/ Single B-Adenoma, hepatocellular, Incidental.Animal: 6832E499 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 562 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 248.6Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 68-89 mm, +3 M-Leukemia, mononuclear, Contributory.Mammary gland . . . Mass, Right, 46-67 mm, +4/ Mottled Dark Irregular M-Adenocarcinoma arising in fibroadenoma,Contributory.Animal: 6832E500 Sex: Female Group: 1 Dose level: 0 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 303.6Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Patchy, Dark, +2/ Irregular Examined; no correlation foundAnimal: 6834F551 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 280.6Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Pale, Friable, +2/ Irregular M-Leukemia, mononuclear, Incidental.Skin . . . . . . . Mass, Thoracic, 21-45 mm, Pale, Firm/ Rt Thoracic (Mammary gland) B-Fibroma, Incidental.Animal: 6834F552 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 574 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 229.7Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm, Dark Red, Firm, +3/ single M-Leukemia, mononuclear, Contributory.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:13Rat/F344/NAnimal: 6834F552 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 574 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 229.7Tissue Gross observations / Comments Correlated microscopic observations(continued)Adrenal glands . . Discolored, Bilateral, Diffuse, Dark Red, +4 Examined; no correlation foundUterus . . . . . . Discolored, Right, 6-10 mm, Black, Soft, +3/ focus B-Polyp, endometrial stromal, Incidental.Liver . . . . . . . Discolored, Diffuse, Pale, Oily, +4 M-Leukemia, mononuclear, Contributory.Animal: 6834F553 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 278.5Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2 M-Leukemia, mononuclear, Incidental.Animal: 6834F555 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 297.4Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Right, Diffuse, Opaque, +4/ Mottled Cataract, Present.Animal: 6834F556 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 672 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 225.7Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Pale M-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 21-45 mm/ Diffuse M-Leukemia, mononuclear, Incidental.Uterus . . . . . . Mass, Right, 21-45 mm, Dark Red/ Irregular B-Polyp, endometrial stromal, Contributory.Animal: 6834F557 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 264.6Tissue Gross observations / Comments Correlated microscopic observationsThyroid glands . . Nodule, Left, 0-2 mm, Firm B-Adenoma, C-cell, Incidental.Uterus . . . . . . Enlarged, Bilateral, +1 Dilatation, Mild.Animal: 6834F558 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.2Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Dark, +1/ Focus Irregular B-Adenoma, pars distalis, Incidental.Liver . . . . . . . Discolored, Diffuse, Mottled, +2 Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:14Rat/F344/NAnimal: 6834F559 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 245.3Tissue Gross observations / Comments Correlated microscopic observationsTail . . . . . . . Amputation, Tip, +2 No correlation entry madeAnimal: 6834F561 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.0Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Nodule, 3-5 mm, Soft B-Adenoma, pars distalis, Incidental.Uterus . . . . . . Mass, Right, 6-10 mm, Dark, Soft/ 2 Round B-Adenoma, endometrial, Incidental.Vagina . . . . . . Mass, 11-15 mm, Dark, Firm/ Diffuse M-Leiomoysarcoma, Incidental.Animal: 6834F562 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 488 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 238.4Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, All Lobes, Diffuse, Pale, +2 Examined; no correlation foundBronchial (TBLN) . Discolored, Diffuse, +4/ Dark Red Hemorrhage, Moderate.Uterus . . . . . . Enlarged, Right, Diffuse, Dark Red, +3 M-Leiomyosarcoma, Contributory.Discolored, Right, Diffuse, Dark Red, +3 M-Leiomyosarcoma, Contributory.Mass, Right, 46-67 mm, Mottled Red, +4/ single M-Leiomyosarcoma, Contributory.Ovaries . . . . . . Enlarged, Left, 6-10 mm, Red Examined; no correlation foundSalivary gland . . Discolored, Bilateral, Diffuse, Brown Examined; no correlation foundAnimal: 6834F563 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 288.7Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm/ Depressed Compression, Mild.Pituitary gland . . Cyst, 3-5 mm, Clear, Watery Cyst, Marked.Uterus . . . . . . Mass, Right, 6-10 mm, Dark, Firm/ Diffuse B-Polyp, endometrial stromal, Incidental.Mammary gland . . . Mass, Thoracic, 21-45 mm, Firm/ Right Thoracic B-Fibroadenoma, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:15Rat/F344/NAnimal: 6834F564 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 221.5Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 6-10 mm/ Depressed Compression, Mild.Discolored, 6-10 mm, Dark/ Patchy Irregular (Pituitary gland) M-Carcinoma, Incidental.Pituitary gland . . Mass, 6-10 mm, Dark, Firm/ Diffuse M-Carcinoma, Incidental.Animal: 6834F565 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 640 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 268.4Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 6-10 mm, +3 Compression, Moderate.Uterus . . . . . . Discolored, Right, 0-2 mm, Dark, Soft, +1/ Focus Oval B-Polyp, endometrial stromal, Incidental.Pituitary gland . . Mass, 6-10 mm, Mottled, Firm, +3/ Diffuse Oval B-Adenoma, pars distalis, Incidental.Mammary gland . . . Mass, Thoracic, 21-45 mm, +3 M-Adenocarcinoma, Incidental.Mass, Lumbar, 21-45 mm, +4 M-Adenocarcinoma, Incidental.Animal: 6834F566 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 508 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 226.8Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Mass, Left, 21-45 mm, Mottled Dark, Firm/ Irregular B-Polyp, endometrial stromal, Incidental.Lungs . . . . . . . Discolored, Diffuse, Pale White, +2 Examined; no correlation foundLiver . . . . . . . Hernia, Medial, 6-10 mm Hepatodiaphragmatic nodule, Present.Discolored, Diffuse, +2/ Pale tan Necrosis, Moderate.Animal: 6834F567 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 710 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 282.2Tissue Gross observations / Comments Correlated microscopic observationsMammary gland . . . Mass, Right, 46-67 mm, Mottled, Firm, +3/ Round B-Fibroadenoma, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:16Rat/F344/NAnimal: 6834F568 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 589 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 203.6Tissue Gross observations / Comments Correlated microscopic observationsMandibular LN . . . Enlarged, 6-10 mm/ Diffuse N-Leukemia, mononuclear, Incidental.Mediastinal LN . . Enlarged, 6-10 mm/ Diffuse N-Leukemia, mononuclear, Incidental.Lungs . . . . . . . Discolored, 0-2 mm, Red, +1/ Focus Round N-Leukemia, mononuclear - capillary involvement,Incidental.Bronchial (TBLN) . Enlarged, 3-5 mm/ Diffuse N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, +3 M-Leukemia, mononuclear, Contributory.Mass, 21-45 mm, Mottled, Firm/ Diffuse Irregular M-Leukemia, mononuclear, Contributory.Mesenteric LN . . . Enlarged, 6-10 mm, +3 N-Leukemia, mononuclear, Incidental.Lymph node other . Enlarged, Submandibular, 6-10 mm N-Leukemia, mononuclear, Incidental.Enlarged, Renal, 11-15 mm N-Leukemia, mononuclear, Incidental.Ovaries . . . . . . Enlarged, Bilateral, 11-15 mm, +3 M-Leukemia, mononuclear, Contributory.Popliteal LN . . . Enlarged, 3-5 mm N-Leukemia, mononuclear, Incidental.Iliac LN . . . . . Enlarged, 6-10 mm N-Leukemia, mononuclear, Incidental.Animal: 6834F569 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 312.4Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm, +1/ Irregular Compression, Mild.Pituitary gland . . Mass, 6-10 mm, Dark, Firm, +2/ Diffuse Irregular B-Adenoma, pars distalis, Incidental.Mandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple Examined; no correlation foundCervix . . . . . . Enlarged, 6-10 mm, Firm, +2/ Diffuse Irregular Examined; no correlation foundAnimal: 6834F570 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 268.6Tissue Gross observations / Comments Correlated microscopic observationsThyroid glands . . Enlarged, Left, 3-5 mm, +2 B-Adenoma, C-cell, Incidental.Cervix . . . . . . Enlarged, 11-15 mm, +3 M-Leiomyosarcoma, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:17Rat/F344/NAnimal: 6834F571 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 723 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 211.9Tissue Gross observations / Comments Correlated microscopic observationsMammary gland . . . Mass, Right, 11-15 mm, Pale, +2/ Rt Abd Single Oval B-Fibroma, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Pale, +3 M-Leukemia, mononuclear, Contributory.Animal: 6834F572 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 688 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 256.4Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Right, Diffuse, Cloudy, +3 Atrophy, Marked.Cataract, Present.Mediastinal LN . . Enlarged, 6-10 mm, +3 N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 68-89 mm, +3 M-Leukemia, mononuclear, Contributory.Discolored, 16-20 mm, Mottled/ Patchy Irregular Necrosis, Marked.Pancreatic LN . . . Enlarged, 6-10 mm, +2 N-Leukemia, mononuclear, Incidental.Animal: 6834F573 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Dark/ Single Oval B-Adenoma, pars distalis, Incidental.Uterus . . . . . . Mass, Left, 6-10 mm, Firm/ Single Oval B-Polyp, endometrial stromal, Incidental.Animal: 6834F574 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.2Tissue Gross observations / Comments Correlated microscopic observationsCervix . . . . . . Enlarged, 6-10 mm, +2 Examined; no correlation foundAnimal: 6834F575 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 309.2Tissue Gross observations / Comments Correlated microscopic observationsCervix . . . . . . Enlarged, 6-10 mm, +2 Examined; no correlation foundSpleen . . . . . . Small, 21-45 mm, Mottled Red, +2 Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:18Rat/F344/NAnimal: 6834F575 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 309.2Tissue Gross observations / Comments Correlated microscopic observations(continued)Liver . . . . . . . Hernia, Median Lobe, 3-5 mm, +1 Hepatodiaphragmatic nodule, Present.Animal: 6834F576 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 685 Dosing phase Status: Found Dead Terminal body weight (g): 212.6Tissue Gross observations / Comments Correlated microscopic observationsSkin . . . . . . . Mass, 6-10 mm, Hard, +1/ Right Side Irregular Cyst, epithelial inclusion, Present.Lungs . . . . . . . Discolored, 3-5 mm, Dark Red, +2/ Multifocus Round Hemorrhage, Mild.Spleen . . . . . . Discolored, 11-15 mm, Yellow, +1/ Irregular Mottled M-Leukemia, mononuclear, Contributory.yellowEnlarged, 46-67 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Mass, Right, 16-20 mm, Mottled Red, Firm, +3/ M-Adenocarcinoma, endometrial, Contributory.IrregularCervix . . . . . . Enlarged, Diffuse, +2 N-Adenocarcinoma, endometrial, Incidental.Liver . . . . . . . Thick, Diffuse, Mottled, +2 M-Leukemia, mononuclear, Contributory.Adrenal glands . . Enlarged, Left, 6-10 mm, Mottled, +2/ Diffuse B-Pheochromocytoma, benign, Incidental.Brain . . . . . . . Deformity, 6-10 mm, +2 Compression, Moderate.Pituitary gland . . Mass, 6-10 mm, +2/ Diffuse B-Adenoma, pars distalis, Incidental.Animal: 6834F577 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 708 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 248.1Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Hernia, Median Lobe, 3-5 mm, Mottled, +3/ Irregular Hepatodiaphragmatic nodule, Present.Pituitary gland . . Enlarged, Diffuse, Mottled, +2 B-Adenoma, pars distalis, Incidental.M-Leukemia, mononuclear, Incidental.Spleen . . . . . . Nodule, 3-5 mm, Mottled, +2/ Confluent M-Leukemia, mononuclear, Contributory.Mediastinal LN . . Enlarged, Multiple, +2/ 2-4 Irregular N-Leukemia, mononuclear, Incidental.Pancreatic LN . . . Enlarged, 6-10 mm, +3/ Multiple Irregular No correlation entry madeIliac LN . . . . . Enlarged, Left, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:19Rat/F344/NAnimal: 6834F578 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 664 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 218.3Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Hernia, Median Lobe, Firm Hepatodiaphragmatic nodule, Present.Animal: 6834F579 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 299.6Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm/ Depressed Compression, Minimal.Liver . . . . . . . Discolored, Diffuse, Mottled, Friable M-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Incidental.Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Patchy Irregular B-Adenoma, pars distalis, Incidental.Animal: 6834F580 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 296.3Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark/ 1 Focus Round B-Adenoma, pars distalis, Incidental.Animal: 6834F581 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 729 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 207.5Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Brown, +4/ Red M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Animal: 6834F582 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 636 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 248.6Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Round Examined; no correlation foundUterus . . . . . . Mass, Right, 46-67 mm, Mottled, Firm, +4/ Diffuse B-Polyp, endometrial stromal, Contributory.IrregularAnimal: 6834F584 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 6-10 mm, +4/ Round Compression, Moderate.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:20Rat/F344/NAnimal: 6834F584 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5Tissue Gross observations / Comments Correlated microscopic observations(continued)Brain . . . . . . . Discolored, Patchy, Dark Red, +2/ Irregular Hemorrhage, Mild.Liver . . . . . . . Mass, 6-10 mm, Pale, Firm, +4/ Multiple Irregular Hyperplasia, hepatocellular, regenerative, Mild.Thick, Red, +4 M-Leukemia, mononuclear, Incidental.Pituitary gland . . Mass, 6-10 mm, Purple, +4/ Round B-Adenoma, pars distalis, Incidental.Animal: 6834F585 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 234.6Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Left, Diffuse, Opaque, +2 Cataract, Present.Pituitary gland . . Discolored, 3-5 mm, +1/ Multifocus Irregular Hyperplasia, focal, Moderate.Animal: 6834F586 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 286.9Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, Diffuse, Mottled Red, +2 Examined; no correlation foundAnimal: 6834F589 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 267.9Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, 0-2 mm, White, +2/ Single Focus Necrosis, Mild.Discolored, Diffuse, Pale, Friable, +3 M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, Dark Red, +2 M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Enlarged, Left, 3-5 mm, Purple, +4/ Oval B-Polyp, endometrial stromal, Incidental.Animal: 6834F590 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 350 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 234.0Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Prolapse, Red, +3 Intussusception, Present.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:21Rat/F344/NAnimal: 6834F591 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.1Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled Red, +1/ Irregular M-Leukemia, mononuclear, Incidental.Animal: 6834F592 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 274.7Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Nodule, Left Lobe, 3-5 mm, Pale, Firm/ Single Round Fibrosis, focal, Mild.Hyperplasia, alveolar epithelial, focal, Mild.Animal: 6834F593 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 725 Dosing phase Status: Found Dead Terminal body weight (g): 257.4Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Enlarged, 6-10 mm, Purple, Soft, +4/ Round B-Adenoma, pars distalis, Incidental.Brain . . . . . . . Deformity, 6-10 mm, Pale, Soft, +4 Compression, Mild.Animal: 6834F594 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 589 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 299.0Tissue Gross observations / Comments Correlated microscopic observationsClitoral gland . . Mass, 46-67 mm, Soft/ Irregular (Mammary gland) B-Fibroadenoma, Contributory.Uterus . . . . . . Nodule, Right, 3-5 mm, Dark, Firm/ Round B-Polyp, endometrial stromal, Incidental.Pituitary gland . . Nodule, 0-2 mm, Dark/ Focus Round B-Adenoma, pars distalis, Incidental.Animal: 6834F595 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 488 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 214.2Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Dilatation, Right, 16-20 mm, Red B-Polyp, endometrial stromal, Incidental.Cervix . . . . . . Thick, 11-15 mm, Pale Examined; no correlation foundAnimal: 6834F596 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 262.2Tissue Gross observations / Comments Correlated microscopic observationsMandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple Irregular N-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:22Rat/F344/NAnimal: 6834F596 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 262.2Tissue Gross observations / Comments Correlated microscopic observations(continued)Ovaries . . . . . . Mass, Right, 6-10 mm, Mottled, Firm, +2/ Diffuse Necrosis, mesenteric fat, Mild.IrregularPituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Angiectasis, Moderate.Liver . . . . . . . Hernia, Median Lobe, 6-10 mm, Firm, +2/ Irregular Hepatodiaphragmatic nodule, Present.Animal: 6834F599 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 561 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 200.0Tissue Gross observations / Comments Correlated microscopic observationsAdrenal glands . . Discolored, Diffuse, Dark Red, +4 M-Leukemia, mononuclear, Incidental.Kidneys . . . . . . Discolored, Diffuse, Black, +4 Pigment accumulation, tubular epithelium, Moderate.Liver . . . . . . . Discolored, All Lobes, Diffuse, Pale, +2 M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, Firm, +3 M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, All Lobes, Diffuse, +2/ Pale Yellow N-Leukemia, mononuclear - capillary involvement,Contributory.Animal: 6834F600 Sex: Female Group: 2 Dose level: 2 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 280.6Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Red, +1/ Irregular B-Adenoma, pars distalis, Incidental.Animal: 6836G651 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 262.8Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Mass, Right, 16-20 mm, Soft/ Single Oval B-Polyp, endometrial stromal, Incidental.Animal: 6836G652 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 277.7Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark Red, Soft/ Single Round Cyst, Moderate.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:23Rat/F344/NAnimal: 6836G653 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 489 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 207.9Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark Red/ Focus Cyst, Mild.Thyroid glands . . Mass, Right, 11-15 mm, Mottled, Firm/ Oval M-Carcinoma, follicular cell, Contributory.Esophagus . . . . . Discolored, 6-10 mm, Dark Red/ Oval Examined; no correlation foundLiver . . . . . . . Nodule, Median Lobe, 3-5 mm, Pale/ Single Round Examined; no correlation foundLymph node other . Enlarged, Cervical, 3-5 mm, Dark Red, Firm Examined; no correlation foundAnimal: 6836G654 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 238.3Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Right, Diffuse, Red, +1 No correlation entry madeBrain . . . . . . . Deformity, 6-10 mm/ Single Depression Compression, Marked.Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental.Animal: 6836G655 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 259.9Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Left, Diffuse, Red, +1 No correlation entry madeBrain . . . . . . . Deformity, 3-5 mm/ Single Depressed Compression, Mild.Liver . . . . . . . Discolored, Diffuse, Mottled Red, Friable, +2/ M-Leukemia, mononuclear, Incidental.IrregularPituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Round B-Adenoma, pars distalis, Incidental.Animal: 6836G657 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 263.5Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark/ Focus Round B-Adenoma, pars distalis, Incidental.Ovaries . . . . . . Discolored, Left, 0-2 mm, Dark/ Patchy Irregular Cyst, rete ovarii, Mild.Cervix . . . . . . Enlarged, +1 Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:24Rat/F344/NAnimal: 6836G659 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 730 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 232.0Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Pale M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 90-112 mm, +4 M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Nodule, Bilateral, 3-5 mm, Dark, Firm, +1/ 2 Oval Angiectasis, Mild.Animal: 6836G660 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 295.8Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 3-5 mm, Pale/ Diffuse Round Infiltration, histiocytic.Lungs . . . . . . . Discolored, Patchy, Dark, +2/ Irregular N-Sarcoma, histiocytic, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, +1 N-Sarcoma, histiocytic, Incidental.Discolored, 3-5 mm, Pale/ Focus Round N-Sarcoma, histiocytic, Incidental.Uterus . . . . . . Discolored, Left, 6-10 mm, Dark/ Patchy B-Polyp, endometrial stromal, Incidental.Liver . . . . . . . Discolored, Diffuse, Mottled, +4 M-Sarcoma. histiocytic, Incidental.Nodule, 3-5 mm, Pale, Firm/ Multiple Irregular M-Sarcoma. histiocytic, Incidental.Kidneys . . . . . . Discolored, Left, 0-2 mm, Pale/ 2-foci Round Nephropathy, chronic, Moderate.N-Sarcoma, histiocytic, Incidental.Animal: 6836G661 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.0Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Mass, Right, 21-45 mm, Red, Soft, +4/ Single Oval B-Polyp, endometrial stromal, Incidental.Ovaries . . . . . . Cyst, Left, 6-10 mm, Yellow, Watery, +4/ Single Round Cyst, follicular, Present.Animal: 6836G663 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 258.5Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, Patchy, Black, +1/ Irregular B-Adenoma, pars distalis, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:25Rat/F344/NAnimal: 6836G664 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 562 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Round Cyst, Mild.Animal: 6836G665 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 511 Dosing phase Status: Found Dead Terminal body weight (g): 191.0Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, All Lobes, Diffuse, Dark Red, +4 Congestion, Mild.Uterus . . . . . . Discolored, Right Horn, Diffuse, Black, +4/ Left Horn B-Polyp, endometrial stromal, Incidental.Brain . . . . . . . Deformity, 6-10 mm/ Depressed Compression, Moderate.Pituitary gland . . Mass, 6-10 mm, Dark Red, Soft/ Round B-Adenoma, pars distalis, Incidental.Ovaries . . . . . . Discolored, Diffuse, Red, +3 Congestion, Mild.Animal: 6836G666 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 226.0Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Small, Left, Diffuse, +1/ Irregular Examined; no correlation foundBrain . . . . . . . Deformity, 6-10 mm, +2/ Irregular Compression, Moderate.Pituitary gland . . Mass, 6-10 mm, Dark, Firm, +2/ Diffuse Irregular B-Adenoma, pars distalis, Incidental.Mandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple Irregular Examined; no correlation foundUterus . . . . . . Mass, Right, 11-15 mm, Firm, +2/ Irregular B-Polyp, endometrial stromal, Incidental.Skin . . . . . . . Crust, Irregular, Dark Red, Hard, +1/ Left eye Fibrosis, Moderate.Animal: 6836G667 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 271.4Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, Diffuse, Mottled Red, +2 Examined; no correlation foundUterus . . . . . . Mass, Left, 6-10 mm, Pale, Firm B-Polyp, endometrial stromal, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:26Rat/F344/NAnimal: 6836G668 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 212.8Tissue Gross observations / Comments Correlated microscopic observationsCervix . . . . . . Enlarged, 6-10 mm, +2/ Diffuse Examined; no correlation foundAdrenal glands . . Enlarged, Right, 6-10 mm, +1/ Diffuse B-Pheochromocytoma, benign, Incidental.Animal: 6836G669 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.3Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Discolored, Right, 11-15 mm, Mottled, +2/ Focus B-Polyp, endometrial stromal, Incidental.IrregularThick, Right, Mottled, Soft, +3/ Lower B-Polyp, endometrial stromal, Incidental.Clitoral gland . . Mass, Left, 11-15 mm, Mottled, Firm, +3/ Single Round B-Adenoma, Incidental.Pituitary gland . . Enlarged, 3-5 mm, Purple, Soft, +3/ Round B-Adenoma, pars distalis, Incidental.Brain . . . . . . . Deformity, 3-5 mm, +3/ Round Compression, Mild.Animal: 6836G670 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 267.4Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Mass, Left, 11-15 mm, Soft/ Single Oval Hyperplasia, cystic endometrial, Moderate.Animal: 6836G671 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 548 Dosing phase Status: Found Dead Terminal body weight (g): 240.6Tissue Gross observations / Comments Correlated microscopic observationsDuodenum . . . . . Discolored, Diffuse, Dark Red, +3 Examined; no correlation foundIleum . . . . . . . Discolored, Diffuse, Dark Red, +3 Examined; no correlation foundJejunum . . . . . . Discolored, Diffuse, Dark Red, +3 Examined; no correlation foundUterus . . . . . . Mass, 21-45 mm, Red, Soft, +4/ Single Irregular M-Leiomyosarcoma, Contributory.Animal: 6836G672 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 283.2Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Purple, +3/ Foci Oval B-Adenoma, pars distalis, Incidental.Mandibular LN . . . Enlarged, 11-15 mm, White, Firm, +3/ Single Oval (Mammary gland) B-Fibroadenoma, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:27Rat/F344/NAnimal: 6836G672 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 283.2Tissue Gross observations / Comments Correlated microscopic observations(continued)Mammary gland . . . Mass, Right, 21-45 mm, Mottled, Firm, +3/ Single Oval B-Fibroadenoma, Incidental.Upper RightAnimal: 6836G673 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.1Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, 0-2 mm, Red/ Multifocal Round Examined; no correlation foundUterus . . . . . . Enlarged, Bilateral, +1 Dilatation, Minimal.Cervix . . . . . . Enlarged, Firm, +1 Examined; no correlation foundAnimal: 6836G674 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 287.6Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Cyst, Left, 6-10 mm, Opaque, Watery/ Single Oval Hyperplasia, cystic endometrial, Moderate.Animal: 6836G675 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 257.6Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Purple, +2/ Single Irregular Cyst, Moderate.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Incidental.Ovaries . . . . . . Cyst, Right, 6-10 mm, Yellow, Watery, +2/ Single Round Cyst, bursa, Present.Animal: 6836G676 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 654 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 232.8Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, All Lobes, Diffuse, Mottled, +1 N-Leukemia, mononuclear - capillary involvement,Contributory.Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +2 M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Enlarged, Bilateral, 11-15 mm, Pale, +3/ Oval B-Polyp, endometrial stromal, Incidental.Pituitary gland . . Discolored, 11-15 mm, Purple, +1/ Foci Irregular Angiectasis, Moderate.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:28Rat/F344/NAnimal: 6836G677 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 268.4Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, Diffuse, Mottled Red, +2 Examined; no correlation foundAnimal: 6836G678 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 696 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 235.4Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Enlarged, 3-5 mm, Purple, Firm, +2/ Round B-Adenoma, pars distalis, Incidental.Clitoral gland . . Mass, 11-15 mm, Purple, Firm, +3/ Single Irregular N-Adenocarcinoma, Incidental.Animal: 6836G679 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 654 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 217.4Tissue Gross observations / Comments Correlated microscopic observationsMammary gland . . . Discolored, Diffuse, Brown, +2 Examined; no correlation foundPituitary gland . . Mass, 6-10 mm, Firm B-Adenoma, pars distalis, Incidental.Brain . . . . . . . Deformity, 6-10 mm Compression, Moderate.Animal: 6836G680 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 645 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 213.1Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 68-89 mm/ Diffuse M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.Lymph node other . Enlarged, Renal, 6-10 mm, Firm/ Oval Bilateral N-Leukemia, mononuclear, Incidental.Pituitary gland . . Discolored, 0-2 mm, Dark/ 1 Focus Round Cyst, Mild.Animal: 6836G681 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 272.3Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark, +1/ Focus Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:29Rat/F344/NAnimal: 6836G682 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 647 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.1Tissue Gross observations / Comments Correlated microscopic observationsMandibular LN . . . Enlarged, 6-10 mm, Pale, +3/ Oval Multiple N-Leukemia, mononuclear, Incidental.Mediastinal LN . . Enlarged, 6-10 mm, Pale, +4/ Multiple Oval N-Leukemia, mononuclear, Incidental.Bronchial (TBLN) . Enlarged, 6-10 mm, Pale, +4/ Oval N-Leukemia, mononuclear, Incidental.Lungs . . . . . . . Discolored, All Lobes, Round, Brown, +4/ Foci N-Leukemia, mononuclear - invasive involvement,Contributory.Lymph node other . Enlarged, Axillary, 11-15 mm, Pale, +3/ Oval N-Leukemia, mononuclear, Incidental.Enlarged, Renal, 6-10 mm, Pale, +3/ Multiple N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory.Thick, Mottled, +3 M-Leukemia, mononuclear, Contributory.Mesenteric LN . . . Enlarged, 6-10 mm, Pale, +4/ Multiple N-Leukemia, mononuclear, Incidental.Pancreatic LN . . . Enlarged, 6-10 mm, Pale, +3/ Multiple N-Leukemia, mononuclear, Incidental.Iliac LN . . . . . Enlarged, Left, 6-10 mm, +2/ Single N-Leukemia, mononuclear, Incidental.Discolored, Left, Black, +3 Examined; no correlation foundAnimal: 6836G683 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 702 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 240.7Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Dilatation, Right, 6-10 mm, Mottled, +2/ Lower Right Dilatation, Mild.B-Polyp, endometrial stromal, Incidental.Mass, Right, 46-67 mm, Purple, +4/ Upper Right Oval B-Polyp, endometrial stromal, Incidental.Harderian gland . . Discolored, Right, Diffuse, Mottled, +3 Pigment, Mild.Pituitary gland . . Discolored, 0-2 mm, Purple, +1/ Single Round Angiectasis, Mild.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:30Rat/F344/NAnimal: 6836G684 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 287.6Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Red, +2/ Focus Round Hyperplasia, focal, Mild.Tiss.not specifi . Mass, Neck, 6-10 mm, Mottled, Firm, +1/ Oval (Mammary gland) B-Fibroadenoma, Incidental.SubcutaneousAnimal: 6836G685 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 540 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 186.6Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Pale M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, Black, +4/ Focus Angiectasis, Moderate.Spleen . . . . . . Enlarged, 46-67 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory.Animal: 6836G686 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 231.0Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm, +3/ Diffuse M-Leukemia, mononuclear, Incidental.Thyroid glands . . Enlarged, Right, 6-10 mm, Dark, Firm, +2/ Diffuse B-Adenoma, C-cell, Incidental.IrregularLungs . . . . . . . Nodule, Right caudal, 0-2 mm, Clear, Firm, +2/ Round N-Leukemia, mononuclear - invasive involvement,Incidental.Bronchial (TBLN) . Enlarged, 6-10 mm, +3/ Diffuse Irregular Inflammation, mixed, Minimal.Animal: 6836G687 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 680 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.0Tissue Gross observations / Comments Correlated microscopic observationsMammary gland . . . Mass, Left, 21-45 mm, Dark, Firm/ Irregular M-Adenocarcinoma, Incidental.Spleen . . . . . . Enlarged, 46-67 mm/ Diffuse M-Leukemia, mononuclear, Contributory.Clitoral gland . . Mass, Left, 21-45 mm, Mottled, Firm/ Diffuse Irregular N-Adenocarcinoma, Incidental.Liver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory.Brain . . . . . . . Deformity, 6-10 mm Compression, Moderate.Pituitary gland . . Mass, 6-10 mm, Dark, Firm/ Diffuse Irregular B-Adenoma, pars distalis, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:31Rat/F344/NAnimal: 6836G688 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 666 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 246.4Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 6-10 mm, +1 B-Thymoma, Incidental.Spleen . . . . . . Enlarged, 68-89 mm, +2 M-Leukemia, mononuclear, Contributory.Pancreatic LN . . . Enlarged, 3-5 mm, +1 N-Leukemia, mononuclear, Incidental.Iliac LN . . . . . Enlarged, 6-10 mm, +1 N-Leukemia, mononuclear, Incidental.Bone, other . . . . Deformity, Rt Fore Paw, +3 Fracture, Present.Animal: 6836G689 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 241.1Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Right, Diffuse, Red, +1 Examined; no correlation foundPituitary gland . . Discolored, Surface, 3-5 mm, Black/ Single Round Cyst, Moderate.Tail . . . . . . . Crust, Surface, Diffuse, Brown, Hard, +4/ Irregular Hyperplasia/hyperkeratosis, Moderate.Brown/TanAnimal: 6836G690 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 236.8Tissue Gross observations / Comments Correlated microscopic observationsUterus . . . . . . Mass, Right, 6-10 mm, Mottled, Firm, +2/ Single Hyperplasia, cystic endometrial, Mild.Animal: 6836G692 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 244.1Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm/ Single Depressed Compression, Mild.Pituitary gland . . Enlarged, 3-5 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental.Lungs . . . . . . . Nodule, Left Lobe, 3-5 mm, Tan, Firm/ Single Round Examined; no correlation foundAnimal: 6836G693 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 658 Dosing phase Status: Found Dead Terminal body weight (g): 260.8Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, Diffuse, Mottled Red, +4 Examined; no correlation foundAdrenal glands . . Mass, Right, 21-45 mm, Mottled, Firm, +4/ Irregular B-Pheochromocytoma, benign, Contributory.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:32Rat/F344/NAnimal: 6836G693 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 658 Dosing phase Status: Found Dead Terminal body weight (g): 260.8Tissue Gross observations / Comments Correlated microscopic observations(continued)Cavities . . . . . Fluid, Abdominal, Dark Red, Gelatinous, +3 No correlation entry madeAnimal: 6836G694 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 255.8Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 0-2 mm, Dark, +1/ Single Round B-Adenoma, pars distalis, Incidental.Thyroid glands . . Enlarged, Left, 3-5 mm, +2/ Single Round B-Adenoma, C-cell, Incidental.Animal: 6836G695 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 661 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 204.4Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Enlarged, 6-10 mm, Purple, +3/ Irregular B-Adenoma, pars distalis, Incidental.Brain . . . . . . . Deformity, 6-10 mm, +3/ Irregular Compression, Marked.Discolored, 3-5 mm, Purple, +2/ Foci Round (Pituitary gland) B-Adenoma, pars intermedia,Contributory.Animal: 6836G697 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 252.0Tissue Gross observations / Comments Correlated microscopic observationsMammary gland . . . Mass, Thoracic, 11-15 mm, Firm/ Rt Thoracic B-Fibroma, Incidental.Animal: 6836G698 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 625 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 226.0Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 3-5 mm, Pale, +3/ Multiple, oval N-Leukemia, mononuclear, Incidental.Bronchial (TBLN) . Enlarged, 6-10 mm, Pale, +3/ Single, oval N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Animal: 6836G699 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 114 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 153.9Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Left, White, +4 Cataract, Present.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:33Rat/F344/NAnimal: 6836G699 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 114 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 153.9Tissue Gross observations / Comments Correlated microscopic observations(continued)Tiss.not specifi . Malocclusion, Teeth, +3 No correlation entry madeAnimal: 6836G700 Sex: Female Group: 3 Dose level: 10 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 209.6Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Small, 21-45 mm, +2 Examined; no correlation foundUterus . . . . . . Mass, Bilateral, 16-20 mm, Mottled, Firm, +3/ Mult B-Polyp, endometrial stromal, Incidental.OvalAnimal: 6838H751 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 659 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 197.9Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Mass, 21-45 mm, Mottled, +4/ Multiple Round M-Sarcoma. histiocytic, Contributory.Spleen . . . . . . Enlarged, 21-45 mm, +2 Examined; no correlation foundLungs . . . . . . . Discolored, Patchy, Dark, +3 N-Sarcoma, histiocytic, Contributory.Animal: 6838H752 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 687 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 216.2Tissue Gross observations / Comments Correlated microscopic observationsMandibular LN . . . Enlarged, 6-10 mm, Firm, +2/ Multiple Irregular N-Leukemia, mononuclear, Incidental.Mediastinal LN . . Enlarged, 6-10 mm, Firm, +2/ Multiple Irregular N-Leukemia, mononuclear, Incidental.Bronchial (TBLN) . Enlarged, 3-5 mm, +2/ Diffuse Irregular N-Leukemia, mononuclear, Incidental.Lymph node other . Enlarged, Submandibular, 16-20 mm, Dark Red, Firm, +3/ N-Leukemia, mononuclear, Incidental.Multiple Irregular BilateralEnlarged, Renal, 6-10 mm, Firm, +2/ Multiple Bilateral N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 68-89 mm, +3/ Diffuse M-Leukemia, mononuclear, Contributory.Ovaries . . . . . . Enlarged, Bilateral, Diffuse, +1 M-Leukemia, mononuclear, Incidental.Uterus . . . . . . Mass, Right, 16-20 mm, Dark, Soft, +2/ Irregular Dilatation, Marked.Mesenteric LN . . . Enlarged, 21-45 mm, Firm, +2/ Irregular N-Leukemia, mononuclear, Incidental.Pancreatic LN . . . Enlarged, 16-20 mm, Firm, +2 N-Leukemia, mononuclear, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:34Rat/F344/NAnimal: 6838H753 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 715 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 188.8Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 6-10 mm, +1/ Diffuse Irregular M-Carcinoma, metastatic, Incidental.Thyroid glands . . Enlarged, Bilateral, 3-5 mm, +2/ Multiple Examined; no correlation foundLungs . . . . . . . Nodule, 3-5 mm, Pale, Firm, +3/ Multiple Irregular N-Carcinoma, metastatic, Contributory.Mass, Right middle, 3-5 mm, Pale, Firm, +3/ Irregular N-Carcinoma, metastatic, Contributory.Discolored, Diffuse, Mottled, +4 N-Carcinoma, metastatic, Contributory.Stomach . . . . . . Mass, 16-20 mm, Pale, Firm/ Irregular M-Carcinoma, metastatic, Incidental.Uterus . . . . . . Mass, Bilateral, 21-45 mm, Pale, Firm M-Adenocarcinoma, endometrial, Contributory.Dilatation, Bilateral, Irregular, Dark, Soft, +4 Dilatation, Marked.Animal: 6838H754 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 267.9Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm/ Depressed Compression, Mild.Pituitary gland . . Mass, 3-5 mm, Dark, Soft/ Single B-Adenoma, pars distalis, Incidental.Animal: 6838H755 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 229.6Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Left, Patchy, Red, +1 Examined; no correlation foundKidneys . . . . . . Cyst, Left, 11-15 mm, Opaque, Watery/ Single Oval Cyst, Moderate.Animal: 6838H756 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 250.7Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Hernia, Median Lobe, 11-15 mm/ Irregular Hepatodiaphragmatic nodule, Present.Lungs . . . . . . . Discolored, 0-2 mm, Pale, Soft/ Multifocal Round Examined; no correlation foundMammary gland . . . Mass, Right, 21-45 mm, Firm/ Right Abdominal B-Fibroadenoma, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:35Rat/F344/NAnimal: 6838H757 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 701 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 183.6Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Cavities . . . . . Fluid, Abdominal, 2.1-5.0 ml, Red, +2 No correlation entry madeKidneys . . . . . . Cyst, Right, +3 Cyst, Moderate.Uterus . . . . . . Focus, Right, 0-2 mm, Purple, +1/ round B-Polyp, endometrial stromal, Incidental.Pituitary gland . . Focus, 0-2 mm, Purple, +1/ round Hemorrhage, Minimal.Animal: 6838H758 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 247.8Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Left Lobe, 0-2 mm, Pale/ Focus Round Examined; no correlation foundAnimal: 6838H759 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 230.5Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Cyst, 0-2 mm, Grey, Watery, +2/ Single Oval Cyst, Mild.Tail . . . . . . . Crust, 6-10 mm, Brown, Hard, +4/ Multiple Irregular Hyperplasia/hyperkeratosis, Marked.Ovaries . . . . . . Cyst, Left, 6-10 mm, Yellow, Watery, +3/ Single Round Cyst, bursa, Present.Animal: 6838H761 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 244.4Tissue Gross observations / Comments Correlated microscopic observationsMandibular LN . . . Enlarged, 3-5 mm, +1/ Multiple N-Leukemia, mononuclear, Incidental.Mammary gland . . . Mass, Left, 11-15 mm, Firm, +2 B-Fibroadenoma, Incidental.Spleen . . . . . . Enlarged, 21-45 mm, +2/ Diffuse Irregular M-Leukemia, mononuclear, Incidental.Bone, rib . . . . . Mass, Left, 11-15 mm, Mottled, Firm, +3/ Irregular M-Osteosarcoma, Incidental.Animal: 6838H762 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 237.7Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 0-2 mm/ Single Depressed Compression, Mild.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:36Rat/F344/NAnimal: 6838H762 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 237.7Tissue Gross observations / Comments Correlated microscopic observations(continued)Eyes/optic nerve . Crust, Left, Diffuse, Red, +1 No correlation entry madeLiver . . . . . . . Discolored, Diffuse, Mottled, Friable, +2/ Irregular Examined; no correlation foundKidneys . . . . . . Cyst, Left, 6-10 mm, Opaque, Watery/ Single Oval Cyst, Mild.Pituitary gland . . Enlarged, 3-5 mm, Dark, Soft/ Single Round Angiectasis, Marked.Animal: 6838H763 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 490 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 229.8Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Pale, +3 Necrosis, Moderate.Uterus . . . . . . Enlarged, Left, 46-67 mm, Soft/ Dark Red/Black B-Polyp, endometrial stromal, Contributory.IrregularAnimal: 6838H764 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 526 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 186.0Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory.Animal: 6838H766 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 478 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 198.3Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 68-89 mm M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, Multiple, Mottled Red, +2 Hemorrhage, Mild.Animal: 6838H767 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 251.5Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Right, Diffuse, Opaque, +3 Atrophy, Marked.Spleen . . . . . . Enlarged, 46-67 mm, +2 M-Leukemia, mononuclear, Incidental.Uterus . . . . . . Mass, Right, Oval, Red, Firm, +2 B-Polyp, endometrial stromal, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:37Rat/F344/NAnimal: 6838H768 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.4Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Dark, +2/ Multifocus Irregular Angiectasis, Moderate.Liver . . . . . . . Thick, Left Lobe, Patchy, +2/ Irregular M-Leukemia, mononuclear, Incidental.Animal: 6838H769 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 232.5Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm/ Single Depressed Compression, Mild.Pituitary gland . . Enlarged, 3-5 mm, Dark/ Single Round B-Adenoma, pars distalis, Incidental.Uterus . . . . . . Intussusception, Right, Single Intussusception, Present.Cervix . . . . . . Mass, 11-15 mm, Dark, Firm/ Single Round B-Polyp, endometrial stromal, Incidental.Animal: 6838H770 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 661 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 198.8Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 6-10 mm, +2/ Oval N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 46-67 mm, +2/ Diffuse M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Mass, Bilateral, 3-5 mm, Pale, Firm/ 2 Round B-Polyp, endometrial stromal, Incidental.Discolored, Left, 6-10 mm, Dark, Soft, +3 B-Polyp, endometrial stromal, Incidental.Ovaries . . . . . . Small, Bilateral, +3 Examined; no correlation foundPituitary gland . . Discolored, 3-5 mm, Purple, +1/ Focus Irregular B-Adenoma, pars distalis, Incidental.Animal: 6838H771 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 217.7Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Hernia, Median Lobe, 6-10 mm, +2/ Multiple Irregular Hepatodiaphragmatic nodule, Present.Lungs . . . . . . . Discolored, Left Lobe, 3-5 mm, White, +1/ Focus Alveolar histiocytosis, Minimal.IrregularCervix . . . . . . Enlarged, 6-10 mm, +1/ Diffuse Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:38Rat/F344/NAnimal: 6838H772 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 729 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 185.1Tissue Gross observations / Comments Correlated microscopic observationsOvaries . . . . . . Small, Right, 0-2 mm, +2 Examined; no correlation foundUterus . . . . . . Mass, Right, 6-10 mm, Pale, Firm/ Single Irregular B-Polyp, endometrial stromal, Incidental.Spleen . . . . . . Discolored, Diffuse, Mottled Red, +2 Necrosis, Marked.M-Leukemia, mononuclear, Contributory.Ileum . . . . . . . Discolored, 3-5 mm, Red, Soft, +2/ Multifoci Oval N-Leukemia, mononuclear, Incidental.Liver . . . . . . . Discolored, Diffuse, Mottled Red, Friable, +2 M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, Left Lobe, 0-2 mm, Pale, Soft/ Single Hyperplasia, alveolar epithelial, focal, Mild.RoundAnimal: 6838H773 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.8Tissue Gross observations / Comments Correlated microscopic observationsMammary gland . . . Mass, Left Inguinal, 46-67 mm, Mottled, Firm, +3/ B-Fibroadenoma, Incidental.IrregularAnimal: 6838H774 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 489 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 190.1Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, 0-2 mm, Dark, Soft/ Multifoci Hemorrhage, Minimal.N-Leukemia, mononuclear - capillary involvement,Contributory.Animal: 6838H775 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 688 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 191.6Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm, +1/ Diffuse M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Discolored, Diffuse, Mottled, +1 M-Leukemia, mononuclear, Contributory.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:39Rat/F344/NAnimal: 6838H776 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 261.4Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Crust, Right, Diffuse, Red, +1 No correlation entry madeLungs . . . . . . . Discolored, All Lobes, 0-2 mm, Red, +1/ Diffuse Round Examined; no correlation foundThyroid glands . . Discolored, Left, 0-2 mm, Dark/ Round, 2 quantity Hyperplasia, C-cell, focal, Moderate.Animal: 6838H777 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 242.5Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Left, Diffuse, Opaque, +3 Cataract, Present.Animal: 6838H778 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 218.1Tissue Gross observations / Comments Correlated microscopic observationsMediastinal LN . . Enlarged, 3-5 mm, Brown, +3/ Single Oval N-Leukemia, mononuclear, Incidental.Spleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Discolored, 6-10 mm, Yellow, +2/ Focus Irregular Necrosis, Moderate.Animal: 6838H779 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.1Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Nodule, 0-2 mm, Soft B-Adenoma, pars distalis, Incidental.Animal: 6838H780 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 236.3Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm, Dark Red, +2 M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Mass, Right, 16-20 mm, Purple, Rubbery, +3/ Round B-Polyp, endometrial stromal, Incidental.Animal: 6838H782 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 735 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 240.3Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Small, Left, Diffuse, +2 No correlation entry madeMammary gland . . . Mass, Right, 21-45 mm, Mottled, Firm, +4/ Irregular B-Fibroadenoma, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:40Rat/F344/NAnimal: 6838H783 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 710 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 196.1Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, +2 Fatty Change, Mild.Brain . . . . . . . Deformity, 6-10 mm, +3/ Irregular Compression, Moderate.Pituitary gland . . Mass, 11-15 mm, Mottled Red, +3/ Round, Diffuse B-Adenoma, pars distalis, Incidental.Animal: 6838H785 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 476 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 230.0Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Diffuse, +3/ Pale Yellow Mineralization, corneal stromal, Mild.Liver . . . . . . . Enlarged, Diffuse, Soft, +1/ Mottled pale M-Leukemia, mononuclear, Contributory.Pancreas . . . . . Small, Diffuse, +3/ Pale Yellow Examined; no correlation foundSpleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, Diffuse, +2/ Dull Yellow N-Leukemia, mononuclear - capillary involvement,Contributory.Discolored, Left Lobe, 0-2 mm, Red/ Focus Round N-Leukemia, mononuclear - capillary involvement,Contributory.Animal: 6838H786 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 716 Dosing phase Status: Found Dead Terminal body weight (g): 240.4Tissue Gross observations / Comments Correlated microscopic observationsThyroid glands . . Enlarged, Bilateral, 3-5 mm, +1/ Diffuse Examined; no correlation foundLungs . . . . . . . Discolored, Diffuse, Mottled, +2 Examined; no correlation foundUterus . . . . . . Mass, Right, 68-89 mm, Dark Red, Firm, +4/ Diffuse Intussusception, Present.IrregularLiver . . . . . . . Hernia, Median Lobe, 6-10 mm, Mottled, Firm, +3/ Hepatodiaphragmatic nodule, Present.IrregularAdrenal glands . . Discolored, Left, Patchy, Dark, +1 Examined; no correlation foundEyes/optic nerve . Discolored, Bilateral, Diffuse, Pale, +2 Examined; no correlation foundLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:41Rat/F344/NAnimal: 6838H787 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 736 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 266.0Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 6-10 mm, +1 Compression, Mild.Liver . . . . . . . Discolored, Diffuse, Mottled Red, +3 M-Leukemia, mononuclear, Incidental.Kidneys . . . . . . Discolored, Bilateral, Diffuse, Mottled Brown, +2/ Nephropathy, chronic, Moderate.IrregularSpleen . . . . . . Enlarged, 46-67 mm, +1 M-Leukemia, mononuclear, Incidental.Pituitary gland . . Mass, 6-10 mm, Mottled, Soft B-Adenoma, pars distalis, Incidental.Animal: 6838H788 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 244.1Tissue Gross observations / Comments Correlated microscopic observationsPituitary gland . . Discolored, 3-5 mm, Dark Red, +2/ Irregular B-Adenoma, pars distalis, Incidental.Animal: 6838H790 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 238.2Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm, +3/ Round Compression, Moderate.Pituitary gland . . Enlarged, 3-5 mm, Purple, +3/ Round B-Adenoma, pars distalis, Incidental.Animal: 6838H791 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 265.6Tissue Gross observations / Comments Correlated microscopic observationsThyroid glands . . Enlarged, Left, 6-10 mm/ Single Oval B-Adenoma, C-cell, Incidental.Lungs . . . . . . . Discolored, All Lobes, 0-2 mm, Red/ Multifocal Round N-Leukemia, mononuclear - capillary involvement,Contributory.Spleen . . . . . . Enlarged, 68-89 mm M-Leukemia, mononuclear, Contributory.Uterus . . . . . . Mass, Right, 3-5 mm, Opaque, Firm/ Single Round B-Polyp, endometrial stromal, Incidental.Liver . . . . . . . Discolored, Diffuse, Mottled, Friable, +3/ Irregular M-Leukemia, mononuclear, Contributory.Pituitary gland . . Discolored, 0-2 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental.Lovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:42Rat/F344/NAnimal: 6838H792 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 730 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 199.7Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 68-89 mm, Dark Red, +3 M-Leukemia, mononuclear, Contributory.Mediastinal LN . . Discolored, Diffuse, Red, +3 Examined; no correlation foundAnimal: 6838H793 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 738 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 231.8Tissue Gross observations / Comments Correlated microscopic observationsSpleen . . . . . . Enlarged, 46-67 mm M-Leukemia, mononuclear, Contributory.Animal: 6838H795 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 716 Dosing phase Status: Found Dead Terminal body weight (g): 219.8Tissue Gross observations / Comments Correlated microscopic observationsLungs . . . . . . . Discolored, All Lobes, Diffuse, Dark Red, +4 Congestion, Mild.Ovaries . . . . . . Discolored, Bilateral, Diffuse, Purple, +4 Examined; no correlation foundUterus . . . . . . Discolored, Bilateral, Diffuse, Purple, +4 Examined; no correlation foundAnimal: 6838H797 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 605 Dosing phase Status: Sacrificed moribund Terminal body weight (g): 223.3Tissue Gross observations / Comments Correlated microscopic observationsLiver . . . . . . . Discolored, Diffuse, Mottled, +3 M-Leukemia, mononuclear, Contributory.Spleen . . . . . . Enlarged, 21-45 mm, Red, +3 M-Leukemia, mononuclear, Contributory.Lungs . . . . . . . Discolored, 0-2 mm, Dark/ Multifocal Round N-Leukemia, mononuclear - capillary involvement,Contributory.Animal: 6838H798 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 256.0Tissue Gross observations / Comments Correlated microscopic observationsEyes/optic nerve . Discolored, Left, Diffuse, Opaque, +4 Cataract, Present.Uterus . . . . . . Enlarged, Left, 6-10 mm, Soft/ Patchy B-Polyp, endometrial stromal, Incidental.Mammary gland . . . Mass, Right, 46-67 mm, Mottled, Firm/ Right Abdomen B-Fibroadenoma, Incidental.Diffuse IrregularLovelace Respiratory Individual Animal Report of Correlated Gross and Microscopic Diagnoses Printed:25-Jun-04Research Institute Study Number:FY01013F Page:43Rat/F344/NAnimal: 6838H799 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 737 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 215.8Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 3-5 mm/ Single Depression Compression, Moderate.Pituitary gland . . Enlarged, 6-10 mm, Dark, Soft/ Single Round B-Adenoma, pars distalis, Incidental.Cervix . . . . . . Enlarged, 6-10 mm, Firm, +3/ Single Examined; no correlation foundAnimal: 6838H800 Sex: Female Group: 4 Dose level: 20 g/m3Day of death: 734 Dosing phase Status: Final phase sacrifice Terminal body weight (g): 247.9Tissue Gross observations / Comments Correlated microscopic observationsBrain . . . . . . . Deformity, 6-10 mm, +2 Compression, Mild.Pituitary gland . . Mass, 6-10 mm, Mottled Red, Firm, +2/ Diffuse B-Adenoma, pars distalis, Incidental.IrregularSpleen . . . . . . Enlarged, 46-67 mm, +3/ Diffuse M-Leukemia, mononuclear, Contributory.Liver . . . . . . . Thick, Diffuse, Mottled, +3/ Irregular M-Leukemia, mononuclear, Contributory.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-8 Histological Comments on TissueLovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6832E452 F 1/1 28-Oct-03 14:55 142 Parathyroid One of pair not represented on slide.6832E453 F 1/1 28-Oct-03 15:53 142 Parathyroid One of pair not represented on slide.6832E454 F 1/1 03-Nov-03 11:51 142 Bronchial (TBLN) TBLN noted missing at trim.04-Feb-04 12:29 142 Ovaries Tissue not represented on slide. Oviducts only on original andrecuts 1, 2.6832E455 F 1/1 18-Nov-03 11:07 142 Parathyroid One of pair not represented on slide.6832E457 F 1/1 04-Nov-03 07:10 142 Parathyroid One of pair not represented on slide.6832E461 F 1/1 05-Feb-04 09:00 142 Parathyroid One of pair not represented on slide.6832E463 F 1/1 05-Nov-03 10:06 142 Parathyroid One of pair not represented on slide.6832E465 F 1/1 04-Nov-03 08:14 142 Parathyroid One of pair not represented on slide.6832E466 F 1/1 18-Nov-03 11:38 142 Rectum Formalin injection artifact6832E467 F 1/1 05-Nov-03 12:26 142 Parathyroid One of pair not represented on slide.6832E471 F 1/1 18-Nov-03 14:13 142 Parathyroid One of pair not represented on slide.6832E472 F 1/1 05-Nov-03 15:21 142 Pituitary gland Focus of chromophobe like cells (without cytologic orstructural changes sufficient to call hyperplasia)6832E473 F 1/1 20-Oct-03 15:50 142 Parathyroid One of pair not represented on slide6832E475 F 1/1 04-Feb-04 12:38 142 Mandibular LN Tissue not represented on slide or recut6832E476 F 1/1 04-Feb-04 12:40 142 Parathyroid Tissue not represented on slide or recut6832E477 F 1/1 04-Nov-03 11:55 142 Parathyroid One of pair not represented on slide.6832E478 F 1/1 04-Feb-04 12:41 142 Parathyroid Tissue not represented on slide or recut6832E479 F 1/1 26-Dec-03 16:38 142 Parathyroid One of pair not represented on slide.6832E480 F 1/1 18-Nov-03 16:14 142 Spinal cord Fragmented sample6832E482 F 1/1 12-Jan-04 12:32 142 Parathyroid No parathyroids, distortion due to thyroid mass6832E485 F 1/1 18-Nov-03 17:16 142 Parathyroid One of pair not represented on slide.6832E487 F 1/1 19-Nov-03 09:07 142 Adrenal glands Mass interpreted as pheochromocytoma (3 foci in current planeof section) with adjacent cortical degeneration.04-Feb-04 12:43 142 Ovaries One of pair not represented on slide or recutLovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 2Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6832E491 F 1/1 18-Nov-03 16:55 142 Parathyroid One of pair not represented on slide.6832E492 F 1/1 04-Feb-04 12:46 142 Parathyroid One of pair not represented on slide.6832E496 F 1/1 05-Feb-04 09:01 142 Parathyroid One of pair not represented on slide.6832E499 F 1/1 04-Feb-04 12:53 142 Bronchial (TBLN) Tissue not represented on slide or recut6834F556 F 2/1 04-Feb-04 12:57 142 Parathyroid One of pair not represented on slide.04-Feb-04 12:58 142 Mandibular LN Tissue not represented on slide or recut6834F562 F 2/1 15-Jan-04 12:08 142 Mesenteric LN Submitted tissue is focus of fat necrosis/steatitis.23-Jan-04 12:25 142 Mammary gland Missing at trim.23-Jan-04 12:24 142 Skin Missing at trim.6834F568 F 2/1 04-Feb-04 13:45 142 Mammary gland Tissue not represented on slide or recut6834F572 F 2/1 09-Jan-04 17:07 142 Pancreas Small amount of exocrine pancreas present6834F577 F 2/1 13-Jan-04 14:57 142 Bronchial (TBLN) Extensive lymphoma, no recut requested.04-Feb-04 13:47 142 Parathyroid One of pair not represented on slide.13-Jan-04 14:56 142 Mandibular LN Extensive lymphoma, no recut requested.13-Jan-04 15:01 142 Pancreas Extensive lymphoma, no recut requested13-Jan-04 15:08 142 Pancreatic LN Tissue submitted as pancreatic lymph node is fat with invasivelymphoma/leukemia.6834F578 F 2/1 06-Jan-04 17:54 142 Parathyroid One of pair not represented on slide.6834F593 F 2/1 04-Feb-04 14:08 142 Bone, femur Minimal marrow on original or recut6834F594 F 2/1 16-Jan-04 11:59 142 Mammary gland In slide 66834F599 F 2/1 04-Feb-04 14:11 142 Pancreas Tissue not represented on slide or recut6836G653 F 3/1 04-Feb-04 14:12 142 Bronchial (TBLN) Tissue not represented on slide or recut19-Jan-04 10:39 142 Esophagus Hemorrhage in adjacent tissue interpreted as immature fibroustissue--origin and significance uncertain.04-Feb-04 14:14 142 Liver Grossly noted nodule not seen on slide or recutLovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 3Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6836G653 F 3/1 19-Jan-04 10:37 142 Lymph node other Bulk of submitted tissue is immature fibrous tissue with mildhistiolymphocytic inflammation. Small amount of lymph node isunremarkable.6836G664 F 3/1 19-Jan-04 10:51 142 Adrenal glands One of pair missing at trim.6836G672 F 3/1 05-Feb-04 12:28 142 Nose/Turbinate 1 Lost in processing (missing from block).6836G679 F 3/1 09-Jan-04 12:02 142 Parathyroid One of pair not represented on slide.6836G682 F 3/1 09-Jan-04 14:17 142 Parathyroid One of pair not represented on slide.09-Jan-04 14:24 142 Mammary gland Missing at trim09-Jan-04 14:24 142 Skin Missing at trim6836G684 F 3/1 20-Feb-04 09:24 142 Tiss.not specifi Gross mass correlated to mammary gland (fibroadenoma)6836G688 F 3/1 13-Jan-04 07:13 142 Mediastinal LN Submitted tissue is thymus containing a benign thymoma.6836G691 F 3/1 04-Feb-04 14:22 142 Larynx Original and recut are fragmentary sections not at optimallevel6836G692 F 3/1 04-Feb-04 16:32 142 Lungs Grossly noted nodule not on slide or recuts.6836G693 F 3/1 07-Jan-04 11:32 142 Parathyroid One of pair not represented on slide.04-Feb-04 15:00 142 Mediastinal LN Tissue not represented on slide or recut6836G695 F 3/1 13-Jan-04 07:27 142 Urinary bladder Missing at trim13-Jan-04 07:42 142 Pituitary gland Mass within brain section (slide 16) interpreted as parsintermedia pituitary adenoma.6836G696 F 3/1 04-Feb-04 15:01 142 Parathyroid One of pair not represented on slide.6836G698 F 3/1 04-Feb-04 15:04 142 Sciatic nerve Tissue not represented on slide or recut07-Jan-04 11:57 142 Bone, femur Missing at trim07-Jan-04 11:58 142 Spinal cord Missing at trim6838H751 F 4/1 11-Nov-03 15:33 142 Parathyroid One of pair not represented on slide.6838H752 F 4/1 11-Nov-03 16:18 142 Parathyroid One of pair not represented on slide.12-Nov-03 11:13 142 Spleen Leukemic cells widely disseminated; present to some degree inmany tissues.6838H753 F 4/1 04-Feb-04 15:17 142 Thyroid glands Inactive gland (large follicles with flattened epithelium).Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 4Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6838H755 F 4/1 12-Nov-03 15:53 142 Ileum Lamina propria of villi often fragmented areas with lymphocytesand plasma cells, interpreted as artifact.6838H762 F 4/1 05-Feb-04 12:30 142 Salivary gland On recut6838H763 F 4/1 17-Oct-03 16:53 142 Uterus Polyp necrotic20-Oct-03 11:08 142 Ovaries Abundant corpora lutea6838H765 F 4/1 28-Oct-03 15:31 142 Parathyroid One of pair not represented on slide.6838H766 F 4/1 04-Feb-04 15:29 142 Mammary gland Tissue not represented on slide or recut6838H770 F 4/1 05-Nov-03 16:14 142 Ovaries No corpora lutea--likely reason for gross description as"small".05-Nov-03 16:04 142 Mammary gland No skin/mammary at trim05-Nov-03 16:04 142 Skin No skin/mammary at trim.6838H771 F 4/1 05-Nov-03 16:21 142 Parathyroid One of pair not represented on slide.6838H772 F 4/1 05-Nov-03 16:43 142 Parathyroid One of pair not represented on slide.05-Nov-03 16:54 142 Ovaries No corporea lutea on one ovary, likely reason for grossdescription of "small".6838H773 F 4/1 05-Nov-03 17:27 142 Pituitary gland Irregularity interpreted to be due to plane of section.6838H774 F 4/1 04-Feb-04 15:31 142 Mammary gland Tissue not represented on slide or recut6838H777 F 4/1 25-Nov-03 09:11 142 Parathyroid One of pair not represented on slide.6838H778 F 4/1 25-Nov-03 09:37 142 Parathyroid One of pair not represented on slide.6838H779 F 4/1 04-Feb-04 16:18 142 Bronchial (TBLN) Tissue not represented on slide or recut25-Nov-03 11:34 142 Parathyroid One of pair not represented on slide.6838H780 F 4/1 04-Feb-04 16:20 142 Mediastinal LN Tissue not represented on slide or recut6838H782 F 4/1 25-Nov-03 13:48 142 Parathyroid One of pair not represented on slide.25-Nov-03 13:57 142 Eyes/optic nerve One eye specimen is fragmentary, could not correlate grossobservation.6838H786 F 4/1 25-Nov-03 16:03 142 Lungs Moderate autolysis in all tissues25-Nov-03 16:02 142 Parathyroid One of pair not represented on slide.Lovelace Respiratory Histological Comments on Tissues Printed:15-Jun-04Research Institute Study Number:FY01013F Page: 5Rat/F344/NAnimal Group/ Date and Time Oper.Number Sex Subgroup Data was entered # Tissue Special histological comment6838H786 F 4/1 25-Nov-03 16:12 142 Brain Focal neuronal swelling and degeneration interpreted asautolysis artifact.6838H787 F 4/1 25-Nov-03 16:31 142 Parathyroid One of pair not represented on slide.6838H788 F 4/1 06-Feb-04 12:23 142 Parathyroid One of pair not represented on slide.6838H792 F 4/1 18-Dec-03 15:17 142 Parathyroid One of pair not represented on slide.6838H797 F 4/1 26-Dec-03 13:40 142 Mammary gland In salivary gland section

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-9 Summary of Missing TissuesLovelace Respiratory Summary Table of Missing Tissues Printed:15-Jun-04Research Institute Study number:FY01013F Page: 1Rat/F344/NTissue AnimalsBronchial (TBLN) 6832E454 6832E499 6834F577 6836G653 6838H762 6838H779Thyroid glands 6832E499* 6838H787* 6838H795*Parathyroid 6832E452* 6832E453* 6832E455* 6832E457* 6832E458* 6832E459* 6832E461* 6832E463* 6832E465* 6832E466* 6832E467*Parathyroid 6832E471* 6832E473* 6832E476 6832E477* 6832E478 6832E479* 6832E480* 6832E482 6832E483* 6832E484* 6832E485*Parathyroid 6832E491* 6832E492* 6832E496* 6832E499* 6834F556* 6834F571* 6834F577* 6834F578* 6834F590* 6834F594* 6834F599*Parathyroid 6836G653* 6836G659* 6836G665* 6836G678* 6836G679* 6836G682* 6836G683* 6836G691* 6836G693* 6836G696* 6838H751*Parathyroid 6838H752* 6838H757* 6838H760* 6838H761* 6838H765* 6838H766* 6838H771* 6838H772* 6838H777* 6838H778* 6838H779*Parathyroid 6838H782* 6838H786* 6838H787* 6838H788* 6838H792* 6838H793* 6838H794* 6838H795* 6838H797* 6838H798*Aorta 6832E476Mandibular LN 6832E453 6832E463 6832E465 6832E475 6832E480 6832E482 6834F556 6834F577 6834F582 6838H751 6838H767Mandibular LN 6838H775Urinary bladder 6836G695Ileum 6836G665Pancreas 6834F577 6834F599Adrenal glands 6834F578* 6836G664*Mesenteric LN 6834F562Ovaries 6832E454 6832E487* 6838H792*Sciatic nerve 6836G698Mammary gland 6832E465 6834F562 6834F568 6836G682 6838H766 6838H770 6838H774Skin 6834F562 6836G682 6838H770Bone, femur 6836G698Spinal cord 6836G698Nose/Turbinate 1 6836G672Pancreatic LN 6834F577Mediastinal LN 6836G693 6838H771 6838H780 6838H782* Only one of the pair is missing

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

N-10 Lesion Incidence Summary with K-S (comparison > control)Lovelace Respiratory Lesion incidence summary with K-S (comparison > control) Printed:30-Jun-04Research Institute Study Number:FY01013F Page: 1Rat/F344/N-- A n i m a l s A f f e c t e d --Controls from group(s): 1 Animal sex: -- F e m a l e s --Dosage group: Ctls 2 3 4T i s s u e s W i t h D i a g n o s e s No. in group: 50 50 50 50Kidneys ........................................Number examined: 50 20 21 50Atrophy 0 0 0 1Cyst 1 0 0 3Degeneration, hyaline droplet 0 0 0 1Dilatation 0 0 0 1Infarct 0 0 0 1Nephropathy, chronic 42 17 15 -43Pigment accumulation, tubular epithelium 0 2 0 2Note: Entries flagged with a - (minus) are significantly higher than control at the 0.05 level using the Kolmogorov-Smirnovone-tailed test.All Graded Diagnoses; Phases: All; Death types: All; Date of death range: 28-Aug-01 To 06-Jun-03

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

O-1 APPENDIX O

STATISTICIAN’S REPORT

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-3 INTRODUCTION

Groups of 50 male/50 female CDF(F344)CrlBR rats were exposed in H2000 whole-body

inhalation chambers at GMVC va por concentrations of 2 g/m 3 

# (low level), 10 g/m 3 

# (mid level),

and 20 g/m 3 

# (high level) 6 hours/day, 5 days/week fo r 104 weeks (520 exposure days). There

was also a control group (0 g/m 3 

# ). Blood was collected after approximately 12 and 18 months

and at terminal sacrifice for evaluation of tota l and differential white blood cell counts. Animals

surviving 104 weeks underwent a final sacrifice. Statistical evaluations were performed for the

following endpoints:

a. Survival as a function of sex and dose group

b. White blood cell count (estimate) an d differential white blood cell counts

c. Histopathological lesions

METHODS

Survival Analysis

The number of days of survival was calculated for each animal in the study. Two female

rats who died subsequent to accidental nose in juries early in the study were deleted from the

analysis. The probabili ty of survival was estimated by the Kaplan-Meier product-limit method

using PROC LIFETEST in SAS Version 8.2. Mean numbers of survival days and time to 25%

mortality were estimated for each dose group. Log -rank tests were used to test the hypothesis

that there are differences among the four groups for each sex. The significance level was set at

p = 0.05. All reported p-values for the survival analysis are two sided.

Analysis of White Blood Cell Total and Differential Cell Counts

For the hematology data, medians and ranges ar e presented because th e distributions are

highly skewed for some variables. Prelimin ary analyses were done using the generalized

estimating equation approach for longitudinal data analysis because there were three time points.

For some variables these anal yses showed significant inter actions between time and group.

Therefore, analyses were done to compare dose groups at each time point and to compare time

points within each dose group. The Krusal-Wal lis test was used for these comparisons.

Analysis of the Incidences of Microscopic Lesions

The incidences of all neoplastic and non-neoplas tic lesions are given as the ratio of the

number of affected animals to the number of an imals with the site examined microscopically.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-4 Three statistical evaluations were performed on the histopathology lesion incidence data:

1) Cochran-Armitage test, which tests whether th e incidence of lesions shows a trend across dose

groups; 2) logistic regression that takes death date into account when assessing the presence of a

dose-dependent trend; and 3) the Fisher’s exact test to compar e incidences among the four dose

groups. The two-sided significance level was set at p = 0.05. If a signi ficant difference was

detected by the Fisher’s test, six possible pair wise comparisons were calculated. Using the

Bonferroni correction for pairwi se comparisons, each pairwise comparison would be considered

significant if p < 0.008.

Fisher’s exact test and the Cochran-Armitage test do not use survival information and are

appropriate in situations where survival is similar among exposure group as is the case for this

study. The Fisher’s exact tests the null hypothesis of equality of prevalences across dose groups

against the alternate hypothesis that the prevalen ces are not equal, while the Cochran-Armitage

tests the null hypothesis of equality across doses against the alternate hyp othesis of a monotonic

increasing or decreasing trend. Th e difference in these hypothesis test s can be seen in the test of

“degeneration, cytoplasmic vacuolization” for fe male adrenal glands. The incidences are 24%,

5%, 0%, and 28% for 0 g/m 3 

# , 2 g/m 3 

# , 10 g/m 3 

# , and 20 g/m 3 

# , respectively. The p-value for the

Fisher’s exact test is 0.006, indicating differenc es among the incidences. However, the p-value

for the Cochran-Armitage test is 0.73, indicati ng no detectable upward or downward trend across

the doses.

RESULTS

Survival

All groups had 50 animals except the mid-level group for females. Two animals in that

group were omitted from the analysis because of nose injuries. Figures O-1 and O-2 show the

survival curves for male and female animals, respectively. The differences among the groups are

not statistically si gnificant for male (p = 0.46) or female animals (p = 0.07). Table O-1 shows

means, standard errors, and day of 25% mortality for male and female animals under each

experimental condition. For the ca lculation of mean and standard errors of survival times, the

last day of the study was used as the value of the su rvival time for animals that were sacrificed at

the time that the study was terminated. Theref ore, the means and standard errors may be

underestimated because some of the animals may have lived longer if the protocol had included

following them for a longer period of time. The results indicate that chronic GMVC inhalation

did not shorten the lifespan of the exposed rats compared to the controls.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-5 Figure O-1. Survival of Male Animals

Figure O-2. Survival of Female Animals

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-6 Table O-1. Mean Survival Da ys and Day of 25% Mortality

for Male and Female Rats

Exposure

Group Male Female

Mean Days of

Survival

(SE) Estimate Day

of 25%

Mortality Mean Days of

Survival

(SE) Estimated Day

of 25%

Mortality

0 g/m 3 

# 652.6 (14.4) 626 665.9 (11.5) 632

2 g/m 3 

# 651.6 (12.8) 633 685.5 (11.9) 680

10 g/m 3 

# 675.3 ( 9.4) 633 680.9 (15.5) 660

20 g/m 3 

# 674.1 ( 9.5) 645 697.3 (10.6) 715

Analysis of White Blood Cell Total and Differential Cell Counts

Results for female and male rats are provide d in Tables O-2 and O-3, respectively. In

many cases there were differences in cell numbers over time, but the diffe rences in control and

high-level animals were in the same directi on. Significant differences between exposed and

control groups occurred primarily in males at the 12-month sampling time.

Analysis of the Incidences of Microscopic Lesions

Results of analyses on microscopic lesions for female and male rats are provided in

Tables O-4 and O-5, respectively. Significan t trends with increasing GMVC exposure

concentration were detected in some cases. Inci dences of lesions did notalways increase with

increasing concentration. In several cases, a lthough a difference was detected by the Fisher’s

test, the lesion incidences were not concentratio n dependent, leading to a lack of similarity

between the results obtained using the Fisher’s test and results us ing the Cochran-Armitage test

and logistic regression. Interpretation of the significance of these differences is provided in the

main report text and in the Pa thologist’s Report (Appendix P).

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-7 Table O-2a. Alterations in Percentages of White Blood Cell Components - Females

Variable 12 months 18 months 24 months

p-value Median (Range) Median (Range) Median (Range)

Neutrophils (%)

0 g/m 3 

# 21 (8, 40) 28 (6, 53) 32 (5, 49) 0.002

20 g/m 3 

# 26 (15, 41) 29 (16, 45) 36 (7, 71) <0.0001

p-value 0.02 0.63 0.053

Band Neutrophils (%)

0 g/m 3 

# 0 (0, 0) 0 (0, 3) 0 (0, 1) 0.04

20 g/m 3 

# 0 (0, 2) 0 (0, 1) 0 (0, 1) 0.64

p-value 0.32 0.98 0.34

Lymphocytes (%)

0 g/m 3 

# 73 (55, 90) 69 (45, 84) 59 (41, 82) <0.0001

20 g/m 3 

# 70 (53, 82) 66 (52, 81) 56 (25, 79) <0.0001

p-value 0.013 0.40 0.23

Monocytes (%)

0 g/m 3 

# 4 (0, 7) 2 (0, 5) 2 (0, 5) <0.0001

20 g/m 3 

# 4 (0, 9) 3 (0, 8) 2 (0, 7) <0.0001

p-value 0.60 0.003 0.83

Eosinophils (%)

0 g/m 3 

# 1 (0, 6) 2 (0, 5) 1 (0, 4) 0.06

20 g/m 3 

# 2 (0, 5) 1 (0, 4) 0 (0, 3) 0.0005

p-value 0.04 0.053 0.10

Basophils (%)

0 g/m 3 

# 0 (0, 1) 0 (0, 0) 0 (0, 0) 0.003

20 g/m 3 

# 0 (0, 1) 0 (0, 0) 0 (0, 1) 0.55

p-value 0.014 1.00 0.41

Atypical Lymphocytes (%)

0 g/m 3 

# 0 (0, 0) 0 (0, 17) 8 (3, 30) <0.0001

20 g/m 3 

# 0 (0, 0) 0 (0, 2) 4 (0, 21) <0.0001

p-value 1.00 0.25 0.02

Blasts (%)

0 g/m 3 

# 0 (0, 0) 0 (0, 1) 0 (0, 3) 0.37

20 g/m 3 

# 0 (0, 0) 0 (0, 0) 0 (0, 3) 0.003

p-value 1.00 0.33 0.35

Nucleated RBC (#/100WBC)

0 g/m 3 

# 0 (0, 4) 2 (0, 14) 5 (1, 42) <0.0001

20 g/m 3 

# 0 (0, 2) 2 (0, 9) 3 (0, 16) <0.0001

p-value 0.91 0.62 0.38

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-8 Table O-2b. Alterations in White Blood Cell Total and Differential Cell Counts - Females

Variable 12 months 18 months 24 months

p-value Median

(Range) Median

(Range) Median

(Range)

WBC Estimate

0 g/m 3 

# 8.6 (4.4, 13.6) 4.4 (2.0, 9.2) 3.7 (1.8, 130.0) <0.0001

20 g/m 3 

# 8.8 (4.8, 12.0) 4.6 (1.8, 8.2) 3.0 (1.4, 40.0) <0.0001

p-value 0.58 0.77 0.14

Absolute Neutrophils

0 g/m 3 

# 2.0 (0.4, 5.0) 1.2 (0.3, 2.8) 1.1 (0.6, 6.5) <0.0001

20 g/m 3 

# 2.1 (1.1, 4.3) 1.3 (0.4, 3.3) 1.1 (0.4, 2.9) <0.0001

p-value 0.27 0.91 0.50

Absolute Band Neutrophils

0 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.1) 0.0 (0.0, 1.3) 0.014

20 g/m 3 

# 0.0 (0.0, 0.2) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.66

p-value 0.32 0.58 0.29

Absolute Lymphocytes

0 g/m 3 

# 6.3 (4.0, 10.5) 3.1 (1.3, 6.9) 1.8 (0.8, 97.5) <0.0001

20 g/m 3 

# 5.8 (3.3, 8.1) 3.1 (1.3, 5.1) 1.3 (0.7, 31.6) <0.0001

p-value 0.15 0.87 0.07

Absolute Monocytes

0 g/m 3 

# 0.3 (0.0, 0.8) 0.1 (0.0, 0.3) 0.1 (0.0, 0.8) <0.0001

20 g/m 3 

# 0.3 (0.0, 0.9) 0.1 (0.0, 0.5) 0.0 (0.0, 0.6) <0.0001

p-value 0.93 0.02 0.42

Absolute Eosinophils

0 g/m 3 

# 0.1 (0.0, 0.5) 0.1 (0.0, 0.3) 0.0 (0.0, 0.2) 0.0008

20 g/m 3 

# 0.1 (0.0, 0.5) 0.0 (0.0, 0.2) 0.0 (0.0, 0.1) <0.0001

p-value 0.12 0.048 0.09

Absolute Basophils

0 g/m 3 

# 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.004

20 g/m 3 

# 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.56

p-value 0.015 1.00 0.41

Absolute Atypical Lymphocytes

0 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.3) 0.3 (0.1, 20.8) <0.0001

20 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.1) 0.1 (0.0, 4.4) <0.0001

p-value 1.00 0.16 0.007

Absolute Blasts

0 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 3.9) 0.12

20 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 1.2) 0.003

p-value 1.00 1.00 0.38

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-9 Table O-3a. Alterations in Percentages of White Blood Cell Components - Males

Variable 12 months 18 months 24 months

p-value Median (Range) Median (Range) Median (Range)

Neutrophils (%)

0 g/m 3 

# 30 (16, 47) 33 (12, 60) 54 (4, 63) 0.004

20 g/m 3 

# 40 (22, 57) 36 (17, 71) 45 (5, 64) 0.46

p-value <0.0001 0.02 0.25

Band Neutrophils (%)

0 g/m 3 

# 0 (0, 1) 0 (0, 1) 0 (0, 0) 0.40

20 g/m 3 

# 0 (0, 2) 0 (0, 1) 0 (0, 0) 0.01

p-value 0.02 0.31 1.00

Lymphocytes (%)

0 g/m 3 

# 65 (45, 82) 61 (30, 80) 40 (2, 75) 0.0001

20 g/m 3 

# 55 (37, 70) 59 (27, 76) 47 (27, 85) 0.13

p-value <0.0001 0.03 0.13

Monocytes (%)

0 g/m 3 

# 4 (0, 8) 4 (1, 9) 4 (1, 6) 0.28

20 g/m 3 

# 3 (1, 9) 4 (0, 9) 1 (0, 4) <0.0001

p-value 0.78 0.40 0.002

Eosinophils (%)

0 g/m 3 

# 1 (0, 5) 2 (0, 6) 1 (0, 5) 0.003

20 g/m 3 

# 2 (0, 6) 2 (0, 6) 1 (0, 3) 0.001

p-value 0.10 0.98 0.97

Basophils (%)

0 g/m 3 

# 0 (0, 1) 0 (0, 1) 0 (0, 0) 0.66

20 g/m 3 

# 0 (0, 1) 0 (0, 0) 0 (0, 0) 0.02

p-value 0.16 0.32 1.00

Atypical Lymphocytes (%)

0 g/m 3 

# 0 (0, 0) 0 (0, 0) 6 (0, 19) <0.0001

20 g/m 3 

# 0 (0, 0) 0 (0, 0) 6 (2, 11) <0.0001

p-value 1.00 1.00 0.87

Blasts (%)

0 g/m 3 

# 0 (0, 0) 0 (0, 0) 0 (0, 0) 1.00

20 g/m 3 

# 0 (0, 0) 0 (0, 0) 0 (0, 3) 0.0004

p-value 1.00 1.00 0.12

Nucleated RBC (#/100WBC)

0 g/m 3 

# 0 (0, 2) 1 (0, 10) 2 (0, 7) <0.0001

20 g/m 3 

# 0 (0, 2) 1 (0, 6) 4 (0, 12) <0.0001

p-value 0.63 0.94 0.08

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

O-10 Table O-3b. Alterations in White Blood Cell Total and Differential Cell Counts - Males

Variable 12 months 18 months 24 months

p-value Median

(Range) Median

(Range) Median

(Range)

WBC Estimate

0 g/m 3 

# 10.0 (4.0, 20.0) 12.0 (6.8, 29.6) 3.7 (2.0, 68.8) 0.0001

20 g/m 3 

# 16.8 (8.8, 29.6) 12.4 (4.4, 36.4) 3.6 (1.6, 362.0) <0.0001

p-value <0.0001 0.50 0.94

Absolute Neutrophils

0 g/m 3 

# 3.3 (1.0, 8.9) 4.1 (1.2, 17.8) 1.9 (1.1, 5.4) 0.0002

20 g/m 3 

# 6.5 (2.5, 13.2) 3.8 (1.6, 24.0) 1.8 (0.7, 25.3) <0.0001

p-value <0.0001 0.60 0.58

Absolute Band Neutrophils

0 g/m 3 

# 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.0 (0.0, 0.0) 0.39

20 g/m 3 

# 0.0 (0.0, 0.4) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.014

p-value 0.02 0.29 1.00

Absolute Lymphocytes

0 g/m 3 

# 6.3 (2.7, 12.2) 7.3 (4.1, 22.7) 1.6 (0.6, 51.6) 0.0005

20 g/m 3 

# 9.2 (4.4, 15.3) 6.2 (2.3, 15.4) 1.4 (0.8, 307.7) <0.0001

p-value <0.0001 0.13 0.48

Absolute Monocytes

0 g/m 3 

# 0.3 (0.0, 1.0) 0.5 (0.1, 2.7) 0.2 (0.0, 1.4) 0.002

20 g/m 3 

# 0.6 (0.1, 1.8) 0.4 (0.0, 1.9) 0.0 (0.0, 0.4) <0.0001

p-value <0.0001 0.47 0.005

Absolute Eosinophils

0 g/m 3 

# 0.1 (0.0, 0.7) 0.3 (0.0, 0.9) 0.0 (0.0, 0.2) <0.0001

20 g/m 3 

# 0.3 (0.0, 1.3) 0.3 (0.0, 0.9) 0.0 (0.0, 0.1) <0.0001

p-value 0.0003 0.84 0.75

Absolute Basophils

0 g/m 3 

# 0.0 (0.0, 0.2) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.66

20 g/m 3 

# 0.0 (0.0, 0.2) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.016

p-value 0.15 0.32 1.00

Absolute Atypical Lymphocytes

0 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.2 (0.0, 13.1) <0.0001

20 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.2 (0.1, 25.3) <0.0001

p-value 1.00 1.00 0.55

Absolute Blasts

0 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.00

20 g/m 3 

# 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.0 (0.0, 3.6) 0.0004

p-value 1.00 1.00 0.13

# O-11 Study Number FY01-013Table O-4. Statistical Evaluation ofMicroscopic Lesions in Females**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Adrenal glands** **B-Pheochromocytoma, benign 1/49 ( 2%) 1/20 ( 5%) 2/21 ( 10%) 1/50 ( 2%) 0.88 0.91 0.28 Cyst 0/49 ( 0%) 0/20 ( 0%) 1/21 ( 5%) 1/50 ( 2%) 0.28 0.33 0.50** **Degeneration, cytoplasmic vacuolization 12/49 ( 24%) 1/20 ( 5%) 0/21 ( 0%) 14/50 ( 28%) 0.73 0.77 0.006 1** **Hyperplasia, cortical, focal 2/49 ( 4%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.49 0.46 0.87 Hyperplasia, focal 1/49 ( 2%) 0/20 ( 0%) 2/21 ( 10%) 2/50 ( 4%) 0.39 0.39 0.44** **M-Carcinoma, metastatic 0/49 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.25 . 1.00 M-Leukemia, mononuclear 3/49 ( 6%) 1/20 ( 5%) 0/21 ( 0%) 3/50 ( 6%) 0.86 0.87 0.85** **Necrosis 1/49 ( 2%) 0/20 ( 0%) 0/21 ( 0%) 0/50 ( 0%) 0.24 . 0.64 Thrombus 1/49 ( 2%) 0/20 ( 0%) 0/21 ( 0%) 0/50 ( 0%) 0.24 . 0.64** **Aorta N-Leukemia, mononuclear - invasive involvement 1/49 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.24 . 0.64** **Bone, femur New bone formation, endosteal 0/50 ( 0%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 0.25 . 1.00** **Bone, other Fracture 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0/0 ( .%) . . .** **Bone, rib M-Osteosarcoma 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) 1/1 (100%) . . .** **Bone, vertebrae N-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . .** **Brain Compression 2/50 ( 4%) 8/25 ( 32%) 9/25 ( 36%) 9/50 ( 18%) 0.07 0.16 0.001** **2 Hemorrhage 1/50 ( 2%) 1/25 ( 4%) 0/25 ( 0%) 0/50 ( 0%) 0.26 0.31 0.78** **Inflammation, chronic 0/50 ( 0%) 0/25 ( 0%) 0/25 ( 0%) 1/50 ( 2%) 0.23 . 1.00 M-Astrocytoma, malignant 0/50 ( 0%) 1/25 ( 4%) 0/25 ( 0%) 0/50 ( 0%) 0.69 0.70 0.33** **Metaplasia, osseous, meninges 0/50 ( 0%) 0/25 ( 0%) 0/25 ( 0%) 1/50 ( 2%) 0.23 . 1.00 Necrosis 1/50 ( 2%) 0/25 ( 0%) 0/25 ( 0%) 0/50 ( 0%) 0.23 . 1.00** **___________________________________________________________________________________________________________________________________ 1** **Pairwise Fisher’s exact tests: p=0.09 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.013 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.82 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.49 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.051 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.007 for 10 g/m** **3 cf. 20 g/m** **3 .** **2 Pairwise Fisher’s exact tests: p=0.002 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.0005 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.051 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=1.00 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.24 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.10 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-12 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Bronchial (TBLN)** **Hemorrhage 1/48 ( 2%) 3/19 ( 16%) 0/20 ( 0%) 4/48 ( 8%) 0.40 0.42 0.09 Inflammation, mixed 0/48 ( 0%) 0/19 ( 0%) 1/20 ( 5%) 0/48 ( 0%) 0.70 0.87 0.29** **N-Leukemia, mononuclear 9/48 ( 19%) 3/19 ( 16%) 7/20 ( 35%) 2/48 ( 4%) 0.12 0.12 0.008 3** **Cecum N-Leukemia, mononuclear 2/49 ( 4%) 1/20 ( 5%) 0/20 ( 0%) 0/49 ( 0%) 0.11 0.18 0.51** **Cervix B-Polyp, endometrial stromal 0/2 ( 0%) 0/5 ( 0%) 0/3 ( 0%) 1/2 ( 50%) 0.08 . 0.33** **M-Leiomyosarcoma 0/2 ( 0%) 1/5 ( 20%) 0/3 ( 0%) 0/2 ( 0%) 0.65 . 1.00 N-Adenocarcinoma, endometrial 0/2 ( 0%) 1/5 ( 20%) 0/3 ( 0%) 0/2 ( 0%) 0.65 0.91 1.00** **Clitoral gland B-Adenoma 0/1 ( 0%) 0/0 ( .%) 1/3 ( 33%) 0/0 ( .%) 0.50 . 1.00** **M-Carcinoma, squamous cell 1/1 (100%) 0/0 ( .%) 0/3 ( 0%) 0/0 ( .%) 0.046 . 0.25 N-Adenocarcinoma 0/1 ( 0%) 0/0 ( .%) 2/3 ( 67%) 0/0 ( .%) 0.25 . 1.00** **Duodenum Inflammation, acute 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.61 0.29** **Eyes/optic nerve Atrophy 1/50 ( 2%) 1/22 ( 5%) 0/24 ( 0%) 2/50 ( 4%) 0.70 0.91 0.76** **Atrophy, retinal, unilateral 0/50 ( 0%) 2/22 ( 9%) 1/24 ( 4%) 0/50 ( 0%) 0.81 0.78 0.018 4** **Cataract 1/50 ( 2%) 3/22 ( 14%) 1/24 ( 4%) 2/50 ( 4%) 0.89 0.87 0.18 Metaplasia, osseous, scleral 1/50 ( 2%) 0/22 ( 0%) 0/24 ( 0%) 0/50 ( 0%) 0.23 . 1.00** **Mineralization, corneal stromal 4/50 ( 8%) 0/22 ( 0%) 0/24 ( 0%) 4/50 ( 8%) 0.99 0.97 0.31 Mineralization, scleral 2/50 ( 4%) 2/22 ( 9%) 2/24 ( 8%) 4/50 ( 8%) 0.45 0.55 0.77** **Neovascularization, corneal 1/50 ( 2%) 0/22 ( 0%) 0/24 ( 0%) 2/50 ( 4%) 0.50 0.71 1.00 Harderian gland** **Pigment 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0/0 ( .%) . . . Heart** **Degeneration, myocyte 3/50 ( 6%) 0/20 ( 0%) 0/20 ( 0%) 3/50 ( 6%) 1.00 0.59 0.65 Fibrosis 1/50 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.25 . 1.00** **Inflammation, focal, chronic 24/50 ( 48%) 7/20 ( 35%) 8/20 ( 40%) 26/50 ( 52%) 0.65 0.73 0.57 M-Leukemia, mononuclear 5/50 ( 10%) 2/20 ( 10%) 0/20 ( 0%) 2/50 ( 4%) 0.14 0.16 0.41** **Thrombus 1/50 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.25 . 1.00 ___________________________________________________________________________________________________________________________________** **3 Pairwise Fisher’s exact tests: p=1.00 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.21 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.051 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=0.27 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.13 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.002 for 10 g/m 3** **cf. 20 g/m 3** **. 4** **Pairwise Fisher’s exact tests: p=0.09 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.32 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.60 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.09 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.32 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-13 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Ileum** **N-Leukemia, mononuclear 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 1.00 0.98 1.00 Iliac LN** **N-Leukemia, mononuclear 2/2 (100%) 2/2 (100%) 2/2 (100%) 0/0 ( .%) . . . Kidneys** **Atrophy 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00 Cyst 1/50 ( 2%) 0/20 ( 0%) 0/21 ( 0%) 3/50 ( 6%) 0.24 0.47 0.52** **Degeneration, hyaline droplet 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00 Dilatation 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00** **Infarct 0/50 ( 0%) 0/20 ( 0%) 0/21 ( 0%) 1/50 ( 2%) 0.24 . 1.00 M-Leukemia, mononuclear 1/50 ( 2%) 1/20 ( 5%) 1/21 ( 5%) 2/50 ( 4%) 0.60 0.57 0.86** **N-Sarcoma, histiocytic 0/50 ( 0%) 0/20 ( 0%) 1/21 ( 5%) 0/50 ( 0%) 0.70 0.89 0.29 Nephropathy, chronic 42/50 ( 84%) 17/20 ( 85%) 15/21 ( 71%) 43/50 ( 86%) 0.99 0.84 0.51** **Pigment accumulation, tubular epithelium 0/50 ( 0%) 2/20 ( 10%) 0/21 ( 0%) 2/50 ( 4%) 0.44 0.42 0.13 Larynx** **Hyperplasia 17/50 ( 34%) 10/50 ( 20%) 5/50 ( 10%) 15/50 ( 30%) 0.41 0.36 0.018 5** **Inflammation, acute 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.19 0.16 0.62 Inflammation, chronic 8/50 ( 16%) 1/50 ( 2%) 6/50 ( 12%) 7/50 ( 14%) 0.84 0.89 0.08** **Inflammation, mixed 28/50 ( 56%) 35/50 ( 70%) 23/50 ( 46%) 33/50 ( 66%) 0.85 0.91 0.07 Metaplasia, squamous 5/50 ( 10%) 10/50 ( 20%) 10/50 ( 20%) 9/50 ( 18%) 0.31 0.50 0.49** **___________________________________________________________________________________________________________________________________ 5** **Pairwise Fisher’s exact tests: p=0.18 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.007 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.83 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.26 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.36 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.02 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-14 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Liver** **Angiectasis 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.98 0.98 1.00 B-Adenoma, hepatocellular 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00** **Congestion 1/50 ( 2%) 0/28 ( 0%) 1/22 ( 5%) 0/50 ( 0%) 0.59 0.59 0.31 Fatty Change 0/50 ( 0%) 1/28 ( 4%) 2/22 ( 9%) 3/50 ( 6%) 0.09 0.24 0.16** **Foci of cellular alteration, basophilic 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.98 . 1.00 Hepatodiaphragmatic nodule 0/50 ( 0%) 5/28 ( 18%) 0/22 ( 0%) 3/50 ( 6%) 0.53 0.60 0.006** **6 Hyperplasia, biliary 35/50 ( 70%) 16/28 ( 57%) 17/22 ( 77%) 24/50 ( 48%) 0.059 0.041 0.049** **7 Hyperplasia, hepatocellular, regenerative 1/50 ( 2%) 1/28 ( 4%) 1/22 ( 5%) 1/50 ( 2%) 0.97 0.89 0.83** **Inflammation, acute 1/50 ( 2%) 0/28 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00 Inflammation, chronic 13/50 ( 26%) 5/28 ( 18%) 3/22 ( 14%) 17/50 ( 34%) 0.39 0.61 0.25** **M-Leukemia, mononuclear 27/50 ( 54%) 17/28 ( 61%) 10/22 ( 45%) 23/50 ( 46%) 0.30 0.27 0.57 M-Sarcoma. histiocytic 0/50 ( 0%) 0/28 ( 0%) 1/22 ( 5%) 1/50 ( 2%) 0.25 0.34 0.31** **Necrosis 3/50 ( 6%) 3/28 ( 11%) 1/22 ( 5%) 5/50 ( 10%) 0.59 0.58 0.79 Thrombus 0/50 ( 0%) 0/28 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.23 . 1.00** **Vacuolization cytoplasmic 5/50 ( 10%) 1/28 ( 4%) 1/22 ( 5%) 1/50 ( 2%) 0.09 0.11 0.36 Lungs** **Alveolar histiocytosis 9/50 ( 18%) 3/50 ( 6%) 3/50 ( 6%) 9/50 ( 18%) 1.00 0.96 0.07 Congestion 1/50 ( 2%) 0/50 ( 0%) 2/50 ( 4%) 1/50 ( 2%) 0.65 0.64 0.90** **Fibrosis, focal 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.56 1.00 Hemorrhage 5/50 ( 10%) 1/50 ( 2%) 1/50 ( 2%) 3/50 ( 6%) 0.38 0.39 0.29** **Hyperplasia, alveolar epithelial, focal 7/50 ( 14%) 1/50 ( 2%) 1/50 ( 2%) 1/50 ( 2%) 0.009 0.017 0.014 8** **Inflammation, acute 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.25 1.00 Inflammation, granulomatous 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 . 1.00** **Inflammation, mixed 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.66 1.00 N-Carcinoma, metastatic 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00** **N-Leukemia, mononuclear - capillary involvement 22/50 ( 44%) 16/50 ( 32%) 12/50 ( 24%) 19/50 ( 38%) 0.39 0.41 0.19 N-Leukemia, mononuclear - invasive involvement 3/50 ( 6%) 1/50 ( 2%) 2/50 ( 4%) 1/50 ( 2%) 0.39 0.40 0.84** **N-Sarcoma, histiocytic 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0.20 0.27 1.00 Lymph node other** **Hemorrhage 1/3 ( 33%) 0/1 ( 0%) 0/3 ( 0%) 0/1 ( 0%) 0.22 . 1.00 Infiltration, histiocytic 1/3 ( 33%) 0/1 ( 0%) 0/3 ( 0%) 0/1 ( 0%) 0.22 . 1.00** **N-Leukemia, mononuclear 2/3 ( 67%) 1/1 (100%) 2/3 ( 67%) 1/1 (100%) 0.71 . 1.00 ___________________________________________________________________________________________________________________________________** **6 Pairwise Fisher’s exact tests: p=0.005 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.24 for 0 g/m** **3 cf. 20 g/m** **3 ; p=0.06 for 2 g/m** **3 cf. 10 g/m** **3 ;** **p=0.13 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.55 for 10 g/m 3** **cf. 20 g/m 3** **. 7** **Pairwise Fisher’s exact tests: p=0.32 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.58 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.04 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.23 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.49 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.04 for 10 g/m** **3 cf. 20 g/m** **3 .** **8 Pairwise Fisher’s exact tests: p=0.06 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.06 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.06 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=1.00 for 2 g/m 3** **cf. 10 g/m 3** **; p=1.00 for 2 g/m 3** **cf. 20 g/m 3** **; p=1.00 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-15 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Mammary gland** **B-Fibroadenoma 0/49 ( 0%) 3/20 ( 15%) 2/22 ( 9%) 5/47 ( 11%) 0.07 0.18 0.029 9** **B-Fibroma 1/49 ( 2%) 2/20 ( 10%) 1/22 ( 5%) 0/47 ( 0%) 0.44 0.38 0.07 Ectasia 3/49 ( 6%) 0/20 ( 0%) 0/22 ( 0%) 1/47 ( 2%) 0.24 0.16 0.53** **Hyperplasia, lobular 1/49 ( 2%) 0/20 ( 0%) 1/22 ( 5%) 2/47 ( 4%) 0.41 0.57 0.83 M-Adenocarcinoma 0/49 ( 0%) 1/20 ( 5%) 1/22 ( 5%) 0/47 ( 0%) 0.99 0.98 0.09** **M-Adenocarcinoma arising in fibroadenoma 1/49 ( 2%) 0/20 ( 0%) 0/22 ( 0%) 0/47 ( 0%) 0.24 . 1.00 Mandibular LN** **Hemorrhage 0/44 ( 0%) 1/19 ( 5%) 0/21 ( 0%) 0/47 ( 0%) 0.67 0.66 0.15 N-Leukemia, mononuclear 12/44 ( 27%) 6/19 ( 32%) 5/21 ( 24%) 5/47 ( 11%) 0.043 0.045 0.12** **Mediastinal LN B-Thymoma 0/50 ( 0%) 0/20 ( 0%) 1/20 ( 5%) 0/47 ( 0%) 0.68 0.69 0.29** **Hemorrhage 4/50 ( 8%) 1/20 ( 5%) 1/20 ( 5%) 1/47 ( 2%) 0.20 0.22 0.62 Infiltration, histiocytic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/47 ( 2%) 0.23 . 0.64** **M-Carcinoma, metastatic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/47 ( 2%) 0.23 . 0.64 N-Leukemia, mononuclear 12/50 ( 24%) 5/20 ( 25%) 5/20 ( 25%) 5/47 ( 11%) 0.11 0.12 0.24** **N-Sarcoma, histiocytic 0/50 ( 0%) 0/20 ( 0%) 1/20 ( 5%) 0/47 ( 0%) 0.68 0.86 0.29 Pigmentation 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/47 ( 2%) 0.23 . 0.64** **Mediastinum N-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . .** **Mesenteric LN Hemorrhage 1/50 ( 2%) 0/19 ( 0%) 1/20 ( 5%) 0/50 ( 0%) 0.58 0.55 0.48** **Inflammation, chronic 1/50 ( 2%) 0/19 ( 0%) 1/20 ( 5%) 0/50 ( 0%) 0.58 0.53 0.48 N-Leukemia, mononuclear 13/50 ( 26%) 3/19 ( 16%) 7/20 ( 35%) 4/50 ( 8%) 0.056 0.06 0.024** **10 N-Sarcoma, histiocytic 0/50 ( 0%) 0/19 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00** **Mesentery M-Carcinoma, metastatic 0/1 ( 0%) 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0.16 . 1.00** **Splenic tissue, "accessory" 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/1 ( 0%) 0.16 . 1.00 Muscle, skeletal** **N-Sarcoma, histiocytic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00 ___________________________________________________________________________________________________________________________________** **9 Pairwise Fisher’s exact tests: p=0.02 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.09 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.03 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=0.66 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.69 for 2 g/m 3** **cf. 20 g/m 3** **; p=1.00 for 10 g/m 3** **cf. 20 g/m 3** **. 10** **Pairwise Fisher’s exact tests: p=0.53 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.56 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.03 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.27 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.38 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.009 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-16 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Nose/Turbinate 1** **Degeneration, hyaline - respiratory epithelium 3/50 ( 6%) 7/50 ( 14%) 6/49 ( 12%) 2/50 ( 4%) 0.67 0.70 0.26 Hyperplasia - respiratory epithelium 0/50 ( 0%) 1/50 ( 2%) 2/49 ( 4%) 2/50 ( 4%) 0.16 0.19 0.58** **Inflammation - nasolacrimal duct 21/50 ( 42%) 15/50 ( 30%) 20/49 ( 41%) 22/50 ( 44%) 0.59 0.60 0.48 Inflammation - respiratory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/49 ( 0%) 1/50 ( 2%) 1.00 0.85 1.00** **Inflammation, mixed 5/50 ( 10%) 5/50 ( 10%) 4/49 ( 8%) 4/50 ( 8%) 0.67 0.69 1.00 Nose/Turbinate 2** **Degeneration, hyaline - olfactory epithelium 4/50 ( 8%) 5/50 ( 10%) 6/50 ( 12%) 10/50 ( 20%) 0.07 0.07 0.36 Degeneration, hyaline - respiratory epithelium 0/50 ( 0%) 1/50 ( 2%) 7/50 ( 14%) 6/50 ( 12%) 0.003 0.008 0.006** **11 Hyperplasia - respiratory epithelium 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 0.79 0.79 0.62** **Inflammation, mixed 3/50 ( 6%) 4/50 ( 8%) 2/50 ( 4%) 2/50 ( 4%) 0.49 0.49 0.90 Metaplasia, secretory - olfactory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00** **Metaplasia, squamous - olfactory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.66 1.00 Nose/Turbinate 3** **Degeneration - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.57 1.00 Degeneration - respiratory epithelium 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 0.79 0.81 0.62** **Degeneration, hyaline - olfactory epithelium 4/50 ( 8%) 2/50 ( 4%) 10/50 ( 20%) 8/50 ( 16%) 0.052 0.058 0.06 Inflammation, mixed 1/50 ( 2%) 3/50 ( 6%) 1/50 ( 2%) 0/50 ( 0%) 0.31 0.29 0.40** **Nose/Turbinate 4 Degeneration - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 . 1.00** **Degeneration, hyaline - olfactory epithelium 3/50 ( 6%) 0/50 ( 0%) 0/50 ( 0%) 3/50 ( 6%) 1.00 0.79 0.09 Inflammation, mixed 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.26 1.00** **Ovaries Congestion 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 0/50 ( 0%) 0.70 0.69 0.31** **Cyst, bursa 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 1/50 ( 2%) 0.27 0.51 0.52 Cyst, epithelial 1/49 ( 2%) 1/21 ( 5%) 0/23 ( 0%) 0/50 ( 0%) 0.26 0.30 0.19** **Cyst, follicular 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 0/50 ( 0%) 0.70 0.89 0.31 Cyst, rete ovarii 0/49 ( 0%) 0/21 ( 0%) 1/23 ( 4%) 0/50 ( 0%) 0.70 . 0.31** **Hemorrhage 1/49 ( 2%) 0/21 ( 0%) 0/23 ( 0%) 0/50 ( 0%) 0.23 . 0.65 M-Leukemia, mononuclear 1/49 ( 2%) 1/21 ( 5%) 1/23 ( 4%) 1/50 ( 2%) 0.98 0.98 0.60** **N-Sarcoma, histiocytic 0/49 ( 0%) 0/21 ( 0%) 0/23 ( 0%) 1/50 ( 2%) 0.24 . 1.00 Necrosis, mesenteric fat 0/49 ( 0%) 1/21 ( 5%) 0/23 ( 0%) 0/50 ( 0%) 0.68 0.59 0.15** **Pancreas Fibrosis 0/50 ( 0%) 0/18 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00** **M-Leukemia, mononuclear 0/50 ( 0%) 1/18 ( 6%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.69 0.13 ___________________________________________________________________________________________________________________________________** **11 Pairwise Fisher’s exact tests: p=0.49 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.012 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.03 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=0.06 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.11 for 2 g/m 3** **cf. 20 g/m 3** **; p=1.00 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-17 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Pancreatic LN** **N-Leukemia, mononuclear 2/2 (100%) 1/1 (100%) 2/2 (100%) 1/1 (100%) . . . Parathyroid** **B-Adenoma 1/47 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.23 . 0.64 Hyperplasia, focal 1/47 ( 2%) 0/20 ( 0%) 0/20 ( 0%) 0/50 ( 0%) 0.23 . 0.64** **Pituitary gland Angiectasis 9/50 ( 18%) 1/32 ( 3%) 3/34 ( 9%) 6/50 ( 12%) 0.47 0.41 0.22** **B-Adenoma, pars distalis 7/50 ( 14%) 13/32 ( 41%) 14/34 ( 41%) 11/50 ( 22%) 0.37 0.64 0.010 12** **B-Adenoma, pars intermedia 0/50 ( 0%) 0/32 ( 0%) 1/34 ( 3%) 0/50 ( 0%) 0.68 0.68 0.40 Cyst 24/50 ( 48%) 9/32 ( 28%) 10/34 ( 29%) 12/50 ( 24%) 0.015 0.011 0.07** **Degeneration 1/50 ( 2%) 0/32 ( 0%) 0/34 ( 0%) 0/50 ( 0%) 0.21 . 1.00 Hemorrhage 5/50 ( 10%) 0/32 ( 0%) 0/34 ( 0%) 10/50 ( 20%) 0.10 0.23 0.002** **13 Hyperplasia, focal 8/50 ( 16%) 3/32 ( 9%) 8/34 ( 24%) 4/50 ( 8%) 0.50 0.43 0.21** **M-Carcinoma 0/50 ( 0%) 1/32 ( 3%) 0/34 ( 0%) 0/50 ( 0%) 0.67 . 0.19 M-Leukemia, mononuclear 0/50 ( 0%) 1/32 ( 3%) 0/34 ( 0%) 1/50 ( 2%) 0.56 0.66 0.57** **Necrosis 0/50 ( 0%) 0/32 ( 0%) 0/34 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Popliteal LN** **N-Leukemia, mononuclear 1/1 (100%) 1/1 (100%) 0/0 ( .%) 0/0 ( .%) . . . Rectum** **Metaplasia, squamous 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.61 0.29 Salivary gland** **M-Leukemia, mononuclear 2/50 ( 4%) 0/20 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.50 0.47 1.00 Skin** **Cyst, epithelial inclusion 0/50 ( 0%) 1/19 ( 5%) 0/20 ( 0%) 0/49 ( 0%) 0.70 0.70 0.14 Fibrosis 0/50 ( 0%) 0/19 ( 0%) 1/20 ( 5%) 0/49 ( 0%) 0.69 . 0.28** **Inflammation, mixed 0/50 ( 0%) 0/19 ( 0%) 1/20 ( 5%) 0/49 ( 0%) 0.69 0.86 0.28 Spinal cord** **Degeneration, white matter 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 1.00 0.95 1.00 Hemorrhage 1/50 ( 2%) 0/20 ( 0%) 1/19 ( 5%) 0/50 ( 0%) 0.59 0.59 0.28** **Necrosis, neuronal 0/50 ( 0%) 0/20 ( 0%) 0/19 ( 0%) 1/50 ( 2%) 0.25 . 1.00 ___________________________________________________________________________________________________________________________________** **12 Pairwise Fisher’s exact tests: p=0.009 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.009 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.44 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=1.00 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.09 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.09 for 10 g/m 3** **cf. 20 g/m 3** **. 13** **Pairwise Fisher’s exact tests: p=0.15 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.08 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.26 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.005 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.005 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-18 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Spleen** **Fibrosis 3/50 ( 6%) 0/22 ( 0%) 1/24 ( 4%) 0/50 ( 0%) 0.11 0.16 0.29 Hemorrhage 0/50 ( 0%) 0/22 ( 0%) 0/24 ( 0%) 1/50 ( 2%) 0.24 . 1.00** **M-Leukemia, mononuclear 27/50 ( 54%) 12/22 ( 55%) 11/24 ( 46%) 23/50 ( 46%) 0.36 0.33 0.81 N-Sarcoma, histiocytic 0/50 ( 0%) 0/22 ( 0%) 1/24 ( 4%) 0/50 ( 0%) 0.70 0.87 0.32** **Necrosis 1/50 ( 2%) 1/22 ( 5%) 0/24 ( 0%) 2/50 ( 4%) 0.70 0.82 0.76 Stomach** **Inflammation, mixed 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.69 0.29 M-Carcinoma, metastatic 0/50 ( 0%) 0/20 ( 0%) 0/20 ( 0%) 1/50 ( 2%) 0.25 . 1.00** **M-Leukemia, mononuclear 1/50 ( 2%) 1/20 ( 5%) 1/20 ( 5%) 0/50 ( 0%) 0.50 0.50 0.28 Ulcer 0/50 ( 0%) 1/20 ( 5%) 0/20 ( 0%) 0/50 ( 0%) 0.70 0.69 0.29** **Tail Hyperplasia/hyperkeratosis 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 1/1 (100%) . . .** **Inflammation, acute 0/0 ( .%) 0/0 ( .%) 1/1 (100%) 0/1 ( 0%) 0.16 . 1.00 Inflammation, mixed 0/0 ( .%) 0/0 ( .%) 0/1 ( 0%) 1/1 (100%) 0.16 . 1.00** **Thyroid glands B-Adenoma, C-cell 1/50 ( 2%) 2/22 ( 9%) 3/22 ( 14%) 2/50 ( 4%) 0.57 0.91 0.16** **B-Adenoma, follicular cell 0/50 ( 0%) 0/22 ( 0%) 0/22 ( 0%) 2/50 ( 4%) 0.10 . 0.76 Cyst, follicular 0/50 ( 0%) 0/22 ( 0%) 1/22 ( 5%) 0/50 ( 0%) 0.70 0.70 0.31** **Hyperplasia, C-cell, focal 3/50 ( 6%) 4/22 ( 18%) 1/22 ( 5%) 6/50 ( 12%) 0.51 0.66 0.34 Hyperplasia, follicular cell 1/50 ( 2%) 0/22 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00** **M-Carcinoma, C-cell 1/50 ( 2%) 0/22 ( 0%) 0/22 ( 0%) 0/50 ( 0%) 0.24 . 1.00 M-Carcinoma, follicular cell 1/50 ( 2%) 0/22 ( 0%) 1/22 ( 5%) 0/50 ( 0%) 0.58 0.55 0.52** **M-Leukemia, mononuclear 0/50 ( 0%) 0/22 ( 0%) 0/22 ( 0%) 1/50 ( 2%) 0.24 . 1.00 Trachea** **Hyperplasia 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.66 1.00 Inflammation, acute 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.057 . 0.25** **Inflammation, mixed 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1.00 0.99 1.00 N-Leukemia, mononuclear 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 1.00 1.00 1.00** **Urinary bladder Hemorrhage 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 0/50 ( 0%) 0.25 . 1.00** **Hyperplasia, papillary 1/50 ( 2%) 0/20 ( 0%) 0/19 ( 0%) 0/50 ( 0%) 0.25 . 1.00 Inflammation, chronic 2/50 ( 4%) 0/20 ( 0%) 0/19 ( 0%) 3/50 ( 6%) 0.59 0.66 0.85** **M-Leukemia, mononuclear 1/50 ( 2%) 0/20 ( 0%) 1/19 ( 5%) 0/50 ( 0%) 0.59 0.58 0.28 ___________________________________________________________________________________________________________________________________** 

# O-19 Study Number FY01-013Table O-4. Statistical Evaluation of Microscopic Lesions in Females (Concluded)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Uterus** **Angiectasis 0/50 ( 0%) 0/24 ( 0%) 1/31 ( 3%) 0/50 ( 0%) 0.70 0.85 0.35 B-Adenoma, endometrial 0/50 ( 0%) 1/24 ( 4%) 0/31 ( 0%) 0/50 ( 0%) 0.67 0.57 0.15** **B-Polyp, endometrial stromal 5/50 ( 10%) 11/24 ( 46%) 11/31 ( 35%) 11/50 ( 22%) 0.22 0.22 0.003 14** **Dilatation 0/50 ( 0%) 1/24 ( 4%) 4/31 ( 13%) 3/50 ( 6%) 0.09 0.12 0.053 Hyperplasia, cystic endometrial 11/50 ( 22%) 4/24 ( 17%) 4/31 ( 13%) 11/50 ( 22%) 0.91 0.56 0.74** **Inflammation, chronic 3/50 ( 6%) 0/24 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.032 . 0.15 Inflammation, mixed 3/50 ( 6%) 0/24 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.032 . 0.15** **Intussusception 1/50 ( 2%) 1/24 ( 4%) 0/31 ( 0%) 2/50 ( 4%) 0.71 0.69 0.69 M-Adenocarcinoma, endometrial 0/50 ( 0%) 1/24 ( 4%) 2/31 ( 6%) 1/50 ( 2%) 0.44 0.59 0.22** **M-Leiomyosarcoma 0/50 ( 0%) 1/24 ( 4%) 1/31 ( 3%) 0/50 ( 0%) 0.98 0.96 0.12 M-Leukemia, mononuclear 2/50 ( 4%) 3/24 ( 13%) 0/31 ( 0%) 1/50 ( 2%) 0.29 0.31 0.12** **Vagina M-Leiomyosarcoma 0/0 ( .%) 1/1 (100%) 0/0 ( .%) 0/0 ( .%) . . .** **Zymbal's gland M-Carcinoma, squamous cell 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . .** **___________________________________________________________________________________________________________________________________ 14** **Pairwise Fisher’s exact tests: p=0.002 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.009 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.17 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.58 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.06 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.21 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-20 Study Number FY01-013Table O-5. Statistical Evaluationof Microscopic Lesions in Males**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Adrenal glands** **B-Pheochromocytoma, benign 7/49 ( 14%) 4/35 ( 11%) 5/30 ( 17%) 7/50 ( 14%) 0.91 0.79 0.95 B-Pheochromocytoma, complex, benign 1/49 ( 2%) 1/35 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.24 0.30 0.69** **Cyst 0/49 ( 0%) 0/35 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Degeneration, cytoplasmic vacuolization 5/49 ( 10%) 2/35 ( 6%) 2/30 ( 7%) 4/50 ( 8%) 0.73 0.55 0.94** **Hyperplasia, cortical, diffuse 0/49 ( 0%) 0/35 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.68 0.18 Hyperplasia, medullary, focal 8/49 ( 16%) 2/35 ( 6%) 5/30 ( 17%) 17/50 ( 34%) 0.013 0.039 0.011** **1 M-Leukemia, mononuclear 3/49 ( 6%) 1/35 ( 3%) 4/30 ( 13%) 2/50 ( 4%) 0.99 0.99 0.35** **M-Pheochromocytoma, malignant 3/49 ( 6%) 0/35 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 0.21 0.39 Necrosis 0/49 ( 0%) 0/35 ( 0%) 1/30 ( 3%) 1/50 ( 2%) 0.24 0.19 0.56** **Thrombus 2/49 ( 4%) 2/35 ( 6%) 3/30 ( 10%) 5/50 ( 10%) 0.21 0.27 0.61 Aorta** **Dilatation 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00 N-Leukemia, mononuclear - invasive involvement 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00** **Bone, femur Inflammation, acute 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00** **New bone formation, endosteal 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.79 0.84 1.00 Bone, other** **Hyperostosis 0/0 ( .%) 1/1 (100%) 0/0 ( .%) 0/1 ( 0%) 0.16 . 1.00 M-Sarcoma, NOS 0/0 ( .%) 0/1 ( 0%) 0/0 ( .%) 1/1 (100%) 0.16 . 1.00** **Brain Compression 6/50 ( 12%) 2/34 ( 6%) 2/31 ( 6%) 4/50 ( 8%) 0.51 0.36 0.85** **Ectasia, ventricular system 2/50 ( 4%) 0/34 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.08 . 0.33 Edema 0/50 ( 0%) 0/34 ( 0%) 0/31 ( 0%) 1/50 ( 2%) 0.21 . 1.00** **Gliosis 1/50 ( 2%) 0/34 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.22 . 1.00 Hemorrhage 1/50 ( 2%) 0/34 ( 0%) 2/31 ( 6%) 0/50 ( 0%) 0.82 0.95 0.18** **Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 2/31 ( 6%) 0/50 ( 0%) 0.55 0.53 0.034 2** **Inflammation, chronic 1/50 ( 2%) 0/34 ( 0%) 0/31 ( 0%) 0/50 ( 0%) 0.22 . 1.00 M-Astrocytoma, malignant 0/50 ( 0%) 1/34 ( 3%) 0/31 ( 0%) 1/50 ( 2%) 0.55 0.60 0.82** **Mineralization 0/50 ( 0%) 0/34 ( 0%) 0/31 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Necrosis 0/50 ( 0%) 0/34 ( 0%) 0/31 ( 0%) 1/50 ( 2%) 0.21 . 1.00** **___________________________________________________________________________________________________________________________________ 1** **Pairwise Fisher’s exact tests: p=0.18 for 0 g/m 3** **cf. 2 g/m 3** **; p=1.00 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.06 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.23 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.003 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.12 for 10 g/m** **3 cf. 20 g/m** **3 .** **2 Pairwise Fisher’s exact tests: p=0.14 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.22 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.14 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-21 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Bronchial (TBLN)** **Hemorrhage 0/49 ( 0%) 3/33 ( 9%) 0/28 ( 0%) 2/47 ( 4%) 0.53 0.66 0.07 N-Leukemia, mononuclear 10/49 ( 20%) 9/33 ( 27%) 7/28 ( 25%) 7/47 ( 15%) 0.48 0.48 0.55** **N-Sarcoma, histiocytic 0/49 ( 0%) 1/33 ( 3%) 0/28 ( 0%) 0/47 ( 0%) 0.70 0.71 0.39 Cecum** **N-Leukemia, mononuclear 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.08 . 0.34 Colon** **B-Leiomyoma 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/49 ( 2%) 0.21 . 0.69 Inflammation, mixed 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.22 . 1.00** **Epididymis Atrophy 4/50 ( 8%) 5/36 ( 14%) 1/31 ( 3%) 7/50 ( 14%) 0.56 0.89 0.36** **Granuloma, sperm 0/50 ( 0%) 1/36 ( 3%) 0/31 ( 0%) 0/50 ( 0%) 0.69 0.71 0.40 Inflammation, chronic 2/50 ( 4%) 0/36 ( 0%) 1/31 ( 3%) 0/50 ( 0%) 0.23 0.26 0.36** **M-Mesothelioma, malignant 0/50 ( 0%) 1/36 ( 3%) 0/31 ( 0%) 2/50 ( 4%) 0.22 0.26 0.47 Eyes/optic nerve** **Atrophy 1/50 ( 2%) 0/34 ( 0%) 0/33 ( 0%) 0/50 ( 0%) 0.21 . 1.00 Atrophy, retinal, unilateral 1/50 ( 2%) 0/34 ( 0%) 3/33 ( 9%) 1/50 ( 2%) 0.57 0.76 0.20** **Cataract 1/50 ( 2%) 0/34 ( 0%) 3/33 ( 9%) 1/50 ( 2%) 0.57 0.76 0.20 Degeneration 1/50 ( 2%) 0/34 ( 0%) 0/33 ( 0%) 0/50 ( 0%) 0.21 . 1.00** **Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 1/33 ( 3%) 1/50 ( 2%) 0.24 0.32 0.57 Inflammation, chronic 0/50 ( 0%) 0/34 ( 0%) 1/33 ( 3%) 0/50 ( 0%) 0.67 0.64 0.20** **Inflammation, mixed 1/50 ( 2%) 2/34 ( 6%) 0/33 ( 0%) 0/50 ( 0%) 0.23 0.25 0.26 M-Leukemia, mononuclear 1/50 ( 2%) 1/34 ( 3%) 0/33 ( 0%) 0/50 ( 0%) 0.24 0.31 0.82** **Metaplasia, osseous, scleral 3/50 ( 6%) 0/34 ( 0%) 0/33 ( 0%) 0/50 ( 0%) 0.030 . 0.11 Mineralization, corneal stromal 3/50 ( 6%) 0/34 ( 0%) 2/33 ( 6%) 1/50 ( 2%) 0.49 0.42 0.45** **Mineralization, scleral 3/50 ( 6%) 1/34 ( 3%) 6/33 ( 18%) 4/50 ( 8%) 0.35 0.41 0.17 Neovascularization, corneal 3/50 ( 6%) 0/34 ( 0%) 2/33 ( 6%) 0/50 ( 0%) 0.19 0.15 0.14** **Harderian gland N-Carcinoma, squamous cell 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . .** **Heart Degeneration, myocyte 2/50 ( 4%) 1/34 ( 3%) 3/30 ( 10%) 3/50 ( 6%) 0.46 0.57 0.65** **Fibrosis 5/50 ( 10%) 5/34 ( 15%) 2/30 ( 7%) 4/50 ( 8%) 0.54 0.47 0.74 Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.63 0.18** **Inflammation, focal, chronic 19/50 ( 38%) 9/34 ( 26%) 10/30 ( 33%) 19/50 ( 38%) 0.87 0.78 0.70 M-Leukemia, mononuclear 4/50 ( 8%) 5/34 ( 15%) 3/30 ( 10%) 5/50 ( 10%) 0.88 0.98 0.80** **Thrombus 0/50 ( 0%) 1/34 ( 3%) 2/30 ( 7%) 2/50 ( 4%) 0.18 0.23 0.27 ___________________________________________________________________________________________________________________________________** 

# O-22 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Ileum** **B-Fibroma 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.22 . 1.00 Hyperplasia, lymphoid 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.08 . 0.33** **N-Leukemia, mononuclear 0/50 ( 0%) 1/34 ( 3%) 0/30 ( 0%) 0/49 ( 0%) 0.69 0.83 0.39 Iliac LN** **Dilatation, sinusoidal 0/3 ( 0%) 0/1 ( 0%) 1/4 ( 25%) 0/2 ( 0%) 0.64 0.42 1.00 N-Leukemia, mononuclear 3/3 (100%) 1/1 (100%) 3/4 ( 75%) 2/2 (100%) 0.64 0.42 1.00** **Jejunum M-Adenocarcinoma 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.08 . 0.34** **Kidneys B-Adenoma, renal tubule 0/50 ( 0%) 0/50 ( 0%) 6/50 ( 12%) 2/50 ( 4%) 0.053 0.09 0.005** **3 Cyst 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 0/50 ( 0%) 0.79 0.76 0.62** **Degeneration, hyaline droplet 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.67 1.00 Infarct 0/50 ( 0%) 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0.53 0.33 0.25** **Inflammation, acute 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 0/50 ( 0%) 0.79 0.75 0.62 M-Carcinoma, renal tubule 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.53 0.61 1.00** **M-Leukemia, mononuclear 4/50 ( 8%) 3/50 ( 6%) 1/50 ( 2%) 1/50 ( 2%) 0.09 0.12 0.46 Nephropathy, chronic 44/50 ( 88%) 47/50 ( 94%) 50/50 (100%) 46/50 ( 92%) 0.25 0.63 0.07** **Pigment accumulation, tubular epithelium 3/50 ( 6%) 3/50 ( 6%) 1/50 ( 2%) 3/50 ( 6%) 0.77 0.99 0.77 Larynx** **Hyperplasia, epithelial 24/50 ( 48%) 15/49 ( 31%) 15/50 ( 30%) 24/50 ( 48%) 0.98 0.79 0.09 Inflammation, chronic 4/50 ( 8%) 2/49 ( 4%) 4/50 ( 8%) 3/50 ( 6%) 0.89 0.95 0.92** **Inflammation, mixed 40/50 ( 80%) 35/49 ( 71%) 41/50 ( 82%) 44/50 ( 88%) 0.17 0.34 0.24 Metaplasia, squamous 8/50 ( 16%) 3/49 ( 6%) 6/50 ( 12%) 6/50 ( 12%) 0.76 0.57 0.51** **Ulceration 1/50 ( 2%) 0/49 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 ___________________________________________________________________________________________________________________________________** **3 Pairwise Fisher’s exact tests: p=0.03 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.49 for 0 g/m** **3 cf. 20 g/m** **3 ; p=0.03 for 2 g/m** **3 cf. 10 g/m** **3 ;** **p=0.49 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.27 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-23 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Liver** **Angiectasis 15/50 ( 30%) 4/40 ( 10%) 8/38 ( 21%) 18/50 ( 36%) 0.32 0.49 0.026 4** **B-Adenoma, hepatocellular 1/50 ( 2%) 0/40 ( 0%) 1/38 ( 3%) 1/50 ( 2%) 0.80 0.95 0.89 Congestion 0/50 ( 0%) 0/40 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00** **Cyst 0/50 ( 0%) 0/40 ( 0%) 1/38 ( 3%) 0/50 ( 0%) 0.67 0.63 0.21 Fatty Change 2/50 ( 4%) 1/40 ( 3%) 1/38 ( 3%) 0/50 ( 0%) 0.20 0.19 0.62** **Foci of cellular alteration, basophilic 1/50 ( 2%) 1/40 ( 3%) 0/38 ( 0%) 0/50 ( 0%) 0.23 0.31 0.84 Hepatodiaphragmatic nodule 1/50 ( 2%) 1/40 ( 3%) 1/38 ( 3%) 2/50 ( 4%) 0.55 0.69 1.00** **Hyperplasia, biliary 45/50 ( 90%) 34/40 ( 85%) 37/38 ( 97%) 46/50 ( 92%) 0.38 0.47 0.28 Hyperplasia, hepatocellular, regenerative 1/50 ( 2%) 3/40 ( 8%) 3/38 ( 8%) 2/50 ( 4%) 0.65 0.69 0.52** **Inflammation, chronic 7/50 ( 14%) 1/40 ( 3%) 0/38 ( 0%) 6/50 ( 12%) 0.65 0.46 0.023 5** **M-Carcinoma, hepatocellular 1/50 ( 2%) 0/40 ( 0%) 0/38 ( 0%) 0/50 ( 0%) 0.20 . 1.00 M-Leukemia, mononuclear 27/50 ( 54%) 29/40 ( 73%) 29/38 ( 76%) 31/50 ( 62%) 0.37 0.31 0.12** **M-Sarcoma, histiocytic 0/50 ( 0%) 1/40 ( 3%) 0/38 ( 0%) 1/50 ( 2%) 0.54 0.50 0.84 M-Sarcoma, undifferentiated 0/50 ( 0%) 0/40 ( 0%) 1/38 ( 3%) 0/50 ( 0%) 0.67 0.79 0.21** **Necrosis 3/50 ( 6%) 4/40 ( 10%) 2/38 ( 5%) 4/50 ( 8%) 0.89 0.86 0.90 Thrombus 0/50 ( 0%) 0/40 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00** **Vacuolization, cytoplasmic 1/50 ( 2%) 3/40 ( 8%) 1/38 ( 3%) 3/50 ( 6%) 0.53 0.57 0.59 Lungs** **Alveolar histiocytosis 7/50 ( 14%) 10/50 ( 20%) 10/50 ( 20%) 11/50 ( 22%) 0.33 0.50 0.77 Autolysis, marked 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00** **B-Adenoma, bronchiolo-alveolar 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.53 0.51 1.00 Congestion 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0.53 0.82 0.25** **Cyst, squamous cell, keratinizing 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00 Fibrosis, focal 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1.00 0.95 1.00** **Hemorrhage 3/50 ( 6%) 7/50 ( 14%) 7/50 ( 14%) 1/50 ( 2%) 0.51 0.58 0.07 Hyperplasia, alveolar epithelial, focal 8/50 ( 16%) 7/50 ( 14%) 2/50 ( 4%) 4/50 ( 8%) 0.08 0.08 0.18** **Hyperplasia, alveolar epithelial, widespread 1/50 ( 2%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.25 1.00 Inflammation, acute 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0.79 0.72 1.00** **Inflammation, granulomatous 0/50 ( 0%) 2/50 ( 4%) 2/50 ( 4%) 1/50 ( 2%) 0.54 0.62 0.76 Inflammation, mixed 1/50 ( 2%) 1/50 ( 2%) 5/50 ( 10%) 2/50 ( 4%) 0.29 0.36 0.32** **Metaplasia, squamous - alveolar epithelium 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0.53 0.44 0.25 Mineralization, uremic 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0.18 . 1.00** **N-Leukemia, mononuclear - capillary involvement 24/50 ( 48%) 31/50 ( 62%) 32/50 ( 64%) 25/50 ( 50%) 0.80 0.66 0.27 N-Leukemia, mononuclear - invasive involvement 1/50 ( 2%) 1/50 ( 2%) 1/50 ( 2%) 1/50 ( 2%) 1.00 0.95 1.00** **N-Sarcoma, histiocytic 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 0/50 ( 0%) 0.53 0.55 0.25 ___________________________________________________________________________________________________________________________________** **4 Pairwise Fisher’s exact tests: p=0.04 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.46 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.67 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=0.22 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.006 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.16 for 10 g/m 3** **cf. 20 g/m 3** **. 5** **Pairwise Fisher’s exact tests: p=0.07 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.018 for 0 g/m 3** **cf. 10 g/m 3** **; p=1.00 for 0 g/m 3** **cf. 20 g/m 3** **; p=1.00 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.13 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.03 for 10 g/m** **3 cf. 20 g/m** **3 .** 

# O-24 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Lymph node other** **Dilatation, sinusoidal 0/6 ( 0%) 1/4 ( 25%) 0/9 ( 0%) 0/7 ( 0%) 0.55 0.71 0.15 Infiltration, histiocytic 0/6 ( 0%) 1/4 ( 25%) 1/9 ( 11%) 0/7 ( 0%) 0.84 0.66 0.51** **N-Leukemia, mononuclear 5/6 ( 83%) 2/4 ( 50%) 7/9 ( 78%) 6/7 ( 86%) 0.70 0.49 0.65 Sinus plasmacytosis 1/6 ( 17%) 0/4 ( 0%) 0/9 ( 0%) 1/7 ( 14%) 0.84 0.67 0.64** **Mammary gland B-Fibroadenoma 0/36 ( 0%) 0/31 ( 0%) 0/29 ( 0%) 1/47 ( 2%) 0.24 . 1.00** **B-Fibroma 2/36 ( 6%) 2/31 ( 6%) 3/29 ( 10%) 1/47 ( 2%) 0.57 0.53 0.49 Cyst 0/36 ( 0%) 0/31 ( 0%) 1/29 ( 3%) 0/47 ( 0%) 0.74 0.80 0.20** **Ectasia 1/36 ( 3%) 0/31 ( 0%) 0/29 ( 0%) 1/47 ( 2%) 0.90 0.88 1.00 Hyperplasia, lobular 0/36 ( 0%) 1/31 ( 3%) 0/29 ( 0%) 5/47 ( 11%) 0.025 0.16 0.056** **N-Sarcoma, histiocytic 0/36 ( 0%) 2/31 ( 6%) 0/29 ( 0%) 0/47 ( 0%) 0.46 0.48 0.09 Mandibular LN** **Hemorrhage 1/40 ( 3%) 0/32 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.18 . 0.68 Hyperplasia, lymphoid 1/40 ( 3%) 0/32 ( 0%) 1/30 ( 3%) 0/48 ( 0%) 0.49 0.51 0.45** **N-Leukemia, mononuclear 13/40 ( 33%) 10/32 ( 31%) 9/30 ( 30%) 9/48 ( 19%) 0.14 0.15 0.42 Sinus plasmacytosis 1/40 ( 3%) 0/32 ( 0%) 0/30 ( 0%) 0/48 ( 0%) 0.18 . 0.68** **Mediastinal LN Hemorrhage 2/49 ( 4%) 1/30 ( 3%) 2/30 ( 7%) 2/50 ( 4%) 0.89 0.98 0.91** **N-Leukemia, mononuclear 9/49 ( 18%) 7/30 ( 23%) 5/30 ( 17%) 8/50 ( 16%) 0.64 0.62 0.86 N-Sarcoma, histiocytic 0/49 ( 0%) 1/30 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.68 0.68 0.38** **Pigmentation 0/49 ( 0%) 1/30 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.68 0.75 0.38 Mediastinum** **N-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) . . . Mesenteric LN** **Hemorrhage 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00 Histiocytosis, sinus 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00** **N-Leukemia, mononuclear 6/50 ( 12%) 3/34 ( 9%) 5/30 ( 17%) 6/50 ( 12%) 0.81 0.74 0.84 N-Sarcoma, histiocytic 0/50 ( 0%) 1/34 ( 3%) 0/30 ( 0%) 0/50 ( 0%) 0.69 0.69 0.39** **Mesentery Inflammation, mixed 0/0 ( .%) 1/1 (100%) 0/1 ( 0%) 0/0 ( .%) 0.16 . 1.00** **M-Mesothelioma, malignant 0/0 ( .%) 0/1 ( 0%) 1/1 (100%) 0/0 ( .%) 0.16 . 1.00 ___________________________________________________________________________________________________________________________________** 

# O-25 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Muscle, skeletal** **Inflammation, chronic 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.46 0.18 M-Leukemia, mononuclear 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.69 0.18** **N-Sarcoma, histiocytic 0/50 ( 0%) 2/34 ( 6%) 0/30 ( 0%) 0/50 ( 0%) 0.57 0.57 0.07 Nose/Turbinate 1** **Degeneration - respiratory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 Degeneration, hyaline - respiratory epithelium 0/50 ( 0%) 3/50 ( 6%) 5/50 ( 10%) 3/50 ( 6%) 0.13 0.12 0.15** **Hyperplasia - respiratory epithelium 3/50 ( 6%) 0/50 ( 0%) 3/50 ( 6%) 4/50 ( 8%) 0.38 0.21 0.23 Inflammation - nasolacrimal duct 11/50 ( 22%) 11/50 ( 22%) 15/50 ( 30%) 12/50 ( 24%) 0.61 0.60 0.78** **Inflammation - respiratory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1.00 0.98 1.00 Inflammation, mixed 7/50 ( 14%) 5/50 ( 10%) 8/50 ( 16%) 6/50 ( 12%) 1.00 0.91 0.89** **M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 Metaplasia, squamous - respiratory epithelium 3/50 ( 6%) 2/50 ( 4%) 1/50 ( 2%) 0/50 ( 0%) 0.06 0.060 0.52** **Metaplasia, squamous - transitional epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 Nose/Turbinate 2** **Degeneration - olfactory epithelium 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 Degeneration - respiratory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 . 1.00** **Degeneration, hyaline - olfactory epithelium 0/50 ( 0%) 5/50 ( 10%) 7/50 ( 14%) 6/50 ( 12%) 0.027 0.026 0.032 6** **Degeneration, hyaline - respiratory epithelium 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 3/50 ( 6%) 0.06 0.10 0.52 Hyperplasia - respiratory epithelium 0/50 ( 0%) 2/50 ( 4%) 2/50 ( 4%) 3/50 ( 6%) 0.12 0.12 0.52** **Inflammation, mixed 4/50 ( 8%) 6/50 ( 12%) 3/50 ( 6%) 5/50 ( 10%) 1.00 0.97 0.84 M-Carcinoma, squamous cell 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00** **M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 Metaplasia, secretory - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.63 1.00** **Metaplasia, squamous - olfactory epithelium 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.59 1.00 Metaplasia, squamous - respiratory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.72 1.00** **Nose/Turbinate 3 Degeneration, hyaline - olfactory epithelium 2/50 ( 4%) 1/50 ( 2%) 7/50 ( 14%) 7/50 ( 14%) 0.017 0.026 0.054** **Inflammation, mixed 4/50 ( 8%) 1/50 ( 2%) 1/50 ( 2%) 3/50 ( 6%) 0.65 0.53 0.46 M-Carcinoma, squamous cell 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.53 0.56 1.00** **M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 __________________________________________________________________________________________________________________________________** **6 Pairwise Fisher’s exact tests: p=0.06 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.012 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.03 for 0 g/m** **3 cf. 20 g/m** **3 ;** **p=0.76 for 2 g/m 3** **cf. 10 g/m 3** **; p=1.00 for 2 g/m 3** **cf. 20 g/m 3** **; p=1.00 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-26 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Nose/Turbinate 4** **Degeneration - olfactory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.65 0.72 1.00 Degeneration, hyaline - olfactory epithelium 0/50 ( 0%) 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 0.20 0.29 1.00** **Inflammation, mixed 2/50 ( 4%) 0/50 ( 0%) 1/50 ( 2%) 2/50 ( 4%) 0.84 0.89 0.76 M-Leukemia, mononuclear 1/50 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00** **N-Carcinoma, squamous cell 0/50 ( 0%) 2/50 ( 4%) 0/50 ( 0%) 2/50 ( 4%) 0.37 0.39 0.34 Pancreas** **M-Carcinoma, ductal cell 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/49 ( 2%) 0.21 . 0.69 M-Leukemia, mononuclear 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.22 . 1.00** **Pancreatic LN N-Leukemia, mononuclear 5/5 (100%) 2/2 (100%) 2/2 (100%) 4/4 (100%) . . .** **Parathyroid Hyperplasia, diffuse 0/45 ( 0%) 0/33 ( 0%) 0/30 ( 0%) 1/46 ( 2%) 0.21 . 1.00** **Hyperplasia, focal 0/45 ( 0%) 0/33 ( 0%) 0/30 ( 0%) 2/46 ( 4%) 0.07 . 0.34 Pituitary gland** **Angiectasis 2/49 ( 4%) 0/37 ( 0%) 0/34 ( 0%) 3/50 ( 6%) 0.57 0.61 0.29 B-Adenoma, pars distalis 9/49 ( 18%) 9/37 ( 24%) 6/34 ( 18%) 5/50 ( 10%) 0.20 0.15 0.34** **Cyst 4/49 ( 8%) 7/37 ( 19%) 7/34 ( 21%) 6/50 ( 12%) 0.58 0.65 0.31 Hemorrhage 3/49 ( 6%) 0/37 ( 0%) 0/34 ( 0%) 2/50 ( 4%) 0.57 0.55 0.27** **Hyperplasia, pars distalis, focal 5/49 ( 10%) 4/37 ( 11%) 3/34 ( 9%) 8/50 ( 16%) 0.42 0.42 0.78 Inflammation, chronic 0/49 ( 0%) 0/37 ( 0%) 0/34 ( 0%) 1/50 ( 2%) 0.21 . 1.00** **M-Leukemia, mononuclear 1/49 ( 2%) 1/37 ( 3%) 1/34 ( 3%) 1/50 ( 2%) 1.00 0.86 1.00 Popliteal LN** **N-Leukemia, mononuclear 2/2 (100%) 0/0 ( .%) 2/2 (100%) 2/2 (100%) . . . Preputial gland** **Cyst, epithelial inclusion 0/4 ( 0%) 0/1 ( 0%) 1/3 ( 33%) 0/2 ( 0%) 0.53 . 0.60 Ectasia 2/4 ( 50%) 1/1 (100%) 2/3 ( 67%) 2/2 (100%) 0.27 0.28 0.80** **Inflammation, chronic 1/4 ( 25%) 0/1 ( 0%) 0/3 ( 0%) 1/2 ( 50%) 0.79 . 0.73 Inflammation, mixed 3/4 ( 75%) 0/1 ( 0%) 0/3 ( 0%) 1/2 ( 50%) 0.23 0.31 0.20** **Prostate Atrophy 3/50 ( 6%) 0/33 ( 0%) 0/29 ( 0%) 5/50 ( 10%) 0.36 0.63 0.13** **Hemorrhage 0/50 ( 0%) 0/33 ( 0%) 0/29 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Hyperplasia 0/50 ( 0%) 0/33 ( 0%) 1/29 ( 3%) 0/50 ( 0%) 0.67 0.70 0.18** **Inflammation, acute 2/50 ( 4%) 1/33 ( 3%) 0/29 ( 0%) 0/50 ( 0%) 0.10 0.19 0.46 Inflammation, mixed 15/50 ( 30%) 12/33 ( 36%) 16/29 ( 55%) 13/50 ( 26%) 0.97 0.80 0.06** **Mineralization 1/50 ( 2%) 0/33 ( 0%) 0/29 ( 0%) 0/50 ( 0%) 0.22 . 1.00 __________________________________________________________________________________________________________________________________** 

# O-27 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Salivary gland** **Degeneration 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 0/30 ( 0%) 1/50 ( 2%) 0.21 . 1.00** **M-Leukemia, mononuclear 0/50 ( 0%) 0/34 ( 0%) 2/30 ( 7%) 1/50 ( 2%) 0.22 0.29 0.17 Sciatic nerve** **N-Leukemia, mononuclear 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00 Seminal vesicle** **Atrophy 15/50 ( 30%) 2/35 ( 6%) 8/37 ( 22%) 18/50 ( 36%) 0.28 0.67 0.006 7** **Dilatation 0/50 ( 0%) 1/35 ( 3%) 1/37 ( 3%) 1/50 ( 2%) 0.47 0.67 0.78 Hyperplasia 0/50 ( 0%) 1/35 ( 3%) 0/37 ( 0%) 0/50 ( 0%) 0.67 . 0.20** **M-Leukemia, mononuclear 1/50 ( 2%) 0/35 ( 0%) 1/37 ( 3%) 0/50 ( 0%) 0.54 0.51 0.83 Skin** **B-Fibroma 2/49 ( 4%) 0/37 ( 0%) 1/35 ( 3%) 0/50 ( 0%) 0.22 0.28 0.32 B-Keratoacanthoma 0/49 ( 0%) 0/37 ( 0%) 0/35 ( 0%) 1/50 ( 2%) 0.21 . 1.00** **B-Tumor, basal cell, benign 0/49 ( 0%) 0/37 ( 0%) 0/35 ( 0%) 1/50 ( 2%) 0.21 . 1.00 B-Tumor, hair follicle, benign 0/49 ( 0%) 0/37 ( 0%) 1/35 ( 3%) 0/50 ( 0%) 0.67 0.80 0.20** **Cyst, epithelial inclusion 0/49 ( 0%) 0/37 ( 0%) 0/35 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Fibrosis 1/49 ( 2%) 2/37 ( 5%) 0/35 ( 0%) 0/50 ( 0%) 0.22 0.23 0.23** **Hyperkeratosis 1/49 ( 2%) 1/37 ( 3%) 2/35 ( 6%) 0/50 ( 0%) 0.67 0.56 0.34 Inflammation, chronic 1/49 ( 2%) 0/37 ( 0%) 0/35 ( 0%) 0/50 ( 0%) 0.20 . 0.71** **Inflammation, mixed 0/49 ( 0%) 3/37 ( 8%) 2/35 ( 6%) 0/50 ( 0%) 0.84 0.76 0.026 8** **M-Carcinoma, sebaceous cell 0/49 ( 0%) 1/37 ( 3%) 0/35 ( 0%) 0/50 ( 0%) 0.67 . 0.42 M-Sarcoma, undifferentiated 0/49 ( 0%) 1/37 ( 3%) 2/35 ( 6%) 0/50 ( 0%) 0.81 0.84 0.09** **N-Sarcoma, histiocytic 0/49 ( 0%) 2/37 ( 5%) 0/35 ( 0%) 0/50 ( 0%) 0.55 0.56 0.09 Necrosis 0/49 ( 0%) 1/37 ( 3%) 0/35 ( 0%) 0/50 ( 0%) 0.67 0.68 0.42** **Spinal cord Degeneration, white matter 1/50 ( 2%) 0/34 ( 0%) 0/30 ( 0%) 0/50 ( 0%) 0.22 . 1.00** **Hemorrhage 1/50 ( 2%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.57 0.82 0.56 Inflammation, acute 0/50 ( 0%) 0/34 ( 0%) 1/30 ( 3%) 0/50 ( 0%) 0.67 0.63 0.18** **___________________________________________________________________________________________________________________________________ 7** **Pairwise Fisher’s exact tests: p=0.006 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.46 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.67 for 0 g/m 3** **cf. 20 g/m 3** **; p=0.09 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.001 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.16 for 10 g/m** **3 cf. 20 g/m** **3 .** **8 Pairwise Fisher’s exact tests: p=0.08 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.17 for 0 g/m** **3 cf. 10 g/m** **3 ; p=1.00 for 2 g/m** **3 cf. 10 g/m** **3 ;** **p=0.07 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.17 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-28 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Continued)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Spleen** **Congestion 0/50 ( 0%) 1/39 ( 3%) 1/38 ( 3%) 0/50 ( 0%) 1.00 1.00 0.35 Fibrosis 3/50 ( 6%) 2/39 ( 5%) 5/38 ( 13%) 0/50 ( 0%) 0.41 0.36 0.052** **Hemorrhage 0/50 ( 0%) 1/39 ( 3%) 0/38 ( 0%) 0/50 ( 0%) 0.67 0.65 0.44 M-Fibrosarcoma 0/50 ( 0%) 0/39 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00** **M-Leukemia, mononuclear 27/50 ( 54%) 31/39 ( 79%) 31/38 ( 82%) 31/50 ( 62%) 0.39 0.36 0.012 9** **N-Sarcoma, histiocytic 0/50 ( 0%) 0/39 ( 0%) 0/38 ( 0%) 1/50 ( 2%) 0.20 . 1.00 Necrosis 2/50 ( 4%) 2/39 ( 5%) 1/38 ( 3%) 1/50 ( 2%) 0.48 0.50 0.94** **Stomach Hyperplasia, squamous epithelial 2/50 ( 4%) 0/34 ( 0%) 0/30 ( 0%) 0/49 ( 0%) 0.08 . 0.33** **Inflammation, mixed 2/50 ( 4%) 1/34 ( 3%) 0/30 ( 0%) 0/49 ( 0%) 0.10 0.18 0.47 Tail** **Cyst, epithelial inclusion 0/1 ( 0%) 1/2 ( 50%) 0/1 ( 0%) 0/0 ( .%) 1.00 . 1.00 Hyperplasia/hyperkeratosis 0/1 ( 0%) 2/2 (100%) 1/1 (100%) 0/0 ( .%) 0.10 . 0.50** **Inflammation, acute 1/1 (100%) 0/2 ( 0%) 0/1 ( 0%) 0/0 ( .%) 0.10 . 0.50 Inflammation, mixed 0/1 ( 0%) 2/2 (100%) 1/1 (100%) 0/0 ( .%) 0.10 . 0.50** **Testes Atrophy 1/50 ( 2%) 4/50 ( 8%) 3/50 ( 6%) 5/50 ( 10%) 0.16 0.19 0.49** **B-Adenoma, interstitial cell 43/50 ( 86%) 47/50 ( 94%) 48/50 ( 96%) 50/50 (100%) 0.003 0.026 0.029 10** **Hemorrhage 0/50 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 1/50 ( 2%) 0.53 0.42 1.00 Hyperplasia, interstitial cell 5/50 ( 10%) 6/50 ( 12%) 3/50 ( 6%) 2/50 ( 4%) 0.16 0.45 0.50** **M-Mesothelioma, malignant 0/50 ( 0%) 1/50 ( 2%) 1/50 ( 2%) 2/50 ( 4%) 0.18 0.21 0.90 Thymus** **Hemorrhage 0/1 ( 0%) 0/0 ( .%) 0/0 ( .%) 1/2 ( 50%) 0.39 . 1.00 M-Leukemia, mononuclear 1/1 (100%) 0/0 ( .%) 0/0 ( .%) 1/2 ( 50%) 0.39 . 1.00** **Thyroid glands B-Adenoma, C-cell 3/50 ( 6%) 4/35 ( 11%) 4/31 ( 13%) 3/50 ( 6%) 0.97 0.93 0.59** **B-Adenoma, follicular cell 2/50 ( 4%) 0/35 ( 0%) 0/31 ( 0%) 3/50 ( 6%) 0.56 0.73 0.42 Cyst, follicular 1/50 ( 2%) 1/35 ( 3%) 3/31 ( 10%) 3/50 ( 6%) 0.22 0.27 0.38** **Hyperplasia, C-cell, focal 4/50 ( 8%) 2/35 ( 6%) 0/31 ( 0%) 7/50 ( 14%) 0.38 0.59 0.14 Hyperplasia, follicular cell 0/50 ( 0%) 0/35 ( 0%) 1/31 ( 3%) 0/50 ( 0%) 0.67 0.80 0.19** **M-Carcinoma, C-cell 0/50 ( 0%) 2/35 ( 6%) 0/31 ( 0%) 0/50 ( 0%) 0.56 0.52 0.08 M-Carcinoma, follicular cell 1/50 ( 2%) 0/35 ( 0%) 1/31 ( 3%) 3/50 ( 6%) 0.18 0.26 0.53** **___________________________________________________________________________________________________________________________________ 9** **Pairwise Fisher’s exact tests: p=0.014 for 0 g/m 3** **cf. 2 g/m 3** **; p=0.012 for 0 g/m 3** **cf. 10 g/m 3** **; p=0.54 for 0 g/m 3** **cf. 20 g/m 3** **; p=1.00 for 2 g/m** **3 cf. 10 g/m** **3 ; p=0.10 for 2 g/m** **3 cf. 20 g/m** **3 ; p=0.06 for 10 g/m** **3 cf. 20 g/m** **3 .** **10 Pairwise Fisher’s exact tests: p=0.32 for 0 g/m** **3 cf. 2 g/m** **3 ; p=0.16 for 0 g/m** **3 cf. 10 g/m** **3 ; p=0.012 for 0 g/m** **3 cf. 20g/m** **3 ;** **p=1.00 for 2 g/m 3** **cf. 10 g/m 3** **; p=0.24 for 2 g/m 3** **cf. 20 g/m 3** **; p=0.49 for 10 g/m 3** **cf. 20 g/m 3** **.**

# O-29 Study Number FY01-013Table O-5. Statistical Evaluation of Microscopic Lesions inMales (Concluded)**___________________________________________________________________________________________________________________________________ Cochran Fisher's** **Exposure Concentration (g/m 3** **) Armitage Logistic Exact Tissue and Diagnosis 0 2 10 20 p-value p-value p-value** **___________________________________________________________________________________________________________________________________ Tiss.not specified** **B-Fibroma 0/1 ( 0%) 0/2 ( 0%) 1/3 ( 33%) 0/5 ( 0%) 0.92 . 0.55 B-Lipoma 1/1 (100%) 0/2 ( 0%) 0/3 ( 0%) 1/5 ( 20%) 0.35 0.29 0.25** **Cyst 0/1 ( 0%) 0/2 ( 0%) 0/3 ( 0%) 1/5 ( 20%) 0.34 . 1.00 Inflammation, mixed 0/1 ( 0%) 0/2 ( 0%) 1/3 ( 33%) 0/5 ( 0%) 0.92 . 0.55** **M-Mesothelioma, malignant 0/1 ( 0%) 0/2 ( 0%) 0/3 ( 0%) 2/5 ( 40%) 0.15 . 0.73 Mammary tissue 0/1 ( 0%) 0/2 ( 0%) 1/3 ( 33%) 0/5 ( 0%) 0.92 0.80 0.55** **Myodegeneration 0/1 ( 0%) 1/2 ( 50%) 0/3 ( 0%) 0/5 ( 0%) 0.25 0.33 0.27 N-Sarcoma, histiocytic 0/1 ( 0%) 1/2 ( 50%) 0/3 ( 0%) 0/5 ( 0%) 0.25 . 0.27** **Splenic tissue, "accessory" 0/1 ( 0%) 0/2 ( 0%) 0/3 ( 0%) 1/5 ( 20%) 0.34 . 1.00 Trachea** **Hyperplasia, epithelial 1/50 ( 2%) 1/49 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.20 0.25 0.62 Inflammation, acute 0/50 ( 0%) 1/49 ( 2%) 0/50 ( 0%) 0/50 ( 0%) 0.65 0.59 0.25** **Inflammation, chronic 1/50 ( 2%) 2/49 ( 4%) 1/50 ( 2%) 1/50 ( 2%) 0.84 0.93 0.82 Inflammation, mixed 1/50 ( 2%) 1/49 ( 2%) 0/50 ( 0%) 4/50 ( 8%) 0.14 0.17 0.15** **Metaplasia, squamous 1/50 ( 2%) 0/49 ( 0%) 0/50 ( 0%) 0/50 ( 0%) 0.18 . 1.00 N-Leukemia, mononuclear 2/50 ( 4%) 0/49 ( 0%) 1/50 ( 2%) 0/50 ( 0%) 0.19 0.21 0.62** **Urinary bladder B-Papilloma, transitional cell 1/50 ( 2%) 0/33 ( 0%) 0/29 ( 0%) 0/50 ( 0%) 0.22 . 1.00** **Hemorrhage 0/50 ( 0%) 0/33 ( 0%) 0/29 ( 0%) 1/50 ( 2%) 0.21 . 1.00 Inflammation, chronic 3/50 ( 6%) 0/33 ( 0%) 0/29 ( 0%) 3/50 ( 6%) 0.98 0.86 0.39** **Inflammation, mixed 0/50 ( 0%) 0/33 ( 0%) 0/29 ( 0%) 1/50 ( 2%) 0.21 . 1.00 M-Leukemia, mononuclear 1/50 ( 2%) 1/33 ( 3%) 0/29 ( 0%) 1/50 ( 2%) 0.82 0.73 1.00** **Zymbal's gland M-Carcinoma, squamous cell 0/0 ( .%) 0/0 ( .%) 0/0 ( .%) 1/1 (100%) . . .** **___________________________________________________________________________________________________________________________________**

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

May 2010

P-1 APPENDIX P

PATHOLOGIST’S REPORT

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-3 INTRODUCTION

Four hundred (400) F344 rats exposed to gasoline MTBE vapor c ondensate (GMVC) in

whole body inhalation exposure chambers were ex amined. Males and females were divided

equally into 4 groups (50 males and 50 females per group) and exposed to 0 g/m 3 

# , 2 g/m 3



# ,

10 g/m 3 

# or 20 g/m 3 

# GMVC for 6 hours/day, 5 days/week for 104 weeks (520 exposure days).

The sole scheduled sacrifice occurred after 104 weeks (520 days) of exposure. Gross necropsy

and tissue collection was pe rformed as specified in the main report text.

METHODS

Hematology

Blood was collected on control and high-level GMVC rats by tail nick at 12 and 18

months of exposure and was collected from a ll final sacrifice rats by cardiac puncture for

assessment of total and differential white bl ood cell counts. Duplicate blood smears were

prepared and read manually for the control and high-le vel groups at all three time points.

Percentages of each nucleated cell type were coun ted. An estimate of the number of white blood

cells in each sample was made according to L RRI SOP. Absolute numbers of each cell type

were calculated by multiplying the fraction of each cell type by the estimated white blood cell

count.

Gross Pathology

As expected in a chronic study, a wide spectrum of gross lesions was documented at

necropsy. Complete gross lesion incidences as well as correlation of gross and histologic lesions

are located in Appendix M (males) and N (females). Gross lesions were examined histologically

in all groups.

Histopathology

All study animals received a complete necropsy. Animals were euthanized with an

overdose of intraperitoneally injected barbiturate anesthetic (Euthasol ® 

# , Virbac AH Inc., Fort

Worth, TX). Body weights and fresh organ weig hts were collected on lungs, liver, kidneys,

adrenals, testes, epididymides, ovaries, uterus, spleen, brain and heart of final sacrifice and

moribund sacrifice animals. An imals found dead received a complete necropsy with tissue

collection, but blood and organ weight data were not routinely collected. Cardiac blood was

collected from animals at final sacrifice for de termination of total a nd differential white blood

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-4 cell counts. Gross lesions, body weights, and organ weights were entered on pre-prepared forms

and then the information was recorded on the Path-Tox database (Version 4.2.2, Module P,

Xybion Medical Systems, Cedar Knolls, NJ).

Lungs were gently instilled via the trachea with 10% neutra l buffered formalin (NBF) to

approximate normal volume. Organs/tissues were immersion fixed in 10% NBF for subsequent

histopathologic examination. Tissues were trimmed, processed routinely, paraffin embedded,

sectioned at 5 μm and stained with hematoxylin and eosin for histopat hologic examination.

All collected tissues and lesions were exam ined histologically in control (0 g/m 3 

# )

animals, high- (20 g/m 3 

# ) level animals, and dead or moribund animals of all groups. Respiratory

tissues (lungs, larynx, trachea and nasal turbinate sections), potential ta rget tissues (testes,

kidneys of males) and gross lesions were examined histologically from fi nal sacrifice low- (2

g/m 3 

# ) and mid- (10 g/m 3 

# ) level animals. Nomenclature of proliferative lesions was based on the

international harmonized nomenclature recomm ended by the Rat Nomenclature Reconciliation

Subcommittee of the Society of Toxicologic Pathologists (see http://www.toxpath.org;

Standardized Rat Nomenclature). Nomenclature of other lesions was routine, widely understood

usage (see Boorman et al., 1990a; Gopinath et al., 1987).

Standard, subjective severity scoring of most nonprolifera tive lesions was based on the

extent of tissue affected by the change and the severity of the change within affected areas.

Typically, a score of 0 (none) = es sentially no tissue a ffected; 1 (minimal) = ~1 to 10% affected,

2 (mild) = ~11 to 25% affected, 3 (moderate) = ~26 to 50% affect ed, 4 (marked) = ~51 to 100%

affected. Severity scores may have been adju sted up or down (usually by 1 point) based on the

intensity of the change within the affected areas.

Because the diagnosis of chronic progre ssive nephropathy encompasses a large

constellation of changes, severity scoring for th is diagnosis was somewhat more complex and is

described in Table P-1.

Statistical Analyses

Statistical analyses of both hematology and histopathology data were conducted as

detailed in the statistician’s report (Appendix O). In the cas e of renal tubule nephropathy and

nasal epithelial degeneration, statistical evaluation of group differences in severity scores was

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-5 performed using the Kolmogorov-Smirnov test with in the Path-Tox software (significance level

p = 0.05; c.f. Algorithms used in Path/Tox System 4.2.2; Vol. I, Chap. 7, pp. 24-25).

Table P-1. Severity Scoring of Chronic Progressive Nephropathy

Score Histologic Findings

0 Essentially no changes of CPN. May have rare scattered prot ein casts in tubules,

mineral concretions.

1 Increased number and size of tubular protein casts; prim arily within tubules at the

corticomedullary junction, some within co llecting ducts. Minor/scattered foci of

basophilic, regenerative tubules. Changes affect less than ~5% of tissue component.

2 Homogeneous protein casts relatively abunda nt within tubules and collecting ducts

(especially at corticomedullary junction). Increased size and fr equency of tubular

basophilia. Accompanying cha nges present, may include small foci of tubular basement

membrane thickening and/or mineralization, interstitial fibrosis , tubular atrophy and

dilatation, minor associated m ononuclear inflammatory infilt rates, glomerular changes

(including mesangial prolifera tion, synechiae, proliferation of parietal epithelium).

Changes may affect up to ~25% of component.

3 As 2 with increased tubu lar atrophy/dilatation/regenera tion, interstitial fibrosis,

increased inflammatory infiltrates, increas ed thickening of basement membranes of

tubules and glomeruli.

4 As 3 with increased severity and extent of changes. Se nescent glomeruli relatively

common. Typically combined change s affect well over 50% of kidney.

RESULTS

Hematology

The high incidence of leukemia in aged F344 rats, other physiologic changes with aging,

sampling differences between time points a nd the limitations of manual hematology ( e.g. , the

small numbers of leukocytes other than neutroph ils and lymphocytes counted) dictate that the

hematology results be interpreted with caution. Trend tests within a group across all sampling

periods frequently show a statistical difference, but are not ex pected to be biologically significant

for the reasons noted above (some specific examples follow). A statistically significant increase

relative to controls in WBC es timate, “absolute” neutrophils, and “absolute” lymphocytes was

noted in high-level group males at 12 months. This change is not present in females and does

not persist in males at 18 or 24 months. It is interpreted as an excitement response probably

resulting from initial blood sampling difficulties. The increase in atypical lymphocytes in both

the control and the high-level group at 24 months is consistentwith the high incidence of

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-6 leukemia in these aged F344 rats. Other statis tically significant cha nges are unlikely to be

biologically significant based on th e small numbers of leukocytes of that type (such as band

neutrophils, monocytes or eosinoph ils) counted in blood smears.

Histopathology

Condensed tables including only microscopic lesions judged to be more relevant as

potential effects of GMVC exposure or those fo r which reviewers indicated an interest are

presented below. Note that all microscopic findings are not included here; refer to the summary

tables in Appendices M and N for a complete listing. Though some comparisons are included

here, see GMVC main report for more complete comparison between findings from this study

and the Baseline Gasoline Vapor Conde nsate (BGVC) study run concurrently.

Proliferative Lesions . Proliferative lesions include hyperplasias and neoplasias (both benign and

malignant). As is evident in the complete lesion incidence summary tables (Appendices M and

N), scattered hyperplasias and neoplasias occur relatively commonly in aged F344 male and

female rats.

Male rats in the mid-level GMVC group de monstrated a significant increase in the

incidence of renal tubule cell ad enomas in mid-dose animals, with 0/50 (0%), 0/50 (0%), 6/50

(12%) and 2/50 (4%) in the control, low, mi d and high groups, respectively (Table P-2).

Although not statistical ly significant alone, there was also an increase in renal tubule carcinomas

in the males (1/50; 2% in low- and 1/50; 2% in high-level males). Combining adenomas and

carcinomas for analysis maintained the statistic ally significant increase in tumors in mid-dose

animals, and additionally showed a significant tr end toward increased incidence with increased

exposure concentration (Table P-2).

Squamous cell carcinoma occurred in nasal se ctions of males with an animal incidence

(incidence of tumor occurring in any of turbinates 2–4) of 1/50 (2%), 2/50 (4%), 0/50 (0%) and

2/50 (4%) for control, low-, mid- and high-dos e animals, respectively, with no statistically

significant differences or trends. In all instances, the tumors were judged to have arisen in the

oral cavity (Appendix M-6). Animal incidence is relevant because the same tumor may occur in

more than one nasal section. This is true for the low- and high-level groups for male nasal

turbinates 3 and 4 (Table P-2), where one anim al in each group has a tumor spanning levels 3

and 4.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-7 No significant changes in in cidence were seen for thyroi d follicular cell adenoma or

carcinoma. Combining thyroid follicular cell adenoma and carcinoma in male rats gave a

combined incidence of 3/50 (6%), 0/35 (0%), 1/31 (3%) and 5/50 (10%) for control, low-, midand high-level groups, respectively. No statis tical signficance was found upon combining the

incidinces of adenomas and carcinomas. Note that one high-dose male had both an adenoma and

a carcinoma, yielding a combined incidence of 5/50 (10%). However, even when counting

adenoma and carcinoma in this animal individua lly, yielding an incidenc e 6/50 (12%) for this

group (arguably the most conservative combined in cidence from a risk a ssessment perspective)

the difference is not significant using Fisher’s exact test; p = 0.130. See e-mail correspondence

from statistician including statistical test in study file). A statistically significant increase in

thyroid follicular cell carcinom as (but not combined adenomas and carcinomas) was observed

among males in the Baseline Gasoline Vapor Condensate study run concurrently (FY01-027).

As expected, there was a high background inciden ce of testicular inters titial adenomas in

control male rats (43/50; 86%). There was a significant trend toward increased incidence with

increased dose (with 47/50; 94% in lows a nd 48/50; 96% in mids), and the incidence among

high-level males (50/50; 100%) was significantly greater than the c ontrol incidence (Table P-2).

Essentially all testes with adenomas had foci of hyperplasia when the testis was not entirely

effaced by tumors. However, the frequent effacemen t of testicular parenchyma by tumors in this

chronic study renders the diagnosis of hyperplasia in testes with tumors of little or no value.

Thus interstitial cell hyperplasia was recorded pr imarily in testes withou t tumors (see Appendix

M).

Mesothelioma was present at a relatively low incidence of 0/50 (0%), 1/50 (2%), 1/50

(2%) and 2/50 (4%) for control, low-, mid- and high-level groups, respectiv ely, and no statistical

differences were noted for this neoplasm. Inci dences in this study were comparable to the

historical incidences for NTP studies (0–10% with a mean of ~3% [Haseman et al., 1998]).

Results are somewhat different from those obtained in the Baseline Gasoline Vapor Condensate

study, were a significant tr end toward increased mesothelioma wa s noted (Fisher’s Exact test). It

should be noted that no testicular mesotheliomas were present in control animals in this or in the

Baseline Gasoline Vapo r Condensate study.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-8 Table P-2. Incidence of Selected Prolifer ative (Neoplastic and Hyperplastic) Lesions

Control

(0 g/m 3 

# ) Low

(2 g/m 3 

# ) Mid

(10 g/m 3 

# ) High

(20 g/m 3 

# )

MALES

Kidney No. examined 50 50 50 50

Adenoma, renal tubule 0 (0%) 0 (0%) 6 (12%) a 

# 2 (4%)

Carcinoma, renal tubule 0 (0%) 1 (2%) 0 (0%) 1 (2%)

Renal tubule adenoma and

carcinoma, combined 0 (0%) 1 (2%) 6 (12%) b 

# 3 (6%)

Nasal

Sections

(Note that

the same

tumor

may

appear in

more than

one

level.) Turbinate Level 1

No. examined 50 50 50 50

Hyperplasia

Avg. severity 3 (6%)

0.2 0 (0%)

0.0 3 (6%)

0.1 4 (8%)

0.2

Turbinate Level 2

No. examined 50 50 50 50

Hyperplasia

Avg. severity 0 (0%)

0.0 2 (4%)

0.1 2 (4%)

0.1 3 (6%)

0.2

Carcinoma, squamous cell 1 (2%) 0 (0%) 0 (0%) 0 (0%)

Turbinate Level 3

No. examined 50 50 50 50

Carcinoma, squamous cell 0 (0%) 1 (2%) 0 (0%) 1 (2%)

Turbinate Level 4

No. examined 50 50 50 50

Carcinoma, squamous cell 0 (0%) 2 (4%) 0 (0%) 2 (4%)

Thyroid No. examined 50 35 31 50

Hyperplasia, follicular cell

Avg. severity 0 (0%)

0.0 0 (0%)

0.0 1 (3%)

0.1 0 (0%)

0.0

Adenoma, follicular cell 2 (4%) 0 (0%) 0 (0%) 3 (6%)

Carcinoma, follicular cell 1 (2%) 0 (0%) 1 (3%) 3 (6%)

Follicular cell adenoma

and carcinoma, combined 3 (6%) 0 (0%) 1 (3%) 5 (10%)

Testes No. examined 50 50 50 50

Adenoma, interstitial cell c 

# 43 (86%) 47 (94%) 48 (96%) 50 (100%) d



# Mesothelioma 0 (0%) 1 (2%) 1 (2%) 2 (4%)

Spleen No. examined 50 39 38 50

Leukemia, mononuclear e 

# 27 (54%) 31 (79%) d 

# 31 (82%) d 

# 31 (62%)

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-9 Table P-2. Incidence of Selected Prolifer ative (Neoplastic and Hyperplastic) Lesions

(Concluded)

Control

(0 g/m 3 

# ) Low

(2 g/m 3 

# ) Mid

(10 g/m 3 

# ) High

(20 g/m 3 

# )

FEMALES

Spleen No. examined 50 22 24 50

Leukemia, mononuclear 27 (54% ) 12 (55%) 11 (46%) 23 (46%)

Mammary

Gland No. examined 49 20 22 47

Fibroadenoma e 

# 0 (0%) 3 (15%) d 

# 2 (9%) 5 (11%) d

a 

# Incidence is significantly different from controls and from the 2 g/m 3 

# group (Fisher’s test).

b 

# Incidence is significantly diffe rent from controls (Fisher’s test). A positive trend toward

increased incidence with increasing dose was found with the Cochran-Armitage test.

c 

# A positive trend with increasing dose was found with the Cochran-Armitage and Logistic

tests. A trend was also detected with Fish er’s test with the incidence among the 20 g/m 3



# group being significantly in creased compared to the control incidence.

d 

# Incidence significantly different from controls (Fisher’s test).

e 

# Trend detected with Fisher’s Exact test.

In males, mononuclear leukemia in the spl een demonstrated statistically significant

increases in low and mid versus control group, th ese are judged unlikely to be a result of GMVC

exposure (see Table P-5 and Discussion).

Female rats had relatively similar incidences of mononuclear leukemia and across groups.

Mammary fibroadenomas were significantly increased in low and high animals, but a

surprisingly low incidence in controls complicat es the interpretation (s ee Table P-6, Discussion,

Appendices M and N).

Nonproliferative Lesions . Nonproliferative lesions includ e degenerative and inflammatory

changes. Such changes are common in many tissu es in aged F344 male and female rats, and

their significance in older animals must be interpreted with caution.

Kidneys of male rats exposed to GMVC ha d significant increases in severity, but not

incidence of chronic progressive nephropathy an d both mid- and high-level males (Table P-3).

Mid- and high-level males also demonstrated a significant increase in incidence (but not

severity) of hyaline degeneration of olfactory epithelium in nasal se ction 2 (located at the level

of the incisive papilla). There was a positive co ncentration-dependent trend toward degeneration

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-10 in the olfactory epithelium of turbinate 3 (locat ed midway between the incisive papilla and molar

teeth).

Table P-3. Nonproliferativ e Lesion Incidences and Severity Scores - Males

Control

(0 g/m 3 

# ) Low

(2 g/m 3 

# ) Mid

(10 g/m 3 

# ) High

(20 g/m 3 

# )

Kidney No. examined 50 50 50 50

Nephropathy, chronic 44 (88%) a 

# 47 (94%) 50 (100%) 46 (92%)

Avg. severity 1.9 2.1 2.6 b 

# 2.7 b



# Nose/Turbinate 2 No. examined 50 50 50 50

Degeneration, hyaline -

olfactory epithelium 0 (0%) 5 (10%) 7 c 

# (14%) 6 c 

# (12%)

Average severity 0.0 0.2 0.2 0.2

Nose/Turbinate 3 No. examined 50 50 50 50

Degeneration, hyaline -

olfactory epithelium 2 (4%) 1 (2%) 7 (14%) 7 (14%) d



# Average severity 0 0 0.2 0.3

Nose/Turbinate 4 No. examined 50 50 50 50

Degeneration, hyaline

- olfactory epithelium 0 0 1 (2%) 1 (2%)

Average severity 0 0 0 0

a 

# Percentage affected is in parentheses adjacent to incidence.

b 

# Significantly higher than cont rols at 0.05 level using Kolmogorov-Smirnov one-tailed test.

c 

# Significantly different from c ontrols at 0.05 level using Fish er’s exact two-tailed test.

d 

# Positive concentration-dependent trend by Coch ran-Armitage and logistic tests. p = 0.054 by

Fisher’s exact (no group comparisons made).

As in males, high-level GMVC-exposed female rats demonstrated a significant increase

in severity (but not incidence) of chronic progressive nephropat hy (Table P-4). Mid- and highlevel females had a significantly increased incide nce (but not severity) of hyaline degeneration of

respiratory epithelium in nasal turbinate section 2.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-11 Table P-4. Nonproliferative Lesion Incidences and Se verity Scores - Females

Control

(0 g/m 3 

# ) Low

(2 g/m 3 

# ) Mid

(10 g/m 3 

# ) High

(20 g/m 3 

# )

Kidney No. examined 50 20 21 50

Nephropathy, chronic 42 (84%) a 

# 17 (85%) 15 (71%) 43 (86%)

Average severity 1.0 1.0 1.0 1.5 b



# Nose/Turbinate 2 No. examined 50 50 50 50

Degeneration, hyaline -

respiratory epithelium 0 (0%) 1 (2%) 7 c 

# (14%) 6 c 

# (12%) d



# Average severity 0.0 0.0 0.3 0.2

a 

# Percentage affected is in parentheses adjacent to incidence.

b 

# Significantly higher than cont rols at 0.05 level using Kolmogorov-Smirnov one-tailed test.

c 

# Significantly different from c ontrols at 0.05 level using Fish er’s exact two-tailed test.

d 

# Positive concentration-dependent trend by Coch ran-Armitage and logistic tests. p = 0.054 by

Fisher’s exact (no group comparisons made).

Lesions Showing Statistical Significance, but Judged Not Likely Due to GMVC Exposure

Other proliferative and nonpro liferative lesions occurred which were not clearly

significant or were judged to have confoundi ng factors which must be considered in

interpretation. For completeness, these lesions are listed for males (Table P-5) and females

(Table P-6). Some findings were decreased in exposed animals compared to controls, these are

not generally discussed.

Some general notes are warranted:

1) A number of diagnoses wh ich appear as statistically significant are confounded by

the fact that the tissues were only exam ined if grossly abnormal. This is

particularly true in low- and mid-level anim als. For example, liver and uterus were

examined histologically in low- and mid- level animals only if a gross lesion was

detected. Thus, the incidence of “le ukemia, monocytic” and “polyp, endometrial

stromal” was skewed upward by a protocol driven sampling bias. For the purpose

of comments in the tables below, this will be termed “gross lesion sampling bias.”

2) The incidence data for the diagnosis of “leukemia, mononuclear” should be

considered only for the spleen . This is typically accepted as the tissue of origin of

this hematopoietic neoplasm (also termed large granular lymphocytic leukemia,

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-12 Fischer rat leukemia, monocytic leukemia , etc.) in F344 rats, and the lesion was

called in the spleen any time it occurred in other tissues. Incidence data for this

diagnosis in other organs ar e often spurious because some tissues were examined

only if abnormal. This is particularly true in low- and mid-level group animals

which had a more limited routine tissue set (“gross lesion sampling bias”).

Table P-5. Lesions Judged Not Attri butable to GMVC Exposure - Males

Tissue Diagnosis Statistical

Finding

(Group) Statistical

Test a 

# Comments

Adrenal

Gland Hyperplasia, medullary,

focal Trend to

increase C-A,

Logistic Increase was not significant versus

controls (Fisher’s) and there is no

evidence of an increase in benign or

malignant tumors in exposed animals.

Mammary

Gland Hyperplasia, lobular Trend to

increase C-A Increase was not significant versus

controls (Fisher’s) and there is no

evidence of an increase in benign or

malignant tumors in exposed animals.

Nose/

Turbinate 3 Degen., hyalineolfactory epithelium Trend to

increase C-A,

Logistic Increase was not significant versus

controls (Fisher’s), but is complementary to the significant increase seen in

nasal section 2.

Spleen Leukemia,

mononuclear Increase

(low, mid) Fisher’s High and variable incidence is

expected, increase was not significant

in highs. A corresponding increase

among females was not present.

a 

# C-A = Cochran-Armitage

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-13 Table P-6. Lesions Judged Not Attri butable to GMVC Exposure - Females

Tissue Diagnosis Statistical

Finding

(Group) Statistical

Test a 

# Comments

Brain Compression Increase

(low, mid) Fisher’s Relatively low incidence among

control females renders interpretation

problematic (Note: this lesion

typically results from pituitary gland

tumors and correlates with those

findings, see comments for that

lesion below).

Liver Hepatodiaphragmatic

nodule Increase

(low) Fisher’s Relatively common congenital

malformation (control incidences

reported from 1–11% b 

# ), can be

affected by gross lesion sampling

bias.

Liver Hyperplasia, biliary Trend to

decrease Logistic Significance only achieved with

Logistic test. Biological significance

uncertain, deemed unlikely.

Lung Hyperplasia, alveolar

epithelial, focal Trend to

decrease C-A,

Logistic Biological significance uncertain,

deemed unlikely.

Mammary

Gland Fibroadenoma Increase

(low, high);

Trend to

increase Fisher’s,

C-A Control incidence of 0% in this study

remarkably low (reports from ~27–

40% b 

# ), rendering interpretation of

significance problematic.

Pituitary

Gland Adenoma, pars distalis Increase

(low, mid) Fisher’s Relatively low incidence among

control females renders interpretation

problematic. Common neoplasm

with historical control incidence high

(~30%, ranges from 14-60% b 

# ), high

males show a minor decrease in

incidence. Biological significance

uncertain, deemed unlikely.

Uterus Polyp, endometrial

stromal Increase

(low, mid) Fisher’s Gross lesion sampling bias, no

evidence of increase in other uterine

hyperplasia, benign or malignant

tumors, control incidence rather low

(reports from 11–37% c 

# ). These

factors render interpretation of

significance problematic.

a 

# C-A = Cochran-Armitage

b 

# Boorman et al., 1990b; Haseman et al., 1998

c 

# Haseman et al., 1998; Leininger and Jokinen, 1990

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-14 DISCUSSION

Proliferative Lesions

Benign tumors of the kidney and testes in ma les are the proliferative lesions documented

most clearly in rats exposed via inhalation to GMVC in this study.

Adenomas of renal tubule epithelial cells are relatively uncommon background lesions in

F344 rats, with an average incidence in ma les of 1.0% (range 0–4%) in NTP study controls

(Haseman et al., 1998). The lack of a typical ex posure concentration response in this study is

difficult to resolve, but the significantly incr eased incidence in mid- (12%) and increased

incidence in high- (4%) level males is presumed to have resulted from GMVC exposure.

Additionally there was a low inci dence of renal tubule carcinoma in low- (2%) and high- (2%)

level males which was not statistically differe nt from controls. Combining adenomas and

carcinomas for analysis (controls 0%, low 2%, mid 10% and high 6 %) maintained the significant

increase in tumors in the mid-dose group and yielded a significant positive exposure-related

trend. These results are consistent with findings of an increased incidence of combined renal

adenomas and carcinomas in the Baseline Ga soline Vapor Condensate Study (FY01-027).

Given the increased severity of chronic pr ogressive nephropathy in mid- and high-level

males, a plausible explanation fo r the increase in renal tubule tumors may be a sustained increase

in cell turnover/prolifer ation and subsequent tumor inducti on via epigenetic mechanisms of

carcinogenesis in male rats, including damage related to alpha-2u globu lin overload (Hard, 1998;

Baetcke et al., 1991). Previous studies with wholly vaporized gasoline, MTBE, and related

compounds have also documented increased nephr opathy in male rats, and increases in renal

tubular adenomas and carcinomas (MacFarland et al., 1984; Medinsky et al., 1999; Bird et al.,

1997). Further consideration of the nonproliferative, bu t potentially relevant lesion of chronic

progressive nephropathy is pr esented below and under the “Nonproliferative Lesions”

discussion.

The increase in renal tubule adenomas and carcinomas in males may be related to the

increased severity of chronic progressive nephropathy through a sustained increase in tubule

epithelial cell turnover, a recognized occurrence in male rats (Hard, 1998). For compounds

inducing renal tumors in male rats through increased alpha-2u globulin accumulation and

subsequent increased renal tubule cell turnover, the human health relevance of the mechanism

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-15 and thus the tumors is often regarded as suspect (Baetcke et al., 1991; Hard, 1998; Hard and

Khan, 2004). Alpha-2u globulin ne phropathy is a plausible mech anism for GMVC related renal

adenomas and carcinomas based on other MT BE and similar compound study reports (and

including the results of a 13-week unpublishe d study on gasoline vapor condensate without

MTBE conducted at LRRI). In F344 male rats after approximately 1 year of age, alpha-2u

globulin overload nephropathy may be masked by age-related chronic pr ogressive nephropathy

(CPN), since both forms of nephr opathy share similar if not iden tical diagnostic hallmarks. The

effect of alpha-2u globulin overl oad nephropathy typically manifest s itself in increased severity,

rather than incidence, since essentially all males surviving past 1 year of age will develop CPN.

Note that GMVC also induced increased severity of nephropathy in females at the highest dose,

although via a different mechanis m since alpha-2u globulin overl oad is male rat specific.

Squamous cell carcinomas (SCC) present in nasa l sections of males [animal incidences of

1/50 (2%), 2/50 (4%), 0/50 (0%) and 2/50 (4%)] were j udged to be of oral origin in all cases.

The low incidences and presence of this neoplas m in a control male render any relationship to

exposure difficult to discern in this study. Histor ical control incidences of this tumor in NTP

inhalation studies are low (~0.6%). However, a large study with cigarette smoke conducted at

this facility in the early 1990’s had an incidence of 0/118 (0%) s quamous cell carcinomas of oral

origin in males and 3/119 (2.5%) in females. No tumors were of nasal origin. While comparison

between this study and the concur rent BGVC study is largely done in the GMVC main report,

note that the BGVC study had none of these tumors (0/50) in control males but one (1/50) in

control females. In the BGVC, there was a tr end for significant increase in squamous cell

carcinomas in males, but no group differences by th e Fisher’s Exact Test. Nonetheless, a minor

but relatively consistent increase in incidence in exposed animal s is present in both studies.

Clearly the whole body method of in halation exposure has the potenti al to result in some degree

of exposure directly to the oral cavity in addition to the system ic exposure from inhalation (from

grooming, etc.).

Interstitial (Leydig) cell adenomas of the testes are very common lesions in male F344

rats, with average reported incidences up to 89% or even 100% in 2-year st udies (Haseman et al.,

1998; Boorman et al., 1990c). Incidence of this benign tumor was similarly high in all groups in

this study as well, but the incidence in high- level males was significantly increased, and an

exposure concentration response was present. While within this study with GMVC the data

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-16 suggest a causal relationship between exposure and testicular inters titial adenomas, the

relationship between treatment with MTBE and induction of testicular interstitial adenomas is on

the whole more equivocal, since background inciden ce of this tumor is quite variable and usually

extremely high [(NTP control incidence for air inhalation controls: for NIH-07 diet avg. =

70.1% with range of 46% to 90%; for NTP-2000 di et avg. = 92.1% with range of 82% to 98%),

and control incidence in the concurrently run Baseline Gasoline Vapor Condensate chronic study

(LRRI study number FY01-027) wa s 48/50 (96%)]. Other MTBE toxicity studies have

documented increases in testicular interstitial cell adenomas (Bird et al., 1997; Belpoggi et al.,

1995). However, in a recent review of the m echanisms of MTBE induced carcinogenicity, the

overall evidence for MTBE induction of testicular interstitial cell adenoma was considered to be

equivocal (Cruzan et al., 2007). Note that the hu man health relevance of interstitial cell tumors

in rats has been called into que stion suggesting little predictive value for humans (Prentice and

Meikle, 1995; Cook et al., 1999).

Leukemia, a well-documented feature of old age in F344 rats, did not appear to be

enhanced by GMVC exposure. Results for splee n, the defining organ for this disease, are shown

for males and females in Table P-2. In males, the incidences of leukemia in the low- and midGMVC levels are greater than controls (Fisher’s test). However, there was no overall significant

trend with exposure concentration as determined by the Cochran-Armitage and logistic tests, and

the incidence of leukemia in high-level males was not different from controls (Fisher’s test). The

incidences of leukemia in GMVC-exposed females we re similar to or lower than control but not

significantly different (Table P-2).

Mammary gland fibroadenoma was significantly increased in lo w- and high-level females

(Tables P-2 and P-6). Interpreta tion of this finding is problema tic due to the atypically low

control incidence of 0% in control females. Cont rol incidences for this lesion have been reported

to range from 27–40% (Boorman et al., 1990b). Th e control incidence in the parallel BGVC

study (LRRI study number FY01-027) was 4/49 (8%). Additionally, increases in this lesion have

not been observed in previous studies with ne at MTBE or wholly vaporized gasoline (Cruzan et

al., 2007; MacFarland et al., 1984). Therefore, it is judged unlikely that the increased incidence

in female mammary gland fibroa denoma was treatment-related.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-17 Nonproliferative Lesions

Males . Chronic progressive nephropathy (CPN) is th e diagnostic terminology for an entity in

rats comprised of a constellation of changes commonly affecting the kidneys of F344 rats.

Lesions in male rats appear earlier and are routinely more severe than those in females

(Montgomery and Seely, 1990). Renal lesions ty pically consist of t ubular degeneration and

regeneration, proteinaceous casts , tubular atrophy and dilatation, interstitial fibrosis, basement

membrane thickening and glomerulosclerosis depe nding on the severity. The severity scoring

for this lesion in describe d in a previous section.

The increased average severity score for CPN in mid- and high-level males is judged to

be a consequence of GMVC exposure. It may re flect damage resulting from increased alpha-2u

globulin associated with hydrocarbon nephropa thy (HN). Some classic hallmarks of

hydrocarbon exposure—including the presence of brightly eo sinophilic cytoplasmic droplets

within tubular epithelium and gr anular casts/linear mineralizati on in the outer stripe of the

medulla—were not apparent even in high-level males (while regi ons of cytoplasmic eosinophilic

droplets occurred, they were similar between cont rols and exposed and not judged representative

of HN). As discussed below however, the abse nce of these hallmarks is not unexpected in

kidneys from aged rats.

Hyaline droplet or protein accumulation in shorter term MTBE studies is reported

(Medinsky, 1999; Lington et al., 1997; Bird et al., 1997), but the cha nge is not necessarily noted

in kidneys from chronic exposur es (Bird et al., 1997; Rudo, 1995) . It is noteworthy that a

chronic t-butyl alcohol exposure study conducted by the NTP also lacks a specific diagnosis of

“hyaline droplet nephropathy,” although such a diagnosis is made duri ng a shorter term (13

week) exposure study (NTP, 1995). Hyaline drop let accumulation is commonly seen with

hydrocarbon exposure, and might be expected w ith GMVC inhalation (Gopinath et al., 1987).

Such a “hydrocarbon nephropathy” may have oc curred as an earlier lesion which was

masked/obscured in these chronically exposed anim als by the progression of CPN. There is also

some evidence that aged male rats are much less sensitive to hydrocarbon nephropathy and that

production of the major protein constituent of hyaline droplets, alpha-2u globulin, is greatly

decreased in old rats (Murty et al., 1988). In addition to renal lesions of hyaline droplet

formation, increased tubular regeneration/prolifer ation and CPN have been previously reported

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-18 in male rats as a result of MTBE and si milar compound exposure (Medinsky et al., 1999;

Lington et al., 1997; Bird et al., 1997 ; Clary, 1997; Borghoff et al., 2001).

The human health significance of the chroni c progressive nephropathy of male rats

associated with accumulation of hyaline droplets containing alpha-2u globulin is suspect. It and

the subsequent development of renal tubule adenom as are often considered male rat specific and

thus not significant for humans (Greaves , 2000; Baetcke et al., 1991; Hard, 1998) though

opinions differ (Melnick, 1992). As previously noted, the typical lesi ons of hyaline droplet

nephropathy were not documented in this study at the chronic timepoints examined, but this is

not unexpected since diagnostic hallmarks (prima rily linear mineralization) to suggest HN at

chronic timepoints and with severe overlying CP N are limited. It should be noted that the

severity of chronic progressive nephropathy wa s increased in high-level females which are not

susceptible to typical alpha-2u globulin related nephropathy. This suggests the possibility that

more than one mechanism may be important in the development of chronic progressive

nephropathy in response to GMVC.

Increased hyaline degeneration of nasal epithe lium (typically olfact ory and respiratory)

characterized by the accumulation of hyaline drop lets/globules is a common, nonspecific finding

in aged rats and is increased in response to a number of toxicants (Boorman et al., 1990d;

Gopinath et al., 1987). Mid- and high-level males had si gnificant increas es in incidence relative

to that seen in control animals in nasal se ction 2, and there was an exposure concentration

response in turbinate 3 for males. The overall inci dence was relatively low, and the severity of

the lesion ranged from minimal to moderate in most exposure groups. While the lesion is likely

exposure related, the significance of this co mmon, minor change by itself is uncertain.

Females . Kidneys of high-level female rats cumula tively demonstrated a slight increase in

overall severity score of chr onic progressive nephropathy. Th ough the minor severity difference

renders interpretation less clear than that in ma les, the increased severi ty of CPN in high-level

females is judged to be an effect of GMVC expos ure. A lesser severity of CPN is typical in

female F344 rats compared to males (Montgomer y and Seely, 1990). Reports of MTBE effects

on kidneys in female rats vary. Some do not report significant differences in female renal lesions

(Lington et al., 1997), others re port increased bromodeoxyuridine labeling of tubular epithelium

or increased CPN incidence and severity (Medinsky et al., 1999; Bird et al., 1997; Clary, 1997).

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-19 As noted for the males, hyaline droplet accumulation in olfactory and respiratory nasal

epithelia is a common, nonspecific response to toxicants in rodent s. While the lesion is likely

exposure related, the significance of this co mmon, minor change by itself is uncertain.

HISTOPATHOLOGY SUMMARY

Statistically significant increases in GMVC ex posure related lesions were seen in both

male (kidney, testes, nasal epithelia) and female (kidney, nasal epithelia) F344 rats. Exposure

related proliferative lesions occurred only in males and consisted of renal tubule adenomas (and

combined adenomas and carcinomas) and testic ular interstitial (Leydig) cell adenomas. The

increase in renal tubule ade nomas was significant only in mi d-level group males relative to

controls (Fisher’s exact test, p ≤ 0.05) and lacked si gnificance using tre nd tests (CochranArmitage and Logistic tests, p ≤ 0.05). Combining renal tubule adenomas and carcinomas

maintained the significant increase in mid-level ma les and also resulted in a significant positive

trend with increased exposure. Renal tubule ne oplasms in rats are influenced by epigenetic

mechanisms related to CPN and this must be taken into account in this study. Increases in

testicular interstitial ce ll adenomas were statistically signific ant relative to controls in high-level

animals (Fisher’s exact test, p ≤ 0.05) and as an expos ure related trend (both Cochran-Armitage

and Logistic tests, p ≤ 0.05). As noted in the discussion section, the variable and typically very

high background incidence of this tumor in aged ra ts must be considered on the whole in risk

assessment.

Nonproliferative lesions related to GMVC exposure were present in kidneys (as an

increase in severity of ch ronic progressive nephropathy ) and nasal epithelia (as hyaline

degeneration ) of both genders . Both mid- and high-level male s had significant increases in the

severity, but not incidence of chronic progressive nephropathy relative to controls (KolmogorovSmirnov test, p ≤ 0.05). The incidence of hyaline degenera tion of olfactory epithelium (nasal

turbinate section 2) was signifi cantly increased in male animal s of mid- and high-level groups

(Fisher’s exact test, p ≤ 0.05), and increased as an exposure related trend (Cochran-Armitage and

Logistic tests, p ≤ 0.05). An exposure-related trend for olf actory epithelial degeneration was also

present in turbinate 3 for males. Kidneys of females exposed to GMVC did not have an

increased incidence (Fisher’s exact test, p ≤ 0.05) or exposure relate d trend to increased

incidence (Cochran-Armitage and Logistic tests, p ≤ 0.05) of chronic progressive nephropathy,

but did demonstrate a significant increase in severity of this lesion in high-level females

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-20 (Kolmogorov-Smirnov test, p ≤ 0.05). Nasal cavities of mid- and high-group females had an

increased incidence of hyaline degeneration of resp iratory epithelium (nasal section 2) relative to

controls (Fisher’s exact test, p ≤ 0.05), and the exposure-related tr end for this change was also

significant (Cochran-Armitage and Logistic tests, p ≤ 0.05).

Hyaline degeneration of olfactory and resp iratory epithelium is characterized by the

accumulation of homogeneous, hyaline eosinophilic gl obules. Small numbers of cells with these

globules are common in aging rodents and in re sponse to toxicants. The significance of the

minor nasal epithelial changes noted in this study is uncertain.

REFERENCES

Baetcke, K. P., Hard, G. C., Rodgers, I. S ., McGaughy, R. E., and Tahan, L. M. (1991). Alpha 2 υ 

# Globulin: Association with Chemically Induced Renal Toxicity and Neoplasia in the

Male Rat. (EPA/625/3-91/019F) Risk Assessment Forum, U.S. Environmental

Protection Agency (U.S. EPA), Washington, D.C.

Belpoggi, F., Soffritti, M., and Maltoni, C. ( 1995). Methyl-Tertiary-Butyl Ether (MTBE)—A

Gasoline Additive—Causes Testicular and Lymphohaematopoietic Cancers in Rats.

Toxicol. Ind. Health 11(2) : 119-149.

Bird, M. G., Burleigh-Flayer, H. D., Chun, J. S., D ouglas, J. F., Kneiss, J. J., and Andrews, L. S.

(1997). Oncogenicity Studies of Inhaled Me thyl-Tertiary-Butyl Ether (MTBE) in CD-1

Mice and F-344 Rats. J. Appl. Toxicol. 17(Suppl. 1) : S45-S55.

Boorman, G. A., Eustis, S. L., Elwell, M. R., and Leininger, J. R., eds. (1990a). Pathology of the

Fischer Rat , 1 st 

# Ed., Academic Press, San Diego, CA.

Boorman, G. A., Wilson, J.T., van Zwieten, M.J., and Eutis, S. L. (1990b). Mammary Gland. In

Pathology of the Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and

Leininger, J. R., eds.), 1 st 

# Ed., pp. 295-314, Academic Press, San Diego, CA.

Boorman, G. A., Chapin, R. E., and Mitsumori, K. (1990c). Testis and Epididymis. In

Pathology of the Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and

Leininger, J. R., eds.), 1 st 

# Ed., pp. 405-418, Academic Press, San Diego, CA.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-21 Boorman, G. A., Morgan, K. T., and Uriah, L. C. (1990d). Nose, Larynx, and Trachea. In

Pathology of the Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and

Leininger, J. R., eds.), 1 st 

# Ed., pp. 315-338, Academic Press, San Diego, CA.

Borghoff, S. J., Prescott, J. S., Janszen, D. B., Wong, B. A., and Everitt, J. I. (2001). Alpha 2uGlobulin Nephropathy, Renal Cell Proliferati on, and Dosimetry of Inhaled Tert-butyl

Alcohol in Male and Female F-344 Rats. Toxicol. Sci. 61(1) :176-186.

Clary, J. J. (1997). Methyl Tert Butyl Ether Systemic Toxicity. Risk Anal. 17(6) : 661-672.

Cook, J. C., Klinefelter, G. R., Ha rdisty, J. F., Sharpe, R. M., a nd Foster, P. M. (1999). Rodent

Leydig Cell Tumorigenesis: A Review of the Physiology, Pathology, Mechanisms, and

Relevance to Humans. Crit. Rev. Toxicol. 29(2) : 169-261.

Cruzan, G., Borghoff, S. J., dePeyster, A., Ha rd, G. C., McClain, M., McGregor, D. G., and

Thomas, M. G. (2007). Methyl Tertiary -Butyl Ether Mode of Action for Cancer

Endpoints in Rodents. Reg. Toxicol. Pharmacol. 47: 156-165.

Gopinath, C., Prentice, D. E., and Lewis, D. J. (1987). Atlas of Experimental Toxicological

Pathology (Gresham, G. A., ed.), MTP Press Limited, Norwell, MA.

Greaves, P. (2000). Histopathology of Preclin ical Toxicity Studies , Elsevier, Amsterdam,

Netherlands.

Hard, G. C. (1998). Mechanisms of Chemically Induced Renal Carcinoge nesis in the Laboratory

Rodent. Toxicol. Pathol. 26(1) : 104-112.

Hard, G. C., and Khan, K. N. (2004). A C ontemporary Overview of Chronic Progressive

Nephropathy in the Laboratory Rat, and its Significance for Human Risk Assessment.

Toxicol. Pathol. 32(2) : 171-180.

Haseman, J. K., Hailey, J. R., and Morris, R. W. (1998). Spontaneous Neoplasm Incidences in

Fischer 344 Rats and B6C3F1 Mice in Two-Y ear Carcinogenicity Studies: A National

Toxicology Program Update. Toxicol. Pathol. 26(3) : 428-441.

Leininger, F. R., and Jokinen, M. P. ( 1990). Oviduct, Uterus, and Vagina. In Pathology of the

Fischer Rat (Boorman, G. A., Eustis, S. L., Elwell, M. R., and Leininger, J. R., eds.), 1 st



# Ed., pp. 443-460, Academic Press, San Diego, CA.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-22 Lington, A. W., Dodd, D. E., Ridlon, S. A., Douglas, J. F., Kneiss, J. J., and Andrews, L. S.

(1997). Evaluation of 13-Week Inhalation Toxicity Study on Methyl T-Butyl Ether

(MTBE) in Fischer 344 Rats. J. Appl. Toxicol. 17(Suppl. 1) : S37-S44.

MacFarland, H. N., Ulrich, C. E., Holdsworth, C. E., Ketchen, D. N., Halliwell, W. H., and

Blum, S. C. (1984). A Chronic Inhala tion Study wth Unleaded Gasoline Vapor. J. Am.

Coll. Toxicol. 3(4): 231-48.

Medinsky, M. A., Wolf, D. C., Cattley, R. C., W ong, B., Janszen, D. B., Farris, G. M., Wright,

G. A., and Bond, J. A. (1999). Effects of a Thirteen-Week Inhalation Exposure to Methyl

Tertiary Butyl Ether on Fische r-344 Rats and CD-1 Mice. Toxicol. Sci. 51(1) : 108-118.

Melnick, R. L. (1992). An Alternative Hypothesi s on the Role of Chemically Induced Protein

Droplet (Alpha 2u-Globulin) Nephropa thy in Renal Carcinogenesis. Regul. Toxicol.

Pharmacol. 16(2) : 111-125.

Montgomery, C. A., and Seely, J. C. (1990). Kidney. In Pathology of the Fischer Rat

(Boorman, G. A., Eustis, S. L., Elwell, M. R., and Leininger, J. R., eds.), 1 st 

# Ed., pp. 127-

153, Academic Press, San Diego, CA.

Murty, C. V., Olson, M. J., Garg, B. D., and R oy, A. K. (1988). Hydrocarbon-Induced Hyaline

Droplet Nephropathy in Male Rats During Senescence. Toxicol. Appl. Pharmacol. 96(2) :

380-392.

National Toxicology Program (1995). Toxico logy and Carcinogenesis Studies of T-Butyl

Alcohol (CAS No. 75-65-0) in F344/N Rats and B6C3F 1 

# Mice (Drinking Water Studies).

Technical Report 436, NIH Publ. No. 95-3167, National Toxicology Program, National

Institutes of Health.

National Toxicology Program website (as of Sept. 2008). Historical Controls.

http://ntp.niehs.nih.gov/ntpweb/inde x.cfm?objectid=92E61F1B-F1F6-975E7D3BED551F07DC0A

Prentice, D. E., and Meikle, A. W. (1995). A Review of Drug-Induced Leydig Cell Hyperplasia

and Neoplasia in the Rat and Some Comparisons with Man. Hum. Exp. Toxicol. 14(7) :

562-572.

# Study Number FY01-013

211(b) Chronic Carcinogenicity Study

Gasoline MTBE Vapor Condensate (GMVC)

P-23 Rudo, K. M. (1995). Methyl Tertiary Butyl Ether (MTBE)—Evaluation of MTBE

Carcinogenicity Studies. Toxicol. Ind. Health 11(2) : 167-173.